{"columns":["study_id","primary_registry","primary_registry_id","acronym","title","study_type","allocation","phases","overall_status","enrollment","conditions","interventions","lead_sponsor","start_date","has_posted_results","n_linked_records"],"rows":[["S000001","ClinicalTrials.gov","NCT03141632","GATE","Effects of GLP-1 Analogues on Fluid Intake in Healthy Volunteers - \"The GATE-Study\"","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","17","Thirst; Water-Electrolyte Imbalance","DRUG:Dulaglutide; OTHER:Placebo","University Hospital, Basel, Switzerland","2016-10-17","FALSE","1"],["S000002","ClinicalTrials.gov","NCT06989177",null,"An Interventional Study Investigating the Effects of Probiotics on Body Weight and Metabolic Homeostasis","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","140","Obesity; Homeostasis; Weight Loss; Probiotic Intervention","BEHAVIORAL:General lifestyle and nutritional education; BEHAVIORAL:Energy-restricted nutritional and lifestyle intervention; DIETARY_SUPPLEMENT:Placebo; DIETARY_SUPPLEMENT:Probiotic; DRUG:semaglutide","Chinese Academy of Sciences","2025-06-10","FALSE","0"],["S000003","ClinicalTrials.gov","NCT06885736","LEAN-PREP","LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide and Tirzepatide Therapy (LEAN-PREP Study)","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","232","Obesity","BEHAVIORAL:Resistance exercise; DIETARY_SUPPLEMENT:Protein Intake","Dasman Diabetes Institute","2025-08-07","FALSE","2"],["S000004","ClinicalTrials.gov","NCT04979611",null,"The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma","INTERVENTIONAL",null,"PHASE1","UNKNOWN","60","Insulinoma","DRUG:68Ga-NOTA-exendin-4","First Affiliated Hospital of Fujian Medical University","2020-08-01","FALSE","0"],["S000005","ClinicalTrials.gov","NCT07091734","TILT-2024","Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","32","Lipodystrophy, Partial","DRUG:Tirzepatide; DRUG:Usual care medications","University of Michigan","2025-09-08","FALSE","0"],["S000006","ClinicalTrials.gov","NCT06818292","GLPsy","Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","10","Healthy","BIOLOGICAL:Liraglutide; BIOLOGICAL:Placebo","Nils Opel","2024-10-21","FALSE","0"],["S000007","ClinicalTrials.gov","NCT07638592",null,"Tirzepatide-Based Prehabilitation Before Elective Ventral and Incisional Hernia Repair in Patients With Obesity:A Prospective Multicenter Cohort Study With a Comparative Control Cohort","OBSERVATIONAL",null,null,"COMPLETED","91","Obese Adults; Hernia Abdominal Wall; Prehabilitation","DRUG:Tirzepatide prehabilitation","Azienda Sanitaria Locale Napoli 2 Nord","2025-01-01","FALSE","0"],["S000008","ClinicalTrials.gov","NCT06541509","SEMAHEART","A Pilot Clinical Trial Investigating Underlying Mechanisms of Semaglutide Therapy in Heart Failure Patients","INTERVENTIONAL",null,"PHASE1; PHASE2","UNKNOWN","10","Heart Failure; Obesity","DRUG:Semaglutide","University Medical Centre Ljubljana","2024-07-10","FALSE","0"],["S000009","ClinicalTrials.gov","NCT01255163",null,"A Pilot Study of Exendin-4 in Alzheimer s Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","57","Alzheimer's Disease; Mild Cognitive Impairment","DRUG:Exendin-4 SC; DRUG:Placebo SC","National Institute on Aging (NIA)","2010-11-21","TRUE","4"],["S000010","ClinicalTrials.gov","NCT03131687",null,"A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","318","Type 2 Diabetes Mellitus","DRUG:tirzepatide; DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2017-05-24","TRUE","4"],["S000011","ClinicalTrials.gov","NCT02100475","DUAL™","A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","31","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin aspart","Novo Nordisk A/S","2014-04","TRUE","0"],["S000012","ClinicalTrials.gov","NCT04259801",null,"Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of NNC0480-0389 in Combination With Semaglutide s.c.","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","152","Healthy Volunteers; Overweight; Obesity; Diabetes Mellitus, Type 2","DRUG:NNC0480-0389; DRUG:Semaglutide; DRUG:Placebo (NNC0480-0389); DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2020-02-17","FALSE","0"],["S000013","ClinicalTrials.gov","NCT07469800",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Participants With Mild to Moderate Hypertension Complicated by Overweight/Obesity Who Have Not Received Antihypertensive Drug Treatment","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","336","Overweight; Obesity; Hypertensive","DRUG:IBI362; DRUG:Placebo","Innovent Biologics (Suzhou) Co. Ltd.","2026-04-23","FALSE","0"],["S000014","ClinicalTrials.gov","NCT02284230","LiRA2","Glycaemic and Cardiovascular Efficacy of Liraglutide in Prediabetic Patients With End-stage Renal Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","WITHDRAWN","0","Kidney Failure, Chronic; Prediabetic State","DRUG:Liraglutide; DRUG:Placebo","Bo Feldt-Rasmussen","2014-12","FALSE","0"],["S000015","ClinicalTrials.gov","NCT04885634","SOCRATES-AF","Semaglutide for the Reduction of Arrhythmia Burden in Overweight and Obese Patients With Atrial Fibrillation (Pilot Study)","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Atrial Fibrillation; Overweight and Obesity","DRUG:Semaglutide Injectable Product; DRUG:Placebo","Axel Brandes","2022-10","FALSE","0"],["S000016","ClinicalTrials.gov","NCT05445232",null,"A Multiple-Dose Drug-Drug Interaction Study to Determine the Effect of LY3437943 on Drug Metabolizing Enzymes","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","32","Obesity","DRUG:LY3437943; DRUG:Midazolam; DRUG:Warfarin; DRUG:Caffeine","Eli Lilly and Company","2022-07-08","FALSE","0"],["S000017","ClinicalTrials.gov","NCT05442450","OSO","Efficacy of Oral Semaglutide in Overweight or Obesity : Randomized Controlled Trial (OSO Study - Oral Semaglutide for Obesity)","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","116","Obesity; Weight Loss","DRUG:oral semaglutide","Asian Institute of Gastroenterology, India","2022-07-10","FALSE","1"],["S000018","ClinicalTrials.gov","NCT07547878","RAPID-CKD","A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD","INTERVENTIONAL","RANDOMIZED","PHASE4","ENROLLING_BY_INVITATION","64","Chronic Kidney Disease; Type 2 Diabetes","DRUG:Finerenone; DRUG:Semaglutide; DRUG:Lotensin; DRUG:Capoten; DRUG:Enalapril; DRUG:Monopril; DRUG:Lisinopril; DRUG:Univasc; DRUG:Aceon; DRUG:Accupril; DRUG:Altace; DRUG:Mavik; DRUG:Edarbi; DRUG:Atacand; DRUG:Avapro; DRUG:Cozaar; DRUG:Benicar; DRUG:Micardis; DRUG:Diovan; DRUG:Invokana; DRUG:Farxiga; DRUG:Jardiance; DRUG:Ertugliflozin; DRUG:Brenzavvy; DRUG:Sotagliflozin","Baylor Research Institute","2026-04-08","FALSE","7"],["S000019","ClinicalTrials.gov","NCT01615978",null,"A Randomised, Double-blind Within Dose Group, Single-centre, Placebo-controlled, Parallel 2-different Dose Group, 14-day Multiple s.c. Doses Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Liraglutide (NNC 90-1170) in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","15","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2003-12","FALSE","0"],["S000020","ClinicalTrials.gov","NCT07779343","OBESIAL","OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","300","Obesity Difficult Airway Airway Management; Obesity Adult Onset; Obesity and Cardiovascular Risk; Obesity Type 2 Diabetes Mellitus","DRUG:Semaglutide (Wegovy) weekly injection; BEHAVIORAL:Behavioral Treatment; OTHER:Weight loss","University of Health Sciences, Algeria","2026-01-22","FALSE","0"],["S000021","ClinicalTrials.gov","NCT07554417",null,"Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","20","GLP - 1; Obesity & Overweight; Muscle Loss; Exercise Intervention; Dietary Assessment","DRUG:Semaglutide; BEHAVIORAL:Dietary Counseling; BEHAVIORAL:Exercise","William Marsh Rice University","2026-04-06","FALSE","0"],["S000022","ClinicalTrials.gov","NCT02964247",null,"LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","303","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2017-03-03","TRUE","3"],["S000023","ClinicalTrials.gov","NCT03331289",null,"SGLT2 INHIBITION AND STIMULATION OF ENDOGENOUS GLUCOSE PRODUCTION [EGP]: Can the Glucagon-like Peptide-1 [GLP-1] Receptor Agonist, Exenatide, Prevent the Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","107","Diabetes Mellitus, Type 2","DRUG:Placebo; DRUG:Exenatide; DRUG:Dapagliflozin; DRUG:Exenatide and Dapagliflozin","The University of Texas Health Science Center at San Antonio","2018-02-28","TRUE","1"],["S000024","ClinicalTrials.gov","NCT06855147",null,"A Single-center, Open-label, Phase Ⅰ Clinical Study of the Absorption, Metabolism, and Excretion of [14C]HRS9531 in Healthy Male Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","7","Type 2 Diabetes Mellitus; Weight Loss","DRUG:[14C]HRS9531","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-04-21","FALSE","0"],["S000025","ClinicalTrials.gov","NCT00806520",null,"Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control Addendum to: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release to Those of Sitagliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin (Study BCB106)","OBSERVATIONAL",null,null,"COMPLETED","16","Type 2 Diabetes",null,"HealthPartners Institute","2008-04","FALSE","0"],["S000026","ClinicalTrials.gov","NCT02292290","T4R","A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Liraglutide vs. a Sulphonylurea","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","99","Type 2 Diabetes","DRUG:Liraglutide; DRUG:Sulfonylurea or Pioglitazone; DRUG:Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide","University of Leicester","2011-04","FALSE","0"],["S000027","ClinicalTrials.gov","NCT00754988",null,"A Multicenter, Randomized, Double-dummy, Placebo and Active-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Sitagliptin and Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin.","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","666","Diabetes Mellitus Type 2","DRUG:Metformin; DRUG:Placebo (matching sitagliptin); DRUG:Placebo (matching taspoglutide); DRUG:Sitagliptin; DRUG:Taspoglutide","Hoffmann-La Roche","2008-10","FALSE","0"],["S000028","ClinicalTrials.gov","NCT07281196",null,"A Real-World Study on Changes in Sleep Apnea Among Patients With Type 2 Diabetes/Obesity and Comorbid OSA After Short-Term Treatment With Semaglutide","OBSERVATIONAL",null,null,"COMPLETED","15","Sleep Apnea Syndrome (OSAS)","DRUG:Semaglutide Subcutaneous Injection","Shanghai Fengxian District Central Hospital","2025-01-01","FALSE","0"],["S000029","ClinicalTrials.gov","NCT00839527",null,"A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","685","Diabetes Mellitus, Type 2","DRUG:placebo to match albiglutide; BIOLOGICAL:albiglutide; DRUG:metformin; DRUG:glimepiride; DRUG:pioglitazone; DRUG:placebo to match pioglitazone","GlaxoSmithKline","2009-02","TRUE","3"],["S000030","ClinicalTrials.gov","NCT02954627","CIMT-LOSEIT-I","Ultrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects Following a Significant Weight Loss","OBSERVATIONAL",null,null,"COMPLETED","200","Osteoarthritis; Obesity","DIETARY_SUPPLEMENT:Dietary Supplement: Intensive dietary intervention","Henrik Gudbergsen","2016-11","FALSE","0"],["S000031","ClinicalTrials.gov","NCT04166773","SYNERGY-NASH","A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","190","Nonalcoholic Steatohepatitis","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2019-11-19","TRUE","7"],["S000032","ClinicalTrials.gov","NCT06588283","TOGETHER-PsO","Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","281","Psoriasis; Obesity","DRUG:Ixekizumab; DRUG:Tirzepatide","Eli Lilly and Company","2024-09-30","FALSE","3"],["S000033","ClinicalTrials.gov","NCT06901245",null,"The Effects of Tirzepatide in Young Adults With Prader-Willi Syndrome, Hypothalamic Obesity and General Non-Syndromic Obesity","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","RECRUITING","36","Prader-Willi Syndrome; Hypothalamic Obesity; Obesity/Therapy","DRUG:Tirzepatide","Grace Kim","2025-05-01","FALSE","0"],["S000034","ClinicalTrials.gov","NCT05407961",null,"A Phase 1b, 2-Part, Investigator- and Participant-Blind, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3532226 in Participants With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","90","Diabetes Mellitus, Type 2","DRUG:LY3532226; DRUG:Placebo; DRUG:Dulaglutide","Eli Lilly and Company","2022-06-07","FALSE","0"],["S000035","ClinicalTrials.gov","NCT03239119",null,"A Phase 3, Randomized, Double-Blind,Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) and Safety of rE-4 in Subjects With Type 2 Diabetes Mellitus Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","456","Type2 Diabetes Mellitus","BIOLOGICAL:rE-4 5 mcg; BIOLOGICAL:rE-4 10 mcg; BIOLOGICAL:Placebo 5 mcg; BIOLOGICAL:Placebo 10 mcg","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","2017-11-30","FALSE","0"],["S000036","ClinicalTrials.gov","NCT02931383","US-LOSEIT-II","Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis Following Liraglutide Treatment, Investigating the Impact on Inflammation","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","150","Osteoarthritis; Obesity","DRUG:Liraglutide 3 mg (Saxenda); DRUG:Liraglutide 3 mg placebo","Henrik Gudbergsen","2016-11","FALSE","0"],["S000037","ClinicalTrials.gov","NCT06651177","TAB","NIDA CTN-0152: Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder: A Pragmatic, Multi-site, Double-blind, Randomized, Placebo-controlled Trial (TAB)","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","310","Opioid Use Disorder; Opioid Use Disorder, Moderate; Opioid Use Disorder, Severe","DRUG:Tirzepatide; OTHER:Placebo","T. John Winhusen, PhD","2026-01-29","FALSE","0"],["S000038","ClinicalTrials.gov","NCT05364931","PROXYMO-ADV","A Phase II Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Cotadutide in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","54","Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis","DRUG:Cotadutide; DRUG:Placebo","AstraZeneca","2022-07-14","TRUE","0"],["S000039","ClinicalTrials.gov","NCT06518837","FITWISE","FITWISE: Feasibility Study of Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer","INTERVENTIONAL",null,"PHASE2","RECRUITING","40","Hormone Receptor-Positive Breast Cancer; HER2-Negative Breast Cancer","DRUG:Tirzepatide","Rutgers, The State University of New Jersey","2024-10-30","FALSE","0"],["S000040","ClinicalTrials.gov","NCT04384081",null,"A Phase I, Single-blinded, Randomized, Multiple Dose, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Different Dose Escalation Schemes of BI 456906 in Healthy Japanese Male Subject With BMI 23-40 kg/m2","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","37","Healthy","DRUG:BI 456906; DRUG:Placebo","Boehringer Ingelheim","2020-06-01","FALSE","0"],["S000041","ClinicalTrials.gov","NCT04969939",null,"Investigation of Efficacy and Safety of NNC0165-1875 as add-on to Semaglutide for Weight Management in Subjects With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","120","Obesity","DRUG:Semaglutide 2.4 mg and NNC0165-1875 2.0 mg; DRUG:Semaglutide 2.4 mg and placebo 2.0 mg; DRUG:Semaglutide 2.4 mg and NNC0165-1875 1.0 mg; DRUG:Semaglutide 2.4 mg and placebo 1.0 mg","Novo Nordisk A/S","2021-07-15","TRUE","0"],["S000042","ClinicalTrials.gov","NCT03235375",null,"A Phase 1, Open-Label, Single Dose, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of MEDI0382 in Subjects With Renal Impairment","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","37","Renal Insufficiency","DRUG:MEDI0382","MedImmune LLC","2017-10-27","FALSE","3"],["S000043","ClinicalTrials.gov","NCT05691712","SURPASS-CN-INS","A Randomized, Phase 3, Double Blind Trial Comparing the Effect of the Addition of Tirzepatide Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Participants With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","257","Diabetes Type 2; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Disease; Endocrine System Diseases","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-02-05","TRUE","1"],["S000044","ClinicalTrials.gov","NCT00931372","RESTORE","Restoration of First Phase Insulin Release in Subjects With Type 2 Diabetes Mellitus With Subcutaneous Injection of 20 µg AVE0010 in a Double-blind, Randomized, Placebo-controlled, Two-way Cross Over Intravenous Glucose Challenge Study.","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","22","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo","Sanofi","2009-06","FALSE","0"],["S000045","ClinicalTrials.gov","NCT01518166",null,"A Two-way Cross-over, Placebo-controlled Interaction Trial in Two Parts (in Healthy Subjects), Studying Liraglutide's Potential Influence on the Absorption Pharmacokinetics of Lisinopril, Atorvastatin, Griseofulvin and Digoxin, and Liraglutide's Potential Influence on Intragastric pH","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","70","Diabetes; Healthy","DRUG:liraglutide; DRUG:placebo; DRUG:atorvastatin; DRUG:lisinopril; DRUG:griseofulvin; DRUG:digoxin","Novo Nordisk A/S","2006-05","FALSE","1"],["S000046","ClinicalTrials.gov","NCT03495102","AWARD-11","A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1842","Diabetes Mellitus, Type 2","DRUG:Dulaglutide","Eli Lilly and Company","2018-04-05","TRUE","3"],["S000047","ClinicalTrials.gov","NCT04847557",null,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","731","Obesity; Heart Failure With Preserved Ejection Fraction (HFpEF)","DRUG:Tirzepatide; OTHER:Placebo","Eli Lilly and Company","2021-04-20","TRUE","10"],["S000048","ClinicalTrials.gov","NCT03068065",null,"Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD)","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","87","Non-Alcoholic Fatty Liver Disease; Type2 Diabetes","DRUG:Liraglutide; DRUG:Metformin; DRUG:Gliclazide","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2014-05","FALSE","0"],["S000049","ClinicalTrials.gov","NCT02974244",null,"A Cohort Study of the Benefits of Bydureon in Customary Clinical Care in the United States","OBSERVATIONAL",null,null,"COMPLETED","7000","Type 2 Diabetes","DRUG:exenatide once weekly; DRUG:basal insulin","AstraZeneca","2014-10-28","FALSE","0"],["S000050","ClinicalTrials.gov","NCT01208649",null,"Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","13","Nonalcoholic Fatty Liver Disease","DRUG:Exenatide","Ruhr University of Bochum","2008-07","FALSE","0"],["S000051","ClinicalTrials.gov","NCT00775684",null,"A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","47","Pre-diabetes; Type 2 Diabetes","DRUG:Exenatide; DRUG:Sitagliptin; DRUG:Glimepiride","University of Pennsylvania","2008-10","TRUE","0"],["S000052","ClinicalTrials.gov","NCT00111540",null,"An Open Label Study to Examine the Long Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE3","COMPLETED","456","Diabetes Mellitus, Type 2","DRUG:exenatide","AstraZeneca","2002-11","FALSE","5"],["S000053","ClinicalTrials.gov","NCT07859150",null,"Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE): a Randomized, Double-Blind, Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","104","Morbid Obesity","DRUG:Semaglutide weekly injection; DRUG:Placabo","General Committee of Teaching Hospitals and Institutes, Egypt","2026-10","FALSE","0"],["S000054","ClinicalTrials.gov","NCT07172867",null,"A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study to Evaluate the Safety, Efficacy and Tolerability of Ofirnoflast (HT-6184) and Semaglutide in Obese or Overweight Participants With Type 2 Diabetes Mellitus (T2DM)","INTERVENTIONAL","RANDOMIZED","PHASE2","WITHDRAWN","0","Diabetes Mellitus, Type 2; Obesity","DRUG:HT-6184; DRUG:HT-6184 Matching Placebo; DRUG:Semaglutide 1 mg","Halia Therapeutics, Inc.","2026-01-06","FALSE","0"],["S000055","ClinicalTrials.gov","NCT01664624",null,"A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on a Stable Dose of Metformin","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","40","Type 2 Diabetes","DRUG:Roflumilast; DRUG:Alogliptin; DRUG:Exenatide; DRUG:Placebo to roflumilast; DRUG:Placebo to alogliptin","AstraZeneca","2012-07","TRUE","0"],["S000056","ClinicalTrials.gov","NCT02754817",null,"A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus","OBSERVATIONAL",null,null,"COMPLETED","611","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide","Novo Nordisk A/S","2016-04-26","FALSE","1"],["S000057","ClinicalTrials.gov","NCT06994650",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","140","Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy","DRUG:HRS9531; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-08-13","FALSE","0"],["S000058","ClinicalTrials.gov","NCT02325960",null,"A Comparison of Exenatide and Insulin Glargine on Glycemic Variability in T2DM Patients Inadequately Controlled With Metformin Monotherapy","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","44","Type 2 Diabetes","DRUG:exenatide; DRUG:Insulin glargine","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2015-01","FALSE","1"],["S000059","ClinicalTrials.gov","NCT01508923",null,"Effect of NNC 90-1170 on 24-hour Glucose and Hormonal Profiles, Gastric Emptying, and Fasting Gluconeogenesis in Type 2 Diabetic Subjects. A Double-blind, Placebo-controlled, Randomised, Cross-over Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","17","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2001-05","FALSE","1"],["S000060","ClinicalTrials.gov","NCT00518115",null,"A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, With Byetta as an Open Label Active Reference, in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","361","Diabetes Mellitus, Type 2","DRUG:Albiglutide (GSK716155) or exenatide","GlaxoSmithKline","2007-04","TRUE","2"],["S000061","ClinicalTrials.gov","NCT05662189",null,"Assessment of Pancreatic Beta Cell Mass and Function with the Aid of Positron Emission Tomography Imaging in Human Diabetes Mellitus","INTERVENTIONAL","NON_RANDOMIZED",null,"RECRUITING","70","Type1diabetes; Type2diabetes; Pre Diabetes; Hyperinsulinism","DRUG:68Ga-exendin-4; OTHER:mixed meal test","Azienda Ospedaliero-Universitaria di Parma","2022-03-15","FALSE","0"],["S000062","ClinicalTrials.gov","NCT04185350",null,"Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma","INTERVENTIONAL",null,"EARLY_PHASE1","UNKNOWN","60","Insulinoma","DRUG:68Ga-NOTA-MAL-Cys39-exendin-4","Nanjing First Hospital, Nanjing Medical University","2019-05-05","FALSE","0"],["S000063","ClinicalTrials.gov","NCT01654120",null,"Liraglutide and Insulin-001 A Randomized Prospective Trial of Liraglutide Added to High-Dose Insulin Therapy vs. High-Dose Insulin Therapy Alone in Insulin-Resistant Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","37","Diabetes Mellitus, Type II","DRUG:Liraglutide; DRUG:Insulin","Mountain Diabetes and Endocrine Center","2011-12","FALSE","0"],["S000064","ClinicalTrials.gov","NCT05946148","NAMELS-18","Effect of Dulaglutide vs Empagliflozin on Non-alcoholic Fatty Liver Disease of Patients With Type 2 Diabetes Mellitus","OBSERVATIONAL",null,null,"COMPLETED","78","Non-Alcoholic Fatty Liver Disease; Liver Steatosis","DRUG:Empagliflozin; DRUG:Dulaglutide; DRUG:Control Rx","National and Kapodistrian University of Athens","2018-06-01","FALSE","0"],["S000065","ClinicalTrials.gov","NCT00845182","PIO-EX","Effect of Pioglitazone With and Without Exenatide on Body Weight, Fat Topography, Beta Cell Function, and Glycemic Control in Type 2 Diabetic Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","43","Type 2 Diabetes; Healthy; Impaired Glucose Tolerance","DRUG:Pioglitazone; DRUG:Exenatide; DRUG:Pioglitazone and Exenatide","The University of Texas Health Science Center at San Antonio","2007-06","TRUE","0"],["S000066","ClinicalTrials.gov","NCT06716424",null,"Multicentre Phase IV Single Arm Clinical Trial to Evaluate the Safety and Efficacy of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in Adult Patients With Type 2 Diabetes Who Are Sub Optimally Controlled on Oral Anti-hyperglycemic Drugs and/or Basal Insulin/GLP-1 RA","INTERVENTIONAL",null,"PHASE4","COMPLETED","105","Type 2 Diabetes","DRUG:iGlarLixi (insulin glargine/lixisenatide)","Sanofi","2025-01-06","FALSE","0"],["S000067","ClinicalTrials.gov","NCT07702461",null,"Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists","OBSERVATIONAL",null,null,"RECRUITING","300","Obesity & Overweight; Diabetes (DM)","DRUG:Glucagon-Like Peptide-1 Agonist (GLP-1)","Ohio State University","2026-06-12","FALSE","4"],["S000068","ClinicalTrials.gov","NCT06732245",null,"A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","224","Obesity and Overweight","DRUG:NA-931; DRUG:Tirzepatide; DRUG:NA-931 150 mg + no Tirzepatide","Biomed Industries, Inc.","2026-08-15","FALSE","0"],["S000069","ClinicalTrials.gov","NCT04537637","PIONEER REAL","A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Denmark","OBSERVATIONAL",null,null,"COMPLETED","99","Diabetes Mellitus, Type 2","DRUG:Oral Semaglutide","Novo Nordisk A/S","2020-08-28","FALSE","2"],["S000070","ClinicalTrials.gov","NCT06629688",null,"The Effect of Parenterally Administred Semaglutide on Intestinal Iron Absorption in Individuals With Type 2 Diabetes Mellitus","INTERVENTIONAL",null,null,"COMPLETED","51","Diabetes Mellitus Type 2; Iron Absorption","DRUG:semaglutide","University Hospital Dubrava","2023-11-01","FALSE","0"],["S000071","ClinicalTrials.gov","NCT07064486",null,"A Phase 3, Randomized, Open Label Trial Comparing Efficacy and Safety of BGM0504 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","152","Type 2 Diabetes (T2DM)","DRUG:BGM0504; DRUG:Semaglutide","BrightGene Bio-Medical Technology Co., Ltd.","2025-07-04","FALSE","0"],["S000072","ClinicalTrials.gov","NCT05714683",null,"A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus® (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","600","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2027-01-31","FALSE","0"],["S000073","ClinicalTrials.gov","NCT05413369",null,"A Randomized, 24 Weeks, Active-controlled, Open-label, 2-arm Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to IDegAsp in Chinese Type 2 Diabetes Mellitus Participants Insufficiently Controlled With Oral Antidiabetic Drug(s)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","582","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide; DRUG:IDegAsp; DRUG:Metformin; DRUG:SGLT2 inhibitor","Sanofi","2022-07-07","TRUE","6"],["S000074","ClinicalTrials.gov","NCT07284979","KaiNETIC-3","A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","1270","Obesity","DRUG:Ribupatide; DRUG:Semaglutide; DRUG:Placebo","Kailera","2025-12-30","FALSE","0"],["S000075","ClinicalTrials.gov","NCT01484262",null,"Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2","OBSERVATIONAL",null,null,"COMPLETED","1344","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:insulin","Novo Nordisk A/S","2011-11-14","FALSE","1"],["S000076","ClinicalTrials.gov","NCT06492330",null,"A Multi-center, Randomized, Double-blind, Placebo-controlled Proof of Concept Study Evaluating the Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","62","Metabolic Dysfunction-Associated Steatohepatitis (MASH); Obesity; Diabetes Mellitus, Type 2","DRUG:CS0159; DRUG:CS0159 placebo","Shanghai Jiao Tong University School of Medicine","2024-07-19","FALSE","0"],["S000077","ClinicalTrials.gov","NCT07783854",null,"Evaluation of a Semaglutide Dose-Tapering Regimen for Weight-Loss Maintenance in Adults With Overweight or Obesity: A Randomized, Non-Inferiority, Open-Label Clinical Study","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","72","Obesity & Overweight","DRUG:Semaglutide Dose-Tapering Regimen; DRUG:Semaglutide Maintenance-Dose Regimen","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2026-09-01","FALSE","0"],["S000078","ClinicalTrials.gov","NCT04081337",null,"A Randomized, Placebo-Controlled, Parallel-Arm Study to Investigate the Effect of Once-Weekly Tirzepatide on Energy Expenditure and Food Intake in Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","55","Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2020-07-09","TRUE","1"],["S000079","ClinicalTrials.gov","NCT06489457","SEMAT","The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","25","Type 2 Diabetes Mellitus; Obesity; Functional Hypogonadism","DRUG:Semaglutide; DRUG:Testosterone Undecanoate","University Medical Centre Ljubljana","2020-09-20","FALSE","1"],["S000080","ClinicalTrials.gov","NCT01296412",null,"A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","653","Diabetes Mellitus, Type 2","DRUG:sitagliptin; DRUG:liraglutide; DRUG:glimepiride; DRUG:metformin","Merck Sharp & Dohme LLC","2011-03-11","TRUE","1"],["S000081","ClinicalTrials.gov","NCT03172494","DUAL™ I China","A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","720","Diabetes; Diabetes Mellitus, Type 2","DRUG:Insulin degludec/liraglutide; DRUG:Insulin degludec; DRUG:Liraglutide","Novo Nordisk A/S","2017-05-26","TRUE","1"],["S000082","ClinicalTrials.gov","NCT01436201",null,"Effect of Dulaglutide (LY2189265) on the Pharmacokinetics of Digoxin in Healthy Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","24","Diabetes Mellitus, Type 2","DRUG:Digoxin; BIOLOGICAL:Dulaglutide","Eli Lilly and Company","2011-09","TRUE","1"],["S000083","ClinicalTrials.gov","NCT07216651",null,"WeDosify Real-World Evidence: Evaluating a Clinical Decision Support and Patient Engagement Tool for Personalized Semaglutide Dosing in Adults With Overweight or Obesity in the United States","OBSERVATIONAL",null,null,"COMPLETED","20","Obesity & Overweight",null,"Closed Loop Medicine","2025-09-23","FALSE","0"],["S000084","ClinicalTrials.gov","NCT03457012","SURE CANADA","SURE CANADA: A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once Weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","462","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2018-03-29","FALSE","2"],["S000085","ClinicalTrials.gov","NCT03059719",null,"A Randomized, Open, Comparative to the Positive-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects Newly Diagnosed as Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","36","Type II Diabetes Mellitus","BIOLOGICAL:Exenatide injection(Byetta); BIOLOGICAL:PB-119 injection","PegBio Co., Ltd.","2015-04-08","FALSE","0"],["S000086","ClinicalTrials.gov","NCT06313528",null,"A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","85","Obesity","DRUG:LY3437943; OTHER:Placebo","Eli Lilly and Company","2024-03-20","FALSE","0"],["S000087","ClinicalTrials.gov","NCT06946628",null,"Combination Therapy With Semaglutide, Empagliflozin and Pioglitazone Versus Standard Therapy in Newly Diagnosed Type 2 Diabetes: a Multi-center Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","296","Diabetes Mellitus","DRUG:Group A (triple combination therapy group); DRUG:Group B (standard therapy group)","Sun Yat-sen University","2025-06-01","FALSE","0"],["S000088","ClinicalTrials.gov","NCT07715929","TEAR-AF","Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients: A Multicenter, Randomized, Open-Label Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","710","Atrial Fibrillation; Obesity & Overweight; Catheter Ablation","DRUG:Tirzepatide; BEHAVIORAL:Structured Lifestyle Intervention","Yunlong Wang","2026-09-01","FALSE","0"],["S000089","ClinicalTrials.gov","NCT04616339",null,"A 2-PART, PHASE 1, OPEN LABEL STUDY WITH A 4-PERIOD, 4-SEQUENCE, CROSSOVER DESIGN IN COHORT 1 AND A 2-PERIOD, 2-SEQUENCE CROSSOVER DESIGN IN COHORT 2 TO COMPARE THE SINGLE DOSE PHARMACOKINETICS OF FIVE DIFFERENT FORMULATIONS OF PF-06882961 ADMINISTERED ORALLY TO OTHERWISE HEALTHY ADULT PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","31","Overweight and/or Obesity","DRUG:PF-06882961 100 mg","Pfizer","2020-11-04","FALSE","0"],["S000090","ClinicalTrials.gov","NCT05140694",null,"A Randomized, Active-comparator Controlled, Parallel-group Study, to Evaluate the Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","135","Metabolic-associated Fatty Liver Disease; Type 2 Diabetes","DRUG:Empagliflozin; DRUG:Dulaglutide; DRUG:Empagliflozin and Dulaglutide","Seoul National University Bundang Hospital","2023-12-01","FALSE","0"],["S000091","ClinicalTrials.gov","NCT07225829","INFLAM MOTION","A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof of Concept Trial to Investigate the Efficacy and Safety of Intra-articular 4P004 in Subjects With Knee Synovitis and Osteoarthritis","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","129","Knee Osteoarthritis; Synovitis of Knee","DRUG:4P004; DRUG:Placebo (NaCl 0.9%)","4Moving Biotech","2025-06-17","FALSE","0"],["S000092","ClinicalTrials.gov","NCT04325581",null,"Effect of Laparoscopic Sleeve Gastrectomy and Liraglutide on Glucose Homeostasis and Intrapancreatic Fat in Obese Patients","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","16","Weight Loss","DRUG:Liraglutide 6 MG/ML; DRUG:Placebos","Post Graduate Institute of Medical Education and Research, Chandigarh","2016-08-01","FALSE","0"],["S000093","ClinicalTrials.gov","NCT05822830","SURMOUNT-5","A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","751","Obesity; Overweight","DRUG:Tirzepatide; DRUG:Semaglutide","Eli Lilly and Company","2023-04-21","TRUE","5"],["S000094","ClinicalTrials.gov","NCT02584075",null,"Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function","INTERVENTIONAL",null,"PHASE4","UNKNOWN","100","Coronary Endothelial Function","DRUG:Byetta (Exenatide); DRUG:Glucophage ( Metformin Hydrochloride)","Beijing Chao Yang Hospital","2015-11","FALSE","0"],["S000095","ClinicalTrials.gov","NCT03987919","SURPASS-2","A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1879","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Semaglutide","Eli Lilly and Company","2019-07-30","TRUE","9"],["S000096","ClinicalTrials.gov","NCT03426085",null,"The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","44","Autonomic Nervous System Diseases; Sweat Gland Diseases; Diabetic Neuropathy With Neurologic Complication","DRUG:Liraglutide 6 mg Solution for Injection; OTHER:Placebo","Eastern Virginia Medical School","2016-05","FALSE","0"],["S000097","ClinicalTrials.gov","NCT01475734",null,"A Single-site, Randomized, Double-blind, Placebo-controlled, Parallel-group, Stepped Glucose Clamp Study to Assess the Effects of Albiglutide on Counter-regulatory Hormone Responses and Recovery From Hypoglycemia in Subjects With Type 2 Diabetes Mellitus.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","44","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; BIOLOGICAL:placebo","GlaxoSmithKline","2011-12","TRUE","2"],["S000098","ClinicalTrials.gov","NCT04067999","SURE SPAIN","SURE SPAIN: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","230","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2019-08-05","FALSE","0"],["S000099","ClinicalTrials.gov","NCT00838916",null,"A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","779","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; DRUG:insulin glargine","GlaxoSmithKline","2009-02","TRUE","4"],["S000100","ClinicalTrials.gov","NCT02650206",null,"Effect of Liraglutide on Macrophage Polarization in Human Adipose Tissue and Peripheral Blood","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","56","Diabetes Mellitus, Type 2; Diabetes Mellitus, Type II; Diabetes Mellitus, Adult-Onset; Inflammation","DRUG:Victoza (liraglutide) with dietician monitoring; OTHER:Placebo with dietician monitoring","Stanford University","2015-01","FALSE","0"],["S000101","ClinicalTrials.gov","NCT05841238",null,"A Multiple Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tablet and Capsule Formulations of LY3502970 in Healthy Overweight and Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","52","Healthy; Obese","DRUG:LY3502970","Eli Lilly and Company","2023-04-26","TRUE","0"],["S000102","ClinicalTrials.gov","NCT07847593","ProSem","The Effect of Probiotics on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Therapy in Patients With Obesity: A Randomized, Double-Blind, Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","102","Obesity (Disorder); GLP-1 Receptor Agonist Treatment; Probiotic Intervention; Diabetes Mellitus Type 2","DIETARY_SUPPLEMENT:Four-strain probiotic formulation; DIETARY_SUPPLEMENT:Maltodextrin (Placebo)","Nordic Biotic Sp. z o.o.","2025-07-09","FALSE","0"],["S000103","ClinicalTrials.gov","NCT02717858",null,"A Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","52","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2016-03-16","FALSE","1"],["S000104","ClinicalTrials.gov","NCT05268627",null,"Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","38","Obesity","DRUG:Liraglutide","Mansoura University","2022-01-27","FALSE","2"],["S000105","ClinicalTrials.gov","NCT05220917","CER-4-T2D","Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","781430","Cardiovascular Events; Type2 Diabetes; Renal Disease","DRUG:SGLT2 inhibitor; DRUG:DPP-4 inhibitor; DRUG:GLP-1RA; DRUG:2nd generation SU","Brigham and Women's Hospital","2021-08-01","FALSE","0"],["S000106","ClinicalTrials.gov","NCT05438186","INSPIRE Turkey","A Retrospective, Multi-centre, Non-interventional Study Investigating the Clinical Parameters Associated With Saxenda® Use and Discontinuation in Patients in Turkey. INSPIRE Turkey (INvestigate the Impact of Saxenda® on Patient's Weight In a REal World Setting in Turkey) Study","OBSERVATIONAL",null,null,"WITHDRAWN","0","Obesity","DRUG:Liraglutide","Novo Nordisk A/S","2022-09-01","FALSE","0"],["S000107","ClinicalTrials.gov","NCT04307797","COCONUT","A Pilot Study on the Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes (COCONUT)","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","10","Type 2 Diabetes; Obesity","DRUG:0.9% Sodium-chloride; DRUG:Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min; DRUG:Glucagon 12.5ng/kg/min and 0.9% saline; DRUG:Glucagon 12.5ng/kg/min","Cambridge University Hospitals NHS Foundation Trust","2022-01-18","FALSE","0"],["S000108","ClinicalTrials.gov","NCT04537923","SURPASS-6","A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1428","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Insulin Lispro (U100)","Eli Lilly and Company","2020-10-19","TRUE","3"],["S000109","ClinicalTrials.gov","NCT05324462","SPIRIT","Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia - A Single-arm, Non-interventional Retrospective Chart Review Study","OBSERVATIONAL",null,null,"COMPLETED","175","Diabetes Mellitus, Type 2","DRUG:IDegLira","Novo Nordisk A/S","2022-03-22","FALSE","2"],["S000110","ClinicalTrials.gov","NCT04238962",null,"A Trial to Demonstrate Bioequivalence Between the Semaglutide D Formulation for the DV3396 Pen-Injector and the Formulation for the PDS290 Pen-Injector Following Subcutaneous Administration of 2 mg Semaglutide","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","111","Overweight; Obesity","DRUG:Semaglutide (administered by DV3396 pen-injector); DRUG:Semaglutide (administered by PDS290 pen-injector)","Novo Nordisk A/S","2020-02-03","FALSE","0"],["S000111","ClinicalTrials.gov","NCT06118203",null,"Evaluation of Circulating Endothelial Inflammatory Biomarkers in Response to GLP-1 Agonist Semaglutide in Acute Pulmonary Embolism","OBSERVATIONAL",null,null,"COMPLETED","18","Pulmonary Embolism","DRUG:Semaglutide","Imperial College London","2022-01-02","FALSE","1"],["S000112","ClinicalTrials.gov","NCT06662383","TRIUMPH-5","A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","800","Obesity","DRUG:Retatrutide; DRUG:Tirzepatide","Eli Lilly and Company","2024-11-01","FALSE","0"],["S000113","ClinicalTrials.gov","NCT07843862",null,"A Phase II, Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of HRS-4729 Injection in Participants With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","240","Type 2 Diabetes","DRUG:HRS-4729 Injection; DRUG:Mazdutide; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-10","FALSE","0"],["S000114","ClinicalTrials.gov","NCT01592279",null,"GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","124","Uncontrolled Type 1 Diabetic Patients","DRUG:liraglutide; DRUG:Insulin injections","Hadassah Medical Organization","2012-06","FALSE","0"],["S000115","ClinicalTrials.gov","NCT03204396","SKIP","Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues - a Randomized, Double-blind, Placebo-controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","256","Glucagon-like Peptide-1; Smoking Cessation; Weight Change, Body; Craving","DRUG:Dulaglutide; DRUG:0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])","University Hospital, Basel, Switzerland","2017-06-26","FALSE","6"],["S000116","ClinicalTrials.gov","NCT02847403","DRINN","Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment?","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","40","Dysglycemia; Cognitive Deficit","DRUG:Exenatide; OTHER:placebo","Azienda Ospedaliero-Universitaria di Parma","2016-02","FALSE","3"],["S000117","ClinicalTrials.gov","NCT01272973",null,"Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","96","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2011-01","FALSE","0"],["S000118","ClinicalTrials.gov","NCT07184086",null,"The Effect of Cagrilintide and Semaglutide Combination Treatment Compared to a Weight-loss Inducing Diet on Energy Metabolism in Persons Living With Obesity: an Open-label Randomised Study","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","80","Obesity","DRUG:CagriSema (Cagrilintide B + semaglutide I); BEHAVIORAL:Low Energy Diet","Novo Nordisk A/S","2025-09-26","FALSE","0"],["S000119","ClinicalTrials.gov","NCT07254572","CASCADES","A Randomized, Open-label, Clinical Trial Evaluating the Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","300","Coronary Artery Disease; PreDiabetes","DRUG:Semaglutide 14 MG [Rybelsus]; DRUG:Dapagliflozin (Forxiga); DRUG:Metformin; BEHAVIORAL:Optimal Medical Therapy (OMT) And Lifestyle Intervention","National Institute of Cardiology, Warsaw, Poland","2025-07-10","FALSE","0"],["S000120","ClinicalTrials.gov","NCT06914141","DUP-TIRZSEMA","Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction","OBSERVATIONAL",null,null,"COMPLETED","28118","Diabetes Mellitus, Type 2; HFpEF - Heart Failure With Preserved Ejection Fraction","DRUG:Tirzepatide; DRUG:Semaglutide","Brigham and Women's Hospital","2025-01-14","FALSE","1"],["S000121","ClinicalTrials.gov","NCT07213466","OBOE-Mayo","Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder - OBOE-Mayo","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","RECRUITING","100","Bipolar I Disorder; Bipolar II Disorder; Schizo Affective Disorder; Obesity; Weight Loss; GLP - 1","BEHAVIORAL:Group Therapy Program; DRUG:semaglutide; DRUG:Phentermine-Topiramate; DRUG:naltrexone and bupropion (combination)","Mayo Clinic","2026-01-19","FALSE","0"],["S000122","ClinicalTrials.gov","NCT07150975",null,"A Multicenter, Randomized, Open-Label, Parallel-Group Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide(Wegovy®) in Adult Obese or Overweight Subjects","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","420","Obesity/Overweight in Adult","DRUG:GZR18; DRUG:Semaglutide(Wegovy® )","Gan & Lee Pharmaceuticals.","2025-09-23","FALSE","0"],["S000123","ClinicalTrials.gov","NCT07223983",null,"Semaglutide Treatment for Alcohol Use Disorder After Metabolic and Bariatric Surgery: A Pilot Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","4","Alcohol Use Disorder; Weight Loss; Bariatric Surgery Patients","DRUG:Semaglutide 1.0 mg","Yale University","2026-03-26","FALSE","1"],["S000124","ClinicalTrials.gov","NCT02870231",null,"A Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","187","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC9204-0530; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2016-08-18","FALSE","0"],["S000125","ClinicalTrials.gov","NCT06042153",null,"Semaglutide for Dialysis-Treated Patients - a Glucose Time in Range Study- DIALYSIS-TIR Study","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","43","Type 2 Diabetes; End Stage Renal Disease on Dialysis","DRUG:Semaglutide; DRUG:Placebo","University of Texas Southwestern Medical Center","2023-12-05","FALSE","0"],["S000126","ClinicalTrials.gov","NCT07317115","MAGvMED","Magnetic Compression Anastomosis in Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes (MAGvMED Study)","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","20","Obesity (Disorder); Obesity & Overweight; Type 2 Diabetes (T2DM)","DEVICE:Magnet System; DRUG:Semaglutide","GT Metabolic Solutions, Inc.","2026-03-18","FALSE","0"],["S000127","ClinicalTrials.gov","NCT03482024",null,"Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","45","Renal Insufficiency; End Stage Renal Disease","DRUG:Tirzepatide","Eli Lilly and Company","2018-03-30","TRUE","1"],["S000128","ClinicalTrials.gov","NCT07309094","ADIPO-CKD","Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease","OBSERVATIONAL",null,null,"RECRUITING","250","Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Obesity; Diabetes Mellitus, Type 2","DRUG:GLP-1 receptor agonist; DRUG:SGLT2 inhibitor; DRUG:Tirzepatide; DRUG:Other drugs","Cardenal Herrera University","2023-09-15","FALSE","7"],["S000129","ClinicalTrials.gov","NCT07340437",null,"Clinical Study of an ¹⁸F-labeled GLP-1R Probe in Insulinoma","OBSERVATIONAL",null,null,"COMPLETED","20","Insulinoma",null,"Sichuan Provincial People's Hospital","2023-02-01","FALSE","0"],["S000130","ClinicalTrials.gov","NCT05418907","ENTRAP","Exendin PET/CT for Paragangliomas","OBSERVATIONAL",null,null,"UNKNOWN","10","Paraganglioma","RADIATION:68Ga-NODAGA-exendin-4 PET/CT","Radboud University Medical Center","2022-06-01","FALSE","1"],["S000131","ClinicalTrials.gov","NCT07349641",null,"Tirzepatide With Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer in Overweight and Obese Women","INTERVENTIONAL",null,"PHASE2","NOT_YET_RECRUITING","55","Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma","OTHER:Medical Device Usage and Evaluation; DRUG:Tirzepatide","National Cancer Institute (NCI)","2026-11-01","FALSE","0"],["S000132","ClinicalTrials.gov","NCT07218445",null,"The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity: A Pilot Study","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","40","Obesity; Menopause Hot Flashes","DRUG:Tirzepatide; DRUG:Placebo","Mayo Clinic","2026-04-08","FALSE","0"],["S000133","ClinicalTrials.gov","NCT02863419","PIONEER 4","Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","711","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2016-08-10","TRUE","11"],["S000134","ClinicalTrials.gov","NCT06568731",null,"A PHASE 1, OPEN- LABEL STUDY TO EVALUATE THE MULTIPLE DOSE PHARMACOKINETICS OF DANUGLIPRON FOLLOWING ORAL ADMINISTRATION IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY","INTERVENTIONAL",null,"PHASE1","COMPLETED","23","Obesity","DRUG:Danuglipron","Pfizer","2024-08-23","FALSE","0"],["S000135","ClinicalTrials.gov","NCT00696657",null,"Investigation of Safety and Efficacy of Five Doses of Semaglutide Versus Placebo and Open-label Liraglutide, as Add on Therapy, in Subjects Diagnosed With Type 2 Diabetes Currently Treated With Metformin or Controlled With Diet and Exercise A 12 Week Multi-centre, Multi National, Double-blind, Placebo-controlled, Randomised, Nine Armed Parallel Group, Dose Finding Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","415","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo; DRUG:liraglutide","Novo Nordisk A/S","2008-06-03","TRUE","2"],["S000136","ClinicalTrials.gov","NCT06534411","REIMAGINE 5","Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1023","Diabetes Mellitus, Type 2","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Tirzepatide","Novo Nordisk A/S","2024-11-05","FALSE","0"],["S000137","ClinicalTrials.gov","NCT06409130",null,"Effects of NNC0194-0499 Alone and in Combination With Semaglutide, of Semaglutide Alone, and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","270","Alcohol-related Liver Disease","DRUG:NNC0194-0499; DRUG:Semaglutide; DRUG:NNC0194-0499 placebo; DRUG:Semaglutide placebo (Group A); DRUG:Cagrilintide + semaglutide; DRUG:Cagrilintide; DRUG:Cagrilintide placebo; DRUG:Semaglutide placebo (Group B)","Novo Nordisk A/S","2024-05-20","FALSE","0"],["S000138","ClinicalTrials.gov","NCT04575844","ZQL008","Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","80","Metabolic Syndrome","DRUG:Liraglutide; OTHER:Exercise training; DRUG:Liraglutide + Exercise training","University of Virginia","2020-11-01","FALSE","3"],["S000139","ClinicalTrials.gov","NCT01784965",null,"Addition of a Glucagon-like Peptide-1 to a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and Cardiovascular Disease.","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","69","Pre-diabetes; Older Adults","DRUG:liraglutide; DRUG:Placebo","Stanford University","2009-12","TRUE","2"],["S000140","ClinicalTrials.gov","NCT04965506",null,"A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","252","Type 2 Diabetes","DRUG:IBI362; OTHER:placebo; OTHER:Dulaglutide","Innovent Biologics (Suzhou) Co. Ltd.","2021-09-06","FALSE","1"],["S000141","ClinicalTrials.gov","NCT05564104",null,"A Study Investigating the Pharmacokinetic Properties of Cagrilintide in Participants With Various Degrees of Hepatic Impairment and Assessing the Absolute Bioavailability of Subcutaneous Cagrilintide in Healthy Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Hepatic Impairment; Healthy Volunteers","DRUG:Cagrilintide","Novo Nordisk A/S","2023-04-05","FALSE","1"],["S000142","ClinicalTrials.gov","NCT02660047","MAGNA VICTORIA","Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","51","Diabetes Mellitus Type 2; Metabolic Syndrome; Cardiovascular Disease; Diastolic Dysfunction; Fatty Liver","DRUG:Liraglutide; DRUG:Liraglutide - Placebo","Leiden University Medical Center","2015-08","FALSE","4"],["S000143","ClinicalTrials.gov","NCT06780449",null,"Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","400","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2025-02-10","FALSE","0"],["S000144","ClinicalTrials.gov","NCT03548935","STEP 1","Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1961","Metabolism and Nutrition Disorder; Overweight or Obesity","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2018-06-04","TRUE","17"],["S000145","ClinicalTrials.gov","NCT07834398",null,"Evaluating the Efficacy of Various Weekly GLP1receptor Agonist Among Obese Individuals Without Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","150","Non-diabetec Obesity; Obesity (Disorder)","DRUG:Dulaglutide; DRUG:Semagludtide; DRUG:Tirzepatide","Zagazig University","2025-11-14","FALSE","0"],["S000146","ClinicalTrials.gov","NCT00529204",null,"Effects Of Exenatide (Byetta®) On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Non-Alcoholic Fatty Liver Disease","INTERVENTIONAL",null,"PHASE2","TERMINATED","1","Diabetes Complications; Fatty Liver","DRUG:exenatide","University of California, Davis","2007-10","TRUE","1"],["S000147","ClinicalTrials.gov","NCT01394952","REWIND","The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","9901","Cardiovascular Disease; Diabetes Mellitus, Type 2","DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2011-07-22","TRUE","21"],["S000148","ClinicalTrials.gov","NCT07660848",null,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Master Protocol Clinical Trial to Investigate the Efficacy and Safety of HRS-4729 Injection and HRS9531 Injection in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","160","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","DRUG:HRS-4729 Injection; DRUG:HRS9531 Injection; DRUG:HRS-4729 Injection Placebo; DRUG:HRS9531 Injection Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-08-14","FALSE","0"],["S000149","ClinicalTrials.gov","NCT05669755","REDEFINE 3","The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","7101","Cardiovascular Disease","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2023-03-01","FALSE","1"],["S000150","ClinicalTrials.gov","NCT06948435",null,"A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","487","Hypertension; Overweight or Obesity","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-04-30","FALSE","0"],["S000151","ClinicalTrials.gov","NCT03244800",null,"A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Different Doses of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","65","Type 2 Diabetes Mellitus","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2017-09-04","TRUE","2"],["S000152","ClinicalTrials.gov","NCT01269034",null,"New Onset Type 1 Diabetes: Role of Exenatide","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","13","Type 1 Diabetes","DRUG:Exenatide; DRUG:Rapid and long acting insulin; DRUG:long acting insulin + rapid acting + 1.25 mcg Exenatide","Albert Einstein College of Medicine","2010-12","TRUE","0"],["S000153","ClinicalTrials.gov","NCT01890993",null,"Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe","OBSERVATIONAL",null,null,"COMPLETED","952","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2013-08","FALSE","0"],["S000154","ClinicalTrials.gov","NCT07770152","GLP1","Semaglutide for Metabolic and Adiposity-Related Targets in Youth With Autism Spectrum Disorder (SMART-ASD)","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","NOT_YET_RECRUITING","42","Autism Spectrum Disorder; Obesity","DRUG:Glucagon-like peptide-1 receptor agonist：Semaglutide; BEHAVIORAL:Lifestyle Management (LSM) Counseling","Children's Hospital Medical Center, Cincinnati","2026-09-01","FALSE","0"],["S000155","ClinicalTrials.gov","NCT05259033","COMBINE 2","A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Semaglutide, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With a GLP 1 Receptor Agonist. COMBINE 2","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","683","Diabetes Mellitus, Type 2","DRUG:IcoSema; DRUG:Semaglutide 1 mg","Novo Nordisk A/S","2022-04-11","TRUE","2"],["S000156","ClinicalTrials.gov","NCT05412004","SURMOUNT-OSA","A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","469","Obstructive Sleep Apnea; Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2022-06-21","TRUE","15"],["S000157","ClinicalTrials.gov","NCT07204249","GEM","Glutide for Ending Methamphetamine","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","162","Methamphetamine-dependence","DRUG:Semaglutide; DRUG:Placebo","San Francisco Department of Public Health","2026-02-26","FALSE","0"],["S000158","ClinicalTrials.gov","NCT07223593","ATTAIN-PAD","A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","1205","Peripheral Arterial Disease","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-10-31","FALSE","0"],["S000159","ClinicalTrials.gov","NCT02963922","SCALE™ Insulin","Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","396","Metabolism and Nutrition Disorder; Obesity","DRUG:Liraglutide 3.0 mg; DRUG:Placebo","Novo Nordisk A/S","2017-02-06","TRUE","1"],["S000160","ClinicalTrials.gov","NCT02518945",null,"Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes. A Randomized Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","26","Type 1 Diabetes Mellitus","DRUG:Dapagliflozin; DRUG:Insulin; DRUG:Liraglutide; DRUG:Dapagliflozin placebo","University at Buffalo","2015-08","TRUE","1"],["S000161","ClinicalTrials.gov","NCT04916470","STEP HFpEF DM","Effect of Semaglutide 2.4 mg Once-weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction, and Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","617","Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (Semaglutide)","Novo Nordisk A/S","2021-06-15","FALSE","14"],["S000162","ClinicalTrials.gov","NCT04938388",null,"Comparison of Oral Semaglutide With Matched Oral Semaglutide Placebo as an Early Treatment for Latino Adults With Type 2 Diabetes Receiving Enhanced Lifestyle Care","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","12","Diabetes Mellitus, Type 2; Glucose Metabolism Disorders (Including Diabetes Mellitus)","DRUG:Semaglutide Pill; DIETARY_SUPPLEMENT:Fresh organic vegetables","Sansum Diabetes Research Institute","2022-01-29","FALSE","0"],["S000163","ClinicalTrials.gov","NCT03523273",null,"Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","136","Obesity","DRUG:Liraglutide; DRUG:Placebo","Michael Camilleri, MD","2017-11-29","TRUE","0"],["S000164","ClinicalTrials.gov","NCT01618162","DUAL™IV","The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","435","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:placebo","Novo Nordisk A/S","2012-08-29","TRUE","3"],["S000165","ClinicalTrials.gov","NCT06904105",null,"A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HRS-7535 Tablets in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","556","Overweight; Obesity","DRUG:HRS-7535 Tablets; DRUG:HRS-7535 Placebo Tablets","Shandong Suncadia Medicine Co., Ltd.","2025-04-10","FALSE","0"],["S000166","ClinicalTrials.gov","NCT05444569",null,"A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of LY3537021 When Combined With GLP-1 Receptor Agonist in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","47","Healthy","DRUG:LY3537021; DRUG:Liraglutide; DRUG:Placebo","Eli Lilly and Company","2022-08-08","FALSE","0"],["S000167","ClinicalTrials.gov","NCT05757531",null,"Disposition of [14C]-LY3437943 Following Subcutaneous Administration in Healthy Male Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","7","Healthy","DRUG:[¹⁴C]-LY3437943","Eli Lilly and Company","2023-03-17","FALSE","0"],["S000168","ClinicalTrials.gov","NCT01342042","SPPS","The Safety, Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese T2DM","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","36","Type 2 Diabetes","BIOLOGICAL:rExenatide-4","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","2011-03","FALSE","1"],["S000169","ClinicalTrials.gov","NCT03385369",null,"A Phase 1, Randomized, Blinded, Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Safety; Healthy Subjects","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2018-01-05","FALSE","0"],["S000170","ClinicalTrials.gov","NCT03798054","Lixilan-O-AP","A Randomized, 24 Week, Active-controlled, Open-label, 3-arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to Insulin Glargine and Lixisenatide in Type 2 Diabetes Mellitus Patients Insufficiently Controlled With Oral Antidiabetic Drug(s)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","878","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide (HOE901/AVE0010); DRUG:Insulin glargine (HOE901); DRUG:Lixisenatide (AVE0010); DRUG:Metformin; DRUG:SGLT2 inhibitor","Sanofi","2019-02-15","FALSE","4"],["S000171","ClinicalTrials.gov","NCT05622045","StoryLCSS","Does Personality Predict Patient Adherence, Health Behaviors, and Weight Loss Outcomes During the Latino Crossover Semaglutide Study (LCSS)? (Story-LCSS Project)","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","59","Obesity; Body Weight Changes","BEHAVIORAL:Voice data","Loma Linda University","2023-02-01","FALSE","1"],["S000172","ClinicalTrials.gov","NCT04153929",null,"A Phase II, Randomized, Parallel Group, Dose-finding Study of Subcutaneously Administered BI 456906 for 16 Weeks, Compared With Placebo and Open-label Semaglutide in Patients With Type 2 Diabetes Mellitus.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","413","Diabetes Mellitus, Type 2","DRUG:BI 456906; DRUG:Placebo; DRUG:Semaglutide","Boehringer Ingelheim","2020-04-30","TRUE","3"],["S000173","ClinicalTrials.gov","NCT02533453","Bydureon","A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE4","COMPLETED","110","Type 2 Diabetes Mellitus","BIOLOGICAL:Bydureon","AstraZeneca","2016-01-28","TRUE","0"],["S000174","ClinicalTrials.gov","NCT07466017",null,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of CS060380 Tablets in Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) and Obesity.","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","130","Metabolic Dysfunction-associated Steatohepatitis (MASH); Obesity","DRUG:semaglutide; DRUG:CS060380; DRUG:Placebo","Cascade Pharmaceuticals, Inc","2026-04-02","FALSE","1"],["S000175","ClinicalTrials.gov","NCT03160261",null,"Effect of Exenatide on Cortisol Secretion","INTERVENTIONAL",null,"PHASE4","COMPLETED","10","Healthy","DRUG:Exenatide Injection","University of Tartu","2017-09-07","FALSE","1"],["S000176","ClinicalTrials.gov","NCT06857942",null,"A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice","INTERVENTIONAL",null,"PHASE4","RECRUITING","200","Psoriasis; Overweight or Obesity","DRUG:Tirzepatide","Eli Lilly and Company","2025-03-19","FALSE","0"],["S000177","ClinicalTrials.gov","NCT04050670",null,"Effect of Injection Site on the Relative Bioavailability of a Single Dose of Tirzepatide in Subjects With Low and High Body Mass Indices","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","54","Healthy","DRUG:Tirzepatide","Eli Lilly and Company","2019-09-13","TRUE","0"],["S000178","ClinicalTrials.gov","NCT01670994",null,"A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma","INTERVENTIONAL","NON_RANDOMIZED","PHASE1; PHASE2","TERMINATED","6","Relapsed or Refractory Multiple Myeloma","BIOLOGICAL:ALT-801","Altor BioScience","2012-08-14","TRUE","0"],["S000179","ClinicalTrials.gov","NCT06983171",null,"Real-World Clinical Practice Study on the Effectiveness of Semaglutide Over 154 Weeks in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","70","MAFLD",null,"Center of target therapy","2025-04-02","FALSE","0"],["S000180","ClinicalTrials.gov","NCT00569907",null,"Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide","OBSERVATIONAL",null,null,"COMPLETED","18","Diabetes Mellitus Type 2",null,"HealthPartners Institute","2007-01","FALSE","2"],["S000181","ClinicalTrials.gov","NCT05205928","SEMA-AP","Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care: a Double-blind, Cross-over, Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","28","Type 1 Diabetes; Diabetes Mellitus, Type 1","DRUG:Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy","McGill University Health Centre/Research Institute of the McGill University Health Centre","2022-10-02","FALSE","3"],["S000182","ClinicalTrials.gov","NCT05533632",null,"Safety and Tolerability of Weekly Semaglutide 0.5 mg or 1.0 mg in Chilean Subjects With Type 2 Diabetes","INTERVENTIONAL",null,"PHASE4","COMPLETED","104","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2022-04-25","TRUE","0"],["S000183","ClinicalTrials.gov","NCT04050553",null,"A Randomized, Placebo-Controlled, Crossover Study to Investigate the Effect of Once-Weekly Tirzepatide on the Counter-Regulatory Response to Hypoglycemia in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","42","Diabetes Mellitus, Type 2; Hypoglycemia","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2020-02-24","TRUE","1"],["S000184","ClinicalTrials.gov","NCT07527195","RASMUS","Effect of CagriSema, Semaglutide and Cagrilintide on Skeletal Muscle Insulin Sensitivity, Composition and Function","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","100","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2026-04-10","FALSE","0"],["S000185","ClinicalTrials.gov","NCT01208012",null,"Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","44","Diabetes Mellitus, Type 2","DRUG:Victoza®","ikfe-CRO GmbH","2010-04","FALSE","1"],["S000186","ClinicalTrials.gov","NCT04944992",null,"A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","145","Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis","DRUG:Efinopegdutide 20 mg/mL; DRUG:Semaglutide 1.34 mg/mL","Merck Sharp & Dohme LLC","2021-08-04","TRUE","2"],["S000187","ClinicalTrials.gov","NCT02472236",null,"An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Digoxin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","16","Healthy","DRUG:PEX168; DRUG:Digoxin","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2015-06-08","FALSE","0"],["S000188","ClinicalTrials.gov","NCT07255209",null,"A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","180","Adolescents With Obesity or Overweight With Weight-Related Comorbidities","DRUG:Placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2025-12-29","FALSE","0"],["S000189","ClinicalTrials.gov","NCT01517412",null,"A 24-week, Open-label, Randomized, 2-arm Parallel Group, Multinational, Multi-center Clinical Trial to Compare the Efficacy and Safety of Lixisenatide Injected Prior to the Main Meal of the Day Versus Lixisenatide Injected Prior to Breakfast in Type 2 Diabetic Patients Not Adequately Controlled on Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","451","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DEVICE:Self-injector pen device (OptiClik®); DRUG:Metformin","Sanofi","2012-02","TRUE","1"],["S000190","ClinicalTrials.gov","NCT06082063","Steno1","Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","2000","Cardiovascular Diseases; Heart Failure; Type 1 Diabetes; Kidney Failure","DRUG:Aspirin tablet; DRUG:Semaglutide; DRUG:Sotagliflozin; DRUG:Finerenone","Steno Diabetes Center Copenhagen","2024-07-01","FALSE","0"],["S000191","ClinicalTrials.gov","NCT01476475",null,"A Randomized, 24-week, Open-label, 2-arm Parallel-group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","323","Type 2 Diabetes Mellitus","DRUG:Insulin glargine /lixisenatide Fixed Ratio Combination; DRUG:Insulin glargine; DRUG:Metformin (Background drug)","Sanofi","2011-11","TRUE","1"],["S000192","ClinicalTrials.gov","NCT07651319",null,"A Phase Ib Clinical Trial, Using Interleukin-2 (IL-2) and Semaglutide in Patients With Alzheimer's Disease","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","RECRUITING","30","Alzheimer Dementia (AD)","DRUG:IL-2 (Aldesleukin); DRUG:Semaglutide Plus IL-2; DRUG:Placebo","The Methodist Hospital Research Institute","2026-09-01","FALSE","0"],["S000193","ClinicalTrials.gov","NCT06131372",null,"Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","626","Chronic Kidney Disease; Type 2 Diabetes; Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2024-04-01","FALSE","0"],["S000194","ClinicalTrials.gov","NCT07169136",null,"Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)","OBSERVATIONAL",null,null,"RECRUITING","20","Polycystic Ovarian Syndrome in Adolescent Females; Obesity (Disorder)","DRUG:GLP-1 Receptor Agonists","Nemours Children's Clinic","2025-09-11","FALSE","0"],["S000195","ClinicalTrials.gov","NCT02249871",null,"A Trial Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","54","Diabetes; Healthy","DRUG:semaglutide; DRUG:Omeprazole","Novo Nordisk A/S","2014-09-24","FALSE","2"],["S000196","ClinicalTrials.gov","NCT06721507",null,"Preoperative Tirzepatide for Bariatric Surgery","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","50","Obesity and Obesity-related Medical Conditions; Bariatric Surgery","DRUG:tirzepatide; BEHAVIORAL:Standard of Care","Marlene Starr","2025-03-27","FALSE","1"],["S000197","ClinicalTrials.gov","NCT06603571",null,"A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","367","Obesity; Overweight","DRUG:LY3841136; DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2024-09-20","FALSE","0"],["S000198","ClinicalTrials.gov","NCT04615871","SEMPATICO","Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","400","Covid19; Myocardial Injury","DRUG:semaglutide","Vladimír Džavík","2021-09-10","FALSE","0"],["S000199","ClinicalTrials.gov","NCT00823992",null,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Taspoglutide on Glycemic Control, and Its Safety and Tolerability, in Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy.","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","305","Diabetes Mellitus Type 2","DRUG:placebo; DRUG:taspoglutide","Hoffmann-La Roche","2009-01","FALSE","0"],["S000200","ClinicalTrials.gov","NCT05536804","TREASURE-CKD","Tirzepatide Study of Renal Function in People With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease Using Multiparametric Magnetic Resonance Imaging","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","134","Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-02-08","FALSE","2"],["S000201","ClinicalTrials.gov","NCT01154933",null,"The Effect of Exenatide on Insulin Requirement, Weight and Inflammation in Obese Type 2 Diabetic Subjects on Insulin","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","24","Type 2 Diabetes","DRUG:exenatide 5 mcg; DRUG:exenatide 10 mcg; DRUG:placebo","University at Buffalo","2008-04","TRUE","1"],["S000202","ClinicalTrials.gov","NCT03456687",null,"Effects of Exenatide on Motor Function and the Brain","INTERVENTIONAL",null,"PHASE1","COMPLETED","5","Parkinson's Disease","DRUG:Exenatide","University of Florida","2018-06-05","FALSE","0"],["S000203","ClinicalTrials.gov","NCT05296733",null,"A Non-randomised, Open-label, 2-part, Parallel-cohort Trial to Evaluate 1) Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of BI 456906 in Patients With Cirrhosis and Varying Degrees of Hepatic Impairment Relative to Healthy Subjects With and Without Overweight/Obesity and 2) Safety and Tolerability of Multiple Subcutaneous Doses of BI 456906 in Patients With Overweight/Obesity With Cirrhosis and Varying Degrees of Hepatic Impairment Relative to Patients With Overweight/Obesity Without Cirrhosis/Hepatic Impairment","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","82","Healthy; Liver Diseases; Obesity","DRUG:BI 456906","Boehringer Ingelheim","2022-04-27","FALSE","1"],["S000204","ClinicalTrials.gov","NCT04431713","MSA","An Open Label, Single Site, 48 Week, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exenatide Once-weekly in the Treatment of Patients With Multiple System Atrophy","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","50","Multiple System Atrophy","DRUG:Exenatide Pen Injector [Bydureon]","University College, London","2020-09-16","TRUE","16"],["S000205","ClinicalTrials.gov","NCT06326060",null,"Investigation of the Safety and Efficacy of Once Weekly NNC0519-0130 in Participants With Overweight or Obesity - a Dose Finding Study","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","354","Obesity","DRUG:NNC0519-0130; DRUG:Placebo; DRUG:Tirzepatide","Novo Nordisk A/S","2024-03-18","FALSE","0"],["S000206","ClinicalTrials.gov","NCT05746039",null,"Feasibility of Semaglutide Therapy for Weight Loss in Advanced Lung Disease: A Pilot Study","INTERVENTIONAL",null,"PHASE1; PHASE2","RECRUITING","8","Obesity; Interstitial Lung Disease; Chronic Obstructive Pulmonary Disease; Sarcoidosis, Pulmonary; Pulmonary Hypertension","DRUG:Semaglutide Pen Injector","University of Pennsylvania","2024-01-29","FALSE","0"],["S000207","ClinicalTrials.gov","NCT01789957",null,"An Open-Label Extension Study of Protocol 2993-112 to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of AC2993 Given Two Times a Day to Subjects Treated With Metformin Alone","INTERVENTIONAL",null,"PHASE3","COMPLETED","225","Type 2 Diabetes Mellitus","DRUG:AC2993","AstraZeneca","2002-09","FALSE","0"],["S000208","ClinicalTrials.gov","NCT05492305",null,"Effect of Glucagon-like Peptide 1 (GLP1) Receptor Agonists on Mental Health in Patients With Obesity and Type 2 Diabetes (T2D): a Mixed Methods Study","OBSERVATIONAL",null,null,"UNKNOWN","20","Diabetes Mellitus; Obesity; Mental Health Issue","DRUG:GLP-1 receptor agonist","King's College London","2022-09","FALSE","0"],["S000209","ClinicalTrials.gov","NCT06263595",null,"Mitigating Harm: Assessing Preoperative Residual Gastric Volumes to Risk Stratify Patients Administering Semaglutide","OBSERVATIONAL",null,null,"COMPLETED","94","Pulmonary Aspiration","DEVICE:gastric antral sonography","University of Calgary","2024-05-31","FALSE","0"],["S000210","ClinicalTrials.gov","NCT06896981",null,"Comparison Between the Effects of Low-Dose Semaglutide With Metformin vs. Metformin Alone Over Metabolic Profile in Obese Polycystic Ovary Syndrome: A Phase II Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","31","Polycystic Ovary Syndrome (PCOS) Women; Obesity","DRUG:Metformin with Semaglutide","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","2025-01-01","FALSE","0"],["S000211","ClinicalTrials.gov","NCT07840729",null,"Identify the Expanded Access Program, if Any. This is Required Unless the Expanded Access Type is \"Individual Patients.\" A Randomized, Parallel, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JMT206 Injection Alone or in Combination With Semaglutide in Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","90","Valid MeSH Conditiongs","DRUG:JMT206 injection; COMBINATION_PRODUCT:Semaglutide injection; DRUG:Placebo injection","Shanghai JMT-Bio Inc.","2026-10-20","FALSE","0"],["S000212","ClinicalTrials.gov","NCT06976372",null,"A Phase 1, Randomized, Double-blind, Multiple-dose Study to Evaluate the Pharmacokinetics of AMG 133 Administered Subcutaneously in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","120","Overweight; Obesity","DRUG:AMG 133","Amgen","2024-08-20","FALSE","0"],["S000213","ClinicalTrials.gov","NCT06672172","OUTSTAND-1","A Phase 3, Randomized, Double-blinded Study to Evaluate the Efficacy and Safety of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise (OUTSTAND-1)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","284","Type 2 Diabetes","DRUG:HRS-7535 tablet; DRUG:HRS-7535 placebo tablet","Shandong Suncadia Medicine Co., Ltd.","2024-09-25","FALSE","1"],["S000214","ClinicalTrials.gov","NCT03693430","STEP 5","Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","304","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo (Semaglutide)","Novo Nordisk A/S","2018-10-05","TRUE","7"],["S000215","ClinicalTrials.gov","NCT01597531",null,"LIRAGLUTIDE AND ORLISTAT TREATMENT FOR PERSISTENT TYPE 2 DIABETES AFTER GASTRIC BANDING: A PILOT STUDY","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","1","Type 2 Diabetes; Gastric Banding","DRUG:Liraglutide; DRUG:Orlistat; DRUG:Liraglutide + Orlistat","East Carolina University","2012-06","FALSE","0"],["S000216","ClinicalTrials.gov","NCT04525300",null,"Changes of Gut Microbiome Following Liraglutide Treatment in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, 28-week Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","300","Obesity","DRUG:Liraglutide; DRUG:placebo","Xiangya Hospital of Central South University","2020-05-24","FALSE","0"],["S000217","ClinicalTrials.gov","NCT04504370","PB119","A Phase III, Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","273","Type 2 Diabetes Mellitus (T2DM)","DRUG:GLP-1 receptor agonist; DRUG:Placebo","PegBio Co., Ltd.","2020-04-27","FALSE","2"],["S000218","ClinicalTrials.gov","NCT06972472",null,"A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","600","Obesity; Overweight; Type 2 Diabetes","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-05-19","FALSE","0"],["S000219","ClinicalTrials.gov","NCT01299012",null,"Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus, a Retrospective Chart Review","OBSERVATIONAL",null,null,"COMPLETED","30","Type 1 Diabetes Mellitus","DRUG:Liraglutide","University at Buffalo","2010-10","FALSE","0"],["S000220","ClinicalTrials.gov","NCT07195994",null,"A Randomized, Single-blind, Controlled, Parallel Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","90","Prediabetes / Type 2 Diabetes","DIETARY_SUPPLEMENT:AMPK Charge+®; DIETARY_SUPPLEMENT:AMPK Charge+® with semaglutide","QuickSilver Scientific","2026-02-05","FALSE","0"],["S000221","ClinicalTrials.gov","NCT04596631","PIONEER TEENS","Efficacy and Safety of Oral Semaglutide Versus Placebo Both in Combination With Metformin and/or Basal Insulin in Children and Adolescents With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","132","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2020-11-02","TRUE","0"],["S000222","ClinicalTrials.gov","NCT07165028",null,"A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","4500","Metabolic Dysfunction-Associated Steatotic Liver Disease","DRUG:Tirzepatide; DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2025-10-15","FALSE","0"],["S000223","ClinicalTrials.gov","NCT06972992",null,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 Injection, for Subcutaneous Use in Combination With Semaglutide in Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","28","Chronic Weight Management","DRUG:ASC47 +Semaglutide; DRUG:Placebo+Semaglutide","Ascletis Pharma (China) Co., Limited","2025-04-18","FALSE","0"],["S000224","ClinicalTrials.gov","NCT01686945",null,"Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","107","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2012-09-19","FALSE","1"],["S000225","ClinicalTrials.gov","NCT06861439","GLOW","Effects of Tirzepatide on Fat-Free Mass, Bone and Physical Function in Older Adults - a Pilot Study","INTERVENTIONAL",null,"PHASE4","ACTIVE_NOT_RECRUITING","40","Obesity","DRUG:Tirzepatide","Wake Forest University Health Sciences","2025-07-07","FALSE","0"],["S000226","ClinicalTrials.gov","NCT03175211",null,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 456906 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","20","Healthy","DRUG:BI 456906; DRUG:Placebo","Boehringer Ingelheim","2017-06-30","FALSE","1"],["S000227","ClinicalTrials.gov","NCT07042672","BETTER-GLP1","Behavioral Therapy With and Without GLP-1 Analogue in Patients With Morbid Obesity and Binge Eating Disorder: A Clinical Prospective Observational Study on Body Weight, Binge Eating Behavior, and Harmful Coping Strategies","OBSERVATIONAL",null,null,"RECRUITING","80","Binge Eating Disorder Associated With Obesity; Binge Eating Disorder; Eating Disorder Binge; Eating Disorders; GLP-1; CBT; Obesity &Amp; Overweight","DRUG:GLP-1; BEHAVIORAL:CBTe Group Therapy","Haukeland University Hospital","2025-07-01","FALSE","0"],["S000228","ClinicalTrials.gov","NCT03375463",null,"Pharmacokinetics, Safety, and Tolerability of a Solution Formulation of LY3298176 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","52","Healthy","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2017-12-19","TRUE","0"],["S000229","ClinicalTrials.gov","NCT00064714",null,"Effect of AC 2993 (Synthetic Exendin-4) - Administered Alone or in Combination With Daclizumab - on Islet Function in Patients With Type I Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","47","Diabetes Mellitus","DRUG:AC2993 (exenatide); DRUG:daclizumab (immunosuppressive)","AstraZeneca","2003-07","FALSE","2"],["S000230","ClinicalTrials.gov","NCT05786521",null,"The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","20","Aging; Diabetes Mellitus, Type 2; PreDiabetes; Overweight and Obesity","DRUG:Semaglutide Injectable Product; BEHAVIORAL:Lifestyle Counseling","The University of Texas Health Science Center at San Antonio","2023-04-01","TRUE","4"],["S000231","ClinicalTrials.gov","NCT01046721",null,"Investigation of the Cardiovascular Effects of Exenatide in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","8","Type 2 Diabetes","DRUG:Exenatide; DRUG:Saline","University of Nottingham","2009-09","FALSE","1"],["S000232","ClinicalTrials.gov","NCT01001104",null,"Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Japanese Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","145","Diabetes Mellitus, Type 2","DRUG:LY2189265; DRUG:Placebo","Eli Lilly and Company","2009-10","TRUE","0"],["S000233","ClinicalTrials.gov","NCT01512108",null,"A 52-week, Multi-centre, Open-labelled, Randomised (2:1), Parallel-group Trial With an Active Control (Two OADs Combination Therapy) to Evaluate the Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Monotherapy","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","363","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:oral anti-diabetic drug","Novo Nordisk A/S","2012-01-10","TRUE","2"],["S000234","ClinicalTrials.gov","NCT03015220","PIONEER 10","Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD in Japanese Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","458","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Dulaglutide","Novo Nordisk A/S","2017-01-10","TRUE","5"],["S000235","ClinicalTrials.gov","NCT03819790","VARIATION 2 SA","Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","119","Diabetes Mellitus, Type 2","DRUG:Basal insulin glargine and lixisenatide; DRUG:Basal insulin Basaglar/Lantus + gliclazide MR; DRUG:Metformin","LMC Diabetes & Endocrinology Ltd.","2018-10-02","FALSE","10"],["S000236","ClinicalTrials.gov","NCT02846233",null,"Is the Stepping-down Approach a Better Option Than Multiple Daily Injections in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","22","Type 2 Diabetes Mellitus","DRUG:GLP1 receptor agonist; DRUG:basal insulin; DRUG:SGLT2 inhibitor; DRUG:Metformin","University of California, San Francisco","2016-08","TRUE","2"],["S000237","ClinicalTrials.gov","NCT01621178","AWARD-7","A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","577","Type 2 Diabetes; Chronic Kidney Disease","DRUG:Dulaglutide; DRUG:Insulin glargine; DRUG:Insulin lispro","Eli Lilly and Company","2012-07","TRUE","2"],["S000238","ClinicalTrials.gov","NCT07407348",null,"Bioequivalence of Two Survodutide (BI 456906) Formulations Via Subcutaneous Administration After Multiple Doses (an Open-label, Randomised, Multiple-dose, Crossover Trial)","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","80","Healthy; Obesity; Overweight","COMBINATION_PRODUCT:Formulation A; COMBINATION_PRODUCT:Formulation B6","Boehringer Ingelheim","2026-03-11","FALSE","0"],["S000239","ClinicalTrials.gov","NCT03861052","SURPASS J-mono","A Phase 3 Study of Tirzepatide Monotherapy Compared to Dulaglutide 0.75 mg in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","636","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Dulaglutide","Eli Lilly and Company","2019-05-07","TRUE","6"],["S000240","ClinicalTrials.gov","NCT01818648",null,"Acute Effects of a Glucagon-like Peptide 1 Analog, Exenatide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition","INTERVENTIONAL","RANDOMIZED","PHASE4","WITHDRAWN","0","Short Bowel Syndrome","DRUG:Exenatide; DRUG:Placebo","Mayo Clinic","2013-03","FALSE","0"],["S000241","ClinicalTrials.gov","NCT07434050",null,"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","140","OSA - Obstructive Sleep Apnea; Obesity","DRUG:XW003 injection; DRUG:placebo with matching volume","Hangzhou Sciwind Biosciences Co., Ltd.","2026-03-02","FALSE","0"],["S000242","ClinicalTrials.gov","NCT04660643","SURMOUNT-4","Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","783","Obesity; Overweight","DRUG:Tirzepatide; OTHER:Placebo","Eli Lilly and Company","2021-03-29","TRUE","10"],["S000243","ClinicalTrials.gov","NCT03292315",null,"The Efficacy of a Once Weekly Glucagon-Like Peptide-1 Agonist on Body Weight/Composition and Metabolic Parameters in Persons With SCI","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","5","Spinal Cord Injuries; Insulin Resistance; Pre Diabetes; Obesity","DRUG:Semaglutide 1MG Injection [Ozempic]; OTHER:No Intervention","James J. Peters Veterans Affairs Medical Center","2018-10-16","FALSE","1"],["S000244","ClinicalTrials.gov","NCT06925334","TLI vs PMI","Clinical Study Comparing Time to Glucose Attainment in Patients With Type 2 Diabetes Mellitus Treated With Degu Insulin Liraglutide Injection Versus Premixed Insulin","INTERVENTIONAL","RANDOMIZED","PHASE4","ENROLLING_BY_INVITATION","170","Type 2 Diabetic Patients","DRUG:Degludec insulin","Beijing Tsinghua Chang Gung Hospital","2024-05-20","FALSE","0"],["S000245","ClinicalTrials.gov","NCT07832799",null,"A Phase 1, Open-label, Randomized, Parallel Group Study to Assess the Relative Bioavailability of Two Maridebart Cafraglutide (AMG 133) Drug Products in Participants Living With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","340","Overweight; Obesity","DRUG:Maridebart Cafraglutide","Amgen","2026-10-12","FALSE","0"],["S000246","ClinicalTrials.gov","NCT01584232",null,"A Phase 3 Study of LY2189265 Compared to Insulin Glargine in Patients With Type 2 Diabetes Mellitus on a Sulfonylurea and/or Biguanide","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","361","Type 2 Diabetes Mellitus","DRUG:LY2189265; DRUG:Insulin glargine; DRUG:Sulfonylureas (SU); DRUG:Biguanide (BG)","Eli Lilly and Company","2012-04","TRUE","2"],["S000247","ClinicalTrials.gov","NCT00833716",null,"An Open-label Trial Investigating the Pharmacokinetics and the Tolerability of NN9535 in Subjects With Normal Renal Function and Various Degrees of Impaired Renal Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","62","Diabetes; Diabetes Mellitus, Type 2; Renal Impairment","DRUG:semaglutide","Novo Nordisk A/S","2009-02-02","FALSE","1"],["S000248","ClinicalTrials.gov","NCT05073692","ON TARGET DM","Comparison of Type 2 Diabetes Pharmacotherapy Regimens Using Targeted Learning","OBSERVATIONAL",null,null,"COMPLETED","241981","Type 2 Diabetes Mellitus; Cardiovascular Diseases","DRUG:SU; DRUG:DPP4; DRUG:SGLT2i; DRUG:GLP-1RA; DRUG:SGLT2i or GLP-1RA; DRUG:Linagliptin (DPP4); DRUG:Exenatide (GLP-1RA); DRUG:Liraglutide (GLP-1RA); DRUG:Empagliflozin (SGLT2i); DRUG:Glimepiride (SU); DRUG:Glipizide (SU); DRUG:Glimepiride (SU) or Glipizide (SU); DRUG:SU or DPP4 (excluding saxagliptin and alogliptin); DRUG:Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)","Kaiser Permanente","2021-07-01","TRUE","2"],["S000249","ClinicalTrials.gov","NCT05260021","SURPASS-PEDS","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","99","Type2 Diabetes; Diabetes Mellitus; Diabetes Mellitus, Type 2; T2D; T2DM (Type 2 Diabetes Mellitus); Glucose Metabolism Disorders; Endocrine System Diseases; Metabolic Disease","DRUG:Tirzepatide Dose 1; DRUG:Tirzepatide Dose 2; DRUG:Placebo","Eli Lilly and Company","2022-04-13","TRUE","2"],["S000250","ClinicalTrials.gov","NCT07374328","TRED","Comparison Of Two Triple Hypoglycemic Regimens In Achieving Glycemic Control And Diabetes Remission In Hospitalized Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Multicenter, Randomized, Clinical Study","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","RECRUITING","240","Type 2 Diabetes","DRUG:Semaglutide (1 Mg Dose); DRUG:Sitagliptin (DPP4 inhibitor)","Second Affiliated Hospital of Guangzhou Medical University","2025-06-01","FALSE","0"],["S000251","ClinicalTrials.gov","NCT02863328","PIONEER 2","Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","822","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:empagliflozin","Novo Nordisk A/S","2016-08-10","TRUE","16"],["S000252","ClinicalTrials.gov","NCT05897398","SEMASEARCH","SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY®","OBSERVATIONAL",null,null,"COMPLETED","1100","Obesity; Bariatric Surgery; Binge Eating Disorder; Syndromic Obesity; Sarcopenic Obesity; Iatrogenic Obesity; Psychotropic Drugs","OTHER:Data collection; OTHER:Blood sampling; OTHER:Questionnaires","Hospices Civils de Lyon","2024-06-10","FALSE","1"],["S000253","ClinicalTrials.gov","NCT07836270",null,"A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Safety and Efficacy of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents (SLIMMER-YOUNG)","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","192","Adolescents With Obesity; Adolescents With Overweight & Weight-related Comorbidities","DRUG:Ecnoglutide Injection; DRUG:placebo with matching volume","Hangzhou Sciwind Biosciences Co., Ltd.","2026-10-31","FALSE","0"],["S000254","ClinicalTrials.gov","NCT06914895","SURPASS-T1D-1","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","905","Type 1 Diabetes; Obesity; Overweight","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2025-04-25","FALSE","0"],["S000255","ClinicalTrials.gov","NCT07868939",null,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","560","Weight Loss","DRUG:VK2735 Oral; DRUG:Placebo Comparator","Viking Therapeutics, Inc.","2026-10-16","FALSE","0"],["S000256","ClinicalTrials.gov","NCT02302976",null,"GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","13","Cocaine Dependence","DRUG:cocaine hydrochloride; DRUG:exenatide; DRUG:placebo","Yale University","2014-11","FALSE","0"],["S000257","ClinicalTrials.gov","NCT03235050",null,"A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","834","Diabetes Mellitus, Type 2","DRUG:MEDI0382 low dose; DRUG:MEDI0382 mid dose; DRUG:MEDI0382 high dose; DRUG:Placebo; DRUG:Liraglutide","AstraZeneca","2017-08-02","TRUE","2"],["S000258","ClinicalTrials.gov","NCT05254418","GLIMP","Effects of Glucagon-Like Peptide-1 Agonists on Metabolism and Ectopic Fat Deposition in Chronic Kidney Disease: A Pilot and Feasibility Study","INTERVENTIONAL",null,"PHASE2","COMPLETED","7","Chronic Kidney Diseases","DRUG:dulaglutide injection","Vanderbilt University Medical Center","2022-03-15","TRUE","0"],["S000259","ClinicalTrials.gov","NCT02014740",null,"Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","100","Type 2 Diabetes; Overweight; Obesity","DRUG:Liraglutide; DRUG:Metformin","University of Miami","2014-03","TRUE","1"],["S000260","ClinicalTrials.gov","NCT05341089",null,"A Phase 1 Multiple-Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of 2 Different Formulations of LY3502970 in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","39","Healthy","DRUG:LY3502970","Eli Lilly and Company","2022-05-17","TRUE","0"],["S000261","ClinicalTrials.gov","NCT07390110",null,"Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)","OBSERVATIONAL",null,null,"COMPLETED","25664","Type 2 Diabetes; Heart Failure","DRUG:Oral semaglutide; DRUG:Sitagliptin","Brigham and Women's Hospital","2026-01-24","FALSE","0"],["S000262","ClinicalTrials.gov","NCT02920190",null,"Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA)","INTERVENTIONAL",null,"PHASE4","WITHDRAWN","0","Monoclonal Gammopathies; Overweight; Obesity","DRUG:Liraglutide","University of Miami","2020-09-01","FALSE","0"],["S000263","ClinicalTrials.gov","NCT05071417","SEPLA","Effect Of Semaglutide In Coronary Atherosclerotic Plaqus Assessed by Coronay CT","INTERVENTIONAL",null,"PHASE3","UNKNOWN","120","Atheroscleroses, Coronary","DRUG:Semaglutide","Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León","2021-11","FALSE","0"],["S000264","ClinicalTrials.gov","NCT04881110","STARDUST","Effects of the Glucagon Like-peptide 1 (GLP-1) Receptor Agonist Liraglutide on Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: a Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","60","Type 2 Diabetes; Peripheral Arterial Disease","DRUG:Liraglutide; OTHER:Control","University of Campania Luigi Vanvitelli","2021-02-01","TRUE","2"],["S000265","ClinicalTrials.gov","NCT07850050",null,"A Multicentre, Randomised, Double-blind, Placebo-controlled 52-week, Phase IIIb Trial to Evaluate the Efficacy and Safety of Survodutide in Peri- and Post-menopausal Women With Overweight or Obesity (SYNCHRONIZE®-HERA)","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","600","Obesity","COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo","Boehringer Ingelheim","2026-10-31","FALSE","0"],["S000266","ClinicalTrials.gov","NCT07728318",null,"Efficacy, Safety and Treatment Satisfaction of Once Weekly Tirzepatide in Obese Type 2 Diabetic Patients at a Tertiary Care Centre","INTERVENTIONAL","NON_RANDOMIZED",null,"NOT_YET_RECRUITING","52","Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight","OTHER:Tirzepatide + Standard Therapy (Intervention Group); OTHER:Standard Oral Antidiabetic Drugs (OADs)","Akhtar Saeed Medical and Dental College","2026-08-12","FALSE","0"],["S000267","ClinicalTrials.gov","NCT07057310",null,"Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women","INTERVENTIONAL","RANDOMIZED","PHASE4","ENROLLING_BY_INVITATION","30","Obesity; Menopause","DRUG:semaglutide or tirzepatide; BEHAVIORAL:Lifestyle modification intervention","Mayo Clinic","2025-05-01","FALSE","0"],["S000268","ClinicalTrials.gov","NCT05810597",null,"A Bioequivalence Study to Compare the Pharmacokinetics of Tirzepatide Administered Subcutaneously by a Test Device (Test Formulation) Versus Reference Device (Reference Formulation) in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","65","Healthy","DRUG:Tirzepatide; DEVICE:Single Dose Pen; DEVICE:Multi-use Prefilled Pen","Eli Lilly and Company","2023-04-03","TRUE","0"],["S000269","ClinicalTrials.gov","NCT07253285",null,"Efficacy, Safety and Pharmacokinetics of Cagrilintide s.c. 2.4 mg as Monotherapy and in Combination With Semaglutide s.c. 2.4 mg (CagriSema) Once Weekly for Weight Management in Chidren and Adolescents With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","460","Overweight; Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2026-01-08","FALSE","0"],["S000270","ClinicalTrials.gov","NCT07095517","PROSPECT","Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors","INTERVENTIONAL",null,"PHASE1","RECRUITING","20","Colorectal Cancer Prevention; Colorectal Adenoma","DRUG:Tirzepatide","Massachusetts General Hospital","2026-02-24","FALSE","0"],["S000271","ClinicalTrials.gov","NCT00948168",null,"6-Months Exenatide and Glucose Homeostasis Determinants in Type 2 Diabetic Patients","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","COMPLETED","34","Type 2 Diabetes Mellitus","DRUG:exenatide (Byetta)","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","2008-07","FALSE","0"],["S000272","ClinicalTrials.gov","NCT07179120",null,"Male Fertility Preservation: Efficacy Evaluation of GLP-1Receptor Agonist Therapy for Infertility in Obese Males - A Multicenter Clinical Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","180","Obesity-related Male Infertility","DRUG:Semaglutide (Rybelsus®); DRUG:Tirzepatide; BEHAVIORAL:Standardized Lifestyle Intervention","First Affiliated Hospital of Wenzhou Medical University","2026-05-01","FALSE","0"],["S000273","ClinicalTrials.gov","NCT06323174","REIMAGINE 1","Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","189","Type 2 Diabetes","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2024-03-19","FALSE","1"],["S000274","ClinicalTrials.gov","NCT04374578","DIVE","Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes: A Multi-center Observational Study","OBSERVATIONAL",null,null,"COMPLETED","100","Type 2 Diabetes","DRUG:Dulaglutide 1.5 MG/ML","Shanghai Zhongshan Hospital","2020-05-08","FALSE","0"],["S000275","ClinicalTrials.gov","NCT07772960","SEMA AUD","Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","90","Alcohol Use Disorder (AUD); Obesity (BMI Equal to or >30)","OTHER:Placebo; DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 2.0 mg","Yale University","2026-10-01","FALSE","1"],["S000276","ClinicalTrials.gov","NCT06361823",null,"An Exploratory Study Assessing the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","74","Idiopathic Intracranial Hypertension","DRUG:Semaglutide; DIETARY_SUPPLEMENT:Low calorie diet","Capital Medical University","2024-05-01","FALSE","1"],["S000277","ClinicalTrials.gov","NCT04235959",null,"A Multiple Dose Titration Study in Chinese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Tirzepatide","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Diabetes Mellitus, Type 2","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2020-10-21","TRUE","1"],["S000278","ClinicalTrials.gov","NCT05230615","PIONEER REAL","A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Italy","OBSERVATIONAL",null,null,"COMPLETED","458","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2022-04-01","FALSE","2"],["S000279","ClinicalTrials.gov","NCT04707313",null,"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06882961 ADMINISTRATION IN ADULTS WITH OBESITY","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","628","Obesity","DRUG:Placebo (Cohorts 1 and 2); DRUG:PF-06882961 (Cohorts 1 and 2); DRUG:Placebo (Cohort 3); DRUG:PF-06882961 (Cohort 3)","Pfizer","2021-01-29","TRUE","1"],["S000280","ClinicalTrials.gov","NCT00755287",null,"A Multicenter, Randomized, Open-label, Active-controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin-naïve Type 2 Diabetic Patients Inadequately Controlled With Metformin and Sulphonylurea Combination Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1072","Diabetes Mellitus Type 2","DRUG:insulin glargine; DRUG:metformin; DRUG:taspoglutide","Hoffmann-La Roche","2008-11","FALSE","1"],["S000281","ClinicalTrials.gov","NCT06344247",null,"Comparison of the Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Obese Patients With Kidney Disease: a Single Center, Prospective, Exploratory Study","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","48","Obesity; Chronic Kidney Diseases","DRUG:RAS inhibitors：Losartan®️/Valsartan®️; DRUG:dapagliflozin：Forxiga®️; DRUG:simagliptin：Forxiga®️","RenJi Hospital","2023-09-01","FALSE","0"],["S000282","ClinicalTrials.gov","NCT01507285",null,"A Randomised, Double-blind, Placebo-controlled, Dose-escalation, Parallel-group, Single and Multiple Dosing Trial of NN90-1170 in Healthy Volunteers and Patients With Type 2 Diabetes to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","1999-08","FALSE","1"],["S000283","ClinicalTrials.gov","NCT03017352","MAG1C","Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases: A Randomised, Placebo-controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","108","Diabetes Mellitus, Type 1","DRUG:Exenatide; DRUG:Placebos","Filip Krag Knop","2016-12","FALSE","4"],["S000284","ClinicalTrials.gov","NCT03789578",null,"A Trial to Investigate Single Dose Pharmacokinetics of NNC0148-0287sema in a Fixed Ratio Compared With Insulin 287 and Semaglutide Given Separately in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","30","Diabetes Mellitus, Type 2","DRUG:NNC0148-0287sema; DRUG:Semaglutide; DRUG:NNC0148-0287","Novo Nordisk A/S","2019-01-17","FALSE","1"],["S000285","ClinicalTrials.gov","NCT02403284",null,"The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","97","Insulin Resistance","DRUG:Liraglutide; DRUG:Sugar Pill","Phoenix VA Health Care System","2013-03","FALSE","0"],["S000286","ClinicalTrials.gov","NCT03560336",null,"Prospective, Multicentre, Open-label, Single-arm, Non-interventional Regulatory Post-marketing Surveillance(rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda® (Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea","OBSERVATIONAL",null,null,"COMPLETED","758","Obesity; Overweight","DRUG:Liraglutide","Novo Nordisk A/S","2018-07-05","FALSE","0"],["S000287","ClinicalTrials.gov","NCT02483299",null,"Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","40","PCOS; Obesity","DRUG:Metformin; DRUG:Glucophage tablets and Victoza","University Medical Centre Ljubljana","2014-01","FALSE","0"],["S000288","ClinicalTrials.gov","NCT06632457",null,"A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","1590","Metabolic Dysfunction Associated Steatohepatitis","COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo matching survodutide","Boehringer Ingelheim","2024-11-12","FALSE","0"],["S000289","ClinicalTrials.gov","NCT03018665",null,"A Randomized,Active-controlled,Open-label Clinical Trial to Evaluate the Effect of GLP-1 Receptor Agonist (Exenatide Injection) in Combination With Metformin Therapy Compared to Premixed Insulin (BIAsp30) in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","200","Diabetes Mellitus, Type 2","DRUG:Exenatide; DRUG:BIAsp30; DRUG:Metformin","The First Hospital of Jilin University","2017-02","FALSE","0"],["S000290","ClinicalTrials.gov","NCT04305587",null,"A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Escalating Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","66","Diabetes Mellitus Type 2","DRUG:PF-07081532; OTHER:Placebo; DRUG:Clopidogrel","Pfizer","2020-03-16","TRUE","1"],["S000291","ClinicalTrials.gov","NCT05478707","MCD-1","Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","47","Diabetes Mellitus, Type 1; Endothelial Dysfunction","DRUG:Dulaglutide; DRUG:Placebo","AdventHealth Translational Research Institute","2023-10-05","FALSE","15"],["S000292","ClinicalTrials.gov","NCT07243171",null,"A Multicenter, Multiple-dose Escalation, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","RECRUITING","126","Overweight and/or Obesity; Weight Management","DRUG:ecnoglutide tablets; DRUG:placebo with matching dosage","Hangzhou Sciwind Biosciences Co., Ltd.","2025-11-18","FALSE","0"],["S000293","ClinicalTrials.gov","NCT03444584",null,"An Exploratory Phase 2a Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of MEDI0382 Versus Placebo in Overweight/Obese Subjects With Type 2 Diabetes Mellitus Treated With Dapagliflozin and Metformin","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","49","Type 2 Diabetes Mellitus","DRUG:MEDI0382; DRUG:Placebo; DRUG:Dapaglifozin; DRUG:Metformin","MedImmune LLC","2018-05-08","TRUE","0"],["S000294","ClinicalTrials.gov","NCT06283667",null,"A Multi-centre, Prospective, Non-interventional, Single-armed, 104 Weeks Post-marketing Study to Investigate Safety and Clinical Parameters of Wegovy® Once Weekly in Patients With Obesity Disease Under Real-world Clinical Practice Conditions","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","1071","Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2024-06-11","FALSE","0"],["S000295","ClinicalTrials.gov","NCT06987695","MARITIME-3-J","A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease (MARITIME 3-J)","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","279","Obesity Disease","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2025-06-13","FALSE","0"],["S000296","ClinicalTrials.gov","NCT00254800",null,"The Effect of Exenatide on Single and Multiple Doses Oral Contraceptive Pharmacokinetics in Healthy Female Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","38","Type 2 Diabetes Mellitus","DRUG:ethinyl estradiol and levonorgestrel; exenatide","AstraZeneca","2005-11","FALSE","1"],["S000297","ClinicalTrials.gov","NCT07055607","PILLAR","A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","1250","Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2025-05-01","FALSE","0"],["S000298","ClinicalTrials.gov","NCT07043361","Semaglutide","Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipid Profile- the Role of Baseline Vitamin D Levels","OBSERVATIONAL",null,null,"COMPLETED","5300","Metabolic Disease","DRUG:semaglutide","Hillel Yaffe Medical Center","2023-12-18","FALSE","11"],["S000299","ClinicalTrials.gov","NCT04687514","DESIRE","Effects of Glucagon-Like Peptide-1 Analogs on Sexuality - a Randomized, Double-blind, Placebo-controlled Trial With Crossover Design","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","26","Sexual Functioning","DRUG:Dulaglutide; DRUG:Placebo","University Hospital, Basel, Switzerland","2021-05-05","FALSE","0"],["S000300","ClinicalTrials.gov","NCT05950516",null,"Efficacy and Safety of Semaglutide Injection (QLG2065) vs. Ozempic® as add-on to Metformin in Type 2 Diabetics.","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","478","Type 2 Diabetes","DRUG:Semaglutide; DRUG:Semaglutide Pen Injector [Ozempic]","Qilu Pharmaceutical Co., Ltd.","2023-07-10","FALSE","0"],["S000301","ClinicalTrials.gov","NCT05469126",null,"A Phase 1, Open-label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Clarithromycin on the Pharmacokinetics of LY3502970 in Healthy Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","26","Healthy","DRUG:LY3502970; DRUG:Clarithromycin","Eli Lilly and Company","2022-08-01","TRUE","0"],["S000302","ClinicalTrials.gov","NCT06565871",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea (OSA)","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","108","Weight Management","DRUG:HRS9531 Injection; DRUG:Placebo Injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-08","FALSE","0"],["S000303","ClinicalTrials.gov","NCT03876015","SURE UK","A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","215","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2019-05-01","FALSE","2"],["S000304","ClinicalTrials.gov","NCT01403025",null,"A Multi-centre, Open Label, Observational, Non-interventional Study to Evaluate the Safety and Effectiveness of Victoza® in Subjects With Type 2 Diabetes Mellitus","OBSERVATIONAL",null,null,"COMPLETED","4121","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2011-07-19","FALSE","0"],["S000305","ClinicalTrials.gov","NCT02597049","AWARD-10","A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","424","Type 2 Diabetes Mellitus","DRUG:Dulaglutide; DRUG:Placebo; DRUG:SGLT2 inhibitor; DRUG:Metformin","Eli Lilly and Company","2015-11","TRUE","3"],["S000306","ClinicalTrials.gov","NCT01508949",null,"NNC 90-1170 Mechanism of Action: A Single-centre, Randomised, Double-blind, Parallel-group, Placebo-controlled Trial Evaluating the Effect of NNC 90-1170 on Weight and Appetite in Obese Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","35","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2001-06","FALSE","1"],["S000307","ClinicalTrials.gov","NCT01288326","ROOTS","A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate the Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes Mellitus","OBSERVATIONAL",null,null,"COMPLETED","254","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2011-02","FALSE","1"],["S000308","ClinicalTrials.gov","NCT05377333",null,"Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","94","Diabetes Mellitus, Type 2","DRUG:LY3457263; DRUG:Placebo; DRUG:Dulaglutide","Eli Lilly and Company","2022-06-02","FALSE","0"],["S000309","ClinicalTrials.gov","NCT04152915",null,"A Trial to Demonstrate Bioequivalence Between Semaglutide D Formulations for the DV3396 Pen-Injector and the Formulation for the PDS290 Semaglutide Pen-Injector","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","68","Healthy Volunteers; Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2019-11-25","FALSE","0"],["S000310","ClinicalTrials.gov","NCT03287076","TEXAIS","A Multicentre, Randomised Controlled Trial of Exenatide Versus Standard Care in Acute Ischemic Stroke (TEXAIS)","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","350","Acute Ischemic Stroke","DRUG:Exenatide Injection","Neuroscience Trials Australia","2017-11-23","FALSE","1"],["S000311","ClinicalTrials.gov","NCT07428525",null,"A Phase 1, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics of AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","36","Hepatic Impairment","DRUG:AMG 133","Amgen","2025-03-14","FALSE","0"],["S000312","ClinicalTrials.gov","NCT07693426",null,"A Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Efsubaglutide Alfa in Chinese Adolescents With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","36","Adolescence Obesity","DRUG:Efsubaglutide Alfa 5 mg QW; DRUG:Efsubaglutide Alfa 10 mg QW; DRUG:Efsubaglutide Alfa 20 mg QW; DRUG:Efsubaglutide Alfa placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2026-07-16","FALSE","0"],["S000313","ClinicalTrials.gov","NCT07617155","RECAP-GLP1","Effects of GLP-1 Agonists on Prevention of HTG-Induced Acute Pancreatitis Recurrence: Protocol for a Randomized Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","396","Hypertriglyceridemia Induced Acute Pancreatitis; Recurrent Acute Pancreatitis; Pancreatitis Relapsing; Hypertriglyceridemia","DRUG:Semaglutide; DRUG:Placebo (Normal Saline)","Peking Union Medical College Hospital","2026-09","FALSE","18"],["S000314","ClinicalTrials.gov","NCT00937079",null,"The Physiology of Glucagon-like-peptide-1 Receptor Expression in Patients With Endogenous Hyperinsulinism - Correlation With Histopathology","OBSERVATIONAL",null,null,"COMPLETED","30","Hyperinsulinism; Hypoglycemia; Insulinoma","OTHER:111In-exendin-4 imaging","University Hospital, Basel, Switzerland","2007-11","FALSE","1"],["S000315","ClinicalTrials.gov","NCT01484873",null,"Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity","INTERVENTIONAL",null,"PHASE2","COMPLETED","10","Obesity; Overweight; Craniopharyngioma","DRUG:Exenatide","Vanderbilt University Medical Center","2012-06","TRUE","1"],["S000316","ClinicalTrials.gov","NCT07117240",null,"Efficacy of Treatment Strategies for Steroid-induced Diabetes - a Comparison of GLP-1 Receptor Agonist Plus Basal Insulin With Intensive Insulin Therapy","INTERVENTIONAL","RANDOMIZED","PHASE4","ENROLLING_BY_INVITATION","100","Steroid-Induced Diabetes; Steroid-Induced Hyperglycemia; Diabetes","DRUG:lixisenatide + glargine; DRUG:Intensive insulin therapy","Medical University of Warsaw","2025-07-10","FALSE","0"],["S000317","ClinicalTrials.gov","NCT06924697",null,"Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients: Study Protocol of a Randomized, Parallel -Controlled Clinical Trial","INTERVENTIONAL","RANDOMIZED",null,"ENROLLING_BY_INVITATION","46","Diabetes Mellitus, Type 2; Nicotine Dependence, Cigarettes","DRUG:Application of GLP-1RAs drugs; DRUG:DPP-4i group","Shanghai East Hospital","2025-06-21","FALSE","1"],["S000318","ClinicalTrials.gov","NCT04775082",null,"Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Below 12 Years: 56-week, Double-blind, Randomised, Placebo-controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","78","Obesity","DRUG:Liraglutide; DRUG:Placebo","Novo Nordisk A/S","2021-03-04","FALSE","2"],["S000319","ClinicalTrials.gov","NCT05225974",null,"A Phase 1 Study of Liraglutide Injection and Victoza® in Healthy Chinese Subjects: An Open, Randomized, Single-Dose and Crossover Study","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Therapeutic Equivalency","DRUG:Liraglutide injection; DRUG:Liraglutide injection(Victoza®)","The Affiliated Hospital of Qingdao University","2021-07-16","FALSE","0"],["S000320","ClinicalTrials.gov","NCT00381342",null,"Safety and Efficacy of Exenatide as Monotherapy in Drug Naive Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","233","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:placebo","AstraZeneca","2006-09","FALSE","3"],["S000321","ClinicalTrials.gov","NCT07812597",null,"A Multicenter, Randomized, Active-Controlled, Open-Label Phase IIb Study Evaluating Safety and Tolerability of Switching to Zovaglutide Injection After Titration to 2.4 mg Semaglutide Injection (Wegovy®) in Adults With Obesity (HORIZON-SWITCH-SZ)","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","210","Obesity","DRUG:zovaglutide Arm 1; DRUG:zovaglutide Arm 2; DRUG:semaglutide","Beijing QL Biopharmaceutical Co.,Ltd","2026-10-12","FALSE","0"],["S000322","ClinicalTrials.gov","NCT07411560",null,"Single-centre Study Investigating the Role of Long-acting Subcutaneous Glucose-dependent Insulinotropic Polypeptide Receptor Agonist (GIP RA) in Combination With Long-acting Subcutaneous Amylin Receptor Agonist on Gastrointestinal Tolerability in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","100","Overweight; Obese","DRUG:Glucose-dependent Insulinotropic Polypeptide (GIP); DRUG:Cagrilintide; DRUG:Placebo GIP","Novo Nordisk A/S","2026-02-09","FALSE","0"],["S000323","ClinicalTrials.gov","NCT07625774","RENEW-CKD","A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Evaluate the Efficacy and Safety of HRS-7535 in Participants With Chronic Kidney Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","3690","Chronic Kidney Disease","DRUG:HRS-7535; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2026-07","FALSE","0"],["S000324","ClinicalTrials.gov","NCT06153758",null,"A Phase 1, 4-Part, Open-Label, Randomized Study With A 5-Period, 4 Sequence, Crossover Design to Compare the Single Dose Pharmacokinetics Between Immediate and Modified Release Formulations of Danuglipron Administered Orally to Healthy Adult Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","33","Healthy Participants; Healthy Subjects","DRUG:Danuglipron","Pfizer","2023-11-27","FALSE","0"],["S000325","ClinicalTrials.gov","NCT03707990",null,"A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0165-1875 as Monotherapy and in Combination With Semaglutide in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","88","Obesity and Overweight","DRUG:NNC0165-1875; DRUG:Placebo (NNC0165-1875); DRUG:Semaglutide","Novo Nordisk A/S","2018-10-15","FALSE","0"],["S000326","ClinicalTrials.gov","NCT07297589","EPIC-CT","Epicardial Cardiac Fat Comparative Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","136","STEMI - ST Elevation Myocardial Infarction; Epicardial Fat","DRUG:Dapagliflozin 10 MG Oral Tablet; DRUG:Semaglutide (Rybelsus®)","Instituto Mexicano del Seguro Social","2025-12-30","FALSE","0"],["S000327","ClinicalTrials.gov","NCT03591718",null,"A Phase I, Blinded Within Dose Groups, Multiple Dose, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Different Titration Schemes of BI 456906 in Patients With Obesity and Overweight.","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","131","Obesity","DRUG:BI 456906; DRUG:Placebo","Boehringer Ingelheim","2018-07-26","FALSE","2"],["S000328","ClinicalTrials.gov","NCT07298915","EXER-MED","The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","24","Obesity & Overweight","DRUG:Tirzepatide; BEHAVIORAL:Exercise","University of Virginia","2026-08","FALSE","0"],["S000329","ClinicalTrials.gov","NCT01885208","SUSTAIN™ 3","Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","813","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:exenatide","Novo Nordisk A/S","2013-12-02","TRUE","18"],["S000330","ClinicalTrials.gov","NCT00393718",null,"Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","400","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:glibenclamide; DRUG:placebo","Novo Nordisk A/S","2006-11","TRUE","5"],["S000331","ClinicalTrials.gov","NCT01077323",null,"A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Byetta (Exenatide) and Other Antidiabetic Agents","OBSERVATIONAL",null,null,"COMPLETED","363766","Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies); Healthy Subjects (Treated With no Diabetes Therapies)","DRUG:exenatide; DRUG:Other antidiabetic therapies; OTHER:No diabetes therapy","AstraZeneca","2004-09","TRUE","0"],["S000332","ClinicalTrials.gov","NCT02889510",null,"Multicentre Randomized Double Blind, Crossover, Placebo Controlled Clinical Trial to Evaluate the Effect of Liraglutide on Lung Function in Patients With Type 2 Diabetes Mellitus (LIRALUNG Study)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","76","Type 2 Diabetes","DRUG:liraglutide; DRUG:placebo","Lecube, Albert, M.D.","2016-10-04","TRUE","2"],["S000333","ClinicalTrials.gov","NCT01517555",null,"A Single Centre, Randomised, Double-blind, Placebo Controlled Trial to Evaluate the Possible Drug-drug Interaction Between Liraglutide and Paracetamol and the Effects of Liraglutide on Postprandial Glucose and Insulin, Gastric Emptying, Appetite Sensations and Energy Intake in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","18","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:paracetamol","Novo Nordisk A/S","2006-10","FALSE","4"],["S000334","ClinicalTrials.gov","NCT06619015","TOTT","The Impact of Pramlintide on Top of Semaglutide in Obese People With Prediabetes","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","WITHDRAWN","0","Obesity; Appetite Regulation; PreDiabetes","DRUG:Pramlintide Acetate 1 MG/ML; DRUG:Semaglutide Pen Injector; DRUG:Sodium Chloride 0.9% Inj","Esbjerg Hospital - University Hospital of Southern Denmark","2025-04-01","FALSE","0"],["S000335","ClinicalTrials.gov","NCT07163624","T2DM","A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of UBT251 Injection in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","211","Type 2 Diabetes Mellitus (T2DM)","DRUG:UBT251 Injection 2.0 mg and UBT251 Injection Placebo; DRUG:UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo; DRUG:UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo; DRUG:UBT251 Injection 6.0 mg and UBT251 Injection Placebo; DRUG:Semaglutide Injection (Ozempic®)","The United Bio-Technology (Hengqin) Co., Ltd.","2025-03-22","FALSE","0"],["S000336","ClinicalTrials.gov","NCT07599046",null,"Effects of Comprehensive Intervention With Fecal Microbiota Transplantation Versus Conventional Treatment on Body Weight and Metabolism in Patients With Obesity Complicated by Type 2 Diabetes Mellitus: A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","20","Obesity Type 2 Diabetes Mellitus","BIOLOGICAL:Fecal microbiota transplantation (FMT); DRUG:Semaglutide (1 Mg Dose); BEHAVIORAL:Calorie-restricted diet","Eighth Affiliated Hospital, Sun Yat-sen University","2026-04-30","FALSE","0"],["S000337","ClinicalTrials.gov","NCT00630825","EGO","The Effect of Dose Titration of LY2189265 in Overweight and Obese Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","262","Diabetes Mellitus Type 2","DRUG:LY2189265; DRUG:Placebo","Eli Lilly and Company","2008-04","TRUE","0"],["S000338","ClinicalTrials.gov","NCT01919489",null,"A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide Versus Glargine Insulin for the Management of Patients With Type 2 Diabetes After Hospital Discharge","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","273","Type 2 Diabetes","DRUG:Liraglutide + OADs; DRUG:Glargine + OADs","Emory University","2014-03","TRUE","0"],["S000339","ClinicalTrials.gov","NCT04971785","WAYFIND","A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","457","Nonalcoholic Steatohepatitis","DRUG:Semaglutide (SEMA); DRUG:Cilofexor (CILO)/Firsocostat (FIR); DRUG:PTM SEMA; DRUG:PTM CILO/FIR","Gilead Sciences","2021-08-09","TRUE","2"],["S000340","ClinicalTrials.gov","NCT01783717",null,"Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage","INTERVENTIONAL",null,null,"UNKNOWN","10","Hypothalamic Obesity; Diabetes Mellitus","DRUG:Exenatide","Huashan Hospital","2012-12","FALSE","0"],["S000341","ClinicalTrials.gov","NCT02838589","EGRABINS1","The Effect of Glucagon-like Peptide 1 (GLP-1) Receptor Agonist on Cerebral Blood Flow Velocity in Non-Stroke Volunteers (EGRABINS1)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","30","Stroke","DRUG:Byetta; DRUG:Isotonic saline","Christina Kruuse","2016-08","FALSE","1"],["S000342","ClinicalTrials.gov","NCT07539415",null,"A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","72","Obesity & Overweight; Type 2 Diabetes","DRUG:DWRX5003; DRUG:DWC202502; DRUG:DWC202503; OTHER:DWRX5003P","Daewoong Pharmaceutical Co. LTD.","2026-05-06","FALSE","0"],["S000343","ClinicalTrials.gov","NCT03737240",null,"A Randomized Controlled Trial Comparing the Safety and Efficacy of IDegLira Versus Basal Bolus in Patients With Poorly Controlled Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","145","Diabetes Mellitus","DRUG:IDegLira; DRUG:Insulin Degludec (U-100); DRUG:Insulin Aspart","Emory University","2019-01-15","TRUE","0"],["S000344","ClinicalTrials.gov","NCT06555146","Sema-RMA","Glucagon-like Peptide-1's Effect on Renal Regional Blood Flow and the Renal Function in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","15","Diabetes Mellitus, Type 2; Kidney Disease, Chronic","DRUG:Semaglutide, 0.5 mg/mL; DRUG:Placebo, Saline","Bispebjerg Hospital","2024-08","FALSE","1"],["S000345","ClinicalTrials.gov","NCT00765817",null,"A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","261","Type 2 Diabetes","DRUG:placebo; DRUG:exenatide","AstraZeneca","2008-10","TRUE","5"],["S000346","ClinicalTrials.gov","NCT05755360","DOORS","A Multicentre, Prospective, Non-Interventional, Single-Arm Study Investigating Glycaemic Control and Patient-Reported Outcomes in Type 2 Diabetes Patients, Uncontrolled on DPP4i Treatment and Who Switch to Oral Semaglutide in a Real-World Setting in Italy","OBSERVATIONAL",null,null,"COMPLETED","291","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2023-02-21","FALSE","0"],["S000347","ClinicalTrials.gov","NCT06914102","DUP-STEP-HFpEF","Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data","OBSERVATIONAL",null,null,"COMPLETED","58387","Diabetes Mellitus, Type 2; HFpEF - Heart Failure With Preserved Ejection Fraction","DRUG:Semaglutide; DRUG:Placebo","Brigham and Women's Hospital","2025-01-14","FALSE","1"],["S000348","ClinicalTrials.gov","NCT03029351","1981","GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","15","Type2 Diabetes; Kidney Diseases","DRUG:Exenatide Extended Release for Inj Susp 2 MG; DRUG:Placebo","University at Buffalo","2017-01-10","TRUE","0"],["S000349","ClinicalTrials.gov","NCT07633639",null,"The Efficacy and Safety of Adjuvant GLP-1 Receptor Agonist Therapy Following Metabolic Bariatric Surgery in Chinese Patients With Obesity: A Prospective, Monocentric, Stratified Randomized Controlled Trial","INTERVENTIONAL","NON_RANDOMIZED",null,"RECRUITING","200","Obesity","COMBINATION_PRODUCT:LSG-Semaglutide group; COMBINATION_PRODUCT:LSG-Mazdutide group; COMBINATION_PRODUCT:LSG-Tirzepatide group; PROCEDURE:LSG group","China-Japan Friendship Hospital","2026-05-01","FALSE","0"],["S000350","ClinicalTrials.gov","NCT06422039",null,"A Clinical Study to Evaluate the Relative Bioavailability of HRS-7535 Tablets of Different Formulating Processes and the Effects of Food on New Formulates (Single Center, Random, Open, Cross)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Type 2 Diabetes Mellitus","DRUG:HRS-7535(D) Tablets; DRUG:HRS-7535(C) Tablets","Shandong Suncadia Medicine Co., Ltd.","2024-05-23","FALSE","0"],["S000351","ClinicalTrials.gov","NCT01156779","SR-Exenatide","A Dose Block-randomized, Double-blind, Placebo-controlled, Dose-escalating, Phase I Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of DA-3091 After Subcutaneous Injection in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","31","Diabetes Mellitus","DRUG:SR-exenatide","Dong-A Pharmaceutical Co., Ltd.","2010-07","FALSE","0"],["S000352","ClinicalTrials.gov","NCT01029886",null,"Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes and Inadequate Glycemic Control Treated With Lifestyle Modification and Oral Antidiabetic Medications","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","912","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:liraglutide","AstraZeneca","2010-01","TRUE","3"],["S000353","ClinicalTrials.gov","NCT07731256",null,"A Randomized-Controlled Trial of Semaglutide for Patients With Chronic Low Back Pain and Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","250","Lower Back Pain; Obesity (BMI>30); Chronic Lower Back Pain; glp1 Agonist","DRUG:Semaglutide (administered by PDS290 pen-injector); DRUG:Placebo (administered by PDS290 pen-injector)","Washington University School of Medicine","2027-02-01","FALSE","7"],["S000354","ClinicalTrials.gov","NCT00974272",null,"Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","39","Type 2 Diabetes Mellitus; Impaired Glucose Tolerance","DRUG:Exenatide; OTHER:Normal Saline","Carl T. Hayden VA Medical Center","2006-08","FALSE","2"],["S000355","ClinicalTrials.gov","NCT06500429",null,"A Proof-of-Concept, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of Oral NG101 in the Treatment of Side Effects in Healthy Adult Participants Administered a Single Subcutaneous Dose of a Glucagon-Like Peptide 1 Agonist","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","120","Overweight and Obesity; Healthy","DRUG:NG101; DRUG:Placebo; DRUG:Semaglutide Injectable Product","Neurogastrx, Inc.","2024-06-24","FALSE","0"],["S000356","ClinicalTrials.gov","NCT02752412","LIXILAN JP-L","A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine With Metformin in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","513","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide (HOE901/AVE0010); DRUG:Insulin glargine U100 (HOE901); DRUG:Metformin","Sanofi","2016-05-17","FALSE","3"],["S000357","ClinicalTrials.gov","NCT01541215","Ellipse™","Efficacy and Safety of Liraglutide in Combination With Metformin Versus Metformin Monotherapy on Glycaemic Control in Children and Adolescents With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","135","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:metformin","Novo Nordisk A/S","2012-11-13","TRUE","3"],["S000358","ClinicalTrials.gov","NCT01767389",null,"Glucagon-like Peptide-1 (GLP-1) Agonists: Treatment Utilization Patterns and Risk of Acute Pancreatitis","OBSERVATIONAL",null,null,"COMPLETED","1","Diabetes Mellitus, Type 2","OTHER:The GLP-1 receptor agonist users; OTHER:DPP-4 inhibitor users; OTHER:Other ADA users","GlaxoSmithKline","2012-09","FALSE","0"],["S000359","ClinicalTrials.gov","NCT01508897",null,"A Randomized, Single-blind, Single-centre, Two-period, Cross-over Trial Investigating the Bioequivalence Between Completed Phase 2 and Planned Phase 3 Formulations of Liraglutide in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","22","Diabetes; Healthy","DRUG:liraglutide","Novo Nordisk A/S","2004-05-28","FALSE","0"],["S000360","ClinicalTrials.gov","NCT07357415","TRIUMPH-9","A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","600","Obesity; Overweight","DRUG:Retatrutide","Eli Lilly and Company","2026-01-24","FALSE","0"],["S000361","ClinicalTrials.gov","NCT01572740",null,"A 36-week, Randomised, Multi-centre, Double-blind, Parallel Group Trial to Investigate the Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Monotherapy in Japanese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","257","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:insulin","Novo Nordisk A/S","2012-04-05","TRUE","2"],["S000362","ClinicalTrials.gov","NCT07627074",null,"Real-world Weight Outcomes in Adults Treated With Semaglutide s.c. 1.0 mg or 1.7 mg for Weight Management: a Non-interventional Cohort Study","OBSERVATIONAL",null,null,"COMPLETED","237211","Overweight; Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2026-05-12","FALSE","0"],["S000363","ClinicalTrials.gov","NCT03689374","SUSTAIN 11","Effect of Semaglutide Once-weekly Versus Insulin Aspart Three Times Daily, Both as Add on to Metformin and Optimised Insulin Glargine (U100) in Subjects With Type 2 Diabetes A 52-week, Multi-centre, Multinational, Open-label, Active-controlled, Two Armed, Parallel-group, Randomised Trial in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","2274","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Insulin aspart; DRUG:Insulin glargine U100","Novo Nordisk A/S","2018-10-01","TRUE","1"],["S000364","ClinicalTrials.gov","NCT06858878","MARITIME-2","A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","1105","Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2025-03-17","FALSE","0"],["S000365","ClinicalTrials.gov","NCT01511185",null,"NNC 90-1170 Mechanism of Action: A Double-blind, Randomized, Single-center, Placebo Controlled, Crossover Study to Examine Beta-cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","20","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2001-02","FALSE","1"],["S000366","ClinicalTrials.gov","NCT06351748","SCHOLAR","Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)","OBSERVATIONAL",null,null,"COMPLETED","34238","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2024-01-02","FALSE","3"],["S000367","ClinicalTrials.gov","NCT06066515","SYNCHRONIZE™-1","A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","726","Obesity","COMBINATION_PRODUCT:survodutide; COMBINATION_PRODUCT:Placebo","Boehringer Ingelheim","2023-11-25","FALSE","4"],["S000368","ClinicalTrials.gov","NCT01739049",null,"The Influence of Appetite-Related Central and Gut Hormones in Modulating Binge Eating Behaviour in Obese and Overweight Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","42","Binge Eating Behaviour","DRUG:Liraglutide; BEHAVIORAL:Diet and Exercise","Universiti Kebangsaan Malaysia Medical Centre","2012-11","FALSE","1"],["S000369","ClinicalTrials.gov","NCT07732738","BS-GLP","The Efficacy and Safety of Bariatric Surgery Combined With GLP-1 Receptor Agonists for Patients With Obesity: A Prospective, Multicenter Cohort Study","INTERVENTIONAL","NON_RANDOMIZED",null,"RECRUITING","400","Obesity","COMBINATION_PRODUCT:BS-GLP1RA group; PROCEDURE:BS group","China-Japan Friendship Hospital","2025-01-01","FALSE","0"],["S000370","ClinicalTrials.gov","NCT02765399",null,"The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis - a Single-center Randomized Controlled Study","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","23","Type 2 Diabetes","DRUG:Liraglutide; DRUG:Placebo","Helsinki University Central Hospital","2015-02-01","TRUE","2"],["S000371","ClinicalTrials.gov","NCT04122716","S-LITE","Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","215","Obesity","DRUG:Liraglutide; BEHAVIORAL:Exercise","Signe Torekov","2016-09","FALSE","31"],["S000372","ClinicalTrials.gov","NCT02648204","SUSTAIN 7","Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1201","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:Dulaglutide","Novo Nordisk A/S","2016-01-06","TRUE","13"],["S000373","ClinicalTrials.gov","NCT03182296",null,"Visualizing Beta Cells in Patients With a History of Gestational Diabetes","INTERVENTIONAL","NON_RANDOMIZED",null,"UNKNOWN","24","Gestational Diabetes","RADIATION:68Ga-NODAGA-exendin-4 PET/CT","Radboud University Medical Center","2016-11-10","FALSE","0"],["S000374","ClinicalTrials.gov","NCT02472717","PLAQUE","Clinical Evaluation of Psoriatic Arthritis Treated With Liraglutide. The PLAQUE Study: Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study","INTERVENTIONAL","RANDOMIZED","PHASE2","WITHDRAWN","0","Psoriatic Arthritis; Psoriasis; Impaired Glucose Tolerance; Type 2 Diabetes","DRUG:liraglutide; OTHER:Placebo","University Health Network, Toronto","2015-05","FALSE","0"],["S000375","ClinicalTrials.gov","NCT07781150","MELIA","Mazdutide Plus Levonorgestrel-Releasing Intrauterine System for Fertility-Sparing Treatment in Overweight or Obese Patients With Atypical Endometrial Hyperplasia or Early Endometrioid Endometrial Cancer","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","128","Obesity; Overweight; Atypical Endometrial Hyperplasia; Endometrial Carcinoma Stage I; Endometrioid Endometrial Cancer","DRUG:Mazdutide(Dual GLP-1R/GCGR Agonist); DRUG:Placebo; DEVICE:Levonorgestrel-releasing intrauterine system","Tongji Hospital","2026-11-01","FALSE","0"],["S000376","ClinicalTrials.gov","NCT00791479",null,"Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients With Type 2 Diabetes Treated Only With Lifestyle Interventions","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","167","Diabetes Mellitus, Type 2","DRUG:LY2189265 and Lifestyle Measures; DRUG:Placebo solution and Lifestyle Measures","Eli Lilly and Company","2008-12","TRUE","1"],["S000377","ClinicalTrials.gov","NCT06851962","EPHIC-DIA2","Open-label, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes.","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","92","Diabetes Mellitus Type 2","DRUG:Metformin; DRUG:Dulaglutide; DRUG:Semaglutide 1.0 mg; DRUG:Empagliflozin (BI 10773); DRUG:Canagliflozin; DRUG:Dapagliflozin; DRUG:pioglitazone; DRUG:Sitagliptin; DRUG:Vildagliptin (Galvus); DRUG:linagliptin","Fundación para la Investigación del Hospital Clínico de Valencia","2025-05-26","FALSE","0"],["S000378","ClinicalTrials.gov","NCT04990024",null,"The Effect of Mediterranean or High Protein/Low Carbohydrate Diet on Arterial Stiffness in Non-diabetic, Obese Patients on Semaglutide: A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","60","Obesity; Weight Loss","OTHER:Dietary Intervention Med Diet; OTHER:Dietary Intervention HP/LC Diet","American University of Beirut Medical Center","2021-07-01","FALSE","0"],["S000379","ClinicalTrials.gov","NCT07782359","NSCLC","Impact of Tirzepatide on Lorlatinib-Associated Weight Gain and Metabolic Derangements in Patients With Non-Small Cell Lung Cancer (NSCLC)","INTERVENTIONAL",null,"PHASE1","NOT_YET_RECRUITING","30","Lung Cancer","DRUG:Tirzepatide","University of Chicago","2026-10","FALSE","0"],["S000380","ClinicalTrials.gov","NCT02928679","IM-LOSEIT-II","Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis Following Liraglutide Treatment, Investigating the Impact on Inflammation","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","150","Osteoarthritis; Obesity","DRUG:Liraglutide 3 mg (Saxenda); DRUG:Liraglutide 3 mg placebo","Henrik Gudbergsen","2016-11","FALSE","0"],["S000381","ClinicalTrials.gov","NCT02467920",null,"Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Switching Premix Human Insulin to Aspart30 in T2DM With Inadequate Glycaemic Control on Premixed Human Insulin and Metformin: a Randomized, Open, Parallel Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","349","Type 2 Diabetes Mellitus","DRUG:glargine + exenatide; DRUG:aspart 30","Huazhong University of Science and Technology","2015-08","FALSE","0"],["S000382","ClinicalTrials.gov","NCT06174779",null,"A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","448","Obesity","DRUG:HM11260C; DRUG:Placebo","Hanmi Pharmaceutical Company Limited","2024-01-03","FALSE","0"],["S000383","ClinicalTrials.gov","NCT01965496",null,"A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 14 Weeks Injection of Polyethylene Glycol Loxenatide","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","64","Type 2 Diabetes","DRUG:PEX168","Jiangsu HengRui Medicine Co., Ltd.","2012-03","FALSE","0"],["S000384","ClinicalTrials.gov","NCT02584582","ALFA-1","The Effect of GLP-1 on Postprandial Glucagon Secretion During Prolonged and Intermittent Stimulation of the GLP-1 Receptor Independent of The Gastric Emptying Rate. A Randomized, Open-label Study in People With Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","UNKNOWN","10","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Exenatide; PROCEDURE:Liquid meal test; OTHER:No drug (Baseline day)","Hvidovre University Hospital","2015-07","FALSE","0"],["S000385","ClinicalTrials.gov","NCT05622123","BetaFIT","The Effects of Faecal Microbiota Transplantation on Beta Cell Preservation in Patients With Newly Diagnosed Type 1 Diabetes","INTERVENTIONAL",null,"PHASE2","UNKNOWN","20","Type 1 Diabetes","DRUG:68Ga-NODAGA-Exendin-4","Radboud University Medical Center","2023-02-23","FALSE","0"],["S000386","ClinicalTrials.gov","NCT01452451",null,"A Double-Masked, Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 2 Study to Determine the Tolerability, Pharmacokinetics, and Pharmacodynamics of the GLP 1 Agonist HM11260C in Adult Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","72","Diabetes Mellitus","DRUG:HM11260C; DRUG:Placebo","Hanmi Pharmaceutical Company Limited","2011-12","FALSE","0"],["S000387","ClinicalTrials.gov","NCT06297603",null,"A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 Inhibitor","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","320","Type 2 Diabetes","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2024-03-15","FALSE","0"],["S000388","ClinicalTrials.gov","NCT04883346",null,"Phase II Trial of Liraglutide (Saxenda(R), Novo Nordisk) in Adolescents With Obesity After Sleeve Gastrectomy: A Pilot Open-Label Study","INTERVENTIONAL",null,"PHASE2","COMPLETED","34","Obesity; Status Post Sleeve Gastrectomy","DRUG:Liraglutide","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","2021-06-21","TRUE","4"],["S000389","ClinicalTrials.gov","NCT03010683",null,"Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","60","Type 2 Diabetes Mellitus; Coronary Artery Disease","DRUG:Liraglutide; DRUG:Metformin","University of Athens","2015-11","TRUE","2"],["S000390","ClinicalTrials.gov","NCT04407234",null,"The Impact of Tirzepatide on Gastric Emptying (GE) in Overweight/Obese Non-diabetic Subjects and in Overweight/Obese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE1","COMPLETED","36","Overweight; Obesity; Diabetes Mellitus, Type 2","DRUG:Tirzepatide; DRUG:Acetaminophen","Eli Lilly and Company","2020-09-15","TRUE","0"],["S000391","ClinicalTrials.gov","NCT07141914",null,"A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World","OBSERVATIONAL",null,null,"COMPLETED","285327","Overweight; Obesity; Heart Failure (HF); Atherosclerotic Cardiovascular Disease (ASCVD); Primary Prevention","OTHER:No treatment given","Novo Nordisk A/S","2025-08-29","FALSE","0"],["S000392","ClinicalTrials.gov","NCT06937099","COMMIT-CD","A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","290","Crohn's Disease; Obesity or Overweight","DRUG:Mirikizumab; DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2025-06-26","FALSE","0"],["S000393","ClinicalTrials.gov","NCT06363747",null,"The Medically Reproducing Bariatric Surgery (MRB) II Study: SEMAGLUTIDE Followed by OPTIFAST in Veterans With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","ACTIVE_NOT_RECRUITING","50","Type 2 Diabetes; Obesity","OTHER:Very Low Calorie Diet","Durham VA Medical Center","2024-06-24","FALSE","3"],["S000394","ClinicalTrials.gov","NCT01937598",null,"Antidiabetic Effects of Adding a DPP-4 Inhibitor (Sitagliptin) to Pre-Existing Treatment With an Incretin Mimetic (Liraglutide) in Patients With Type 2 Diabetes Treated With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","16","Type 2 Diabetes","DRUG:Placebo; OTHER:Mixed meal test; DRUG:Liraglutide; DRUG:Sitagliptin","Michael A. Nauck","2013-08","TRUE","0"],["S000395","ClinicalTrials.gov","NCT04865770","REMODEL","Renal Mode of Action of Semaglutide in Patients With Type 2 Diabetes and Chronic Kidney Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","106","Diabetes Mellitus, Type 2; Chronic Kidney Disease","DRUG:Semaglutide; DRUG:Placebo (Semaglutide)","Novo Nordisk A/S","2021-04-28","TRUE","9"],["S000396","ClinicalTrials.gov","NCT02655770",null,"Influence of Liraglutide on Diastolic Cardiac Function and Myocardial Perfusion as Determined by Magnetic Resonance Imaging in Patients With Type 2 Diabetes: a Double-blind Randomized Parallel-group Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","40","Diabetes Mellitus Type 2; Diastolic Dysfunction; Cardiac MRI; Myocardial Perfusion","DRUG:Liraglutide; DRUG:Placebo","Copenhagen University Hospital, Rigshospitalet","2016-02","FALSE","1"],["S000397","ClinicalTrials.gov","NCT06164873",null,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of IBI362 9 mg in Chinese Participants With Obesity (GLORY-2)","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","462","Obesity","DRUG:IBI362; DRUG:Placebo","Innovent Biologics (Suzhou) Co. Ltd.","2023-12-27","FALSE","2"],["S000398","ClinicalTrials.gov","NCT00856986",null,"The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes. A 26 Week, Randomised, Open-label, Parallel-group, Multicentre, Multinational Trial With a 26 Week Extension","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","987","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:insulin detemir; DRUG:metformin","Novo Nordisk A/S","2009-03","TRUE","3"],["S000399","ClinicalTrials.gov","NCT07282041","RADIANT","Role of Glucagon-like Peptide 1 Receptor Agonist (GLP1 RA) Dulaglutide on Cerebral Hemodynamics In Patients With Severe and symptomAtic steNosis of inTracranial Internal Carotid Artery or Middle Cerebral Artery With Impaired Cerebral Vasodilatory Reserve- an Open-label Randomised Clinical Trial (RADIANT)","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","RECRUITING","130","Intracranial Atherosclerosis; Stroke, Ischemic","DRUG:Dulaglutide","National University of Singapore","2025-12-17","FALSE","0"],["S000400","ClinicalTrials.gov","NCT00679042",null,"Islet Transplantation in Type 1 Diabetic Patients Using the UIC Protocol, Phase 3","INTERVENTIONAL",null,"PHASE3","ACTIVE_NOT_RECRUITING","21","Type 1 Diabetes Mellitus","BIOLOGICAL:Islets of Langerhans transplantation","CellTrans Inc.","2007-09-05","TRUE","0"],["S000401","ClinicalTrials.gov","NCT04091373",null,"A Phase 1, Randomized, Open-label, Single Center, Three Period Cross-over Study to Evaluate the Pharmacokinetics of Single Dose Administration of Cotadutide in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","36","Type 2 Diabetes Mellitus","COMBINATION_PRODUCT:cotadutide multidose pen injection","MedImmune LLC","2019-09-27","FALSE","0"],["S000402","ClinicalTrials.gov","NCT00637273",null,"A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release(Once Weekly) to Those of Sitagliptin and a Thiazolidinedione in Subjects With Type 2 Diabetes Mellitus Treated With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","514","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:sitagliptin; DRUG:pioglitazone; DRUG:placebo tablet; DRUG:placebo once weekly","AstraZeneca","2008-01","TRUE","7"],["S000403","ClinicalTrials.gov","NCT02089256",null,"Effect of Repeated Administration of Liraglutide on Insulinogenic Indices","INTERVENTIONAL",null,"PHASE4","COMPLETED","10","Healthy","DRUG:Liraglutide","University of Tartu","2014-06","FALSE","3"],["S000404","ClinicalTrials.gov","NCT01722266",null,"Liraglutide in the Treatment of Type 1 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","72","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Placebo","University at Buffalo","2012-11-01","TRUE","9"],["S000405","ClinicalTrials.gov","NCT02527200",null,"Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","56","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2015-11-09","TRUE","1"],["S000406","ClinicalTrials.gov","NCT07846865","TIRZE-PAP","Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","NOT_YET_RECRUITING","256","Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive","DEVICE:Continuous Positive Airway Pressure; DRUG:Tirzepatide","Woolcock Institute of Medical Research","2026-10-01","FALSE","0"],["S000407","ClinicalTrials.gov","NCT03954834","SURPASS-1","A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","478","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2019-06-03","TRUE","6"],["S000408","ClinicalTrials.gov","NCT06390501",null,"The Effect of Weekly Semaglutide Treatment on Energy Expenditure","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","60","Obesity; Drug","DRUG:Semaglutide; DRUG:Placebo","Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences","2024-04-01","FALSE","0"],["S000409","ClinicalTrials.gov","NCT02516657",null,"Effect of Liraglutide on Glycemic Control, Glucagon Secretion and Inflammatory Markers in Adolescents With Type 1 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE3","COMPLETED","5","Type 1 Diabetes","DRUG:Liraglutide","University at Buffalo","2012-05","TRUE","0"],["S000410","ClinicalTrials.gov","NCT02895672",null,"A Real-world, Observational Study of GLP-1 Therapy Added to Basal Insulin in Patients With Type 2 Diabetes Mellitus","OBSERVATIONAL",null,null,"COMPLETED","150","Type 2 Diabetes Mellitus","DRUG:GLP-1 therapy","Albany College of Pharmacy and Health Sciences","2016-08","FALSE","2"],["S000411","ClinicalTrials.gov","NCT04311411",null,"Effect of Tirzepatide on Energy Intake and Appetite-and Reward-Related Brain Areas in Overweight/Obese Subjects: A Placebo-Controlled 6-Week Study With Functional MRI","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","114","Obesity; Overweight","DRUG:Tirzepatide; DRUG:Placebo; DRUG:Liraglutide","Eli Lilly and Company","2020-08-24","TRUE","1"],["S000412","ClinicalTrials.gov","NCT05989711","IMPACT","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","212","Non-Alcoholic Steatohepatitis (NASH)","DRUG:Pemvidutide; DRUG:Placebo","Altimmune, Inc.","2023-07-27","FALSE","2"],["S000413","ClinicalTrials.gov","NCT00353834",null,"The Effect of Exenatide Compared to Lantus Insulin on Vascular Function Before and After a Meal Tolerance Test in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","72","Type 2 Diabetes Mellitus","DRUG:Exenatide; DRUG:Glargine Insulin","Joslin Diabetes Center","2006-08","TRUE","0"],["S000414","ClinicalTrials.gov","NCT00717457",null,"Randomized, Active Controlled, Open Label Study to Compare Taspoglutide vs Exenatide as add-on Treatment to Metformin and/or Thiazolidinediones in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1189","Diabetes Mellitus Type 2","DRUG:exenatide; DRUG:taspoglutide","Hoffmann-La Roche","2008-07","FALSE","1"],["S000415","ClinicalTrials.gov","NCT00976937",null,"A Randomized, Double-blind, Double-dummy, 2-arm Parallel-group, Multicenter 24-week Study Comparing the Efficacy and Safety of AVE0010 to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 and Not Adequately Controlled With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","319","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Lixisenatide Placebo; DEVICE:Pen auto-injector; DRUG:Sitagliptin; DRUG:Sitagliptin Placebo; DRUG:Metformin","Sanofi","2009-08","TRUE","0"],["S000416","ClinicalTrials.gov","NCT05745701",null,"A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND CYCLOSPORINE ON THE SINGLE-DOSE PHARMACOKINETICS OF PF-07081532 IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","16","Healthy","DRUG:PF-07081532; DEVICE:Cyclosporine; DRUG:Itraconazole","Pfizer","2023-02-22","TRUE","0"],["S000417","ClinicalTrials.gov","NCT04773977",null,"Clinical Study to Evaluate the Pharmacokinetics and Safety of IBI362 Lyophilized Powder and IBI362 Liquid Formulation in Healthy Chinese Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Overweight/Obesity","DRUG:IBI362 liquid formulation; DRUG:IBI362 lyophilized powder","Innovent Biologics (Suzhou) Co. Ltd.","2021-03-03","FALSE","0"],["S000418","ClinicalTrials.gov","NCT03041792",null,"A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-ARM, PARALLEL METHODOLOGY STUDY TO ASSESS THE EFFECT OF LIRAGLUTIDE ON FOOD INTAKE IN OBESE SUBJECTS","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","61","Obesity","DRUG:Liraglutide; OTHER:Placebo","Pfizer","2017-02-20","TRUE","0"],["S000419","ClinicalTrials.gov","NCT01722227",null,"Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Placebo","University at Buffalo","2012-11","FALSE","0"],["S000420","ClinicalTrials.gov","NCT05292911",null,"A 12-Week Extension Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","64","Non-Alcoholic Fatty Liver Disease","DRUG:ALT-801; OTHER:Placebo","Altimmune, Inc.","2022-03-09","FALSE","1"],["S000421","ClinicalTrials.gov","NCT07374445",null,"The Timing for Liraglutide in Patients Remaining Obese at 6 Months After Metabolic Surgery: an Observational Study","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","COMPLETED","100","Obesity; Weight Loss; Bariatric Surgery","DRUG:Liraglutide injection; BEHAVIORAL:Diet and exercise guidelines","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2023-09-01","FALSE","0"],["S000422","ClinicalTrials.gov","NCT07401992","SEMAPSO","Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","62","Psoriasis (PsO); Obesity & Overweight; Diabetes Mellitus - Type 2","DRUG:Semaglutide (Rybelsus®); DRUG:Placebo","Hospital Universitario Dr. Jose E. Gonzalez","2026-01-15","FALSE","0"],["S000423","ClinicalTrials.gov","NCT02276196","ELIXIRS","A Phase 4, Mono-center, Randomized, Open Label, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist Lixisenatide Versus Insulin Glulisine on Renal Physiology and Biomarkers in Insulin Glargine-treated Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","40","Diabetic Kidney Disease; Diabetic Nephropathy; Diabetes Mellitus; Glucagon-Like Peptide 1","DRUG:Lixisenatide; DRUG:Insulin glulisine","Amsterdam UMC, location VUmc","2014-09","FALSE","1"],["S000424","ClinicalTrials.gov","NCT02490176",null,"Effects of Liraglutide on Hemodynamic Parameters in Patients With Heart Failure","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","50","Heart Failure","DRUG:liraglutide; DRUG:placebo","Chinese PLA General Hospital","2015-07","FALSE","3"],["S000425","ClinicalTrials.gov","NCT06825182",null,"Survey on the Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes and Interventional Study of GLP-1RA: a Multicenter, Prospective Study","INTERVENTIONAL",null,"PHASE3","RECRUITING","1000","Type 2 Diabetes Mellitus","DRUG:Outpatient newly diagnosed type 2 diabetes subjects; DRUG:Inpatient newly diagnosed type 2 diabetes subjects","Nanjing First Hospital, Nanjing Medical University","2024-11-07","FALSE","0"],["S000426","ClinicalTrials.gov","NCT02911818","MODEL","Combining Lifestyle Modification and Liraglutide to Improve Weight Loss and Health Outcomes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","150","Obesity","BEHAVIORAL:CMS-recommended lifestyle counseling; DRUG:Liraglutide 3.0mg; OTHER:Portion-Controlled Diet; DRUG:Placebo Oral Tablet; DRUG:Phentermine 15 MG; BEHAVIORAL:Extension Study CMS-recommended lifestyle counseling","University of Pennsylvania","2016-09","TRUE","3"],["S000427","ClinicalTrials.gov","NCT07382024","TREAT-AF","Tirzepatide to Reduce Recurrence and Burden After Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Trial","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","200","Atrial Fibrillation Ablation; Persistent Atrial Fibrillation; Obesity & Overweight","DRUG:Tirzepatide; OTHER:Standard Care (in control arm)","National Taiwan University Hospital","2026-06-16","FALSE","0"],["S000428","ClinicalTrials.gov","NCT02793154",null,"A Randomized, Open-label, Active-Controlled, Parallel-Group, Exploratory Study on the Effects of Repeated Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","4","Diabetes Mellitus, Type 2","DRUG:Exenatide; DRUG:Albiglutide","GlaxoSmithKline","2016-09-26","TRUE","0"],["S000429","ClinicalTrials.gov","NCT05813912",null,"Protocol Title: A Single Arm Study Investigating the Glycaemic Control and Safety of Adding Semaglutide to Insulin Icodec in Participants With Type 2 Diabetes Qualifying for Treatment Intensification Short Title: A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes","INTERVENTIONAL",null,"PHASE3","COMPLETED","148","Diabetes Mellitus, Type 2","DRUG:Insulin Icodec; DRUG:Semaglutide","Novo Nordisk A/S","2023-09-22","TRUE","1"],["S000430","ClinicalTrials.gov","NCT05209165",null,"Semaglutide as Treatment of Overweight and Obese Individuals to Reduce Atrial Fibrillation Burden","INTERVENTIONAL","RANDOMIZED","PHASE4","SUSPENDED","132","Atrial Fibrillation; Obesity; Overweight","DRUG:Semaglutide; DRUG:Placebo","San Francisco Veterans Affairs Medical Center","2023-05","FALSE","0"],["S000431","ClinicalTrials.gov","NCT07441252",null,"Phase 2b Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Maridebart Cafraglutide in Adult Participants Living With Elevated Liver Fat and Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","180","Overweight or Obesity and Elevated Liver Fat","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2026-03-05","FALSE","0"],["S000432","ClinicalTrials.gov","NCT00761540",null,"A Dose Escalation Study to Investigate the Pharmacokinetics, Tolerability and Safety of Liraglutide After Multiple s.c. Doses in Healthy Chinese Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","37","Diabetes; Healthy","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2008-10","FALSE","1"],["S000433","ClinicalTrials.gov","NCT04184947",null,"Cardiovascular Outcomes of Type 2 Diabetic Patients Treated With SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Real-life. An Observational Study Using Clinical-administrative Data","OBSERVATIONAL",null,null,"COMPLETED","10000","Type 2 Diabetes","DRUG:SGLT2 inhibitor; DRUG:GLP-1 receptor agonist","University of Padova","2014-03-01","FALSE","1"],["S000434","ClinicalTrials.gov","NCT05073835","BARI-STEP","BARI-STEP:A Double-blinded, Randomised, Placebo-controlled Trial of Semaglutide 2.4 mg in Patients With Poor Weight-loss Following Bariatric Surgery.","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","70","Obesity; Diabetes; Metabolic Syndrome","DRUG:Semaglutide 3 mg; DRUG:Placebo","University College, London","2022-11-01","FALSE","1"],["S000435","ClinicalTrials.gov","NCT00516074",null,"A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","54","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:placebo","AstraZeneca","2007-09","TRUE","1"],["S000436","ClinicalTrials.gov","NCT05173714",null,"Sit Less, Interact and Move More (SLIMM) 2 Study","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","156","Chronic Kidney Diseases; Obesity","BEHAVIORAL:SLIMM; BEHAVIORAL:Standard Resistance Training; BEHAVIORAL:Guided Resistance Training; DRUG:Placebo; DRUG:Semaglutide","Srinvasan Beddhu","2021-12-01","FALSE","0"],["S000437","ClinicalTrials.gov","NCT01107717",null,"Durability of Early Initial Combination Therapy With Exenatide/Pioglitazone/Metformin vs Conventional Therapy in New Onset Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","318","Diabetes","DRUG:metformin\\pioglitazone\\exenatide; DRUG:metformin, glyburide and glargine","The University of Texas Health Science Center at San Antonio","2009-01","TRUE","4"],["S000438","ClinicalTrials.gov","NCT06045221","ACHIEVE-3","A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1698","Type 2 Diabetes","DRUG:Orforglipron; DRUG:Semaglutide","Eli Lilly and Company","2023-09-22","TRUE","1"],["S000439","ClinicalTrials.gov","NCT05616052",null,"Prospective Randomized Controlled Study on the Improvement of Body Weight Among Overweight and Obese Patients Through Different Smeglutide Administration Methods","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","80","Weight Change, Body","DRUG:Semaglutide","Huashan Hospital","2022-12-01","FALSE","1"],["S000440","ClinicalTrials.gov","NCT06862908",null,"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Subjects With HFpEF（Heart Failure With Preserved ejectIon Fraction）or HFmrEF（Heart Failure With Mildly Reduced Ejection Fraction）Combined With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","141","Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced Ejection Fraction","OTHER:placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2025-03-26","FALSE","0"],["S000441","ClinicalTrials.gov","NCT00082407",null,"Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","505","Diabetes Mellitus, Type 2","DRUG:exenatide; DRUG:biphasic insulin aspart","AstraZeneca","2003-11","TRUE","3"],["S000442","ClinicalTrials.gov","NCT06897475",null,"A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c Goal","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","200","Type 2 Diabetes","DRUG:LY3457263; DRUG:Placebo","Eli Lilly and Company","2025-03-28","FALSE","0"],["S000443","ClinicalTrials.gov","NCT04137328",null,"Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","60","Diabetic Neuropathic Pain","DRUG:Liraglutide; DRUG:insulin","Fudan University","2019-11-30","FALSE","4"],["S000444","ClinicalTrials.gov","NCT05762744",null,"Pharmacogenomics of GLP1 Receptor Agonists","INTERVENTIONAL","RANDOMIZED","PHASE1","TERMINATED","63","Type 2 Diabetes","DRUG:Exenatide Injection (before the first FSIGT); DRUG:Exenatide injection before the second FSIGT)","University of Maryland, Baltimore","2016-06-01","TRUE","1"],["S000445","ClinicalTrials.gov","NCT04175665",null,"Semaglutide in Patients With Type 2 Diabetes: Real-world Analysis in the Canadian LMC Diabetes Registry: The SPARE Study","OBSERVATIONAL",null,null,"COMPLETED","1133","Type 2 Diabetes","DRUG:Semaglutide","LMC Diabetes & Endocrinology Ltd.","2020-01-06","FALSE","0"],["S000446","ClinicalTrials.gov","NCT02152371","AWARD-9","A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg With Placebo on Glycemic Control in Patients With Type 2 Diabetes on Basal Insulin Glargine","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","300","Diabetes Mellitus, Type 2","DRUG:Dulaglutide; DRUG:Placebo; DRUG:Insulin Glargine; DRUG:Metformin","Eli Lilly and Company","2014-05","TRUE","2"],["S000447","ClinicalTrials.gov","NCT06352892",null,"A Phase 1, Open-label, Randomized, Parallel-group, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 133 Administered Subcutaneously in Chinese Subjects With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","20","Obesity","DRUG:Maridebart Cafraglutide","Amgen","2024-04-25","FALSE","0"],["S000448","ClinicalTrials.gov","NCT05579977",null,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE RANGING, DOSE FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-07081532, AND OPEN LABEL ORAL SEMAGLUTIDE, IN ADULTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON METFORMIN, AND SEPARATELY PF-07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","902","Diabetes Mellitus; Obesity","DRUG:PF-07081532; OTHER:Placebo; DRUG:Rybelsus","Pfizer","2022-10-27","TRUE","2"],["S000449","ClinicalTrials.gov","NCT06132204",null,"A Single-dose, Open-label/Pharmacokinetic and Safety Studies of HRS-7535 in Subjects With Moderate Renal Insufficiency and Healthy Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","16","Type 2 Diabetes","DRUG:HRS-7535 Tablets","Shandong Suncadia Medicine Co., Ltd.","2023-12-21","FALSE","0"],["S000450","ClinicalTrials.gov","NCT05347758",null,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7535 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","UNKNOWN","106","Healthy Subjects","DRUG:HRS-7535; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2022-05-01","FALSE","1"],["S000451","ClinicalTrials.gov","NCT02548585",null,"A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Overweight and Obese Subjects With a History of Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","113","Type 2 Diabetes Mellitus","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2015-12-09","TRUE","6"],["S000452","ClinicalTrials.gov","NCT00658021",null,"Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes.","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","122","Type 2 Diabetes","DRUG:Placebo; DRUG:Exenatide","AstraZeneca","2008-05-30","TRUE","1"],["S000453","ClinicalTrials.gov","NCT06706284",null,"Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","RECRUITING","50","Spinal Cord Injuries; Type 2 Diabetes","DRUG:Semaglutide Injectable Product; OTHER:Placebo","Marzieh Salehi","2025-04-11","FALSE","0"],["S000454","ClinicalTrials.gov","NCT06492135",null,"Safety, Tolerability and Pharmacokinetics Study of Multiple Rising Subcutaneous Doses of Survodutide in Chinese Participants With Overweight or Obesity (BMI 24.0 to 40.0 kg/m2) (Non-randomization, Open Label, Parallel Group Design)","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","30","Overweight; Obesity","DRUG:survodutide","Boehringer Ingelheim","2024-08-12","FALSE","0"],["S000455","ClinicalTrials.gov","NCT02455076",null,"Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","150","Type 2 Diabetes","DRUG:Exenatide; DRUG:Glargine; DRUG:Rapid-acting insulin analogs","Emory University","2015-09","TRUE","1"],["S000456","ClinicalTrials.gov","NCT02016911",null,"Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide (NNC0113-0217) in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","56","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2013-12-12","FALSE","2"],["S000457","ClinicalTrials.gov","NCT01554618",null,"A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","84","Children and Adolescent With Type 2 Diabetes","DRUG:Exenatide Once Weekly; DRUG:Placebo","AstraZeneca","2011-12-02","TRUE","1"],["S000458","ClinicalTrials.gov","NCT05352815","COMBINE 1","A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Insulin Icodec, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin.","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1291","Diabetes Mellitus, Type 2","DRUG:IcoSema; DRUG:Insulin icodec","Novo Nordisk A/S","2022-06-01","TRUE","3"],["S000459","ClinicalTrials.gov","NCT07693608","TRI-MR","An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder Using fMRI to Identify Novel Neural Biomarkers","INTERVENTIONAL",null,"PHASE2","ENROLLING_BY_INVITATION","45","Obesity; Methamphetamine Use Disorder; Cocaine Use Disorder; Stimulant Use Disorders","DRUG:Tirzepatide","University of Texas Southwestern Medical Center","2026-08-19","FALSE","0"],["S000460","ClinicalTrials.gov","NCT04538352","TRANSITION-T2D","Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (TRANSITION-T2D) A Prospective Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","60","Type 2 Diabetes","DRUG:Semaglutide; DRUG:Insulin Degludec; DRUG:Insulin aspart","The Cleveland Clinic","2021-01-18","TRUE","1"],["S000461","ClinicalTrials.gov","NCT07707778",null,"Reversing the Biological Clock: Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","ENROLLING_BY_INVITATION","60","Human Immunodeficiency Virus (HIV); Metabolic Dysfunction Associated Steatotic Liver Disease; Dyslipidaemia; Diabetes Mellitus; Obesity & Overweight; Metabolic Syndrome","DRUG:Tirzepatide","National Taiwan University Clinical Trial Center","2026-06-25","FALSE","0"],["S000462","ClinicalTrials.gov","NCT02527993",null,"Treatment of Hypoglycemia Following Gastric Bypass Surgery","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","11","Hypoglycemia; Obesity; Surgery","DRUG:Glucobay (acarbose); DRUG:Januvia (sitagliptin); DRUG:Verapamil HEXAL (verapamil); DRUG:Victoza (liraglutide); DRUG:Signifor (pasireotide); DEVICE:Continuous glucose monitoring (CGM); DIETARY_SUPPLEMENT:Meal tolerance test (MTT)","Zealand University Hospital","2015-10","FALSE","1"],["S000463","ClinicalTrials.gov","NCT00154414",null,"Effect of Liraglutide on Glycaemic Control in Japanese Subjects With Type 2 Diabetes.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","226","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2005-01","FALSE","2"],["S000464","ClinicalTrials.gov","NCT07607587",null,"Tolerability of Cagrilintide in People With Obesity That Discontinued GLP-1-RA Therapies Due to Gastrointestinal Adverse Events: a Double-blinded Randomised Feasibility Study","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","114","Obesity; Overweight","DRUG:Cagrilintide; DRUG:Placebo (matched to Cagrilintide)","Novo Nordisk A/S","2026-05-29","FALSE","0"],["S000465","ClinicalTrials.gov","NCT05468632","MIRAGE","A Multicentre, Single-arm, Retrospective Study Investigating Glycaemic Control in GLP-1 Naive Participants With Type 2 Diabetes Who Initiated Once-weekly Semaglutide (OZEMPIC) in a Real World Setting in North Macedonia","OBSERVATIONAL",null,null,"COMPLETED","314","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2022-07-05","FALSE","0"],["S000466","ClinicalTrials.gov","NCT03341429","BARIOPTIMISE","BARI-OPTIMISE: a Double-blinded, Randomised, Placebo-controlled Trial of Liraglutide 3.0 mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Following Bariatric Surgery","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","70","Obesity","DRUG:Liraglutide Pen Injector [Saxenda]; DRUG:Placebo","University College, London","2018-08-22","FALSE","3"],["S000467","ClinicalTrials.gov","NCT07319975",null,"Comparison of the Effects of Semaglutide and Tirzepatide Treatments in Combination With Exercise in Obesity Management","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","48","Obesity","DRUG:Semaglutide; DRUG:Tirzepatide; BEHAVIORAL:Tirzepatide+Exercise; BEHAVIORAL:Semaglutide+Exercise","Istanbul Galata University","2025-12-29","FALSE","0"],["S000468","ClinicalTrials.gov","NCT03919929","TEAL","Treating PCOS With Semaglutide vs Active Lifestyle Intervention","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","60","PCOS; Adolescent Obesity; NAFLD","DRUG:Semaglutide 3mg and 7mg [Rybelsus]; OTHER:Weight loss diet","University of Colorado, Denver","2019-05-03","TRUE","1"],["S000469","ClinicalTrials.gov","NCT06699329",null,"A Clinical Study to Evaluate the Effect of MK-0616 and Semaglutide on Their Respective Pharmacokinetics in Healthy Adult Participants","INTERVENTIONAL",null,"PHASE1","COMPLETED","38","Healthy","DRUG:Enlicitide Decanoate; DRUG:Semaglutide","Merck Sharp & Dohme LLC","2024-01-22","FALSE","0"],["S000470","ClinicalTrials.gov","NCT06640972",null,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","68","Triglycerides; Weight Gain Trajectory; Cholesterol, Elevated","DRUG:RDX-002; DRUG:Placebo","Response Pharmaceuticals","2024-09-27","TRUE","0"],["S000471","ClinicalTrials.gov","NCT01619345",null,"Pharmacoscintigraphic Investigation NN9924 in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","27","Diabetes; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2012-06","FALSE","1"],["S000472","ClinicalTrials.gov","NCT05295875",null,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","391","Obesity/Overweight","DRUG:ALT-801; OTHER:Placebo","Altimmune, Inc.","2022-03-31","FALSE","0"],["S000473","ClinicalTrials.gov","NCT02308254","Lixi","Effects of Lixisenatide on Gastric Emptying, Glycaemia and 'Postprandial' Blood Pressure in Type 2 Diabetes and Healthy Subjects.","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","UNKNOWN","30","Diabetes Mellitus; Gastroparesis","DRUG:Lixisenatide; DRUG:Placebo","Royal Adelaide Hospital","2013-11","FALSE","10"],["S000474","ClinicalTrials.gov","NCT06657209",null,"Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","104","Diabetes Mellitus, Type 2; Diabetes; Type 2 Diabetes; Pre Diabetes","PROCEDURE:Insulin resistance testing; PROCEDURE:OGTT; PROCEDURE:Fat biopsy; RADIATION:DXA scan; PROCEDURE:MRI; PROCEDURE:1H-MRS; DRUG:Tirzepatide; DRUG:Pioglitazone","Stanford University","2025-01-13","FALSE","0"],["S000475","ClinicalTrials.gov","NCT06077864",null,"A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","5531","Obesity","COMBINATION_PRODUCT:survodutide; COMBINATION_PRODUCT:Placebo","Boehringer Ingelheim","2023-11-20","FALSE","1"],["S000476","ClinicalTrials.gov","NCT01515592",null,"A Randomised, Double-blind Within Dose Group, Single Centre, Placebo-controlled, Dose Escalation, Multiple s.c. Dose Study to Assess the Safety and Tolerability of Liraglutide 20 ug/kg and 25 ug/kg in Healthy Japanese Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2006-01","FALSE","1"],["S000477","ClinicalTrials.gov","NCT00856609",null,"The Effects of Exenatide (Byetta) on Energy Expenditure and Weight Loss in Non-Diabetic Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","150","Weight Loss; Obesity","DRUG:Byetta (exenatide); BEHAVIORAL:Weight loss; OTHER:Metabolic Chamber; DRUG:Placebo","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","2009-03-03","TRUE","4"],["S000478","ClinicalTrials.gov","NCT06719011",null,"A Randomized, Placebo Controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0174 1213 in Male Participants With Overweight or Obesity.","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","178","Obesity; Overweight","DRUG:NNC0174-1213 A; DRUG:Cagrilintide B; DRUG:Placebo A (NNC0174 1213 A)","Novo Nordisk A/S","2024-12-03","FALSE","0"],["S000479","ClinicalTrials.gov","NCT07812636","TIDE","Combination Tirzepatide and Levonorgestrel Intrauterine Device Therapy for Endometrial Intraepithelial Neoplasia (EIN) and Grade 1 Endometrioid Endometrial Carcinoma: A Pilot Window-of-Opportunity Study","INTERVENTIONAL",null,"EARLY_PHASE1","NOT_YET_RECRUITING","15","Grade 1 Endometrial Endometrioid Carcinoma; Endometrial Intraepithelial Neoplasia; Metabolic Comorbidities","DRUG:Tirzepatide","Milton S. Hershey Medical Center","2026-11-01","FALSE","0"],["S000480","ClinicalTrials.gov","NCT05931367","TRIUMPH-4","A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","445","Obesity; Overweight; Osteo Arthritis Knee","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2023-08-01","FALSE","0"],["S000481","ClinicalTrials.gov","NCT04187300",null,"A Trial to Demonstrate Bioequivalence Between Semaglutide Formulation D With the DV3396 Pen-injector and Formulation B With the PDS290 Pen-injector in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","68","Overweight; Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2019-12-16","FALSE","0"],["S000482","ClinicalTrials.gov","NCT02759107",null,"A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","142","Healthy; Type 2 Diabetes Mellitus (T2DM)","DRUG:Tirzepatide; DRUG:Placebo; DRUG:Dulaglutide","Eli Lilly and Company","2016-05-11","TRUE","1"],["S000483","ClinicalTrials.gov","NCT03086330","SUSTAIN 9","Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus. A 30-week Randomised, Double-blind, Placebo-controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","302","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2017-03-15","TRUE","1"],["S000484","ClinicalTrials.gov","NCT02207348",null,"A Randomised, Open-label, Single-centre, Two-period, Cross-over Trial Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide","Novo Nordisk A/S","2014-08","FALSE","0"],["S000485","ClinicalTrials.gov","NCT06894784","SEMPA","Semaglutide And Empagliflozin Combination Therapy Added To Automated Insulin Delivery In Adults With Type 1 Diabetes (SEMPA)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","36","Diabetes Type 1","DRUG:Intervention Period 1: Semaglutide + Empagliflozin; DRUG:Intervention Period 2: Semaglutide + Empagliflozin Placebo; DRUG:Intervention Period 3: Semaglutide Placebo + Empagliflozin; DRUG:Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo","McGill University Health Centre/Research Institute of the McGill University Health Centre","2025-04","FALSE","22"],["S000486","ClinicalTrials.gov","NCT02231684",null,"A Randomised, Single Centre, Two Period, Incomplete Cross Over Trial in Healthy Subjects Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","42","Diabetes; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2014-09","FALSE","0"],["S000487","ClinicalTrials.gov","NCT02685852",null,"A Pilot Study Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia Post-RYGB","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","11","Hyperinsulinemic Hypoglycemia","DRUG:Exenatide; DRUG:Acarbose; DRUG:Exenatide Placebo; DRUG:Acarbose Placebo","University of Minnesota","2016-02","FALSE","0"],["S000488","ClinicalTrials.gov","NCT00866658","GETGOAL-L-ASIA","A Randomized, Double-Blind, Placebo-Controlled, 2-arm Parallel-group, Multicenter Study With a 24-Week Treatment Period Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Sulfonylurea","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","311","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector; DRUG:Sulfonylurea; DRUG:Basal Insulin","Sanofi","2009-03","TRUE","3"],["S000489","ClinicalTrials.gov","NCT04867785",null,"A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","281","Type 2 Diabetes","DRUG:LY3437943; DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2021-05-13","TRUE","4"],["S000490","ClinicalTrials.gov","NCT07825857","T-STEM","Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","228","Methamphetamine Use Disorder","DRUG:Tirzepatide; DRUG:Placebo (saline)","University of Texas Southwestern Medical Center","2026-10-01","FALSE","0"],["S000491","ClinicalTrials.gov","NCT00713830","GETGOAL-S","A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of a Sulfonylurea in Patients With Type 2 Diabetes Not Adequately Controlled With Sulfonylurea","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","859","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector; DRUG:Sulfonylurea; DRUG:Metformin","Sanofi","2008-07","TRUE","4"],["S000492","ClinicalTrials.gov","NCT01272219",null,"Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","3731","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2011-06-01","TRUE","20"],["S000493","ClinicalTrials.gov","NCT06582875",null,"Advancing ADPKD Treatment With GLP-1RA: A Study of Glucagon-Like Peptide-1 Receptor Agonists' Efficacy, Safety, and Mechanism","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","126","Autosomal Dominant Polycystic Kidney; Obesity","DRUG:Tirzepatide; OTHER:Placebo","University of Colorado, Denver","2025-03-06","FALSE","2"],["S000494","ClinicalTrials.gov","NCT01357889",null,"A Multidose Study in Subjects With Type 2 Diabetes Mellitus to Assess the Pharmacokinetics and Pharmacodynamics of Albiglutide","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","283","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide (GSK716155)","GlaxoSmithKline","2011-07","TRUE","1"],["S000495","ClinicalTrials.gov","NCT06182618",null,"Retrospective Analysis of Outpatient Intervention Effects in Patients With Metabolic Syndrome","OBSERVATIONAL",null,null,"UNKNOWN","400","Metabolic Syndrome","OTHER:dietary, semaglutide or/and metformin","Second Affiliated Hospital, Zhejiang University, School of Medicine","2023-06-01","FALSE","0"],["S000496","ClinicalTrials.gov","NCT01638260",null,"Liraglutide With or Without NEAT in Type 2 Diabetes Mellitus; Effects on HbA1c, Weight, Blood Pressure, Quality of Life and Health Care Costs.","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","22","Type 2 Diabetes Mellitus","DRUG:Liraglutide; BEHAVIORAL:NEAT","Maastricht University Medical Center","2012-10","FALSE","0"],["S000497","ClinicalTrials.gov","NCT07030621","STARS","Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","436","Acute Ischemic Stroke","DRUG:Semaglutide 0.5 mg; DRUG:Normal Saline","RenJi Hospital","2025-07-01","FALSE","4"],["S000498","ClinicalTrials.gov","NCT06909006","OBES1TY","Obesity and Semaglutide in Type 1 Diabetes Therapy: A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","122","Obesity in Diabetes; Obesity/Therapy; Type 1 Diabetes Mellitus (T1DM); Insulin Sensitivity/Resistance; Semaglutide; Lipidomics; Metabolomics; Weight Loss; Glycemic Control for Diabetes Mellitus","DRUG:Semaglutide 2.4mg; DRUG:Semaglutide placebo","Nordsjaellands Hospital","2025-10","FALSE","0"],["S000499","ClinicalTrials.gov","NCT02909933",null,"Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","30","Polycystic Ovary Syndrome; Obesity","DRUG:liraglutide; DRUG:metformin and liraglutide","University Medical Centre Ljubljana","2015-07","FALSE","1"],["S000500","ClinicalTrials.gov","NCT07859163",null,"Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain: a Randomized, Double-blind, Placebo-controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","100","Morbid Obesity","DRUG:Semaglutide weekly injection; DRUG:Placebo","General Committee of Teaching Hospitals and Institutes, Egypt","2026-10","FALSE","0"],["S000501","ClinicalTrials.gov","NCT05040087","CHANGE","Changing the Natural History of Type 2 Diabetes (\"CHANGE\" Study)","INTERVENTIONAL","RANDOMIZED",null,"ACTIVE_NOT_RECRUITING","127","Type 2 Diabetes","OTHER:Intensification of diabetes medication based largely on HbA1c levels; OTHER:Intensification of diabetes medication based on glucose levels","Foundation for Atlanta Veterans Education and Research, Inc.","2021-09-01","FALSE","0"],["S000502","ClinicalTrials.gov","NCT07310563",null,"A Phase 1, Randomized, Open-label, Parallel-group, Drug-drug Interaction Study to Evaluate the Effect of Antiemetic Medication on the Pharmacokinetics of AMG 133 in Participants Living With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","59","Overweight; Obesity","DRUG:AMG 133; DRUG:Ondansetron","Amgen","2024-12-10","FALSE","0"],["S000503","ClinicalTrials.gov","NCT06388187",null,"Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","300","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2024-06-24","FALSE","0"],["S000504","ClinicalTrials.gov","NCT06015893",null,"Semaglutide Therapy for Alcohol Reduction (STAR): A Proof-of-Concept Phase II Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","63","Addiction; Alcohol Use Disorder","BEHAVIORAL:Take Control; DRUG:Semaglutide","National Institute on Drug Abuse (NIDA)","2023-10-17","FALSE","8"],["S000505","ClinicalTrials.gov","NCT07720414",null,"Effects of GLP-1 RAs on Human Lactation Outcomes","OBSERVATIONAL",null,null,"RECRUITING","18","Lactation; Weight Loss","DRUG:Injected GLP-1 Receptor Agonists and Dual Agonists","University of Colorado, Denver","2026-07","FALSE","0"],["S000506","ClinicalTrials.gov","NCT02380521",null,"Effect of Exenatide Once Weekly on Cardiovascular Risk Markers in Patients With Type-2 Diabetes","INTERVENTIONAL",null,"PHASE4","COMPLETED","60","Type 2 Diabetes Mellitus","DRUG:Exenatide once weekly (BYDUREON™)","University of Palermo","2015-01","FALSE","6"],["S000507","ClinicalTrials.gov","NCT06884293",null,"A Multicenter, Randomized, Open-label Phase III Study to Compare the Efficacy and Safety of IBI362 and Semaglutide in Chinese Overweight or Obese Subjects With Metabolic Dysfunction-associated Fatty Liver Disease (GLORY-3)","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","479","Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)","DRUG:IBI362; DRUG:semaglutide","Innovent Biologics (Suzhou) Co. Ltd.","2025-05-09","FALSE","0"],["S000508","ClinicalTrials.gov","NCT02730377","LIRA-PRIME","Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","1991","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:alpha-glucosidase inhibitors; DRUG:DPP-4 inhibitors; DRUG:meglitinides; DRUG:SGLT-2 inhibitors; DRUG:sulphonylurea; DRUG:thiazolidinediones","Novo Nordisk A/S","2016-03-28","TRUE","5"],["S000509","ClinicalTrials.gov","NCT06499857","SEMINAL-AF","Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","200","Overweight or Obesity; Atrial Fibrillation","DRUG:Semaglutide; DRUG:Placebo","University of Chicago","2025-04-14","FALSE","0"],["S000510","ClinicalTrials.gov","NCT03648281",null,"SURE DENMARK/SWEDEN: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","333","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2018-08-24","FALSE","2"],["S000511","ClinicalTrials.gov","NCT04822181","ESSENCE","The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","1205","Non-alcoholic Steatohepatitis","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2021-04-01","FALSE","11"],["S000512","ClinicalTrials.gov","NCT04979130","SIB","A Randomized Parallel Comparison of Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","69","Type 2 Diabetes; Chronic Inflammation; Intestinal Permeability","DRUG:Semaglutide; DRUG:Placebo","University of Colorado, Denver","2022-01-01","FALSE","1"],["S000513","ClinicalTrials.gov","NCT06900075",null,"Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Every Two Weeks in Patients with Type 2 Diabetes: a Multicenter, Randomized, Open-Label Study","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","88","Type 2 Diabetes","DRUG:Efsubaglutide Alfa 3mg Q2W and 1mg QW; DRUG:Efsubaglutide Alfa 1mg QW and 3mg Q2W","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2025-07-30","FALSE","0"],["S000514","ClinicalTrials.gov","NCT00870194",null,"A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","255","Type 2 Diabetes Mellitus","DRUG:exenatide and sitagliptin; DRUG:exenatide and placebo","AstraZeneca","2009-03","TRUE","1"],["S000515","ClinicalTrials.gov","NCT06918405",null,"Efficacy and Safety of Tirzepatide for Weight Management in Overweight or Obese Adult Individuals With or Without Type 2 Diabetes Mellitus: A Real-World Study in Bangladesh","INTERVENTIONAL",null,"PHASE3","ACTIVE_NOT_RECRUITING","440","Obesity and Obesity-related Medical Conditions","DRUG:Tirzepatide","Chittagong Medical College","2025-01-01","FALSE","0"],["S000516","ClinicalTrials.gov","NCT07537088",null,"Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","468","T2DM (Type 2 Diabetes Mellitus); CKD - Chronic Kidney Disease","DRUG:Dulaglutide; DRUG:SGLT2i; DRUG:Finerenone","First Affiliated Hospital of Wannan Medical College","2026-05","FALSE","0"],["S000517","ClinicalTrials.gov","NCT06401746",null,"Assessment of Gastric Function Using Body Surface Gastric Mapping in Patients on Semaglutide (Ozempic)","OBSERVATIONAL",null,null,"COMPLETED","9","Semaglutide-Induced Gastric Motility; Gastroparesis","DEVICE:Gastric Alimetry","University of Western Sydney","2024-05-01","TRUE","1"],["S000518","ClinicalTrials.gov","NCT00753896",null,"Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin","INTERVENTIONAL",null,"PHASE3","COMPLETED","134","Type 2 Diabetes","DRUG:exenatide","AstraZeneca","2008-10","TRUE","1"],["S000519","ClinicalTrials.gov","NCT05071898","PORT","Pharmacogenetics of Response to GLP1R Agonists","INTERVENTIONAL",null,"PHASE1","RECRUITING","600","Obesity; Diabetes Type 2","DRUG:Semaglutide Pen Injector [Ozempic]","University of Maryland, Baltimore","2022-04-11","FALSE","1"],["S000520","ClinicalTrials.gov","NCT05882032",null,"A Phase 1, Multicenter, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Hepatic Function and Participants With Mild, Moderate, or Severe Hepatic Impairment","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","29","Healthy; Hepatic Insufficiency","DRUG:LY3502970","Eli Lilly and Company","2023-06-13","TRUE","0"],["S000521","ClinicalTrials.gov","NCT03548987","STEP 4","Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity Who Have Reached Target Dose During run-in Period","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","902","Metabolism and Nutrition Disorder; Obesity","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2018-06-04","TRUE","11"],["S000522","ClinicalTrials.gov","NCT04017832","PIONEER 12","China Multi-regional Clinical Trial: Efficacy and Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus Treated With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1441","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide; DRUG:Sitagliptin; DRUG:Placebo (oral semaglutide); DRUG:Placebo (sitagliptin)","Novo Nordisk A/S","2019-07-29","TRUE","1"],["S000523","ClinicalTrials.gov","NCT06974851",null,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","140","Bstructive Sleep Apnea (OSA) and Obesity","DRUG:HRS9531; DRUG:HRS9531placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-07-25","FALSE","0"],["S000524","ClinicalTrials.gov","NCT06836284",null,"Evaluation of a Digital Treatment Tool in Combination With Obesity Medications","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","40","Childhood Obesity; Treatment Adherence","DEVICE:Digi-physical treatment tool, Evira; DRUG:Obesity medication with liraglutide or semaglutide","Karolinska Institutet","2026-02-13","FALSE","0"],["S000525","ClinicalTrials.gov","NCT05881837",null,"A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","249","Overweight or Obesity","DRUG:HRS9531 injection; DRUG:HRS9531 injection Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2023-06-13","FALSE","0"],["S000526","ClinicalTrials.gov","NCT07135245",null,"Improved Treatment and Monitoring of Alzheimer's Disease - a Randomized Controlled Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","180","Alzheimer Disease (AD)","DRUG:Semaglutide (Rybelsus®) combined with other interventions; OTHER:Placebo; DRUG:Semaglutide (Rybelsus®)","Rune Skovgaard Rasmussen","2026-01-01","FALSE","0"],["S000527","ClinicalTrials.gov","NCT07301437",null,"A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","120","Overweight and Obese Adults","DRUG:liraglutide monotherapy; DRUG:liraglutide combined with orlistat","The Fourth Affiliated Hospital of Zhejiang University School of Medicine","2026-05-01","FALSE","0"],["S000528","ClinicalTrials.gov","NCT04143945",null,"A Trial to Compare the Injection Site Pain Experience of 0.25 mg Semaglutide B and Semaglutide D Administered sc","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","104","Healthy Volunteers Diabetes Mellitus, Type 2; Healthy Volunteers Overweight; Healthy Volunteers Obesity","DRUG:Semaglutide (administered by DV3396 pen); DRUG:Semaglutide (administered by PDS290 pen)","Novo Nordisk A/S","2019-10-28","TRUE","1"],["S000529","ClinicalTrials.gov","NCT07588984","FLOURISH","GLP-1 Medication & Behavioral Health on Weight and Metabolic Outcomes: FLOURISH (Functional Longitudinal Outcomes Under Intentional Small Habits) & THRIVE (Trajectories of Health, Resilience & Integrated Vitality Evaluation) Cohort Study","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","2310","Obesity & Overweight; Weight Loss; Preventative Health; Body Weight; Cardiovascular Disease Risk Factor","BEHAVIORAL:Noom Weight; BEHAVIORAL:Free Tier; BEHAVIORAL:Education-only control; DRUG:Semaglutide; DRUG:Tirzepatide; DRUG:Microdose semaglutide; DRUG:Microdose tirzepatide","Noom Inc.","2026-04-30","FALSE","0"],["S000530","ClinicalTrials.gov","NCT01664247",null,"The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","346","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec; DRUG:placebo; DRUG:liraglutide","Novo Nordisk A/S","2012-10-01","TRUE","1"],["S000531","ClinicalTrials.gov","NCT00551343",null,"Contribution of a GLP-1 Agonist to Appetite Regulation, Metabolism and Body Composition in Subjects With Prader-Willi Syndrome.","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","20","Prader-Willi Syndrome","DRUG:Exenatide","Garvan Institute of Medical Research","2007-10","FALSE","0"],["S000532","ClinicalTrials.gov","NCT06363487","OxSENSE","Effects of Single-dose Semaglutide on Cognition and Energy in Healthy Volunteers","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","70","Cognitive Change","DRUG:Semaglutide, 0.5 mg/mL; OTHER:Placebo, 0.9% NaCl 1.5mL","University of Oxford","2024-06-06","FALSE","6"],["S000533","ClinicalTrials.gov","NCT06948422",null,"A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","974","Hypertension","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-04-30","FALSE","1"],["S000534","ClinicalTrials.gov","NCT03480022","SAXAPCOS","A Randomized Placebo-controlled Double Blind Trial of Liraglutide 3 mg [Saxenda] on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With Polycystic Ovary Syndrome (PCOS)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","88","Pre Diabetes; Polycystic Ovary Syndrome; Obesity Android","DRUG:Liraglutide Pen Injector [Saxenda]; DRUG:Placebo Liraglutide Pen Injector","Woman's","2018-09-26","TRUE","2"],["S000535","ClinicalTrials.gov","NCT02043054","LYDIA","Impact of Liraglutide on Cardiac Function and Structure in Young Adults With Type 2 Diabetes: an Open-label, Randomised Active-comparator Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","90","Type 2 Diabetes Mellitus; Cardiovascular Disease","DRUG:Liraglutide; DRUG:Sitagliptin","University of Leicester","2013-12-16","FALSE","2"],["S000536","ClinicalTrials.gov","NCT00612794",null,"Multiple-Dose Study to Examine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2148568 Long-Acting Release in Japanese Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","30","Type 2 Diabetes","DRUG:exenatide once weekly; DRUG:placebo","AstraZeneca","2007-09","FALSE","1"],["S000537","ClinicalTrials.gov","NCT07387094",null,"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","140","OSA - Obstructive Sleep Apnea; Obesity","DRUG:XW003 injection; DRUG:placebo with matching volume","Hangzhou Sciwind Biosciences Co., Ltd.","2026-02-09","FALSE","0"],["S000538","ClinicalTrials.gov","NCT07803705",null,"Efficacy of Mazdutide on Fatty Pancreas in Overweight or Obese Adults: A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","194","Fatty Pancreas; Overweight; Obesity","DRUG:mazdutide; OTHER:Placebo matching mazdutide","Tongji Hospital","2026-11-15","FALSE","0"],["S000539","ClinicalTrials.gov","NCT05144984",null,"Investigation of the Safety and Efficacy of Semaglutide s.c. in Combination With NNC0480-0389 in Participants With Type 2 Diabetes - a Dose Finding Study","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","500","Diabetes Mellitus, Type 2","DRUG:NNC0480-0389; DRUG:Semaglutide; DRUG:Placebo (NNC080-0389); DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2021-11-29","TRUE","0"],["S000540","ClinicalTrials.gov","NCT07467447","GZBF","A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","300","Obesity","DRUG:Retatrutide (LY3437943); DRUG:Placebo; BEHAVIORAL:Standardized diet and physical activity counseling throughout the study.","Hudson Biotech","2026-02-15","FALSE","0"],["S000541","ClinicalTrials.gov","NCT07413913",null,"Bioequivalence of Survodutide (BI 456906) When Administered Via Pre-filled Syringe (Formulation A) and Pre Filled Pen (Formulation B2) in Male and Female Trial Participants Who Are Healthy or Otherwise Healthy With Overweight/Obesity (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Trial)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","56","Healthy; Obesity","COMBINATION_PRODUCT:Survodutide formulation A; COMBINATION_PRODUCT:Survodutide formulation B2","Boehringer Ingelheim","2026-03-03","FALSE","0"],["S000542","ClinicalTrials.gov","NCT07609160",null,"Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals: a Randomized Controlled Trial Protocol","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","108","Obesity; Sarcopenia; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities","OTHER:Resistance exercise; OTHER:Lifestyle recommendations","Acibadem University","2026-11-01","FALSE","0"],["S000543","ClinicalTrials.gov","NCT07357740",null,"A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","WITHDRAWN","0","Diabetes Mellitus, Type 2","DRUG:CagriSema; DRUG:Placebo CagriSema","Novo Nordisk A/S","2026-08-27","FALSE","0"],["S000544","ClinicalTrials.gov","NCT04200625",null,"Effects of Semaglutide vs Dulaglutide on Epicardial Adipose Tissue Thickness in Subjects With Type 2 Diabetes and Obesity","OBSERVATIONAL",null,null,"COMPLETED","80","Epicardial Fat",null,"University of Miami","2019-09-24","FALSE","0"],["S000545","ClinicalTrials.gov","NCT03596450",null,"Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","1278","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Standard of care","Novo Nordisk A/S","2018-07-13","TRUE","6"],["S000546","ClinicalTrials.gov","NCT07727473",null,"A Prospective, Open-label, Exploratory Interventional Trial of Preoperative Semaglutide Prior to Radical Prostatectomy for Intermediate-risk Localized Prostate Cancer","INTERVENTIONAL",null,"EARLY_PHASE1","NOT_YET_RECRUITING","20","Prostate Cancer","DRUG:Semaglutide 2.4 mg","Banner Health","2026-07","FALSE","0"],["S000547","ClinicalTrials.gov","NCT05034783",null,"A Pilot Prospective Comparison of [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients","INTERVENTIONAL",null,"EARLY_PHASE1","UNKNOWN","20","Insulinoma","DRUG:[68Ga]Ga-HBED-CC-exendin-4; DRUG:[68Ga]Ga-NOTA-exendin-4","Peking Union Medical College Hospital","2021-10-01","FALSE","1"],["S000548","ClinicalTrials.gov","NCT02735031",null,"Effect of the GLP-1 Receptor Agonist Exenatide on Impaired Hypoglycaemic Awareness in Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","10","Diabetes Mellitus, Type 1; Hypoglycemia","DRUG:Exenatide; DRUG:Placebo","Radboud University Medical Center","2017-02-21","FALSE","0"],["S000549","ClinicalTrials.gov","NCT02686177","ANGIOSAFE 1","Effect of GLP-1 on Angiogenesis, Angiosafe Type 2 Diabetes Study 1","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","50","Type 2 Diabetes","DRUG:Liraglutide; DRUG:Metformin or sulfonylurea","Assistance Publique - Hôpitaux de Paris","2016-05-18","FALSE","1"],["S000550","ClinicalTrials.gov","NCT07173712",null,"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control on Oral Hypoglycemic Agents: A Multicenter, Open-Label, Randomized Controlled Study","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","324","Type 2 Diabetes","DRUG:CSII; DRUG:Insulin glargine /lixisenatide Fixed Ratio Combination; DRUG:Insulin Degludec and Insulin Aspart Injection; DRUG:Insulin Glargine (HOE901 - U300); DRUG:Metformin","Yanbing Li","2026-03-15","FALSE","0"],["S000551","ClinicalTrials.gov","NCT07274644",null,"Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus With Metabolic Dysfunction-associated Steatotic Liver Disease: A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","36","Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus Type 2","DRUG:iGlarLixi; DRUG:IGlar U100","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2025-03-29","FALSE","0"],["S000552","ClinicalTrials.gov","NCT07109700",null,"A Randomized, Double-blind, Placebo and Active Comparator-controlled Phase 2 Study to Evaluate the Efficacy and Safety of HDM1005 in Subjects With T2DM With Inadequate Glycemic Control After Diet/Exercise or Metformin Therapy","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","216","Type 2 Diabetes","DRUG:HDM1005 1; DRUG:HDM1005 2; DRUG:HDM1005 3; DRUG:HDM1005 4; DRUG:Placebo; DRUG:Dulaglutide 1.5 MG","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-04-30","FALSE","0"],["S000553","ClinicalTrials.gov","NCT04641312",null,"A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 in Healthy Participants and in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","67","Healthy; Type 2 Diabetes","DRUG:LY3457263; DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2020-11-25","FALSE","1"],["S000554","ClinicalTrials.gov","NCT03672812",null,"Randomized Clinical Trial to Evaluate the Use of Liraglutide in Individuals With Brain Death and Anti-inflammatory and Anti-apoptotic Effects on Organs to be Transplanted","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","50","Brain Death","DRUG:Liraglutide","Hospital de Clinicas de Porto Alegre","2018-09-01","FALSE","0"],["S000555","ClinicalTrials.gov","NCT04303819",null,"The Effect of Exenatide on Fasting Bile Acids in Newly Diagnosed Type 2 Diabetes Mellitus Patients, a Pilot Study","OBSERVATIONAL",null,null,"COMPLETED","38","Type 2 Diabetes Mellitus in Obese","DRUG:Exenatide treatment","Beijing Chao Yang Hospital","2020-01-05","FALSE","1"],["S000556","ClinicalTrials.gov","NCT07555730",null,"Effect of AI-assisted Multi-domain Lifestyle Intervention Versus Tirzepatide Treatment on Weight Loss Maintenance in Adults With Type 2 Diabetes: a Randomized Clinical Trial.","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","400","Overweight or Obesity; Type 2 Diabetes; Weight Loss Maintenance","BEHAVIORAL:AI assisted multi-domain lifestyle intervention; DRUG:Tirzepatide","Huazhong University of Science and Technology","2026-04-30","FALSE","0"],["S000557","ClinicalTrials.gov","NCT04061200","EmpaSema","Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria - A Double Blinded, Randomised, Placebo Controlled, Parallel, Single Center Study","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","80","Type 2 Diabetes With Renal Manifestations","DRUG:Semaglutide, 1.34 mg/mL; OTHER:Placebo, 1,34 mg/mL; DRUG:Empagliflozin 25 MG","Steno Diabetes Center Copenhagen","2019-11-01","FALSE","2"],["S000558","ClinicalTrials.gov","NCT06589765",null,"A Phase 3, Randomized, Double-blinded Study to Evaluate the Efficacy and Safety of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (OUTSTAND-2)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","810","Type 2 Diabetes","DRUG:HRS-7535 tablet; DRUG:dapagliflozin tablet","Shandong Suncadia Medicine Co., Ltd.","2024-09-27","FALSE","1"],["S000559","ClinicalTrials.gov","NCT01524705","FLAT-SUGAR","FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","102","Type 2 Diabetes","DRUG:Insulin Glargine; DRUG:Metformin; DRUG:Prandial insulin; DRUG:Exenatide","University of Washington","2012-08","TRUE","2"],["S000560","ClinicalTrials.gov","NCT01658501",null,"Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the Pharmacodynamic Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Once-Weekly Subcutaneous Dosing in Adult Subjects With Inadequately Treated Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","593","Type 2 Diabetes Mellitus","DRUG:50 mg PB1023; DRUG:70 mg PB1023; DRUG:100 mg PB1023; DRUG:Placebo (0.9% Sodium Chloride); DRUG:Victoza®; OTHER:Diet and Exercise; DRUG:Metformin; DRUG:Sulfonylurea; DRUG:Metformin and Sulfonylurea","PhaseBio Pharmaceuticals Inc.","2012-07","FALSE","0"],["S000561","ClinicalTrials.gov","NCT07868354",null,"An Open-label, Multiple-arm Study to Assess Tolerability in Participants With Overweight or Obesity, With or Without Type 2 Diabetes, When Switching From Tirzepatide to Zenagamtide","INTERVENTIONAL",null,"PHASE1","NOT_YET_RECRUITING","60","Overweight; Obesity; Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Zenagamtide","Novo Nordisk A/S","2026-10-08","FALSE","0"],["S000562","ClinicalTrials.gov","NCT07817251",null,"Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","210","Diabetes Mellitus, Type 2","DRUG:CagriSema","Novo Nordisk A/S","2026-09-16","FALSE","0"],["S000563","ClinicalTrials.gov","NCT07221591",null,"Relative Bioavailability of Two Survodutide (BI 456906) Formulations When Administered Subcutaneously Via Pre-filled Syringe Over 28 Weeks (an Open-label, Randomised, Multiple Dose, Parallel Group Trial)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","100","Healthy","COMBINATION_PRODUCT:survodutide","Boehringer Ingelheim","2025-11-05","FALSE","0"],["S000564","ClinicalTrials.gov","NCT05443568","PIONEER REAL","A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Israel","OBSERVATIONAL",null,null,"COMPLETED","155","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2023-03-09","FALSE","0"],["S000565","ClinicalTrials.gov","NCT06852391","JOULE-MARS","JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity - a Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","74","Obesity (Disorder)","DRUG:Semaglutide Pen Injector; BEHAVIORAL:Behavioural Lifestyle Program (BLP)","McMaster University","2025-06-18","FALSE","0"],["S000566","ClinicalTrials.gov","NCT01761318","MAGNA VICTORIA","Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","50","Diabetes Mellitus Type 2; Metabolic Syndrome; Cardiovascular Disease; Diastolic Dysfunction; Fatty Liver","DRUG:Liraglutide; DRUG:Liraglutide - Placebo","Leiden University Medical Center","2013-11","FALSE","17"],["S000567","ClinicalTrials.gov","NCT03885297",null,"Investigation of the Metabolic Effects of 3mg Liraglutide on Patients With Overweight or Obesity","OBSERVATIONAL",null,null,"COMPLETED","43","Overweight; Obesity; Infertility, Female","DRUG:Saxenda; OTHER:Lifestyle modification; DIAGNOSTIC_TEST:Metabolomics; DIAGNOSTIC_TEST:miRNA","University Hospitals Coventry and Warwickshire NHS Trust","2019-01-18","FALSE","0"],["S000568","ClinicalTrials.gov","NCT04034524",null,"An Observational Study of Glycemic Control and Cardiovascular Outcomes Among Patients With Type 2 Diabetes Newly Initiating Glucagon-like Peptide-1 Receptor Agonists (GLP1) Versus Basal Insulin in Routine Care Settings","OBSERVATIONAL",null,null,"UNKNOWN","20000","Diabetes Mellitus, Type 2","DRUG:GLP-1 receptor agonist; DRUG:Insulin","Brigham and Women's Hospital","2019-05-01","FALSE","0"],["S000569","ClinicalTrials.gov","NCT00744224","PREDEX","Prednisolone-induced Impairment of Glucose Metabolism and Beta-cell Dysfunction and the Protective Effects of Exenatide: a Single-center, Randomized, Double-blind, Placebo-controlled Crossover Study in Healthy Volunteers","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","8","Glucocorticoid-induced Glucometabolic Abnormalities; Glucocorticoid-induced Beta-cell Dysfunction","DRUG:Placebo; DRUG:Prednisolone; DRUG:Prednisolone and Exenatide","Amsterdam UMC, location VUmc","2009-02","FALSE","1"],["S000570","ClinicalTrials.gov","NCT01076842",null,"The Effect of Detemir Compared to Exenatide and/or the Combination of Detemir and Exenatide on Glycemic Control and Weight in Patients With Type 2 Diabetes Mellitus Who Have Failed Oral Hypoglycemic Agents","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","75","Diabetes Type 2","DRUG:Insulin-Levemir; DRUG:Exenatide-Bayetta; DRUG:Insulin-Levemir and Exenatide-Bayetta; DEVICE:SenseWear Pro3® armband; DEVICE:DexCom CGM","Novo Nordisk A/S","2008-04","FALSE","0"],["S000571","ClinicalTrials.gov","NCT05161429","BESTMED","BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","OBSERVATIONAL",null,null,"UNKNOWN","550000","Diabetes Mellitus, Type 2","DRUG:DPP4; DRUG:GLP-1 receptor agonist; DRUG:Basal Insulin; DRUG:SLGT2; DRUG:SU","Brigham and Women's Hospital","2021-07-01","FALSE","0"],["S000572","ClinicalTrials.gov","NCT03279731","BELIEVE","Liraglutide 3.0mg/d for the Treatment of Binge Eating Disorder","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","36","Binge-Eating Disorder","DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml; DRUG:Placebo","Kelly Allison","2017-09-29","TRUE","0"],["S000573","ClinicalTrials.gov","NCT07429045",null,"A Phase 1, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AMG 133 in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","44","Overweight and Obesity","DRUG:AMG 133","Amgen","2025-03-11","FALSE","0"],["S000574","ClinicalTrials.gov","NCT03350191",null,"A PET/CT Study to Assess the Receptor Occupancy by SAR425899 After Repeat Dosing Using Radiolabelled Tracers for the Glucagon and GLP-1 Receptor in Overweight to Obese T2DM Patients","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","13","Type 2 Diabetes Mellitus","DRUG:SAR425899; DRUG:[68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer); DRUG:[68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)","Sanofi","2017-12-20","FALSE","1"],["S000575","ClinicalTrials.gov","NCT04779697",null,"GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","96","Obesity","DRUG:GLP-1 analogue - semaglutide; OTHER:Placebo","Yale University","2021-02-01","TRUE","0"],["S000576","ClinicalTrials.gov","NCT03357380",null,"A Trial Investigating the Effect of Subcutaneous Semaglutide on Liver Fibrosis Assessed by Magnetic Resonance Elastography in Subjects With Non-alcoholic Fatty Liver Disease","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","67","Hepatobiliary Disorders; Non-alcoholic Fatty Liver Disease","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2017-11-28","FALSE","3"],["S000577","ClinicalTrials.gov","NCT07382180","TIR-REAL","More Than Weight Loss: Real-World Tirzepatide Use in Post-Bariatric Weight Regain and Preoperative Obesity Care","OBSERVATIONAL",null,null,"COMPLETED","254","Obesity & Overweight; Weight Regain; Obesity, Morbid","DRUG:Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician","Azienda Sanitaria Locale Napoli 2 Nord","2025-02-01","FALSE","0"],["S000578","ClinicalTrials.gov","NCT07654062","DREAM-PRE","Efficacy and Safety of Mazdutide in Adults With Prediabetes: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial (DREAM-PRE)","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","150","Prediabetes; Impaired Fasting Glucose; Impaired Glucose Tolerance (Prediabetes)","DRUG:Mazdutide; DRUG:Placebo; BEHAVIORAL:Standardized Lifestyle Intervention","Shandong Provincial Hospital","2026-07","FALSE","7"],["S000579","ClinicalTrials.gov","NCT07628127",null,"A Randomized, Double-blind, Placebo-controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","332","Obesity; Overweight","DRUG:VRB-103; OTHER:Placebo; DRUG:VRB-101","Verdiva Bio Dev Limited","2026-07-06","FALSE","0"],["S000580","ClinicalTrials.gov","NCT05931380","ATTAIN-J","A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Japanese Adult Participants With Obesity Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","238","Obesity","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2023-07-31","TRUE","0"],["S000581","ClinicalTrials.gov","NCT01324388",null,"Pharmacokinetic and Pharmacodynamic Effect of LY2189265 on Lisinopril in Subjects With Hypertension and Metoprolol in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","51","Diabetes Mellitus, Type 2","BIOLOGICAL:LY2189265; DRUG:Metoprolol; DRUG:Lisinopril; DRUG:Placebo","Eli Lilly and Company","2011-03","TRUE","0"],["S000582","ClinicalTrials.gov","NCT05132088","OASIS 2","Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in East Asian Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","201","Overweight and Obesity","DRUG:semaglutide 50 mg; DRUG:placebo (semaglutide)","Novo Nordisk A/S","2021-11-16","TRUE","2"],["S000583","ClinicalTrials.gov","NCT07605247","TREAT-EC","TREAT-EC (Tirzepatide in the Treatment of Endometrial Cancer) A Phase II Pilot Clinical Trial.","INTERVENTIONAL",null,"PHASE2","NOT_YET_RECRUITING","30","Endometrial Cancer","DRUG:Tirzepatide; DEVICE:LNG-IUD plus tirzepatide","Rutgers, The State University of New Jersey","2026-06-01","FALSE","0"],["S000584","ClinicalTrials.gov","NCT03191396","SUSTAIN 10","Efficacy and Safety of Semaglutide 1.0 mg Once-weekly Versus Liraglutide 1.2 mg Once-daily as add-on to 1-3 Oral Anti-diabetic Drugs (OADs) in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","577","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Liraglutide","Novo Nordisk A/S","2017-06-27","TRUE","2"],["S000585","ClinicalTrials.gov","NCT03684642","AMPLITUDE-D","A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","908","Type 2 Diabetes Mellitus","DRUG:Efpeglenatide; DRUG:Dulaglutide; DRUG:Background therapy Metformin","Sanofi","2018-09-26","TRUE","0"],["S000586","ClinicalTrials.gov","NCT06339086",null,"A Multicenter, Randomized, Open-label and Parallel-controlled Phase III Study to Compare the Efficacy and Safety of Semaglutide Injection With Ozempic® in the Treatment of Type 2 Diabetes Subjects With Poor Glycemic Control on Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","478","Type 2 Diabetes Mellitus","DRUG:Semaglutide Injection; DRUG:Semaglutide Injection(Ozempic®); DRUG:Metformin","Chengdu Brilliant Pharmaceutical Co., Ltd.","2024-04","FALSE","0"],["S000587","ClinicalTrials.gov","NCT01175473",null,"An Open-label, Randomized Two-arm Parallel Group Study to Compare the Effects of 4-week QD Treatment With Lixisenatide or Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","148","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DEVICE:Pen auto-injector; DRUG:Liraglutide; DEVICE:Pre-filled pen injector; DRUG:Metformin","Sanofi","2010-08","TRUE","1"],["S000588","ClinicalTrials.gov","NCT07676331","CLARA","Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","168","Hormone-receptor-positive Breast Cancer; Early Breast Cancer","DRUG:Tirzepatide; DRUG:Letrozole (Aromatase Inhibitors)","Universitaire Ziekenhuizen KU Leuven","2026-08-01","FALSE","0"],["S000589","ClinicalTrials.gov","NCT07239570","CKD-bioMatch","A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease: A Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","125","Chronic Kidney Disease(CKD)","DRUG:Dapagliflozin; DRUG:Semaglutide; DRUG:Finerenone","Peter Rossing","2025-06-20","FALSE","0"],["S000590","ClinicalTrials.gov","NCT03347968",null,"A Phase 1, Open-label Study to Compare the Pharmacokinetics and Pharmacodynamics of Warfarin and Esmolol in the Absence and Presence of MEDI0382 in Healthy Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","22","Healthy Volunteers","BIOLOGICAL:MEDI0382; DRUG:Warfarin; DRUG:Esmolol","MedImmune LLC","2017-11-27","FALSE","1"],["S000591","ClinicalTrials.gov","NCT03492580",null,"Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","OBSERVATIONAL",null,null,"COMPLETED","714582","Diabetes Mellitus, Type 2; Cardiovascular Diseases","DRUG:Canagliflozin; DRUG:Empagliflozin; DRUG:Dapagliflozin; DRUG:Dipeptidyl Peptidase-4 (DPP-4) Inhibitors; DRUG:Glucagon-like Peptide-1 (GLP-1) Agonist; DRUG:Anti-hyperglycemic Agents (AHA); DRUG:Thiazolidinediones (TZD); DRUG:Sulfonylureas (SU); DRUG:Insulin","Janssen Research & Development, LLC","2018-02-22","FALSE","0"],["S000592","ClinicalTrials.gov","NCT04621227",null,"A PHASE 1, OPEN -LABEL, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF TWO STEADY STATE DOSE LEVELS OF PF-06882961 ON THE PHARMACOKINETICS OF SINGLE ORAL DOSES OF ROSUVASTATIN AND MIDAZOLAM IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OBESITY","INTERVENTIONAL",null,"PHASE1","COMPLETED","16","Obesity","DRUG:PF-06882961; DRUG:Rosuvastatin; DRUG:Midazolam","Pfizer","2020-12-15","TRUE","0"],["S000593","ClinicalTrials.gov","NCT03951753",null,"The Effect of Tirzepatide on α and β Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","117","Diabetes Mellitus, Type 2","DRUG:Tirzepatide; DRUG:Semaglutide; DRUG:Placebo","Eli Lilly and Company","2019-06-28","TRUE","2"],["S000594","ClinicalTrials.gov","NCT02417142",null,"Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","70","Schizophrenia; Schizoaffective Disorder","DRUG:Exenatide; DRUG:Placebo","University of Massachusetts, Worcester","2014-09","TRUE","0"],["S000595","ClinicalTrials.gov","NCT02022254",null,"An Open-label, One-sequence Cross Over, Single Centre Trial, Investigating the Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","24","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:placebo; DRUG:metformin; DRUG:warfarin","Novo Nordisk A/S","2013-12-17","FALSE","1"],["S000596","ClinicalTrials.gov","NCT05313529","LIGHT-MCI","Effects of Liraglutide, Empagliflozin and Linagliptin on Mild Cognitive Impairment Remission in Type 2 Diabetes (LIGHT-MCI): A Multicentre, Randomised Controlled Trial With An Extension Phase","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","396","Type 2 Diabetes Mellitus; Mild Cognitive Impairment","DRUG:Liraglutide; DRUG:Empagliflozin; DRUG:Linagliptin","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2022-10-08","FALSE","3"],["S000597","ClinicalTrials.gov","NCT01612468",null,"Liraglutide in Type 1 Diabetes. A Randomised, Double-blind, Placebo Controlled Study of the Effect of Liraglutide as an Additional Treatment to Insulin on HbA1c, Body Weight and Hypoglycaemia in Poorly Regulated Type 1 Diabetes Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","100","Diabetes Mellitus, Type 1; Overweight","DRUG:Liraglutide; DRUG:Placebo","Steno Diabetes Center Copenhagen","2012-06","FALSE","3"],["S000598","ClinicalTrials.gov","NCT02168491","LixiBIT","Feasibility of Once-daily Administered GLP-1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin in Patients With Type-2 Diabetes Mellitus Not Achieving Therapeutic Targets With Premixed Insulin","INTERVENTIONAL",null,"PHASE3","COMPLETED","10","Type 2 Diabetes Mellitus","DRUG:Lixisenatide; DRUG:Insulin glargine","Medical University of Vienna","2014-11","TRUE","1"],["S000599","ClinicalTrials.gov","NCT02918279",null,"Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity. 56-week, Double-blind, Randomised, Parallel-group, Placebo-controlled Multi-national Trial Followed by a 26-week Period Off Study-drug","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","251","Metabolism and Nutrition Disorder; Obesity","DRUG:Liraglutide; DRUG:Placebo","Novo Nordisk A/S","2016-09-29","TRUE","4"],["S000600","ClinicalTrials.gov","NCT02162550",null,"Effect of Bydureon on Carotid Atherosclerosis Progression in T2DM","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","148","Type 2 Diabetes","DRUG:Bydureon; DRUG:placebo","Phoenix VA Health Care System","2014-06","FALSE","1"],["S000601","ClinicalTrials.gov","NCT06989203",null,"An Intervention Study Investigating Effect of Dietary Protein Supplementation on Body Weight and Metabolic Homeostasis","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","140","Obesity; Weight Loss; Protein Supplementation","BEHAVIORAL:General lifestyle and nutritional education; BEHAVIORAL:Calorie-restricted balanced diet; DRUG:semaglutide; DIETARY_SUPPLEMENT:Dietary protein supplementation","Chinese Academy of Sciences","2025-06-10","FALSE","0"],["S000602","ClinicalTrials.gov","NCT02060266",null,"A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","7","Diabetes; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2014-02-04","FALSE","1"],["S000603","ClinicalTrials.gov","NCT06649045","ATTAIN-OSA","A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","712","OSA; Overweight or Obesity","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2024-10-22","FALSE","1"],["S000604","ClinicalTrials.gov","NCT02963766","AWARD-PEDS","A Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","154","Type 2 Diabetes","DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2016-12-29","TRUE","2"],["S000605","ClinicalTrials.gov","NCT04889157",null,"AN 8-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-06882961 IN CHINESE ADULTS WITH TYPE 2 DIABETES MELLITUS","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","20","Diabetes Mellitus, Type 2","DRUG:PF-06882961; DRUG:Placebo","Pfizer","2021-07-07","TRUE","1"],["S000606","ClinicalTrials.gov","NCT03795701",null,"To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","73","Obesity","DRUG:Saxenda®; OTHER:Placebo","Texas Tech University","2019-01-08","FALSE","0"],["S000607","ClinicalTrials.gov","NCT03811561","FOCUS","Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","1500","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-05-08","FALSE","0"],["S000608","ClinicalTrials.gov","NCT03648554","REALIST","A Multicentre Controlled and Randomized Study Assessing the Effect of Dulaglutide add-on to Dietary Reinforcement Versus Dietary Reinforcement Alone in Patients With Type 2 Diabetes and Carriers of a Non-alcoholic Steatohepatitis","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","93","Diabetes Mellitus, Type 2; NASH - Nonalcoholic Steatohepatitis","DRUG:dulaglutide (TRULICITY®) 1.5 mg; OTHER:reinforced dietary monitoring","Central Hospital, Nancy, France","2019-09-01","FALSE","0"],["S000609","ClinicalTrials.gov","NCT00960661",null,"A Randomized Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes Who Were Previously Treated by Basal Insulin Glargine With Either Metformin or Metformin and Sulfonylurea","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1036","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:insulin lispro; DRUG:Metformin; DRUG:Insulin/ Glargine","AstraZeneca","2009-09","TRUE","2"],["S000610","ClinicalTrials.gov","NCT03940742",null,"A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","32","Hepatic Insufficiency","DRUG:Tirzepatide","Eli Lilly and Company","2019-07-22","TRUE","1"],["S000611","ClinicalTrials.gov","NCT07280403",null,"Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss: a Pilot Trial","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","60","Weight Loss","BEHAVIORAL:Low Carbohydrate; BEHAVIORAL:Low Fat","INQUIS Clinical Research","2024-09-12","FALSE","0"],["S000612","ClinicalTrials.gov","NCT06571383",null,"Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c.2.4 mg Once-weekly","INTERVENTIONAL",null,"PHASE4","ACTIVE_NOT_RECRUITING","500","Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2024-09-17","FALSE","0"],["S000613","ClinicalTrials.gov","NCT07262762",null,"A Post-marketing Real-world Study for Evaluating Effectiveness and Safety of Spartina® (Tirzepatide Manufactured by CinnaGen) in Patients With Obesity and Overweight","OBSERVATIONAL",null,null,"COMPLETED","175","Obesity & Overweight",null,"Cinnagen","2025-11-11","FALSE","0"],["S000614","ClinicalTrials.gov","NCT01843127",null,"A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide Active-control Period","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Type 2 Diabetes Mellitus","DRUG:Ranolazine; DRUG:Placebo; DRUG:Exenatide","Gilead Sciences","2013-04","FALSE","0"],["S000615","ClinicalTrials.gov","NCT04605861",null,"A Multicenter, Randomized, Double-blinded, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","414","Obese; Overweight","DRUG:Liraglutide; DRUG:Placebo","Shanghai Zhongshan Hospital","2020-08-18","FALSE","1"],["S000616","ClinicalTrials.gov","NCT06758583",null,"An Open-label, Randomized, Parallel-group, Single-center Trial to Compare Pharmacokinetics of Dapiglutide After a Single Subcutaneous Dose of the Drug Product Concentrations 10 mg/mL or 25 mg/mL in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","30","Overweight and Obesity","DRUG:Dapiglutide 7.5 mg","Zealand Pharma","2024-12-23","FALSE","0"],["S000617","ClinicalTrials.gov","NCT02975297",null,"Exenatide Once Weekly for Smoking Cessation: A Randomized Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","84","Smoking Cessation","DRUG:Exenatide; DRUG:NRT; BEHAVIORAL:Counseling; DRUG:Placebo","The University of Texas Health Science Center, Houston","2016-07","TRUE","2"],["S000618","ClinicalTrials.gov","NCT06967389","MODERN","Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity (MODERN)","OBSERVATIONAL",null,null,"RECRUITING","50","Obesity and Overweight; Obese Adolescents; Weight Management; Weight Loss; Cardiovascular Disease Risk Factor","DRUG:Ozempic®","John Bauer","2025-06-12","FALSE","0"],["S000619","ClinicalTrials.gov","NCT04829903",null,"Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin: Results From a Randomized Double Blinded Clinical Trial","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","116","Type 2 Diabetes Treated With Insulin; Obesity; Adolescent Obesity","DRUG:Dulaglutide; DRUG:Liraglutide","Corporacion Parc Tauli","2020-01-02","FALSE","0"],["S000620","ClinicalTrials.gov","NCT07505303",null,"A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of ECC4703 as an Adjunct to Semaglutide in Adults With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","151","Adult Obesity; Weight Management","DRUG:ECC4703; DRUG:Placebo; DRUG:Semaglutide","Eccogene","2026-03-23","FALSE","0"],["S000621","ClinicalTrials.gov","NCT04537624","PIONEER REAL","A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Switzerland","OBSERVATIONAL",null,null,"COMPLETED","194","Diabetes Mellitus, Type 2","DRUG:Oral Semaglutide","Novo Nordisk A/S","2020-08-24","FALSE","2"],["S000622","ClinicalTrials.gov","NCT05553093",null,"Nanjing First Hospital, Nanjing Medical University","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","150","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Insulin Glargine","Nanjing First Hospital, Nanjing Medical University","2022-03-15","FALSE","0"],["S000623","ClinicalTrials.gov","NCT06180616","TZP-T1D","Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity: A Placebo-Matched Randomised Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","40","Type 1 Diabetes Mellitus; Overweight and Obesity","DRUG:Tirzepatide","Royal North Shore Hospital","2026-12","FALSE","1"],["S000624","ClinicalTrials.gov","NCT04777409","EVOKE Plus","A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1840","Early Alzheimer´s Disease","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2021-05-18","FALSE","11"],["S000625","ClinicalTrials.gov","NCT01234649",null,"Effects of Intervention With the Glucagon-like Peptide 1 (GLP-1) Analog Liraglutide Plus Metformin Versus Metformin Monotherapy in Overweight/Obese Women With Metabolic Defects and Recent History of Gestational Diabetes Mellitus (GDM)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","153","Gestational Diabetes Mellitus; Type 2 Diabetes Mellitus; Metabolic Syndrome; Impaired Glucose Tolerance; Disorder of Glucose Regulation","DRUG:Metformin XR plus placebo; DRUG:Metformin XR plus liraglutide","Woman's","2011-08-11","TRUE","1"],["S000626","ClinicalTrials.gov","NCT03638778",null,"A Trial Comparing Exposure of Semaglutide When Dosing New Formulations of Oral Semaglutide to Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","105","Diabetes Mellitus, Type 2","DRUG:Semaglutide 3 mg; DRUG:Semaglutide 7 mg; DRUG:Semaglutide B 3 mg; DRUG:Semaglutide B 7 mg; DRUG:Semaglutide C 3 mg; DRUG:Semaglutide C 7 mg; DRUG:Semaglutide D 3 mg; DRUG:Semaglutide D 7 mg","Novo Nordisk A/S","2018-08-17","FALSE","0"],["S000627","ClinicalTrials.gov","NCT05294458",null,"A Single Part, Three-Way Crossover, Randomised, Open-Label Study Designed to Evaluate the Relative and Absolute Bioavailability Following a Single Subcutaneous Injection of a Novel High Concentration Subcutaneous Formulation of Cotadutide Against a Low Concentration Subcutaneous Formulation and Intravenous (IV) Formulation for Reference, in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","10","Non-alcoholic Steatohepatitis; Type 2 Diabetes Mellitus (T2DM); Chronic Kidney Disease","DRUG:cotadutide solution for injection","AstraZeneca","2022-03-28","FALSE","0"],["S000628","ClinicalTrials.gov","NCT06400615",null,"Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","40","OSA","DRUG:AD109","Apnimed","2024-05-20","FALSE","0"],["S000629","ClinicalTrials.gov","NCT05064735",null,"Effect of Subcutaneous Semaglutide 2.4 mg Once-weekly Compared to Placebo in Subjects With Obesity and Knee Osteoarthritis","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","407","Obesity","DRUG:semaglutide 2.4 mg; DRUG:semaglutide 2.4 mg (placebo)","Novo Nordisk A/S","2021-10-01","TRUE","1"],["S000630","ClinicalTrials.gov","NCT07242534","SEQ","Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","62","Infertility; Obesity","DRUG:Semaglutide; OTHER:No pre-treatment","Fundacion Dexeus","2026-01-19","FALSE","10"],["S000631","ClinicalTrials.gov","NCT01508806",null,"A Single-centre, Open-label, Trial Investigating the Pharmacokinetics and the Tolerability of Liraglutide in Subjects With Normal Renal Function and in Subjects With Impaired Renal Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","30","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2005-08","FALSE","1"],["S000632","ClinicalTrials.gov","NCT00935532",null,"Parallel Group Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus Treated With Oral Antidiabetic(s)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","427","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:insulin glargine","AstraZeneca","2009-07","TRUE","2"],["S000633","ClinicalTrials.gov","NCT04172987",null,"Effect of Tirzepatide on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","40","Healthy","DRUG:Tirzepatide; DRUG:EE/NGM","Eli Lilly and Company","2020-02-26","TRUE","0"],["S000634","ClinicalTrials.gov","NCT01599338",null,"Influence du Victoza (Liraglutide,Analogue GLP-1) Sur Les Performances Gustatives, le Rassasiement Sensoriel spécifique, le Liking et le Wanting Chez Les Patients diabétiques de Type 2.","INTERVENTIONAL",null,null,"COMPLETED","30","Type 2 Diabetes Mellitus; Overweight","DRUG:Liraglutide","Centre Hospitalier Universitaire Dijon","2011-01","FALSE","0"],["S000635","ClinicalTrials.gov","NCT06849843",null,"A Multicenter, Randomized, Controlled Clinical Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients With Poor Glycemic Control After Diet and Exercise Intervention.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","59","Type2 Diabetes","DRUG:Efsubaglutide Alfa Injection","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2024-12-18","FALSE","0"],["S000636","ClinicalTrials.gov","NCT04020445",null,"Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","150","HBA1c; Body Weight; Hypoglycemia","OTHER:de-escalation of complex insulin regimens","Bekes County Central Hospital","2016-01-01","FALSE","1"],["S000637","ClinicalTrials.gov","NCT07178145",null,"MRI of Epicardial Adipose Tissue Composition: Development of Methods and Application to Heart Failure With Preserved Ejection Fraction","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","RECRUITING","192","Heart Failure Preserved Ejection Fraction; Epicardial Adipose Tissue","DRUG:GLP-1RA","University of Virginia","2025-11-20","FALSE","1"],["S000638","ClinicalTrials.gov","NCT06256419",null,"Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University","INTERVENTIONAL",null,null,"RECRUITING","300","Type 2 Diabetes Mellitus; Susceptibility, Genetic","DRUG:GLP-1 receptor agonist; DRUG:responders group and nonresponders group","The Affiliated Hospital of Xuzhou Medical University","2024-01-01","FALSE","0"],["S000639","ClinicalTrials.gov","NCT07112872",null,"A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","330","Type 2 Diabetes Mellitus","DRUG:RO7795081; DRUG:Semaglutide; DRUG:Placebo","Hoffmann-La Roche","2025-08-19","FALSE","0"],["S000640","ClinicalTrials.gov","NCT07677865","GLP1-AD-TTE","GLP-1 Receptor Agonists Prevent Alzheimer's Disease Onset, Not Progression: Resolving the Real-World-Randomised Trial Paradox Across Five Continents","OBSERVATIONAL",null,null,"COMPLETED","213891","Alzheimer Disease; Diabetes Mellitus Type 2; Obesity & Overweight","DRUG:GLP-1 Receptor Agonists; DRUG:DPP-4 Inhibitors","West China Hospital","2007-01-01","FALSE","0"],["S000641","ClinicalTrials.gov","NCT02150707",null,"The Differential Effects of Diabetes Therapy on Inflammation","OBSERVATIONAL",null,null,"COMPLETED","17","Diabetic Nephropathy; Type 2 Diabetes","DRUG:Dipeptidyl-Peptidase IV Inhibitors; DRUG:Glucagon-Like Peptide 1","University College Dublin","2014-05","FALSE","2"],["S000642","ClinicalTrials.gov","NCT01951651",null,"Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","24","Type 2 Diabetes Mellitus","DRUG:Exenatide; DRUG:Glipizide","Baylor College of Medicine","2010-04","TRUE","0"],["S000643","ClinicalTrials.gov","NCT06931028",null,"A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Assess the Efficacy and Safety of IBI362 in Chinese Subjects With Moderate-to-Severe Obstructive Sleep Apnea and BMI≥28 kg/m2 (GLORY-OSA)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","260","Sleep Apnea; Obstructive; Obesity","OTHER:placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2025-06-12","FALSE","0"],["S000644","ClinicalTrials.gov","NCT04001231",null,"A Phase 1, Open-Label Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety, and Tolerability of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE1","WITHDRAWN","0","Type 2 Diabetes","DRUG:Exenatide Once-Weekly Suspension","AstraZeneca","2020-06-30","FALSE","0"],["S000645","ClinicalTrials.gov","NCT06370728",null,"A Drug-Drug Interaction Study to Assess the Effect of Carbamazepine on the Pharmacokinetics of Orforglipron in Healthy Participants","INTERVENTIONAL",null,"PHASE1","COMPLETED","30","Healthy","DRUG:Orforglipron; DRUG:Carbamazepine","Eli Lilly and Company","2024-05-06","TRUE","0"],["S000646","ClinicalTrials.gov","NCT02941367","LixiRam","International, Randomized, Open Label Study to Compare the Safety and Efficacy of Lixisenatide vs. Sulfonylurea on Top of Basal Insulin Treatment in Type 2 Diabetes Mellitus Subjects Who Elect to Fast During Ramadan","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","184","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Sulfonylurea; DRUG:metformin; DRUG:basal insulin","Sanofi","2017-02-23","FALSE","3"],["S000647","ClinicalTrials.gov","NCT01507272",null,"A Randomised, Double-blind, Placebo-controlled, Dose Escalation Trial of Single Doses of NNC90-1170 to Assess Tolerability, Pharmacokinetics, Pharmacodynamics and Absolute Bioavailability in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","34","Diabetes; Healthy","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","1999-03","FALSE","2"],["S000648","ClinicalTrials.gov","NCT04324229","Liragest","Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes","INTERVENTIONAL","RANDOMIZED",null,"ACTIVE_NOT_RECRUITING","80","Gestational Diabetes","DRUG:Liraglutide 6 MG/ML [Victoza]; DRUG:Placebos","Turku University Hospital","2020-02-07","FALSE","0"],["S000649","ClinicalTrials.gov","NCT06865365",null,"Prospective, Randomized, Controlled Trial of Preoperative Use of Saxenda (Liraglutide) Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","72","Obesity, Adolescent","DRUG:Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions; BEHAVIORAL:Dietologic measures and lifestyle optimization for weight loss","Medical University of Vienna","2025-05-01","FALSE","0"],["S000650","ClinicalTrials.gov","NCT02008682",null,"The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes.(LIRA-DPP-4 CHINA™)","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","368","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:sitagliptin","Novo Nordisk A/S","2013-12","TRUE","1"],["S000651","ClinicalTrials.gov","NCT04314622",null,"A Randomized, Double-Blind, Placebo-controlled Study of Supaglutide on the Safety, Pharmacokinetics and Pharmacodynamics, and Efficacy in Chinese Patients With Type 2 Diabetes.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","40","Diabetes Mellitus, Type 2","DRUG:Supaglutide; DRUG:Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2020-04-14","FALSE","1"],["S000652","ClinicalTrials.gov","NCT06738979",null,"A Multicenter, Randomized, Open, Parallel Controlled Phase III Study Comparing the Efficacy and Safety of Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","408","Obesity","DRUG:TQF3510 (Semaglutide Injection); DRUG:Wegovy®","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","2025-03-20","FALSE","0"],["S000653","ClinicalTrials.gov","NCT01509742",null,"Effect of NNC 90-1170 on Hypoglycaemic Counterregulation During Stepwise Hypoglycaemic Clamp in Type 2 Diabetic Subjects. A Double-blind, Placebo-controlled, Randomised, 2-period Cross-over Trial","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","19","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2001-04","FALSE","0"],["S000654","ClinicalTrials.gov","NCT06921486",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Clinical Trial to Evaluate the Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","ACTIVE_NOT_RECRUITING","1003","Obesity and Overweight","DRUG:Phase IIb：Efsubaglutide Alfa 5 mg QW; DRUG:Phase IIb：Efsubaglutide Alfa 10 mg QW; DRUG:Phase IIb：Efsubaglutide Alfa 20 mg QW; DRUG:Phase IIb：Efsubaglutide Alfa 20 mg Q2W; DRUG:Phase IIb：Placebo; DRUG:Phase III：Recommended Phase 3 Dose High Dose; DRUG:Phase III：Recommended Phase 3 Dose Low Dose; DRUG:Phase III：Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2025-03-31","FALSE","1"],["S000655","ClinicalTrials.gov","NCT02140983","LGT","Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","41","Insulin Resistance; Dementia","DRUG:Liraglutide; DRUG:Placebo","Stanford University","2013-08","FALSE","0"],["S000656","ClinicalTrials.gov","NCT03115424",null,"Effect of GLP-1 Receptor Agonism on Weight and Caloric Intake in Subjects After Sleeve Gastrectomy","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","46","Obesity","DRUG:Saxenda; DRUG:Placebos; PROCEDURE:RYGB","Mayo Clinic","2017-06-22","TRUE","0"],["S000657","ClinicalTrials.gov","NCT06660173",null,"A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","409","Type 2 Diabetes Mellitus (T2DM)","DRUG:Maridebart Cafraglutide; DRUG:Placebo","Amgen","2024-11-07","FALSE","0"],["S000658","ClinicalTrials.gov","NCT07527910",null,"A Two-Part, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of ALN-PNP With and Without a GLP1R Agonist in Adults With Homozygous PNPLA3-Related Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","204","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","DRUG:ALN-PNP; DRUG:Tirzepatide; DRUG:Placebo","Regeneron Pharmaceuticals","2026-05-22","FALSE","0"],["S000659","ClinicalTrials.gov","NCT04969627",null,"Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","60","Polycystic Ovary Syndrome","DRUG:Metformin; DRUG:Exenatide","Bing He","2021-01-04","FALSE","0"],["S000660","ClinicalTrials.gov","NCT07517042",null,"Achieving Sustained Weight Control Via Exercise, Nutrition & Drugs (Mazdutide) (ASCEND- 1 Trial)","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","420","Obesity; Weight Control","DRUG:Mazdutide; BEHAVIORAL:Intensive Lifestyle Intervention","Shanghai Zhongshan Hospital","2026-06-10","FALSE","0"],["S000661","ClinicalTrials.gov","NCT03371862","SLIPS","Pilot Study of the GLP-1 Agonist, Liraglutide, on Decreasing Parenteral Support Requirements in Short Bowel Patients.","INTERVENTIONAL",null,"PHASE2","WITHDRAWN","0","Short Bowel Syndrome","DRUG:Liraglutide Pen Injector [Victoza]","Imperial College London","2017-10-20","FALSE","0"],["S000662","ClinicalTrials.gov","NCT01408888",null,"Study to Evaluate the Effect of LY2189265 on Sitagliptin Pharmacokinetics in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","29","Diabetes Mellitus, Type 2","BIOLOGICAL:LY2189265; DRUG:Sitagliptin","Eli Lilly and Company","2011-08","TRUE","0"],["S000663","ClinicalTrials.gov","NCT00500370",null,"A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","163","Obesity","DRUG:exenatide; DRUG:placebo","AstraZeneca","2007-06","TRUE","1"],["S000664","ClinicalTrials.gov","NCT07040592","HARP","Feasibility, Acceptability, and Preliminary Efficacy of Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: An Open-Label Pilot Study","INTERVENTIONAL",null,"PHASE2","RECRUITING","30","Alcohol Use Disorder (AUD); HIV","DRUG:semaglutide","Yale University","2026-01-15","FALSE","0"],["S000665","ClinicalTrials.gov","NCT03878706",null,"The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular Risk","OBSERVATIONAL",null,null,"RECRUITING","240","Diabetes Mellitus, Type 2",null,"University of Athens","2017-11-03","FALSE","7"],["S000666","ClinicalTrials.gov","NCT06659744",null,"Emulation of Effects of Injectable Semaglutide on Cardiovascular Outcomes in Individuals With Type 2 Diabetes: SUSTAIN6 Trial","OBSERVATIONAL",null,null,"COMPLETED","158310","Diabetes Mellitus, Type 2","DRUG:New use of semaglutide injection; DRUG:New initiation of sitagliptin","Brigham and Women's Hospital","2024-10-24","FALSE","1"],["S000667","ClinicalTrials.gov","NCT06854614","STAY-LEAN","Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","150","Obesity","OTHER:Comprehensive weight loss; OTHER:Enhanced lifestyle changes; DRUG:Tirzepatide; DRUG:Naltrexone-Bupropion; DRUG:Phentermine-Topiramate; DRUG:Semaglutide (Wegovy®)","The Cleveland Clinic","2025-03-01","FALSE","0"],["S000668","ClinicalTrials.gov","NCT07391267",null,"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide - a Randomized Controlled Trial.","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","90","Chronic Kidney Diseases; MAFLD","DRUG:Semaglutide Oral Tablet; OTHER:Placebo; OTHER:Standard medical treatment","Institute of Liver and Biliary Sciences, India","2026-02-01","FALSE","0"],["S000669","ClinicalTrials.gov","NCT07523633","HASHTAG","A Randomized, Double-Blind, Placebo-Controlled Trial of Semaglutide for Reducing Cannabis Use in Adults With Cannabis Use Disorder","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","100","Cannabis Use Disorder; Cannabis Use Disorders; Cannabis Abuse; Cannabis Dependence; Cannabis Addiction","DRUG:semaglutide; DRUG:Placebo","Anders Fink-Jensen, MD, DMSci","2026-04-30","FALSE","0"],["S000670","ClinicalTrials.gov","NCT03555994",null,"An Exploratory Phase 2, Randomised, Double-blind, Placebo-controlled, and Open-label Active Comparator Study to Evaluate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","51","Type 2 Diabetes Mellitus","DRUG:MEDI0382; DRUG:Placebo; DRUG:Liraglutide","MedImmune LLC","2018-05-31","TRUE","1"],["S000671","ClinicalTrials.gov","NCT05598008","Desire PLUS","The Desire PLUS Study - Effects of Glucagon-like-Peptide-1 Analogues on Sexuality: a Prospective Open-label Study","OBSERVATIONAL",null,null,"COMPLETED","85","Sexual Desire",null,"University Hospital, Basel, Switzerland","2022-11-25","FALSE","0"],["S000672","ClinicalTrials.gov","NCT01297062",null,"A Randomized, Phase 1, Three-Period, Placebo- and Positive-Controlled, Double-Blind, Crossover Study to Assess the Electrophysiological Effects of Exenatide at Therapeutic and Supratherapeutic Concentrations on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","94","Healthy Subjects","DRUG:Exenatide; DRUG:Moxifloxacin; DRUG:Placebo comparator","AstraZeneca","2011-02","TRUE","0"],["S000673","ClinicalTrials.gov","NCT02803918",null,"Randomized, Double-blind, Placebo-controlled, Dose Escalation, Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin and/or Basal Insulin","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","23","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DRUG:Basal Insulin; DRUG:Metformin","Sanofi","2017-05-17","FALSE","1"],["S000674","ClinicalTrials.gov","NCT04426474",null,"A Multiple-Dose Study in Participants With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of LY3502970","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","68","Diabetes Mellitus, Type 2","DRUG:LY3502970; DRUG:Placebo","Eli Lilly and Company","2020-10-08","TRUE","0"],["S000675","ClinicalTrials.gov","NCT02070510",null,"An Open-label, Single Arm, Sequential, Single Centre Trial Investigating the Influence of Oral Semaglutide (NNC0113-0217) on Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","52","Diabetes; Healthy","DRUG:semaglutide; DRUG:lisinopril; DRUG:warfarin; DRUG:placebo","Novo Nordisk A/S","2014-02-27","FALSE","1"],["S000676","ClinicalTrials.gov","NCT03829891",null,"A Randomized, Open-label, Controlled,Parallel-group Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","60","Type 2 Diabetes Mellitus","DRUG:Beinaglutide; DRUG:glargine","Xijing Hospital","2018-08-07","FALSE","1"],["S000677","ClinicalTrials.gov","NCT01455896",null,"A Randomized, Multi-Center Study to Evaluate Cardiovascular Outcomes With ITCA 650 in Patients Treated With Standard of Care for Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","4156","Type 2 Diabetes","DRUG:ITCA 650; OTHER:ITCA placebo","Intarcia Therapeutics","2013-03","FALSE","3"],["S000678","ClinicalTrials.gov","NCT05582096",null,"A Dose-Escalation Treatment, Phase 1, Investigator- and Participant-Blind, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3457263 in Combination With Tirzepatide in Overweight or Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","38","Overweight; Obesity","DRUG:LY3457263; DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2022-11-11","FALSE","0"],["S000679","ClinicalTrials.gov","NCT03352869",null,"Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","183","Polycystic Ovary Syndrome; Overweight and Obesity; Disorder of Glucose Regulation","DRUG:Exenatide; DRUG:Metformin","RenJi Hospital","2017-11-28","FALSE","7"],["S000680","ClinicalTrials.gov","NCT03288740",null,"A Single-centre, Randomised, Double-blind, Placebo-controlled, Multiple-dose Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","36","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide 0.5 mg; DRUG:Placebo (semaglutide 0.5 mg); DRUG:Semaglutide 1.0 mg; DRUG:Placebo (semaglutide 1.0 mg)","Novo Nordisk A/S","2017-09-21","FALSE","2"],["S000681","ClinicalTrials.gov","NCT05479591","GLIDE","Glycaemic Control and Management in Adult Type 2 Diabetes Patients Previously Treated With Premix Insulins and Initiating Treatment With IDegLira in Routine Clinical Practice in Croatia: A 36-week Single Arm, Prospective, Multi-centre, Non-interventional Study","OBSERVATIONAL",null,null,"WITHDRAWN","0","Diabetes Mellitus, Type 2","DRUG:IDegLira","Novo Nordisk A/S","2022-07-30","FALSE","0"],["S000682","ClinicalTrials.gov","NCT04208620",null,"A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","16","Type 2 Diabetes","DRUG:Placebo; DRUG:Cotadutide","AstraZeneca","2020-01-21","FALSE","1"],["S000683","ClinicalTrials.gov","NCT03929679","SURE NL","A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Onceweekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","218","Diabetes Mellitus, Type 2","DRUG:semaglutide","Novo Nordisk A/S","2019-05-28","FALSE","1"],["S000684","ClinicalTrials.gov","NCT07444073",null,"Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","440","Aging; Obesity & Overweight","OTHER:Not applicable. This is an observational study.","National University of Singapore","2026-06-01","FALSE","0"],["S000685","ClinicalTrials.gov","NCT07319286",null,"Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","ENROLLING_BY_INVITATION","50","Menstrual Irregularities; Type1 Diabetes Mellitus; Glucagon-Like Peptide-1 Receptor Agonists; Female Reproductive Health","DRUG:Dulaglutide","Ain Shams University","2025-08-04","FALSE","1"],["S000686","ClinicalTrials.gov","NCT07220473",null,"The Moody Longevity Trial: Tirzepatide to Slow Biological Aging","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","90","Aging; LONGEVITY 1","DRUG:Zepbound","The University of Texas Medical Branch, Galveston","2026-02-27","FALSE","0"],["S000687","ClinicalTrials.gov","NCT06292065","GUST","Gastric Ultrasound To Assess Gastric Contents In Patients On Semaglutide Therapy","INTERVENTIONAL",null,null,"COMPLETED","88","Gastroparesis","DIAGNOSTIC_TEST:Point-of-care gastric ultrasound","Nils Vlaeminck","2024-04-16","FALSE","0"],["S000688","ClinicalTrials.gov","NCT03824002",null,"Arterial Stiffness and Endothelial Function Indexes, Relationships With Clinical and Laboratory Variables in a Group of Diabetic Patients in Treatment With Dulaglutide: a Case-control Study","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","92","Diabetes Mellitus","DRUG:Dulaglutide; DRUG:Aspart insulin; DRUG:Glargine; DRUG:Metformin; DRUG:Repaglinide","University of Palermo","2017-04-01","FALSE","1"],["S000689","ClinicalTrials.gov","NCT01843075","ELAD","Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","204","Alzheimer's Disease","DRUG:Liraglutide; DRUG:Placebo","Imperial College London","2014-01","FALSE","10"],["S000690","ClinicalTrials.gov","NCT00950677","T2DM","The Effect of the Glucagon Suppressors Pramlintide and Exenatide on Postprandial Glucose Metabolism in Children With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","16","Type 2 Diabetes","DRUG:Byetta (exenatide); DRUG:Symlin (pramlintide)","Baylor College of Medicine","2009-07","FALSE","0"],["S000691","ClinicalTrials.gov","NCT03959865","GLP-1REWIN","Effectiveness and Persistence of Therapy With GLP-1 Receptor Agonists in Clinical Practice. A Multicenter Retrospective Study","OBSERVATIONAL",null,null,"UNKNOWN","6000","Type 2 Diabetes","DRUG:Long-acting GLP-1RA; DRUG:Short-acting GLP-1RA; DRUG:Human-based GLP-1RA; DRUG:Exendin-based GLP-1RA; DRUG:Fixed ratio BI/GLP-1RA combination; DRUG:Flexible BI/GLP-1RA combination","University of Padova","2018-12-19","FALSE","6"],["S000692","ClinicalTrials.gov","NCT07465965",null,"A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic (PK) of Single-dose Administration of Semaglutide Nasal Spray (WL1006) in Adult Overweight or Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","60","Overweight; Obesity","DRUG:Semaglutide Nasal Spray; DRUG:Placebo; DRUG:Semaglutide Injection","Shanghai World Leader Pharmaceutical Co., Ltd.","2026-03-02","FALSE","0"],["S000693","ClinicalTrials.gov","NCT02194595","PREVAIL","Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","105","Type 2 Diabetes","DRUG:Basal insulin and exenatide; DRUG:Basal insulin only; DRUG:Basal insulin and bolus insulin","Mount Sinai Hospital, Canada","2014-09","FALSE","1"],["S000694","ClinicalTrials.gov","NCT04387201",null,"GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","COMPLETED","23","Glucose Intolerance; Overweight and Obesity; Drug Effect; Adiposity","DRUG:Cyanocobalamin; DRUG:Dulaglutide","The University of Texas Health Science Center, Houston","2020-05-15","TRUE","0"],["S000695","ClinicalTrials.gov","NCT03434119","LixiLan-D","A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua™100/33 Versus Lantus® in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","241","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide; DRUG:Insulin glargine (HOE901); DRUG:Background therapy","Sanofi","2018-02-20","TRUE","0"],["S000696","ClinicalTrials.gov","NCT05936151",null,"A Phase 2b, Double-Blind Study to Investigate the Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","146","Overweight or Obesity; CKD; Type 2 Diabetes","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2023-07-20","FALSE","1"],["S000697","ClinicalTrials.gov","NCT01468181",null,"A 52-Week, Open-Label, Long-Term Safety Study of LY2189265 in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","NON_RANDOMIZED","PHASE3","COMPLETED","394","Type 2 Diabetes Mellitus","DRUG:LY2189265; DRUG:Sulfonylureas (SU); DRUG:Biguanides (BG); DRUG:alpha-glucosidase inhibitor (a-GI); DRUG:Thiazolidinedione (TZD); DRUG:Glinides","Eli Lilly and Company","2011-11","TRUE","0"],["S000698","ClinicalTrials.gov","NCT02084251",null,"Safety, Tolerability and Pharmacokinetics of Single Dose of PB-119 in Healthy Volunteers","INTERVENTIONAL",null,"PHASE1","COMPLETED","70","Type II Diabetes","DRUG:PB-119","PegBio Co., Ltd.","2014-02","FALSE","1"],["S000699","ClinicalTrials.gov","NCT04876027",null,"Dulaglutide and Calorie Restrict Diet (CRD) in Overweight/Obese Patients With Polycystic Ovary Syndrome","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","68","Polycystic Ovary Syndrome","DRUG:GLP-1 RAs; OTHER:calorie restricted diet","Shanghai 10th People's Hospital","2021-05-15","FALSE","0"],["S000700","ClinicalTrials.gov","NCT06659718",null,"Emulation of the Effects of Oral Semaglutide on Cardiovascular Outcomes in Individuals With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease: SOUL Trial","OBSERVATIONAL",null,null,"COMPLETED","43650","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide; DRUG:Sitagliptin","Brigham and Women's Hospital","2024-10-24","FALSE","0"],["S000701","ClinicalTrials.gov","NCT05670379","LIBERATE-1","A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Exenatide Implant","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Overweight and Obesity; Type2diabetes","COMBINATION_PRODUCT:Exenatide Implant; DRUG:Bydureon BCise (exenatide extended release); DRUG:Semaglutide, 1.0 mg/mL","Vivani Medical, Inc","2024-12-20","FALSE","0"],["S000702","ClinicalTrials.gov","NCT01817569",null,"Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)","OBSERVATIONAL",null,null,"COMPLETED","2948","Type 2 Diabetes",null,"AstraZeneca","2011-02-13","FALSE","0"],["S000703","ClinicalTrials.gov","NCT02229383",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glargine Compared to Placebo Added to Titrated Basal Insulin Glargine in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine With or Without Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","464","Diabetes Mellitus","DRUG:Exenatide; DRUG:Exenatide matching placebo","AstraZeneca","2014-09-06","TRUE","3"],["S000704","ClinicalTrials.gov","NCT05478603",null,"A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO COMPARE THE PHARMACOKINETICS OF PF-07081532 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","24","Hepatic Impairment; Healthy Volunteers","DRUG:PF-07081532","Pfizer","2022-08-01","TRUE","0"],["S000705","ClinicalTrials.gov","NCT02721888","LIRA-NAFLD/LIP","Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes","INTERVENTIONAL",null,"PHASE4","TERMINATED","127","Type 2 Diabetes","DRUG:Liraglutide; DRUG:MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy); BIOLOGICAL:Blood sample; OTHER:Kinetic substudy (10 patients)","Centre Hospitalier Universitaire Dijon","2012-07-10","FALSE","3"],["S000706","ClinicalTrials.gov","NCT00035984",null,"A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Twice Daily in Subjects With Type 2 Diabetes Mellitus Treated With Metformin and a Sulfonylurea","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","734","Diabetes Mellitus, Non-Insulin-Dependent","DRUG:AC2993; DRUG:Placebo","AstraZeneca","2002-05","FALSE","3"],["S000707","ClinicalTrials.gov","NCT01516255",null,"A Thorough QTc Evaluation of the Effect of Liraglutide on Cardiac Repolarization in Healthy Volunteers: A Randomized, Double-blind, Placebo-controlled, Two Period Crossover Study Followed by Open-label Moxifloxacin (Positive Control) Administration","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","64","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:moxifloxacin; PROCEDURE:electrocardiogram (ECG)","Novo Nordisk A/S","2006-07","FALSE","1"],["S000708","ClinicalTrials.gov","NCT01876849",null,"An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE3","COMPLETED","275","Type 2 Diabetes Mellitus","DRUG:exenatide","AstraZeneca","2003-12","FALSE","0"],["S000709","ClinicalTrials.gov","NCT02109315","DIAB-01","Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.","INTERVENTIONAL","RANDOMIZED","PHASE1","WITHDRAWN","0","Type 1 Diabetes Mellitus","DRUG:Vitamine C; DRUG:Liraglutide 6 mg","Anna Cruceta","2014-05","FALSE","0"],["S000710","ClinicalTrials.gov","NCT06994338",null,"Phase II Evaluation of Tirzepatide in Adults With Alcohol Use Disorder and Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","42","Alcohol Use Disorder; Obesity and Overweight; Alcohol","DRUG:Tirzepatide; DRUG:Placebo injections","University of Southern California","2025-10-06","FALSE","0"],["S000711","ClinicalTrials.gov","NCT05218915",null,"Effect of Glucagon-like Peptide 1 Receptor Agonist in Combination with Insulin on Glycaemic Variability and Time-in-range in Diabetic Kidney Disease: a Randomised Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","95","Diabetes Mellitus; Diabetic Kidney Disease","DRUG:Dulaglutide; DRUG:Insulin Degludec; DEVICE:Continuous glucose monitor","Elaine Chow","2022-01-28","FALSE","0"],["S000712","ClinicalTrials.gov","NCT02963935","SCALE™ IBT","Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","282","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo; BEHAVIORAL:CMS Intensive Behavior Therapy","Novo Nordisk A/S","2017-02-06","TRUE","5"],["S000713","ClinicalTrials.gov","NCT00044668",null,"An Open-Label Study to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety of AC2993 Given Two Times a Day to Subjects With Type 2 Diabetes Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination","INTERVENTIONAL","NON_RANDOMIZED","PHASE3","COMPLETED","155","Diabetes Mellitus, Type 2","DRUG:AC2993","AstraZeneca","2002-08","FALSE","2"],["S000714","ClinicalTrials.gov","NCT06068946","VENTURE","A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","176","Weight Loss","BIOLOGICAL:VK2735; BIOLOGICAL:Placebo","Viking Therapeutics, Inc.","2023-08-31","FALSE","1"],["S000715","ClinicalTrials.gov","NCT05616013",null,"A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","507","Obesity; Obese; Overweight or Obesity","BIOLOGICAL:Bimagrumab; DRUG:Semaglutide; OTHER:Placebo","Eli Lilly and Company","2022-11-16","TRUE","3"],["S000716","ClinicalTrials.gov","NCT03574597","SELECT","SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","17604","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2018-10-24","TRUE","29"],["S000717","ClinicalTrials.gov","NCT06221696","PWR-FAST","Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways): A Randomized, Placebo-Controlled, Double-Blind Clinical Trial","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","160","Overweight and Obesity","DIETARY_SUPPLEMENT:Active Fiber Supplement Group; OTHER:Placebo Group","S.LAB (SOLOWAYS)","2023-06-12","FALSE","0"],["S000718","ClinicalTrials.gov","NCT06323161","REIMAGINE 3","Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes as Add on to Once-daily Basal Insulin With or Without Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","274","Type 2 Diabetes","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2024-03-26","FALSE","1"],["S000719","ClinicalTrials.gov","NCT02081118",null,"A Phase II, 16-week, Double-blind, Placebo-controlled, Parallel-group, Randomised, Multicentre Trial to Assess Effect on Glycaemic Control of Three Doses of HM11260C in Subjects With Inadequately Controlled Type 2 Diabetes Receiving a Stable Dose of Metformin","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","209","Type 2 Diabetes","DRUG:HM11260C; DRUG:Placebo","Hanmi Pharmaceutical Company Limited","2014-02","FALSE","1"],["S000720","ClinicalTrials.gov","NCT06097390",null,"A Study Investigating the Pharmacokinetic Properties When Dosing Different Formulations of Semaglutide to Healthy Male Participants - Oral Formulation III","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","121","Healthy Participants","DRUG:Semaglutide","Novo Nordisk A/S","2023-09-28","FALSE","0"],["S000721","ClinicalTrials.gov","NCT07485062","MOTIVATE","Metabolic Optimization and Training InterVentions for Aging and Type 2 Diabetes to Enhance Cognition: the MOTIVATE Study","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","164","Type 2 Diabetes; Cognitive Decline in Older Adults","DRUG:semaglutide; BEHAVIORAL:Moderate-Intensity Resistance Exercise; BEHAVIORAL:Balance and Tone (BAT) Exercise","Western University, Canada","2026-09-01","FALSE","0"],["S000722","ClinicalTrials.gov","NCT07570810",null,"A Single -Center, Randomized, Double-blind, Placebo-controlled Proof of Exploratory Study Evaluating the Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","30","Type 2 Diabetes; Obesity; Non-alcoholic Fatty Liver Disease","DRUG:CS0159; DRUG:CS0159 placebo; DRUG:Semaglutide","Shanghai Jiao Tong University School of Medicine","2026-06-01","FALSE","0"],["S000723","ClinicalTrials.gov","NCT01911468",null,"Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","36","PCOS; Obesity","DRUG:metformin; DRUG:liraglutide; DRUG:metformin and liraglutide","University Medical Centre Ljubljana","2011-11","FALSE","1"],["S000724","ClinicalTrials.gov","NCT07218354","CRAVE","CSP #2041 - Cessation or Reduction of Alcohol Consumption in VEterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder (CRAVE)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","622","Alcohol Use Disorder","DRUG:Semaglutide; DRUG:Placebo","VA Office of Research and Development","2026-07-28","FALSE","0"],["S000725","ClinicalTrials.gov","NCT01857895",null,"An Open-Label Exploratory Study to Investigate the Feasibility of Administering Exenatide by Continuous Subcutaneous Infusion to Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","10","Obesity","DRUG:Exenatide","GlaxoSmithKline","2013-05-16","FALSE","1"],["S000726","ClinicalTrials.gov","NCT02243098",null,"An Open-label, One-sequence Cross Over, Single Centre Trial, Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","31","Diabetes; Healthy","DRUG:semaglutide; DRUG:digoxin; DRUG:atorvastatin","Novo Nordisk A/S","2014-09-16","FALSE","1"],["S000727","ClinicalTrials.gov","NCT03010475",null,"A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects.","INTERVENTIONAL",null,"PHASE1","COMPLETED","41","Diabetes; Healthy","DRUG:Furosemide; DRUG:Rosuvastatin; DRUG:SNAC; DRUG:Semaglutide","Novo Nordisk A/S","2017-01-05","FALSE","1"],["S000728","ClinicalTrials.gov","NCT07010432","RAMBO","The Role of the Amylin Analogue Cagrilintide in Bone Metabolism During Weight Loss in Postmenopausal Women With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","144","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2025-06-12","FALSE","0"],["S000729","ClinicalTrials.gov","NCT07558863","GLP-1-CAN","A Study on the Effect of GLP-1 Receptor Agonist (GLP-1RA) Intervention on Cardiac Autonomic Neuropathy in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","60","Type 2 Diabetes; Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)","DRUG:GLP-1 Receptor Agonists","The First Affiliated Hospital with Nanjing Medical University","2026-04-01","FALSE","3"],["S000730","ClinicalTrials.gov","NCT07107334",null,"A Pilot Study to Estimate Early Clinical Efficacy Signals of a Glucagon-like Peptide 1 Receptor Agonist (GLP-1RA) Administration in Conjunction With Levonorgestrel Intrauterine Device (LNG-IUD) in Obese Patients With Endometrioid Intraepithelial Neoplasia","INTERVENTIONAL",null,"PHASE2","RECRUITING","20","Endometrioid Endometrial Adenocarcinoma","DRUG:Glucagon-like peptide 1 receptor agonist","University of Florida","2026-04-07","FALSE","0"],["S000731","ClinicalTrials.gov","NCT05067621",null,"Semaglutide, 2.4mg, Once Weekly: Effects on Beta-cell Preservation and Reduction of Intrahepatic Triglyceride Content in Obese Youth With Prediabetes (IGT)/Early Type 2 Diabetes (T2D) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","60","Type 2 Diabetes Mellitus; Impaired Glucose Tolerance; Non-Alcoholic Fatty Liver Disease; Obesity, Childhood","DRUG:Semaglutide Pen Injector; DRUG:Placebo","Yale University","2023-07-17","FALSE","1"],["S000732","ClinicalTrials.gov","NCT05756764",null,"Pilot Study of the Effect of Weight Loss by Pharmacotherapy on Chronic Pro-tumor Inflammatory Cells","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","30","Obesity","DRUG:Semaglutide; DRUG:Phentermine-Topiramate combination; DRUG:Phentermine; DRUG:Tirzepatide; DRUG:Topiramate; DRUG:Diethylpropion; DRUG:Naltrexone/Bupropion; DRUG:Liraglutide","Louisiana State University Health Sciences Center in New Orleans","2023-06-01","FALSE","0"],["S000733","ClinicalTrials.gov","NCT06847399","LIBERATE","Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder: A Randomized Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","105","Obesity and Overweight; Binge Eating Disorder","DRUG:Tirzepatide; DRUG:Lisdexamfetamine Dimesylate; BEHAVIORAL:Guided self-help cognitive behavioral therapy; DRUG:Placebo (oral); DRUG:Placebo (injection)","Johns Hopkins University","2025-09-17","FALSE","0"],["S000734","ClinicalTrials.gov","NCT06054698",null,"A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Overweight or Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","61","Overweight or Obesity","DRUG:HRS9531 injection; DRUG:HRS9531 injection Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2023-10-16","FALSE","0"],["S000735","ClinicalTrials.gov","NCT07462663","SHAPE-ENDO","SHAPE-ENDO (Strategic Hormonal Approach & Prehabilitation in Endometrial Cancer): An Open-Label, Pilot Randomized Clinical Trial Comparing Standard Immediate Surgery Versus a Multimodal Metabolic Optimization and Prehabilitation Strategy Before Surgery in Patients With Atypical Endometrial Hyperplasia or Low-Risk Endometrioid Endometrial Cancer and BMI ≥40 kg/m²","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","80","Endometrial Cancer; Endometrial Cancer Stage I; Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I; Atypical Endometrial Hyperplasia; Endometrial Intraepithelial Neoplasia; Obesity & Overweight; BMI>40; Obesity; Obesity Grade III","DRUG:GLP-1 Receptor Agonist; DEVICE:Levonorgestrel IUD (Lng-IUD); DRUG:Oral Progestins; BEHAVIORAL:Dietetic-Nutritional intervention; BEHAVIORAL:Structured Exercise and Prehabilitation Program; PROCEDURE:Endometrial Biopsy With or Without Hysteroscopy; PROCEDURE:Radiologic Surveillance (MRI and Transvaginal Ultrasound); PROCEDURE:Standar upfront Surgery","Hospital Universitari de Bellvitge","2027-01","FALSE","5"],["S000736","ClinicalTrials.gov","NCT01798264",null,"A Phase Ib, Randomized, Open-Label, Multi-Center, 4-Week Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITCA 650 in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","44","Type 2 Diabetes","DRUG:ITCA 650 (exenatide in DUROS)","Intarcia Therapeutics","2009-02","TRUE","1"],["S000737","ClinicalTrials.gov","NCT03856632","LEAF","Novel Medical Adjunctive Therapy to Catheter Ablation For Atrial Fibrillation (AF)","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","60","Atrial Fibrillation","DRUG:Liraglutide; OTHER:RFM; DRUG:Anti Arrhythmics; PROCEDURE:Afib Catheter Ablation","University of Miami","2019-03-18","FALSE","1"],["S000738","ClinicalTrials.gov","NCT05966272",null,"A Multi-center, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","199","Type 2 Diabetes","DRUG:HRS9531 injection; DRUG:HRS9531 injection Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2023-08-12","FALSE","0"],["S000739","ClinicalTrials.gov","NCT06874751","SCORE","Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World","OBSERVATIONAL",null,null,"COMPLETED","45456","Overweight; Obesity; Atherosclerotic Cardiovascular Disease (ASCVD)","OTHER:No treatment given","Novo Nordisk A/S","2024-12-06","FALSE","1"],["S000740","ClinicalTrials.gov","NCT07754045",null,"Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Oral LUM-201 as an Adjunct to Oral Semaglutide for Improving Physical Function in Older Adults With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","202","Obesity & Overweight","DRUG:LUM-201; DRUG:Placebo; DRUG:Semagludtide","Lumos Pharma","2027-02-15","FALSE","0"],["S000741","ClinicalTrials.gov","NCT07653412","Diagenix","Prediction of Response to GLP-1/GIP Receptor Agonists in Obesity Using Genetic Risk Score and SNP Profiling: A Prospective Cohort Study.","OBSERVATIONAL",null,null,"RECRUITING","220","Obesity (Disorder); Anti-obesity Agents; Precision Medicine","DRUG:Semaglutide or Tirzepatide","National and Kapodistrian University of Athens","2026-04-22","FALSE","2"],["S000742","ClinicalTrials.gov","NCT01061775",null,"Effects of Exenatide on Hypothalamic Obesity","INTERVENTIONAL",null,"PHASE1; PHASE2","COMPLETED","19","Hypothalamic Obesity","DRUG:Exenatide","Children's Hospitals and Clinics of Minnesota","2010-01","TRUE","0"],["S000743","ClinicalTrials.gov","NCT02075281",null,"A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","297","Obesity","BIOLOGICAL:HM11260C; BIOLOGICAL:Placebo","Hanmi Pharmaceutical Company Limited","2014-02","FALSE","3"],["S000744","ClinicalTrials.gov","NCT04097600",null,"A Comparative Bioavailability Trial of Steady State Semaglutide Exposure With the Current Formulation (Semaglutide) and a New Formulation (Semaglutide D) of Oral Semaglutide in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","274","Healthy Volunteers; Type 2 Diabetes","DRUG:Oral semaglutide","Novo Nordisk A/S","2019-09-30","FALSE","0"],["S000745","ClinicalTrials.gov","NCT07387796","CLIN-GLP1","Clinical and Neurobehavioral Changes With GLP-1 (Glucagon-like Peptide-1) Discontinuation","INTERVENTIONAL",null,null,"RECRUITING","40","Drug Discontinuation; Substance Use Disorders; Eating Behavior Changes; Tirzepatide","OTHER:Discontinuation and Reinitiation of Tirzepatide","The University of Texas at Dallas","2026-10","FALSE","0"],["S000746","ClinicalTrials.gov","NCT07697391","AI-LIFE-T2D-OB","A Multicenter Randomized Controlled Trial Evaluating AI-Assisted Intensive Lifestyle Intervention Versus Tirzepatide for Glycemic and Weight Management in Patients With Obesity and Newly Diagnosed Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","285","Obesity; Diabetes Mellitus, Type 2","BEHAVIORAL:AI-Assisted Intensive Lifestyle Intervention; DRUG:Tirzepatide; BEHAVIORAL:Standard Lifestyle Management","The First Affiliated Hospital of Anhui Medical University","2026-07-20","FALSE","0"],["S000747","ClinicalTrials.gov","NCT00811460",null,"A Double-blind, Crossover, Randomized, Placebo-controlled Study to Investigate the Effect of Two Different Doses of Taspoglutide IRF Administered as Continuous Subcutaneous Infusion on First- and Second-phase Insulin Secretion in Type 2 Diabetic Patients","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","18","Diabetes Mellitus Type 2","DRUG:Placebo; DRUG:taspoglutide","Hoffmann-La Roche","2008-11","FALSE","0"],["S000748","ClinicalTrials.gov","NCT02683746",null,"A Repeat-dose Study in Subjects With Type 2 Diabetes Mellitus to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics, of Albiglutide Liquid Drug Product","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","308","Diabetes Mellitus, Type 2","DRUG:Lyophilized albiglutide DCC pen injector; DRUG:Lyophilized albiglutide DCC pen injector matching placebo; DRUG:Albiglutide liquid auto-injector; DRUG:Albiglutide liquid auto-injector matching placebo","GlaxoSmithKline","2016-03-16","TRUE","1"],["S000749","ClinicalTrials.gov","NCT07662213","Eluminate-2","A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","1200","Type 2 Diabetes Mellitus","DRUG:Elecoglipron; DRUG:Semaglutide","AstraZeneca","2026-07-06","FALSE","0"],["S000750","ClinicalTrials.gov","NCT04520490","BASIC2","Brain Systems and Behaviors Underlying Response to Obesity Treatment in Children","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","63","Childhood Obesity","BEHAVIORAL:Family Based Behavioral Treatment; DRUG:Exenatide 2 mg [Bydureon]; DRUG:Placebo","Seattle Children's Hospital","2021-01-28","FALSE","0"],["S000751","ClinicalTrials.gov","NCT05607680",null,"A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","610","Obesity Or Overweight","DRUG:Placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2022-11-14","FALSE","3"],["S000752","ClinicalTrials.gov","NCT00577824",null,"Efficacy and Safety of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","181","Type 2 Diabetes","DRUG:exenatide; DRUG:placebo","AstraZeneca","2008-01","TRUE","3"],["S000753","ClinicalTrials.gov","NCT06987669","aGLP1-GUS","Gastric Emptying Assessed by Gastric Ultrasound (US) in Healthy Volunteers and Semaglutide Users: Cohort Study","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","155","Diabetes Type 2; Obesity and Overweight","DIAGNOSTIC_TEST:Gastric Ultrasound","Clinica Alemana de Santiago","2025-05-17","FALSE","0"],["S000754","ClinicalTrials.gov","NCT05872620","ATTAIN-2","A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1613","Obesity; Overweight; Type 2 Diabetes","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2023-06-05","TRUE","2"],["S000755","ClinicalTrials.gov","NCT03496298","AMPLITUDE-O","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","4076","Type 2 Diabetes Mellitus","DRUG:Efpeglenatide (SAR439977); DRUG:Placebo","Sanofi","2018-04-27","TRUE","5"],["S000756","ClinicalTrials.gov","NCT07760532",null,"A Prospective Observational Study of Facial Aging in Identical Twins Using Three-Dimensional Imaging","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","200","Facial Skin Aging; Facial Volume Loss; Wrinkle Appearance","DRUG:GLP-1 Receptor Agonists","Ponsky Facial Aesthetics And Plastic Surgery, Llc","2026-08-08","FALSE","0"],["S000757","ClinicalTrials.gov","NCT07446998","PLATEAU","PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm in Patients Treated With Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, for Weight Reduction","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","239","Obesity & Overweight; Mobility Disability; HOMA-IR","DRUG:Enobosarm; DRUG:Semaglutide (Wegovy) weekly injection","Veru Inc.","2026-03-26","FALSE","0"],["S000758","ClinicalTrials.gov","NCT03671733",null,"Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","150","Obesity","DRUG:Liraglutide; DRUG:Exenatide; DRUG:Exenatide Microspheres for Injection","Xiangya Hospital of Central South University","2018-09-01","FALSE","0"],["S000759","ClinicalTrials.gov","NCT06937749",null,"A Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy and Safety of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","165","Metabolic Dysfunction-associated Steatohepatitis (MASH)","DRUG:Placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2025-07-01","FALSE","0"],["S000760","ClinicalTrials.gov","NCT06606821","IDEAL-COR","The Effects of Tirzepatide on Coronary Plaque Lipid Content and Myocardial Microvascular Function in Overweight and Obese People With Coronary Disease - The IDEAL-COR Study","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","124","Coronary Artery Disease; Coronary Microvascular Dysfunction; Overweight or Obesity; Stable Angina Pectoris; Chronic Coronary Artery Disease; Atherosclerosis Cardiovascular Disease","DRUG:Tirzepatide; DRUG:Placebo","Tina Vilsbøll","2024-10-01","FALSE","10"],["S000761","ClinicalTrials.gov","NCT04940078",null,"Investigation of Pharmacokinetics Following Co-administration of Cagrilintide (NNC0174-0833) and Semaglutide Versus Separate Injections in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","40","Obesity & Overweight","DRUG:Cagrilintide; DRUG:semaglutide; DRUG:Cagrilintide and semaglutide","Novo Nordisk A/S","2021-07-07","FALSE","0"],["S000762","ClinicalTrials.gov","NCT03712098","DAL","Glucagon-like Peptide-1 Receptor Agonists as Novel Pharmacotherapies for Nicotine Dependence","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","40","Smoking Cessation; Weight, Body","DRUG:Liraglutide; DRUG:Placebo; BEHAVIORAL:Smoking Cessation Counseling","Rebecca Ashare","2018-11-29","TRUE","0"],["S000763","ClinicalTrials.gov","NCT02973321",null,"A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","296","Type 2 Diabetes Mellitus","DRUG:SAR425899; DRUG:Placebo; DRUG:Liraglutide; DRUG:Metformin","Sanofi","2016-12-02","TRUE","1"],["S000764","ClinicalTrials.gov","NCT01514487",null,"A Randomised, Double-blind, Single-centre, Three-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Each of the Two New Liraglutide Formulations at pH 7.9 and 8.15 and the Planned Phase 3 Formulation at pH 7.7","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Diabetes; Healthy","DRUG:liraglutide","Novo Nordisk A/S","2005-01-13","FALSE","0"],["S000765","ClinicalTrials.gov","NCT07091500",null,"Effect of GLP-1 Receptor Agonist Therapy With and Without Exercise Training on Muscle Mass and Physical Function in People With Obesity","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","40","Obesity; Skeletal Muscle; Brain Connectivity","BEHAVIORAL:Exercise training; DRUG:Semaglutide; BEHAVIORAL:Therapy Cessation","Washington University School of Medicine","2025-08-11","FALSE","0"],["S000766","ClinicalTrials.gov","NCT06072963",null,"Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","80","Alzheimer Disease; Mild Cognitive Impairment; Metabolic Syndrome","DRUG:Semaglutide; DRUG:Intranasal insulin; OTHER:Semaglutide placebo; OTHER:Intranasal insulin placebo","Rutgers, The State University of New Jersey","2024-01-30","FALSE","11"],["S000767","ClinicalTrials.gov","NCT02930265",null,"Chinese People's Liberation Army General Hospital","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","400","Ischemic Cardiomyopathy","DRUG:Liraglutide","Chinese PLA General Hospital","2016-09","FALSE","13"],["S000768","ClinicalTrials.gov","NCT07379333",null,"A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","118","Type 2 Diabetes","DRUG:HM11260C; DRUG:Placebo","Hanmi Pharmaceutical Company Limited","2026-04-13","FALSE","0"],["S000769","ClinicalTrials.gov","NCT06546384","GLP-1 RA","Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","64","Adiposity; Fatty Liver; Alcohol Use Disorder","DRUG:Semaglutide; BEHAVIORAL:Weight reduction recommendations (nutritional and exercise)","Insel Gruppe AG, University Hospital Bern","2026-11-01","FALSE","0"],["S000770","ClinicalTrials.gov","NCT05706506",null,"An Open-Label, Single-Arm, Phase 4 Study to Assess Glycemic Control When Adults With Type 2 Diabetes Switch From a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2)","INTERVENTIONAL",null,"PHASE4","COMPLETED","152","Type 2 Diabetes; Diabetes Mellitus, Type 2","DRUG:Tirzepatide","Eli Lilly and Company","2023-03-08","TRUE","0"],["S000771","ClinicalTrials.gov","NCT04487743",null,"Efficacy and Safety of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, 28-week Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","300","Obesity","DRUG:Liraglutide; DRUG:placebo","Xiangya Hospital of Central South University","2020-05-09","FALSE","0"],["S000772","ClinicalTrials.gov","NCT06901648",null,"Efficacy and Safety of HS-20094, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients With Type 2 Diabetes: a Randomized, Placebo-controlled and Active Comparator-controlled Phase 2 Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","275","Type 2 Diabetes","DRUG:HS-20094; DRUG:Dulaglutide; DRUG:Palcebo","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2024-02-06","FALSE","0"],["S000773","ClinicalTrials.gov","NCT02832999","LIRAVIS","Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in a Sub Saharan African Population With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","14","Type 2 Diabetes Mellitus","DRUG:sub cutaneous liraglutide; DRUG:Oral Vildagliptin","Yaounde Central Hospital","2016-01","FALSE","0"],["S000774","ClinicalTrials.gov","NCT04781998",null,"Is Pharmacological Treatment With the Glucagon-like Peptide-1 Receptor Agonist Liraglutide 3mg (Saxenda®) Once-daily a Viable Treatment for Weight Management in Forensic Psychiatry Patients? A Feasibility Study.","INTERVENTIONAL",null,"PHASE4","COMPLETED","24","Mental Disorder; Metabolic Disturbance; Feasibility; Overweight and Obesity; Liraglutide","DRUG:liraglutide 3 mg (Saxenda®) once-daily","Anders Fink-Jensen, MD, DMSci","2021-07-01","FALSE","0"],["S000775","ClinicalTrials.gov","NCT07423247",null,"Safety and Efficacy of Tirzepatide (Spartina) in Obese Kidney Transplant Recipients: A Pilot Study on Weight Loss, Gastrointestinal Tolerability, and Graft Function","INTERVENTIONAL",null,"PHASE4","RECRUITING","30","Tirzepatide","DRUG:Tirzepatide","Shahid Beheshti University of Medical Sciences","2026-01-01","FALSE","0"],["S000776","ClinicalTrials.gov","NCT03130426","REMIT-iGL","Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","161","Type 2 Diabetes Mellitus","DRUG:iGlarLixi; DRUG:Insulin Glargine; DRUG:Metformin; BEHAVIORAL:Lifestyle therapy","Population Health Research Institute","2017-06-27","FALSE","0"],["S000777","ClinicalTrials.gov","NCT06484114","REMAIN-1","A Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, Pivotal Study to Assess the Efficacy of Revita® Duodenal Mucosal Resurfacing (DMR) on Body Weight Maintenance in Participants With Obesity and Who Have Achieved at Least 15% Weight Loss on Tirzepatide Obesity Pharmacotherapy","INTERVENTIONAL","RANDOMIZED",null,"ACTIVE_NOT_RECRUITING","315","Obesity; Weight Change Trajectory; Weight Change, Body","DEVICE:Revita Duodenal Mucosal Resurfacing (DMR); DEVICE:Sham","Fractyl Health Inc.","2024-09-01","FALSE","0"],["S000778","ClinicalTrials.gov","NCT05433584","SURPASS-EARLY","A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","780","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Antihyperglycemic medication","Eli Lilly and Company","2022-08-01","FALSE","1"],["S000779","ClinicalTrials.gov","NCT07202247",null,"A Phase II Randomized Study of Interventions for Metabolic Protection Against Cardiometabolic Toxicity During Androgen Deprivation Therapy (IMPACT-ADT)","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","60","Prostate Carcinoma; Recurrent Prostate Carcinoma","DRUG:Antiandrogen Therapy; BEHAVIORAL:Behavioral Intervention; PROCEDURE:Biospecimen Collection; PROCEDURE:Cardiac Computerized Tomographic Angiography; PROCEDURE:Computed Tomography; OTHER:Electronic Health Record Review; OTHER:Internet-Based Intervention; BEHAVIORAL:Lifestyle Counseling; OTHER:Medical Device Usage and Evaluation; OTHER:Nutritional Intervention; OTHER:Questionnaire Administration; RADIATION:Radiation Therapy; OTHER:Referral; DRUG:Semaglutide; OTHER:Short-Term Fasting; DRUG:Tirzepatide","City of Hope Medical Center","2025-11-05","FALSE","0"],["S000780","ClinicalTrials.gov","NCT06856291","TRIM-IR","Treatment Response to Incretin Mimetics in Non-diabetic Obese Patients With and Without Insulin Resistance (TRIM-IR)","OBSERVATIONAL",null,null,"COMPLETED","40","Obesity and Obesity-related Medical Conditions; Obesity and Overweight; Insulin Sensitivity/Resistance; Semaglutide",null,"ETH Zurich","2025-03-15","FALSE","0"],["S000781","ClinicalTrials.gov","NCT06396416",null,"Obesity Management for Kidney TRANSPLANTation: a Vanguard Study for an Innovative Randomized Controlled Trial, Embedded in Routine Care (OK-TRANSPLANT 2)","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","60","Obesity; Chronic Kidney Disease","DRUG:Semaglutide; BEHAVIORAL:Virtual Weight Management Coaching","Western University, Canada","2024-09-26","FALSE","1"],["S000782","ClinicalTrials.gov","NCT06621316",null,"To Explore the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Multiple Doses of HRS-7535 in Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","74","Overweight or Obesity","DRUG:HRS-7535 Tablet; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2024-10-30","FALSE","0"],["S000783","ClinicalTrials.gov","NCT01976858",null,"A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 8 Weeks Injection of Polyethylene Glycol Loxenatide","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","50","Type 2 Diabetes","DRUG:PEX168","Jiangsu HengRui Medicine Co., Ltd.","2011-06","FALSE","0"],["S000784","ClinicalTrials.gov","NCT01149421",null,"The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","755","Diabetes Mellitus, Type 2","DRUG:LY2189265; DRUG:Placebo","Eli Lilly and Company","2010-06","TRUE","1"],["S000785","ClinicalTrials.gov","NCT06326047",null,"Investigation of the Safety and Efficacy of Once Weekly NNC0519-0130 in Participants With Type 2 Diabetes - a Dose Finding Study","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","299","Diabetes Mellitus, Type 2","DRUG:NNC0519-0130; DRUG:Placebo; DRUG:Trizepatide","Novo Nordisk A/S","2024-03-18","FALSE","0"],["S000786","ClinicalTrials.gov","NCT05564117","OASIS 4","Efficacy and Safety of Oral Semaglutide 25 mg Once Daily in Adults With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","307","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2022-10-11","TRUE","1"],["S000787","ClinicalTrials.gov","NCT04417582",null,"Evaluation of Life Style Modification Medical and Surgical Treatment Modalities in Patients With Obesity: An Observational Study","OBSERVATIONAL",null,null,"UNKNOWN","1000","Obesity; Weight Change, Body; Obesity; Endocrine; Obesity, Metabolically Benign","PROCEDURE:bariatric surgey","Marmara University","2020-01-01","FALSE","0"],["S000788","ClinicalTrials.gov","NCT01451905",null,"GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","12","Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI","DRUG:Liraglutide; DRUG:Placebo","University Hospital, Gentofte, Copenhagen","2011-08","FALSE","0"],["S000789","ClinicalTrials.gov","NCT01524770",null,"Comparative Pharmacokinetics of Dulaglutide After Administration Via an Auto-injector and a Manual Syringe in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","50","Diabetes Mellitus, Type 2","BIOLOGICAL:Dulaglutide","Eli Lilly and Company","2012-03","TRUE","0"],["S000790","ClinicalTrials.gov","NCT00434954",null,"Effect of Exenatide Plus Metformin vs. Premixed Human Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Inadequate Control of Type 2 Diabetes on Oral Antidiabetic Treatment","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","494","Type 2 Diabetes Mellitus","DRUG:exenatide twice daily (BID); DRUG:premixed insulin aspart twice daily (BID)","AstraZeneca","2007-02","TRUE","2"],["S000791","ClinicalTrials.gov","NCT02229396",null,"A 28-week, Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study With a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simultaneous Administration of Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg Compared to Exenatide Once Weekly 2 mg Alone and Dapagliflozin Once Daily 10 mg Alone in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","695","Diabetes Mellitus","DRUG:Exantide with Dapagliflozin; DRUG:Exentide; DRUG:Dapagliflozin","AstraZeneca","2014-09-04","TRUE","8"],["S000792","ClinicalTrials.gov","NCT00975286","GetGoal-Duo1","A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","446","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DRUG:Insulin glargine; DEVICE:Pen auto-injector; DRUG:Metformin; DRUG:Thiazolidinedione (TZD)","Sanofi","2009-10","TRUE","6"],["S000793","ClinicalTrials.gov","NCT01018173",null,"A Randomized Double Blind, Placebo-controlled Clinical Trial to Assess the Effects of Taspoglutide (RO5073031) on Cardiovascular Outcomes in Subjects With Inadequately Controlled Type 2 Diabetes and Established Cardiovascular Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","2118","Diabetes Mellitus Type 2","DRUG:placebo; DRUG:taspoglutide","Hoffmann-La Roche","2010-01","FALSE","0"],["S000794","ClinicalTrials.gov","NCT07203677",null,"Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)","OBSERVATIONAL",null,null,"COMPLETED","49065","Type2 Diabetes Mellitus; Atherosclerotic Cardiovascular Disease","DRUG:Initiation of tirzepatide; DRUG:Initiation of sitagliptin","Brigham and Women's Hospital","2025-09-19","FALSE","1"],["S000795","ClinicalTrials.gov","NCT03955575","BAM-LIRA","Treatment of Bile Acid Malabsorption With Liraglutide","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","52","Bile Acid Malabsorption","DRUG:Liraglutide 6 MG/ML; DRUG:Colesevelam","Filip Krag Knop","2019-03-07","FALSE","0"],["S000796","ClinicalTrials.gov","NCT03007329","EXENDA","A 24 Week Monocentric Prospective Randomized, Placebo-controlled Trial to Evaluate Efficacy of Combination of Exenatide and Dapagliflozin Compared to Dapagliflozin and Placebo and Its Effects on Hepatic, Myocardial and Pancreatic Fat Distribution in Patients With Uncontrolled Type 2 Diabetes Mellitus.","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","34","Steatosis, Liver; Type2 Diabetes","DRUG:Exenatide; DRUG:Exenatide matching Placebo; DRUG:Dapagliflozin","Medical University of Vienna","2017-03-08","FALSE","1"],["S000797","ClinicalTrials.gov","NCT07767175",null,"A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","142","Overweight; Obesity","DRUG:NNC0721-8060; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2026-08-12","FALSE","0"],["S000798","ClinicalTrials.gov","NCT06176365","SYNCHRONIZE™JP","A Phase III, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of Survodutide Administered Subcutaneously Compared With Placebo in Patients With Obesity Disease in Japanese","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","274","Obesity","DRUG:Survodutide; DRUG:Placebo matching survodutide","Boehringer Ingelheim","2024-01-16","FALSE","1"],["S000799","ClinicalTrials.gov","NCT01250834",null,"Effect of LY2189265 on the Pharmacokinetics of Atorvastatin in Healthy Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","27","Healthy Volunteers","DRUG:Atorvastatin; BIOLOGICAL:LY2189265","Eli Lilly and Company","2010-12","TRUE","1"],["S000800","ClinicalTrials.gov","NCT07671248",null,"A 12-Week Phase 3 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Tirzepatide-Assisted-Psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study","INTERVENTIONAL",null,"PHASE3","NOT_YET_RECRUITING","15","Cannabis Use Disorder, Moderate; Cannabis Use Disorder, Severe","DRUG:Tirzepatide","McMaster University","2026-08-01","FALSE","0"],["S000801","ClinicalTrials.gov","NCT05766709",null,"Investigation of Pharmacokinetics Following Administration of NNC0194-0499 and Semaglutide as Co-formulation Versus Separate Injections in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","53","Non-alcoholic Steatohepatitis","DRUG:NNC0194-0499; DRUG:Semaglutide; DRUG:NNC0194-0499/Semaglutide A (40/3.20 mg/mL); DRUG:NNC0194-0499/Semaglutide A (40/0.33mg/mL)","Novo Nordisk A/S","2023-03-02","FALSE","0"],["S000802","ClinicalTrials.gov","NCT03325387",null,"A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","56","Healthy","DRUG:LY3305677; DRUG:Placebo","Eli Lilly and Company","2017-10-27","FALSE","1"],["S000803","ClinicalTrials.gov","NCT01253304",null,"A Single Dose Pharmacokinetic Study of LY2189265 in Subjects With Varying Degrees of Hepatic Impairment","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","26","Diabetes Mellitus, Type 2","DRUG:LY2189265","Eli Lilly and Company","2010-11","TRUE","0"],["S000804","ClinicalTrials.gov","NCT05478252",null,"Investigation of Clinical Comparability of Semaglutide Drug Products Based on the Proposed and the Approved Drug Substance Manufacturing Processes in Participants With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","388","Diabetes Mellitus, Type 2","DRUG:Semaglutide J; DRUG:Semaglutide B","Novo Nordisk A/S","2022-08-03","TRUE","0"],["S000805","ClinicalTrials.gov","NCT02496221",null,"A Randomized, Double-blind, Single-dose, Placebo Controlled, 2-way Cross-over Study Evaluating Effect of Albiglutide on Cholecystokinin-induced Gallbladder Emptying in Fasting Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","20","Diabetes Mellitus, Type 2","DRUG:Albiglutide 50 mg; DRUG:Placebo; DRUG:CCK (Kinevac)","GlaxoSmithKline","2015-06-11","TRUE","1"],["S000806","ClinicalTrials.gov","NCT02931344","BIO-LOSEIT-I","Biomarkers in Obese Patients With Knee Osteoarthritis Following a Significant Weight Loss","INTERVENTIONAL",null,null,"UNKNOWN","200","Osteoarthrtis; Obesity","DIETARY_SUPPLEMENT:Dietary Supplement: Dietary Supplement: Intensive dietary intervention","Henrik Gudbergsen","2016-11","FALSE","0"],["S000807","ClinicalTrials.gov","NCT06986993","ONSET","Impact of Semaglutide Administration on Tobacco Use Behavior and Related Mechanisms Among Smokers With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","40","Tobacco Use","DRUG:Semaglutide; DRUG:Placebo","University of Oklahoma","2024-07-01","FALSE","0"],["S000808","ClinicalTrials.gov","NCT05700877","STENO INTEN-CT","Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes: THE STENO INTEN-CT STUDY","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","7300","Type 2 Diabetes; Cardiovascular Diseases","OTHER:CAC-based treatment strategy; OTHER:Standard treatment","Per Løgstrup Poulsen","2023-01-12","FALSE","1"],["S000809","ClinicalTrials.gov","NCT07509112","SHIFT","Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study","INTERVENTIONAL",null,"PHASE2","NOT_YET_RECRUITING","40","Methamphetamine Use Disorder","DRUG:12 weeks of weekly subcutaneous semaglutide injection","Kirby Institute","2026-09","FALSE","0"],["S000810","ClinicalTrials.gov","NCT06802081","TIRO-AF","TIRO-AF: TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","100","Atrial Fibrillation; Obesity","DRUG:Tirzepatide; DRUG:Placebo","The Cleveland Clinic","2025-04-08","FALSE","0"],["S000811","ClinicalTrials.gov","NCT04731272",null,"Effect of GLP-1 Agonist Therapy on Insulin Secretion in Adults With Pancreatic Insufficient Cystic Fibrosis and Abnormal Glucose Tolerance: a Randomized, Open-label, Cross-over Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","30","Cystic Fibrosis; Pancreatic Insufficiency; Abnormal Glucose Tolerance; Diabetes","DRUG:Dulaglutide 0.75Mg/0.5Ml Inj Pen","University of Pennsylvania","2021-07-16","FALSE","0"],["S000812","ClinicalTrials.gov","NCT02972645",null,"A First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","66","Healthy","DRUG:LY3305677; DRUG:Placebo","Eli Lilly and Company","2016-12-05","FALSE","0"],["S000813","ClinicalTrials.gov","NCT02608853",null,"Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants","OBSERVATIONAL",null,null,"COMPLETED","9999","Diabetes; Diabetes Mellitus, Type 2","OTHER:No treatment given","Novo Nordisk A/S","2015-01","FALSE","0"],["S000814","ClinicalTrials.gov","NCT03884075",null,"Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)","INTERVENTIONAL","NON_RANDOMIZED","PHASE2","RECRUITING","104","Non-Alcoholic Steatohepatitis; Non-Alcoholic Fatty Liver Disease","DRUG:Semaglutide","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","2019-07-24","FALSE","1"],["S000815","ClinicalTrials.gov","NCT01206101",null,"A 52 Week Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multi-Center, Multinational Trial In Islet Cell Transplant Subjects With Type 1 Diabetes Mellitus To Determine If The Early Use Of Liraglutide As An Adjunct To Standard Care Increases The Proportion Of Subjects Achieving Insulin Independence After First Transplantation","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","3","Diabetes; Diabetes Mellitus, Type 1","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2012-03-21","TRUE","0"],["S000816","ClinicalTrials.gov","NCT07728812","PhenoRXPrag","Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy (PhenoRX Pragmatic Trial)","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","424","Obesity & Overweight","GENETIC:Genetic Test; DRUG:Anti-Obesity Medication (AOM) treatment","Phenomix Sciences","2026-09-01","FALSE","0"],["S000817","ClinicalTrials.gov","NCT06745128",null,"Tirzepatide for Individuals With Comorbid Obesity and Methamphetamine Use Disorder","INTERVENTIONAL",null,"PHASE2","COMPLETED","35","Obesity; Methamphetamine Use Disorder","DRUG:Tirzepatide","University of Texas Southwestern Medical Center","2025-02-03","FALSE","3"],["S000818","ClinicalTrials.gov","NCT05586802","KLIN-HEALTH","Dissecting the Importance of Sex Steroids Balance for Metabolic and Reproductive Health in Men With Klinefelter Syndrome: a Randomized Controlled Study","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","150","Klinefelter Syndrome","DRUG:Anastrozole; DRUG:Semaglutide; DRUG:human chorionic gonadotropin; DRUG:Testosterone gel","Georgios Papadakis","2023-03-21","FALSE","0"],["S000819","ClinicalTrials.gov","NCT05152277",null,"A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administered HRS9531","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","90","Type 2 Diabetes","DRUG:HRS9531; OTHER:placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2021-12-06","FALSE","2"],["S000820","ClinicalTrials.gov","NCT02020629",null,"Effect of Lixisenatide on Glucagon Secretion During Hypoglycemia in Patients With Insulin-treated Type 2 Diabetes","INTERVENTIONAL",null,"PHASE4","COMPLETED","18","Type 2 Diabetes","DRUG:Lixisenatide","Lund University","2013-12","FALSE","1"],["S000821","ClinicalTrials.gov","NCT06461377",null,"The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","50","Type 2 Diabetes; Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)","DRUG:Glucagon-like peptide-1 receptor agonist：Semaglutide","The First Affiliated Hospital with Nanjing Medical University","2024-06-13","FALSE","3"],["S000822","ClinicalTrials.gov","NCT02660736",null,"A Randomized, Double-blind, Single-dose, Crossover Study to Compare Two Albiglutide Drug Products for Bioequivalence in Healthy Adult Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","59","Diabetes Mellitus, Type 2","DRUG:Albiglutide Liquid Auto-injector; DRUG:Albiglutide Lyophilized DCC Pen Injector; DRUG:Placebo Liquid Auto-injector; DRUG:Placebo Lyophilized DCC Pen injector","GlaxoSmithKline","2016-02","FALSE","1"],["S000823","ClinicalTrials.gov","NCT05322200",null,"Potential Impact of Oral Semaglutide on Coronary Artery Disease Progression Following Acute Coronary Syndrome: The POST-ACS Study","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","140","Diabetes Mellitus; Acute Coronary Syndrome; Coronary Artery Disease","RADIATION:A computerized tomography (CT) coronary angiogram; PROCEDURE:Vicorder (Skidmore medical, UK); OTHER:Blood tests for inflammation and oxidative stress markers","Swansea Bay University Health Board","2022-08-31","FALSE","0"],["S000824","ClinicalTrials.gov","NCT01345734","Lead-Ph","Liraglutide Effectiveness and Safety Data From Routine Clinical Practice in Philippines Study. A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes Mellitus in Philippines","OBSERVATIONAL",null,null,"COMPLETED","1056","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2011-09-01","FALSE","1"],["S000825","ClinicalTrials.gov","NCT07781371","SCALA-TK-CM","SCALA-TK-CM: Semaglutide and CArdiometabolic Real-Life Atlas - TürKiye CardioMetabolic Epidemiology Study: A Retrospective Real-World Cohort Study","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","100000","Obesity; Type 2 Diabetes (T2D); Prediabetes; Cardiovascular Disease (CVD); Dyslipidemia; Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); Chronic Kidney Disease (CKD)","OTHER:No treatment given","Novo Nordisk A/S","2026-08-20","FALSE","0"],["S000826","ClinicalTrials.gov","NCT00872378","AGREE","A Pilot Study of the Effects of BYETTA® (Exenatide) on Weight Loss in Morbidly Obese Non Diabetic Patients Following Adjustable Gastric Banding","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","UNKNOWN","28","Morbid Obesity","DRUG:Exenatide; DRUG:Placebo","Advanced Specialty Care","2009-02","FALSE","0"],["S000827","ClinicalTrials.gov","NCT02461589",null,"Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","706","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2015-09-21","TRUE","1"],["S000828","ClinicalTrials.gov","NCT07094568","TiLi-BONE","Comparative Investigation of Changes in Body Composition and Bone Turnover Markers in People With Obesity After Treatment With Tirzepatide Versus Liraglutide. A Prospective Cohort Study.","OBSERVATIONAL",null,null,"RECRUITING","72","Obesity (Disorder)",null,"National and Kapodistrian University of Athens","2025-05-23","FALSE","10"],["S000829","ClinicalTrials.gov","NCT03970044",null,"Effectiveness of Once-weekly Exenatide (BCise) Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","67","Diabetes Mellitus, Type 2","DRUG:Exenatide 2 MG; DRUG:Dapagliflozin 10 MG","Consano Clinical Research, LLC","2019-07-02","FALSE","0"],["S000830","ClinicalTrials.gov","NCT00667732","MEXELIN","Metformin, Exenatide, and Glargine Insulin in Combination for Treatment of Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","41","Type 2 Diabetes","DRUG:exenatide; DRUG:placebo","Oregon Health and Science University","2007-03","TRUE","0"],["S000831","ClinicalTrials.gov","NCT05429593",null,"A Study Comparing Exposure of Semaglutide and Dapagliflozin Dosed Orally as Mono-components Versus in a Fixed-dose Combination","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","152","Healthy Volunteers","DRUG:Semaglutide; DRUG:Dapagliflozin; DRUG:Semaglutide/dapagliflozin","Novo Nordisk A/S","2022-06-22","FALSE","0"],["S000832","ClinicalTrials.gov","NCT05040971","STEP 10","Efficacy and Safety of Subcutaneous Semaglutide 2.4 mg Once-weekly in Subjects With Obesity and Prediabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","207","Obesity","DRUG:Semaglutide 2.4 mg; DRUG:Placebo","Novo Nordisk A/S","2021-09-06","TRUE","1"],["S000833","ClinicalTrials.gov","NCT02743598",null,"Effects of Liraglutide on Cognition, Chronic Inflammation and Glycemic Control in Overweight and Obese, HIV-infected Subjects With Type 2 Diabetes.","INTERVENTIONAL",null,"PHASE4","TERMINATED","4","HIV Infection; Diabetes Mellitus Type 2; Obesity; Overweight; Metabolic Syndrome","DRUG:Liraglutide","Temple University","2016-09","FALSE","0"],["S000834","ClinicalTrials.gov","NCT04817644",null,"A Trial Investigating Semaglutide and SNAC Concentrations in Breastmilk Following Administration of Multiple Doses of Oral Semaglutide in Healthy, Lactating Females","INTERVENTIONAL",null,"PHASE1","COMPLETED","14","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2021-09-10","FALSE","0"],["S000835","ClinicalTrials.gov","NCT03225209","MRB","Medically Reproducing Bariatric Surgery","INTERVENTIONAL",null,"PHASE2","COMPLETED","5","Type 2 Diabetes Mellitus","OTHER:OPTIFAST","Moahad S Dar","2018-01-31","FALSE","0"],["S000836","ClinicalTrials.gov","NCT06975111",null,"Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","INTERVENTIONAL","NON_RANDOMIZED","PHASE2; PHASE3","RECRUITING","200","Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular","DRUG:Metformin; DRUG:semaglutide; DRUG:Anti-hypertensives; DRUG:Lipid Lowering Medication; BEHAVIORAL:Life style intervention; DRUG:Fezolinetant; DRUG:Hormonal therapy","University of Colorado, Denver","2026-03-01","FALSE","0"],["S000837","ClinicalTrials.gov","NCT01558271",null,"A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","492","Type 2 Diabetes Mellitus","DRUG:LY2189265; DRUG:Placebo; DRUG:Liraglutide","Eli Lilly and Company","2012-03","TRUE","2"],["S000838","ClinicalTrials.gov","NCT02001363",null,"Protective Effect of Glucagonlike Peptide-1 on Reperfusion Injury in Patients With Acute Myocardial Infarction","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","90","Acute Myocardial Infarction","DRUG:liraglutide (Novo Nordisk, Bagsværd, Denmark); DRUG:liraglutide placebo (Novo Nordisk)","Chen Wei Ren, MD","2013-11","FALSE","6"],["S000839","ClinicalTrials.gov","NCT02394314",null,"A Phase 1, Single-ascending-dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","362","Healthy Volunteers","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2015-02","FALSE","0"],["S000840","ClinicalTrials.gov","NCT07282769",null,"Once Weekly Semaglutide Treatment of Trichotillomania: An Open-Label Study","INTERVENTIONAL",null,"PHASE2","NOT_YET_RECRUITING","10","Trichotillomania (Hair-Pulling Disorder); Trichotillomania; Hair Pulling Disorder; Hair Pulling; Hair-Pulling Disorder","DRUG:Semaglutide","University of Chicago","2026-06","FALSE","0"],["S000841","ClinicalTrials.gov","NCT01515553",null,"A Randomized, Double-blind, Single-centre, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between the Phase 3a Formulation of Liraglutide (Formulation 4) and the Planned Phase 3b Formulation (Final Formulation 4)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","22","Diabetes; Healthy","DRUG:liraglutide","Novo Nordisk A/S","2007-01","FALSE","0"],["S000842","ClinicalTrials.gov","NCT06734273",null,"Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss","INTERVENTIONAL","RANDOMIZED","EARLY_PHASE1","ACTIVE_NOT_RECRUITING","42","Obesity and Obesity-related Medical Conditions","DRUG:Mounjaro; PROCEDURE:Sleeve Gastrectomy","Nicholas Skertich","2025-03-10","FALSE","0"],["S000843","ClinicalTrials.gov","NCT06003153","GLUCOSE-MGH","GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH","INTERVENTIONAL",null,"PHASE4","RECRUITING","125","Genetic Predisposition; Metabolic Diseases; Type 2 Diabetes","DRUG:oral semaglutide; OTHER:Mixed Meal Tolerance Test (MMTT)","Massachusetts General Hospital","2024-03-12","FALSE","0"],["S000844","ClinicalTrials.gov","NCT03444142",null,"Effect of the Weekly Administration of Exenatide LAR or Dulaglutide on the Variability of Blood Pressure and Heart Rate of 24 Hours in Patients With Type 2 Diabetes Mellitus Without Pharmacological Treatment.","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","30","Diabetes Mellitus, Type 2","DRUG:Exenatide LAR; DRUG:Dulaglutide","University of Guadalajara","2017-11-17","FALSE","0"],["S000845","ClinicalTrials.gov","NCT06633783",null,"A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of Semaglutide Injection and Wegovy® for Weight Loss in Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","370","Obesity","DRUG:Semaglutide","Hangzhou Jiuyuan Gene Engineering Co. Ltd.,","2024-10-30","FALSE","0"],["S000846","ClinicalTrials.gov","NCT07701005","GLP-NIT","Early Changes in Non-Invasive Hepatic and Metabolic Indices After Incretin-Based Therapy in Patients With Overweight or Obesity: Real-World Evidence From a Turkish Cohort","OBSERVATIONAL",null,null,"COMPLETED","154","Steatosis of Liver; Metabolic Liver Injury; Obesity; Overweight; Insulin Resistance","DRUG:Semaglutide; DRUG:Tirzepatide","Goztepe Prof Dr Suleyman Yalcın City Hospital","2024-01-01","FALSE","0"],["S000847","ClinicalTrials.gov","NCT02408705",null,"A Randomized, Double Blind, Two-period Cross-over Trial Investigating the Effect of Liraglutide as Add on to Intensive Insulin Treatment on the Endogenous Glucose Production in Subjects With C-peptide Positive Type 1 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","14","Type 1 Diabetes Mellitus","DRUG:Liraglutide; DRUG:Placebo; DRUG:Mixed Meal Tolerance Test with paracetamol","Medical University of Graz","2015-01","FALSE","1"],["S000848","ClinicalTrials.gov","NCT01572753",null,"A Single Centre, Multiple Dose, Open Label Randomised Trial to Evaluate the Effect of Post Dose Meal Timings and the Effect of Volume of Water With Dosing on the Pharmacokinetic Properties of Oral Semaglutide in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","161","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2012-04-12","FALSE","2"],["S000849","ClinicalTrials.gov","NCT07021937","PLASTIC","Investigating Brain PLASTICity and GLP-1 Receptor Agonists in the Treatment of Obesity: The PLASTIC Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","120","Obesity/Therapy","DRUG:Semaglutide 1.7mg subcutaneous; DRUG:Placebo","University of Colorado, Denver","2026-06-15","FALSE","0"],["S000850","ClinicalTrials.gov","NCT05005741",null,"A Randomized Controlled, Open-label, Multi-center Study With 16-week Beinaglutide or Dulaglutide Assessing Effects on Glucose Control and Weight Loss in Type 2 Diabetes With Overweight or Obesity.","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","120","Diabetes Mellitus, Type 2; Overweight or Obesity","DRUG:Beinaglutide; DRUG:Dulaglutide","Second Xiangya Hospital of Central South University","2021-05-01","FALSE","0"],["S000851","ClinicalTrials.gov","NCT03743025",null,"Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","28","Stress Hyperglycemia","DRUG:Dulaglutide Injection; OTHER:Saline Injection","Emory University","2019-03-08","TRUE","0"],["S000852","ClinicalTrials.gov","NCT00849017",null,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","309","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; BIOLOGICAL:albiglutide uptitration; BIOLOGICAL:placebo","GlaxoSmithKline","2009-01","TRUE","4"],["S000853","ClinicalTrials.gov","NCT07654374",null,"A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","1100","Obesity; Overweight; Chronic Weight Management; Type2 Diabetes Mellitus","DRUG:aleniglipron; DRUG:Placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2026-07-17","FALSE","0"],["S000854","ClinicalTrials.gov","NCT05134662",null,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability, Pharmacodynamics and Pharmacokinetics of ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","55","Type 2 Diabetes","DRUG:ALT-801; OTHER:Placebo","Altimmune, Inc.","2022-02-01","FALSE","0"],["S000855","ClinicalTrials.gov","NCT05424003",null,"A Randomized Double Blinded Placebo-Controlled Trial of Semaglutide to Prevent Weight Gain Following Liver Transplantation","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","50","NAFLD","DRUG:Semaglutide Pen Injector; DRUG:Placebo","University of Virginia","2024-02-22","FALSE","0"],["S000856","ClinicalTrials.gov","NCT07244003","MESSAGE","Efficacy and Safety of the Triple Combination Therapy of Met/SGLT-2i/GLP-1RA or Other Oral Antidiabetic Drugs in Patients With Type 2 Diabetes Exhibiting Poor Glycemic Control","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","430","T2DM (Type 2 Diabetes Mellitus)","DRUG:Metformin; DRUG:Triple Therapy of Other Oral Antidiabetic Drugs; DRUG:ganagliflozin; DRUG:liraglutide","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-03-29","FALSE","0"],["S000857","ClinicalTrials.gov","NCT04893148",null,"Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes Insufficiently Controlled by Insulin Glargine and Metformin Combination Therapy","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","40","Type 2 Diabetes Mellitus; Glucose, High Blood","DRUG:IGlarLixi; DRUG:Dulaglutide","Chungbuk National University Hospital","2020-05-26","FALSE","0"],["S000858","ClinicalTrials.gov","NCT02696148",null,"A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2016-03-14","FALSE","1"],["S000859","ClinicalTrials.gov","NCT00813020",null,"A Randomised, Single Centre, Double-blind, Incomplete Block Trial to Test for Equivalence Between Subcutaneous Injections of the GLP-1 Analogue NN9535 in 1 mg/ml, 3 mg/ml and 10 mg/ml Concentrations in Healthy Male Subject","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","44","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide","Novo Nordisk A/S","2009-01","FALSE","0"],["S000860","ClinicalTrials.gov","NCT00620282",null,"The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial With an Open-label Glimepiride Arm","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","49","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:glimepiride","Novo Nordisk A/S","2008-02","TRUE","3"],["S000861","ClinicalTrials.gov","NCT05302596",null,"Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With GLP-1 Receptor Agonist Treatment","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","16","Obesity; Aging","DRUG:Semaglutide Pen Injector","State University of New York at Buffalo","2022-09-01","TRUE","0"],["S000862","ClinicalTrials.gov","NCT00395746",null,"Effect of Liraglutide in Combination With Sulfonylurea (SU) on Glycaemic Control in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","264","Diabetes; Diabetes Mellitus, Type 2","DRUG:sulfonylurea; DRUG:liraglutide","Novo Nordisk A/S","2006-10","TRUE","7"],["S000863","ClinicalTrials.gov","NCT03987074",null,"A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","109","Nonalcoholic Steatohepatitis","DRUG:Semaglutide; DRUG:Firsocostat; DRUG:Cilofexor","Gilead Sciences","2019-07-29","TRUE","1"],["S000864","ClinicalTrials.gov","NCT01147627",null,"Comparison of Exenatide, Insulin or Pioglitazone on Glycaemic Control and β-cell Function in Drug-naïve Type 2 Diabetic Patients: A Multicentre Randomized Parallel-group Trial","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","416","Diabetes Mellitus, Type 2; Newly Diagnosed","DRUG:exenatide injection; DRUG:Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R; DRUG:Pioglitazone","Sun Yat-sen University","2010-08","TRUE","0"],["S000865","ClinicalTrials.gov","NCT02160990",null,"Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","20","Obesity","DRUG:Exenatide; DRUG:Placebo","Mayo Clinic","2014-06","TRUE","1"],["S000866","ClinicalTrials.gov","NCT03038620",null,"Impact of Liraglutide 3.0 on Body Fat Distribution, Visceral Adiposity, and Cardiometabolic Risk Markers In Overweight and Obese Adults at High Risk for Cardiovascular Disease","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","235","Obesity, Visceral; Cardiovascular Diseases; Fat Disorder","DRUG:Liraglutide; DRUG:Placebo","University of Texas Southwestern Medical Center","2017-01","TRUE","4"],["S000867","ClinicalTrials.gov","NCT03768518","GLP-1-CHI","The Physiology of Glucagon-like-peptide-1 Espression in Patients With Endogenous Hyperinsulinism: Correlation With Histopathology","OBSERVATIONAL",null,null,"UNKNOWN","40","Congenital Hyperinsulinism","DIAGNOSTIC_TEST:68Ga-exendin-4 PET/CT","Radboud University Medical Center","2018-02-07","FALSE","0"],["S000868","ClinicalTrials.gov","NCT07090343","REVERSE-TAVR","Semaglutide for Reducing Cardiovascular Events in Patients Undergoing Transcatether Aortic Valve Replacement","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","826","Aortic Stenosis; Heart Failure","DRUG:Wegovy ®; DRUG:Placebo","Leiden University Medical Center","2026-04-01","FALSE","2"],["S000869","ClinicalTrials.gov","NCT05232708",null,"A Study to Demonstrate Bioequivalence Between Semaglutide Formulation for the DV3396 Pen-injector and the Formulation for the PDS290 Semaglutide Pen-injector","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","18","Healthy Volunteers (Diabetes Mellitus, Type 2)","DRUG:Semaglutide B, 1.34 mg/mL; DRUG:Semaglutide D, 1.0 mg/mL","Novo Nordisk A/S","2022-01-19","FALSE","0"],["S000870","ClinicalTrials.gov","NCT02014259",null,"Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","71","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2013-12-11","FALSE","2"],["S000871","ClinicalTrials.gov","NCT07859176",null,"Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery: a Randomized, Double-blind Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","100","Morbid Obesity","DRUG:Semaglutide weekly injection; DRUG:Placebo","General Committee of Teaching Hospitals and Institutes, Egypt","2026-10","FALSE","0"],["S000872","ClinicalTrials.gov","NCT06987513",null,"RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","100","Alcohol Use Disorder (AUD)","DRUG:Pemvidutide; OTHER:Placebo","Altimmune, Inc.","2025-05-15","FALSE","0"],["S000873","ClinicalTrials.gov","NCT01794143","GRADE","Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","7850","Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications","DRUG:Sulfonylurea (glimepiride); DRUG:DPP-4 inhibitor (sitagliptin); DRUG:GLP-1 receptor agonist (liraglutide); DRUG:Insulin (glargine)","GRADE Study Group","2013-05","TRUE","23"],["S000874","ClinicalTrials.gov","NCT06435676",null,"A Phase I Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HRS9531 Tablets in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","72","Overweight or Obesity; Type 2 Diabetes","DRUG:HRS9531; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-06-04","FALSE","0"],["S000875","ClinicalTrials.gov","NCT01602913",null,"Incident Type II Diabetes Mellitus Among Patients Exposed to the Combination of Pravastatin and Paroxetine","OBSERVATIONAL",null,null,"COMPLETED","1","Depression, Postpartum","DRUG:Pravastatin alone; DRUG:Paroxetine alone; DRUG:Pravastatin and paroxetine combined","GlaxoSmithKline","2011-12","FALSE","0"],["S000876","ClinicalTrials.gov","NCT01855490",null,"A Pilot Study to Determine the Effects of a Single Dose of Exenatide (Byetta ®) on the Acute Metabolic Responses to a Mixed Meal or Intravenous Glucose Tolerance Test in Patients With Type 1 Diabetes","INTERVENTIONAL",null,"PHASE1","COMPLETED","17","Type 1 Diabetes","DRUG:Exenatide","Yale University","2012-01","FALSE","0"],["S000877","ClinicalTrials.gov","NCT05759897",null,"A 16-week Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HRS-7535 in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","180","Type 2 Diabetes","DRUG:HRS-7535; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2023-02-28","FALSE","1"],["S000878","ClinicalTrials.gov","NCT02054897","SUSTAIN™1","Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","388","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-02-03","TRUE","13"],["S000879","ClinicalTrials.gov","NCT06565611","BMT-801","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide With Tirzepatide (GLP-1/GIP) for the Treatment of Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","108","Obesity","DRUG:bremelanotide; DRUG:tirzepatide","Palatin Technologies, Inc","2024-08-05","FALSE","0"],["S000880","ClinicalTrials.gov","NCT07281937","EVOLVE-2","A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","206","Obesity; Overweight","DRUG:VRB-101; DRUG:Placebo","Verdiva Bio Dev Limited","2025-11-25","FALSE","0"],["S000881","ClinicalTrials.gov","NCT01965509",null,"A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 12 Weeks Injection of Polyethylene Glycol Loxenatide Add to Metformin","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","120","Type 2 Diabetes","DRUG:PEX168 or placebo","Jiangsu HengRui Medicine Co., Ltd.","2012-05","FALSE","0"],["S000882","ClinicalTrials.gov","NCT06952530",null,"A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","487","Hypertension","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-04-30","FALSE","0"],["S000883","ClinicalTrials.gov","NCT04657939","Lean-DM","Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","57","Diabetes Mellitus, Type 2","DRUG:Liraglutide; DRUG:Pioglitazone","University of Leeds","2020-12-01","FALSE","1"],["S000884","ClinicalTrials.gov","NCT02967757",null,"In-market Utilisation of Liraglutide Used for Weight Management in Europe: a Retrospective Medical Record Review Study.","OBSERVATIONAL",null,null,"COMPLETED","316","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide","Novo Nordisk A/S","2016-12-22","FALSE","1"],["S000885","ClinicalTrials.gov","NCT02303730",null,"Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","76","Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease","DRUG:Exenatide; DRUG:insulin glargine","Fudan University","2015-03","FALSE","9"],["S000886","ClinicalTrials.gov","NCT07803744",null,"A Phase 1, Investigator- and Participant- Blinded, Randomized, Placebo-Controlled, Single-Dose Study to Investigate the Impact of Tirzepatide on Gastric Emptying in Adult Participants With Type 1 Diabetes Mellitus and Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","18","Diabetes Mellitus, Type 1; Overweight; Obesity","DRUG:Tirzepatide; DRUG:Acetaminophen; DRUG:Placebo","Eli Lilly and Company","2026-09-11","FALSE","0"],["S000887","ClinicalTrials.gov","NCT04862234",null,"Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","16","Hyperglycemia Stress","DRUG:Dulaglutide; DRUG:Placebo; DEVICE:Continuous glucose monitor (CGM), blinded","Emory University","2021-08-06","TRUE","0"],["S000888","ClinicalTrials.gov","NCT05172999",null,"A Randomized Controlled Pilot Study of Polyethylene Glycol Loxenatide Plus LNG-IUS in Women With Endometrial Atypical Hyperplasia","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","30","Atypical Endometrial Hyperplasia; Obesity; Fertility Issues","DEVICE:levonorgestrel-releasing intrauterine system; DRUG:Polyethylene Glycol Loxenatide","Fudan University","2022-01-08","FALSE","0"],["S000889","ClinicalTrials.gov","NCT05936138",null,"A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","24","Renal Insufficiency; Healthy","DRUG:LY3502970","Eli Lilly and Company","2023-07-13","TRUE","0"],["S000890","ClinicalTrials.gov","NCT07597018",null,"Bioequivalence Study of Cagrilintide B + Placebo Semaglutide I and Cagrilintide D Once Weekly in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","234","Obesity; Overweight","DRUG:Cagrilintide D; DRUG:Cagrilintide B and placebo semaglutide I","Novo Nordisk A/S","2026-05-18","FALSE","0"],["S000891","ClinicalTrials.gov","NCT06118008",null,"A Multiple-dose, Randomized, Double-blind, Placebo and Positive Controlled Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-20094 in Subjects With Type 2 Diabetes.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","54","Type 2 Diabetes","DRUG:HS-20094 5mg; DRUG:HS-20094 10mg; DRUG:HS-20094 15mg; DRUG:HS-20094 20mg","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2023-05-31","FALSE","1"],["S000892","ClinicalTrials.gov","NCT01514149",null,"A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of 17 Weeks of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","73","Type 2 Diabetes Mellitus (T2DM)","DRUG:CJC-1134-PC Injection; DRUG:Weekly placebo for CJC-1134-PC Injection","ConjuChem","2011-09","TRUE","0"],["S000893","ClinicalTrials.gov","NCT06961643",null,"Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Mild and Moderate Hepatic Impairment and Normal Hepatic Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","24","Diabetes Mellitus","DRUG:HRS-7535 Tables","Shandong Suncadia Medicine Co., Ltd.","2025-06-05","FALSE","0"],["S000894","ClinicalTrials.gov","NCT04263415",null,"The Effects of Semaglutide on Modulation of Taste Sensitivity, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Responses in Women With PCOS and Obesity: a Randomized, Single-blind, Placebo-controlled Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","30","PCOS; Semaglutide; Taste, Altered; Tongue Tissue Transcriptome; Gastric Emptying; Central Neural Response","DRUG:Semaglutide; OTHER:Placebo","University Medical Centre Ljubljana","2019-11-02","FALSE","2"],["S000895","ClinicalTrials.gov","NCT05482789",null,"Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes","INTERVENTIONAL",null,"PHASE4","RECRUITING","13","Gestational Diabetes","DRUG:Exenatide","Maisa N. Feghali, MD","2023-04-12","FALSE","0"],["S000896","ClinicalTrials.gov","NCT05984238","EMINENT-2","Endoscopic Application of Pulsed Electric Fields Using the Endogenex Generation 2 System for Duodenal Mucosal Regeneration for EliMination of INsulin in the treatmENT of Type 2 Diabetes: a Randomized Double-blind Sham Controlled Trial to Evaluate Safety, Feasibility and Efficacy Study","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","33","Diabetes Mellitus, Type 2","DEVICE:PEF therapy using the Endogenex Device; DRUG:Semaglutide, 1.0 mg/mL; OTHER:Sham procedure","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","2023-08-03","FALSE","0"],["S000897","ClinicalTrials.gov","NCT07845578",null,"An Investigation of the Effect of High Dose s.c. Semaglutide on Gastric Emptying in Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","60","Obesity; Overweight","DRUG:Semaglutide; DRUG:Placebo semaglutide; DRUG:Paracetamol","Novo Nordisk A/S","2026-09-25","FALSE","0"],["S000898","ClinicalTrials.gov","NCT00039026",null,"A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With a Sulfonylurea Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","377","Diabetes Mellitus, Non-Insulin-Dependent","DRUG:AC2993; DRUG:Placebo","AstraZeneca","2002-02","FALSE","3"],["S000899","ClinicalTrials.gov","NCT06693843","ACCESS","A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","230","Obesity, Overweight, or Chronic Weight Management","DRUG:Aleniglipron or Placebo; DRUG:Aleniglipron","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2024-10-28","FALSE","1"],["S000900","ClinicalTrials.gov","NCT05360147",null,"Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","30","Type 2 Diabetes Mellitus","DRUG:Liraglutide; DRUG:Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides","Third Military Medical University","2021-01-20","FALSE","0"],["S000901","ClinicalTrials.gov","NCT06788626","GALLOP2","Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","390","Acute Ischemic Stroke; Large Vessel Occlusion; Neuroprotective Drugs; Endovascular Treatment","DRUG:Semaglutide 0.5 mg; OTHER:Standard medical treatment","Wei Hu","2025-02","FALSE","1"],["S000902","ClinicalTrials.gov","NCT06727838",null,"A Single-center, Open-label, Fixed-sequence, Self-controlled Pharmacokinetics Study of Metformin and HRS-7535 in Healthy Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","18","Diabetes","DRUG:HRS-7535 tablets; DRUG:Metformin Hydrochloride Extended-release Tablets; DRUG:Metformin Hydrochloride Tablets","Shandong Suncadia Medicine Co., Ltd.","2024-12-31","FALSE","0"],["S000903","ClinicalTrials.gov","NCT01513525",null,"A Randomised, Open-label, Single Centre, Three Period Cross-over Trial in Healthy Subjects Comparing the Pharmacokinetic Profiles After Single Dose Administration of Liraglutide at Three Different Injection Sites","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","21","Diabetes; Healthy","DRUG:liraglutide","Novo Nordisk A/S","2007-02","FALSE","1"],["S000904","ClinicalTrials.gov","NCT01798706","GetGoal-O","A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","350","Type 2 Diabetes","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DRUG:Antidiabetic background therapy","Sanofi","2013-06","TRUE","3"],["S000905","ClinicalTrials.gov","NCT01144338",null,"Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","14752","Type 2 Diabetes Mellitus","DRUG:Exenatide Once Weekly; DRUG:Placebo","AstraZeneca","2010-06-18","TRUE","26"],["S000906","ClinicalTrials.gov","NCT07481747","SURMOUNT-1","Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","2539","Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities","DRUG:Tirzepatide; DRUG:Placebo; BEHAVIORAL:Reduced-calorie diet","Hudson Biotech","2026-02-02","FALSE","0"],["S000907","ClinicalTrials.gov","NCT07718126","PRIME","Short-term Mazdutide Plus Lifestyle Intervention Versus Placebo for Pre-hepatectomy Prehabilitation in Living Liver Donors With MASLD: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","60","Metabolic Dysfunction-Associated Steatohepatitis; Hepatic Steatosis; Living Liver Donors","DRUG:Mazdutide; DRUG:Placebo (Normal Saline); BEHAVIORAL:Lifestyle Optimization","West China Hospital","2026-09-01","FALSE","0"],["S000908","ClinicalTrials.gov","NCT05443191","PIONEER REAL","A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Finland","OBSERVATIONAL",null,null,"COMPLETED","50","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2022-10-20","FALSE","0"],["S000909","ClinicalTrials.gov","NCT04093752",null,"A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","917","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Insulin Glargine","Eli Lilly and Company","2019-12-09","TRUE","3"],["S000910","ClinicalTrials.gov","NCT06361238",null,"Perioperative Application of Liraglutide for the Prevention of Postoperative Delirium Among Elderly Patients with Type 2 Diabetes Undergoing Cardiac Surgery: a Single-Center Randomized Controlled Study","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","260","Delirium, Postoperative","DRUG:Liraglutide injection; DRUG:Placebo injection","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2024-11-19","FALSE","0"],["S000911","ClinicalTrials.gov","NCT07325435","Beta","Beta Cell Function in Type 2 Diabetes in Black Patients: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","60","Type 2 Diabetes (T2DM)","DRUG:SGLT-2 inhibitor; DRUG:GLP1-RA","MaryAnn Banerji","2024-12-21","FALSE","3"],["S000912","ClinicalTrials.gov","NCT01938235","EMPRES","Exenatide for Myocardial Protection During Reperfusion Study: A Double-blind, Placebo-controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","198","Myocardial Infarction","DRUG:Exenatide; DRUG:Placebo","University Health Network, Toronto","2014-02","FALSE","0"],["S000913","ClinicalTrials.gov","NCT07738276","DUAL-HFrEF","Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity: A Double-Blinded Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","60","Heart Failure and Reduced Ejection Fraction; Obesity & Overweight; Tirzepatide","DRUG:Tirzepatide; DRUG:Placebo","Shahid Beheshti University of Medical Sciences","2026-07-18","FALSE","8"],["S000914","ClinicalTrials.gov","NCT05421338",null,"A Phase I, Open-label, Single-dose, Single-arm Trial to Investigate Metabolism and Pharmacokinetics of BI 456906 (C-14) Administered Subcutaneously to (Otherwise) Healthy Male Volunteers With Normal Body Weight, Overweight or Obesity","INTERVENTIONAL",null,"PHASE1","COMPLETED","6","Healthy","DRUG:BI 456906 (C-14)","Boehringer Ingelheim","2022-07-04","FALSE","0"],["S000915","ClinicalTrials.gov","NCT07041983","SEM-TIR","Effects of Anti-obesity Medications on 24h Energy Metabolism and Body Composition in Patients With Obesity","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","30","Obesity","DRUG:anti obesity medication","University of Pisa","2025-07-01","FALSE","0"],["S000916","ClinicalTrials.gov","NCT06352424",null,"A Single-dose, Randomized, Placebo-controlled Phase I Study on the Effects of a Subcutaneous Dose of BI 1820237 and BI 456906, and Combination Thereof on Functional MRI Measurements in Otherwise Healthy Male and Female Individuals With Obesity/Overweight (Single-blind, Cross-over Design)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","23","Obesity","DRUG:BI 456906; DRUG:BI 1820237; DRUG:Placebo for BI 1820237; DRUG:Placebo for BI 456906","Boehringer Ingelheim","2024-04-30","FALSE","0"],["S000917","ClinicalTrials.gov","NCT03631186",null,"SURE SWITZERLAND: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","215","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2018-09-12","FALSE","2"],["S000918","ClinicalTrials.gov","NCT06475586",null,"Effect of Semaglutide on the Inflammatory Response and Clinical Course of Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","30","Psoriasis Vulgaris; Diabetes Type 2","DRUG:Semaglutide","University of Banja Luka","2023-05-03","FALSE","2"],["S000919","ClinicalTrials.gov","NCT07866183","TIFFANY","Trial of Innovative Fat-loss Focused Approaches in Patients With Class I Obesity: a Comparative Study","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","120","Class I Obesity","DRUG:Tirzepatide; DEVICE:Transcutaneous auricular vagus nerve stimulation","National Medical Research Center for Therapy and Preventive Medicine","2026-06-29","FALSE","0"],["S000920","ClinicalTrials.gov","NCT06149260",null,"An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma","INTERVENTIONAL",null,"PHASE1","UNKNOWN","10","Scleroderma, Systemic; Fibrosis; Semaglutide","DRUG:Semaglutide Pen Injector","Second Xiangya Hospital of Central South University","2024-02-29","FALSE","0"],["S000921","ClinicalTrials.gov","NCT06567327",null,"A Two-Part Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Multiple Dose Pharmacokinetics of Danuglipron Following Oral Administration and The Effects of Steady-State Danuglipron on the Pharmacokinetics of Single Oral Dose of Atorvastatin and Rosuvastatin in Otherwise Healthy Adult Participants With Overweight or Obesity","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","82","Obesity","DRUG:Danuglipron; DRUG:Atorvastatin; DRUG:Rosuvastatin","Pfizer","2024-08-28","FALSE","0"],["S000922","ClinicalTrials.gov","NCT02970942",null,"This Trial is Conducted Globally. The Aim of This Trial is to Investigate Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","320","Hepatobiliary Disorders; Non-alcoholic Steatohepatitis","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2016-11-30","TRUE","9"],["S000923","ClinicalTrials.gov","NCT06519656",null,"A Clinical Efficacy Study of Mazdutide in the Treatment of Polycystic Ovary Syndrome","INTERVENTIONAL",null,"PHASE1; PHASE2","COMPLETED","43","Polycystic Ovary Syndrome","DRUG:Mazdutide","Shanghai Zhongshan Hospital","2024-10-21","FALSE","0"],["S000924","ClinicalTrials.gov","NCT03199261",null,"The Pharmacokinetic Comparison and Bioequivalence Evaluation of Two 10-µg Recombinant Exendin-4 Formulations in Chinese Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Type 2 Diabetes","DRUG:rE-4 Injection; DRUG:rE-4 Freeze-dried Powder","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","2016-12-23","FALSE","0"],["S000925","ClinicalTrials.gov","NCT02931370","US-LOSEIT-I","Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis Following a Significant Weight Loss, Investigating the Impact on Inflammation","OBSERVATIONAL",null,null,"COMPLETED","200","Osteoarthritis; Obesity","DIETARY_SUPPLEMENT:Dietary Supplement: Intensive dietary intervention","Henrik Gudbergsen","2016-11","FALSE","0"],["S000926","ClinicalTrials.gov","NCT01617434",null,"The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","451","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2012-09","TRUE","3"],["S000927","ClinicalTrials.gov","NCT06632444",null,"A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","1800","Metabolic Dysfunction Associated Steatohepatitis (MASH); Liver Fibrosis","COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo","Boehringer Ingelheim","2024-10-14","FALSE","0"],["S000928","ClinicalTrials.gov","NCT06298799","GLP1 treatment","RETRO-PROSPECTIVE OPEN STUDY TO ASSES GENETIC VARIABILITY AS A BASIS FOR PREDICTION OF THE RESPONSE TO GLP1 TREATMENT","INTERVENTIONAL",null,null,"UNKNOWN","400","Type 2 Diabetes; Obesity","GENETIC:DNA Sequencing and Analysis; GENETIC:differential expression analysis with RNA-sequencing (RNA seq) experiments","GENGE","2023-10-01","FALSE","0"],["S000929","ClinicalTrials.gov","NCT07795164","PERFORMA","A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","1800","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","DRUG:Pemvidutide; OTHER:Placebo","Altimmune, Inc.","2026-07-30","FALSE","0"],["S000930","ClinicalTrials.gov","NCT03361098","DECREASE","Combined Effects of SGLT2 Inhibition and GLP-1 Receptor Agonism on Food Intake, Body Weight and Central Satiety and Reward Circuits in Obese T2DM Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","65","Type 2 Diabetes Mellitus; Obesity","DRUG:Dapagliflozin 10mg; DRUG:Exenatide; OTHER:placebo exenatide; OTHER:placebo dapagliflozin","Amsterdam UMC, location VUmc","2017-09-18","FALSE","12"],["S000931","ClinicalTrials.gov","NCT05892432",null,"Randomized, Controlled Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","50","Alcohol Use Disorder","DRUG:Semaglutide 3 MG [Rybelsus]; DRUG:Semaglutide 7 MG [Rybelsus]; DRUG:Placebo","University of Colorado, Denver","2024-01-11","FALSE","0"],["S000932","ClinicalTrials.gov","NCT02210871",null,"A Multi-centre, Open-label, Parallel-group Trial Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","44","Diabetes; Diabetes Mellitus, Type 2; Hepatic Impaired","DRUG:semaglutide","Novo Nordisk A/S","2014-08-07","FALSE","1"],["S000933","ClinicalTrials.gov","NCT02320045",null,"A Phase 1 Study to Evaluate the Pharmacokinetics of ITCA 650 in Subjects With Mild and Moderate Renal Impairment Compared to the Pharmacokinetics of Subjects With Normal Renal Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","38","Renal Insufficiency","DRUG:ITCA 650 (Exenatide in osmotic mini pump)","Intarcia Therapeutics","2014-11","FALSE","0"],["S000934","ClinicalTrials.gov","NCT07325500","REINFORCE","Incretin Microdosing for Cardiometabolic Health in People With HIV: The REINFORCE Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","30","Weight Gain","DRUG:Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly; DRUG:Dose escalation to 2 mg semaglutide weekly then no semaglutide","The University of Texas Health Science Center, Houston","2026-02-12","FALSE","0"],["S000935","ClinicalTrials.gov","NCT07855900",null,"A Phase IIIb, Open-label, Pragmatic Study Evaluating Initiation Strategies for Survodutide, Including de Novo Use and Switching From Semaglutide or Tirzepatide, in Participants With Overweight/Obesity Without Diabetes Mellitus-SYNCHRONIZE® - START","INTERVENTIONAL","NON_RANDOMIZED","PHASE3","NOT_YET_RECRUITING","350","Obesity","COMBINATION_PRODUCT:Survodutide","Boehringer Ingelheim","2026-11-07","FALSE","0"],["S000936","ClinicalTrials.gov","NCT03260881",null,"Effects of Liraglutide on Epicardial Fat Pro-Inflammatory Genes in Type 2 Diabetes and Coronary Artery Disease","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","38","Type2 Diabetes; Coronary Artery Disease","DRUG:Liraglutide Pen Injector [Victoza]; DRUG:matching liraglutide-placebo pre-filled pens","University of Miami","2018-09-01","TRUE","1"],["S000937","ClinicalTrials.gov","NCT02251431",null,"MB001-067 A PROSPECTIVE, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, RANDOMIZED TRIAL OF EXTENDED RELEASE EXENATIDE VERSUS PLACEBO (COHORT A) AND A PROSPECTIVE, SINGLE GROUP, OPEN-LABEL, BLINDED OUTCOME TRIAL OF EXTENDED RELEASE EXENATIDE (COHORT B) IN DIABETIC PATIENTS WITH TYPE 4 CARDIORENAL SYNDROME (EXTEND-CRS TRIAL) AMENDMENT 3","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","57","Type 2 Diabetes Mellitus; Chronic Kidney Disease; Left Ventricular Diastolic Dysfunction","DRUG:BYDUREON; DRUG:Placebo","Baylor Research Institute","2015-11","TRUE","2"],["S000938","ClinicalTrials.gov","NCT01098539",null,"A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Renal Impairment","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","507","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; DRUG:sitagliptin","GlaxoSmithKline","2010-05","TRUE","2"],["S000939","ClinicalTrials.gov","NCT06517212","TRIM-EBC","Adjuvant Tirzepatide Plus Standard of Care Endocrine Therapy in Patients With Obesity or Overweight Who Have Hormone Receptor-positive, HER2-negative, Node-positive Early Breast Cancer, With Molecular Residual Disease (MRD), as Determined by Circulating Tumor DNA (ctDNA)","INTERVENTIONAL",null,"PHASE2","RECRUITING","48","Breast Cancer; Breast Neoplasms; Breast Cancers","DRUG:Tirzepatide","Baylor Research Institute","2024-11-26","FALSE","1"],["S000940","ClinicalTrials.gov","NCT02477865",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIIa Clinical Study Evaluating PEGylated Loxenatide Injection（PEX168）in Monotherapy of Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","406","Type 2 Diabetes Mellitus","DRUG:PEX168(100µg); DRUG:PEX168(200µg); DRUG:Placebo","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2014-03-23","FALSE","0"],["S000941","ClinicalTrials.gov","NCT07292519",null,"Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","46","Alcohol Use Disorder (AUD); Overweight or Obese; Comorbidities and Coexisting Conditions","DRUG:Tirzepatide; BEHAVIORAL:Take Control CBT Module; OTHER:Placebo","South West Sydney Local Health District","2026-01-15","FALSE","0"],["S000942","ClinicalTrials.gov","NCT07046819",null,"A Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Phase 2 Study of Efficacy and Safety of Tirzepatide in Individuals With Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","120","Metabolic Alcohol-associated Liver Disease; Alcohol Use Disorder","DRUG:Tirzepatide; OTHER:Placebo","National Institute on Alcohol Abuse and Alcoholism (NIAAA)","2026-06-11","FALSE","1"],["S000943","ClinicalTrials.gov","NCT00135330",null,"An Evaluation of the Metabolic Effects of Exenatide, Rosiglitazone, and Exenatide Plus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","137","Diabetes Mellitus, Type 2","DRUG:exenatide; DRUG:rosiglitazone","AstraZeneca","2005-10","TRUE","2"],["S000944","ClinicalTrials.gov","NCT06154486",null,"Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study","OBSERVATIONAL",null,null,"COMPLETED","30","Pneumonia, Aspiration; Anesthesia","DRUG:semaglutide use","Hospital Israelita Albert Einstein","2023-06-19","FALSE","3"],["S000945","ClinicalTrials.gov","NCT07302802",null,"Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice","OBSERVATIONAL",null,null,"RECRUITING","70","Monogenic Obesity","DRUG:Semaglutide (administered by PDS290 pen-injector)","Prof. Dr. Martin Wabitsch","2025-12-01","FALSE","2"],["S000946","ClinicalTrials.gov","NCT07398222",null,"Ultrasonographic Evaluation of Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study","OBSERVATIONAL",null,null,"RECRUITING","30","Full Stomach Status","OTHER:Ultrasonographic evaluation of gastric content","Hospital Israelita Albert Einstein","2026-01-26","FALSE","0"],["S000947","ClinicalTrials.gov","NCT06792422","ABSALON","Additive Benefits of Semaglutide for Open-AngLe Glaucoma - an Opportunity for Neuroprotection","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","126","Primary Open Angle Glaucoma (POAG); Open-Angle Glaucoma; Glaucoma","DRUG:Oral semaglutide; DRUG:Placebo","Glostrup University Hospital, Copenhagen","2025-01","FALSE","0"],["S000948","ClinicalTrials.gov","NCT02073929","LIPT","A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","72","Polycystic Ovary Syndrome; Cardiovascular Disease","DRUG:Liraglutide for 26 weeks; DRUG:placebo","Jens Faber","2014-03","TRUE","1"],["S000949","ClinicalTrials.gov","NCT06222437",null,"Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy","INTERVENTIONAL",null,"PHASE1","WITHDRAWN","0","Polycystic Ovary Syndrome","DRUG:Semaglutide","Methodist Health System","2026-02","FALSE","0"],["S000950","ClinicalTrials.gov","NCT05671653",null,"A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF TWO STEADY-STATE DOSE LEVELS OF PF-07081532 ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, OMEPRAZOLE AND AN ORAL CONTRACEPTIVE, AND THE EFFECT OF STEADY-STATE SEMAGLUTIDE ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, IN OBESE ADULT FEMALE PARTICIPANTS","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","TERMINATED","32","Obesity","DRUG:PF-07081532; DRUG:Semaglutide","Pfizer","2023-01-19","TRUE","1"],["S000951","ClinicalTrials.gov","NCT05520775",null,"Human Laboratory Screening of Semaglutide for Alcohol Use Disorder","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","48","Alcohol Use Disorder; Cigarette Smoking","DRUG:Semaglutide; DRUG:Sham/placebo","University of North Carolina, Chapel Hill","2022-09-02","TRUE","2"],["S000952","ClinicalTrials.gov","NCT04029272",null,"Study on the Effect of Metformin vs Metformin Combined With GLP-1 RA (Exenatide) on Overweight/Obese Patients With Polycystic Ovary Syndrome (PCOS)","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","80","Polycystic Ovary Syndrome","DRUG:Metformin; DRUG:Exenatide 2 MG","Peking Union Medical College Hospital","2019-07-20","FALSE","2"],["S000953","ClinicalTrials.gov","NCT03819153","FLOW","Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","3533","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-06-17","TRUE","29"],["S000954","ClinicalTrials.gov","NCT02541734","GLP1-EX-GELO","Effect of Gelofusine on 111In-DTPA-AHX-Lys40-Exendin 4 Uptake in the Kidney","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","12","Diabetes Mellitus, Non-Insulin-Dependent; Diabetes Mellitus","DRUG:Gelofusine; RADIATION:111In-exendin 4 SPECT/CT; DRUG:Placebo","Radboud University Medical Center","2015-08","FALSE","0"],["S000955","ClinicalTrials.gov","NCT01590433",null,"A Prospective Study of Patterns, Predictors, and Mechanisms of Weight Loss With Exenatide Treatment in Overweight and Obese Women Without Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","249","Obesity","DRUG:Exenatide; DRUG:Placebo; BEHAVIORAL:Dietary counseling","Jody Dushay","2012-03","TRUE","1"],["S000956","ClinicalTrials.gov","NCT07855133",null,"An Open-label, Multiple-arm Study to Assess Tolerability in Participants With Overweight or Obesity, With or Without Type 2 Diabetes, When Switching From Semaglutide to Zenagamtide","INTERVENTIONAL",null,"PHASE1","NOT_YET_RECRUITING","60","Overweight; Obesity; Type 2 Diabetes","DRUG:Semaglutide; DRUG:Zenagamtide","Novo Nordisk A/S","2026-09-30","FALSE","0"],["S000957","ClinicalTrials.gov","NCT03363906",null,"Relative Bioavailability of an Investigational Single Dose of Dulaglutide After Subcutaneous Administration by a Single Dose Pen Compared to a Prefilled Syringe in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","27","Healthy","DRUG:Dulaglutide (Reference); DRUG:Dulaglutide (Test)","Eli Lilly and Company","2017-12-07","TRUE","0"],["S000958","ClinicalTrials.gov","NCT06762314",null,"Comparative Clinical Study to Evaluate the Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes Inadequately Controlled by Insulin Therapy","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","114","Diabetes","DRUG:Insulin; DRUG:Semaglutide; DRUG:Empagliflozin","Mostafa Bahaa","2025-01-20","FALSE","0"],["S000959","ClinicalTrials.gov","NCT07115069","REFORM","Conduct of the REsponses in Function and Outcomes From RYGB vs. Medication Study (REFORM) Study by Research Coordinators","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","60","Obesity","DRUG:GLP-1 receptor agonist; PROCEDURE:Gastric Bypass Surgery (laparoscopic); PROCEDURE:Gastric Bypass Surgery (robotic)","Vanderbilt University Medical Center","2025-08-09","FALSE","0"],["S000960","ClinicalTrials.gov","NCT06914154","DUP-SUMMIT","Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data","OBSERVATIONAL",null,null,"COMPLETED","11265","Diabetes Mellitus, Type 2; Heart Failure With Preserved Ejection Fraction (HFPEF)","DRUG:Tirzepatide; DRUG:Placebo","Brigham and Women's Hospital","2025-01-14","FALSE","1"],["S000961","ClinicalTrials.gov","NCT07630454","TEAR-AF-HFpEF","Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Obese and HFpEF: A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","602","Atrial Fibrillation; Heart Failure With Preserved Ejection Fraction (HFpEF); Tirzepatide","DRUG:Tirzepatide; BEHAVIORAL:Structured Lifestyle Intervention","Yunlong Wang","2026-08-01","FALSE","0"],["S000962","ClinicalTrials.gov","NCT05305794","TOLEDDO","Effect of Weekly GLP1 Agonist Treatment in \"Double Diabetes\": a Randomized Open-label Study","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","76","Double Diabetes","DRUG:Insulin + semaglutide treatment; DRUG:Usual insulin treatment; BIOLOGICAL:Biological check-up","Centre Hospitalier Universitaire Dijon","2022-07-12","FALSE","0"],["S000963","ClinicalTrials.gov","NCT01917656","LIRA-Ramadan™","Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","343","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:metformin; DRUG:sulphonylurea","Novo Nordisk A/S","2014-01-09","TRUE","2"],["S000964","ClinicalTrials.gov","NCT04643301","LIBAR","Liraglutide for Low-responders After Bariatric Surgery","INTERVENTIONAL",null,null,"WITHDRAWN","0","Obesity; Obesity, Morbid","DRUG:Liraglutide Pen Injector","Zuyderland Medisch Centrum","2020-12-21","FALSE","0"],["S000965","ClinicalTrials.gov","NCT00082381",null,"Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","551","Diabetes Mellitus, Type 2","DRUG:Exenatide (AC2993); DRUG:Insulin glargine","AstraZeneca","2003-06","TRUE","3"],["S000966","ClinicalTrials.gov","NCT07847515",null,"Effects of Tirzepatide on Gut Microbiota and the Recovery Pattern of Gastric Emptying After Drug Withdrawal in Obese Patients","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","80","Obesity / Overweight","DRUG:Tirzepatide","Nanjing First Hospital, Nanjing Medical University","2027-02-01","FALSE","0"],["S000967","ClinicalTrials.gov","NCT01517568",null,"A Single-Centre, Open Label Trial Investigating the Metabolites in Plasma, Urine and Faeces After a Single Subcutaneous Dose of [3H]-Liraglutide to Healthy Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","7","Diabetes; Healthy","DRUG:liraglutide [3H]","Novo Nordisk A/S","2006-11","FALSE","1"],["S000968","ClinicalTrials.gov","NCT05793450",null,"Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","20","Renal Impairment","DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2023-05-05","FALSE","0"],["S000969","ClinicalTrials.gov","NCT06501326",null,"Clinical Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism-associated Fatty Liver Disease (MAFLD)","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","102","Non-alcoholic Fatty Liver Disease; Obesity","DRUG:Liraglutide; DRUG:Orlistat","Affiliated Hospital of Nantong University","2023-11-01","FALSE","0"],["S000970","ClinicalTrials.gov","NCT07768813",null,"Bioequivalence of Survodutide (BI 456906) When Administered Via Pre-filled Syringe (Formulation A) and Vial (Formulation B2) in Male and Female Trial Participants Who Are Healthy or Otherwise Healthy But Overweight/Obese (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Trial)","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","44","Healthy; Obesity","COMBINATION_PRODUCT:Survodutide formulation A; DRUG:Survodutide formulation B2","Boehringer Ingelheim","2026-09-02","FALSE","0"],["S000971","ClinicalTrials.gov","NCT07368855",null,"Changes in Psychiatric Symptoms, Eating Disorder Behaviors, and Health Behaviors Following Six Months of GLP-1 Treatment for Obesity","INTERVENTIONAL",null,null,"COMPLETED","90","Obesity; Depression; GLP-1","DRUG:GLP-1","University of California, San Diego","2024-05-01","FALSE","0"],["S000972","ClinicalTrials.gov","NCT04823208",null,"A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","64","Diabetes Mellitus, Type 2","DRUG:LY3437943; DRUG:Placebo","Eli Lilly and Company","2021-05-24","FALSE","0"],["S000973","ClinicalTrials.gov","NCT07740291","TIA","Tirzepatide Impact Assessment: Exploring Health and Wellness Outcomes","INTERVENTIONAL","NON_RANDOMIZED",null,"RECRUITING","27","Obesity & Overweight; Cardiometabolic Health Indicators; Addiction; Eating Disorders; Mental Health","DRUG:GLP-1 Receptor Agonist Therapy; BEHAVIORAL:Structured Lifestyle Intervention","Texas Tech University","2025-01-02","FALSE","0"],["S000974","ClinicalTrials.gov","NCT01856790",null,"Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes","INTERVENTIONAL",null,"EARLY_PHASE1","COMPLETED","15","Type 1 Diabetes","DEVICE:ePID closed loop system; DRUG:liraglutide","Jennifer Sherr","2013-02","TRUE","0"],["S000975","ClinicalTrials.gov","NCT06393348",null,"A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","155","Type 2 Diabetes","DRUG:HRS-7535; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2024-05-17","FALSE","0"],["S000976","ClinicalTrials.gov","NCT04016974",null,"A Multiple-dose, Single-centre, Randomised, Double-blind, Placebo-controlled Trial to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Chinese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Healthy Volunteers; Diabetes Mellitus, Type 2","DRUG:Oral semaglutide; DRUG:Placebo","Novo Nordisk A/S","2019-10-08","FALSE","1"],["S000977","ClinicalTrials.gov","NCT05857085","ENDIS","Impact of Additional Treatment With Empagliflozin or Semaglutide on Endothelial Function and Other Clinical Parameters and Biomarkers in T1DM Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","90","Endothelial Dysfunction; Diabetes Mellitus, Type 1; Biomarkers; Endothelial Progenitor Cells; SGLT 2 Inhibitors; Incretins; Glucose Excursions; FMD; FPF; Arterial Stiffness","DRUG:Semaglutide Pen Injector [Ozempic]; DRUG:Empagliflozin 10 MG","General and Teaching Hospital Celje","2021-12-15","FALSE","0"],["S000978","ClinicalTrials.gov","NCT03534310","LETHE","Intensive Lifestyle Modifications With or Without Liraglutide 3 mg Versus Sleeve Gastrectomy: A 3 Arm Randomized Controlled Pilot Study (LETHE)","INTERVENTIONAL","NON_RANDOMIZED",null,"COMPLETED","75","Obesity","DRUG:LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML); OTHER:lifestyle modification; OTHER:sleeve gastrectomy","Catholic University of the Sacred Heart","2015-11-02","FALSE","0"],["S000979","ClinicalTrials.gov","NCT04189848",null,"A Trial to Complare the Injection Site Pain Experience of Semaglutide 0.25 mg and Dulaglutide 0.75 mg Administered sc","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","104","Healthy Volunteers; Diabetes Mellitus, Type 2; Overweight; Obesity","DRUG:Semaglutide; DRUG:Dulaglutide","Novo Nordisk A/S","2019-12-03","TRUE","1"],["S000980","ClinicalTrials.gov","NCT03292185",null,"A Single Centre, Randomised, Double-blind, Three-period Cross-over Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin degludec; DRUG:liraglutide","Novo Nordisk A/S","2017-09-29","FALSE","0"],["S000981","ClinicalTrials.gov","NCT07628985",null,"BALANCE-DM2: A Multiregional, Randomized, Multicenter, Active-Controlled Confirmatory Phase III Study to Evaluate the Efficacy and Safety of Bofanglutide (GZR18) in Latin American Adults With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","374","Type 2 Diabetes Mellitus (T2DM)","BIOLOGICAL:Bofanglutide; BIOLOGICAL:Semaglutide","Carnot Laboratories","2026-09","FALSE","2"],["S000982","ClinicalTrials.gov","NCT05893043",null,"A Phase 1, Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","18","Healthy Volunteers","DRUG:GSBR-1290; OTHER:Placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2023-04-24","FALSE","0"],["S000983","ClinicalTrials.gov","NCT07456774","SPOTLIGHT","A Retrospective Database Study to Compare Cardiovascular and Renal Outcomes of Ozempic® (OW Semaglutide) Versus Other Anti-Diabetic Drugs in Chinese T2D Patients","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","100000","Type 2 Diabetes",null,"Novo Nordisk A/S","2026-02-13","FALSE","0"],["S000984","ClinicalTrials.gov","NCT06269120",null,"SEMA-CardioDiab HUNGARY: A Multicentre, Prospective, Non-interventional Study to Evaluate Glycemic Control and Weight Changes in Patients With Type 2 Diabetes Initiating Treatment With Oral Semaglutide by Cardiologists or Diabetologists as Part of Local Clinical Practice in Hungary","OBSERVATIONAL",null,null,"COMPLETED","243","Type 2 Diabetes","DRUG:Oral Semaglutide","Novo Nordisk A/S","2024-09-30","FALSE","0"],["S000985","ClinicalTrials.gov","NCT01146678",null,"A Randomized, Cross-over, Open, Euglycemic Clamp Study on the Relative Bioavailability and Activity of 0.6 U/kg Insulin Glargine and 20 μg Lixisenatide, Given as On-site Mix Compared to Separate Simultaneous Injections in Subjects With Type 1 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","22","Type 1 Diabetes Mellitus","DRUG:Insulin glargine HOE901; DRUG:Lixisenatide AVE0010","Sanofi","2010-06","FALSE","0"],["S000986","ClinicalTrials.gov","NCT02404376","COMBAT-MI","COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","378","ST Elevation Acute Myocardial Infarction","DRUG:Exenatide; OTHER:Remote Ischemic Conditioning (RIC); DRUG:Placebo","Hospital Universitari Vall d'Hebron Research Institute","2016-03","FALSE","1"],["S000987","ClinicalTrials.gov","NCT07206290","ARTIST-CKD","Albuminuria Reduction Trial and Investigation With Survodutide Treatment in CKD","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","120","Chronic Kidney Disease","DRUG:Survodutide (BI 456906); DRUG:Placebo","University Medical Center Groningen","2026-03-02","FALSE","0"],["S000988","ClinicalTrials.gov","NCT03611582","STEP 3","Effect and Safety of Semaglutide 2.4 mg Once-weekly as Adjunct to Intensive Behavioural Therapy in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","611","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2018-08-01","TRUE","8"],["S000989","ClinicalTrials.gov","NCT02910570",null,"The Association Between Weight Loss With Subsequent Maintenance Using Liraglutide and Changes in Skin Autoflouresence in Overweight or Obese Patients With Knee Osteoarthritis - a Substudy to \"Effect of Liraglutide on Body Weight and Pain in Overweight or Obese Patients With Knee Osteoarthritis: A Randomised, Double Blind, Placebo-controlled, Parallel Group, Single-centre Trial\" (NCT02905864)","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","150","Osteoarthritis, Knee","DRUG:Liraglutide 3 mg (Saxenda); DRUG:Liraglutide 3 mg placebo","Parker Research Institute","2016-11","FALSE","0"],["S000990","ClinicalTrials.gov","NCT04057261","Lirabolic","Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Type 2 Diabetes; Cardiovascular Diseases","DRUG:Liraglutide Pen Injector [Victoza]; DRUG:Placebo","RWTH Aachen University","2020-11","FALSE","0"],["S000991","ClinicalTrials.gov","NCT06052566",null,"An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Efinopegdutide (MK-6024) in Participants With Moderate and Severe Hepatic Impairment","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","22","Non-alcoholic Steatohepatitis; Hepatic Impairment","DRUG:Efinopegdutide","Merck Sharp & Dohme LLC","2023-11-21","TRUE","0"],["S000992","ClinicalTrials.gov","NCT04004988",null,"A Study to Compare the Pharmacokinetics of Tirzepatide Administered Subcutaneously by an Autoinjector Versus Prefilled Syringe in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","47","Healthy","DRUG:Tirzepatide; DEVICE:Prefilled syringe (PFS); DEVICE:Auto-injector (AI)","Eli Lilly and Company","2019-08-19","TRUE","0"],["S000993","ClinicalTrials.gov","NCT03590626","D-LIFT","Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","60","Non Alcoholic Fatty Liver Disease; Type2 Diabetes Mellitus","DRUG:Dulaglutide","Medanta, The Medicity, India","2019-01-01","FALSE","7"],["S000994","ClinicalTrials.gov","NCT02127541",null,"New Imaging Procedure for the Localisation of Insulinoma","INTERVENTIONAL",null,null,"COMPLETED","52","Endogenous Hyperinsulinaemic Hypoglycaemia","OTHER:Ga -exendin PET/CT, In- exendin SPECT/CT, MRI","University Hospital, Basel, Switzerland","2014-01-06","FALSE","4"],["S000995","ClinicalTrials.gov","NCT07765160",null,"A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Characteristics of a Single Subcutaneous Administration of IBI3040 in Healthy Participants and Multiple Subcutaneous Administrations in Overweight or Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","96","Healthy Participants; Overweight or Obese Participants","DRUG:SAD: subcutaneous injection in the abdomen; DRUG:MAD: subcutaneous injection in the abdomen","Innovent Biologics (Suzhou) Co. Ltd.","2026-08-30","FALSE","0"],["S000996","ClinicalTrials.gov","NCT07400588","GSBR-1290","A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety and Tolerability of Aleniglipron in Adult Participants With Type 2 Diabetes Mellitus Living With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","58","Obese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Loss","DRUG:Aleniglipron; DRUG:Placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2025-12-01","FALSE","0"],["S000997","ClinicalTrials.gov","NCT05794581",null,"A Randomized, Double-Blind, Placebo and Comparator-Controlled Crossover Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Type 1 Diabetes","DRUG:CT-868; DRUG:Placebo; DRUG:Victoza","Carmot Therapeutics, Inc.","2023-03-21","FALSE","0"],["S000998","ClinicalTrials.gov","NCT07627191",null,"GLP-1 Receptor Agonist Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer","INTERVENTIONAL","NON_RANDOMIZED","EARLY_PHASE1","RECRUITING","30","Pancreatic Cancer; Colorectal Cancer; Hepatocellular Carcinoma","DRUG:GLP1-RA (semaglutide)","University of Arizona","2026-10-10","FALSE","0"],["S000999","ClinicalTrials.gov","NCT02072096","IMPERIUM","An Individualized treatMent aPproach for oldER patIents: A Randomized, Controlled stUdy in Type 2 Diabetes Mellitus (IMPERIUM)","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","192","Diabetes Mellitus, Type 2","DRUG:Glimepiride; DRUG:Metformin; DRUG:Pioglitazone; DRUG:Acarbose; DRUG:Linagliptin; DRUG:Sitagliptin; DRUG:Liraglutide; DRUG:Insulin Glargine; DRUG:Exenatide once weekly (QW); DRUG:Exenatide twice daily (BID)","Eli Lilly and Company","2014-02","TRUE","1"],["S001000","ClinicalTrials.gov","NCT05502562","PIONEER REAL","A Multicentre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Initiation of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in India","OBSERVATIONAL",null,null,"COMPLETED","388","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2023-02-24","FALSE","1"],["S001001","ClinicalTrials.gov","NCT07220642","RENEW 1","Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","300","Obesity; Overweight","DRUG:Cagrilintide; DRUG:Placebo","Novo Nordisk A/S","2025-11-05","FALSE","0"],["S001002","ClinicalTrials.gov","NCT01270191",null,"The Effects of Short-Term Exenatide Therapy on the Beta-Cell Function and Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","160","Type 2 Diabetes","DRUG:Exenatide; DRUG:Humulin-N","Taipei Veterans General Hospital, Taiwan","2010-11","FALSE","1"],["S001003","ClinicalTrials.gov","NCT02200991",null,"A Randomized, Multicenter, Open-Label, Parallel-Group, 28 Days Phase IV Study Comparing The Postprandial Plasma Glucose Profile of Lixisenatide With That of Sitagliptin Add-On to Insulin Glargine in Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","136","Type 2 Diabetes Mellitus","DRUG:LIXISENATIDE AVE0010; DRUG:Sitagliptin; DRUG:Insulin glargine HOE901","Sanofi","2014-08","FALSE","1"],["S001004","ClinicalTrials.gov","NCT00622323",null,"Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients","OBSERVATIONAL",null,null,"COMPLETED","41","Type 2 Diabetes Mellitus",null,"AstraZeneca","2008-02","FALSE","0"],["S001005","ClinicalTrials.gov","NCT02442791","GLIP1","GLP-1 Analogs for Neuroprotection After Out-of-hospital Cardiac Arrest, a Randomized Clinical Trail","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","120","Cardiac Arrest; Coma","DRUG:Byetta (Lilly, Exenatide); OTHER:20% Human Albumin","Jesper Kjaergaard","2014-06","FALSE","4"],["S001006","ClinicalTrials.gov","NCT00241423",null,"Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes Using Metformin or Metformin Plus a Thiazolidinedione","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","30","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:Placebo","AstraZeneca","2005-10","FALSE","1"],["S001007","ClinicalTrials.gov","NCT05056246",null,"A Phase I, Open-label, Randomized, Parallel-arm, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","34","Healthy Participants","DRUG:AMG 133","Amgen","2021-09-10","TRUE","0"],["S001008","ClinicalTrials.gov","NCT05498610",null,"Investigation of Pharmacokinetic Properties of Subcutaneously co Administered Single Doses of NNC0480-0389 and Semaglutide in Healthy Chinese Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Diabetes Mellitus, Type 2","DRUG:NNC0480 0389; DRUG:Semaglutide","Novo Nordisk A/S","2022-08-11","FALSE","0"],["S001009","ClinicalTrials.gov","NCT07295223","GALACTUS","GLP-1 and Antidiabetic SGLT2 Agents for Myocardial Infarction and Ultrasensitive Inflammatory Surveillance: An Open-Label Pilot Study","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","44","Acute Myocardial Infarction With ST Elevation","DRUG:Dapagliflozin 10 MG Oral Tablet; DRUG:Semaglutide (Rybelsus®)","Instituto Mexicano del Seguro Social","2025-12-30","FALSE","0"],["S001010","ClinicalTrials.gov","NCT06774079",null,"A Randomized Clinical Trial to Determine the Effect of Dual Glucose-dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonist-mediated Weight Loss and Diet on Crohn's Disease Clinical Response: a Pilot Study","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","24","Crohn Disease","DRUG:Tirzepatide; BEHAVIORAL:Mediterranean diet","University of Miami","2025-03-05","FALSE","0"],["S001011","ClinicalTrials.gov","NCT06373146",null,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","392","Obesity","DRUG:Tirzepatide; DRUG:Mibavademab; DRUG:Tirzepatide-Placebo; DRUG:Mibavademab-Placebo","Eli Lilly and Company","2024-04-24","FALSE","0"],["S001012","ClinicalTrials.gov","NCT05702905",null,"Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome: a Prospective, Randomized, Open, Controlled Study","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","75","PCOS (Polycystic Ovary Syndrome); Semaglutide","DRUG:Metformin Hydrochloride 500 MG; DRUG:Semaglutide, 1.34 mg/mL; DRUG:Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG; BEHAVIORAL:calorie-restricted diet; BEHAVIORAL:physical exercise","Peking University First Hospital","2023-05-09","FALSE","11"],["S001013","ClinicalTrials.gov","NCT06075667",null,"Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (SURMOUNT-ADOLESCENTS)","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","160","Obesity; Overweight","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-10-16","FALSE","0"],["S001014","ClinicalTrials.gov","NCT06717698",null,"Efficacy, Safety and Pharmacokinetics of NNC0519-0130 Once Weekly s.c. Versussemaglutide 1.0 mg and Placebo in People With Chronic Kidney Disease, With or Without Type 2 Diabetes, and With Overweight or Obesity: a Proof-of-concept and Dose-finding Study","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","465","Chronic Kidney Disease","DRUG:NNC0519-0130; DRUG:Placebo; DRUG:Semaglutide","Novo Nordisk A/S","2024-12-02","FALSE","0"],["S001015","ClinicalTrials.gov","NCT04466345",null,"Adjunctive Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder: a Randomized, Double-Blind, Placebo-Controlled Study","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","72","Major Depressive Disorder","BIOLOGICAL:Semaglutide; BIOLOGICAL:Placebo","University Health Network, Toronto","2021-10-06","FALSE","2"],["S001016","ClinicalTrials.gov","NCT07101939","PROACT","A Two-part, Phase 2a Randomized, Part Parallel-group, Double-blind Placebo-controlled Cross-over Multi-center Study to Evaluate the Effect of Two Dose Levels of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass in Obese Patients During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","120","Obesity; Muscle Loss","DRUG:(S)-pindolol benzoate; DRUG:Semaglutide; DRUG:Placebo to (S)-pindolol benzoate","Actimed Therapeutics Ltd","2025-06-23","FALSE","0"],["S001017","ClinicalTrials.gov","NCT03962010",null,"A Phase 2, 12-Week, Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate Efficacy and Safety of GX-G6 on Glycaemic Control Versus Placebo and Open-Label Dulaglutide in Patients With Uncontrolled Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","78","Type 2 Diabetes Mellitus","DRUG:GX-G6; DRUG:Control","Genexine, Inc.","2019-06-01","FALSE","0"],["S001018","ClinicalTrials.gov","NCT07169942",null,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Study Evaluating the Effects of Aleniglipron (GSBR-1290) on Body Composition in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2)","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","71","Obesity, Overweight, or Chronic Weight Management","DRUG:aleniglipron or placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2025-08-15","FALSE","0"],["S001019","ClinicalTrials.gov","NCT02020616",null,"Safety, Tolerability, Pharmacokinetics, and Efficacy of LY3053102 With 12 Weeks of Treatment in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","TERMINATED","60","Type 2 Diabetes Mellitus","DRUG:LY3053102; DRUG:Exenatide ER; DRUG:Placebo; DRUG:Metformin","Eli Lilly and Company","2013-12","TRUE","0"],["S001020","ClinicalTrials.gov","NCT00097500",null,"A Phase 3, Randomized, Open Label, Comparator-Controlled, Parallel Group, Multicenter Study to Compare the Effects of Exenatide and Insulin Glargine on Beta Cell Function and Cardiovascular Risk Markers in Subjects With Type 2 Diabetes Treated With Metformin Who Have Not Achieved Target HbA1c","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","69","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:Insulin glargine; DRUG:Metformin","AstraZeneca","2004-09","TRUE","5"],["S001021","ClinicalTrials.gov","NCT01518101","PREFER","A Randomized, Open-label, Cross-over Study to Evaluate Patient Preferences for Eucreas® Versus Victoza® as add-on to Metformin in Type 2 Diabetes Mellitus Patients Who Did Not Have Adequate Glycaemic Control With Metformin.","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","62","Type 2 Diabetes","DRUG:Vildagliptin/ Metformin; DRUG:Liraglutide; DRUG:Metformin","Novartis Pharmaceuticals","2012-01","FALSE","1"],["S001022","ClinicalTrials.gov","NCT07845500",null,"A PHASE 3 STUDY TO EVALUATE THE SWITCH TO MONTHLY BEROBENATIDE FOR MAINTAINING WEIGHT IN ADULTS WHO ARE ON WEEKLY SEMAGLUTIDE OR TIRZEPATIDE (VESPER-SWITCH)","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","660","Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity","DRUG:Semaglutide; DRUG:Tirzepatide; DRUG:Berobenatide","Pfizer","2026-10-01","FALSE","0"],["S001023","ClinicalTrials.gov","NCT07745504","RENEW 4","A Placebo-controlled Comparability Study to Compare Two Presentations of Cagrilintide for Weight Management in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","285","Overweight; Obesity","DRUG:Cagrilintide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2026-08-04","FALSE","0"],["S001024","ClinicalTrials.gov","NCT07769047",null,"Breast Cancer Survivors With Obesity - Semaglutide's Impact on Preclinical Markers of Cardiovascular Disease","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","50","Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8","PROCEDURE:Biospecimen Collection; PROCEDURE:Dual X-ray Absorptiometry; OTHER:Functional Assessment; BEHAVIORAL:Lifestyle Counseling; DRUG:Semaglutide","Mayo Clinic","2026-09-01","FALSE","0"],["S001025","ClinicalTrials.gov","NCT07468552",null,"Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Tirzepatide for Treatment of Cannabis Use Disorder (CUD)","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","100","Cannabis Use Disorder","DRUG:Tirzepatide; DRUG:Placebo","National Institute on Drug Abuse (NIDA)","2026-11-15","FALSE","0"],["S001026","ClinicalTrials.gov","NCT07099742",null,"A Study of Real-World Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) in Bangladesh","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","364","Obesity","DRUG:Tirzepatide; BEHAVIORAL:Life Style Modification","Dr. Md. Alimur Reza","2026-11","FALSE","3"],["S001027","ClinicalTrials.gov","NCT01302327",null,"GLP Analogs for Diabetes in Wolfram Syndrome Patients","INTERVENTIONAL",null,null,"WITHDRAWN","0","Diabetes Mellitus Associated With Genetic Syndrome; Wolfram Syndrome","DRUG:Exenatide","Hadassah Medical Organization","2011-03-01","FALSE","1"],["S001028","ClinicalTrials.gov","NCT02476760",null,"The Use of Incretin-based Drugs and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","1417914","Diabetes Mellitus, Type 2","DRUG:DPP-4 inhibitors; DRUG:GLP-1 analogs; DRUG:Insulins; DRUG:Biguanides; DRUG:Sulfonylureas; DRUG:Thiazolidinediones; DRUG:Alpha-glucosidase inhibitors; DRUG:Meglitinides","Canadian Network for Observational Drug Effect Studies, CNODES","2014-03","FALSE","1"],["S001029","ClinicalTrials.gov","NCT06935838",null,"Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV","INTERVENTIONAL",null,"PHASE2","COMPLETED","12","Obesity and Overweight; HIV; Chronic Inflammation","DRUG:Tirzepatide","University of Hawaii","2025-11-12","FALSE","2"],["S001030","ClinicalTrials.gov","NCT02586831","DIPIT","A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","WITHDRAWN","0","Diabetes Mellitus, Type 1; Hypoglycemia; Autoimmune Diseases; Diabetes Mellitus","DRUG:Anti-Thymocyte Globulin (ATG); DRUG:Interleukin 2; DRUG:Exenatide; DRUG:Adalimumab; OTHER:ATG Placebo; OTHER:IL-2 Placebo; OTHER:Adalimumab Placebo; OTHER:Exenatide Placebo","Camillo Ricordi and Jay Skyler","2024-06-01","FALSE","0"],["S001031","ClinicalTrials.gov","NCT06982846",null,"A Randomized, Placebo-Controlled, Parallel Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","80","Type 2 Diabetes Mellitus","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2025-06-06","FALSE","0"],["S001032","ClinicalTrials.gov","NCT03842202",null,"Effect of Semaglutide 2.4 mg Once-weekly on Gastric Emptying in Subjects With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","72","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2019-02-15","FALSE","1"],["S001033","ClinicalTrials.gov","NCT04451837",null,"Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","200","Type2 Diabetes","DRUG:Semaglutide; DRUG:Dapagliflozin","Region Skane","2020-09-10","FALSE","1"],["S001034","ClinicalTrials.gov","NCT01766245",null,"A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","28","Diabetes; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2012-12","FALSE","0"],["S001035","ClinicalTrials.gov","NCT05929066","TRIUMPH-1","A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","2335","Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2023-07-10","FALSE","1"],["S001036","ClinicalTrials.gov","NCT02349802","BCB119","Evaluation of the Single-Use Pre-Filled Autoinjector","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","3052","Healthy Subjects","DRUG:Auto-injector with exenatide suspension; DRUG:Syringe with exenatide suspension","AstraZeneca","2013-02","FALSE","0"],["S001037","ClinicalTrials.gov","NCT02451527",null,"An Open-label，Single-arm，Sequential，Single-center Clinical Trial of the Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection (PEX168) in Healthy Adult Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","16","Healthy","DRUG:Digoxin; DRUG:PEX168","First Affiliated Hospital Xi'an Jiaotong University","2015-05","FALSE","0"],["S001038","ClinicalTrials.gov","NCT07073053",null,"The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","60","Glucagon-Like Peptide-1 Receptor Agonists; Type 2 Diabetes; Coronary Arterial Disease (CAD)","DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 0.5 mg","Taipei Veterans General Hospital, Taiwan","2025-10-01","FALSE","0"],["S001039","ClinicalTrials.gov","NCT04601753","PIONEER REAL","A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Sweden","OBSERVATIONAL",null,null,"COMPLETED","194","Diabetes Mellitus, Type 2","DRUG:Oral Semaglutide","Novo Nordisk A/S","2020-11-12","FALSE","3"],["S001040","ClinicalTrials.gov","NCT03208881",null,"Ultrasound Assessment of the Adventitia, Extra-media (EMT) and Veia Jugularis Interna Thickness in Obese Subjects Following a Significant Weight Loss","OBSERVATIONAL",null,null,"UNKNOWN","80","Osteoarthritis, Obesity","DIETARY_SUPPLEMENT:Dietary Supplement: Intensive dietary intervention","Henrik Gudbergsen","2017-07-15","FALSE","0"],["S001041","ClinicalTrials.gov","NCT02488057",null,"Improving Beta Cell Function in Mexican American Women With Prediabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","360","Pre-Diabetes","DRUG:Liraglutide; BEHAVIORAL:Weight loss","Ohio State University","2016-05","FALSE","2"],["S001042","ClinicalTrials.gov","NCT01620463",null,"A Randomised, Double-blind, Single-centre, Placebo-controlled, Ascending Single s.c. Dose, Sequential Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 90-1170 in Healthy Japanese Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2002-12","FALSE","0"],["S001043","ClinicalTrials.gov","NCT06507475","REALISED","Real World Effectiveness of Oral Semaglutide in Thailand Patients With Type 2 Diabetes: an Observational, Multicentre, Retrospective Cohort Study REAL-world Effectiveness of Oral Semaglutide In a Cohort of Thai patientS With Type 2 Diabetes treatED With Oral Antidiabetic Medications (REALISED) Study","OBSERVATIONAL",null,null,"COMPLETED","209","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2024-09-07","FALSE","0"],["S001044","ClinicalTrials.gov","NCT06109311","ACHIEVE-5","A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","546","Type 2 Diabetes","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2023-11-10","TRUE","2"],["S001045","ClinicalTrials.gov","NCT02647944",null,"Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","40","Obesity","DRUG:Liraglutide; DRUG:Placebo","Mayo Clinic","2015-12-18","TRUE","4"],["S001046","ClinicalTrials.gov","NCT01923181",null,"Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","632","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:oral placebo","Novo Nordisk A/S","2013-12-02","TRUE","1"],["S001047","ClinicalTrials.gov","NCT06267092",null,"An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment (CagriSema) on Appetite and Functional Brain Activity in People With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","164","Overweight; Obesity","OTHER:No treatment given; DRUG:Cagrilintide and Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2024-02-15","FALSE","0"],["S001048","ClinicalTrials.gov","NCT06820281","TIRTLE2","Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","44","Type 1 Diabetes Mellitus","DRUG:Tirzepatide 2.5mg weekly; DRUG:Placebo injection (normal saline)","Victor Chang Cardiac Research Institute","2026-07-07","FALSE","1"],["S001049","ClinicalTrials.gov","NCT06201819",null,"Liraglutide Effectiveness in Preoperative Weight-loss for Patients With Severe Obesity Undergoing Bariatric-metabolic Surgery.","INTERVENTIONAL",null,"PHASE4","COMPLETED","37","Weight Loss; Bariatric Surgery Candidate; Obesity, Morbid","DRUG:Liraglutide injection","Hospital Civil Juan I. Menchaca","2022-12-18","FALSE","0"],["S001050","ClinicalTrials.gov","NCT02496611",null,"Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","100","Severe Obesity","DRUG:Weight loss with pharmacotherapy; DRUG:Weight loss without pharmacotherapy","University of Minnesota","2015-12","TRUE","2"],["S001051","ClinicalTrials.gov","NCT04007107",null,"A Trial to Compare the Injection Site Pain Experience of 0.25 mg Semaglutide sc Administered by 2 Different Products","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","103","Healthy Volunteers Diabetes Mellitus, Type 2; Healthy Volunteers Overweight; Healthy Volunteers Obesity","DRUG:Semaglutide (administered by DV3396 pen); DRUG:Semaglutide (administered by PDS290 pen)","Novo Nordisk A/S","2019-06-27","TRUE","1"],["S001052","ClinicalTrials.gov","NCT07787936","GLIDE-HF","GLIDE-HF Registry: A Prospective, Single-Center, Observational Cohort of Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction, With GLP-1/GIP Receptor Agonist Therapy as an Observed Exposure and Serial Exercise Echocardiographic Phenotyping","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","150","Heart Failure With Preserved Ejection Fraction; Obesity; Diastolic Heart Failure; Pulmonary Hypertension; Iron Deficiency","DRUG:GLP-1 / GIP receptor agonist","Miedziowe Centrum Zdrowia SA","2027-01-01","FALSE","0"],["S001053","ClinicalTrials.gov","NCT01455922",null,"A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Type 2 Diabetes","DRUG:ITCA 650; DRUG:glimepiride","Intarcia Therapeutics","2013-02","FALSE","0"],["S001054","ClinicalTrials.gov","NCT05668936",null,"A Thorough QTc Evaluation of the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants: A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel Study With a Nested Crossover Design for Positive Control With Moxifloxacin Administration","INTERVENTIONAL","RANDOMIZED","PHASE1","TERMINATED","31","Non-alcoholic Steatohepatitis","DRUG:Cotadutide; DRUG:Cotadutide-placebo; DRUG:Moxifloxacin; DRUG:Moxifloxacin-placebo","AstraZeneca","2023-01-03","FALSE","0"],["S001055","ClinicalTrials.gov","NCT05963022",null,"A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Tirzepatide Monotherapy Compared With Placebo in Chinese Participants With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","206","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-08-21","TRUE","1"],["S001056","ClinicalTrials.gov","NCT04305002",null,"Effect of Exenatide on Disease Progression in Early Parkinson's Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","60","Parkinson Disease","DRUG:Exenatide; DRUG:Placebo","Center for Neurology, Stockholm","2020-01-21","FALSE","0"],["S001057","ClinicalTrials.gov","NCT03841630",null,"A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3437943 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","45","Healthy","DRUG:LY3437943; DRUG:Placebo","Eli Lilly and Company","2019-03-13","FALSE","0"],["S001058","ClinicalTrials.gov","NCT00894322",null,"A Two-Cohort, Single- and Repeat Dose Study to Examine the Pharmacokinetics, Tolerability, and Safety of Ready to Use Exenatide Once Weekly in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","65","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; OTHER:Placebo","AstraZeneca","2009-04","TRUE","0"],["S001059","ClinicalTrials.gov","NCT07605572","GALENOS","Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity","OBSERVATIONAL",null,null,"RECRUITING","100","Dry Eye Disease (DED); Diabete Mellitus; GLP-1; Ocular Surface; Diabetes Type 2; Cornea",null,"Attikon Hospital","2026-03-01","FALSE","0"],["S001060","ClinicalTrials.gov","NCT02104739",null,"Comparative Effects of Antidiabetic Medications on Postprandial Hyperlipidemia, Free Fatty Acid Signaling, and Endothelial Dysfunction in Individuals With Prediabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","21","Prediabetes; Obesity","DRUG:Exenatide; DRUG:Saxagliptin; DRUG:Exenatide extended-release (ER); OTHER:Placebo","The University of Texas Health Science Center, Houston","2014-04","TRUE","1"],["S001061","ClinicalTrials.gov","NCT07483801","DECODE","DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","112","Cardiovascular Diseases","DRUG:semaglutide; DRUG:Tirzepatide","Cambridge University Hospitals NHS Foundation Trust","2026-03","FALSE","0"],["S001062","ClinicalTrials.gov","NCT07303556","ICDDTKZ26","Improving the Diagnosis and Treatment of Cardiovascular Diseases in Kazakhstan by Introducing Correction of Metabolism With Glucagon-like Peptide 1 (GLP-1) Drugs","INTERVENTIONAL","NON_RANDOMIZED",null,"ACTIVE_NOT_RECRUITING","120","Heart Failure; Diabete Type 2; Arterial Hypertension","DRUG:Tirzepatide (Mounjaro); DRUG:dapagliflozin, empagliflozin, metformin","Nazarbayev University","2024-12-18","FALSE","0"],["S001063","ClinicalTrials.gov","NCT04617275",null,"A 12-WEEK, PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN AND IN NON-DIABETIC ADULTS WITH OBESITY","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","151","Diabetes; Obesity","DRUG:PF-06882961; OTHER:Placebo","Pfizer","2021-01-06","TRUE","1"],["S001064","ClinicalTrials.gov","NCT01644500","AWARD-CHN1","The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","737","Type 2 Diabetes Mellitus","DRUG:Dulaglutide; DRUG:Glimepiride; DRUG:Placebo as Capsules; DRUG:Placebo as SC Injection","Eli Lilly and Company","2012-07","TRUE","9"],["S001065","ClinicalTrials.gov","NCT00154401",null,"Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","177","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2005-01","FALSE","5"],["S001066","ClinicalTrials.gov","NCT06217848",null,"The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study","INTERVENTIONAL",null,"EARLY_PHASE1","UNKNOWN","50","Panhypopituitarism; Craniopharyngioma; Hypothalamic Obesity","DRUG:Saxenda","Seoul National University Hospital","2022-11-28","FALSE","0"],["S001067","ClinicalTrials.gov","NCT03500484",null,"Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.","INTERVENTIONAL","RANDOMIZED","EARLY_PHASE1","TERMINATED","13","Obesity, Childhood; Neural Development","DRUG:Liraglutide","Yale University","2018-06-06","TRUE","0"],["S001068","ClinicalTrials.gov","NCT01769378","AWARD-8","A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","300","Type 2 Diabetes Mellitus","DRUG:Placebo; DRUG:Dulaglutide; DRUG:Glimepiride","Eli Lilly and Company","2013-01","TRUE","1"],["S001069","ClinicalTrials.gov","NCT06864026",null,"A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.","INTERVENTIONAL",null,"PHASE4","ACTIVE_NOT_RECRUITING","200","Psoriatic Arthritis; Overweight or Obesity","DRUG:Tirzepatide","Eli Lilly and Company","2025-03-06","FALSE","1"],["S001070","ClinicalTrials.gov","NCT04513704",null,"Oral Semaglutide Pharmacokinetics in Healthy Subjects, Effect of Dosing Schedules","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","156","Healthy Volunteers Type 2 Diabetes","DRUG:Oral Semaglutide","Novo Nordisk A/S","2020-08-28","FALSE","1"],["S001071","ClinicalTrials.gov","NCT07717814",null,"A Phase 1, Randomized, Open-label, Single-dose, Parallel Group Study to Assess the Relative Bioavailability of AMG 133 Administered Using One of Three Drug Products in Participants Living With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","154","Overweight and Obesity","DRUG:AMG 133 (frozen liquid); DRUG:AMG 133 (liquid)","Amgen","2024-11-26","FALSE","0"],["S001072","ClinicalTrials.gov","NCT03353948",null,"The Effect of Liraglutide on Pregnancy Rates in Obese Women With PCOS Undergoing in Vitro Fertilization: a Pilot Randomized Study","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","30","Polycystic Ovary Syndrome; Obesity; Infertility, Female","DRUG:MET; DRUG:COMBI","University Medical Centre Ljubljana","2014-09-01","FALSE","1"],["S001073","ClinicalTrials.gov","NCT07058155","OPTIMAL","OPTIMAL Trial: Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","70","Liver Cirrhoses; Portal Hypertension Related to Cirrhosis; Severe Obesity; TIPS","PROCEDURE:Transjugular Intrahepatic Portosystemic Shunt (TIPS); PROCEDURE:Sleeve Gastrectomy; DRUG:Anti-Obesity Pharmacotherapy (Class Effect); BEHAVIORAL:Lifestyle Counseling - Diet & Physical-Activity Program","The Cleveland Clinic","2025-12-17","FALSE","0"],["S001074","ClinicalTrials.gov","NCT02465515",null,"A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","9463","Diabetes Mellitus","BIOLOGICAL:Albiglutide 30 mg; BIOLOGICAL:Albiglutide 50 mg; BIOLOGICAL:Albiglutide matching placebo","GlaxoSmithKline","2015-07-01","TRUE","7"],["S001075","ClinicalTrials.gov","NCT01733758",null,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","494","Diabetes Mellitus, Type 2","DRUG:Albiglutide 30 mg weekly; DRUG:Albiglutide 50 mg weekly; DRUG:Placebo; DRUG:Liraglutide 0.9 mg daily","GlaxoSmithKline","2013-02","TRUE","0"],["S001076","ClinicalTrials.gov","NCT06801015",null,"A Randomized, Placebo-Controlled Trial of the Effects of Long-Acting GLP-1 or Dual Incretin (GLP-1 and GIP) Modulation on Gastric Motor Functions","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","30","Obesity","DRUG:Semaglutide; DRUG:Tirzepatide; DRUG:Placebo","Mayo Clinic","2025-10-01","FALSE","0"],["S001077","ClinicalTrials.gov","NCT04184622","SURMOUNT-1","Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","2539","Overweight; Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2019-12-04","TRUE","26"],["S001078","ClinicalTrials.gov","NCT06482112",null,"A Phase 2a Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Different Dosing Regimens of Efinopegdutide (MK-6024) in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","124","Metabolic Dysfunction-Associated Steatotic Liver Disease; Non-alcoholic Fatty Liver Disease; Nonalcoholic Fatty Liver Disease; Liver Disease","DRUG:Efinopegdutide","Merck Sharp & Dohme LLC","2024-07-29","TRUE","0"],["S001079","ClinicalTrials.gov","NCT02750930",null,"An Open-label Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE4","TERMINATED","8","Diabetes Mellitus, Type 2","DRUG:Albiglutide; DEVICE:Auto-injector","GlaxoSmithKline","2016-10-07","TRUE","0"],["S001080","ClinicalTrials.gov","NCT00044694",null,"A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Short-Term, Dose-Response Study to Examine the Effect on Glucose Control and Safety and Tolerability of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","156","Diabetes Mellitus, Non-Insulin-Dependent","DRUG:Placebo 0.01 mL; DRUG:Placebo 0.02 mL; DRUG:Placebo 0.03 mL; DRUG:Placebo 0.04 mL; DRUG:AC2993 2.5 mcg; DRUG:AC2993 5.0 mcg; DRUG:AC2993 7.5 mcg; DRUG:AC2993 10.0 mcg","AstraZeneca","2002-08","FALSE","1"],["S001081","ClinicalTrials.gov","NCT04763564",null,"Efficacy of Liraglutide Therapy in Patients With an Ileal -Pouch Anal Anastomosis (IPAA) and Chronic High Bowel Frequency","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","8","Pouchitis; Irritable Pouch Syndrome","DRUG:Liraglutide Pen Injector; DRUG:Placebo Pen Injector","University of North Carolina, Chapel Hill","2022-03-22","TRUE","1"],["S001082","ClinicalTrials.gov","NCT04524832",null,"A Randomised Trial Investigating Steady State Semaglutide Exposure of 25 and 50 mg of Oral Semaglutide in Different Formulations in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","290","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2020-09-29","FALSE","0"],["S001083","ClinicalTrials.gov","NCT01596504",null,"An Open-label, Randomized, Three-parallel-group Study on Pharmacodynamic Effects of 8-week QD Treatment With Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","142","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Liraglutide; DRUG:Insulin Glargine; DRUG:Metformin","Sanofi","2012-05","TRUE","1"],["S001084","ClinicalTrials.gov","NCT07573163",null,"A Randomized Clinical Trial of Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","34","Mild Autonomous Cortisol Secretion (MACS); Adrenalectomy; Status","DRUG:Tirzepatide; OTHER:Standard medical treatment","Alaa Sada","2026-07-27","FALSE","2"],["S001085","ClinicalTrials.gov","NCT07668414","AMAZE 7","Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","650","Overweight; Obesity","DRUG:Zenagamtide; DRUG:Semaglutide; DRUG:Placebo (matched to semaglutide); DRUG:Placebo (matched to zenagamtide)","Novo Nordisk A/S","2026-09-22","FALSE","0"],["S001086","ClinicalTrials.gov","NCT05024032","SURMOUNT-CN","Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","210","Obesity; Overweight; Metabolism and Nutrition Disorder","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2021-09-01","TRUE","4"],["S001087","ClinicalTrials.gov","NCT06410352",null,"Effectiveness of Pharmacologic, Surgical, and Dietetic Weight Loss Methods on Lifespan in Patients With Metabolic Syndrome: a Comparative Clinical Trial","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","RECRUITING","220","Metabolic Syndrome","DRUG:Semaglutide, Empagliflozin; PROCEDURE:Minigastric bypass; DIETARY_SUPPLEMENT:Analimentary detoxication; BEHAVIORAL:Ramadan fast's weight loss","University Medical Center, Kazakhstan","2024-03-01","FALSE","0"],["S001088","ClinicalTrials.gov","NCT06703021","ACCESS II","A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, and Efficacy of Increasing Optimal Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity (ACCESS II)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","85","Obesity; Overweight; Chronic Weight Management","DRUG:aleniglipron or placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2024-12-20","FALSE","0"],["S001089","ClinicalTrials.gov","NCT05813925",null,"Efficacy and Safety of Cagrilintide S.C. 2.4 mg in Combination With Semaglutide S.C. 2.4 mg (CagriSema S.C. 2.4 mg/2.4 mg) Once-Weekly in East Asian Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","331","Obesity or Overweight","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo Semaglutide","Novo Nordisk A/S","2023-04-03","FALSE","1"],["S001090","ClinicalTrials.gov","NCT05803421","ACHIEVE-4","A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","2749","Type 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidney Disease","DRUG:Orforglipron; DRUG:Insulin Glargine","Eli Lilly and Company","2023-04-03","FALSE","1"],["S001091","ClinicalTrials.gov","NCT07307235",null,"Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents-a Pragmatic Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","1316","Type 2 Diabetes","DRUG:iGlarLixi (insulin glargine/lixisenatide); DRUG:standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)","Shanghai Zhongshan Hospital","2025-12-13","FALSE","0"],["S001092","ClinicalTrials.gov","NCT00496860",null,"Phase I Study of ALT-801 in Patients With Progressive Metastatic Malignancies","INTERVENTIONAL",null,"PHASE1","COMPLETED","26","Progressive Metastatic Malignancies","BIOLOGICAL:ALT-801","Altor BioScience","2007-05","TRUE","1"],["S001093","ClinicalTrials.gov","NCT03297879",null,"Beijing Chao-Yang Hospital, Capital Medical University","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","COMPLETED","230","Type2 Diabetes","DRUG:Exenatide or metformin hydrochloride","Beijing Chao Yang Hospital","2013-01-01","FALSE","2"],["S001094","ClinicalTrials.gov","NCT00294723","LEAD-3","Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","746","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:glimepiride; DRUG:placebo","Novo Nordisk A/S","2006-02","TRUE","19"],["S001095","ClinicalTrials.gov","NCT03520062","LIRAP","The Effect of Liraglutide on Pancreatic Hormones and Its Size","INTERVENTIONAL",null,null,"COMPLETED","14","Obesity","DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml","Nicolai Jacob Wewer Albrechtsen","2017-08-15","FALSE","0"],["S001096","ClinicalTrials.gov","NCT07009860",null,"RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","121","Alcohol-associated Liver Disease","DRUG:Pemvidutide; OTHER:Placebo","Altimmune, Inc.","2025-06-16","FALSE","0"],["S001097","ClinicalTrials.gov","NCT00359762",null,"Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1029","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:glimepiride","AstraZeneca","2006-09","TRUE","3"],["S001098","ClinicalTrials.gov","NCT00803920",null,"CGM Substudy, Addendum 2, of the Following Exenatide LAR Protocol 2993LAR-105: A Randomized, Open-Label, Multicenter, Comparator Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects With Type 2 Diabetes Mellitus Managed With Diet Modification and Exercise and/or Oral Antidiabetic Medications)","OBSERVATIONAL",null,null,"COMPLETED","8","Type 2 Diabetes Mellitus",null,"HealthPartners Institute","2006-12","FALSE","0"],["S001099","ClinicalTrials.gov","NCT04311424",null,"Disposition of [14C]-Tirzepatide Following Subcutaneous Administration in Healthy Male Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","6","Healthy","DRUG:14C Tirzepatide","Eli Lilly and Company","2020-07-28","TRUE","0"],["S001100","ClinicalTrials.gov","NCT05503927",null,"Wegovy® (Semaglutide) Database Study: A Population-based Cohort Study to Investigate Safety Outcomes of Exposure to Wegovy During Pregnancy","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","2701","Pregnancy; Obesity; Overweight","OTHER:No Intervention","Novo Nordisk A/S","2020-02-01","FALSE","0"],["S001101","ClinicalTrials.gov","NCT01324505",null,"An Open-label, One-sequence Cross-over, Single Centre Trial Investigating the Influence of Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug After Multiple Dose Administration of Semaglutide in Subjects With Type 2 Diabetes","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","43","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo; DRUG:Microgyn®","Novo Nordisk A/S","2011-03","FALSE","0"],["S001102","ClinicalTrials.gov","NCT00736229",null,"Intensive Exenatide Therapy in Hyperglycemic Patients Admitted to the Coronary Intensive Care Unit","INTERVENTIONAL",null,"PHASE4","COMPLETED","40","Hyperglycemia; Acute Coronary Syndromes; Myocardial Infarction","DRUG:Exenatide","Saint Luke's Health System","2008-08","TRUE","2"],["S001103","ClinicalTrials.gov","NCT04228354",null,"A Trial to Demonstrate Bioequivalence Between Semaglutide Drug Product Concentrations 0.68 mg/mL and 1.0 mg/mL","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","28","Healthy Volunteers; Overweight; Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2020-01-29","FALSE","0"],["S001104","ClinicalTrials.gov","NCT05891587","STAR-T","Semaglutide Therapy for Alcohol Reduction - Tulsa","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","80","Alcohol Use Disorder","DRUG:Semaglutide; DRUG:Placebo","Oklahoma State University Center for Health Sciences","2023-07-07","FALSE","0"],["S001105","ClinicalTrials.gov","NCT04666987",null,"A Prospective, Non-interventional, Single Arm Study Investigating Long-term Glycaemic Control in Patients With Type 2 Diabetes Initiating Xultophy® (IDegLira) in a Realworld Setting in Italy","OBSERVATIONAL",null,null,"COMPLETED","359","Diabetes Mellitus, Type 2","DRUG:Insulin degludec and liraglutide (IDegLira)","Novo Nordisk A/S","2020-10-21","FALSE","0"],["S001106","ClinicalTrials.gov","NCT04639414","COMBAT_T2_NASH","Combined Active Treatment in Type 2 Diabetes With NASH","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","192","Type 2 Diabetes; Non-alcoholic Steatohepatitis (NASH); Non-alcoholic Fatty Liver Disease (NAFLD)","DRUG:Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector; DRUG:Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide; DRUG:Placebo matching empagliflozin and placebo pen injector matching semaglutide","German Diabetes Center","2021-03-26","FALSE","1"],["S001107","ClinicalTrials.gov","NCT06254014",null,"A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of JY09 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","270","Type 2 Diabetes Mellitus","DRUG:Exendin-4 Fc fusion protein injection; DRUG:Placebo","Beijing Dongfang Biotech Co., Ltd.","2024-07-10","FALSE","0"],["S001108","ClinicalTrials.gov","NCT03574584",null,"An Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of NNC0165-1562 and Semaglutide in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","37","Metabolism and Nutrition Disorders; Overweight or Obesity","DRUG:NNC0165-1562; DRUG:Semaglutide; DRUG:Placebo (NNC0165-1562)","Novo Nordisk A/S","2018-06-18","FALSE","0"],["S001109","ClinicalTrials.gov","NCT01845259","GREAT","Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? A Randomized, Double-blinded, Placebo-controlled Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","103","Impaired Glucose Tolerance Associated With Drugs","DRUG:Liraglutide; DRUG:Liraglutide Placebo","Psychiatric Centre Rigshospitalet","2013-04","FALSE","3"],["S001110","ClinicalTrials.gov","NCT07559136",null,"A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of HRS9531 Injection in Chinese Adolescents With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","48","Overweight and Obesity","DRUG:HRS9531 injection；Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-06-12","FALSE","0"],["S001111","ClinicalTrials.gov","NCT07176663","Tirzepatide","Safety and Effectiveness of Tirzepatide(Spartina )in Chronic Kidney Failure a Single-center Study","INTERVENTIONAL",null,null,"NOT_YET_RECRUITING","15","Obesity","DRUG:Tirzepatide","Shahid Beheshti University of Medical Sciences","2026-02-01","FALSE","0"],["S001112","ClinicalTrials.gov","NCT03757130",null,"A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 598 in Subjects With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","50","Obesity","DRUG:AMG 598; DRUG:Placebo; DRUG:Liraglutide","Amgen","2018-11-26","TRUE","0"],["S001113","ClinicalTrials.gov","NCT07539584",null,"Adiponectin and Its Role in the Treatment of Patients With Metabolic Disorders","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","130","Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD); Type 2 Diabetes Mellitus (T2DM)","DRUG:SGLT2 inhibitor; DRUG:GLP-1 RA","Moscow Regional Research and Clinical Institute (MONIKI)","2022-03-01","FALSE","0"],["S001114","ClinicalTrials.gov","NCT01501084",null,"Effects of the GLP-1 Exenatide on Intrinsic Brain Activity in Lean and Obese Women","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","34","Obesity","DRUG:Exenatide; DRUG:Normal saline .2cc subcutaneous injection","University of California, Los Angeles","2011-12","FALSE","0"],["S001115","ClinicalTrials.gov","NCT07734792","TOPAZ","Effect of Tirzepatide on Functional Outcomes in Patients With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy: A Multicenter, Randomized, Controlled, Blinded Outcome Assessment Trial","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","NOT_YET_RECRUITING","726","Acute Ischemic Stroke (AIS)","DRUG:Tirzepatide; OTHER:Standard Medical Care (SMC)","yifang zhu","2026-09-20","FALSE","11"],["S001116","ClinicalTrials.gov","NCT05390307","OTID","Obesity Treatment to Improve Diabetes","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","60","Type 1 Diabetes","DRUG:Liraglutide / Semaglutide; DRUG:Dapagliflozin; DRUG:Liraglutide or Semaglutide / Dapagliflozin; DRUG:Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition; OTHER:Usual care","Dasman Diabetes Institute","2023-04-01","FALSE","2"],["S001117","ClinicalTrials.gov","NCT05051566",null,"A Multiple Dose Study in Healthy Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","26","Healthy","DRUG:LY3502970; DRUG:Esomeprazole","Eli Lilly and Company","2021-09-16","TRUE","0"],["S001118","ClinicalTrials.gov","NCT06759701",null,"Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study","INTERVENTIONAL",null,"EARLY_PHASE1","RECRUITING","30","Diabetes; Prostate Cancer","DRUG:Tirzepatide","M.D. Anderson Cancer Center","2025-07-02","FALSE","0"],["S001119","ClinicalTrials.gov","NCT01907854","LIRA-SWITCH™","Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","407","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:sitagliptin; DRUG:placebo","Novo Nordisk A/S","2013-12-02","TRUE","1"],["S001120","ClinicalTrials.gov","NCT07156539",null,"A Study of HS-20094 Versus Dulaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabete","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","546","Type 2 Diabetes","DRUG:HS-20094 Injection; DRUG:Dulaglutide Injection","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2025-09-30","FALSE","0"],["S001121","ClinicalTrials.gov","NCT06050577",null,"The Effect of Oral Semaglutide on Bone Turnover in Patients With Type 2 Diabetes: a Randomized Placebo-controlled Clinical Trial - (SOBER II)","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","64","Type 2 Diabetes; Osteopenia","DRUG:oral Semaglutide/Rybelsus; DRUG:Placebo","Odense University Hospital","2024-06-07","FALSE","0"],["S001122","ClinicalTrials.gov","NCT06260722",null,"A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","1250","Diabetes Mellitus, Type 2","DRUG:Retatrutide; DRUG:Semaglutide","Eli Lilly and Company","2024-02-21","FALSE","0"],["S001123","ClinicalTrials.gov","NCT03421119",null,"A Phase III, Randomized, Parallel, Double-blind, and Non-inferiority Clinical Trial to Compare Efficacy and Safety of CinnaGen-liraglutide to Innovator Liraglutide Product (Victoza®) in Patients With Type II Diabetes (T2D)","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","300","Diabetes Mellitus, Type 2","DRUG:Liraglutide 6 MG/ML Pen Injector; DRUG:Metformin; DRUG:Sulfonylurea/non-sulfonylurea insulin secretagogues","Cinnagen","2019-06-20","FALSE","6"],["S001124","ClinicalTrials.gov","NCT05444153","PIONEER START","Efficacy and Safety of Early Initiation of Oral Semaglutide 50 mg Once Daily Versus Empagliflozin 25 mg Once Daily in Younger Patients With Newly Diagnosed Type 2 Diabetes and Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Empagliflozin","Novo Nordisk A/S","2022-10-06","FALSE","0"],["S001125","ClinicalTrials.gov","NCT02787551","LixiLan-G","A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","514","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/lixisenatide fixed ratio combination; DRUG:liraglutide; DRUG:exenatide; DRUG:exenatide extended-release; DRUG:albiglutide; DRUG:dulaglutide; DRUG:Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)","Sanofi","2016-07-06","TRUE","9"],["S001126","ClinicalTrials.gov","NCT05530577",null,"Effects of Semaglutide on Nicotine Intake and Smoking Lapse","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","24","Tobacco Use Disorder; Nicotine Addiction","DRUG:Semaglutide; DRUG:Sham/placebo","University of North Carolina, Chapel Hill","2022-10-07","TRUE","1"],["S001127","ClinicalTrials.gov","NCT05360537",null,"Effects of Degludec/Liraglutide on Time in Range, Markers of Inflammation and Endothelial Dysfunction Compared to Scheme Insulin Basal Bolus, in a Population of Diabetic Inpatients and Possible Correlation With Intra-hospital Mortality Rates","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","100","Diabetes Mellitus, Type 2","DRUG:Insulin Degludec / Liraglutide Injectable Product; DRUG:Insulin Glargine","University of Palermo","2021-04-01","FALSE","0"],["S001128","ClinicalTrials.gov","NCT01021527",null,"A Randomized, 4-Period Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","12","Healthy","OTHER:Comparator: Treatment A; DRUG:Comparator: Treatment B; DRUG:Comparator: Treatment C; PROCEDURE:Comparator: graded glucose infusion","Merck Sharp & Dohme LLC","2008-02","FALSE","0"],["S001129","ClinicalTrials.gov","NCT01505673",null,"Adding Liraglutide to High Dose Insulin: Breaking the Cycle","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","71","Type 2 Diabetes Mellitus; Obesity","DRUG:Liraglutide; DRUG:Saline","Ildiko Lingvay","2012-01","TRUE","2"],["S001130","ClinicalTrials.gov","NCT01075282","AWARD-2","A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","810","Diabetes Mellitus, Type 2","DRUG:Insulin Glargine; DRUG:LY2189265; DRUG:Metformin; DRUG:Glimepiride","Eli Lilly and Company","2010-02","TRUE","3"],["S001131","ClinicalTrials.gov","NCT02501161","DUAL™ VIII","A Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1012","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin glargine","Novo Nordisk A/S","2016-01-31","TRUE","3"],["S001132","ClinicalTrials.gov","NCT01181986",null,"Exenatide and Postprandial Endothelial Dysfunction: Effects and Mechanisms","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","76","Type 2 Diabetes Mellitus","DRUG:Exenatide SC; DRUG:Exenatide IV; DRUG:Placebo SC; DRUG:Exendin-9; DRUG:Placebo IV","Carl T. Hayden VA Medical Center","2010-08","TRUE","0"],["S001133","ClinicalTrials.gov","NCT00344851",null,"Comparison of the Effects of Monotherapy With Exenatide or Metformin to Combined Exenatide and Metformin Therapy on Menstrual Cyclicity in Overweight Women With Polycystic Ovary Syndrome","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","60","Polycystic Ovary Syndrome","DRUG:metformin, exenatide or combined (metformin & exenatide )","Metabolic Center of Louisiana Research Foundation","2006-06","FALSE","1"],["S001134","ClinicalTrials.gov","NCT06257966",null,"A Phase 3, Multi-center, Open-label, Randomized Study to Evaluate the Efficacy and Safety of JY09 Versus Dulaglutide in Patients With T2DM Inadequately Controlled by Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","600","Type2 Diabetes Mellitus","DRUG:Exendin-4 Fc fusion protein injection(1.2mg）; DRUG:Exendin-4 Fc fusion protein injection（2.4mg）; DRUG:Dulaglutide; DRUG:Metformin","Beijing Dongfang Biotech Co., Ltd.","2024-07-17","FALSE","0"],["S001135","ClinicalTrials.gov","NCT07357766",null,"A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Overweight; Obesity","DRUG:Cagrisema; DRUG:Placebo CagriSema","Novo Nordisk A/S","2026-06-22","FALSE","0"],["S001136","ClinicalTrials.gov","NCT00849056",null,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","310","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; DRUG:placebo","GlaxoSmithKline","2009-01","TRUE","2"],["S001137","ClinicalTrials.gov","NCT07797101","B-REACH","Efficacy and Safety of Mazdutide Injection for the Treatment of Overweight Patients With Compensated Cirrhosis and Clinically Significant Portal Hypertension","INTERVENTIONAL",null,null,"NOT_YET_RECRUITING","50","Cirrhosis; Portal Hypertension; Fatty Liver Disease; GLP-1","DRUG:Mazdutide injection","The Second Affiliated Hospital of Chongqing Medical University","2026-09-01","FALSE","0"],["S001138","ClinicalTrials.gov","NCT07415954",null,"Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","270","Diabetes Mellitus, Type 2","DRUG:NNC0662-0419; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2026-04-17","FALSE","0"],["S001139","ClinicalTrials.gov","NCT07060456",null,"A Phase III, Multicenter, Randomized, Double Blinded, Parallel-controlled Study Comparing the Efficacy and Safety of HRS9531 Versus Placebo in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin.","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","300","Type 2 Diabetes","DRUG:HRS9531; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-07-25","FALSE","0"],["S001140","ClinicalTrials.gov","NCT07589322","COMPARE-AT","Comparative Adipose Tissue and Cardiometabolic System Remodeling by Tirzepatide and Semaglutide: an AI-integrated Multimodal Metabolomics and Translational Mechanistic Study","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","120","Obesity and Metabolic Syndrome","DRUG:Tirzepatide with lifestyle modification; DRUG:Semaglutide with lifestyle modification","Tri-Service General Hospital (TSGH)","2026-03-31","FALSE","0"],["S001141","ClinicalTrials.gov","NCT06318442",null,"How GLP-1 Analogues Prevent Steroid-Induced Diabetes","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","60","Steroid-Induced Diabetes; Steroid Induced Hyperglycemia","DRUG:Semaglutide Oral Product; DRUG:Metformin Oral Tablet; DRUG:Placebo","Imperial College London","2024-05-15","FALSE","0"],["S001142","ClinicalTrials.gov","NCT05659368",null,"Towards a Personalized Precision Medicine in Rare Disease: Tirzepatide (a Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 Receptor Agonist) Monotherapy in Patients With Wolfram Syndrome Type 1","INTERVENTIONAL",null,"PHASE2","UNKNOWN","10","Wolfram Syndrome","DRUG:Tirzepatide","Ospedale San Raffaele","2024-01-01","FALSE","0"],["S001143","ClinicalTrials.gov","NCT03492697",null,"A Phase 1, Open-label Study In Healthy Subjects To Evaluate The Pharmacokinetics Of Pf-06882961 Following Single Oral Administration Of Immediate Release Tablets And An Immediate Release Oral Solution In The Fed State, And Controlled Release Tablets In The Fed And Fasted States","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","12","Healthy Subjects","DRUG:PF-06882961 Immediate Release Tablet; DRUG:PF-06882961 Controlled Release Tablet (long); DRUG:PF-06882961 Controlled Release Tablet (short); DRUG:PF-06882961 Immediate Release Solution","Pfizer","2018-04-30","FALSE","0"],["S001144","ClinicalTrials.gov","NCT07649759","MBNGT","Mindfulness-Based Nutrition Group Therapy as an Adjunct to GLP-1 Treatment of Obesity","INTERVENTIONAL","RANDOMIZED",null,"ACTIVE_NOT_RECRUITING","40","Obesity & Overweight; Emotional Eating Behaviour; Mindful Eating Intervention","BEHAVIORAL:Mindfulness-based nutritional group therapy (MBNGT)","Bern University of Applied Sciences","2026-02-01","FALSE","0"],["S001145","ClinicalTrials.gov","NCT00976391",null,"A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared With the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","586","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide + insulin glargine; DRUG:insulin glargine + preprandial lispro insulin","GlaxoSmithKline","2009-09","TRUE","1"],["S001146","ClinicalTrials.gov","NCT02449603",null,"Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes : a Randomised Open Parallel-controlled Study","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","150","Type 2 Diabetes Mellitus","DRUG:Exenatide; DRUG:Biphasic insulin Aspart 30","Xijing Hospital","2015-11","FALSE","2"],["S001147","ClinicalTrials.gov","NCT07836140",null,"An Investigator-Initiated, Randomized, Open-Label, Active-Controlled Study Comparing the Effects of BGM0504 Injection Versus Semaglutide Injection on Insulin Sensitivity and Body Weight in Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","60","Obesity / Overweight","DRUG:semaglutide; DRUG:BGM0504 Administered SC","Second Affiliated Hospital of Soochow University","2024-04-22","FALSE","0"],["S001148","ClinicalTrials.gov","NCT01232946",null,"Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","30","Type 2 Diabetes","DRUG:liraglutide; DRUG:insulin detemir; DRUG:liraglutide plus insulin detemir","Indiana University","2012-01","TRUE","1"],["S001149","ClinicalTrials.gov","NCT00873223",null,"Insulin Detemir Co-administered With Liraglutide: An Open Label Trial to Assess Insulin Detemir and Liraglutide Pharmacokinetics and Pharmacodynamics Following Liraglutide Therapy in Subjects With Type 2 Diabetes","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","33","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:insulin detemir","Novo Nordisk A/S","2009-03","FALSE","1"],["S001150","ClinicalTrials.gov","NCT02718950","i-LAB","Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans","INTERVENTIONAL",null,"PHASE3","UNKNOWN","20","Obesity; Type 2 Diabetes Mellitus","DRUG:Liraglutide 3.0 mg","University of Campinas, Brazil","2016-06","FALSE","0"],["S001151","ClinicalTrials.gov","NCT04862923","PIONEER REAL","A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in the United Kingdom","OBSERVATIONAL",null,null,"COMPLETED","336","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2021-05-12","FALSE","2"],["S001152","ClinicalTrials.gov","NCT06634927",null,"A Randomized, Open-label, Single-dose, Parallel-controlled Phase I Clinical Trial Comparing the Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","68","Type 2 Diabetes","DRUG:Ozempic®; DRUG:HDG1901","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-09-22","FALSE","0"],["S001153","ClinicalTrials.gov","NCT02849080","PIONEER 7","Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","504","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:sitagliptin","Novo Nordisk A/S","2016-09-20","TRUE","10"],["S001154","ClinicalTrials.gov","NCT05567796","REDEFINE 1","Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","3400","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2022-11-01","FALSE","3"],["S001155","ClinicalTrials.gov","NCT04046822",null,"Could Gut Microbiome Contribute to the Therapeutic Effect of Liraglutide 3.0 mg? A Randomized Double Blind Placebo Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","70","Obesity; Weight Loss; Microbiome","DRUG:Liraglutide 6 MG/ML [Saxenda]; DRUG:Placebo","Federico II University","2019-01-09","FALSE","1"],["S001156","ClinicalTrials.gov","NCT04232969","Exenatide-PD3","A Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","194","Parkinson's Disease","DRUG:Exenatide extended release 2mg (Bydureon)","University College, London","2020-01-20","FALSE","4"],["S001157","ClinicalTrials.gov","NCT01652729","DURATION-NEO-2","A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","365","Diabetes Type 2","DRUG:Exenatide once weekly suspension; DRUG:Sitagliptin; DRUG:Placebo","AstraZeneca","2013-02","TRUE","2"],["S001158","ClinicalTrials.gov","NCT05649137",null,"Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity and Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","512","Obesity; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2023-01-04","TRUE","3"],["S001159","ClinicalTrials.gov","NCT01928329",null,"A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","79","Type I Diabetes","DRUG:Exenatide (Bydureon®); DRUG:Placebo","Yale University","2013-09","TRUE","0"],["S001160","ClinicalTrials.gov","NCT07581145","SEMAFOOT2","The SEMAFOOT2 Pilot Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","52","Foot Ulcer Due to Type 2 Diabetes Mellitus","DRUG:Semaglutide, 1.34 mg/mL; DRUG:Placebo","Ole Lander Svendsen","2026-04-24","FALSE","0"],["S001161","ClinicalTrials.gov","NCT05514535",null,"Efficacy and Safety of Once-weekly Semaglutide S.C. 2.0 mg as Add-on to Dose-reduced Insulin Glargine vs Titrated Insulin Glargine in Participants With Type 2 Diabetes and Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","573","Diabetes Mellitus, Type 2; Obesity","DRUG:Semaglutide; DRUG:Insuline glargine U100 (reduced); DRUG:Insuline glargine U100 (titrated)","Novo Nordisk A/S","2022-08-29","TRUE","0"],["S001162","ClinicalTrials.gov","NCT01572649",null,"A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Placebo","Sanofi","2012-05","FALSE","0"],["S001163","ClinicalTrials.gov","NCT01056549",null,"Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans.","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","15","Hyperlipidemia","DRUG:exenatide","University Health Network, Toronto","2010-01","FALSE","1"],["S001164","ClinicalTrials.gov","NCT05437848","COTA China PK","A Phase 1 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Cotadutide in Chinese Overweight/Obese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","16","Diabetes","DRUG:Experimental: Cotadutide; OTHER:Placebo","AstraZeneca","2022-02-25","FALSE","0"],["S001165","ClinicalTrials.gov","NCT01695109",null,"The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","16","Healthy Human Male Subjects","DRUG:Liraglutide; DRUG:Placebo","Medical University of Vienna","2010-11","FALSE","0"],["S001166","ClinicalTrials.gov","NCT06639464","SHORE","Semaglutide for the Treatment of Opioid Use Disorder: A Pilot Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","46","Opioid Use Disorder","DRUG:Semaglutide; OTHER:Placebo","Brigham and Women's Hospital","2025-06-02","FALSE","0"],["S001167","ClinicalTrials.gov","NCT07160257",null,"A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","56","Type 2 Diabetes Mellitus","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2025-08-05","FALSE","0"],["S001168","ClinicalTrials.gov","NCT07858331","PIVOT","Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","880","Obesity; Chronic Kidney Disease; Chronic Renal Disease; CKD","DRUG:Semaglutide; BEHAVIORAL:Virtual Weight Management Coaching","Kristin Clemens","2027-01-01","FALSE","0"],["S001169","ClinicalTrials.gov","NCT01147731",null,"An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Albiglutide in Healthy Adult Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","16","Diabetes Mellitus, Type 2","BIOLOGICAL:warfarin plus albiglutide","GlaxoSmithKline","2010-06-04","FALSE","2"],["S001170","ClinicalTrials.gov","NCT07820111",null,"GLP-RA , DIABETIC , NON-DIABETIC , BMI ,TYG-index , HDL-C","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","159","Obese Diabetics; Obese Non Diabetic","DRUG:Dulaglutide 1.5 MG/ML; DRUG:Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution; DRUG:Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician; DRUG:Dulaglutide 0.75mg subcutaneous injection; DRUG:Semaglutide 1.0 mg; DRUG:Tirzepatide (Flexible titration)","Zagazig University","2025-10-18","FALSE","0"],["S001171","ClinicalTrials.gov","NCT04373967",null,"A Phase III,Randomized,Parallel,Open-label,Multicenter Trial to Compare the Efficacy and Safety of Liraglutide and Victoza® in Patients With Type 2 Diabetes Inadequately Controlled by Oral Metformin Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","424","Type 2 Diabetes","DRUG:Victoza®.; DRUG:Metformin Hydrochloride; DRUG:TQZ2451","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","2020-04-29","FALSE","0"],["S001172","ClinicalTrials.gov","NCT06497595","STAY-STRONG","Exercise and Nutritional Intervention to Reduce the Risk of Sarcopenia in Older Adults With Type 2 Diabetes and Obesity Treated With Semaglutide: A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","60","Type 2 Diabetes Mellitus in Obese","BEHAVIORAL:Wegovy (2.4 Mg Dose) + exercise & nutrition; OTHER:Wegovy (2.4 Mg Dose) + usual care","Sheba Medical Center","2025-05-11","FALSE","0"],["S001173","ClinicalTrials.gov","NCT00845507",null,"A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults With Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","54","Weight Gain","DRUG:Exenatide; DRUG:Placebo","University of Cincinnati","2008-12","TRUE","1"],["S001174","ClinicalTrials.gov","NCT01511393",null,"Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","6750","Diabetes; Diabetes Mellitus, Type 2; Medullary Thyroid Carcinoma; Weight Management","OTHER:No treatment given","Novo Nordisk A/S","2012-01","FALSE","1"],["S001175","ClinicalTrials.gov","NCT06937203",null,"A Phase 1/2A Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","RECRUITING","150","Obesity; Diabetes Mellitus, Type 2","DRUG:ARO-ALK7; DRUG:Placebo","Arrowhead Pharmaceuticals","2025-05-09","FALSE","0"],["S001176","ClinicalTrials.gov","NCT07128082","LOCITT","The Long COVID Treatment Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","1000","Long COVID","DRUG:Tirzepatide; DRUG:Placebo","Scripps Translational Science Institute","2025-10-30","FALSE","0"],["S001177","ClinicalTrials.gov","NCT07336862","BS-GLP","The Efficacy and Safety of Bariatric Surgery Combined With GLP-1 Receptor Agonists for Patients With Severe Obesity: A Prospective, Multicenter Cohort Study","INTERVENTIONAL","NON_RANDOMIZED","PHASE1; PHASE2","RECRUITING","200","Obesity","COMBINATION_PRODUCT:BS-GLP group; PROCEDURE:BS group","China-Japan Friendship Hospital","2024-01-01","FALSE","0"],["S001178","ClinicalTrials.gov","NCT04478708",null,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 133 in Subjects With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","110","Obesity","BIOLOGICAL:maridebart cafraglutide; DRUG:Placebo","Amgen","2020-08-07","TRUE","1"],["S001179","ClinicalTrials.gov","NCT01006889",null,"A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)","INTERVENTIONAL",null,"PHASE4","COMPLETED","24","Nonalcoholic Fatty Liver Disease; Type 2 Diabetes Mellitus","DRUG:Exenatide","University of Florida","2008-01","TRUE","0"],["S001180","ClinicalTrials.gov","NCT05751720",null,"Effect on Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis in Patients With Type 2 Diabetes Mellitus on Treatment With Gastric Inhibitory Polypeptide / Glucagon Like Peptide-1 Analogue (Tirzpatide)","INTERVENTIONAL",null,"PHASE1; PHASE2","UNKNOWN","30","Non-Alcoholic Fatty Liver Disease; Non-alcoholic Steatohepatitis; Type 2 Diabetes; Liver Fat","DRUG:GIP/GLP-1a","Dr Adnan Agha","2023-10-01","FALSE","0"],["S001181","ClinicalTrials.gov","NCT07293325",null,"Assessing the Role of GLP-1 Receptor Agonist Semaglutide and Dual GLP-I/GIP Receptor Agonist Tirzepatide in Delaying Genetic Aging in Adult Obese Patients Using the iWatchAge Technology","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","66","Adults With Simple Obesity","DRUG:Semaglutide; DRUG:Tirzepatide; DRUG:Metformin","Second Affiliated Hospital, Zhejiang University, School of Medicine","2025-06-02","FALSE","0"],["S001182","ClinicalTrials.gov","NCT07156591",null,"Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention: A Single-Center, Prospective, Observational Study","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","460","Gastric Retention","PROCEDURE:Esophagogastroduodenoscopy","Fudan University","2025-09-15","FALSE","0"],["S001183","ClinicalTrials.gov","NCT04904913",null,"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","328","Overweight/ Obesity","DRUG:IBI362; OTHER:placebo","Innovent Biologics (Suzhou) Co. Ltd.","2021-06-08","FALSE","3"],["S001184","ClinicalTrials.gov","NCT01624259","AWARD-6","A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide With Once-Daily Liraglutide in Patients With Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation of LY2189265 in Diabetes-6)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","599","Type 2 Diabetes","DRUG:LY2189265; DRUG:Liraglutide; DRUG:Metformin","Eli Lilly and Company","2012-06","TRUE","4"],["S001185","ClinicalTrials.gov","NCT01169779","GetGoal-M-Asia","Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (With or Without Sulfonylurea): a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With 24-week Treatment Period","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","391","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector; DRUG:Metformin; DRUG:Sulfonylurea","Sanofi","2010-07","TRUE","2"],["S001186","ClinicalTrials.gov","NCT03928379",null,"A Multiple-Ascending Dose Study in Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Diabetes Mellitus, Type 2","DRUG:LY3305677; DRUG:Placebo","Eli Lilly and Company","2019-10-27","FALSE","1"],["S001187","ClinicalTrials.gov","NCT07668765","GLP-PROCT","Early Proctologic Effects of GLP-1 Receptor Agonist Therapy in Morbidly Obese Patients: A Prospective Cohort Study With Baseline and 3-Month Proctologic Assessment","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","100","Morbid Obesity; Anorectal Diseases; Drug-Related Side Effects and Adverse Reactions; Constipation; Diarrhea","DRUG:GLP-1 receptor agonist therapy","Gazi University","2026-08","FALSE","3"],["S001188","ClinicalTrials.gov","NCT04683237",null,"Megestrol Acetate Versus Liraglutide Plus Megestrol Acetate in Obese Women with Endometrial Atypical Hyperplasia: a Randomized Controlled Pilot Clinical Study","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","WITHDRAWN","0","Atypical Endometrial Hyperplasia; Obese; Fertility Issues","DRUG:Liraglutide Injection; DRUG:Megestrol Acetate 160 MG","Xiaojun Chen","2021-03-20","FALSE","0"],["S001189","ClinicalTrials.gov","NCT03598621",null,"A Trial to Demonstrate Bioequivalence Between Semaglutide Formulations for the DV3372 Device and the Formulation for the PDS290 Semaglutide Pen-injector","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","68","Diabetes Mellitus, Type 2","DRUG:Semaglutide, 0.5 mg/mL; DRUG:Semaglutide, 1.0 mg/mL; DRUG:Semaglutide, 1.34 mg/mL; DRUG:Semaglutide, 2.0 mg/mL; DEVICE:DV3372, 0.5 mg/mL; DEVICE:DV3372, 1.0 mg/mL; DEVICE:PDS290; DEVICE:NovoPen®4","Novo Nordisk A/S","2018-07-23","FALSE","0"],["S001190","ClinicalTrials.gov","NCT07650149","OPTIMIZE-GEN","OPTIMIZE GEN - Outcomes of Persistence and Treatment With tIrzepatide deterMined by Genetic, mIcrobiological & bEhavioral Factors in obEsity","OBSERVATIONAL",null,null,"RECRUITING","200","Obesity & Overweight; Obesity; Genetics","DIAGNOSTIC_TEST:genetic polymorphism; DIAGNOSTIC_TEST:gut microbiome","Jan Kochanowski University","2026-05-23","FALSE","0"],["S001191","ClinicalTrials.gov","NCT03985293",null,"A 16-WEEK, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","412","Diabetes Mellitus, Type 2","DRUG:Placebo; DRUG:PF-06882961","Pfizer","2019-10-15","TRUE","1"],["S001192","ClinicalTrials.gov","NCT06536023",null,"A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of IBI362 in Chinese Obese Adolescent Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","36","Adolescents With Obesity","DRUG:IBI362; DRUG:IBI362 placebo","Innovent Biologics (Suzhou) Co. Ltd.","2024-08-30","FALSE","1"],["S001193","ClinicalTrials.gov","NCT00701935",null,"Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","80","Diabetes Mellitus","DRUG:placebo; DRUG:exenatide","AstraZeneca","2008-08","TRUE","0"],["S001194","ClinicalTrials.gov","NCT07610174","SYNCARDIA-HF","A Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group, Phase IIb Proof-of-Concept Clinical Trial of Semaglutide Added to Dapagliflozin Versus Dapagliflozin Monotherapy in Patients With Heart Failure and Previous Surgical Prosthetic Valve Replacement","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","160","Heart Failure; Heart Valve Prosthesis","DRUG:semaglutide; DRUG:Dapagliflozin (10mg Tab)","Kafrelsheikh University","2025-06-02","FALSE","0"],["S001195","ClinicalTrials.gov","NCT01664676",null,"A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","11","Type 2 Diabetes Mellitus","DRUG:Liraglutide; DRUG:Placebo-liraglutide","University of Aarhus","2012-12","FALSE","0"],["S001196","ClinicalTrials.gov","NCT07868835",null,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants Without Type 2 Diabetes Mellitus Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","560","Weight Loss","DRUG:VK2735; DRUG:Placebo comparator","Viking Therapeutics, Inc.","2026-10-15","FALSE","0"],["S001197","ClinicalTrials.gov","NCT01595789","AddHope2","Adding Liraglutide to the Backbone Therapy of Biguanide in Patients With Coronary Artery Disease and Newly Diagnosed Type-2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","41","Coronary Artery Disease; Diabetes Mellitus, Type 2","DRUG:Liraglutide; DRUG:Placebo","Haugaard, Steen Bendix, M.D., DMSc","2012-05","FALSE","6"],["S001198","ClinicalTrials.gov","NCT01191268",null,"The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","884","Diabetes Mellitus, Type 2","DRUG:Insulin Glargine; DRUG:LY2189265; DRUG:Insulin Lispro","Eli Lilly and Company","2010-11","TRUE","5"],["S001199","ClinicalTrials.gov","NCT02058147","LixiLan-O","A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1170","Type 2 Diabetes","DRUG:Insulin glargine/lixisenatide Fixed Ratio Combination; DRUG:Insulin glargine (HOE901); DRUG:Lixisenatide (AVE0010); DRUG:Metformin","Sanofi","2014-02","TRUE","16"],["S001200","ClinicalTrials.gov","NCT06974825",null,"A Randomized, Double-blind, Placebo and Positive Drug Parallel-controlled Phase IIa Clinical Study Protocol to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of Multiple-dose BGM0504 Injection in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","67","Type 2 Diabetes","DRUG:BGM0504 Administered SC; DRUG:Semaglutide Administered SC; DRUG:Placebo Administered SC","BrightGene Bio-Medical Technology Co., Ltd.","2023-08-30","FALSE","0"],["S001201","ClinicalTrials.gov","NCT03341013",null,"A Phase 1, Randomized, Cross-over, Two-period Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382 in Healthy Adult Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Type 2 Diabetes Mellitus","DRUG:MEDI0382 Formulation 2; DRUG:MEDI0382 Formulation 3","MedImmune LLC","2017-11-30","FALSE","0"],["S001202","ClinicalTrials.gov","NCT05016882",null,"Efficacy and Safety Investigation of NNC0194-0499 Co-administered With Semaglutide in Subjects With Non-alcoholic Steatohepatitis: a Dose-ranging, Placebo Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","698","Non-alcoholic Steatohepatitis","DRUG:NNC0194 0499 50 mg/mL; DRUG:Placebo (NNC0194-0499); DRUG:Semaglutide 3 mg/mL; DRUG:Semaglutide placebo; DRUG:NNC0174 0833 10 mg/mL; DRUG:NNC0174 0833 placebo","Novo Nordisk A/S","2021-08-31","FALSE","2"],["S001203","ClinicalTrials.gov","NCT06422624",null,"An Open Label, Single Dose, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Semaglutide Extended-release Injectable Suspension in Normal Healthy, Adult, Human Study Participants Under Fasting Condition","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","UNKNOWN","14","Diabetes Mellitus, Type 2","DRUG:Semaglutide Extended-release for Injectable Suspension, 1 mg; DRUG:Semaglutide Extended-release for Injectable Suspension, 4 mg; DRUG:Semaglutide Extended-release for Injectable Suspension, 8 mg","Bostal Drug Delivery Co., Ltd","2024-08","FALSE","0"],["S001204","ClinicalTrials.gov","NCT00763815","GETGOAL-P","A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Pioglitazone in Patients With Type 2 Diabetes Not Adequately Controlled With Pioglitazone","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","484","Diabetes Mellitus Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector; DRUG:Pioglitazone; DRUG:Metformin","Sanofi","2008-09","TRUE","1"],["S001205","ClinicalTrials.gov","NCT01269008","Closedloop","CLOSED LOOP SYSTEM IN TYPE 1 DIABETES MANAGEMENT COMPARISON WITH PRAMLINTIDE Vs EXENATIDE","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","13","Type 1 Diabetes","DEVICE:Medtronic ePID 2.0","Albert Einstein College of Medicine","2010-12","FALSE","0"],["S001206","ClinicalTrials.gov","NCT02201550",null,"Regulation of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide (Victoza)","OBSERVATIONAL",null,null,"COMPLETED","9","Type 2 Diabetes Mellitus",null,"Hvidovre University Hospital","2013-02","FALSE","0"],["S001207","ClinicalTrials.gov","NCT01724060","FPS","The Effects of Current Treatments of Obesity on Food Preferences, Gut Hormones, Bile Acids and Hepatic Glucose Output in Humans.","OBSERVATIONAL",null,null,"COMPLETED","80","Obesity; Type 2 Diabetes Mellitus",null,"Imperial College London","2012-09","TRUE","0"],["S001208","ClinicalTrials.gov","NCT05933499",null,"Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","63","Obesity","DRUG:Bimagrumab; DRUG:Tirzepatide; DIETARY_SUPPLEMENT:Calcium/Vitamin D; BEHAVIORAL:Lifestyle and nutrition counseling","Massachusetts General Hospital","2025-11-05","FALSE","0"],["S001209","ClinicalTrials.gov","NCT07078838",null,"A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","40","Endometrial Cancer; Endometrial Intraepithelial Neoplasia; Grade 1 Endometrial Endometrioid Carcinoma","DRUG:Tirzepatide","UNC Lineberger Comprehensive Cancer Center","2027-01","FALSE","0"],["S001210","ClinicalTrials.gov","NCT05890976","OASIS 3","Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in Chinese Adults With Overweight or Obesity (OASIS 3)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","200","Overweight; Obesity","DRUG:Semaglutide; DRUG:Semaglutide Placebo","Novo Nordisk A/S","2023-05-30","FALSE","0"],["S001211","ClinicalTrials.gov","NCT01472640",null,"A Randomised, Double-blind, Placebo-controlled Study of the Effect of LIraglutide on Left VEntricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes (The LIVE-study)","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","240","Hyperglycemia; Chronic Heart Failure","DRUG:liraglutide; DRUG:placebo","Flyvbjerg, Allan, DMSc","2011-11","FALSE","2"],["S001212","ClinicalTrials.gov","NCT01300260",null,"The Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose Infusion","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Diabetes Mellitus, Type 2","BIOLOGICAL:LY2189265; DRUG:Placebo; DRUG:Insulin; DRUG:Glucose; DRUG:Glucagon","Eli Lilly and Company","2011-02","TRUE","0"],["S001213","ClinicalTrials.gov","NCT06289504",null,"An Open-label, One-sequence Cross-over, Single-centre Trial, Investigating the Influence of CagriSema on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Atorvastatin in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","34","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Atorvastatin; DRUG:Warfarin","Novo Nordisk A/S","2024-02-27","FALSE","0"],["S001214","ClinicalTrials.gov","NCT02118376",null,"Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status in Female Patients With Type 2 Diabetes and Obesity","INTERVENTIONAL",null,null,"UNKNOWN","20","Obesity","DRUG:Exenatide","Shanghai 10th People's Hospital","2014-08","FALSE","1"],["S001215","ClinicalTrials.gov","NCT01507389",null,"A Single-centre, Open-label Trial Investigating the Pharmacokinetics and the Safety Profile After a Single Dose of Liraglutide in Subjects With Hepatic Impairment and in Subjects With Normal Hepatic Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","24","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2006-03","FALSE","0"],["S001216","ClinicalTrials.gov","NCT04844918","SURMOUNT-J","Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","267","Obesity","DRUG:Tirzepatide; OTHER:Placebo","Eli Lilly and Company","2021-05-10","TRUE","4"],["S001217","ClinicalTrials.gov","NCT02298192","DUAL™ VI","A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","420","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide","Novo Nordisk A/S","2014-11-21","TRUE","1"],["S001218","ClinicalTrials.gov","NCT04865744",null,"The Effect of Semaglutide on Pituitary Function","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","10","Healthy","DRUG:Semaglutide 7 MG Oral Tablet; DRUG:Placebo; DRUG:Semaglutide 14 MG Oral Tablet","University of Tartu","2021-05-19","FALSE","0"],["S001219","ClinicalTrials.gov","NCT02128932","SUSTAIN™ 4","Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1089","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:insulin glargine","Novo Nordisk A/S","2014-08-04","TRUE","12"],["S001220","ClinicalTrials.gov","NCT06256549",null,"A Multicenter, Randomized, Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","272","Type 2 Diabetes","DRUG:GZR18; DRUG:Semaglutide","Gan and Lee Pharmaceuticals, USA","2023-08-09","FALSE","1"],["S001221","ClinicalTrials.gov","NCT02064348",null,"A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects: A Randomised, Double-Blind,Placebo-Controlled, Three-Arm Parallel Trial With a Nested Cross-Over Design for Positive Control With Moxifloxacin Administration","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","168","Diabetes; Healthy","DRUG:semaglutide; DRUG:placebo; DRUG:moxifloxacin","Novo Nordisk A/S","2014-02-26","FALSE","1"],["S001222","ClinicalTrials.gov","NCT00375492",null,"Effect on Weight Loss of Exenatide Versus Placebo in Subjects With Type 2 Diabetes Participating in a Lifestyle Modification Program","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","196","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:placebo","AstraZeneca","2006-09","TRUE","1"],["S001223","ClinicalTrials.gov","NCT01725126",null,"A Double-blind [Sponsor Unblinded], Randomized, Placebo-controlled, Staggered-parallel Study to Investigate the Safety, Tolerability, and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","53","Obesity","DRUG:GSK2890457; DRUG:Metformin; DRUG:Placebo; DRUG:Liraglutide","GlaxoSmithKline","2013-02-10","TRUE","1"],["S001224","ClinicalTrials.gov","NCT00905255","GETGOAL-MONO","A Randomized, Open Label, Parallel-group (One-step Titration and Two-step Titration), Multicenter 52-Week Study Followed by a 24-Week Extension Assessing the Safety and Tolerability of AVE0010 Monotherapy in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","69","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DEVICE:Pen auto-injector","Sanofi","2009-05","TRUE","1"],["S001225","ClinicalTrials.gov","NCT01940965",null,"An Open-Label, Multicenter 52-Week Study Assessing the Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes","INTERVENTIONAL","NON_RANDOMIZED","PHASE3","COMPLETED","294","Type 2 Diabetes Mellitus","DRUG:lixisenatide AVE0010; DRUG:biguanide; DRUG:TZD; DRUG:alpha-GI; DRUG:glinide","Sanofi","2013-09","FALSE","1"],["S001226","ClinicalTrials.gov","NCT07816744","DANWRAP","The Danish Trial of Weight Loss to Reduce Atrial Fibrillation Progression","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","480","Atrial Fibrillation (AF); Obesity & Overweight","OTHER:Structured weight loss program including behavioral support and optional meal re-placement or pharmacotherapy with Glucagon-like peptide-1 receptor agonists (GLP1-RA); OTHER:Standard Care (in control arm)","Axel Brandes","2026-10-01","FALSE","0"],["S001227","ClinicalTrials.gov","NCT06449625","PROTECT","Semaglutide Treatment for PRevention Of Toxicity in High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","40","Intestinal Mucositis; Inflammation; Chemotherapeutic Toxicity","DRUG:Semaglutide Pen Injector [Ozempic]; DRUG:Placebo","Klaus Gottlob Müller","2024-08-12","FALSE","1"],["S001228","ClinicalTrials.gov","NCT05545800",null,"Efficacy and Safety Of Different Hypoglycemic Regimens Compared With Premixed Insulin In Patients With Type 2 Diabetes Receiving Short-term Intensive Insulin Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","78","Type 2 Diabetes Mellitus","DRUG:metformin+empagliflozin+insulin glargine; DRUG:IDegLira; DRUG:premixed insulin analogues","Xiangya Hospital of Central South University","2022-09-01","FALSE","0"],["S001229","ClinicalTrials.gov","NCT07417306",null,"A Multicenter, Randomized, Open-label, Parallel-controlled, Phase 3 Study to Compare the Efficacy and Safety of HDM1005 Versus Mazdutide in Subjects With T2DM Inadequate Glycemic Control by Metformin Monotherapy or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","912","Type 2 Diabetes","DRUG:HDM1005 1; DRUG:HDM1005 2; DRUG:Mazdutide","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-03-27","FALSE","0"],["S001230","ClinicalTrials.gov","NCT04504396",null,"A Multicenter, Randomized, Double-blinded, Placebo-controlled Trial Comparing the Efficacy and Safety of PB-119 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","620","Type 2 Diabetes Mellitus (T2DM)","DRUG:GLP-1 receptor agonist; DRUG:Placebo","PegBio Co., Ltd.","2020-06-23","FALSE","0"],["S001231","ClinicalTrials.gov","NCT07574723","TiTRE","Tirzepatide Titration to Reduce Side Effects (TiTRE) in Individuals With Obesity","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","68","Obesity","DRUG:Tirzepatide (Per-label titration); DRUG:Tirzepatide (Flexible titration)","Dasman Diabetes Institute","2026-05-15","FALSE","0"],["S001232","ClinicalTrials.gov","NCT02560376",null,"68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis","INTERVENTIONAL",null,"EARLY_PHASE1","UNKNOWN","100","Insulinoma; Nesidioblastosis","DRUG:68Ga-NOTA-exendin-4","Peking Union Medical College Hospital","2014-02","FALSE","1"],["S001233","ClinicalTrials.gov","NCT01381926","CMBD","Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist (UAB Core Center for Basic Skeletal Research)","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","14","Type 2 Diabetes Mellitus; Bone Remodeling","DRUG:exenatide; DRUG:Saline","University of Alabama at Birmingham","2011-02","TRUE","0"],["S001234","ClinicalTrials.gov","NCT01847313",null,"Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","20","Diabetic Kidney Disease","DRUG:Liraglutide","Karl Neff","2013-04","TRUE","8"],["S001235","ClinicalTrials.gov","NCT02313220","Dapalost","A 24-week, Single Centre, Randomized, Parallel-group, Double-blind, Placebo Controlled Phase II Study With an Optional 28-week Open-label Extension to Evaluate the Efficacy on Body Weight of Dapagliflozin 10 mg Once Daily in Combination With Exenatide 2 mg Once Weekly in Obese Non-diabetic Subjects.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","50","Obesity","DRUG:Dapagliflozin; DRUG:Exenatide; DRUG:Placebo","Uppsala University","2014-12","FALSE","0"],["S001236","ClinicalTrials.gov","NCT02773368","DUALTM IX","A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","420","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin glargine","Novo Nordisk A/S","2016-05-23","TRUE","1"],["S001237","ClinicalTrials.gov","NCT02501850","EGLIPA","The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","40","Diabetes Mellitus Type 2","DRUG:Liraglutide; DRUG:metformin","Hospital Universitari Vall d'Hebron Research Institute","2014-10","FALSE","0"],["S001238","ClinicalTrials.gov","NCT07071974",null,"Relative Bioavailability of Two BI 456906 Formulations After Subcutaneous Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Trial)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","16","Healthy","COMBINATION_PRODUCT:BI 456906 formulation A; DRUG:BI 456906 formulation B2","Boehringer Ingelheim","2025-07-28","FALSE","0"],["S001239","ClinicalTrials.gov","NCT01588418",null,"Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","15","Impaired Glucose Tolerance (IGT); Diabetes","DRUG:Exenatide; DRUG:Placebo","The University of Texas Health Science Center at San Antonio","2010-07","TRUE","3"],["S001240","ClinicalTrials.gov","NCT06391710",null,"A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","203","Heart Failure With Preserved Ejection Fraction","DRUG:HRS9531; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-05-06","FALSE","0"],["S001241","ClinicalTrials.gov","NCT05035082","REALYSE","REALYSE - Comparative Effectiveness of Once-daily Oral Semaglutide Versus Any Other Oral Glucose-lowering Medication in a Real-world Adult Population With Type 2 Diabetes on Metformin Monotherapy in US Based Health Care Systems - a Pragmatic Randomized Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","1018","Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:oral glucose-lowering medications (commercially available)","Novo Nordisk A/S","2021-09-01","TRUE","0"],["S001242","ClinicalTrials.gov","NCT00734474",null,"A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","1202","Diabetes Mellitus, Type 2","DRUG:LY2189265; DRUG:Sitagliptin; DRUG:Placebo solution; DRUG:Placebo tablet; DRUG:Metformin","Eli Lilly and Company","2008-08","TRUE","7"],["S001243","ClinicalTrials.gov","NCT04535960","NATRIURETIC","Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: \"NATRIURETIC\" Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","36","Type 2 Diabetes Mellitus","DRUG:Empagliflozin 25 MG + Liraglutide 1.8 MG; DRUG:Liraglutide 1.8 MG + Empagliflozin 25 MG","University Health Network, Toronto","2019-01-24","FALSE","0"],["S001244","ClinicalTrials.gov","NCT04083820","SURE FRANCE","A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","521","Diabetes Mellitus, Type 2","DRUG:semaglutide","Novo Nordisk A/S","2019-09-16","FALSE","1"],["S001245","ClinicalTrials.gov","NCT05285397",null,"Liraglutide's Effect on Weight Loss in Patients After Secondary Bariatric Surgery ; a Randomized Double-blind Controlled Study.","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","60","Morbid Obesity","DRUG:Liraglutide Pen Injector [Saxenda]","General Committee of Teaching Hospitals and Institutes, Egypt","2022-03-10","FALSE","1"],["S001246","ClinicalTrials.gov","NCT01870297",null,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3025876 in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","72","Type 2 Diabetes Mellitus","DRUG:LY3025876; DRUG:Placebo; DRUG:Liraglutide","Eli Lilly and Company","2013-06","TRUE","0"],["S001247","ClinicalTrials.gov","NCT02750410",null,"A Phase 4 Study of Efficacy and Safety of Dulaglutide When Added to Insulin Treatment With or Without Oral Antidiabetic Medication in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","159","Type 2 Diabetes","DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2016-08","TRUE","2"],["S001248","ClinicalTrials.gov","NCT05804513",null,"The Effect of Lixisenatide on the Effect of Pituitary Hormones","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","10","Healthy; Type 1 Diabetes","DRUG:Placebo; DRUG:Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector","University of Tartu","2023-04-17","FALSE","0"],["S001249","ClinicalTrials.gov","NCT05829460",null,"Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia","INTERVENTIONAL","RANDOMIZED","PHASE2","WITHDRAWN","0","Endometrial Hyperplasia","DRUG:Semaglutide; DRUG:Placebo; DRUG:LNG-IUD (Progestin); BEHAVIORAL:Telemedicine behavioral weight program","Washington University School of Medicine","2025-03-12","FALSE","0"],["S001250","ClinicalTrials.gov","NCT02423824","COGDYS-GLP1","Exploring the Neural Substrates of Cognitive Dysfunction With Glucagon-like Peptide-1 Agonists","INTERVENTIONAL","NON_RANDOMIZED","PHASE3","COMPLETED","21","Bipolar Disorder; Major Depressive Disorder","BIOLOGICAL:Liraglutide","University Health Network, Toronto","2015-05","FALSE","0"],["S001251","ClinicalTrials.gov","NCT01089569",null,"Evaluation of Insulin Glargine and Exenatide: A Randomized Clinical Trial With Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","60","Type 2 Diabetes","DRUG:Exenatide; DRUG:Insulin Glargine","HealthPartners Institute","2010-04","TRUE","1"],["S001252","ClinicalTrials.gov","NCT06797869",null,"Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","142","Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy","DRUG:CagriSema (Cagrilintide B and Semaglutide I); DRUG:Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)","Novo Nordisk A/S","2025-01-29","FALSE","0"],["S001253","ClinicalTrials.gov","NCT01117350","EAGLE","A 24-week, Multicenter, International, Randomized (1:1), Parallel-group, Open-label, Comparative Study of Insulin Glargine Versus Liraglutide in Insulin-naïve Patients With Type 2 Diabetes Treated With Oral Agents and Not Adequately Controlled, Followed by a 24-week Extension Period With Insulin Glargine for Patients Not Adequately Controlled With Liraglutide","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","978","Diabetes Mellitus, Type 2","DRUG:Insulin glargine; DRUG:Liraglutide; DRUG:Metformin","Sanofi","2010-07","TRUE","0"],["S001254","ClinicalTrials.gov","NCT05996874",null,"Investigation of the Effect of Dosing Conditions on the Pharmacokinetics of New Oral Semaglutide Formulation in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","121","Healthy Participants","DRUG:Semaglutide","Novo Nordisk A/S","2023-08-12","FALSE","0"],["S001255","ClinicalTrials.gov","NCT07502508",null,"Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants With Type 2 Diabetes Not Achieving Glycemic Targets Despite GLP-1-Based Therapy","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","60","Type 2 Diabetes","DRUG:icovamenib 100 mg; DRUG:Placebo","Biomea Fusion Inc.","2026-04-30","FALSE","0"],["S001256","ClinicalTrials.gov","NCT07282613","REIMAGINEYOUNG","Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","80","Diabetes Mellitus, Type 2","DRUG:CagriSema (Cagrilintide B and Semaglutide I); DRUG:Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)","Novo Nordisk A/S","2026-08-04","FALSE","0"],["S001257","ClinicalTrials.gov","NCT01722240","1966","Liraglutide in Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","69","Type 1 Diabetes","DRUG:Liraglutide 1.8mg; DRUG:Placebo","University at Buffalo","2012-11-01","TRUE","0"],["S001258","ClinicalTrials.gov","NCT07275697","WAIT","Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","200","Atrial Fibrillation (AF); Obesity & Overweight","DRUG:Semaglutide 2.4 mg; BEHAVIORAL:Standard medical treatment","Emma Svennberg","2026-03-23","FALSE","0"],["S001259","ClinicalTrials.gov","NCT02960659",null,"Therapeutic Targets in African-American Youth With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","24","Type 2 Diabetes","DRUG:Liraglutide; DRUG:Metformin","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","2017-05-09","TRUE","1"],["S001260","ClinicalTrials.gov","NCT05870462","SEMA-VR","Semaglutide and Vascular Regeneration in People With Diabetes and/or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","100","Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Obesity","DRUG:Semaglutide Pen Injector","Canadian Medical and Surgical Knowledge Translation Research Group","2023-04-29","FALSE","4"],["S001261","ClinicalTrials.gov","NCT02417103",null,"Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","2","Obesity","DRUG:GLP-1 (Liraglutide); DRUG:Placebo","Universitätsklinikum Hamburg-Eppendorf","2011-12","FALSE","0"],["S001262","ClinicalTrials.gov","NCT05630586","ASSET","The Safety and Efficacy of Acute Subcutaneous Administration of Semaglutide in Non-diabetic Patients With Acute Ischemic Stroke: A Multicentre, Phase 2, Prospective, Randomized, Open-label, Blinded Endpoint Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","380","Acute Ischemic Stroke","DRUG:Semaglutide; OTHER:Standard care","Aarhus University Hospital","2023-04-12","FALSE","0"],["S001263","ClinicalTrials.gov","NCT07092605",null,"Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures: For Use in Healthy Individuals Ages 18-65 Who Seek to Improve Their Health and Longevity Through Low-dose (Microdosed) GLP1 Receptor Agonists","INTERVENTIONAL","RANDOMIZED","EARLY_PHASE1","ENROLLING_BY_INVITATION","150","Longevity; Quality of Life; Mood; Inflammation; Immune Health; Pain Management; Weight Management; Alertness","DRUG:GLP-1; DRUG:Placebo","AgelessRx","2024-11-01","FALSE","3"],["S001264","ClinicalTrials.gov","NCT02650479",null,"Two-Part, Randomized, Placebo and Active-Controlled, Double-Blind, Thorough QT Study Evaluating the Effects of Intravenous Exenatide on Cardiac Repolarization in Healthy Male and Female Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","82","Healthy Adult Male and Female Volunteers","DRUG:Exenatide; DRUG:Placebo; DRUG:Moxifloxacin; DRUG:Palonosetron","Intarcia Therapeutics","2016-01","FALSE","0"],["S001265","ClinicalTrials.gov","NCT06720246","Balance","Effects of Bariatric Surgery and Pharmacological Therapy with Liraglutide on Motivational and Inhibitory Processes: Cognitive-Behavioral Markers of Long-Term Weight Loss. a Study on Patients with Obesity.","OBSERVATIONAL",null,null,"RECRUITING","50","Obesity and Overweight",null,"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","2024-06-26","FALSE","0"],["S001266","ClinicalTrials.gov","NCT01098461",null,"A Dose Finding Study of GSK716155 Versus Placebo in the Treatment of Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","215","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; BIOLOGICAL:placebo","GlaxoSmithKline","2010-04","TRUE","3"],["S001267","ClinicalTrials.gov","NCT00085969",null,"A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","99","Diabetes Mellitus, Type 2","DRUG:Placebo 0.04 mL twice daily; DRUG:Placebo 0.04 mL once daily; DRUG:Placebo 0.08 mL once daily; DRUG:B - Exenatide 10 mcg twice daily; DRUG:C - Exenatide 10 mcg once daily; DRUG:Exenatide 20 mcg once daily","AstraZeneca","2003-09","FALSE","1"],["S001268","ClinicalTrials.gov","NCT07728669","NutriSteppe","Efficacy of a Digital Dietary Intervention (NutriSteppe Application) in Improving Metabolic Parameters in Adults With Type 2 Diabetes Mellitus, Obesity or Overweight With Comorbidities Who Are Receiving GLP-1 Receptor Agonist Therapy and Other Medications Prescribed Under Routine Clinical Protocols","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","120","Type 2 Diabetes Mellitus (T2DM); Obesity (Disorder); Overweight; Metabolic Syndrome","BEHAVIORAL:NutriSteppe Digital Dietary Intervention","Kazakh Academy of Nutrition","2026-07-20","FALSE","0"],["S001269","ClinicalTrials.gov","NCT06221969",null,"Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1024","Type 2 Diabetes","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Tirzepatide","Novo Nordisk A/S","2024-01-16","FALSE","0"],["S001270","ClinicalTrials.gov","NCT06120556",null,"Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes: an Italian Monocentric Retrospective Study","OBSERVATIONAL",null,null,"COMPLETED","130","Diabetes Mellitus, Type 2","DRUG:GLP-1 receptor agonist","Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari","2023-06-10","FALSE","0"],["S001271","ClinicalTrials.gov","NCT07271251",null,"A Study Investigating Clinical Comparability of Two Formulations of Oral Semaglutide in Japanese Participants With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","267","Type 2 Diabetes","DRUG:Oral semaglutide","Novo Nordisk A/S","2025-12-01","FALSE","0"],["S001272","ClinicalTrials.gov","NCT03645408",null,"The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers","INTERVENTIONAL","RANDOMIZED","PHASE1","TERMINATED","8","Alcohol Use Disorder","DRUG:Exenatide; OTHER:Sham injection","Boston Medical Center","2019-05-02","TRUE","0"],["S001273","ClinicalTrials.gov","NCT06215196","ESSENCE","Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","81","Overweight and Obesity","DIETARY_SUPPLEMENT:Fiber Supplement Group; OTHER:placebo","S.LAB (SOLOWAYS)","2023-04-14","FALSE","0"],["S001274","ClinicalTrials.gov","NCT07743983",null,"A Randomized, Open-Label, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety, and Diabetes Remission of BGM0504 Injection Compared With Semaglutide Injection in Early-Stage Chinese Type 2 Diabetes Mellitus Patients With Obesity and Inadequate Glycemic and Weight Control Despite Diet and Exercise Intervention（BRIGHT-1）","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","372","Type 2 Diabetes (T2DM)","DRUG:BGM0504; DRUG:semaglutide","BrightGene Bio-Medical Technology Co., Ltd.","2026-09-17","FALSE","0"],["S001275","ClinicalTrials.gov","NCT07755085",null,"Does the Preoperative Use of GLP-1 Agonists Change Outcomes in Patients Waiting for Total Hip and Knee Arthroplasty: A Pilot Randomized Control Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","100","Arthritis; Obesity & Overweight; GLP - 1","DRUG:GLP-1 Receptor Agonists + Behavioral modification; BEHAVIORAL:Behavioral + placebo","Nova Scotia Health Authority","2026-10-01","FALSE","1"],["S001276","ClinicalTrials.gov","NCT01336023","DUAL™ I","A 26 Week Randomised, Parallel Three-arm, Open-label, Multi-centre, Multinational Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide Versus Insulin Degludec or Liraglutide Alone, in Subjects With Type 2 Diabetes Treated With 1-2 Oral Anti-diabetic Drugs (OADs)With a 26 Week Extension","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1663","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin degludec; DRUG:liraglutide","Novo Nordisk A/S","2011-05-23","TRUE","10"],["S001277","ClinicalTrials.gov","NCT06333080","DIACRON","The Effect of Adherence to Oral Semaglutide on Glycaemic Control in People With Type 2 Diabetes Treated With Metformin (DIACRON) - An Open-label Clinical Trial","OBSERVATIONAL",null,null,"TERMINATED","1","Diabetes Mellitus, Type 2",null,"Aalborg University Hospital","2023-11-01","FALSE","2"],["S001278","ClinicalTrials.gov","NCT00781937",null,"Effect of Liraglutide on Long-term Weight Maintenance and Additional Weight Loss Induced by a 4 to 12 Week Low Calorie Diet in Obese Subjects; A 56 Week Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Trial With a 12 Week Follow-up Period","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","422","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2008-10-30","TRUE","8"],["S001279","ClinicalTrials.gov","NCT06659679",null,"Emulation of the Effects of Oral Semaglutide on Cardiovascular Outcomes in Individuals With Type 2 Diabetes: PIONEER6 Trial","OBSERVATIONAL",null,null,"COMPLETED","26126","Diabetes Mellitus, Type 2","DRUG:New use of oral semaglutide; DRUG:New initiation of sitagliptin","Brigham and Women's Hospital","2024-10-24","FALSE","0"],["S001280","ClinicalTrials.gov","NCT06113341",null,"A Multi-centre, Prospective, Single-arm, Non-interventional Study Describing the Use of the Dose Check App in People Living With Type 2 Diabetes Mellitus and Treated With IDegLira in a Real-world Setting in Italy","OBSERVATIONAL",null,null,"WITHDRAWN","0","Diabetes Mellitus, Type 2","DRUG:IDegLira","Novo Nordisk A/S","2024-11-07","FALSE","0"],["S001281","ClinicalTrials.gov","NCT06439056",null,"An Open, Single Ascending Dose, Phase 1 Study to Assess the Pharmacokinetics, Safety, and Tolerability of NEX-22A, a Subcutaneous Prolonged-release Injection, in Male and Female Participants With Type 2 Diabetes","INTERVENTIONAL",null,"PHASE1","COMPLETED","12","Type 2 Diabetes","DRUG:NEX-22A, a prolonged release formulation of liraglutide","Nanexa AB","2024-05-27","FALSE","0"],["S001282","ClinicalTrials.gov","NCT06009653","TRZ","Effect of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE4","WITHDRAWN","0","Obesity; Metabolic Disease","BEHAVIORAL:Standard Care; BEHAVIORAL:Culturally-tailored dietary and behavioral intensive lifestyle intervention; DRUG:Placebo; DRUG:Tirzepatide","Washington University School of Medicine","2023-09-13","FALSE","0"],["S001283","ClinicalTrials.gov","NCT07739537","PATHS-T2D","Polygenic Assessment and Testing of Heterogeneity and Subtypes in Type 2 Diabetes (PATHS-T2D): A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses","INTERVENTIONAL",null,"PHASE4","NOT_YET_RECRUITING","100","Diabete Type 2; Pharmacogenomic Drug Interaction","DRUG:Orforglipron","Massachusetts General Hospital","2026-10-01","FALSE","0"],["S001284","ClinicalTrials.gov","NCT07706088","T-DPN","Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy: A Randomized, Open Label, Controlled Study","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","40","Neuropathy, Small Fiber; Diabete Mellitus","DRUG:Tirzepatide 2.5mg weekly; DRUG:all standard of care to diabetic patient besides tirzepatide","Post Graduate Institute of Medical Education and Research, Chandigarh","2026-07","FALSE","0"],["S001285","ClinicalTrials.gov","NCT02794402","Combat-JUDO","A Parallel, Double-blinded, Randomized, 6 Months, Two Arms Study With Lifestyle Intervention and Bydureon® or Lifestyle Intervention and Placebo in Adolescents With Obesity to Explore Differences With Regard to Change in BMI SDS","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","44","Obesity","DRUG:Exenatide; BEHAVIORAL:Placebo","Uppsala University","2015-09","FALSE","2"],["S001286","ClinicalTrials.gov","NCT05819853","RESTORE","Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome","INTERVENTIONAL","NON_RANDOMIZED","PHASE3","RECRUITING","80","PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries; Obese","DRUG:Semaglutide Injectable Product (Wegovy and/or Ozempic)","University of Colorado, Denver","2023-11-03","FALSE","0"],["S001287","ClinicalTrials.gov","NCT03730662","SURPASS-4","Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","2002","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Insulin Glargine","Eli Lilly and Company","2018-11-20","TRUE","8"],["S001288","ClinicalTrials.gov","NCT04251156","STEP7","Effect and Safety of Semaglutide 2.4 mg Once-weekly on Weight Management in Subjects With Overweight or Obesity.","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","375","Overweight; Obesity; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2020-12-08","TRUE","2"],["S001289","ClinicalTrials.gov","NCT07758231","TAP","Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics","INTERVENTIONAL",null,"PHASE1","NOT_YET_RECRUITING","5","GLP-1; Alcohol","DRUG:Acute Ethanol Dose","University of Wisconsin, Madison","2026-10","FALSE","0"],["S001290","ClinicalTrials.gov","NCT05569772","SERENA","Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes: a Double Blind RCT","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","252","Glucose Intolerance After a Recent History of Gestational Diabetes","DRUG:Semaglutide Pen Injector; DRUG:Semaglutide placebo","Universitaire Ziekenhuizen KU Leuven","2023-09-14","FALSE","1"],["S001291","ClinicalTrials.gov","NCT03619330",null,"Effects of Liraglutide and Testosterone Replacement Therapy on Features of Hypogonadism and Weight Loss in Obese Men With Persistent Features of Hypogonadism.","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","30","Hypogonadism; Obesity","DRUG:liraglutide; DRUG:Testosterone","University Medical Centre Ljubljana","2014-12","FALSE","0"],["S001292","ClinicalTrials.gov","NCT02773381",null,"A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","15","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2016-06-02","FALSE","1"],["S001293","ClinicalTrials.gov","NCT06754163","STEP@STAH","Pilot Study Designed in a Phase IV Clinical Trial Framework: Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients in a Secure Mental Healthcare Setting","INTERVENTIONAL",null,"PHASE4","ACTIVE_NOT_RECRUITING","20","Obesity and Obesity-related Medical Conditions; Psychiatric Disorders","DRUG:Semaglutide in combination with a healthy lifestyle intervention (diet and exercise)","St Andrew's Healthcare","2025-01-01","FALSE","1"],["S001294","ClinicalTrials.gov","NCT05548647","STABLE Wt Loss","Short- and Long-term Effects of Once Weekly Semaglutide 2.4 mg on Appetite, Eating Behavior, and Psychosocial Status","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","120","Obesity","BEHAVIORAL:Behavioral Treatment; DRUG:Placebo; DRUG:Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]","University of Pennsylvania","2022-07-26","TRUE","1"],["S001295","ClinicalTrials.gov","NCT05819138","T1-DISCO","Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","60","Diabetes Mellitus, Type 1","DRUG:Semaglutide Pen Injector; DRUG:Placebo","University of Colorado, Denver","2023-06-21","FALSE","0"],["S001296","ClinicalTrials.gov","NCT04008290","LIRHV","The Effect of Liraglutide on MMC Activity, Gastrointestinal Hormones, Hunger Ratings and ad Libitum Food Intake in Healthy Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","15","Obesity","DRUG:0.6 mg Liraglutide; DRUG:Placebo","Universitaire Ziekenhuizen KU Leuven","2020-04-01","FALSE","0"],["S001297","ClinicalTrials.gov","NCT04190160","XETD2","Unicenter Interventional Study Aimed at Improving the Quality of Life in a Group of Very Old Patients With Type 2 Diabetes With Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)","INTERVENTIONAL",null,null,"COMPLETED","35","Type2 Diabetes","DRUG:IDegLira","Stefano Rizza","2018-11-19","FALSE","0"],["S001298","ClinicalTrials.gov","NCT03889496","GLP1-ex-vivo","Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin","INTERVENTIONAL",null,null,"TERMINATED","12","Diabetes Mellitus","RADIATION:indium-111-exendin SPECT/CT","Radboud University Medical Center","2015-11-16","FALSE","1"],["S001299","ClinicalTrials.gov","NCT07361874","IMPACT-MACS","IMPACT-MACS Study: Investigating the Mechanisms, Pathophysiology, and Cardiometabolic Treatment in Mild Autonomous Cortisol Secretion","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","75","Mild Autonomous Cortisol Secretion (MACS); Autonomous Cortisol Secretion (ACS); Subclinical Cushing's; Mild Autonomous Cortisol Excess","PROCEDURE:Intervention 1: Adrenalectomy; DRUG:Intervention 2: Semaglutide","University of Texas Southwestern Medical Center","2026-03-05","FALSE","0"],["S001300","ClinicalTrials.gov","NCT06937060","SEMPSO","Effect of Semaglutide in Patients With Psoriasis and Obesity","INTERVENTIONAL",null,"PHASE3","RECRUITING","14","Psoriasis (PsO); Obesity and Overweight","BIOLOGICAL:semaglutide","The University of Hong Kong","2025-03-20","FALSE","0"],["S001301","ClinicalTrials.gov","NCT06980623",null,"Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","26000","Type 2 Diabetes; Heart Failure","DRUG:Tirzepatide; DRUG:Semaglutide","Brigham and Women's Hospital","2025-01-01","FALSE","0"],["S001302","ClinicalTrials.gov","NCT06962280","SURPASS-T1D-2","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Tirzepatide Once Weekly Compared to Placebo in Adults With Type 1 Diabetes and Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","465","Type 1 Diabetes; Obesity; Overweight","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2025-05-12","FALSE","0"],["S001303","ClinicalTrials.gov","NCT02321878",null,"Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)","OBSERVATIONAL",null,null,"COMPLETED","1092","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2014-12-15","FALSE","0"],["S001304","ClinicalTrials.gov","NCT04615910","Ver-A-image","A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","30","Diabetes Mellitus","RADIATION:68Ga-NODAGA-exendin-4 PET/CT","Radboud University Medical Center","2021-07-01","FALSE","0"],["S001305","ClinicalTrials.gov","NCT00099320",null,"Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","182","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:Placebo","AstraZeneca","2004-05","FALSE","2"],["S001306","ClinicalTrials.gov","NCT03383068","PCOS","Research of Intensive Metabolic Intervention Before Pregnancy in Polycystic Ovary Syndrome","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","160","PCOS; Impaired Glucose Tolerance","DRUG:Acarbose 100 MG; DRUG:Exenatide; DRUG:Orlistat; DRUG:Metformin","RenJi Hospital","2018-01-01","FALSE","0"],["S001307","ClinicalTrials.gov","NCT07272343",null,"A Study on the Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes Combined With Metabolic-associated Fatty Liver Disease and Its Molecular Mechanisms","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","100","Type 2 Diabetes Mellitus (T2DM); Semaglutide; Caloric Restriction","DRUG:semaglutide; BEHAVIORAL:caloric restriction","Second Affiliated Hospital of Nanchang University","2023-02-10","FALSE","0"],["S001308","ClinicalTrials.gov","NCT00877890",null,"A Randomized, Open-Label, Parallel-Group, Comparator-Controlled, Multicenter Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","254","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:exenatide twice daily","AstraZeneca","2009-03","TRUE","4"],["S001309","ClinicalTrials.gov","NCT06888167","META-BETA","Experimental, Drug-free, Cross-sectional, Single-centre Study to Assess the Association Between Metabotypes of Dietary (Poly)Phenols and Beta-cell Mass and Function.","INTERVENTIONAL","NON_RANDOMIZED",null,"RECRUITING","40","Healthy Volunteer","OTHER:Study setting","Azienda Ospedaliero-Universitaria di Parma","2024-10-14","FALSE","2"],["S001310","ClinicalTrials.gov","NCT06650007",null,"A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase III Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","218","Diabetes Mellitus, Type 2","DRUG:HRS9531 Injection; DRUG:HRS9531 Placebo Injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-11-08","FALSE","0"],["S001311","ClinicalTrials.gov","NCT03061214","SUSTAIN","Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","868","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide 0.5 mg; DRUG:Semaglutide 1.0 mg; DRUG:Sitagliptin placebo; DRUG:Sitagliptin; DRUG:Semaglutide placebo 0.5 mg; DRUG:Semaglutide placebo 1.0 mg","Novo Nordisk A/S","2017-08-28","TRUE","2"],["S001312","ClinicalTrials.gov","NCT07165158",null,"The Effect of Semaglutide on Osteoporotic Fractures in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","150","Osteoporosis; Osteoporosis Fracture; T2DM","DRUG:semaglutide combined with metformin","The First Affiliated Hospital of Xiamen University","2025-09-15","FALSE","0"],["S001313","ClinicalTrials.gov","NCT06161844",null,"A Phase 3, Randomized, Open-label, Parallel-group, Multicenter, Controlled Study to Evaluate Efficacy and Safety of Semaglutide Injection (HD1916) vs. Ozempic® as add-on to Metformin in Patients With Type 2 Diabetics Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","506","Type 2 Diabetes Mellitus","DRUG:semaglutide injection (HD1916); DRUG:Ozempic®","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","2024-02-23","FALSE","0"],["S001314","ClinicalTrials.gov","NCT02611232",null,"Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","42","Type 1 Diabetes","DRUG:Victoza®; DRUG:Placebo","University of Oulu","2015-12","FALSE","1"],["S001315","ClinicalTrials.gov","NCT07497399","TAG-MS","Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis (TAG-MS): A Phase 2, Randomized, Double-Blind, Parallel-Arm Study","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","120","Multiple Sclerosis","DRUG:NLY01; DRUG:Placebo","Johns Hopkins University","2026-04-28","FALSE","0"],["S001316","ClinicalTrials.gov","NCT02492763",null,"A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","176","Type II Diabetes Mellitus","DRUG:MK-8521; DRUG:Placebo; DRUG:Liraglutide; DRUG:Metformin","Merck Sharp & Dohme LLC","2015-07-27","TRUE","0"],["S001317","ClinicalTrials.gov","NCT02674893","GLP1 et Goût","Comparative Study of Gustatory Performance, Sensory Specific Satiation, Liking and Wanting in Patients With Type 2 Diabetes","INTERVENTIONAL",null,"PHASE4","TERMINATED","48","Type 2 Diabetes; Overweight","DRUG:Liraglutide; OTHER:Observation alone","Centre Hospitalier Universitaire Dijon","2014-02-04","FALSE","1"],["S001318","ClinicalTrials.gov","NCT01787916","LIDO","Cross-over, Double-blind, Unicentric, 52 Week Trial of Liraglutide in Type 1 Diabetes.","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","15","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Placebos","CHU de Quebec-Universite Laval","2013-04","TRUE","1"],["S001319","ClinicalTrials.gov","NCT04878393","PIONEER REAL","A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters and Safety Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Japan","OBSERVATIONAL",null,null,"COMPLETED","650","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2021-04-30","FALSE","1"],["S001320","ClinicalTrials.gov","NCT07430332",null,"Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","15","Stage 1 Diabetes Mellitus, Type 1","DRUG:Semaglutide; DRUG:Placebo","Children's Hospital Medical Center, Cincinnati","2027-09-01","FALSE","2"],["S001321","ClinicalTrials.gov","NCT04702516",null,"The Effect of Semaglutide (Ozempic) on Bone Turnover in Patients With Increased Fracture Risk: a Randomized Placebo-controlled Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","UNKNOWN","64","Osteopenia","DRUG:Ozempic; DRUG:Placebo","Morten Frost","2021-03-24","FALSE","1"],["S001322","ClinicalTrials.gov","NCT01373216","Executive","EXEnatide in Patients Undergoing Coronary Artery Bypass Grafting for Improved glUcose conTrol and hemodynamIc ValuEs","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","38","Coronary Artery Disease; Decreased Left Ventricular Function","DRUG:Exenatide","Charles University, Czech Republic","2011-06","FALSE","1"],["S001323","ClinicalTrials.gov","NCT00360334",null,"An Open Label Study Comparing Exenatide With Basal Insulin in Achieving an HbA1c of ≤ 7.4% With Minimum Weight Gain, in Type 2 Diabetes Patients Who Are Not Achieving Adequate HbA1c Control on Oral Anti Diabetic Therapies Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","235","Type 2 Diabetes","DRUG:exenatide; DRUG:insulin glargine","AstraZeneca","2006-06","TRUE","2"],["S001324","ClinicalTrials.gov","NCT07564414",null,"A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","2500","Obesity; Type 2 Diabetes","DRUG:Cagrisema; DRUG:Semaglutide","Novo Nordisk A/S","2026-05-21","FALSE","0"],["S001325","ClinicalTrials.gov","NCT07559500",null,"Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD), a Phase 1b Study","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","176","Alcohol Use Disorder (AUD)","DRUG:Tirzepatide; DRUG:Placebo; DRUG:[11C]raclopride plus drug; DRUG:[11C]NNC-112","National Institute on Alcohol Abuse and Alcoholism (NIAAA)","2026-05-20","FALSE","0"],["S001326","ClinicalTrials.gov","NCT03144271",null,"A Randomised, Double-blind, Placebo-controlled, Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","58","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:Placebo","Novo Nordisk A/S","2007-06-11","FALSE","0"],["S001327","ClinicalTrials.gov","NCT01511692",null,"A 4 Week Single Center, Double-dummy, Randomised Double-blind, Balanced Incomplete Latin Square Design Study to Evaluate the Effects of Liraglutide on Appetite in Subjects With Type 2 Diabetes Compared to Glimepiride and Placebo","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","43","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:glimepiride","Novo Nordisk A/S","2005-11","FALSE","1"],["S001328","ClinicalTrials.gov","NCT01952145","DUAL™ V","A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","557","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin glargine","Novo Nordisk A/S","2013-09-20","TRUE","13"],["S001329","ClinicalTrials.gov","NCT07056803",null,"Sex Related Outcomes in Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus: A 12-month Real-world Study","OBSERVATIONAL",null,null,"COMPLETED","212","Diabetes Mellitus Type 2","DRUG:Oral semaglutide; DRUG:subcutaneous semaglutide","University of Palermo","2024-01-01","FALSE","0"],["S001330","ClinicalTrials.gov","NCT07272837","GLIMMER","GLP-1 Receptor Agonist-Induced Muscle Mass Evaluation and Retention","OBSERVATIONAL",null,null,"RECRUITING","50","Type 2 Diabetes; Obesity; Semaglutide; GLP-1; Diabetes",null,"University of Alberta","2026-05-15","FALSE","0"],["S001331","ClinicalTrials.gov","NCT06438146","LIROH","Liraglutide for Management of Obesity in People Living With HIV on Dolutegravir-based Antiretroviral Therapy: a Single-arm Acceptability Study in South Africa","INTERVENTIONAL",null,"PHASE4","UNKNOWN","40","Obesity; HIV Infections","DRUG:Liraglutide","Brigham and Women's Hospital","2024-05-02","FALSE","3"],["S001332","ClinicalTrials.gov","NCT07677995",null,"Repositioning Omega-3 Fatty Acids For Treatment Of Glycaemia And Cardiometabolic Disease","INTERVENTIONAL","RANDOMIZED",null,"ENROLLING_BY_INVITATION","60","Type 2 Diabetes; Cardiovascular Disease; Omega-3 Fatty Acids","DIETARY_SUPPLEMENT:Omega-3 Fatty Acids; DRUG:Semaglutide 0.25 mg; DIETARY_SUPPLEMENT:Placebo","University of Ulster","2026-09","FALSE","0"],["S001333","ClinicalTrials.gov","NCT07104383",null,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","1100","Weight Loss","DRUG:VK2735","Viking Therapeutics, Inc.","2025-06-23","FALSE","1"],["S001334","ClinicalTrials.gov","NCT04379856",null,"A Phase I/II Proof of Concept, Open-Label, Repeat Dose, Dose Escalation Study of NM-002 in Adult Patients With Short Bowel Syndrome (SBS)","INTERVENTIONAL","NON_RANDOMIZED","PHASE1; PHASE2","UNKNOWN","12","Short Bowel Syndrome","DRUG:NM-002","9 Meters Biopharma, Inc.","2020-06-23","FALSE","0"],["S001335","ClinicalTrials.gov","NCT06727331","STREAM","Tirzepatide for the Treatment of Alcohol Use Disorder: A Pilot Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","20","Alcohol Use Disorder (AUD)","DRUG:Tirzepatide; OTHER:Saline Placebo","Brigham and Women's Hospital","2025-09-15","FALSE","0"],["S001336","ClinicalTrials.gov","NCT04552470",null,"AN 8-WEEK PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TWICE DAILY PF-06882961 ADMINISTRATION IN JAPANESE ADULTS WITH TYPE 2 DIABETES MELLITUS","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","37","Type 2 Diabetes Mellitus","DRUG:Placebo; DRUG:PF-06882961","Pfizer","2020-10-26","TRUE","0"],["S001337","ClinicalTrials.gov","NCT01973231","LIRA-LIXI™","Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","404","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:lixisenatide","Novo Nordisk A/S","2013-10","TRUE","4"],["S001338","ClinicalTrials.gov","NCT04839237",null,"The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients","INTERVENTIONAL","NON_RANDOMIZED","PHASE2","WITHDRAWN","0","Obesity","DRUG:Liraglutide; DRUG:Liraglutide;metformin","Xiangya Hospital of Central South University","2017-12-01","FALSE","0"],["S001339","ClinicalTrials.gov","NCT04199728",null,"Use of a GLP-1R Agonist to Treat Opioid Use Disorder","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","27","Opiate Substitution Treatment; Opioid-Related Disorders","DRUG:Liraglutide Pen Injector; DRUG:Placebo","Milton S. Hershey Medical Center","2021-10-18","TRUE","2"],["S001340","ClinicalTrials.gov","NCT05696847",null,"A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 Years to 11 Years) With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","28","Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-02-07","TRUE","0"],["S001341","ClinicalTrials.gov","NCT01507038",null,"Phase II Clinical Trial to Investigate the Efficacy, Safety and Pharmacokinetics of YH14617 After Once Weekly or Biweekly Administration in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","84","Diabetes Mellitus","DRUG:YH14617; DRUG:Placebo","Yuhan Corporation","2011-12","FALSE","0"],["S001342","ClinicalTrials.gov","NCT07622992","OPTI-OAGB","Efficacy of Preoperative Tirzepatide, Ketogenic Diet, and Standard Care on 1-Year Weight Loss After One Anastomosis Gastric Bypass (OAGB)","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","96","Obesity (BMI > 35) and Diabetes Mellitus; Obesity (BMI > 35) and Dyslipemia; Obesity (BMI > 35) and High Blood Pressure",null,"Mario Musella MD","2027-01-01","FALSE","0"],["S001343","ClinicalTrials.gov","NCT03182192",null,"Visualizing Beta Cells in Patients With Hyperinsulinemic Hypoglycemia After Bariatric Surgery","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","UNKNOWN","12","Hypoglycemia","RADIATION:68Ga-NODAGA-exendin-4 PET/CT","Radboud University Medical Center","2016-04-01","FALSE","0"],["S001344","ClinicalTrials.gov","NCT03087032","LiraGooD","Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight / Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled Study","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","164","Type 2 Diabetes Patients; Overweight and Obesity; Hyperglycaemia (Diabetic)","DRUG:Liraglutide; DRUG:insulin glargine","The First Affiliated Hospital of Xiamen University","2019-01-10","FALSE","0"],["S001345","ClinicalTrials.gov","NCT01573806","PEPS","Phase 1-2 Study of the Pharmacology of Exenatide in Pediatric Sepsis","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","WITHDRAWN","0","Septic Shock; Inflammation; Glucose Homeostasis; Organ Dysfunction; Health-related Quality of Life","DRUG:Exenatide; DRUG:Exenatide vehicle","Seattle Children's Hospital","2012-10","FALSE","2"],["S001346","ClinicalTrials.gov","NCT01301092",null,"A Study to Evaluate the Safety, Tolerability, and Absolute Bioavailability of Subcutaneous LY2189265","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","30","Diabetes Mellitus, Type II","BIOLOGICAL:LY2189265","Eli Lilly and Company","2011-02","TRUE","0"],["S001347","ClinicalTrials.gov","NCT03929744",null,"A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","133","Healthy","DRUG:LY3502970; DRUG:Placebo; DRUG:Atorvastatin; DRUG:Simvastatin; DRUG:Midazolam","Eli Lilly and Company","2019-06-12","TRUE","2"],["S001348","ClinicalTrials.gov","NCT03015519",null,"A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Albiglutide for the Treatment of Type 2 Diabetes Mellitus in Pediatric Patients","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Diabetes Mellitus, Type 2","DRUG:Albiglutide; DRUG:Placebo","GlaxoSmithKline","2017-08-14","FALSE","0"],["S001349","ClinicalTrials.gov","NCT06739044",null,"A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection With Ozempic ® in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","494","Type 2 Diabetes","DRUG:Ozempic®; DRUG:HDG1901","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2023-09-20","FALSE","1"],["S001350","ClinicalTrials.gov","NCT03923114","iPAVE","iPAVE - Imaging Pituitary ActiVation by Exendin","INTERVENTIONAL","NON_RANDOMIZED",null,"COMPLETED","20","Diabetes Mellitus, Type 2","RADIATION:Ga-68-NODAGA-exendin-4 PET/CT","Radboud University Medical Center","2019-05-23","FALSE","1"],["S001351","ClinicalTrials.gov","NCT00978393",null,"A Randomised, Placebo-controlled, Double-blind, Incomplete Cross-over Design Trial to Evaluate the Effects of Liraglutide on Gastric Emptying, Energy Expenditure and Appetite, and to Evaluate Liraglutide Pharmacokinetics in Non-diabetic Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","49","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide","Novo Nordisk A/S","2009-09-16","FALSE","1"],["S001352","ClinicalTrials.gov","NCT05136287","SEVERAL","SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.","OBSERVATIONAL",null,null,"COMPLETED","140","Weight Loss; Diabetes Mellitus, Type 2; Quality of Life; Safety Issues","DRUG:GLP-1 receptor agonist","Jose Seijas Amigo","2022-02-01","FALSE","9"],["S001353","ClinicalTrials.gov","NCT03989232","SUSTAIN FORTE","Efficacy and Safety of Semaglutide 2.0 mg s.c. Once-weekly Compared to Semaglutide 1.0 mg s.c. Once-weekly in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","961","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-06-19","TRUE","3"],["S001354","ClinicalTrials.gov","NCT05646706","STEP UP","Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1407","Obesity","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2023-01-04","TRUE","4"],["S001355","ClinicalTrials.gov","NCT01003184",null,"Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulphonylurea","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","222","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:insulin detemir","AstraZeneca","2009-10","TRUE","1"],["S001356","ClinicalTrials.gov","NCT00943501",null,"Liraglutide: A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Pediatric (10-17 Years Old) With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","21","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2009-11","FALSE","2"],["S001357","ClinicalTrials.gov","NCT02953665",null,"A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","63","Parkinson Disease","DRUG:Liraglutide; DRUG:Placebo","Cedars-Sinai Medical Center","2017-04-03","TRUE","2"],["S001358","ClinicalTrials.gov","NCT06778967","Optimum 2","A Multicenter, Randomized, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Metformin Monotherapy or in Combination With Sodium-dependent Glucose Transporter 2 (SGLT2) Inhibitors or Sulfonylureas","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","1100","Type 2 Diabetes Mellitus (T2DM)","DRUG:GZR18; DRUG:semaglutide","Gan & Lee Pharmaceuticals.","2025-02-13","FALSE","0"],["S001359","ClinicalTrials.gov","NCT07554638",null,"Identifying Therapeutic Mechanisms for Incretin-Based Treatment in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF)","INTERVENTIONAL",null,"PHASE4","RECRUITING","50","Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Obesity","DRUG:Tirzepatide","Columbia University","2026-08-07","FALSE","0"],["S001360","ClinicalTrials.gov","NCT04012255",null,"A Trial to Demonstrate Bioequivalence Between Semaglutide Formulations With the DV3396 Pen-injector and With the PDS290 Pen-injector in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","TERMINATED","29","Overweight; Obesity","DRUG:Semaglutide (administered by DV3396 pen); DRUG:Semaglutide (administered by PDS290 pen)","Novo Nordisk A/S","2019-07-15","FALSE","0"],["S001361","ClinicalTrials.gov","NCT05193578","HISTORI","Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","154","Schizophrenia; Prediabetic State","DRUG:Semaglutide, 1.34 mg/mL; OTHER:Placebo","Jan Frystyk","2022-01-01","FALSE","3"],["S001362","ClinicalTrials.gov","NCT00882050",null,"Intravenous Exenatide (Byetta) for the Treatment of Perioperative Hyperglycemia: Rollover Phase I/II Trial","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","104","Euglycemia; Hypoglycemia; Hyperglycemia","DRUG:Exenatide 0.27 ng/kg/min; DRUG:Exenatide 0.41 ng/kg/min; DRUG:Placebo","Thomas Jefferson University","2009-03","TRUE","0"],["S001363","ClinicalTrials.gov","NCT04560998","STRIDE","Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","792","Diabetes Mellitus, Type 2; Peripheral Arterial Disease","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2020-10-01","TRUE","7"],["S001364","ClinicalTrials.gov","NCT06859268","TRIUMPH-6","A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","643","Obesity","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2025-03-05","FALSE","0"],["S001365","ClinicalTrials.gov","NCT06383390",null,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","10000","Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2024-04-30","FALSE","1"],["S001366","ClinicalTrials.gov","NCT02042664",null,"Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics","INTERVENTIONAL","NON_RANDOMIZED","PHASE3","COMPLETED","44","Obesity; Diabetes","DRUG:BYETTA treatment; DRUG:Metformine","Assistance Publique Hopitaux De Marseille","2011-01","FALSE","1"],["S001367","ClinicalTrials.gov","NCT03767543","LixilanOne CAN","A Randomized, 26-week, Open-label, 2-treatment Arm, Parallel Group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed-ratio Combination (Soliqua™) Titrated Using a Simple Titration Algorithm (One Unit Daily Adjustment) Compared With Insulin Glargine/Lixisenatide Fixed-ratio Combination (Soliqua™) Titrated by Weekly Adjustment in Patients With Type 2 Diabetes Mellitus (T2DM)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","265","Type 2 Diabetes Mellitus","DRUG:INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010","Sanofi","2019-03-11","FALSE","4"],["S001368","ClinicalTrials.gov","NCT06060392","Sema-Lit","Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus: Sema-Lit","INTERVENTIONAL","NON_RANDOMIZED",null,"RECRUITING","50","Liver Transplant; Complications; Diabete Mellitus","DRUG:Semaglutide Pill","Medanta, The Medicity, India","2023-10-30","FALSE","2"],["S001369","ClinicalTrials.gov","NCT02059564",null,"A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","UNKNOWN","44","Diabetes Mellitus","DRUG:HM11260C; DRUG:Placebo; DRUG:Victoza","Hanmi Pharmaceutical Company Limited","2013-12","FALSE","1"],["S001370","ClinicalTrials.gov","NCT06415214","SOLID-DKD","A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HRS-7535 in Adults With Diabetic Kidney Disease in Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","281","Diabetic Kidney Disease, Type 2 Diabetes","DRUG:Placebo; DRUG:HRS-7535","Shandong Suncadia Medicine Co., Ltd.","2024-06-21","FALSE","2"],["S001371","ClinicalTrials.gov","NCT01140893","EXEPUMP","Effects of EXEnatide on Glycemic Control and Weight Over 26 Weeks in Continuous Subcutaneous Insulin Infusion (CSII) Treated Patients With Type 2 Diabetes : a Phase 2/3 Double Blind randoMized Placebo-controlled Trial.","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","UNKNOWN","110","Type 2 Diabetes","DRUG:Exenatide; DRUG:Placebo","University Hospital, Caen","2010-11","FALSE","0"],["S001372","ClinicalTrials.gov","NCT06672549","ADVANCE","A Master Protocol for a Randomized, Controlled, Clinical Platform Trial to Investigate the Efficacy and Safety of Interventions for Chronic Weight Management in Pediatric Participants With Obesity or Overweight","INTERVENTIONAL",null,"PHASE3","RECRUITING","125","Obesity; Overweight","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2024-11-18","FALSE","0"],["S001373","ClinicalTrials.gov","NCT05356104","GAPP-SVD","GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) - A Pilot Study","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","110","Cerebral Small Vessel Disease","DRUG:GLP-1 receptor agonist","Chinese University of Hong Kong","2022-05-25","FALSE","0"],["S001374","ClinicalTrials.gov","NCT03713684","AMPLITUDE-L","A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","370","Type 2 Diabetes Mellitus","DRUG:Efpeglenatide SAR439977; DRUG:Placebo; DRUG:Background therapy","Sanofi","2018-11-09","TRUE","0"],["S001375","ClinicalTrials.gov","NCT03936049",null,"Replication of the LEADER Diabetes Trial in Healthcare Claims","OBSERVATIONAL",null,null,"COMPLETED","168690","Diabetes","DRUG:Liraglutide; DRUG:DPP-4 inhibitor","Brigham and Women's Hospital","2017-09-22","FALSE","0"],["S001376","ClinicalTrials.gov","NCT07838740",null,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735 Administration in Adults Who Are Obese (BMI ≥ 30 kg/m2) Without Comorbidities","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","270","Obese Adults","DRUG:VK2735 Drug; DRUG:Placebo","Viking Therapeutics, Inc.","2025-11-18","FALSE","0"],["S001377","ClinicalTrials.gov","NCT07575399",null,"A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","300","Obesity or Overweight","DRUG:Maridebart Cafraglutide","Amgen","2026-05-11","FALSE","0"],["S001378","ClinicalTrials.gov","NCT07035704","PasGras","De-Risking Metabolic, Environmental and Behavioral Determinants of Obesity in Children, Adolescents and Young Adults","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","200","Overweight (BMI &gt; 25)","DIETARY_SUPPLEMENT:MeD enriched with mushrooms; DIETARY_SUPPLEMENT:MeD enriched the Lebanese herbal mixture Za'atar; DIETARY_SUPPLEMENT:MeD Diet + semaglutinine or compatible treatment+ Za'atar or Mushroom (to be defined)","piero portincasa","2025-09-15","FALSE","0"],["S001379","ClinicalTrials.gov","NCT00099333",null,"An Exploratory Study of the Safety of Substituting Exenatide for Insulin in Patients With Type 2 Diabetes Who Have Been Using Insulin in Combination With Oral Antidiabetic Therapy","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","49","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:Insulin","AstraZeneca","2004-02","FALSE","2"],["S001380","ClinicalTrials.gov","NCT02877355",null,"Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes","INTERVENTIONAL",null,"PHASE1","COMPLETED","55","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide","Novo Nordisk A/S","2016-08-22","FALSE","3"],["S001381","ClinicalTrials.gov","NCT02692716","PIONEER 6","A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","3183","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2017-01-17","TRUE","24"],["S001382","ClinicalTrials.gov","NCT06863363",null,"A Multicenter, Randomized, Open-label, Parallel-controlled Clinical Trial Comparing the Efficacy and Safety of PEG-rhGH Injection Combined with Semaglutide Injection Versus Semaglutide Injection Monotherapy in Body Composition of Non-Diabetic Obese Adults","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","212","Non-diabetic Obesity","DRUG:PEG-rhGH Injection + Semaglutide Injection; DRUG:Semaglutide Injection","Shanghai Zhongshan Hospital",null,"FALSE","0"],["S001383","ClinicalTrials.gov","NCT06959784",null,"Evidence Based Evaluation of Incretin Drugs in Reducing the Risk of Cardiovascular and Cerebrovascular Events and Promoting the Remission of Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","ENROLLING_BY_INVITATION","142","Diabetes Mellitus; Cardiovascular Diseases; Cerebrovascular Disease","DRUG:semaglutide; DRUG:Metformin","China-Japan Friendship Hospital","2024-01-01","FALSE","0"],["S001384","ClinicalTrials.gov","NCT07588438","REAL-TIRZEPY","Prospective Cohort Study to Evaluate the Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Persons With Obesity Without Diabetes and Type 2 Diabetes Mellitus With or Without Obesity in Paraguay.","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","RECRUITING","160","Obesity; Diabetes Mellitus, Type 2","DRUG:Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.)","Las Rías Medical Center","2026-07-27","FALSE","0"],["S001385","ClinicalTrials.gov","NCT03861039",null,"A Phase 3, Long-Term Safety Study of Tirzepatide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus (SURPASS J-combo)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","443","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Oral antihyperglycemic medication (OAM)","Eli Lilly and Company","2019-03-30","TRUE","2"],["S001386","ClinicalTrials.gov","NCT06901349",null,"A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","WITHDRAWN","0","Obesity; Overweight","DRUG:Bimagrumab; DRUG:Tirzepatide; DRUG:Bimagrumab Placebo; DRUG:Tirzepatide Placebo","Eli Lilly and Company","2025-05-23","FALSE","0"],["S001387","ClinicalTrials.gov","NCT07713992",null,"Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide: A Multicenter, Prospective, Randomized Controlled Trial (IIT)","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","72","Type 2 Diabetes Mellitus (T2DM); Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus","DRUG:Mazdutide(Dual GLP-1R/GCGR Agonist); DRUG:Semaglutide (1 Mg Dose)","Tianjin Medical University","2026-09-15","FALSE","8"],["S001388","ClinicalTrials.gov","NCT07245771",null,"A Randomized, Double-Blind, Placebo-Controlled Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","RECRUITING","104","Obesity &Amp; Overweight","DRUG:RN3161; DRUG:Placebo Control; DRUG:Tirzepatide","Ikaria Bioscience Pty Ltd","2025-11-04","FALSE","0"],["S001389","ClinicalTrials.gov","NCT06352411",null,"Pharmacokinetics, Safety, and Tolerability of BI 456906 Following Subcutaneous Injection in Male and Female Participants With Mild, Moderate and Severe Renal Impairment in Comparison to Participants With Normal Renal Function (Mono-centric, Open-label Study With Parallel Matched-pair Design)","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","42","Healthy; Renal Impairment","COMBINATION_PRODUCT:BI 456906","Boehringer Ingelheim","2024-05-15","FALSE","0"],["S001390","ClinicalTrials.gov","NCT00886626",null,"GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children: A Randomized, Controlled, Pilot Study","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","12","Obesity, Morbid","DRUG:Exenatide","University of Minnesota","2009-05","TRUE","1"],["S001391","ClinicalTrials.gov","NCT06814938",null,"A Novel Precision Medicine Approach For Obesity: A Randomized, Multi-Center Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","135","Obesity","DRUG:Semaglutide; DRUG:Placebo","Mayo Clinic","2025-02-21","FALSE","0"],["S001392","ClinicalTrials.gov","NCT02773355",null,"Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients","OBSERVATIONAL",null,null,"COMPLETED","27","Obesity","DRUG:liraglutide 3.0 mg","Novo Nordisk A/S","2016-05-16","FALSE","0"],["S001393","ClinicalTrials.gov","NCT01508858",null,"A Double-blind, Two Period Cross-over, Single Centre Trial in Healthy Subjects Investigating the Influence on the Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Drug After Multiple Dose Administration of Liraglutide","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","21","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:levonorgestrel / ethinylestradiol","Novo Nordisk A/S","2006-11","FALSE","1"],["S001394","ClinicalTrials.gov","NCT05663515","EXCEED","EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs","OBSERVATIONAL",null,null,"RECRUITING","24000","Pancreatic Cancer","DRUG:Exenatide; DRUG:Non-GLP-1 RA based glucose lowering drugs","AstraZeneca","2024-09-30","FALSE","0"],["S001395","ClinicalTrials.gov","NCT06771115",null,"A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","175","Obesity","DRUG:Placebo; DRUG:VTX3232 30 mg; DRUG:Placebo in combination with semaglutide; DRUG:VTX3232 30 mg in combination with semaglutide","Zomagen Biosciences Ltd.","2025-01-07","TRUE","0"],["S001396","ClinicalTrials.gov","NCT07760948","PRESERVE-HMB","Preserving the Metabolic Engine: Effects of HMB Supplementation on Skeletal Muscle Structure and Function During Semaglutide-Associated Weight Loss in Older Adults","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","90","Type 2 Diabetes Mellitus (T2DM); Sarcopenia; Obesity; Muscle Loss; Older Adults","DIETARY_SUPPLEMENT:Calcium-HMB Plus Vitamin D3; OTHER:Matching placebo","Vanderbilt University Medical Center","2026-12-01","FALSE","0"],["S001397","ClinicalTrials.gov","NCT01562678",null,"Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","28","Diabetes; Effects of Liraglutide Administration on Brain Activity; Weight Loss; Hunger","DRUG:Liraglutide; DRUG:Placebo","Beth Israel Deaconess Medical Center","2012-03","TRUE","2"],["S001398","ClinicalTrials.gov","NCT06449235",null,"Efficacy and Safety of Omarigliptin, A Weekly Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Management: Real-World Evaluation in Bangladesh","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","UNKNOWN","938","Type2diabetes","DRUG:Omarigliptin; DRUG:Sulphonylureas; DRUG:Metformin; DRUG:Other DPP4-i; DRUG:Thiazolidinediones; DRUG:Alpha-Glucosidase Inhibitor; DRUG:Glucagon-Like Peptide-1; DRUG:Receptor Agonists (GLP1RA); DRUG:SGLT2 inhibitors","Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","2024-09","FALSE","0"],["S001399","ClinicalTrials.gov","NCT05230589","PIONEER REAL","A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Saudi Arabia","OBSERVATIONAL",null,null,"COMPLETED","194","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2022-04-25","FALSE","0"],["S001400","ClinicalTrials.gov","NCT04809220","AWARD-JPN","A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","591","Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders; Metabolic Disease; Endocrine System Diseases; Hypoglycemic Agents; Type 2 Diabetes Mellitus (T2DM)","DRUG:Dulaglutide; DRUG:Oral antihyperglycemics","Eli Lilly and Company","2021-04-13","TRUE","1"],["S001401","ClinicalTrials.gov","NCT05652647",null,"A PHASE 1, OPEN-LABEL, 2-PERIOD, FIXED SEQUENCE STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF [14C]PF-07081532 AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-07081532 IN HEALTHY MALE PARTICIPANTS USING A [14C]-MICROTRACER APPROACH","INTERVENTIONAL",null,"PHASE1","COMPLETED","6","Healthy Participants","DRUG:Oral [14C]PF-07081532; DRUG:Oral PF-07081532 and IV [14C]PF-07081532","Pfizer","2022-12-21","TRUE","0"],["S001402","ClinicalTrials.gov","NCT00422058",null,"Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","564","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:orlistat; DRUG:placebo","Novo Nordisk A/S","2007-01-10","TRUE","6"],["S001403","ClinicalTrials.gov","NCT01866748",null,"Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","170","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2013-05","FALSE","0"],["S001404","ClinicalTrials.gov","NCT01648582","AWARD-CHN2","The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","774","Type 2 Diabetes Mellitus","DRUG:Dulaglutide; DRUG:Insulin glargine; DRUG:Metformin; DRUG:Sulfonylureas","Eli Lilly and Company","2012-07","TRUE","10"],["S001405","ClinicalTrials.gov","NCT04741074","RAISE-KT","A RAndomized trIal Examining the Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy for Patients With Stage 4-5 CKD or Dialysis-dependent ESKD","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","15","CKD; Diabetic Kidney Disease; Type 2 Diabetes Mellitus in Obese; Obesity; Severe Obesity","DRUG:Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution; DRUG:Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution","Geisinger Clinic","2021-07-23","TRUE","0"],["S001406","ClinicalTrials.gov","NCT07592546","THRIVE","Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","NOT_YET_RECRUITING","240","Class I/II Obesity","DRUG:semaglutide","Alain Dagher","2026-08-01","FALSE","0"],["S001407","ClinicalTrials.gov","NCT06903923",null,"Bone Metabolism in Adolescents Undergoing GLP-1 Receptor Agonist Therapy","INTERVENTIONAL","NON_RANDOMIZED","PHASE2","RECRUITING","120","Obesity in Children; Bone Strength; GLP - 1; Lifestyle Modification; Bone Density; Obesity","DRUG:GLP-1 receptor agonist; BEHAVIORAL:Lifestyle intervention","University of Virginia","2025-07-31","FALSE","0"],["S001408","ClinicalTrials.gov","NCT06913023","SPOT-DM","Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus","INTERVENTIONAL",null,"PHASE2; PHASE3","NOT_YET_RECRUITING","37","Kidney Transplant Recipient","DRUG:Semaglutide 0.25 mg; DRUG:Semaglutide 0.5 mg; DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 1.7mg subcutaneous; DRUG:Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]","University Health Network, Toronto","2026-09-05","FALSE","0"],["S001409","ClinicalTrials.gov","NCT02058160","LixiLan-L","A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","736","Type 2 Diabetes","DRUG:Insulin glargine/lixisenatide (HOE901/AVE0010); DRUG:Insulin glargine (HOE901); DRUG:Metformin (Background Drug)","Sanofi","2014-01","TRUE","17"],["S001410","ClinicalTrials.gov","NCT04440345",null,"Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","60","Overweight or Obesity","DRUG:IBI362; DRUG:Placebo","Innovent Biologics (Suzhou) Co. Ltd.","2020-06-16","FALSE","4"],["S001411","ClinicalTrials.gov","NCT06500143","RESIDUAL","The RESIDUAL Study : Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery: a Cross-sectional Study","OBSERVATIONAL",null,null,"COMPLETED","94","Gastric Retention","DIAGNOSTIC_TEST:Gastric ultrasound","Ciusss de L'Est de l'Île de Montréal","2024-10-09","FALSE","1"],["S001412","ClinicalTrials.gov","NCT02231658",null,"Effects of Victoza® (Liraglutide) Versus Lyxumia® (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion","INTERVENTIONAL","RANDOMIZED","PHASE1","TERMINATED","109","Diabetes Mellitus","DRUG:Liraglutide; DRUG:Lixisenatide","Profil Institut für Stoffwechselforschung GmbH","2015-07-16","FALSE","1"],["S001413","ClinicalTrials.gov","NCT06828055",null,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","280","Weight Loss","DRUG:Placebo; DRUG:VK2735","Viking Therapeutics, Inc.","2024-12-18","FALSE","0"],["S001414","ClinicalTrials.gov","NCT07429032",null,"A Phase 1, Randomized, Double Blind, Multiple Dose, Placebo-controlled, Parallel Group Study to Evaluate the Impact of AMG 133 on Gastric Emptying in Participants Living With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","57","Overweight or Obesity","DRUG:AMG 133; DRUG:Placebo; DRUG:Acetaminophen","Amgen","2025-04-17","FALSE","0"],["S001415","ClinicalTrials.gov","NCT06700538",null,"A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-INHBE in Adult Volunteers With Obesity With and Without Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","RECRUITING","180","Obesity","DRUG:ARO-INHBE; DRUG:Placebo; DRUG:Tirzepatide","Arrowhead Pharmaceuticals","2024-12-04","FALSE","0"],["S001416","ClinicalTrials.gov","NCT05467514",null,"Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE3","COMPLETED","35","Diabetes Mellitus, Type 1","DRUG:Liraglutide","David Sanchez Garcia","2022-07-01","FALSE","0"],["S001417","ClinicalTrials.gov","NCT02545738","LIRALBU","Antiproteinuric Effects of Liraglutide Treatment in Patients With Type 2 Diabetes and Albuminuria: A Randomised, Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","32","Diabetic Kidney Disease","DRUG:Liraglutide; DRUG:placebo","Steno Diabetes Center Copenhagen","2015-04","FALSE","4"],["S001418","ClinicalTrials.gov","NCT06642584",null,"A Study Investigating the Pharmacokinetic Properties When Dosing Different Formulations of Semaglutide to Healthy Male Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","90","Healthy Volunteers Type 2 Diabetes","DRUG:Semaglutide B; DRUG:Semaglutide J; DRUG:Semaglutide L; DRUG:Semaglutide M; DRUG:Semaglutide N","Novo Nordisk A/S","2024-10-15","FALSE","0"],["S001419","ClinicalTrials.gov","NCT01795248",null,"The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","105","Gestational Diabetes Mellitus","DRUG:Liraglutide; DRUG:Placebo","Tina Vilsboll","2012-07","FALSE","5"],["S001420","ClinicalTrials.gov","NCT03538743",null,"A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF-06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","98","Type 2 Diabetes Mellitus","DRUG:Placebo; DRUG:PF-06882961","Pfizer","2018-06-25","TRUE","1"],["S001421","ClinicalTrials.gov","NCT07213323","PROBIO-GLP1","Evaluation of the Efficacy of Probiotics on Digestive Quality of Life in Patients Initiating GLP-1 Receptor Agonists for the Treatment of Obesity. A Randomized, Double-blind Trial","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","50","Obesity &Amp; Overweight; Digestive Disorders","DIETARY_SUPPLEMENT:Probiotics (Natural product); OTHER:Placebo","Hospices Civils de Lyon","2026-08-05","FALSE","0"],["S001422","ClinicalTrials.gov","NCT02324842",null,"Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","45","Type 2 Diabetes Mellitus","DRUG:Canagliflozin; DRUG:Liraglutide","The University of Texas Health Science Center at San Antonio","2014-11","TRUE","2"],["S001423","ClinicalTrials.gov","NCT03034941",null,"Short Term Weight Loss With Liraglutide and Metformin Before IVF in Infertile Obese PCOS Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","35","Obesity; PCOS","DRUG:Metformin; DRUG:Liraglutide + metformin","University Medical Centre Ljubljana","2014-04","FALSE","1"],["S001424","ClinicalTrials.gov","NCT03611322",null,"A Trial to Compare Pharmacokinetic Properties of Semaglutide Following Subcutaneous Administration of Semaglutide 1 mg by the DV3372 Device and by the PDS290 Semaglutide Pen-injector","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","54","Diabetes Mellitus, Type 2","DRUG:Semaglutide, 0.25 mg; DRUG:Semaglutide, 0.5 mg; DRUG:Semaglutide, 1.0 mg; DEVICE:DV3372; DEVICE:PDS290 pen-injector","Novo Nordisk A/S","2018-08-08","FALSE","0"],["S001425","ClinicalTrials.gov","NCT04019197",null,"Effects of GLP-l Receptor Agonists on Cardiometabolic Alterations in HIV-associated Lipohypertrophy","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","108","HIV/AIDS; Lipohypertrophy; Obesity","DRUG:Semaglutide Injectable Product; DRUG:Placebo","Case Western Reserve University","2019-05-16","TRUE","7"],["S001426","ClinicalTrials.gov","NCT04854083","MitoSema","Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes - Effects on Glucose Metabolism, Prevention of Weight Regain and Peripheral Tissue Metabolic Activation","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","50","Type2 Diabetes","DRUG:Semaglutide, 1.34 mg/mL; DRUG:Placebo","Kirsi Pietiläinen","2022-02-17","FALSE","0"],["S001427","ClinicalTrials.gov","NCT06287307","SEABAR","Semaglutide 2.4mg for Low Responders After Bariatric Surgery","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","152","Obesity; Obesity, Morbid; Weight Gain","OTHER:Placebo; DRUG:Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]","Zuyderland Medisch Centrum","2024-05","FALSE","7"],["S001428","ClinicalTrials.gov","NCT07720466",null,"Prospective Evaluation of Salivary Calcium Levels, Salivary Function, and Dental Hard Tissue Changes in Patients Receiving GLP-1 Receptor Agonist Therapy","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","40","Obesity; Dental Erosion; Saliva Collection; Saliva Altered","PROCEDURE:Unstimulated Whole Saliva Collection; PROCEDURE:Salivary Analysis; PROCEDURE:Oral Examination and BEWE Assessment; PROCEDURE:Standardized Intraoral Photography","Bilecik Seyh Edebali Universitesi","2026-08-17","FALSE","2"],["S001429","ClinicalTrials.gov","NCT07188545","DASH-CKMH","Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","23280000","Cardiovascular Kidney Metabolic Syndrome","DRUG:Intervention; DRUG:Active Comparator","Ohio State University","2025-09-15","FALSE","0"],["S001430","ClinicalTrials.gov","NCT07114419",null,"A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Efsubaglutide Alfa Injection in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","200","Obesity and Overweight","DRUG:Efsubaglutide Alfa 20 mg QW; DRUG:Efsubaglutide Alfa 40 mg QW; DRUG:Efsubaglutide Alfa 40 mg Q2W; DRUG:Efsubaglutide Alfa 80 mg QW; DRUG:Efsubaglutide Alfa 80 mg Q4W; OTHER:Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2025-08-25","FALSE","0"],["S001431","ClinicalTrials.gov","NCT02082496",null,"Exploration of the Physiological Effect of GLP-1 in Obese Adults Diagnosed With Obesity Causing Genetic Mutations","INTERVENTIONAL","NON_RANDOMIZED","PHASE2","COMPLETED","50","Obesity","DRUG:Liraglutide","University of Copenhagen","2014-06","FALSE","0"],["S001432","ClinicalTrials.gov","NCT06287437",null,"A Single-center, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Effectiveness and Safety of Low-frequency Injection of HRS9531 in Control of Weight Regain in Obese Subjects With and Without Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","72","Obesity","DRUG:HRS9531; DRUG:HRS9531 placebo","Shanghai Zhongshan Hospital","2024-01-01","FALSE","0"],["S001433","ClinicalTrials.gov","NCT03883412","ZQL007","Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","60","Type2 Diabetes","OTHER:Exercise; DRUG:Liraglutide","University of Virginia","2019-02-28","FALSE","0"],["S001434","ClinicalTrials.gov","NCT06734312","MAINTAIN","Gastric Fundal Mucosal Ablation for Weight Management in Patients Stopping Glucagon-like Peptide-1 Receptor Agonists","INTERVENTIONAL",null,null,"RECRUITING","20","Obesity and Obesity-related Medical Conditions; Obesity and Overweight; Obesity Prevention; Obesity Recidivism; GLP-1; Ablation Techniques","DEVICE:Gastric Fundal Mucosal Ablation (GFMA)","Dr. Christopher McGowan","2025-01-01","FALSE","2"],["S001435","ClinicalTrials.gov","NCT06821919","NETs","Evaluating the Effect of Hemodialysis Modality and New Anti-glycemic Drugs on NETosis on in Hemodialysis and Diabetic Patient, and Assessment of NETosis in Various Kidney Diseases","OBSERVATIONAL",null,null,"RECRUITING","70","Diabetes Mellitus; Kidney Disease",null,"Western Galilee Hospital-Nahariya","2024-05-13","FALSE","0"],["S001436","ClinicalTrials.gov","NCT03101930",null,"Cardiovascular Effects of GLP-1 Receptor Activation","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","329","Obesity; PreDiabetes","DRUG:Liraglutide; DRUG:Sitagliptin; OTHER:hypocaloric diet; DRUG:Placebos; DRUG:Exendin (9-39)","Vanderbilt University Medical Center","2017-05-01","TRUE","1"],["S001437","ClinicalTrials.gov","NCT00917267",null,"A Comparator-Controlled Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control (HbA1c) and Safety in Asian Subjects With Type 2 Diabetes Mellitus Managed With Oral Antidiabetic Medications","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","691","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:exenatide twice daily","AstraZeneca","2009-07","TRUE","2"],["S001438","ClinicalTrials.gov","NCT02235961",null,"A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects.","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","163","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC9204-0530; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2014-09-04","FALSE","0"],["S001439","ClinicalTrials.gov","NCT00707031","GETGOAL-X","A Randomized, Open-label, Active-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 Versus Exenatide on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","639","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DEVICE:Pen auto-injector; DRUG:Exenatide; DEVICE:Prefilled pen injector; DRUG:Metformin","Sanofi","2008-06","TRUE","2"],["S001440","ClinicalTrials.gov","NCT04897802",null,"Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study)","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","42","Hypopituitarism; Central Diabetes Insipidus; Panhypopituitarism; Psychological Disorder; Social Isolation; Hypothalamic Diseases; Pituitary Diseases; Oxytocin Deficiency","DRUG:Experimental: GLP1-RA (exenatide) administration; DRUG:Control: Placebo administration","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","2021-09-13","FALSE","0"],["S001441","ClinicalTrials.gov","NCT06841445",null,"A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Tablet in Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","166","Chronic Management of Body Weight","DRUG:HRS9531 Tablet; DRUG:HRS9531 Tablet placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-04-07","FALSE","0"],["S001442","ClinicalTrials.gov","NCT00993720",null,"Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","30","Diabetes Mellitus","DRUG:Liraglutide; OTHER:continuous insulin therapy","Hvidovre University Hospital","2009-10","FALSE","2"],["S001443","ClinicalTrials.gov","NCT06604624",null,"To Evaluate a Multicenter, Randomized, Open, Positive Parallel Controlled Phase III Clinical Trial of Semaglutide Injection (HD1916) in the Treatment of Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","462","Weight Management","DRUG:HD1916; DRUG:semaglutide","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2024-09-20","FALSE","0"],["S001444","ClinicalTrials.gov","NCT07775846",null,"QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","820","Type 2 Diabetic Kidney Disease","DRUG:empagliflozin; DRUG:Finerenone; DRUG:Mazdutide; DRUG:Finerenone Placebo; DRUG:Mazdutide Placebo; DRUG:Angiotensin Receptor Blocker (ARB)","Huijie Zhang","2026-09-01","FALSE","0"],["S001445","ClinicalTrials.gov","NCT06283641",null,"Multicentre, Single-arm, Non-interventional Regulatory Post- Marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.","OBSERVATIONAL",null,null,"COMPLETED","300","Obesity","DRUG:Liraglutide","Novo Nordisk A/S","2024-04-08","FALSE","2"],["S001446","ClinicalTrials.gov","NCT03745885",null,"A Randomized, Double-blind, Placebo-controlled Study the Efficacy and Safety of Supaglutide in Chinese Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","48","Diabetes Mellitus, Type 2","DRUG:Supaglutide injection; DRUG:Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2018-12-04","FALSE","1"],["S001447","ClinicalTrials.gov","NCT01879917","NewLira","A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Trial of Liraglutide Treatment in Subjects With Newly Diagnosed Type 1 Diabetes.","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","65","Diabetes Mellitus, Type 1","DRUG:Liraglutide; DRUG:Placebo","Hvidovre University Hospital","2014-02","FALSE","0"],["S001448","ClinicalTrials.gov","NCT06132477",null,"Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","150","Morbid Obesity; Metabolic Syndrome; Diabetes Mellitus; Hypertension; Obstructive Sleep Apnea of Adult","DRUG:GLP-1 receptor agonist","University of Missouri-Columbia","2024-02-01","FALSE","9"],["S001449","ClinicalTrials.gov","NCT07232719","TRIUMPH-8","A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","250","Obesity; Overweight","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2025-11-17","FALSE","0"],["S001450","ClinicalTrials.gov","NCT06890611",null,"A Phase 1, Relative Bioavailability Study of Bimagrumab (LY3985863) Test and Reference Materials, and Bimagrumab Test Material Coadministration and Coformulation With Tirzepatide (LY900042), in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","125","Healthy","DRUG:Bimagrumab; DRUG:Tirzepatide; DRUG:Bimagrumab + Tirzepatide Coformulation","Eli Lilly and Company","2025-03-25","FALSE","0"],["S001451","ClinicalTrials.gov","NCT07684144",null,"A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","950","Obesity; Overweight; Diabetes Mellitus, Type 2","DRUG:Maridebart Cafraglutide; DRUG:Placebo","Amgen","2026-07-29","FALSE","0"],["S001452","ClinicalTrials.gov","NCT02535299","Par-4；GLP-1","The Correlation Between Par-4 and Telomere-telomerase System in the New Dignosised Type 2 Diabetes Patients Who Received GLP-1 Analog or Metformin Treatment","INTERVENTIONAL",null,"PHASE4","UNKNOWN","200","GLP-1；Metformin；Telomere-telomerase System；Par-4","DRUG:Liraglutide; DRUG:Metformin","Third Military Medical University","2016-06","FALSE","0"],["S001453","ClinicalTrials.gov","NCT00537719",null,"A Single-Blind, Randomized, Placebo-Controlled Study in Healthy Men and Women to Determine the Effect of Single Subcutaneous Injections of GSK716155 on Gastric Emptying Time for Solid and Liquid Components of a Meal","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","34","Diabetes Mellitus, Type 2","DRUG:GSK716155; DRUG:Placebo","GlaxoSmithKline","2007-12-07","FALSE","1"],["S001454","ClinicalTrials.gov","NCT03167411",null,"A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","20","Type2 Diabetes Mellitus","DRUG:Bexagliflozin; DRUG:Exenatide Injection","Theracos","2017-05-24","TRUE","0"],["S001455","ClinicalTrials.gov","NCT00299871",null,"A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","542","Type 2 Diabetes","DRUG:LIXISENATIDE (AVE0010)","Sanofi","2006-02","FALSE","1"],["S001456","ClinicalTrials.gov","NCT07563699",null,"A Prospective, Multicenter, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus","INTERVENTIONAL","NON_RANDOMIZED","PHASE1; PHASE2","RECRUITING","24","Diabete Type 2","DRUG:SG Depot 2 mg; DRUG:SG Depot 4 mg; DRUG:SG Depot 6 mg; DRUG:SG Depot 8 mg","Mapi Pharma Ltd.","2026-08-09","FALSE","0"],["S001457","ClinicalTrials.gov","NCT06704763",null,"A Drug-Drug Interaction, Single-arm, Open-label Study to Assess the Effect of Quinidine on the Pharmacokinetics of Orforglipron in Healthy Participants","INTERVENTIONAL",null,"PHASE1","COMPLETED","27","Healthy","DRUG:Orforglipron; DRUG:Midazolam; DRUG:Quinidine","Eli Lilly and Company","2024-12-06","TRUE","0"],["S001458","ClinicalTrials.gov","NCT05294536",null,"A Randomized, Open-label, Two-period, and Double-cross Comparative Study on the Pharmacokinetics of Liraglutide Injection (RD12014) and Victoza® in Healthy Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","50","Type 2 Diabetes","DRUG:Liraglutide injection,RD12014; DRUG:Liraglutide injection,Victoza","Sunshine Lake Pharma Co., Ltd.","2020-06-22","FALSE","1"],["S001459","ClinicalTrials.gov","NCT02473809","LIRABONE","The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","60","Diabetes Complications; Osteoporosis","DRUG:Liraglutide; DRUG:Placebo","University of Aarhus","2015-08","FALSE","3"],["S001460","ClinicalTrials.gov","NCT02284009",null,"Study 110933: Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","67","Diabetes Mellitus, Type 1","BIOLOGICAL:Albiglutide weekly injection; BIOLOGICAL:Placebo weekly injection; BIOLOGICAL:Insulin","GlaxoSmithKline","2014-10-10","TRUE","1"],["S001461","ClinicalTrials.gov","NCT03993132",null,"Cardiovascular Outcomes, and Mortality in Danish Patients With Type 2 Diabetes Who Initiate Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA): A Danish Nationwide Comparative Effectiveness Study [EMPLACEtm]","OBSERVATIONAL",null,null,"COMPLETED","26774","Diabetes Mellitus, Type 2","DRUG:Empagliflozin; DRUG:Liraglutide","Boehringer Ingelheim","2018-10-01","TRUE","1"],["S001462","ClinicalTrials.gov","NCT07832084","OFF-RAMP","OFF-RAMP Feasibility: a Pilot Trial Comparing Different Off-ramping Strategies for Maintaining Weight Loss Among Adults Using Incretin Based Therapies for Obesity","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","60","Obesity & Overweight; Cardiometabolic Health Indicators","DRUG:GLP-1 dose reduction; DRUG:non-GLP weight loss medication; DRUG:Maintenance of GLP-1 dose; BEHAVIORAL:Resistance exercise regimen; BEHAVIORAL:Lifestyle/nutrition counseling","Jing Luo","2026-11-01","FALSE","0"],["S001463","ClinicalTrials.gov","NCT06207877",null,"An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment(CagriSema) on Energy Intake, Appetite and Gastric Emptying in People With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","62","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2024-02-23","FALSE","1"],["S001464","ClinicalTrials.gov","NCT05610800",null,"A Randomized Controlled Trial of Exenatide as an Adjunct to Nicotine Patch for Smoking Cessation and Prevention of Post-Cessation Weight Gain","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","140","Smoking Cessation; Weight Gain","DRUG:Exenatide 2 milligram (mg) Injection; DRUG:Placebo; DRUG:Nicotine patch; BEHAVIORAL:Smoking Cessation Counseling","The University of Texas Health Science Center, Houston","2022-12-07","FALSE","2"],["S001465","ClinicalTrials.gov","NCT05689099",null,"A Study to Demonstrate Bioequivalence Between Semaglutide Drug Product Concentrations 0.68 mg/mL and 1.34 mg/mL","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","20","Diabetes Mellitus, Type 2; Healthy Participants","DRUG:Semaglutide B, 1.34 mg/mL; DRUG:Semaglutide B, 0.68 mg/mL","Novo Nordisk A/S","2023-01-17","FALSE","0"],["S001466","ClinicalTrials.gov","NCT02944500",null,"Saxenda: Underlying Mechanisms and Clinical Outcomes","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","28","Obesity","DRUG:liraglutide; OTHER:Placebo","Beth Israel Deaconess Medical Center","2016-11","FALSE","3"],["S001467","ClinicalTrials.gov","NCT07190144",null,"Coronary Flow Reserve Changes After Semaglutide Treatment","OBSERVATIONAL",null,null,"COMPLETED","122","The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients; Obesity &Amp; Overweight",null,"Ekrem Bilal Karaayvaz","2025-01-07","FALSE","2"],["S001468","ClinicalTrials.gov","NCT06003465",null,"A Relative Bioavailability Study to Compare the Pharmacokinetics of LY3437943 Administered Subcutaneously by a Test Device (Test Formulation) Versus Reference Device (Reference Formulation) in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","57","Healthy","DRUG:LY3437943; DEVICE:Test; DEVICE:Reference","Eli Lilly and Company","2023-08-29","FALSE","0"],["S001469","ClinicalTrials.gov","NCT06584916",null,"A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Orforglipron Once Daily Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","376","Obesity; Overweight","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2024-09-13","FALSE","1"],["S001470","ClinicalTrials.gov","NCT01455883",null,"A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Type 2 Diabetes","DRUG:ITCA 650 60 mcg/day; DRUG:glimepiride","Intarcia Therapeutics","2013-02","FALSE","0"],["S001471","ClinicalTrials.gov","NCT05348122",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled，Dulaglutide-controlled Phase Ⅱ Trial Exploring Optimal Dosing Regimen for TG103 Injection Monotherapy in Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","240","Type 2 Diabetes Mellitus","DRUG:TG103,Q2W; DRUG:TG103,QW; DRUG:Placebo,Q2W; DRUG:Placebo,QW; DRUG:Dulaglutide,QW","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2022-06-15","FALSE","0"],["S001472","ClinicalTrials.gov","NCT05035095","OASIS 1","Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in Subjects With Overweight or Obesity (OASIS 1)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","667","Obesity; Overweight","DRUG:Oral semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2021-09-13","TRUE","2"],["S001473","ClinicalTrials.gov","NCT04941521",null,"Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study","INTERVENTIONAL",null,"PHASE1; PHASE2","COMPLETED","3","Cocaine Use Disorder","DRUG:Exenatide 2 mg [Bydureon]; BEHAVIORAL:Drug Counseling","The University of Texas Health Science Center, Houston","2021-06-24","TRUE","1"],["S001474","ClinicalTrials.gov","NCT06037252",null,"A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Tirzepatide Doses in Participants With Type 2 Diabetes and Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","414","Type 2 Diabetes; Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-09-21","FALSE","0"],["S001475","ClinicalTrials.gov","NCT01235819",null,"Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","20","Type 1 Diabetes","DRUG:Insulin; DRUG:Sitagliptin; DRUG:Exenatide","Command Hospital, India","2010-11","FALSE","1"],["S001476","ClinicalTrials.gov","NCT07153471","ATTAIN-OA PAIN","A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","800","Osteoarthritis","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-09-15","FALSE","0"],["S001477","ClinicalTrials.gov","NCT03707171",null,"Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","NON_RANDOMIZED","PHASE3","COMPLETED","30","Type 2 Diabetes Mellitus","DRUG:Liraglutide; DRUG:placebo","Third Military Medical University","2018-10-01","FALSE","1"],["S001478","ClinicalTrials.gov","NCT01444898",null,"Effects of Exenatide on Obesity and Appetite in Overweight Patients With Prader-Willi Syndrome","INTERVENTIONAL",null,null,"COMPLETED","10","Prader-Willi Syndrome","DRUG:Exenatide","Children's Hospital Los Angeles","2012-03","TRUE","4"],["S001479","ClinicalTrials.gov","NCT06977438","GLOW","GLOW (GLP-1 Plus Lifestyle for Overall Wellness)","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","1020","Obesity, Childhood","DRUG:Semaglutide","University of Minnesota","2026-10-15","FALSE","0"],["S001480","ClinicalTrials.gov","NCT01326871",null,"A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer","INTERVENTIONAL","NON_RANDOMIZED","PHASE1; PHASE2","COMPLETED","68","Transitional Cell Carcinoma of Bladder; Urethra Cancer; Ureter Cancer; Malignant Tumor of Renal Pelvis","DRUG:Cisplatin; DRUG:Gemcitabine; BIOLOGICAL:ALT-801","Altor BioScience","2011-09-06","TRUE","0"],["S001481","ClinicalTrials.gov","NCT07492563",null,"Effectiveness and Safety of Tirzepatide (t.g.) in Patients Treated at the Obesity Unit of the Department of Endocrinology of the Hospital de Clínicas, Faculty of Medical Sciences, UNA: Phase 4 Study","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","300","Obesity; Type 2 Diabetes Mellitus; Overweight With Comorbidities","DRUG:Tirzepatide (T.G.)","LABORATORIOS INDUFAR","2026-03","FALSE","0"],["S001482","ClinicalTrials.gov","NCT06608433","PIANO","Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function - the PIANO Study","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","22","Healthy Volunteer Study; HPA; Cortisol Deficiency; Adrenal Insufficiency","DRUG:semaglutide; DRUG:Placebo","University Hospital, Basel, Switzerland","2025-01-16","FALSE","0"],["S001483","ClinicalTrials.gov","NCT05158244",null,"A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE ORAL DOSES OF PF-07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","34","Type 2 Diabetes Mellitus","DRUG:PF-07081532; DRUG:Placebo","Pfizer","2021-12-22","TRUE","1"],["S001484","ClinicalTrials.gov","NCT00672399",null,"A Placebo- and Positive-Controlled Study of the Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","70","Healthy Subjects","DRUG:exenatide; DRUG:Moxifloxacin; DRUG:Placebo","AstraZeneca","2008-04","FALSE","0"],["S001485","ClinicalTrials.gov","NCT06057077",null,"A Randomized Clinical Trial Comparing Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","UNKNOWN","120","Type 1 Diabetes","DRUG:Semaglutide weekly injection","Ministry of Health, Saudi Arabia","2024-01-01","FALSE","3"],["S001486","ClinicalTrials.gov","NCT02212067",null,"A Single-centre, Randomised, Double-blind, Multiple-dose, Placebo-controlled, Parallel-group Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","87","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-08-11","FALSE","1"],["S001487","ClinicalTrials.gov","NCT01511198",null,"NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","223","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:metformin","Novo Nordisk A/S","2001-02","FALSE","2"],["S001488","ClinicalTrials.gov","NCT03232112","EXALT","Does Glucagon-like Peptide (GLP-1) Receptor Agonist Stimulation Reduce Alcohol Intake in Patients With Alcohol Dependence?","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","152","Alcohol Dependence, in Remission; Addiction, Alcohol","DRUG:Exenatide 2 MG Injection; DRUG:BD PosiFlush (saline)","Anders Fink-Jensen, MD, DMSci","2017-08-07","FALSE","1"],["S001489","ClinicalTrials.gov","NCT02928471","IM-LOSEIT-I","Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis Following a Significant Weight Loss, Investigating the Impact on Inflammation (A Substudy to \"Effect of Liraglutide on Body Weight and Pain in Overweight or Obese Patients With Knee Osteoarthritis: A Randomised, Double Blind, Placebo-controlled, Parallel Group, Single-centre Trial\" (NCT02905864)","OBSERVATIONAL",null,null,"COMPLETED","200","Osteoarthritis; Obesity","DIETARY_SUPPLEMENT:Intensive dietary intervention","Henrik Gudbergsen","2016-11","FALSE","0"],["S001490","ClinicalTrials.gov","NCT07829198","TirBaS","Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","70","Obesity","DRUG:Tirzepatide; DRUG:Placebo","Universidade do Porto","2027-01","FALSE","0"],["S001491","ClinicalTrials.gov","NCT02315001","LIONESS","The Physiological Effects of GLP-1 on Haemodynamics During Exercise in Patients With Ischaemic Heart Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","26","Ischaemic Heart Disease; Coronary Heart Disease; Chronic Stable Angina","DRUG:Liraglutide; OTHER:Placebo","King's College London","2014-01","FALSE","2"],["S001492","ClinicalTrials.gov","NCT03642600",null,"Novel Strategies in Weight Loss in Women With Polycystic Ovary Syndrome: do Changes in the Gut Microbiome Play a Role?","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","21","PCOS; Obesity; Metabolic Syndrome","DIETARY_SUPPLEMENT:dietary advice plus myo-inositol and folic acid; DRUG:dietary advice plus Liraglutide Pen Injector","Universitaire Ziekenhuizen KU Leuven","2019-02-28","FALSE","0"],["S001493","ClinicalTrials.gov","NCT06173778",null,"A Randomized Controlled Trial of Once-Weekly Semaglutide for Limiting Post-Smoking Cessation Weight Gain in Adult Smokers With Overweight/Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","197","Obesity; Overweight; Cigarette Smoking","DRUG:semaglutide 2.4mg; DRUG:Placebo; DRUG:Nicotine Replacement Therapy (NRT, nicotine patch); BEHAVIORAL:Brief Smoking Cessation Counseling","The University of Texas Health Science Center, Houston","2024-04-23","FALSE","1"],["S001494","ClinicalTrials.gov","NCT06269107","COMBINE 4","A 40-week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Daily Insulin Glargine 100 Units/mL in Participants With Type 2 Diabetes Inadequately Controlled on Oral Anti Diabetic Drugs COMBINE 4","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","485","Type 2 Diabetes","DRUG:IcoSema; DRUG:Insulin glargine","Novo Nordisk A/S","2024-02-15","FALSE","1"],["S001495","ClinicalTrials.gov","NCT06387199","SEMA SMA","Alleviating Carbohydrate Counting Using Weekly Subcutaneous Semaglutide Injections in People with Type 1 Diabetes on Closed-Loop Insulin Therapy: a 2x4 Factorial Randomized Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","RECRUITING","26","Type 1 Diabetes; Diabetes Mellitus","DRUG:Semaglutide with 4 meal strategies; DRUG:Placebo with 4 meal strategies","McGill University Health Centre/Research Institute of the McGill University Health Centre","2024-12-01","FALSE","0"],["S001496","ClinicalTrials.gov","NCT01179048","LEADER®","A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","9341","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2010-08-31","TRUE","63"],["S001497","ClinicalTrials.gov","NCT06541678",null,"A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Itraconazole and Cyclosporine on the Single-Dose Pharmacokinetics of Danuglipron in Healthy Adult Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","16","Healthy","DRUG:Danuglipron; DRUG:Cyclosporine; DRUG:Itraconazole","Pfizer","2024-12-23","FALSE","0"],["S001498","ClinicalTrials.gov","NCT02207374","SUSTAIN™","Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Who Are Insufficiently Controlled on Diet/Exercise Therapy or OAD Monotherapy","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","601","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:DPP-4 inhibitor","Novo Nordisk A/S","2014-08-04","TRUE","5"],["S001499","ClinicalTrials.gov","NCT04601740","PIONEER REAL","A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in The Netherlands","OBSERVATIONAL",null,null,"COMPLETED","145","Diabetes Mellitus, Type 2","DRUG:Oral Semaglutide","Novo Nordisk A/S","2020-11-17","FALSE","2"],["S001500","ClinicalTrials.gov","NCT06354660",null,"A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","537","Diabetes Type 2","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2024-04-10","FALSE","1"],["S001501","ClinicalTrials.gov","NCT06965413","GYMINDA","A Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Assess Efficacy, Safety, and Tolerability of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","285","Obesity; Overweight; Overweight With One Weight Related Comorbidity","DRUG:RO7204239; DRUG:RO7204239 Matching Placebo; DRUG:Tirzepatide","Hoffmann-La Roche","2025-05-05","FALSE","0"],["S001502","ClinicalTrials.gov","NCT00318461","LEAD-2","Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1091","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:metformin; DRUG:glimepiride; DRUG:placebo","Novo Nordisk A/S","2006-05","TRUE","18"],["S001503","ClinicalTrials.gov","NCT01319240",null,"A Trial to Investigate Pharmacokinetics, Safety and Tolerability of Insulin Degludec/Liraglutide (A3) Compared With Insulin Degludec and Liraglutide in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Diabetes; Healthy","DRUG:insulin degludec; DRUG:insulin degludec/liraglutide; DRUG:liraglutide","Novo Nordisk A/S","2011-03","FALSE","0"],["S001504","ClinicalTrials.gov","NCT01620489",null,"Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment. A 26-week Double-blind Placebo-controlled, Randomised, Multicentre, Multi-national, Parallel-group Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","279","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2012-06-14","TRUE","3"],["S001505","ClinicalTrials.gov","NCT07732218",null,"Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial","INTERVENTIONAL",null,"PHASE4","COMPLETED","95","Type 2 Diabetes","DRUG:Semaglutide (Ozempic®)","Rehman Medical Institute - RMI","2022-07-04","FALSE","0"],["S001506","ClinicalTrials.gov","NCT01432938",null,"The Effect of Dulaglutide (LY2189265) on the Pharmacokinetics and Pharmacodynamics of Single Dose Warfarin in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","28","Diabetes Mellitus, Type 2","BIOLOGICAL:dulaglutide; DRUG:Warfarin","Eli Lilly and Company","2011-09","TRUE","1"],["S001507","ClinicalTrials.gov","NCT04873050","SWEET","A Randomized, Placebo-controlled, Double Blind Trial of Semaglutide 1mg (Ozempic®) on Regression to Normoglycemia in WomEn with a Recent History of Gestational DiabETes Mellitus: the SWEET Study","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","102","Pre Diabetes; Postpartum Disorder","DRUG:Semaglutide Pen Injector [Ozempic]; DRUG:Placebo semaglutide pen injector","Woman's","2022-01-13","FALSE","0"],["S001508","ClinicalTrials.gov","NCT07150962",null,"A Phase I Clinical Study Comparing the Relative Bioavailability, Safety and Tolerability of the First-generation and Second-generation Formulations of HRS9531 Tablets and Exploring the Safety, Tolerability and Pharmacokinetic Characteristics of Single-dose Escalation of the Second-generation Formulation","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","168","Overweight or Obesity","DRUG:HRS-9531 Tablet","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-10-15","FALSE","0"],["S001509","ClinicalTrials.gov","NCT01147718",null,"An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Digoxin When Coadministered With Albiglutide in Healthy Adult Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","30","Diabetes Mellitus, Type 2","BIOLOGICAL:digoxin plus albiglutide","GlaxoSmithKline","2010-06-11","FALSE","2"],["S001510","ClinicalTrials.gov","NCT02249910",null,"An Open-label, Single Arm, Sequential, Single Centre Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","32","Diabetes; Healthy","DRUG:semaglutide; DRUG:metformin; DRUG:digoxin; DRUG:placebo","Novo Nordisk A/S","2014-09-18","FALSE","1"],["S001511","ClinicalTrials.gov","NCT04994288",null,"Efficacy and Safety of Once-weekly Supaglutide Versus Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","547","Type2 Diabetes","BIOLOGICAL:Supaglutide injection; OTHER:placebo injection","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2021-08-03","FALSE","4"],["S001512","ClinicalTrials.gov","NCT06411210",null,"Obesity Complicating Type 1 Diabetes in Young Adults: Physiology and Impact of GLP-1 Analogue Anti-obesity Treatment on Cardiometabolic Risk Factors","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","54","Diabetes type1; Obesity","DRUG:Semaglutide Pen Injector; DRUG:Placebo","Yale University","2024-07-16","FALSE","0"],["S001513","ClinicalTrials.gov","NCT04952779",null,"A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec / Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea","OBSERVATIONAL",null,null,"COMPLETED","750","Diabetes Mellitus, Type 2","DRUG:Xultophy® (insulin degludec/liraglutide)","Novo Nordisk A/S","2021-06-02","FALSE","0"],["S001514","ClinicalTrials.gov","NCT06039826",null,"A Phase 1 Study to Investigate the Effect of LY3437943 on the Pharmacokinetics of the Combined Oral Contraceptive Ethinyl Estradiol and Drospirenone in Female Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","46","Overweight","DRUG:LY3437943; DRUG:Ethinyl Estradiol; DRUG:Drospirenone","Eli Lilly and Company","2023-09-12","FALSE","0"],["S001515","ClinicalTrials.gov","NCT06830343",null,"A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic of SYH9017 in Chinese Participants With Overweight and Obesity Following Single and Multiple Doses","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","66","Overweight or Obesity","DRUG:SYH9017; DRUG:Placebo; DRUG:Wegovy ®","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2025-02-27","FALSE","0"],["S001516","ClinicalTrials.gov","NCT03985384","STOP","Effect of Semaglutide on Coronary Atherosclerosis Plaque Progression in Type 2 Diabetics","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","140","Type 2 Diabetes; Coronary Artery Disease","DRUG:Semaglutide 2 MG/1.5 ML Subcutaneous Solution; DRUG:Placebo","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","2019-04-30","FALSE","0"],["S001517","ClinicalTrials.gov","NCT06792955",null,"A Single-center, Single-dose, Randomized, Open-label, Single-period, Parallel Bioequivalence Study of HRS9531 Injection Solution in Multi-dose Pens and Single-dose Pens in Overweight/Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","120","Overweight/Obesity","DRUG:HRS9531 injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-02-11","FALSE","0"],["S001518","ClinicalTrials.gov","NCT06058585","CAPTIVATE","The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","2000","Chronic Kidney Diseases","DRUG:Finerenone; DRUG:Placebo Finerenone; DRUG:Semaglutide; DRUG:Placebo semaglutide","The George Institute","2024-09-04","FALSE","2"],["S001519","ClinicalTrials.gov","NCT04559815","PIONEER REAL","A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Canada","OBSERVATIONAL",null,null,"COMPLETED","194","Diabetes Mellitus, Type 2","DRUG:Oral Semaglutide","Novo Nordisk A/S","2020-10-21","FALSE","2"],["S001520","ClinicalTrials.gov","NCT05029076",null,"Human Bioequivalence Test of Liraglutide Injection","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","28","Type 2 Diabetes","DRUG:Liraglutide injection; DRUG:Victoza","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","2019-05-21","FALSE","1"],["S001521","ClinicalTrials.gov","NCT04495140",null,"A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD STUDY IN HEALTHY ADULT MALE PARTICIPANTS TO ASSESS THE MASS BALANCE, ABSOLUTE BIOAVAILABILITY, FRACTION ABSORBED, AND PHARMACOKINETICS OF [14C]PF-06882961","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","6","Healthy Volunteer","DRUG:[14C]PF-06882961, 50 mg; DRUG:PF-06882961, 50 mg and [14C]PF-06882961, 100 ug","Pfizer","2020-07-22","FALSE","0"],["S001522","ClinicalTrials.gov","NCT02055014",null,"Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","72","Type 2 Diabetes; Obesity; Diabesity","DRUG:Liraglutide; DEVICE:Duodenal-jejunal bypass liner - Endobarrier device","Sandwell & West Birmingham Hospitals NHS Trust","2013-07","FALSE","2"],["S001523","ClinicalTrials.gov","NCT05896384",null,"A Non-randomised, Open-label Phase I Trial to Evaluate the Effect of BI 456906 at Different Dose Levels of Multiple Subcutaneous Doses in a Titration Scheme on the Single Dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Otherwise Healthy Women With Overweight/Obesity","INTERVENTIONAL",null,"PHASE1","COMPLETED","32","Healthy","DRUG:BI 456906; DRUG:Microgynon®","Boehringer Ingelheim","2023-12-21","FALSE","0"],["S001524","ClinicalTrials.gov","NCT02577848",null,"Effects of Liraglutide on Left Ventricular Function in Patients With Non-ST-Segment Elevation Myocardial Infarction","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","90","Myocardial Infarction","DRUG:GLP-1; DRUG:Placebo","Chinese PLA General Hospital","2015-10","FALSE","1"],["S001525","ClinicalTrials.gov","NCT02147925","LIGHT-ON","Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","75","Non-alcoholic Fatty Liver Disease","DRUG:Liraglutide combined with metformin; DRUG:Insulin glargine combined with metformin; DRUG:Sitagliptin combined with metformin","Sun Yat-sen University","2014-08","FALSE","0"],["S001526","ClinicalTrials.gov","NCT07417618","INTERCEPT","Comparative Effectiveness of Dulaglutide, Semaglutide, and Tirzepatide in Preventing Cardiovascular Events in Patients With Type 2 Diabetes and Obesity With or Without Atherosclerotic Cardiovascular Disease.","OBSERVATIONAL",null,null,"COMPLETED","60000","Type 2 Diabetes; Overweight; ASCVD","DRUG:Dulaglutide; DRUG:Semaglutide; DRUG:Tirzepatide; DRUG:Sitagliptin","Brigham and Women's Hospital","2026-01-27","FALSE","0"],["S001527","ClinicalTrials.gov","NCT05254314","GATA-3","Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-related, Symptomatic Asthma (GATA-3)","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","100","Asthma","DRUG:Semaglutide Pen Injector 2.4mg weekly; OTHER:Placebo","Vanderbilt University Medical Center","2022-10-11","FALSE","1"],["S001528","ClinicalTrials.gov","NCT01270789","LIBRA","A Randomized Controlled Study Assessing the Effect of Liraglutide on the Preservation of Beta-Cell Function in Patients With Type 2 Diabetes Mellitus: The LIraglutide and Beta-cell RepAir (LIBRA) Study","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","63","Type 2 Diabetes","DRUG:Liraglutide; DRUG:placebo","Mount Sinai Hospital, Canada","2011-01","FALSE","3"],["S001529","ClinicalTrials.gov","NCT04102189",null,"Effect and Safety of Semaglutide 2.4 mg Once Weekly on Weight Management in Adolescents With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","201","Overweight; Obesity","DRUG:Semaglutide; OTHER:Placebo","Novo Nordisk A/S","2019-10-07","TRUE","5"],["S001530","ClinicalTrials.gov","NCT06467604",null,"CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","7","Obesity","BEHAVIORAL:Surveys; OTHER:Indirect Calorimetry; OTHER:Body composition; OTHER:Anthropometrics","University of California, Davis","2024-11-01","FALSE","1"],["S001531","ClinicalTrials.gov","NCT07670884",null,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","675","Chronic Management of Body Weight","DRUG:HRS9531 Tablet; DRUG:HRS9531 Tablet Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-07-24","FALSE","0"],["S001532","ClinicalTrials.gov","NCT03856047",null,"Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","706","Overweight; Obesity","DRUG:NNC0174-0833; DRUG:Placebo (NNC0174-0833); DRUG:Liraglutide 3.0 mg; DRUG:Placebo (Liraglutide 3.0 mg)","Novo Nordisk A/S","2019-03-01","TRUE","1"],["S001533","ClinicalTrials.gov","NCT05579249",null,"Effectiveness of Semaglutide 2.4 mg vs. Commercially Available Medications for Chronic Weight Management in Participants With Obesity in a Multi-employer Setting in The US - a Pragmatic Clinical Study","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","500","Obesity","DRUG:Semaglutide; DRUG:Orlistat; DRUG:Phentermine/Topiramate; DRUG:Naltrexone/Bupropion; DRUG:Liraglutide","Novo Nordisk A/S","2023-01-19","TRUE","0"],["S001534","ClinicalTrials.gov","NCT05893576",null,"A Relative Bioavailability Study of Single-dose, Randomized, Open-label, Single-period, Parallel Design of HRS9531 Injection Using Different Manufacturing Processes in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","50","Type 2 Diabetes","DRUG:HRS9531","Fujian Shengdi Pharmaceutical Co., Ltd.","2023-05-15","FALSE","0"],["S001535","ClinicalTrials.gov","NCT02640118","Px-Lixi","The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects -a Delineation of Extrapancreatic Effects","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","24","Diabetes After Total Pancreatectomy","DRUG:Lixisenatide; DRUG:Lixisenatide-Placebo; OTHER:Standardized liquid meal","University Hospital, Gentofte, Copenhagen","2015-08","FALSE","1"],["S001536","ClinicalTrials.gov","NCT02129985","T2DMRS","Effect of Short-term Intensive Insulin Sequential Exenatide Therapy on Beta Cell Function and Glycaemic Control in Patients With Newly Diagnosed Type 2 Diabetes :a Multicenter Prospective Randomized Control Study","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","100","Type 2 Diabetes","DRUG:Exenatide; DRUG:Metformin","xiaolong zhao","2014-02","FALSE","0"],["S001537","ClinicalTrials.gov","NCT05606913",null,"Efficacy and Safety of IBI362 Versus Dulaglutide as add-on to Metformin and/or SGLT2 Inhibitor or TZD in Subjects With Type 2 Diabetes (DREAMS-2)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","731","Type 2 Diabetes","DRUG:dulaglutide; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2023-01-06","FALSE","1"],["S001538","ClinicalTrials.gov","NCT06827002",null,"Cissus Quadrangularis (CQR-300®) and Dichrostachys Glomerata (Dyglomera®) Extracts Increase GLP-1 Levels and Inhibit Dipeptidyl Phosphate-4 Activity in Healthy Overweight and Obese Adults","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","ACTIVE_NOT_RECRUITING","248","Obesity and Overweight; Appetite Regulation","DRUG:Dichrostachys glomerata; DRUG:Cissus quadrangularia; DRUG:Dextrin; DRUG:Semaglutide (Rybelsus®)","University of Yaounde 1","2023-03-29","FALSE","4"],["S001539","ClinicalTrials.gov","NCT07229157",null,"A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, Parallel Group Study With Nested Crossover Comparison to Assess the Effect of Maridebart Cafraglutide on QT/QTc Intervals in Participants Living With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","81","Overweight; Obesity","DRUG:Maridebart Cafraglutide; DRUG:Moxifloxacin; DRUG:Placebo for Maridebart Cafraglutide; DRUG:Placebo for Moxifloxacin","Amgen","2025-10-22","FALSE","0"],["S001540","ClinicalTrials.gov","NCT07326111","PERIODS","A Clinical Trial of Tirzepatide (LY3298176) in Subjects With Overweight or Obesity and PCOS-related Ovarian Dysfunction","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","198","Polycystic Ovary Syndrome (PCOS); Obesity & Overweight","DRUG:Tirzepatide as an adjunct to lifestyle intervention; DRUG:Placebo as an adjunct to lifestyle intervention","University of Bonn","2025-12-09","FALSE","0"],["S001541","ClinicalTrials.gov","NCT07294950","REST","Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: a Randomized Controlled Trial Comparing Gradual Dose Reduction With Immediate Treatment Cessation.","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","98","Obesity (Disorder); Weight Change; Blood Pressure Monitoring; Appetite Regulation","DRUG:Gradual dose reduction of semaglutide; DRUG:Abrupt cessation of semaglutide","Mount Sinai Hospital, Canada","2026-02-01","FALSE","1"],["S001542","ClinicalTrials.gov","NCT01237197",null,"Exenatide in Extreme Pediatric Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","26","Obesity","DRUG:Exenatide; DRUG:Placebo","University of Minnesota","2010-10","TRUE","1"],["S001543","ClinicalTrials.gov","NCT04873245","QUEST","Lifestyle Counseling and Medication for Adolescent Weight Management","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","120","Obesity, Childhood","BEHAVIORAL:Intensive Behavioral Program; DRUG:Semaglutide and Behavioral Program","University of Minnesota","2022-03-15","FALSE","0"],["S001544","ClinicalTrials.gov","NCT02244164",null,"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","INTERVENTIONAL","NON_RANDOMIZED",null,"TERMINATED","5","Type 2 Diabetes; Incretinomimetics; Pancreas","DRUG:Incretinomimetics; DRUG:DPP-4 inhibitors","Erasme University Hospital","2014-10","FALSE","3"],["S001545","ClinicalTrials.gov","NCT06908694","GAINPCCONTROL","GLP1-Receptor Agonists in Men With Prostate Cancer: Control of Cardiovascular Risk Factors and Prostate Biomarkers","INTERVENTIONAL",null,"PHASE4","ACTIVE_NOT_RECRUITING","20","Prostate Cancer","DRUG:Semaglutide Pen Injector","Hamilton Health Sciences Corporation","2025-07-02","FALSE","0"],["S001546","ClinicalTrials.gov","NCT07187830","ADIPOLIVE","Region-specific Adipose Tissues and Liver Changes Associated With Semaglutide Treatment in Chronic Kidney Disease Patients","OBSERVATIONAL",null,null,"RECRUITING","52","Chronic Kidney Disease in Type 2 Diabetes; Obesity & Overweight",null,"University of Alberta","2026-02-23","FALSE","0"],["S001547","ClinicalTrials.gov","NCT06099067","HARRP","Harmonizing RCT-Duplicate Emulations: A Real World Replication Program Analyzing Three Clinical Trials, CANVAS, LEADER, and SAVOR TIMI in Type 2 Diabetes Mellitus","OBSERVATIONAL",null,null,"COMPLETED","239990","Type 2 Diabetes Mellitus","DRUG:Canagliflozin; DRUG:DPP4 inhibitor; DRUG:Liraglutide; DRUG:Saxagliptin; DRUG:2nd generation Sulfonylurea","AstraZeneca","2020-05-15","FALSE","0"],["S001548","ClinicalTrials.gov","NCT01785771",null,"An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c","INTERVENTIONAL",null,"PHASE3","TERMINATED","100","Type 2 Diabetes","DRUG:ITCA 650 (exenatide in DUROS)","Intarcia Therapeutics","2013-05","FALSE","1"],["S001549","ClinicalTrials.gov","NCT06439277",null,"Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","300","Obesity; Weight Gain","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2024-06-03","FALSE","0"],["S001550","ClinicalTrials.gov","NCT02119819",null,"Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","420","Diabetes Mellitus, Type 2","DRUG:LY2944876; DRUG:Exenatide extended-release; DRUG:Placebo; DRUG:Metformin","OPKO Health, Inc.","2014-04","TRUE","1"],["S001551","ClinicalTrials.gov","NCT02090673",null,"Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea","OBSERVATIONAL",null,null,"COMPLETED","1711","Diabetes Mellitus Type 2","DRUG:Exenatide","AstraZeneca","2009-02","FALSE","1"],["S001552","ClinicalTrials.gov","NCT03724981",null,"Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","312","Diabetes Mellitus, Type 2","DRUG:Dulaglutide Pen; DRUG:Semaglutide Pen","Eli Lilly and Company","2018-10-18","TRUE","1"],["S001553","ClinicalTrials.gov","NCT02845219",null,"A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females","INTERVENTIONAL",null,"PHASE1","COMPLETED","25","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:SNAC; DRUG:Microgynon®","Novo Nordisk A/S","2016-07","FALSE","1"],["S001554","ClinicalTrials.gov","NCT07135141","SMART","Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity:A Multicenter, Randomized, Double-Blind, Placebo-Controlled Superiority Trial","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","256","Severe Obesity","DRUG:Sleeve gastrectomy plus early mazdutide initiation; DRUG:Sleeve gastrectomy followed with early mazdutide placebo initation","Beijing Friendship Hospital","2025-09-30","FALSE","0"],["S001555","ClinicalTrials.gov","NCT05486065",null,"Investigation of Once-weekly Semaglutide S.C. Dose-Response in Patients With Type 2 Diabetes and Overweight - a Participant- and Investigator-blinded and Sponsor Open-label Study","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","245","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2022-08-08","TRUE","1"],["S001556","ClinicalTrials.gov","NCT03175120","DUAL™ II China","A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","453","Diabetes; Diabetes Mellitus, Type 2","DRUG:Insulin degludec/liraglutide; DRUG:Insulin degludec","Novo Nordisk A/S","2017-05-26","TRUE","0"],["S001557","ClinicalTrials.gov","NCT01777282",null,"A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","374","Diabetes Mellitus","DRUG:Albiglutide; DRUG:Sulfonylurea; DRUG:Biguanide; DRUG:Glinide; DRUG:Thiazolidinedione; DRUG:Alpha-glucosidase inhibitor","GlaxoSmithKline","2013-02-23","TRUE","1"],["S001558","ClinicalTrials.gov","NCT06049329",null,"Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Doses of Oral NNC0487-0111 in Japanese Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","36","Obesity","DRUG:NNC0487-0111; DRUG:Placebo (NNC0487-0111)","Novo Nordisk A/S","2023-09-14","FALSE","0"],["S001559","ClinicalTrials.gov","NCT05623839",null,"A Multiple Dose Titration Study in Participants With Obesity or Overweight to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Overweight; Obesity","DRUG:LY3305677; DRUG:Placebo","Eli Lilly and Company","2022-11-16","FALSE","1"],["S001560","ClinicalTrials.gov","NCT02138045","TODINELI","A Randomized, Double-blinded, Single-centre, Parallel-group, Placebo-controlled, Prospective Trial of Neuroprotective Effect of Liraglutide for Treatment of Diabetic Neuropathy.","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","39","Diabetes Mellitus, Type 1; Type 1 Diabetes Mellitus","DRUG:Placebo treatment; DRUG:Liraglutide treatment","Aalborg University Hospital","2014-05","FALSE","2"],["S001561","ClinicalTrials.gov","NCT06374875","FLAMES","A Prospective Multicenter International Randomized Controlled Trial Comparing Surgical and Medical Therapies in the Treatment of Advanced Metabolic Dysfunction Associated Steatohepatitis","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","120","Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); Non-Alcoholic Fatty Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis (MASH); Liver Fibrosis; Obesity","PROCEDURE:Metabolic surgery; DRUG:Incretin-Based Therapy","The Cleveland Clinic","2024-07-11","FALSE","0"],["S001562","ClinicalTrials.gov","NCT06739122",null,"A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE3","RECRUITING","55","Type 2 Diabetes","DRUG:Dulaglutide","Eli Lilly and Company","2025-01-10","FALSE","0"],["S001563","ClinicalTrials.gov","NCT00763451","GETGOAL-F1","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 in Two Titration Regimens on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","484","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector; DRUG:Metformin","Sanofi","2008-09","TRUE","2"],["S001564","ClinicalTrials.gov","NCT01782261",null,"Pilot Study on Incretin Effect on the Immunological Phenotype in Healthy Subjects and in Type 1 Diabetic Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","15","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Saxagliptin","Medical University of Graz","2012-02","FALSE","0"],["S001565","ClinicalTrials.gov","NCT07229170","GLP1-TASTE","Changes in Taste Perception, Eating Habits, and Other Behavioral Aspects Associated With the Use of GLP-1 Receptor Agonists in Patients Undergoing Weight Loss Treatment: A Retrospective Observational Study.","OBSERVATIONAL",null,null,"RECRUITING","150","Obesity & Overweight; Taste Alterations; Weight Loss; Eating Behavior Changes",null,"San Raffaele Telematic University","2025-12-01","FALSE","1"],["S001566","ClinicalTrials.gov","NCT00809705",null,"A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Investigate the Effect of Taspoglutide on Gastric Emptying Measured by a Paracetamol Test After Single Dose and After Multiple Doses in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","60","Diabetes Mellitus Type 2","DRUG:Placebo; DRUG:taspoglutide","Hoffmann-La Roche","2008-12","FALSE","0"],["S001567","ClinicalTrials.gov","NCT06648031","DehydraTECH","A Phase 1B, Randomized, Open-label, Active-controlled, Parallel, Multiple-dose Study Comparing the Safety, Pharmacokinetics and Efficacy of Dehydratech Cannabidiol and Glucagon-like Peptide 1 Agonists Alone and in Combination, in Overweight or Obese, pre-and Type 2 Diabetic Participants.","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","148","Type2diabetes","DRUG:Arm 1 - DehydraTECH-CBD alone; DRUG:Arm 2 - DehydraTECH-semaglutide alone; DRUG:Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide; DRUG:Arm 4 - Rybelsus medication (semaglutide) alone; DRUG:Arm 5- Tirzepatide","Lexaria Bioscience Corp.","2024-12-04","FALSE","0"],["S001568","ClinicalTrials.gov","NCT07073417",null,"A Multicenter, Randomized, Open-label, Treatment Switching Phase II Study to Evaluate the Efficacy and Safety of XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","163","Obesity; Weight Management","DRUG:XW003 injection; DRUG:semaglutide injection","Hangzhou Sciwind Biosciences Co., Ltd.","2025-07-28","FALSE","1"],["S001569","ClinicalTrials.gov","NCT02229240",null,"Study GLP111892: Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Diabetes Mellitus, Type 2","DRUG:Albiglutide; DRUG:Matching albiglutide placebo","GlaxoSmithKline","2015-08","FALSE","0"],["S001570","ClinicalTrials.gov","NCT05340868","GAROS","Genetics of the Acute Response to Oral Semaglutide (GAROS)","INTERVENTIONAL",null,null,"RECRUITING","1000","PreDiabetes; Prediabetic State; Obesity","DRUG:Semaglutide Pill","Medical University of Bialystok","2022-09-01","FALSE","0"],["S001571","ClinicalTrials.gov","NCT04707469","PIONEER PLUS","Efficacy and Safety of Once-daily Oral Semaglutide 25 mg and 50 mg Compared With 14 mg in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1606","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide","Novo Nordisk A/S","2021-01-15","TRUE","3"],["S001572","ClinicalTrials.gov","NCT07859189",null,"Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery: a Randomized, Double-blind Strategy Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","100","Morbid Obesity","DRUG:Semaglutide weekly injection; DRUG:Placebo","General Committee of Teaching Hospitals and Institutes, Egypt","2026-10","FALSE","0"],["S001573","ClinicalTrials.gov","NCT02170324",null,"GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","20","Obesity","DRUG:Exenatide; DRUG:Placebo","Xiang Guang-da","2014-06","FALSE","0"],["S001574","ClinicalTrials.gov","NCT07156331","REBUILD","Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","20","Type 2 Diabetes",null,"Kristin Clemens","2025-10-01","FALSE","0"],["S001575","ClinicalTrials.gov","NCT07622810",null,"BALANCE-OBS: A Multiregional, Randomized, Multicenter, Active-Controlled Confirmatory Phase III Study to Evaluate the Efficacy and Safety of Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","352","Obesity & Overweight","DRUG:Bofanglutida; DRUG:Semaglutide","Carnot Laboratories","2026-09","FALSE","0"],["S001576","ClinicalTrials.gov","NCT05162183",null,"Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data","OBSERVATIONAL",null,null,"COMPLETED","3474","Diabetes","DRUG:Glimepiride; DRUG:Liraglutide","Brigham and Women's Hospital","2019-09-01","FALSE","0"],["S001577","ClinicalTrials.gov","NCT07443956","COMBAT-PsA","Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","45","Psoriatic Arthritis (PsA); Obesity & Overweight","DRUG:Ixekizumab; DRUG:Tirzepatide","NHS Greater Glasgow and Clyde","2026-03-09","FALSE","0"],["S001578","ClinicalTrials.gov","NCT06824051",null,"A Phase 1, Double-blind, Two-arm, Mechanism of Action Study to Investigate the Effect of Orforglipron on Body Composition in Adult Participants With Obesity or Overweight, Without Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","120","Obesity; Overweight","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-02-17","FALSE","0"],["S001579","ClinicalTrials.gov","NCT06548490",null,"GLP-1R Agonist Treatment for Opioid Use Disorder","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","200","Opioid Use Disorder; Opioid Abuse and Addiction; Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorder; Opioid","DRUG:Semaglutide Pen Injector; DRUG:Placebo","Milton S. Hershey Medical Center","2025-01-27","FALSE","2"],["S001580","ClinicalTrials.gov","NCT01435980",null,"Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","60","Type 2 Diabetes","PROCEDURE:Gastric Bypass; DRUG:Exenatide","Wu Qinan","2008-02","FALSE","0"],["S001581","ClinicalTrials.gov","NCT00614120",null,"Effect of Liraglutide or Glimepiride Added to Metformin on Glycaemic Control in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","929","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo; DRUG:glimepiride; DRUG:metformin","Novo Nordisk A/S","2008-01","TRUE","5"],["S001582","ClinicalTrials.gov","NCT03151005",null,"Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","70","Polycystic Ovary Syndrome (PCOS); Overweight; Obesity","DRUG:Metformin-GLP-1 Receptor Agonist; DRUG:Metformin-Oral Contraceptive(OC)","Xinqiao Hospital of Chongqing","2017-07-01","TRUE","3"],["S001583","ClinicalTrials.gov","NCT02638805",null,"An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","136","Diabetes Mellitus, Type 2","DRUG:ITCA 650 Osmotic Mini Pump 20/60 mcg/day; DRUG:ITCA 650 Osmotic Mini Pump 60 mcg/day; DRUG:Metformin; DRUG:Liraglutide","Intarcia Therapeutics","2015-12","FALSE","0"],["S001584","ClinicalTrials.gov","NCT00318422","LEAD-1","Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes.","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1041","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:rosiglitazone; DRUG:glimepiride","Novo Nordisk A/S","2006-05","FALSE","15"],["S001585","ClinicalTrials.gov","NCT07171723","SILENCED","Effects of Antagonizing the Ghrelin Receptor in Individuals With Obesity on Treatment With Semaglutide","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","24","Obesity &Amp; Overweight","BIOLOGICAL:Liver-Expressed Antimicrobial Peptide 2 (LEAP2); OTHER:Placebo (saline)","University Hospital, Gentofte, Copenhagen","2025-09-01","FALSE","0"],["S001586","ClinicalTrials.gov","NCT06403761",null,"Effect of CagriSema, Semaglutide and Cagrilintide on Insulin Sensitivity and Pancreatic Endocrine Function in Adults With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","158","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Cagrilintide; DRUG:Placebo semaglutide; DRUG:Placebo cagrilintide","Novo Nordisk A/S","2024-05-06","FALSE","0"],["S001587","ClinicalTrials.gov","NCT01789086",null,"A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","21","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2013-02","FALSE","1"],["S001588","ClinicalTrials.gov","NCT00517283",null,"A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","17","Type 2 Diabetes Mellitus","DRUG:exenatide and placebo; DRUG:Exenatide and placebo","AstraZeneca","2005-01","FALSE","0"],["S001589","ClinicalTrials.gov","NCT07389941","SPICE-AF","Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation (SPICE-AF)","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","240","Atrial Fibrillation (AF)","DRUG:Semaglutide (SEMA)","University of Luebeck","2026-10","FALSE","0"],["S001590","ClinicalTrials.gov","NCT03668470","DIAMOND GLP1","Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes : A Randomized Double-blind Placebo-controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","45","Adult Subjects With Type1Diabetes and Insulin Microsecretion","DRUG:Dulaglutide; DRUG:Placebo","Hospices Civils de Lyon","2019-01-31","FALSE","0"],["S001591","ClinicalTrials.gov","NCT03882970","SURPASS-3","A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1444","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Insulin Degludec","Eli Lilly and Company","2019-04-01","TRUE","13"],["S001592","ClinicalTrials.gov","NCT07540754",null,"A Multi-center, Single-dose, Parallel-group, Open-label Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","RECRUITING","24","Diabetes Mellitus; Weight Loss","DRUG:HRS9531 Injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-05-26","FALSE","0"],["S001593","ClinicalTrials.gov","NCT06440980",null,"A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants With Obesity or Overweight Who Are Otherwise Healthy.","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","533","Healthy; Obese; Overweight; Obesity","DRUG:Orforglipron","Eli Lilly and Company","2024-06-24","TRUE","1"],["S001594","ClinicalTrials.gov","NCT01821846",null,"A 6-month, Multi-centre, Open Labelled, Non-randomized, Non-interventional, Safety Study of Liraglutide (Victoza®) in Subjects With Type 2 Diabetes Mellitus in Korea","OBSERVATIONAL",null,null,"COMPLETED","64","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2013-11-20","FALSE","0"],["S001595","ClinicalTrials.gov","NCT07249554",null,"Preliminary Safety and Efficacy of Semaglutide and Naltrexone Combination Therapy for Alcohol Use Disorder","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","45","Alcohol Use Disorder","DRUG:Placebo; DRUG:Glucagon-Like Peptide-1 Agonist (GLP-1); DRUG:Naltrexone (oral tablets)","Johns Hopkins University","2026-11","FALSE","0"],["S001596","ClinicalTrials.gov","NCT06939088","DUALPSYCHIATRY","Effect of Tirzepatide on Alcohol Intake and Reward Processing in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","108","Alcohol Use Disorder; Alcohol Abuse/Dependence; Alcohol Dependence; Alcoholism; Schizophrenia Disorders; Schizophrenia and Disorders With Psychotic Features; Schizophrenia and Schizophrenia Spectrum Psychosis; Schizophrenia","DRUG:Tirzepatide; DRUG:Placebo","Anders Fink-Jensen, MD, DMSci","2025-05-05","FALSE","0"],["S001597","ClinicalTrials.gov","NCT00460941",null,"A Double-blind, Placebo-controlled Titration Study to Investigate the Tolerability, Safety and Pharmacodynamic Profile of a GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","133","Diabetes Mellitus Type 2","DRUG:Placebo; DRUG:Taspoglutide 20mg; DRUG:Taspoglutide 20mg-30mg; DRUG:Taspoglutide 20mg-40mg","Hoffmann-La Roche","2007-04","FALSE","1"],["S001598","ClinicalTrials.gov","NCT05780905",null,"Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","50","Diabetes Mellitus, Type 2; Stroke (CVA) or Transient Ischemic Attack","DRUG:Semaglutide Auto-Injector; OTHER:Placebo","University of Washington","2024-01-11","FALSE","0"],["S001599","ClinicalTrials.gov","NCT01960179",null,"An Open-label, Multicenter 24-Week And 52-Week Study Assessing The Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes","INTERVENTIONAL",null,"PHASE3","COMPLETED","361","Type 2 Diabetes Mellitus","DRUG:lixisenatide AVE0010","Sanofi","2013-11","FALSE","0"],["S001600","ClinicalTrials.gov","NCT04074161","STEP 8","Effect and Safety of Subcutaneous Semaglutide 2.4 mg Once Weekly Compared to Liraglutide 3.0 mg Once Daily on Weight Management in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","338","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo (semaglutide); DRUG:Liraglutide; DRUG:Placebo (liraglutide)","Novo Nordisk A/S","2019-09-11","TRUE","4"],["S001601","ClinicalTrials.gov","NCT00851773",null,"A Randomised, Double Blind, Placebo-controlled, Parallel-group, Multiple Doses, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics Profiles of NN9535 in Healthy Male Japanese and Caucasian Subjects After Weekly Subcutaneous Injections.","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","84","Diabetes; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2009-02","FALSE","0"],["S001602","ClinicalTrials.gov","NCT06495931",null,"A Single-center, Single-arm, Open, Fixed-sequence, Self-controlled Study of the Pharmacokinetic Effects of HRS-1780, Henagliflozin, Metformin, and HRS-7535 in Healthy Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","24","Type 2 Diabetes Mellitus","DRUG:HRS-1780 tablets; DRUG:HR20033 tablets; DRUG:HRS-7535 tablets","Shandong Suncadia Medicine Co., Ltd.","2024-07-15","FALSE","0"],["S001603","ClinicalTrials.gov","NCT03899402",null,"Triple Therapy for Type 1 Diabetes With Insulin, Semaglutide, and Dapagliflozin","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","ACTIVE_NOT_RECRUITING","78","Type 1 Diabetes Mellitus","DRUG:Insulin; DRUG:Semaglutide; DRUG:Dapagliflozin; DRUG:Placebo to Dapagliflozin","State University of New York at Buffalo","2019-05-01","FALSE","1"],["S001604","ClinicalTrials.gov","NCT03189953","GLP-1-AHH","68Ga-NODAGA-exendin-4 PET/CT in Patients With AHH - a Prospective Comparative Evaluation of Preoperative Imaging","INTERVENTIONAL",null,"PHASE1; PHASE2","COMPLETED","56","Insulinoma","RADIATION:68Ga-NODAGA-exendin 4 PET/CT","Radboud University Medical Center","2015-04","FALSE","0"],["S001605","ClinicalTrials.gov","NCT05882045","TRIUMPH-3","A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1946","Obesity; Cardiovascular Diseases","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2023-05-30","FALSE","0"],["S001606","ClinicalTrials.gov","NCT05093205",null,"A PHASE 1, OPEN-LABEL, TWO-PART STUDY TO EVALUATE THE EFFECT OF TWO STEADY-STATE DOSE LEVELS OF PF-06882961 ON THE PHARMACOKINETICS OF SINGLE ORAL DOSES OF ATORVASTATIN AND MIDAZOLAM IN HEALTHY ADULTS AND AN ORAL CONTRACEPTIVE IN HEALTHY POST-MENOPAUSAL FEMALES","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","35","Healthy Adults","DRUG:PF-06882961; DRUG:Atorvastatin; DRUG:Midazolam; DRUG:Levonorgestrel & Ethinyl Estradiol","Pfizer","2021-10-25","TRUE","0"],["S001607","ClinicalTrials.gov","NCT07428746","GLOW","Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes","INTERVENTIONAL",null,"PHASE3","RECRUITING","20","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Emory University","2026-05-07","FALSE","0"],["S001608","ClinicalTrials.gov","NCT04039503","SURPASS-5","Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","475","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2019-08-30","TRUE","7"],["S001609","ClinicalTrials.gov","NCT06911203",null,"A Phase II, Randomized Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BGM0504 Compared to Tirzepatide in Adults Who Have Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","96","Obesity","DRUG:BGM0504; DRUG:Tirzepatide","BrightGene Bio-Medical Technology Co., Ltd.","2025-04-09","FALSE","0"],["S001610","ClinicalTrials.gov","NCT07754461",null,"A Phase III, Randomised, Double-blind, Parallel-group, 56-week Study, Evaluating the Efficacy and Safety of Survodutide (BI 456906), Compared With Placebo, in Participants With Type 2 Diabetes, as an Adjunct to Diet and Physical Activity Alone or in Combination With Either Oral Antidiabetic Medications or Insulin","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","600","Type 2 Diabetes","DRUG:Placebo; DRUG:Survodutide","Boehringer Ingelheim","2026-08-24","FALSE","0"],["S001611","ClinicalTrials.gov","NCT02255266",null,"Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice","OBSERVATIONAL",null,null,"COMPLETED","1788","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2015-03-26","FALSE","1"],["S001612","ClinicalTrials.gov","NCT06065540","REIMAGINE 2","Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","2734","Type 2 Diabetes Mellitus","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2023-09-27","FALSE","1"],["S001613","ClinicalTrials.gov","NCT06654960",null,"A Single Center, Open-label, Single Cohort, Fixed Sequence Trial, Investigating the Influence of HRS9531 Injection on Pharmacokinetics of Metformin in Healthy Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","20","Type 2 Diabetes","DRUG:HRS9531 injection; DRUG:Metformin Hydrochloride tablets","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-11-05","FALSE","0"],["S001614","ClinicalTrials.gov","NCT03315780",null,"A Phase 4 Study to Evaluate Glucodynamic Effects of Dulaglutide in Japanese Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","12","Type 2 Diabetes","DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2017-10-28","TRUE","1"],["S001615","ClinicalTrials.gov","NCT02443155",null,"A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","308","Diabetes; Diabetes Mellitus, Type 1","DRUG:NNC0114-0006; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2015-11-10","TRUE","2"],["S001616","ClinicalTrials.gov","NCT07770282",null,"Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome: A Multicentre, Double-Blind, Randomised Controlled Trial (ESCaMS Trial)","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","600","Schizophrenia Disorder; Metabolic Syndrome; Antipsychotic-induced Weight Gain; Cardiovascular Risk; Insulin Resistance","DRUG:Semaglutide + TAU; DRUG:Placebo + TAU","All India Institute of Medical Sciences, Bhubaneswar","2026-12-01","FALSE","0"],["S001617","ClinicalTrials.gov","NCT03987308",null,"Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Treatment of Patients With Newly Diagnosed Type 2 Diabetes: a Multicenter, Randomized Open Trial Study With Parallel Controls","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","115","Type 2 Diabetic Patients; T2DM (Type 2 Diabetes Mellitus); T2DM","DRUG:Beinaglutide; DRUG:Insulin aspart","Beijing Hospital","2019-07-02","FALSE","0"],["S001618","ClinicalTrials.gov","NCT03600480",null,"Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","96","Obesity; Overweight","DRUG:NNC0174-0833; DRUG:Semaglutide; DRUG:Placebo (NNC0174-0833)","Novo Nordisk A/S","2018-07-25","FALSE","1"],["S001619","ClinicalTrials.gov","NCT00964262",null,"A Dose Block-randomized, Double-blind, Placebo-controlled, Dose-escalating Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of SR Exenatide (PT302) After Subcutaneous Injection in Healthy Male Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","34","Type 2 Diabetes Mellitus","DRUG:SR Exenatide (PT302); DRUG:Placebo","Peptron, Inc.","2009-08","FALSE","1"],["S001620","ClinicalTrials.gov","NCT06751589",null,"Pilot Weight Loss Intervention With Dual GIP/GLP-1 Receptor Agonist Therapy in Patients With Endometrial Cancer and Obesity, Overweight, With or Without Diabetes","INTERVENTIONAL",null,"EARLY_PHASE1","RECRUITING","36","Endometrial Cancer","DRUG:Tirzepatide","Memorial Sloan Kettering Cancer Center","2024-12-19","FALSE","0"],["S001621","ClinicalTrials.gov","NCT06184568",null,"A Multicenter, Randomized, Open-label Phase 3 Study Comparing the Efficacy and Safety of IBI362 Versus Semaglutide in Chinese Participants With Early Type 2 Diabetes and Obesity (DREAMS-3)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","349","Type 2 Diabetes; Obesity","DRUG:IBI362; DRUG:Semaglutide","Innovent Biologics (Suzhou) Co. Ltd.","2024-02-29","FALSE","1"],["S001622","ClinicalTrials.gov","NCT01254123","EXAMI","Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","40","Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).","DRUG:Exenatide infusion; DRUG:Placebo infusion.","Amsterdam UMC, location VUmc","2009-11","FALSE","2"],["S001623","ClinicalTrials.gov","NCT01458210",null,"Effect of Dulaglutide (LY2189265) on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","22","Diabetes Mellitus, Type 2","DRUG:Ortho-Cyclen; BIOLOGICAL:Dulaglutide","Eli Lilly and Company","2011-10","TRUE","1"],["S001624","ClinicalTrials.gov","NCT07457424","DIGRAT","Direct Measurement of Changes in Food Selection and Intake Behaviour After Using the Maximum Dose of GLP-1 Receptor Agonists","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","140","Metabolic Disease; Obesity & Overweight","DRUG:semaglutide 1 mg weekly injection","University College Dublin","2022-02-17","FALSE","0"],["S001625","ClinicalTrials.gov","NCT02783196","LIR-CG","Advantages of Liraglutide Mediated Through Its Effect on Clock Gene mRNA Expression","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","14","Type 2 Diabetes","DRUG:Liraglutide; DRUG:Placebo","Tel Aviv University","2016-07","FALSE","0"],["S001626","ClinicalTrials.gov","NCT02057172",null,"A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","254","Type 2 Diabetes","DRUG:HM11260C; DRUG:liraglutide; DRUG:Placebo","Hanmi Pharmaceutical Company Limited","2014-01","FALSE","3"],["S001627","ClinicalTrials.gov","NCT01755572","BOLT","Hormonal Regulation of Systolic Blood Pressure in Response to the GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist, Liraglutide.","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","22","Type 2 Diabetes; Systolic Hypertension","DRUG:Liraglutide; DRUG:Placebo","Mount Sinai Hospital, Canada","2013-01","FALSE","1"],["S001628","ClinicalTrials.gov","NCT01753362",null,"LIRAGLUTIDE IN OVERWEIGHT PATIENTS WITH TYPE 1 DIABETES","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","84","Type 1 Diabetes","DRUG:liraglutide; DRUG:placebo","University at Buffalo","2012-12","TRUE","0"],["S001629","ClinicalTrials.gov","NCT05813795",null,"A Phase 3, Multi-center, Randomized, Double-Blind and Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Adults With Overweight or Obesity (SLIMMER)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","664","Weight Management","DRUG:Ecnoglutide Low Dosage; DRUG:Ecnoglutide Medium Dosage; DRUG:Ecnoglutide High Dosage; DRUG:Placebo","Hangzhou Sciwind Biosciences Co., Ltd.","2023-04-05","FALSE","1"],["S001630","ClinicalTrials.gov","NCT01768559","GetGoal-Duo-2","A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","894","Type 2 Diabetes","DRUG:Lixisenatide (AVE0010); DRUG:Insulin glulisine QD; DRUG:Insulin glulisine TID; DRUG:Insulin Glargine (Mandatory background drug); DRUG:Metformin (Background drug)","Sanofi","2013-01","TRUE","4"],["S001631","ClinicalTrials.gov","NCT01515579",null,"A Randomized, Double-blind, Single-centre, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between the Phase 2 Formulation of Liraglutide at pH 7.7 (Formulation 3) and the Phase 3 Formulation at pH 8.15 (Formulation 4)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","22","Diabetes; Healthy","DRUG:liraglutide","Novo Nordisk A/S","2006-04","FALSE","0"],["S001632","ClinicalTrials.gov","NCT07382388",null,"A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","70","Psoriasis","COMBINATION_PRODUCT:Weight loss and psoriasis treatment; COMBINATION_PRODUCT:psoriasis treatment","Peking University Third Hospital","2026-01-28","FALSE","0"],["S001633","ClinicalTrials.gov","NCT05013229",null,"A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Daily Insulin Glargine 100 Units/mL Combined With Insulin Aspart, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin. COMBINE 3","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","679","Diabetes Mellitus, Type 2","DRUG:IcoSema; DRUG:Insulin glargine; DRUG:insulin aspart","Novo Nordisk A/S","2021-11-30","FALSE","3"],["S001634","ClinicalTrials.gov","NCT03322631",null,"A Multiple-Ascending Dose Study in Japanese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","48","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2017-11-15","TRUE","0"],["S001635","ClinicalTrials.gov","NCT02079870",null,"A Single-centre, Randomised, Double-blind Two-period Cross-over Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","30","Diabetes; Metabolism and Nutrition Disorder; Obesity","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-03-06","FALSE","2"],["S001636","ClinicalTrials.gov","NCT05313802",null,"A Multiple Dose Study in Healthy Overweight and Obese Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","72","Healthy; Obese","DRUG:LY3502970","Eli Lilly and Company","2022-05-26","TRUE","0"],["S001637","ClinicalTrials.gov","NCT07254715",null,"Does Itopride Improve Semaglutide Induced Gastroparesis Ultrasound Before Anesthesia? Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","60","Semaglutide-Induced Gastric Motility; Anesthesia","DRUG:Itopride HCI 50 mg; DRUG:Placebo","Ain Shams University","2026-01-01","FALSE","0"],["S001638","ClinicalTrials.gov","NCT00744926",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide Compared to Placebo, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","373","Diabetes Mellitus Type 2","DRUG:placebo; DRUG:taspoglutide","Hoffmann-La Roche","2008-08","FALSE","0"],["S001639","ClinicalTrials.gov","NCT03233178","ALT","Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study","OBSERVATIONAL",null,null,"COMPLETED","4000","T2DM (Type 2 Diabetes Mellitus); Fatty Liver; NAFLD","OTHER:Non-interventional","LMC Diabetes & Endocrinology Ltd.","2017-01","FALSE","1"],["S001640","ClinicalTrials.gov","NCT03347890","LIRAOB","Central Nervous System Effects of Liraglutide® 3.0 mg on Reward Mechanisms in Obese Patients Without Diabetes, in Relation to Food Addiction. A Randomized, Single-centre, Double-blind, Placebo Controlled Clinical Trial.","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","70","Obesity","DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo","Zoltan Pataky","2018-03-05","FALSE","0"],["S001641","ClinicalTrials.gov","NCT06041217","STEP12","Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Adults With Overweight and Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","242","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2023-09-15","TRUE","1"],["S001642","ClinicalTrials.gov","NCT01364584","Exenatide","Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","23","Type 2 Diabetes","DRUG:Exenatide; DRUG:Placebo","University of Colorado, Denver","2010-10","TRUE","0"],["S001643","ClinicalTrials.gov","NCT07842640",null,"A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection, for Subcutaneous Use (Once-monthly Formulation) in Adult Participants With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","84","Chronic Weight Management","DRUG:ASC35 Injection B, for subcutaneous use; DRUG:ASC35 Placebo Injection B, for subcutaneous use; DRUG:Tirzepatide","Ascletis Pharma (China) Co., Limited","2026-08-27","FALSE","0"],["S001644","ClinicalTrials.gov","NCT03625778",null,"A Randomized, Blinded, Placebo-controlled Study to Assess Pharmacokinetics, Safety, and Tolerability of Ascending Doses of MEDI0382 in Non-diabetic Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","51","Obesity","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2018-08-14","FALSE","0"],["S001645","ClinicalTrials.gov","NCT06595797",null,"A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","144","Obese Subjects With Polycystic Ovary Syndrome (PCOS)","DRUG:HRS9531; DRUG:HRS9531placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-09","FALSE","0"],["S001646","ClinicalTrials.gov","NCT06577090","CBeyond","A Phase 2 Study of QW Nimacimab Injection, Compared to Placebo Injection and QW Weekly Nimacimab Injection Co-administered With Semaglutide in Participants Who Are Overweight or Obese","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","136","Obesity","BIOLOGICAL:Nimacimab injection; BIOLOGICAL:Nimacimab placebo injection; COMBINATION_PRODUCT:semaglutide injection; BIOLOGICAL:Nimacimab 300 mg injection","Skye Bioscience, Inc.","2024-08-22","FALSE","0"],["S001647","ClinicalTrials.gov","NCT07227948",null,"Repurposing Semaglutide for the Treatment of Cocaine Use Disorder: a Pilot Mechanistic Study","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","75","Cocaine Use Disorder","DRUG:Semaglutide; DRUG:Placebo; BEHAVIORAL:cognitive behavioral therapy (CBT).","The University of Texas Health Science Center, Houston","2026-01-15","FALSE","1"],["S001648","ClinicalTrials.gov","NCT06171152",null,"Examining the Utility of GLP-1 Agonists as Neuroprotective Agents Through a Pilot Clinical Trial in High Risk Population With Neurocognitive Deficits and Obesity","INTERVENTIONAL","RANDOMIZED","EARLY_PHASE1","SUSPENDED","30","Multiple Sclerosis; Long COVID; Long Covid19; Obese; Obesity; Obesity, Morbid; Acute Leukemia in Remission","DRUG:Liraglutide Pen Injector [Saxenda]; OTHER:Medication Diary","University of Chicago","2024-01-26","FALSE","0"],["S001649","ClinicalTrials.gov","NCT07619989",null,"Adjunctive Transcutaneous Auricular Vagus Nerve Stimulation in Overweight or Obese Patients With a Suboptimal Weight-Loss Response to Incretin Receptor Agonists: A Single-Center, Randomized, Sham-Controlled Study","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","24","Obesity & Overweight","DEVICE:transcutaneous auricular vagus nerve stimulation; DEVICE:Sham","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2026-08-01","FALSE","0"],["S001650","ClinicalTrials.gov","NCT05751226",null,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Different Titration Schedules of Subcutaneous Doses of BI 1820237 Alone or Together With Either Semaglutide or BI 456906 in Otherwise Healthy Male and Female Individuals With Obesity/Overweight (Multiple Dose, Single-blind, Randomised, Placebo-controlled, Parallel Group Design)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","88","Healthy; Obesity","DRUG:BI 1820237; DRUG:semaglutide; DRUG:Placebo; DRUG:BI 456906","Boehringer Ingelheim","2023-04-11","FALSE","0"],["S001651","ClinicalTrials.gov","NCT06192108","ACHIEVE-2","A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","962","Type 2 Diabetes","DRUG:Orforglipron; DRUG:Dapagliflozin","Eli Lilly and Company","2024-01-10","FALSE","2"],["S001652","ClinicalTrials.gov","NCT02058940",null,"Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury","INTERVENTIONAL",null,"PHASE4","COMPLETED","8","Brain Injuries","DRUG:Exenatide","University of North Carolina, Chapel Hill","2015-08","TRUE","0"],["S001653","ClinicalTrials.gov","NCT04881760",null,"A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","338","Obesity; Overweight","DRUG:LY3437943; DRUG:Placebo","Eli Lilly and Company","2021-05-20","TRUE","6"],["S001654","ClinicalTrials.gov","NCT01676116","DUAL™ III","The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III -GLP-1 Switch)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","438","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:liraglutide; DRUG:exenatide","Novo Nordisk A/S","2012-08-29","TRUE","3"],["S001655","ClinicalTrials.gov","NCT04878406",null,"Investigation of Safety, Tolerability and Pharmacokinetics of Subcutaneously Co-administered Single Doses of NNC0480-0389 and Semaglutide in Healthy Japanese Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Healthy Volunteers Type 2 Diabetes","DRUG:NNC0480-0389; DRUG:Placebo (NNC0480-0389); DRUG:Semaglutide; DRUG:Placebo (Semaglutide)","Novo Nordisk A/S","2021-05-18","FALSE","0"],["S001656","ClinicalTrials.gov","NCT05606471","SemVLCD","The Anabolic Effects of GLP-1 Agonism to Prevent Lean Muscle Losses During Very-low Calorie Diets (VLCDs) for Weight Loss","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","45","Type 2 Diabetes Mellitus in Obese","DRUG:Semaglutide Pen Injector [Ozempic]; DIETARY_SUPPLEMENT:Very-low Calorie Diet","University of Nottingham","2021-09-15","FALSE","0"],["S001657","ClinicalTrials.gov","NCT07605052",null,"Investigation of Pharmacokinetics of Two Different Presentations of Cagrilintide in Participants With Overweight and Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","50","Overweight; Obesity","DRUG:Cagrilintide B; DRUG:Cagrilintide D","Novo Nordisk A/S","2026-05-20","FALSE","0"],["S001658","ClinicalTrials.gov","NCT00938158",null,"An Adaptive Design Study for the Assessment of the Pharmacokinetics of Albiglutide in Subjects With Normal Renal Function and Subjects With Moderate-to-severe Renal Impairment and Hemodialysis.","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","75","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide","GlaxoSmithKline","2009-08-05","FALSE","2"],["S001659","ClinicalTrials.gov","NCT03948347","LAMP","Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus: A Prospective, Multicenter, Randomized, Blank-controlled，Blinded End-point Study.","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","1708","Ischemic Stroke; Transient Ischemic Attack; Type 2 Diabetes Mellitus","DRUG:Liraglutide","First Affiliated Hospital of Jinan University","2019-06-25","FALSE","2"],["S001660","ClinicalTrials.gov","NCT06725693",null,"Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease","OBSERVATIONAL",null,null,"RECRUITING","500","GLP1-R-related Disease; Tumor; Insulinoma; Positron Emission Tomography","DIAGNOSTIC_TEST:18F/68Ga-Exendin 4","Tianjin Medical University","2019-02-01","FALSE","1"],["S001661","ClinicalTrials.gov","NCT05779644",null,"Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","300","Metformin; Obesity, Abdominal; Diabetes Mellitus, Type 2; Abdominal Fat; Non-Alcoholic Fatty Liver Disease; Metabolism Disorder, Glucose; Metabolism Disorder, Lipid","DRUG:Liraglutide; DRUG:Semaglutide; DRUG:Metformin","RenJi Hospital","2023-02-23","FALSE","0"],["S001662","ClinicalTrials.gov","NCT06772532",null,"Relative Bioavailability of Three Different BI 456906 Formulations Following Subcutaneous Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Three-period, Three-sequence Crossover Trial)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","30","Healthy","COMBINATION_PRODUCT:BI 456906 - Formulation A; DRUG:BI 456906 - Formulation B; DRUG:BI 456906 - Formulation C","Boehringer Ingelheim","2025-02-10","FALSE","0"],["S001663","ClinicalTrials.gov","NCT01212133","Lead-In","A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India","OBSERVATIONAL",null,null,"COMPLETED","1386","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2010-11","FALSE","1"],["S001664","ClinicalTrials.gov","NCT02928614","BIO-LOSEIT-II","Biomarkers in Obese Patients With Knee Osteoarthritis Following Long-term Weight Maintenance","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","150","Osteoarthritis; Obesity","DRUG:Liraglutide 3 mg (Saxenda); DRUG:Liraglutide 3 mg placebo","Henrik Gudbergsen","2016-11","FALSE","0"],["S001665","ClinicalTrials.gov","NCT04143802",null,"A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","72","Diabetes Mellitus, Type 2","DRUG:LY3437943; DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2019-12-18","FALSE","2"],["S001666","ClinicalTrials.gov","NCT03498001","LICAS-MR","Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging","INTERVENTIONAL",null,null,"COMPLETED","42","Type II Diabetes","DRUG:GLP-1 agonists; PROCEDURE:Cardiac MRI; OTHER:Follow up by phone","Centre Hospitalier Universitaire Dijon","2018-04-16","FALSE","1"],["S001667","ClinicalTrials.gov","NCT05111912",null,"A Phase 2, Open-label, Randomised, Dose-Finding Study of XW003, Once-Weekly Human Glucagon-Like Peptide 1 Analogue, Compared With Once-Daily Liraglutide 3 mg in Adult Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","206","Obesity","DRUG:XW003; DRUG:Saxenda","Sciwind Biosciences APAC CO Pty. Ltd.","2021-11-30","FALSE","0"],["S001668","ClinicalTrials.gov","NCT07523711",null,"A Phase 1, Open-label Study to Assess the Effect of Maridebart Cafraglutide (AMG 133) on the Pharmacokinetics of Oral Contraceptives in Postmenopausal Female Participants Living With Overweight or Obesity","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","49","Overweight; Obesity","DRUG:COC; DRUG:Maridebart Cafraglutide","Amgen","2026-04-09","FALSE","0"],["S001669","ClinicalTrials.gov","NCT05195944",null,"The GLP-1 Agonist Semaglutide for the Treatment of Metabolic Disease in Liver Transplant Recipients: A Phase IV, Randomized Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","ENROLLING_BY_INVITATION","58","Liver Transplant; Complications; Diabetes Mellitus; NASH - Nonalcoholic Steatohepatitis; NAFLD","DRUG:Semaglutide Treatment; DRUG:Sitagliptin 100mg","University Health Network, Toronto","2022-10-26","FALSE","0"],["S001670","ClinicalTrials.gov","NCT03745937",null,"A Phase 2a Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MEDI0382 in Overweight/Obese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","20","Type 2 Diabetes Mellitus","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2019-01-07","TRUE","0"],["S001671","ClinicalTrials.gov","NCT06910839",null,"A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-07976016 AND PF-06882961 IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY","INTERVENTIONAL",null,"PHASE1","TERMINATED","21","Overweight; Obesity","DRUG:PF-07976016; DRUG:PF-06882961","Pfizer","2025-03-13","FALSE","0"],["S001672","ClinicalTrials.gov","NCT01575301","DIRECTGLP","DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists","INTERVENTIONAL",null,null,"COMPLETED","411","Diabetes","DRUG:Exenatide, Liraglutide","University of Dundee","2011-03","FALSE","0"],["S001673","ClinicalTrials.gov","NCT07619495",null,"Comparative Effectiveness of Semaglutide and Dulaglutide in Patients at Low, Moderate, and High Cardiovascular Risk With Type 2 Diabetes and Overweight","OBSERVATIONAL",null,null,"COMPLETED","120000","Type 2 Diabetes Mellitus; Obesity; Overweight","DRUG:Semaglutide; DRUG:Dulaglutide","Brigham and Women's Hospital","2026-01-20","FALSE","0"],["S001674","ClinicalTrials.gov","NCT00313001",null,"Effects of NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) BID and QD vs. Byetta™ Exenatide) BID on Glycemic Control: A Multicenter, 24-Week, Open-Label, Parallel Group Study in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets With Metformin and a Sulfonylurea","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","373","Diabetes; Diabetes Mellitus, Type 2","DRUG:biphasic insulin aspart; DRUG:exenatide","Novo Nordisk A/S","2006-04","FALSE","1"],["S001675","ClinicalTrials.gov","NCT05925959",null,"Preoperative Weight Loss for Open Abdominal Wall Reconstruction","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","258","Abdominal Wall Hernia","OTHER:Preoperative Weight Management Program","Benjamin T. Miller","2023-06-19","FALSE","0"],["S001676","ClinicalTrials.gov","NCT05333003","Sema","Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity for Metformin Non-responders: a Single-blind Randomized Control Trial","INTERVENTIONAL","RANDOMIZED",null,"ACTIVE_NOT_RECRUITING","92","Schizophrenia Spectrum Disorders","DRUG:Semaglutide; OTHER:Placebo","Centre for Addiction and Mental Health","2022-05-25","FALSE","0"],["S001677","ClinicalTrials.gov","NCT06186622",null,"A Drug-Drug Interaction Study to Assess the Effect of Orforglipron on the Pharmacokinetics of Digoxin, Simvastatin, Rosuvastatin, Acetaminophen, and Midazolam in Healthy Overweight and Obese Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","50","Healthy; Obese; Overweight","DRUG:Orforglipron; DRUG:Simvastatin; DRUG:Digoxin; DRUG:Rosuvastatin; DRUG:Acetaminophen; DRUG:Midazolam; DRUG:Sodium Bicarbonate","Eli Lilly and Company","2024-01-02","TRUE","0"],["S001678","ClinicalTrials.gov","NCT07313761",null,"A Phase 1, Open-label, Randomized, Parallel Group Study to Assess the Relative Bioavailability of Maridebart Cafraglutide (AMG 133) as Two Subcutaneous Presentations in Participants Living With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","349","Overweight and Obesity","DRUG:Maridebart Cafraglutide","Amgen","2025-12-15","FALSE","0"],["S001679","ClinicalTrials.gov","NCT07747805","GLIMR COPD","GLIMR COPD: GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","30","COPD; Obesity & Overweight; Sarcopenia","DRUG:Tirzepatide","The Cleveland Clinic","2026-08-28","FALSE","2"],["S001680","ClinicalTrials.gov","NCT07059377","GLP1-SC","Semaglutide for Smoking Cessation in Patients With Diabetes: A Pilot Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","100","Diabetes Mellitus, Type 2; Nicotine Addiction; Tobacco Dependence","DRUG:Semaglutide; DRUG:Nicotine replacement","Ottawa Heart Institute Research Corporation","2026-02-13","FALSE","0"],["S001681","ClinicalTrials.gov","NCT01988545",null,"GLP-1's Influence on Intestinal Blood Flow","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","8","Healthy","OTHER:1,5 nmol/kg,GLP-1 sc injection; OTHER:1,5 nmol/kg GLP-1 9-36amide, sc injection; OTHER:Exendin-4 ;10 ug,sc injection; OTHER:saline","Zealand University Hospital","2013-11-01","FALSE","0"],["S001682","ClinicalTrials.gov","NCT05435677",null,"A Study Investigating the Pharmacokinetic Properties of a Single Dose of IcoSema Compared With Insulin Icodec and Semaglutide Given Separately in Chinese Participants With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","20","Diabetes Mellitus, Type 2","DRUG:IcoSema; DRUG:insulin icodec; DRUG:semaglutide","Novo Nordisk A/S","2022-06-22","FALSE","1"],["S001683","ClinicalTrials.gov","NCT07423481","SEMAFOLLOW","SEMAFOLLOW - Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity: Observational, National Cohort, Real-world Study in France","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","3000","Obesity & Overweight","OTHER:SEMAFOLLOW questionnaire","Nantes University Hospital","2026-10-01","FALSE","0"],["S001684","ClinicalTrials.gov","NCT06301256",null,"An Open-label Single Center Study to Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe Hidradenitis Suppurativa","INTERVENTIONAL",null,null,"UNKNOWN","20","Hidradenitis Suppurativa","DRUG:TIRZEPATIDE","Florida Academic Centers Research and Education, LLC","2024-03-11","FALSE","1"],["S001685","ClinicalTrials.gov","NCT02673931","GLORIOUS","Efficacy of a Glucagon-like-peptide-1 Agonist and Restrictive vs. Liberal Oxygen Supply in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement - a 2-by-2 Factorial Designed, Randomized Clinical Study","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","1400","Coronary Disease; Shock, Cardiogenic; Renal Failure; Stroke; Brain Injury; Aortic Valve Disease","DRUG:Byetta (Lilly, Exenatide); DRUG:Conoxia (AGA, oxygen); DRUG:20% Human Albumin","Copenhagen University Hospital, Rigshospitalet","2016-02","FALSE","2"],["S001686","ClinicalTrials.gov","NCT07521631",null,"A Phase 2, Randomized, Open-Label, Controlled Trial to Evaluate the Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","372","Obesity","DRUG:HDM1005 dose level 1; DRUG:HDM1005 dose level 2; DRUG:HDM1005 dose level 3; DRUG:Tirzepatide","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-03-31","FALSE","0"],["S001687","ClinicalTrials.gov","NCT03036800","STRIVE","EFFECTIVENESS AND COST OF INTEGRATING A PROTOCOL WITH USE OF LIRAGLUTIDE 3.0 MG INTO AN OBESITY SERVICE: (STRIVE Study)","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","392","Obesity; Weight Loss; Diabetes Mellitus","DRUG:Saxenda; OTHER:Specialist Obesity Management Services","University of Leicester","2017-11-28","TRUE","2"],["S001688","ClinicalTrials.gov","NCT02507128",null,"Effects of Glucagon Like Peptide-1 on No-reflow in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","190","Acute ST-segment Elevation Myocardial Infarction","DRUG:liraglutide; DRUG:placebo","Chen Wei Ren, MD","2015-07","FALSE","1"],["S001689","ClinicalTrials.gov","NCT04624672","NOVO-GLP1","GLP-1 Agonists as Neoadjuvant Therapy for Surgical Treatment of Type 2 Diabetes: A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","3","Diabetes Mellitus, Type 2","DRUG:Semaglutide (1 Mg Dose); DRUG:Placebo","Geisinger Clinic","2021-08-25","TRUE","0"],["S001690","ClinicalTrials.gov","NCT05303857","SEMA","Randomized, Double-blind, Placebo Controlled, Parallel Group, Prospective Clinical Study to Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","107","Diabetes Mellitus, Type 2","DRUG:Semaglutide Pen Injector; DRUG:Placebo","University of Erlangen-Nürnberg Medical School","2022-03-03","FALSE","1"],["S001691","ClinicalTrials.gov","NCT01974544","PRODIGIES","Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","150","Type 2 Diabetes","DRUG:Best medical treatment; PROCEDURE:gastric bypass; PROCEDURE:sleeve gastrectomy; DRUG:General interventions for all groups: blood presure; DRUG:General interventions for all groups: dysilipidemia; BEHAVIORAL:General interventions for all groups: lifestyle","Pontificia Universidad Catolica de Chile","2013-05","FALSE","0"],["S001692","ClinicalTrials.gov","NCT05574439","RESETTLE","Young Adults With Early-onset Obesity Treated With Semaglutide -The RESETTLE Study","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","246","Obesity, Adolescent","BEHAVIORAL:TCOC treatment; DRUG:Semaglutide 3 mg/ml; DRUG:Placebo (Semaglutide 3 mg/ml)","Signe Torekov","2022-05-30","FALSE","8"],["S001693","ClinicalTrials.gov","NCT01667900",null,"Pharmacokinetics of a Single Dulaglutide Dose in Healthy Chinese Subjects and of Multiple Dulaglutide Doses in Chinese Patients With T2DM","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","58","Diabetes Mellitus, Type 2; Healthy Volunteers","DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2012-08","TRUE","1"],["S001694","ClinicalTrials.gov","NCT07817875",null,"Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","150","Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2026-09-25","FALSE","0"],["S001695","ClinicalTrials.gov","NCT05441267","ASCEND PLUS","A Study of Cardiovascular Events iN Diabetes Plus","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","21296","Diabetes Mellitus, Type 2","DRUG:Semaglutide Oral Tablet; DRUG:Placebo oral tablet","University of Oxford","2023-03-13","FALSE","0"],["S001696","ClinicalTrials.gov","NCT06671821",null,"HRS-7535-202 Follow-up Study: A Long-term Evaluation of Safety, Tolerability, and Efficacy in Obese Subjects (Open-label, Extension Trial)","INTERVENTIONAL","NON_RANDOMIZED","PHASE2","COMPLETED","81","Chronic Weight Management","DRUG:HRS-7535","Shandong Suncadia Medicine Co., Ltd.","2024-11-20","FALSE","0"],["S001697","ClinicalTrials.gov","NCT05153564",null,"Investigation of the Effect of Subcutaneously Co-administered Semaglutide and NNC0480-0389 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) in Healthy Postmenopausal Females","INTERVENTIONAL",null,"PHASE1","COMPLETED","27","Diabetes Mellitus, Type 2","DRUG:Semaglutide 1.34 mg/mL; DRUG:Semaglutide 3.0 mg/mL; DRUG:NNC0480-0389 10 mg/mL; DRUG:NNC0480-0389 30 mg/mL; DRUG:Microgynon®","Novo Nordisk A/S","2021-12-13","FALSE","0"],["S001698","ClinicalTrials.gov","NCT07297238",null,"Therapeutic Efficacy of GLP-1 on Intestinal Barrier Function in Patients With Short Bowel Syndrome and Intestinal Failure: A Preliminary Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","20","Short Bowel Syndrome (SBS); Intestinal Failure","DRUG:GLP-1 Receptor Agonists","Jinling Hospital, China","2026-01-24","FALSE","5"],["S001699","ClinicalTrials.gov","NCT04909333","FAST","Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","29","Endogenous Hyperinsulinism","DRUG:Exenatide; DRUG:0.9% saline solution","University Hospital, Basel, Switzerland","2021-04-29","FALSE","2"],["S001700","ClinicalTrials.gov","NCT07000955",null,"Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg Administered Multiple Times in Chinese Patients With Moderate to Severe Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","ACTIVE_NOT_RECRUITING","98","Obesity","DRUG:Tirzepatide; DRUG:Placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2025-06-17","FALSE","0"],["S001701","ClinicalTrials.gov","NCT01785043","LAED001","Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users: A Randomized, Open-label, Parallel-group and Active Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","13","DIABETES Mellitus Type 2 Not Well Controlled","DRUG:Liraglutide; DRUG:Sitagliptin","Anna Cruceta","2013-03","FALSE","0"],["S001702","ClinicalTrials.gov","NCT00993304",null,"A Trial to Assess the Effect of Liraglutide on Postprandial Triglyceride Levels in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","20","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2009-10","FALSE","3"],["S001703","ClinicalTrials.gov","NCT00983021",null,"A Trial to Test for Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9068 and Compared With NN1250 and NN2211 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Diabetes; Healthy","DRUG:insulin degludec/liraglutide; DRUG:insulin degludec; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2009-09","FALSE","1"],["S001704","ClinicalTrials.gov","NCT02898506",null,"Incretin-based Therapy in Late Preclinical Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","13","Type 1 Diabetes","DRUG:Victoza®; DRUG:Placebo","University of Oulu","2016-03","FALSE","1"],["S001705","ClinicalTrials.gov","NCT07734870",null,"Tirzepatide for Treatment of CCCA","INTERVENTIONAL",null,"PHASE2","RECRUITING","20","Central Centrifugal Cicatricial Alopecia (CCCA)","DRUG:Tirzepatide","Johns Hopkins University","2026-09-15","FALSE","1"],["S001706","ClinicalTrials.gov","NCT07223242","TEXPEF","Tailored Exercise Training Study Among Adults With HFpEF","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","RECRUITING","120","HFpEF - Heart Failure With Preserved Ejection Fraction; Diabetic Cardiomyopathies","BEHAVIORAL:Moderate-intensity continuous training (MCT); BEHAVIORAL:Resistance training; DRUG:Weight loss","University of Texas Southwestern Medical Center","2025-02-18","FALSE","0"],["S001707","ClinicalTrials.gov","NCT01469351",null,"Neurodegenerative Changes in Alzheimer's Disease: Identifying Potential Effects of Liraglutide on Degenerative Changes","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","34","Alzheimers Disease","DRUG:Liraglutide; DRUG:non-active study drug","University of Aarhus","2012-01","FALSE","7"],["S001708","ClinicalTrials.gov","NCT04027023",null,"Pilot Study for Evaluation of the Impact of Intensive Short-Term Drug Therapy on Beta-Cell Function and Insulin Resistance in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE4","UNKNOWN","9","Diabetes Mellitus, Type 2","DRUG:Diabetes mellitus Type 2 De-escalation treatment (DET)","Sciema UG","2019-10-30","FALSE","0"],["S001709","ClinicalTrials.gov","NCT07756359","PROP-ZEP","Efficacy of the Dual GIP - GLP-1 Receptor Agonist Tirzepatide in Patients With an Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","20","Pouch, Ileal; Pouches, Ileoanal; Bowel Diseases, Inflammatory","DRUG:Tirzepatide; DRUG:Loperamide; DRUG:Diphenoxylate/Atropine","University of North Carolina, Chapel Hill","2026-09","FALSE","11"],["S001710","ClinicalTrials.gov","NCT06972459",null,"A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","800","Obesity; Overweight","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-05-15","FALSE","0"],["S001711","ClinicalTrials.gov","NCT05119179",null,"Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes","INTERVENTIONAL",null,"PHASE4","RECRUITING","300","PreDiabetes","DRUG:Semaglutide","The University of Texas Health Science Center, Houston","2021-11-22","FALSE","0"],["S001712","ClinicalTrials.gov","NCT04657003","SURMOUNT-2","Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","938","Type 2 Diabetes; Overweight; Obesity","DRUG:Tirzepatide; OTHER:Placebo","Eli Lilly and Company","2021-03-29","TRUE","9"],["S001713","ClinicalTrials.gov","NCT07046273",null,"A Multicenter, Randomized, Open, Parallel-controlled, Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","496","Type 2 Diabetes (T2DM)","DRUG:F027; DRUG:Ozempic®","Shandong New Time Pharmaceutical Co., LTD","2025-08-01","FALSE","0"],["S001714","ClinicalTrials.gov","NCT01542242",null,"Liraglutide Use in Prader-Willi Syndrome","INTERVENTIONAL",null,"PHASE4","TERMINATED","1","Diabetes Mellitus Type 2; Prader Willi Syndrome","DRUG:Liraglutide","Vancouver General Hospital","2012-02","FALSE","2"],["S001715","ClinicalTrials.gov","NCT07808879","HBED-CC-PEG6-E","[68Ga]Ga-HBED-CC-PEG6-Exendin-4 PET/CT Imaging in the Diagnosis of Insulinoma","INTERVENTIONAL",null,null,"RECRUITING","20","Insulinoma","DIAGNOSTIC_TEST:[68Ga]Ga-HBED-CC-PEG6-exendin-4 PET/CT; DIAGNOSTIC_TEST:[68Ga]Ga-HBED-CC-exendin-4 PET/CT","Peking Union Medical College Hospital","2026-10-01","FALSE","0"],["S001716","ClinicalTrials.gov","NCT04287179","SUSTAIN SWITCH","Effect and Safety of Two Different Dose-escalation Regimens for Once-weekly Semaglutide s.c. in Subjects With Type 2 Diabetes Mellitus Previously Treated With GLP-1 RAs","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2020-03-09","FALSE","0"],["S001717","ClinicalTrials.gov","NCT04777396","EVOKE","A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1840","Early Alzheimer's Disease","DRUG:Semagludtide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2021-05-18","FALSE","11"],["S001718","ClinicalTrials.gov","NCT05705388",null,"Comparison of Efficacy and Safety of POSE 2.0 Procedure Compared to GLP-1 Agonist in a Cohort of Patients for Management of Obesity: a Single-center Randomized Crossover-controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","50","Obesity","DEVICE:POSE2.0 Endoscopic Gastric Remodeling; DRUG:Liraglutide injection","Emirates Health Services (EHS)","2023-01-16","FALSE","0"],["S001719","ClinicalTrials.gov","NCT00971659",null,"Acute Effect of a GLP-1-Analogue (Exenatide) and of a DPP-4-Inhibitor (Sitagliptin) in Subjects With Type 2 Diabetes Treated With Insulin Glargine Once Daily","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","48","Type 2 Diabetes","DRUG:insulin glargine + exenatide + preexisting metformin; DRUG:insulin glargine + sitagliptin + preexisting metformin; DRUG:insulin glargine + preexisting metformin","Profil Institut für Stoffwechselforschung GmbH","2008-01","FALSE","1"],["S001720","ClinicalTrials.gov","NCT05726227","STEP Young","Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","212","Obesity","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2023-07-07","FALSE","0"],["S001721","ClinicalTrials.gov","NCT05041673",null,"Efficacy of Vildagliptin, Liraglutide and Empagliflozin in the Management of Fatty Liver Disease Among Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","120","Fatty Liver, Nonalcoholic; Diabetes Mellitus, Type 2","DRUG:Metformin","Alexandria University","2021-02-23","FALSE","0"],["S001722","ClinicalTrials.gov","NCT05869903","ATTAIN-1","A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","3127","Obesity; Overweight; Overweight or Obesity","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2023-06-05","TRUE","3"],["S001723","ClinicalTrials.gov","NCT02344186",null,"Effects of Liraglutide on Endoplasmic (ER) Stress in Obese Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","12","Type 2 Diabetes","DRUG:Liraglutide","Temple University","2014-05","FALSE","0"],["S001724","ClinicalTrials.gov","NCT06191848","STOP KNEE-OA","Effect of Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA): A Randomized, Double-Blind, Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","352","Obesity; Knee Osteoarthritis; Osteoarthritis, Knee","DRUG:Tirzepatide; DRUG:Placebo","University of Melbourne","2024-11-19","FALSE","1"],["S001725","ClinicalTrials.gov","NCT03182426",null,"Autologous Hematopoietic Stem Cell Mobilization (Plerixafor) and Immunologic Reset in New Onset Type 1 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","22","Diabetes Mellitus, Type 1","DRUG:Plerixafor; DRUG:Alemtuzumab; DRUG:Anakinra; DRUG:Etanercept; DRUG:Liraglutide","University of Alberta","2017-08-15","FALSE","0"],["S001726","ClinicalTrials.gov","NCT06630585","AID-JUNCT","GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes: A Prospective, Randomized, Clinical Study - The AID-JUNCT Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","42","Type 1 Diabetes (T1D)","DRUG:Tirzepatide","University of Bern","2025-02-14","FALSE","0"],["S001727","ClinicalTrials.gov","NCT06506175",null,"A Phase I Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","100","Weight Management; Type 2 Diabetes","DRUG:HRS9531 tablets","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-07","FALSE","0"],["S001728","ClinicalTrials.gov","NCT06916065",null,"A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate the Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of Eloralintide, and Single and Multiple Weekly Subcutaneous Doses of Eloralintide With Tirzepatide in Participants With Overweight or Obesity","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","188","Overweight; Obesity","DRUG:Eloralintide and Tirzepatide; DRUG:Eloralintide","Eli Lilly and Company","2025-04-09","FALSE","0"],["S001729","ClinicalTrials.gov","NCT06643728",null,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","252","Obesity; Overweight","DRUG:Bimagrumab; DRUG:Tirzepatide; DRUG:Bimagrumab Placebo; DRUG:Tirzepatide Placebo","Eli Lilly and Company","2024-10-21","FALSE","0"],["S001730","ClinicalTrials.gov","NCT06856928",null,"Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","16","Obesity; Drug","OTHER:Meal Challenge","University of Colorado, Denver","2025-03","FALSE","0"],["S001731","ClinicalTrials.gov","NCT03115099",null,"A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3325656 After Single Dose in Healthy Subjects and Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","80","Diabetes Mellitus, Type 2","DRUG:LY3325656; DRUG:Placebo; DRUG:Liraglutide; DRUG:Sitagliptin","Eli Lilly and Company","2017-05-31","FALSE","1"],["S001732","ClinicalTrials.gov","NCT02098395","ADJUNCT TWO™","A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","835","Diabetes; Diabetes Mellitus, Type 1","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2014-05","TRUE","4"],["S001733","ClinicalTrials.gov","NCT07446439",null,"The Thetis Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","280","Nausea and Vomiting; Obesity","DRUG:Tradipitant; DRUG:Placebo","Vanda Pharmaceuticals","2026-03-27","FALSE","0"],["S001734","ClinicalTrials.gov","NCT02905864","LOSEIT","Effect of Liraglutide on Body Weight and Pain in Overweight or Obese Patients With Knee Osteoarthritis: A Randomised, Double Blind, Placebo-controlled, Parallel Group, Single-centre Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","150","Osteoarthritis; Obesity","DRUG:Liraglutide 3 mg (Saxenda); DRUG:Liraglutide 3 mg placebo","Henrik Gudbergsen","2016-11","FALSE","5"],["S001735","ClinicalTrials.gov","NCT02713477",null,"A Randomized, Open Label, Placebo-controlled, 4-sequence, 4-period, 4-treatment Crossover Study to Investigate the Postprandial Glucodynamic Response to Single Dose of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","20","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010; DRUG:Insulin glargine HOE901; DRUG:Placebo","Sanofi","2016-04","FALSE","1"],["S001736","ClinicalTrials.gov","NCT06217887",null,"Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients: a Randomized, Parallel Controlled Clinical Trial","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","58","Type 2 Diabetes Mellitus; Cognitive Function Abnormal","DRUG:loxenatide Group; DRUG:Gliclazide Group","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2020-05-10","FALSE","2"],["S001737","ClinicalTrials.gov","NCT00603239",null,"Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","165","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:placebo","AstraZeneca","2008-01","TRUE","2"],["S001738","ClinicalTrials.gov","NCT01473953",null,"Investigation on Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects. A Randomised, Double-blind, Placebo-controlled Trial Investigating Subcutaneously Single Dose Escalation of a Sustained Release Formulation of Liraglutide Lysine in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","31","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:liraglutide-depot; DRUG:placebo","Novo Nordisk A/S","2011-10","TRUE","0"],["S001739","ClinicalTrials.gov","NCT06686134",null,"Comprehensive Clinical Evaluation Study of GLP-1RA","OBSERVATIONAL",null,null,"RECRUITING","492","T2DM",null,"LI YAN","2024-07-01","FALSE","1"],["S001740","ClinicalTrials.gov","NCT03552757","STEP 2","Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity and Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1210","Obesity; Overweight","DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 2.4 mg; DRUG:Placebo I (Semaglutide); DRUG:Placebo II (Semaglutide)","Novo Nordisk A/S","2018-06-04","TRUE","15"],["S001741","ClinicalTrials.gov","NCT02906930","PIONEER 1","Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only.","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","703","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2016-09-20","TRUE","10"],["S001742","ClinicalTrials.gov","NCT06200467",null,"A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Parallel Group With Nested Crossover Design Trial With Moxifloxacin as Positive Control to Evaluate the Effects of Multiple Subcutaneous Doses of BI 456906 in a Titration Scheme on Cardiac Safety Parameters in (Otherwise) Healthy Male and Female Subjects With Overweight/Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","110","Overweight; Obesity","COMBINATION_PRODUCT:BI 456906; COMBINATION_PRODUCT:Placebo to BI 456906; DRUG:Moxifloxacin; DRUG:Placebo to moxifloxacin","Boehringer Ingelheim","2024-03-13","FALSE","0"],["S001743","ClinicalTrials.gov","NCT05573230",null,"A Phase 1, Open-Label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Cyclosporine on the Pharmacokinetics of LY3502970 in Healthy Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","32","Healthy","DRUG:Midazolam; DRUG:LY3502970; DRUG:Cyclosporine","Eli Lilly and Company","2022-10-17","TRUE","0"],["S001744","ClinicalTrials.gov","NCT07734311",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Ecnoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","360","Knee Osteoarthritis; Obesity","DRUG:Ecnoglutide Injection; DRUG:placebo with matching volume","Hangzhou Sciwind Biosciences Co., Ltd.","2026-08-03","FALSE","0"],["S001745","ClinicalTrials.gov","NCT07858864","GLP1-SARCO","Evaluation of the Relationship Between GLP-1 Receptor Agonist Use and Sarcopenia in Non-Diabetic Obese Individuals: A Prospective Descriptive Study","OBSERVATIONAL",null,null,"RECRUITING","42","Obesity; Sarcopenia","DRUG:GLP-1 receptor agonist (e.g., semaglutide, tirzepatide) - prescribed by the treating physician as standard care; the study does not assign or alter treatment.","Istanbul Saglik Bilimleri University","2026-05-30","FALSE","3"],["S001746","ClinicalTrials.gov","NCT07737522",null,"Myocardial Metabolic Flux in Patients With Pulmonary Arterial Hypertension (PAH) in Response to GLP-1 Agonist Therapy: a Physiological Study Using 31-Phosphorus MR Spectroscopy","INTERVENTIONAL",null,"PHASE2","NOT_YET_RECRUITING","32","Pulmonary Arterial Hypertension","DRUG:GLP-1 agonist","Imperial College London","2026-10-01","FALSE","0"],["S001747","ClinicalTrials.gov","NCT06836037",null,"A Single and Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics of MK-6024 in Healthy Chinese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","56","Healthy","DRUG:Efinopegdutide; DRUG:Placebo","Merck Sharp & Dohme LLC","2022-09-05","FALSE","1"],["S001748","ClinicalTrials.gov","NCT01715428",null,"Effects of Liraglutide on Cardio-Metabolic Risk Markers","OBSERVATIONAL",null,null,"COMPLETED","300","Type-2 Diabetes",null,"University of Palermo","2012-06","FALSE","6"],["S001749","ClinicalTrials.gov","NCT06420739",null,"Improving Patient Safety for Surgical Patients on Semaglutide: A Gastric Ultrasound Initiative","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","100","Fasting","DIAGNOSTIC_TEST:Gastric Ultrasound","University Health Network, Toronto","2024-03-25","FALSE","0"],["S001750","ClinicalTrials.gov","NCT00766857",null,"The Effect of Exenatide Compared to Insulin Glargine on Cardiac Function and Metabolism in Type 2 Diabetic Patients With Congestive Heart Failure: a Randomized Comparator-controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","27","Type 2 Diabetes Mellitus; Congestive Heart Failure","DRUG:exenatide; DRUG:Insulin glargine","Amsterdam UMC, location VUmc","2009-05","FALSE","1"],["S001751","ClinicalTrials.gov","NCT05268237",null,"A Phase Ib/IIa, Single Ascending Dose Study of the Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","RECRUITING","15","Diabete Type 2","DRUG:Liraglutide; DRUG:Placebo","Biolingus","2023-04-25","FALSE","0"],["S001752","ClinicalTrials.gov","NCT06762600",null,"A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Subcutaneous Injections of HRS-4729 Injection in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","102","Overweight or Obesity","DRUG:HRS-4729 injection; DRUG:HRS-4729 injection placebo; DRUG:HRS9531 injection; DRUG:HRS9531 injection placebo; DRUG:Acetaminophen","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-01-16","FALSE","0"],["S001753","ClinicalTrials.gov","NCT03835013","COCOA","A Comparison of the Haemodynamic and Metabolic Effects of Intravenous Glucagon-like Peptide-1, Glucagon and Glucagon-like Peptide-1:Glucagon Co-agonism in Healthy Male Participants","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","26","Cardiovascular Diseases","DRUG:Saline 0.9%; DRUG:Glucagon (25ng/kg/min); DRUG:Glucagon (50ng/kg/min); DRUG:Exenatide","Cambridge University Hospitals NHS Foundation Trust","2019-02-11","FALSE","0"],["S001754","ClinicalTrials.gov","NCT01687582",null,"Clinical and Histopathological Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients","INTERVENTIONAL",null,null,"COMPLETED","10","Type 2 Diabetes; Psoriasis","DRUG:GLP-1 analog","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","2012-01","FALSE","2"],["S001755","ClinicalTrials.gov","NCT07027969","METSAFE","Efficacy of Cardiometabolic Risk Factor Control Through Metabolic Surgery on Management and Severity of Atrial Fibrillation: METSAFE Randomized Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","100","Atrial Fibrillation; Obesity and Obesity-related Medical Conditions","PROCEDURE:Roux-en-Y Gastric Bypass or Sleeve Gastrectomy; DRUG:Anti-Obesity Medication (AOM) treatment","Ali Aminian","2026-11-01","FALSE","0"],["S001756","ClinicalTrials.gov","NCT06613854","E-SEMPA","Effect of Early Combination Antihyperglycemic Treatment With Metformin and Oral Semaglutide vs. Metformin and Empagliflozin on Glycemic and Metabolic Control in Individuals With Short Duration Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","90","Type 2 Diabetes Mellitus (T2DM)","DRUG:Oral semaglutide; DRUG:Empagliflozin 10 mg","University Medical Centre Ljubljana","2024-10-01","FALSE","0"],["S001757","ClinicalTrials.gov","NCT07354880","TEACH","Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","30","Obesity & Overweight; Adult Congenital Heart Disease","DRUG:Treatment with tirzapatide; DRUG:Treatment with placebo","University Medical Centre Ljubljana","2026-01-20","FALSE","0"],["S001758","ClinicalTrials.gov","NCT04972396",null,"An Open-label Study of the Effect of ALT-801 on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin, Digoxin, and the Combined Oral Contraceptive Ethinylestradiol/Levonorgestrel in Healthy Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","40","NASH - Nonalcoholic Steatohepatitis","DRUG:Pemvidutide; DRUG:Metformin; DRUG:Atorvastatin; DRUG:Warfarin; DRUG:Digoxin; DRUG:Ethinylestradiol and Levonorgestrel","Altimmune, Inc.","2021-09-15","FALSE","0"],["S001759","ClinicalTrials.gov","NCT07347080","CR059101","A Single-Center, Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"EARLY_PHASE1","RECRUITING","9","T2DM","DRUG:Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））","The First Affiliated Hospital of Henan University of Science and Technology","2026-01-20","FALSE","0"],["S001760","ClinicalTrials.gov","NCT02420262",null,"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","506","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin glargine; DRUG:insulin aspart","Novo Nordisk A/S","2015-07-26","TRUE","6"],["S001761","ClinicalTrials.gov","NCT06426446","TELE-SEMA","Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data","INTERVENTIONAL",null,null,"UNKNOWN","80","Obesity","DEVICE:Withings Body Comp Pro","Assistance Publique - Hôpitaux de Paris","2024-06-01","FALSE","8"],["S001762","ClinicalTrials.gov","NCT01226966","EVIDENCE","Conditions for Prescribing Liraglutide in Medical Practice and Assessment of Maintenance Level, Tolerability, and Efficacy of Victoza® (Liraglutide) in Subjects With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","3152","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2010-09","FALSE","2"],["S001763","ClinicalTrials.gov","NCT06817356",null,"A Phase 2, Double-Blind, Proof of Concept Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","308","Alcohol Use Disorder","DRUG:Mazdutide; DRUG:Placebo","Eli Lilly and Company","2025-02-06","FALSE","0"],["S001764","ClinicalTrials.gov","NCT03987451",null,"Investigation of Efficacy and Safety of Semaglutide s.c. Once-weekly Versus Placebo in Subjects With Non-alcoholic Steatohepatitis and Compensated Liver Cirrhosis","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","71","Non-alcoholic Steatohepatitis","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-06-18","TRUE","4"],["S001765","ClinicalTrials.gov","NCT07668388",null,"Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","300","Diabetes Mellitus, Type 2","DRUG:UBT251; DRUG:UBT251 Placebo; DRUG:Semaglutide; DRUG:Semaglutide Placebo","Novo Nordisk A/S","2026-06-22","FALSE","0"],["S001766","ClinicalTrials.gov","NCT03961256",null,"A Phase 2, Prospective, Randomized, Multicenter, Open-Label, Controlled Trial to Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","9","Pre Diabetes","DRUG:Exenatide SR","Mayo Clinic","2019-05-09","TRUE","0"],["S001767","ClinicalTrials.gov","NCT05046873",null,"A Study to Investigate the Pharmacokinetics of Semaglutide and NNC0480-0389 When Subcutaneously Administered as a Co-formulation or as Separate Injections in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","16","Diabetes Mellitus, Type 2","DRUG:Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL; DRUG:semaglutide 1.34 mg/mL (placebo); DRUG:Semaglutide 1.34 mg/mL; DRUG:NNC0480-0389 A 10 mg/mL","Novo Nordisk A/S","2021-09-06","FALSE","0"],["S001768","ClinicalTrials.gov","NCT00641056",null,"Efficacy of Once-Weekly Exenatide Long-Acting Release and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","467","Type 2 Diabetes Mellitus","DRUG:Exenatide Once Weekly; DRUG:Insulin Glargine","AstraZeneca","2008-04","TRUE","10"],["S001769","ClinicalTrials.gov","NCT02650596",null,"Effects of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","68","Heart Failure","DRUG:GLP-1; DRUG:Placebo","Shi Yang","2016-01","FALSE","3"],["S001770","ClinicalTrials.gov","NCT07695454",null,"31P-MRS and MRI Imaging in Semaglutide Study","OBSERVATIONAL",null,null,"RECRUITING","10","Type 2 Diabetes; BMI Greater Than 30","RADIATION:31P-MRS and MRI","The Cleveland Clinic","2026-07-30","FALSE","0"],["S001771","ClinicalTrials.gov","NCT03466567",null,"A Trial Investigating the Effect of Probenecid and Ciclosporin on the Pharmacokinetics of SNAC in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","21","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Probenecid; DRUG:Ciclosporin","Novo Nordisk A/S","2018-03-15","FALSE","0"],["S001772","ClinicalTrials.gov","NCT06246799",null,"Comparative Effectiveness of Two Initial Combination Therapies in Patients With New Onset Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","256","Type 2 Diabetes (Adult Onset)","DRUG:Tirzepatide; DRUG:Pioglitazone; DRUG:Sitagliptin; DRUG:Metformin HCI XR","The University of Texas Health Science Center at San Antonio","2024-11-07","FALSE","0"],["S001773","ClinicalTrials.gov","NCT06605287",null,"A Study to Observe the Progress of Diabetes After Supaglutide Injection for 52 or 28 Weeks Treatment in Type 2 Diabetes Patients","OBSERVATIONAL",null,null,"UNKNOWN","100","Type 2 Diabetes Mellitus",null,"Nanjing First Hospital, Nanjing Medical University","2023-03-13","FALSE","1"],["S001774","ClinicalTrials.gov","NCT01147692",null,"An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Albiglutide in Healthy Adult Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","40","Diabetes Mellitus, Type 2","BIOLOGICAL:simvastatin plus albiglutide","GlaxoSmithKline","2010-05-19","FALSE","1"],["S001775","ClinicalTrials.gov","NCT06820099",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS-7535 in Subjects With Heart Failure, Mild Reduction/Preservation of Ejection Fraction, and Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","225","Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity","DRUG:HRS-7535 tablet; DRUG:HRS-7535 tablet placebo","Shandong Suncadia Medicine Co., Ltd.","2025-04-10","FALSE","0"],["S001776","ClinicalTrials.gov","NCT07225816",null,"Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","RECRUITING","71","Obesity","DRUG:Liraglutide; DRUG:Oral Semaglutide; DRUG:Semaglutide","Novo Nordisk A/S","2025-11-07","FALSE","0"],["S001777","ClinicalTrials.gov","NCT02475499",null,"The Use of Incretin-based Drugs and the Risk of Pancreatic Cancer in Patients With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","886172","Diabetes Mellitus, Type 2","DRUG:DPP-4 inhibitors; DRUG:GLP-1 analogs; DRUG:Sulfonylureas; DRUG:Biguanides; DRUG:Thiazolidinediones; DRUG:Alpha-glucosidase inhibitors; DRUG:Meglitinides","Canadian Network for Observational Drug Effect Studies, CNODES","2014-03","FALSE","1"],["S001778","ClinicalTrials.gov","NCT05788328",null,"A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO ESTIMATE THE EFFECT OF PF-07081532 ADMINISTRATION ON THE SINGLE-DOSE PHARMACOKINETICS OF DABIGATRAN AND ROSUVASTATIN IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","TERMINATED","16","Healthy","DRUG:Dabigatran etexilate (DE); DRUG:Rosuvastatin; DRUG:PF-07081532","Pfizer","2023-03-27","TRUE","1"],["S001779","ClinicalTrials.gov","NCT05669599",null,"A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","592","Obesity; Overweight; Type 2 Diabetes Mellitus","BIOLOGICAL:Maridebart Cafraglutide; DRUG:Placebo","Amgen","2023-01-18","FALSE","1"],["S001780","ClinicalTrials.gov","NCT01392898","ELEGANT","The Effect of Liraglutide on Insulin-associated wEight GAiN in Patients With Type 2 Diabetes Mellitus (ELEGANT Trial)","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","50","Type 2 Diabetes Mellitus","DRUG:liraglutide; DRUG:Insulin","Radboud University Medical Center","2012-02","FALSE","1"],["S001781","ClinicalTrials.gov","NCT05912621",null,"Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","66","Obesity; Overweight and Obesity; Overweight","DRUG:Tirzepatide","Stanford University","2023-11-09","FALSE","0"],["S001782","ClinicalTrials.gov","NCT02187250",null,"Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","45","PCOS; Obesity","DRUG:metformin; DRUG:liraglutide; DRUG:roflumilast","University Medical Centre Ljubljana","2014-03","FALSE","1"],["S001783","ClinicalTrials.gov","NCT07313813","GBGT","A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Dulaglutide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","20","Type 2 Diabetes Mellitus (T2DM)","DRUG:Dulaglutide","Eli Lilly and Company","2025-12-29","FALSE","0"],["S001784","ClinicalTrials.gov","NCT05978713",null,"A Study to Evaluate Tirzepatide Concentrations in Breastmilk Following Administration of Single Dose of Tirzepatide by Subcutaneous Injection in Healthy Lactating Females","INTERVENTIONAL",null,"PHASE1","COMPLETED","11","Healthy","DRUG:Tirzepatide","Eli Lilly and Company","2023-07-31","TRUE","0"],["S001785","ClinicalTrials.gov","NCT07801820",null,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","240","Type 2 Diabetes Mellitus (T2DM)","DRUG:MWN109 1; DRUG:MWN109 2; DRUG:MWN109 3; DRUG:MWN109 4; DRUG:Placebo; DRUG:Semaglutide Tablets","Shanghai Minwei Biotechnology Co., Ltd","2026-06-23","FALSE","0"],["S001786","ClinicalTrials.gov","NCT01126580",null,"The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","807","Diabetes Mellitus, Type 2","DRUG:Metformin; DRUG:LY2189265; DRUG:Placebo (oral); DRUG:Placebo (subcutaneous)","Eli Lilly and Company","2010-05","TRUE","5"],["S001787","ClinicalTrials.gov","NCT07096908",null,"Treatment With Tirzepatide of the Disease of Obesity in People With Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","60","Type1diabetes; Obesity","DRUG:Tirzepatide; DRUG:Placebo","Dasman Diabetes Institute","2025-07-31","FALSE","1"],["S001788","ClinicalTrials.gov","NCT01790308",null,"Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function in Newly-diagnosed Type 2 Diabetic Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","100","Diabetes Mellitus, Type 2","DRUG:CSII; DRUG:Liraglutide","Sun Yat-sen University","2013-02","FALSE","0"],["S001789","ClinicalTrials.gov","NCT01455909",null,"A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Type 2 Diabetes","DRUG:ITCA 650 60 mcg/day; DRUG:sitagliptin","Intarcia Therapeutics","2013-02","FALSE","0"],["S001790","ClinicalTrials.gov","NCT04261933","SURE GERMANY","A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","789","Diabetes Mellitus, Type 2","DRUG:semaglutide","Novo Nordisk A/S","2020-02-13","FALSE","1"],["S001791","ClinicalTrials.gov","NCT04109547","PIONEER 11","China Multi-regional Clinical Trial: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","521","Diabetes Mellitus, Type 2","DRUG:Oral semaglutide; DRUG:Placebo","Novo Nordisk A/S","2019-10-01","TRUE","1"],["S001792","ClinicalTrials.gov","NCT01272232",null,"Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","846","Metabolism and Nutrition Disorder; Obesity","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2011-06-01","TRUE","16"],["S001793","ClinicalTrials.gov","NCT07438444",null,"A Phase 4, Open-Label, Single-Arm, 46-Week Study to Investigate the Safety and Efficacy With Tirzepatide in Adult Indian Participants With Either Type 2 Diabetes or Obesity","INTERVENTIONAL",null,"PHASE4","ACTIVE_NOT_RECRUITING","344","Diabetes Mellitus, Type 2; Obesity; Overweight","DRUG:Tirzepatide","Eli Lilly and Company","2026-02-27","FALSE","0"],["S001794","ClinicalTrials.gov","NCT01755416",null,"Phase 1 Study of Medtronic Closed Loop Device With ePID Algorithm and Enlite Sensors on Adjuvant Therapy With Insulin and Liraglutide to Minimize Post-prandial Hyperglycemia","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","18","Type 1 Diabetes","DRUG:Closed loop with sensor and Insulin; DRUG:Closed loop with sensor, Insulin and Liraglutide","Albert Einstein College of Medicine","2013-01","TRUE","0"],["S001795","ClinicalTrials.gov","NCT06811324",null,"The Effects of Tirzepatide Use on Muscle and Vascular Function Among Obese Older Adults","INTERVENTIONAL",null,"PHASE2","RECRUITING","20","Obesity Prevention; Sarcopenia in Elderly; Cardiovascular Function; GLP - 1; Weight Loss","DRUG:Tirzepatide","The University of Texas Health Science Center at San Antonio","2026-04-01","FALSE","6"],["S001796","ClinicalTrials.gov","NCT04216589",null,"A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)","INTERVENTIONAL",null,"PHASE2","COMPLETED","51","HIV Infections; Non-Alcoholic Fatty Liver Disease","DRUG:Semaglutide","National Institute of Allergy and Infectious Diseases (NIAID)","2021-02-19","TRUE","4"],["S001797","ClinicalTrials.gov","NCT05702931","Sema-RTx","Safety and Efficacy of Oral Semaglutide in Hyperglycaemic Patients After Renal Transplantation","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","104","Hyperglycemia; Renal Transplant Complication Primary Non-Function; Diabetes","DRUG:Semaglutide 14 MG [Rybelsus]; DRUG:Placebo","Copenhagen University Hospital, Rigshospitalet","2024-09-19","FALSE","0"],["S001798","ClinicalTrials.gov","NCT06808802",null,"A Phase 1, Open-label, Single-arm Study to Investigate the Effect of Retatrutide on Metoprolol Pharmacokinetics in Healthy Participants","INTERVENTIONAL",null,"PHASE1","COMPLETED","30","Healthy","DRUG:Retatrutide; DRUG:Metoprolol","Eli Lilly and Company","2025-02-03","FALSE","0"],["S001799","ClinicalTrials.gov","NCT07551492",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Participants With Atherosclerotic Cardiovascular Disease (ASCVD)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","9262","Atherosclerotic Cardiovascular Disease","DRUG:HRS9531; DRUG:HRS9531 placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-05-29","FALSE","0"],["S001800","ClinicalTrials.gov","NCT05221229","GOAL-AF","Feasibility Study of GLP-1 Analogues for the Optimization of Outcomes in High BMI Patients Undergoing AbLation for Atrial Fibrillation","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","29","Atrial Fibrillation; Recurrence; Overweight and Obesity; Liraglutide","DRUG:Liraglutide plus upstream risk factors modification advice and consultation","University Hospital Birmingham","2022-04-17","FALSE","2"],["S001801","ClinicalTrials.gov","NCT06027567","IIH:DUAL","Glucagon-like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as Treatment of Idiopathic Intracranial Hypertension","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","38","Idiopathic Intracranial Hypertension; Intracranial Pressure; Obesity; Pseudotumor Cerebri Syndrome; Papilledema; Weight Loss","DRUG:Semaglutide; DIETARY_SUPPLEMENT:Very Low Calorie Diet; BEHAVIORAL:Dietician counselling","Rigmor Højland Jensen","2022-09-02","FALSE","0"],["S001802","ClinicalTrials.gov","NCT07096739",null,"Tolerance and Acceptance of a High Protein Nutrition Shake in Individuals Treated With the GLP-1 Receptor Agonist Semaglutide: a Single Arm, Open Label Study","INTERVENTIONAL",null,null,"COMPLETED","20","GLP-1 Concentration","DIETARY_SUPPLEMENT:High protein shake","Kate Farms Inc","2025-08-01","FALSE","1"],["S001803","ClinicalTrials.gov","NCT07226765","MARITIME-OSA-2","A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure Therapy and Living With Overweight or Obesity (MARITIME-OSA-2)","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","250","Obstructive Sleep Apnea","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2025-11-25","FALSE","0"],["S001804","ClinicalTrials.gov","NCT07364175","SOLUTION-Pilot","Standard of Care or Weight Loss Drug Therapy in Obesity-related Hypertension - Pilot Study","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","60","Hypertension; Obesity & Overweight","DRUG:Tirzepatide; DRUG:Anti-Hypertensive medications","Cambridge University Hospitals NHS Foundation Trust","2026-01","FALSE","0"],["S001805","ClinicalTrials.gov","NCT00635492",null,"CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy - A European Observational Study of Patients With Type 2 Diabetes Initiating Injectable Therapy to Determine Time to Treatment Change, Factors Associated With Treatment Changes and Outcomes Over 24 Months","OBSERVATIONAL",null,null,"COMPLETED","2515","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:any human insulin or analog insulin(s) given in any regimen by subcutaneous injection","AstraZeneca","2008-01","TRUE","5"],["S001806","ClinicalTrials.gov","NCT02456428",null,"Incretin-based Drugs and the Risk of Heart Failure: A Multi-center Network Observational Study","OBSERVATIONAL",null,null,"COMPLETED","1499650","Type 2 Diabetes Mellitus","DRUG:DPP-4 inhibitors; DRUG:GLP-1 analogs; DRUG:Insulins; DRUG:Biguanides; DRUG:Sulfonylureas; DRUG:Thiazolidinediones; DRUG:Alpha-glucosidase inhibitors; DRUG:Meglitinides","Canadian Network for Observational Drug Effect Studies, CNODES","2014-03","FALSE","1"],["S001807","ClinicalTrials.gov","NCT02973100",null,"A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","318","Type 2 Diabetes","DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2016-12","TRUE","0"],["S001808","ClinicalTrials.gov","NCT01215968",null,"A Study to Evaluate the Effect of LY2189265 on Gastric Emptying Using Scintigraphy in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","38","Diabetes Mellitus, Type 2","BIOLOGICAL:LY2189265; DRUG:Placebo","Eli Lilly and Company","2010-09","TRUE","0"],["S001809","ClinicalTrials.gov","NCT07619508",null,"Comparative Effectiveness of Tirzepatide and Semaglutide in Patients at Cardiovascular Risk With Overweight or Obesity But Without Diabetes","OBSERVATIONAL",null,null,"COMPLETED","100000","Obesity; Overweight","DRUG:Tirzepatide; DRUG:Semaglutide","Brigham and Women's Hospital","2026-02-10","FALSE","0"],["S001810","ClinicalTrials.gov","NCT07621640","BAT-Sema","Brown Adipose Tissue as a Mechanistic Determinant of GLP-1 Receptor Agonist Treatment Response in Adults With Obesity: A Multicenter Prospective Cohort Study Using ¹⁸FDG-PET/CT and Cold Stimulation Protocol","INTERVENTIONAL",null,null,"NOT_YET_RECRUITING","80","Obesity; Metabolic Syndrome; Brown Adipose Tissue","DRUG:Semaglutide (Wegovy®); PROCEDURE:¹⁸FDG-PET/CT with cold stimulation; PROCEDURE:Liver MRI (PDFF + MRE)","Hallym University","2026-06","FALSE","0"],["S001811","ClinicalTrials.gov","NCT01499108","Liratime","Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes","INTERVENTIONAL",null,"PHASE4","COMPLETED","32","Type 2 Diabetes","DRUG:liraglutide","Peter Rossing","2012-08","FALSE","1"],["S001812","ClinicalTrials.gov","NCT00943917",null,"Phase 2 Study of ITCA 650 in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","155","Type 2 Diabetes","OTHER:ITCA 650; DRUG:Exenatide Injection; OTHER:Ex Inj/ITCA 650","Intarcia Therapeutics","2009-08","TRUE","2"],["S001813","ClinicalTrials.gov","NCT06297616",null,"A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3841136 Monotherapy, and LY3841136 in Combination With Tirzepatide, in Japanese Participants With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","128","Obesity; Overweight","DRUG:LY3841136; DRUG:LY3841136-Placebo; DRUG:Tirzepatide; DRUG:Tirzepatide-Placebo","Eli Lilly and Company","2024-04-15","FALSE","0"],["S001814","ClinicalTrials.gov","NCT05816057",null,"A Multicenter, Randomized, Open-label, and Parallel Assignment Phase III Study to Compare the Efficacy and Safety of Semaglutide Injection With Ozempic® in Combination With Metformin in the Treatment of Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","476","Diabetes Mellitus, Type 2","BIOLOGICAL:semaglutide injection","Hangzhou Jiuyuan Gene Engineering Co. Ltd.,","2022-07-25","FALSE","0"],["S001815","ClinicalTrials.gov","NCT07629401",null,"Pre-approval Expanded Access of Retatrutide (LY3437943)","EXPANDED_ACCESS",null,null,"AVAILABLE",null,"Obesity; Obesity-related Complications","DRUG:Retatrutide","Eli Lilly and Company",null,"FALSE","0"],["S001816","ClinicalTrials.gov","NCT05597202","DOTAFLAME","Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes","INTERVENTIONAL",null,"PHASE4","UNKNOWN","22","Type 2 Diabetes","DRUG:Semaglutide, 2.0 mg/mL","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","2023-01-01","FALSE","0"],["S001817","ClinicalTrials.gov","NCT02920385",null,"A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","45","Diabetes; Healthy","DRUG:Semaglutide; DRUG:SNAC; DRUG:Levothyroxine; DRUG:Placebo","Novo Nordisk A/S","2016-10-10","FALSE","0"],["S001818","ClinicalTrials.gov","NCT06182891",null,"Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","300","Type 2 Diabetic Nephropathy","DRUG:Dulaglutide Injection","The Affiliated Hospital of Xuzhou Medical University","2021-10-30","FALSE","1"],["S001819","ClinicalTrials.gov","NCT07241390",null,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","7140","Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-12-01","FALSE","0"],["S001820","ClinicalTrials.gov","NCT05784402",null,"A Randomised Study to Investigate Steady State Semaglutide Exposure of a New Formulation of Oral Semaglutide in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","264","Healthy Participants","DRUG:Semaglutide J; DRUG:Semaglutide C","Novo Nordisk A/S","2023-03-16","FALSE","0"],["S001821","ClinicalTrials.gov","NCT07819227","FINESSE-CKD","Optimization of Albuminuria Lowering Therapies to Individual Patients With CKD Using FINErenone and SEmaglutide","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","41","Chronic Kidney Disease","DRUG:Finerenone (BAY 94-8862); DRUG:Semaglutide 14 MG [Rybelsus]; DRUG:Finerenone and Semaglutide","University Medical Center Groningen","2025-02-11","FALSE","0"],["S001822","ClinicalTrials.gov","NCT07017270","GUARD-1","Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","100","Kidney Disease, Chronic; Diabetes; Dialysis; End Stage Kidney Disease (ESRD)","DRUG:Semaglutide Pen","Unity Health Toronto","2025-11-27","FALSE","0"],["S001823","ClinicalTrials.gov","NCT02084654",null,"Randomized Trial Investigating Exenatide for Diabetes Prevention in Obese, Insulin-Resistant Individuals With Prediabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","66","Pre Diabetes; Insulin Resistance","DRUG:Exenatide 5 and 10 mcg 2 times a day; DRUG:placebo","Stanford University","2007-11","FALSE","0"],["S001824","ClinicalTrials.gov","NCT01128894",null,"A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","841","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; DRUG:liraglutide","GlaxoSmithKline","2010-05","TRUE","1"],["S001825","ClinicalTrials.gov","NCT06715514","DECLARED-CT","Effects of Combined Menopausal Hormone Therapy and GLP-1 Receptor Agonist Therapy on Glucose and Energy Homeostasis in Early Postmenopausal Women With or at Risk of Diabetes","INTERVENTIONAL","RANDOMIZED",null,"ACTIVE_NOT_RECRUITING","96","Menopause; Type 2 Diabetes","DRUG:GLP-1 Receptor Agonist; DRUG:Menopausal Hormone Therapy","Lia Bally","2025-02-18","FALSE","0"],["S001826","ClinicalTrials.gov","NCT01509755",null,"Dose-response Relationship of Five Dose Levels of NNC90-1170 and Placebo on Glycaemic Control in Type 2 Diabetic Patients Compared to OHA Treatment. A 12-week Multi-centre, Double-blind, Randomised, Parallel Group Trial With an Open Labelled OHA Arm","INTERVENTIONAL",null,"PHASE2","COMPLETED","196","Diabetes; Diabetes Mellitus, Type 2","DRUG:placebo; DRUG:liraglutide; DRUG:glimepiride","Novo Nordisk A/S","2000-10","FALSE","2"],["S001827","ClinicalTrials.gov","NCT04186494",null,"The Benefit of a Liraglutide-based Weight Management Alone or in Addition to Standard CPAP Therapy on Metabolic Function in Patients With Obstructive Sleep Apnoea (OSA) - an Explorative, Proof-of-concept Study","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","30","Sleep Apnea, Obstructive","DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml; DEVICE:Continuous positive airway pressure treatment; COMBINATION_PRODUCT:Liraglutide and CPAP","St Vincent's University Hospital, Ireland","2019-12-02","FALSE","7"],["S001828","ClinicalTrials.gov","NCT06396429",null,"Efficacy and Safety of HRS9531 in Overweight or Obese Participants: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","567","Overweight or Obesity","DRUG:HRS9531 injection; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-05-13","FALSE","0"],["S001829","ClinicalTrials.gov","NCT03182231",null,"Visualizing Beta Cells in Patients With T2D Before and After Bariatric Surgery","INTERVENTIONAL",null,"PHASE1; PHASE2","UNKNOWN","12","Diabetes Mellitus, Type 2; Bariatric Surgery Candidate","RADIATION:68Ga-NODAGA-exendin-4 PET/CT","Radboud University Medical Center","2016-10-07","FALSE","1"],["S001830","ClinicalTrials.gov","NCT06976853",null,"Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","60","Crohn Disease (CD)","DRUG:Tirzepatide; DRUG:Standard of care treatment","Washington University School of Medicine","2025-05-13","FALSE","0"],["S001831","ClinicalTrials.gov","NCT06338553","GLP-TEP","Optimizing Stage 2 T1DM Management: Assessing the Impact of GLP-1Ra on Metabolic Outcomes in Patients Receiving Teplizumab","INTERVENTIONAL","RANDOMIZED","EARLY_PHASE1","RECRUITING","24","Type 1 Diabetes","DRUG:Semaglutide (Rybelsus®); DRUG:Placebo","Vanderbilt University Medical Center","2024-06-12","FALSE","0"],["S001832","ClinicalTrials.gov","NCT02077946",null,"A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden","OBSERVATIONAL",null,null,"COMPLETED","1059","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:sitagliptin","Novo Nordisk A/S","2014-02-10","FALSE","1"],["S001833","ClinicalTrials.gov","NCT06465186",null,"Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","85","Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; NAFLD; Metabolic Dysfunction-associated Steatotic Liver Disease; Metabolic Dysfunction-associated Steatohepatitis","COMBINATION_PRODUCT:Efinopegdutide; COMBINATION_PRODUCT:Placebo","Merck Sharp & Dohme LLC","2024-07-12","FALSE","0"],["S001834","ClinicalTrials.gov","NCT05501483","DiaSpax","Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone and Semaglutide","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","60","Type 2 Diabetes","DRUG:Pioglitazone 45 mg; DRUG:Empagliflozin 25 MG; DRUG:Semaglutide 7 MG","Karolinska Institutet","2023-02-08","FALSE","0"],["S001835","ClinicalTrials.gov","NCT06692348",null,"A Phase 1, Open-Label, Multiple-Dose Study to Investigate the Comparability of the Pharmacokinetics of Orforglipron (LY3502970) Single Capsule and Multiple Capsules in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","86","Healthy","DRUG:Orforglipron","Eli Lilly and Company","2024-12-13","FALSE","0"],["S001836","ClinicalTrials.gov","NCT06575738","PRESSURE","Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide - in Adolescents (the PRESSURE Trial)","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","40","Obesity; Adolescent Obesity; Body-Weight Trajectory; Weight Loss Trajectory; Bariatric Surgery; Anti-obesity Agents","DRUG:Injectable semaglutide or injectable tirzepatide; BEHAVIORAL:Standard postoperative care","University of Colorado, Denver","2024-10-11","FALSE","0"],["S001837","ClinicalTrials.gov","NCT07284511","TZP","Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel Trial","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","RECRUITING","105","Type 1 Diabetes; Type 1 Diabetes Mellitus; T1D; T1DM; T1DM - Type 1 Diabetes Mellitus","DRUG:Tirzepatide; DEVICE:Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM); BEHAVIORAL:Carbohydrate Counting; BEHAVIORAL:No Meal Announcement","McGill University Health Centre/Research Institute of the McGill University Health Centre","2026-05-19","FALSE","11"],["S001838","ClinicalTrials.gov","NCT02467790",null,"Kinetic Study of Human Pharmacokinetics in Normal Renal Function, and Renal Insufficiency Subject of Polyethylene Glycol Loxenatide (PEX168)(Open, Non-randomized, Parallel-group)","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","UNKNOWN","24","Type 2 Diabetes Mellitus","DRUG:PEX168","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2015-02","FALSE","1"],["S001839","ClinicalTrials.gov","NCT01620476",null,"A Randomised, Double-blind, Single-centre, Placebo-controlled, 21-day Multiple s.c. Doses, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide (NNC 90-1170) in Healthy Japanese Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Diabetes; Healthy","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2003-09","FALSE","0"],["S001840","ClinicalTrials.gov","NCT07724340",null,"A Phase 2, Randomized, Double-blind, Placebo-Controlled, Multi-center Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","150","Adults With Overweight/Obesity and Type 2 Diabetes","DRUG:AT673 low dose; DRUG:AT673 high dose; DRUG:Placebo","Antag Therapeutics","2026-06-19","FALSE","0"],["S001841","ClinicalTrials.gov","NCT07677891",null,"A Randomized, Open-Label, Multicenter, Active-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Switching From Once-Weekly Dulaglutide to Once-Monthly PG-102(MG12) in Patients With Type 2 Diabetes Mellitus Receiving Stable Dulaglutide Therapy","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","60","Type 2 Diabetes","DRUG:PG-102(MG12); DRUG:Dulaglutide","ProGen. Co., Ltd.","2026-10","FALSE","0"],["S001842","ClinicalTrials.gov","NCT00729326",null,"Comparison of the Effect of Exenatide vs. Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","83","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:sitagliptin; DRUG:placebo","AstraZeneca","2008-08","TRUE","0"],["S001843","ClinicalTrials.gov","NCT03770728","AMPLITUDE-S","A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","312","Type 2 Diabetes Mellitus","DRUG:Efpeglenatide SAR439977; DRUG:Placebo; DRUG:Background therapy: Metformin alone or in combination with SU","Sanofi","2019-08-01","TRUE","0"],["S001844","ClinicalTrials.gov","NCT05443334","PIONEER REAL","A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Spain","OBSERVATIONAL",null,null,"COMPLETED","465","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2022-07-28","FALSE","1"],["S001845","ClinicalTrials.gov","NCT04469855",null,"Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®. A Multi-centre, Open-label, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Effectiveness of Ozempic® (Semaglutide) in Japanese Patients With Type 2 Diabetes Mellitus Under Normal Clinical Practice Condition","OBSERVATIONAL",null,null,"COMPLETED","3217","Diabetes Mellitus, Type 2","DRUG:semaglutide","Novo Nordisk A/S","2020-07-27","FALSE","0"],["S001846","ClinicalTrials.gov","NCT03672604","NLY01-H1","A Phase 1, Single- and Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of NLY01 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","96","Safety and Tolerability in Healthy Volunteers","DRUG:NLY01","Neuraly, Inc.","2018-09-19","FALSE","2"],["S001847","ClinicalTrials.gov","NCT03136484","SUSTAIN 8","Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","788","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Canagliflozin; DRUG:Placebo (canagliflozin); DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2017-03-15","TRUE","6"],["S001848","ClinicalTrials.gov","NCT05766358","EXPEND-FU","Role Of Metabolic Adaptation In Weight Regain: Expend Follow-Up","OBSERVATIONAL",null,null,"COMPLETED","27","Weight Loss; Weight Gain; Obesity","BEHAVIORAL:Intensive lifestyle change therapy; DRUG:Tirzepatide","Pennington Biomedical Research Center","2022-10-06","FALSE","0"],["S001849","ClinicalTrials.gov","NCT04174755","SWIFT","Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","80","Obesity; HIV-1-infection","DRUG:Semaglutide Injectable Product; BEHAVIORAL:Standard of care","University College Dublin","2022-06-22","FALSE","2"],["S001850","ClinicalTrials.gov","NCT04109508",null,"A Comparative Bioavailability Trial of Steady State Semaglutide Exposure With the Current Formulation (Semaglutide) and a New Formulation (Semaglutide C) of Oral Semaglutide in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","278","Healthy Volunteers; Type 2 Diabetes","DRUG:Oral semaglutide","Novo Nordisk A/S","2019-10-02","FALSE","0"],["S001851","ClinicalTrials.gov","NCT07226778",null,"A Phase 1, Open-label, Randomized, Parallel-group Study to Assess the Relative Bioavailability of Maridebart Cafraglutide (AMG 133) as Two Subcutaneous Presentations in Participants Living With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","348","Overweight; Obesity","DRUG:Maridebart Cafraglutide","Amgen","2025-10-10","FALSE","0"],["S001852","ClinicalTrials.gov","NCT00560417",null,"A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","339","Diabetes Mellitus, Type 2","DRUG:Insulin Lispro Protamine Suspension; DRUG:Insulin Glargine","Eli Lilly and Company","2007-11","TRUE","0"],["S001853","ClinicalTrials.gov","NCT02616003",null,"A Novel Preoperative Conditioning Therapy in Giant Obese Patients With the Combination of Liraglutide and a Leucine-Based Amino-Acid Infusion and Caloric Restriction","INTERVENTIONAL",null,"PHASE4","COMPLETED","50","Morbid Obesity; Bariatric Surgery Candidate","DRUG:Liraglutide; OTHER:Aminosteril hepa 8%; DIETARY_SUPPLEMENT:Caloric diet with 1000 kcal","Sana Klinikum Offenbach","2014-04","FALSE","3"],["S001854","ClinicalTrials.gov","NCT02777073","1974","Effects of Single Doses of Liraglutide and Dapagliflozin on Hyperglycemia and Ketogenesis in Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","43","Type 1 Diabetes","DRUG:Victoza; DRUG:Placebo; DRUG:Dapagliflozin 10mg Tab","University at Buffalo","2016-03-01","TRUE","0"],["S001855","ClinicalTrials.gov","NCT03060980",null,"A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","245","Diabetes Mellitus, Type 2","DRUG:ITCA 650 20/60 mcg/day; DRUG:Empagliflozin (oral); DRUG:Glimepiride (oral)","Intarcia Therapeutics","2017-03-03","FALSE","0"],["S001856","ClinicalTrials.gov","NCT06235086",null,"A Multicenter, Randomized, Open-label, Controlled Phase 3 Trial of TG103 Injection in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","632","Type 2 Diabetes Mellitus","DRUG:TG103; DRUG:Dulaglutide","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2024-04-08","FALSE","0"],["S001857","ClinicalTrials.gov","NCT01511159",null,"A Single-Centre, Open-Label, Five-Period Crossover Trial In Healthy Male Volunteers Investigating the Relative Bioavailability of NNC 90-1170 By Pulmonary Administration Compared To A Subcutaneous Injection","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Diabetes; Healthy","DRUG:liraglutide; DRUG:placebo; DRUG:insulin human","Novo Nordisk A/S","2001-10","FALSE","0"],["S001858","ClinicalTrials.gov","NCT05147896","SAMAS","Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","100","Diabetes Mellitus, Type 2; Atherosclerosis","DRUG:Semaglutide Oral Tablet","University Medical Centre Ljubljana","2022-05-01","FALSE","1"],["S001859","ClinicalTrials.gov","NCT05815680",null,"A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","48","Overweight Subjects; Obese Subjects","DRUG:metformin; DRUG:digoxin; DRUG:IBI362; DRUG:warfarin; DRUG:atorvastatin","Innovent Biologics (Suzhou) Co. Ltd.","2023-04-06","FALSE","0"],["S001860","ClinicalTrials.gov","NCT07088718","DUP-SURPASS","Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data","OBSERVATIONAL",null,null,"COMPLETED","44671","Type 2 Diabetes; Major Adverse Cardiac Events; Cardiovascular (CV) Risk","DRUG:Tirzepatide; DRUG:Dulaglutide","Brigham and Women's Hospital","2024-10-01","FALSE","1"],["S001861","ClinicalTrials.gov","NCT00259896",null,"A Randomized, Open-label, Placebo-controlled, Repeat-dose Study to Assess the Pharmacokinetics and Pharmacodynamics of 5 Micrograms Exenatide Administered Subcutaneously Twice Daily for 7 Days in Healthy Normal Volunteers and in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","30","Type 2 Diabetes Mellitus; Diabetes Mellitus, Type 2","DRUG:exenatide","GlaxoSmithKline","2005-10","FALSE","0"],["S001862","ClinicalTrials.gov","NCT01388361","BEGIN™","A Trial Comparing the Efficacy and Safety of Adding Liraglutide Versus Addition of Insulin Aspart With the Largest Meal to Insulin Degludec, Both in Combination With Metformin, in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification (BEGIN™: VICTOZA® ADD-ON)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","413","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec; DRUG:insulin aspart; DRUG:liraglutide","Novo Nordisk A/S","2011-09","TRUE","1"],["S001863","ClinicalTrials.gov","NCT07037459","MARITIME-HF","A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","5056","Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2025-06-25","FALSE","0"],["S001864","ClinicalTrials.gov","NCT06803888",null,"Efficacy and Safety of Bariatric Surgery, Semaglutide Once Weekly, and Tirzepatide Once Weekly in Patients With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","140","Obesity and Obesity-related Medical Conditions","PROCEDURE:Bariatric Surgery; DRUG:Semaglutide; DRUG:Tirzepatide","Ali Aminian","2025-01-29","FALSE","0"],["S001865","ClinicalTrials.gov","NCT07654361",null,"A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of Multiple Maintenance Doses of Once Daily Oral Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and a Weight-Related Comorbidity","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","3600","Obesity; Overweight; Chronic Weight Management","DRUG:Aleniglipron; DRUG:Placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2026-07-13","FALSE","0"],["S001866","ClinicalTrials.gov","NCT05788965",null,"Efficacy and Safety of GLP-1 Agonist Therapy in Overweight and Obese Subjects With Cystic Fibrosis-related Diabetes: a Pilot Study","INTERVENTIONAL",null,"PHASE2; PHASE3","COMPLETED","8","Cystic Fibrosis; Cystic Fibrosis-related Diabetes","DRUG:Semaglutide","University of Minnesota","2023-10-16","TRUE","0"],["S001867","ClinicalTrials.gov","NCT06716216",null,"A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of BGM0504 Versus Semaglutide Once Weekly As Add-on Therapy to Metformin And/or Sulfonylureas in Patients with Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","537","Type 2 Diabetes Mellitus (T2DM)","DRUG:Drug: 5 mg BGM0504 Administered SC; DRUG:Drug:10 mg BGM0504 Administered SC; DRUG:Drug: Semaglutide Administered SC","BrightGene Bio-Medical Technology Co., Ltd.","2024-11-29","FALSE","0"],["S001868","ClinicalTrials.gov","NCT02205528",null,"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2a Study With an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily NNC0090-2746 in Type 2 Diabetic Patients Inadequately Controlled With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","108","Diabetes; Diabetes Mellitus Type 2","DRUG:Liraglutide; DRUG:Metformin; DRUG:Placebo; DRUG:NNC0090-2746","Novo Nordisk A/S","2014-08-18","FALSE","1"],["S001869","ClinicalTrials.gov","NCT07037433","MARITIME-CV","A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","12800","Atherosclerotic Cardiovascular Disease; Overweight; Obesity","DRUG:Maridebart Cafraglutide; DRUG:Placebo","Amgen","2025-07-25","FALSE","0"],["S001870","ClinicalTrials.gov","NCT05877547",null,"A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","381","Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD; Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis","DRUG:Efinopegdutide; DRUG:Semaglutide; DRUG:Placebo","Merck Sharp & Dohme LLC","2023-06-23","FALSE","0"],["S001871","ClinicalTrials.gov","NCT01954147",null,"Umbilical Cord Mesenchymal Stem Cell Infusion With Liraglutide in Type 2 Diabetes Mellitus","INTERVENTIONAL","NON_RANDOMIZED","PHASE1; PHASE2","UNKNOWN","100","Type 2 Diabetes","DRUG:GLP-1; BIOLOGICAL:SC; OTHER:Standard Medical Treatment","Diabetes Care Center of Nanjing Military Command","2013-10","FALSE","1"],["S001872","ClinicalTrials.gov","NCT02305381","SUSTAIN™ 5","Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","397","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-12-01","TRUE","10"],["S001873","ClinicalTrials.gov","NCT05822609","RT1D","Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","60","Diabetic Kidney Disease; Type 1 Diabetes","DRUG:Semaglutide; OTHER:Placebo","University of Washington","2024-04-05","FALSE","1"],["S001874","ClinicalTrials.gov","NCT01832532",null,"Pilot 2: Glucagon-like Peptide-1 in Sleep Disordered Breathing","INTERVENTIONAL","NON_RANDOMIZED","PHASE1; PHASE2","COMPLETED","34","Sleep Apnea; Sleep Disordered Breathing","DRUG:liraglutide","Children's Hospital Medical Center, Cincinnati","2013-04","TRUE","0"],["S001875","ClinicalTrials.gov","NCT07639021",null,"Evaluation of Different Dose Escalation Regimens for NNC0662-0419 in Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","233","Obesity","DRUG:NNC0662-0419; DRUG:Semaglutide; DRUG:NNC0662-0419 Placebo; DRUG:Semaglutide placebo","Novo Nordisk A/S","2026-06-09","FALSE","0"],["S001876","ClinicalTrials.gov","NCT01930188","SUSTAIN™ 2","Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1231","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:sitagliptin; DRUG:placebo","Novo Nordisk A/S","2013-12-02","TRUE","16"],["S001877","ClinicalTrials.gov","NCT04771273",null,"Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","295","Non-alcoholic Steatohepatitis (NASH)","DRUG:Survodutide; DRUG:Placebo","Boehringer Ingelheim","2021-04-27","TRUE","3"],["S001878","ClinicalTrials.gov","NCT01093729",null,"A Dose Block-randomized, Double-blind, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM11260C After Subcutaneous Administration in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","41","Healthy","DRUG:HM11260C","Hanmi Pharmaceutical Company Limited","2010-02","FALSE","0"],["S001879","ClinicalTrials.gov","NCT07143227",null,"A Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of XW003 Injection in Chinese Adolescents With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","48","Obese Adolescents; Obesity","DRUG:XW003 injection; DRUG:placebo with matching volume","Hangzhou Sciwind Biosciences Co., Ltd.","2025-08-25","FALSE","0"],["S001880","ClinicalTrials.gov","NCT07200622",null,"Evaluating the Effects of GLP-1 Analogue, Oral Semaglutide, in Patients With Alzheimer's Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","60","Alzheimer Disease","DRUG:Semaglutide (Rybelsus®); DRUG:Placebo","Imperial College London","2025-09-25","FALSE","0"],["S001881","ClinicalTrials.gov","NCT06143956",null,"A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","1481","Obesity; Overweight","DRUG:LY3305677; DRUG:LY3841136; DRUG:Tirzepatide; DRUG:LY3549492; DRUG:LY3532226; DRUG:Placebo","Eli Lilly and Company","2023-11-17","FALSE","0"],["S001882","ClinicalTrials.gov","NCT06764056","METAfoie","Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Through an Individualized Nutritionnal Approach and Semaglutide Therapy.","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","120","Metabolic Associated Fatty Liver Disease; Metabolic Associated-dysfunction Steatohepatitis (MASH); Obesity","DRUG:semaglutide; OTHER:Diet","Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","2025-01","FALSE","0"],["S001883","ClinicalTrials.gov","NCT06069622",null,"The Role of Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment of Overweight/Obese Individuals for Improving Adverse Cardiometabolic Phenotype Associated With CAV-1 Deficiency","OBSERVATIONAL",null,null,"RECRUITING","30","Overweight and Obesity","DIAGNOSTIC_TEST:24-hour ambulatory blood pressure; DIETARY_SUPPLEMENT:Liberal salt diet","Brigham and Women's Hospital","2023-11-01","FALSE","0"],["S001884","ClinicalTrials.gov","NCT00855439",null,"A Single-center,Proof of Concept,Randomized,Controlled Parallel Group Clinical Trial of the Effects of Exenatide vs. a Long Acting Insulin Analog to Evaluate the Efficacy of Exenatide in Patients With Diabetic Neuropathy and Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","46","Type 2 Diabetes Mellitus; Diabetic Peripheral Neuropathy","DRUG:Exenatide; DRUG:Glargine","University of Michigan","2008-06","TRUE","1"],["S001885","ClinicalTrials.gov","NCT04126603",null,"Impact of Semaglutide (Long Acting GLP1 Agonist) on Peripheral Blood Derived CD34+ Endothelial Cells (EPCs) and Subcutaneous Fat Derived Mesenchymal Stromal Cells ( MSCs) in Type 2 Diabetes Subjects","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","10","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebos","Sabyasachi Sen","2019-08-01","TRUE","0"],["S001886","ClinicalTrials.gov","NCT05929079","TRIUMPH-2","A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1152","Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2023-07-11","FALSE","1"],["S001887","ClinicalTrials.gov","NCT02229227",null,"Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","814","Diabetes Mellitus, Type 2","DRUG:Albiglutide; DRUG:Insulin Glargine and Insulin Lispro","GlaxoSmithKline","2014-11-21","TRUE","1"],["S001888","ClinicalTrials.gov","NCT02146079",null,"A Single-centre, Parallel-group, Randomised, Double-blind, Placebocontrolled, Multiple-dose Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","44","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-05-21","FALSE","1"],["S001889","ClinicalTrials.gov","NCT06588296","TOGETHER-PsA","Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","279","Psoriatic Arthritis; Obesity","DRUG:Ixekizumab; DRUG:Tirzepatide","Eli Lilly and Company","2024-09-24","FALSE","3"],["S001890","ClinicalTrials.gov","NCT04575194",null,"Cardiovascular and Metabolic Effects of Drugs for the Treatment of Obesity","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","UNKNOWN","40","Obesity; Blood Pressure","DRUG:Liraglutide 6 MG/ML [Saxenda]; DRUG:Naltrexone-Bupropion Combination","National and Kapodistrian University of Athens","2020-09-08","FALSE","0"],["S001891","ClinicalTrials.gov","NCT04616027",null,"A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO EVALUATE THE PHARMACOKINETICS OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT RENAL IMPAIRMENT","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","42","Diabetes Mellitus, Type 2; Renal Impairment; Healthy","DRUG:PF-06882961 20 mg","Pfizer","2021-01-13","TRUE","1"],["S001892","ClinicalTrials.gov","NCT00838903",null,"A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1049","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; DRUG:sitagliptin; DRUG:glimepiride; DRUG:metformin; BIOLOGICAL:placebo albiglutide; DRUG:placebo sitagliptin; DRUG:placebo glimepiride","GlaxoSmithKline","2009-02","TRUE","2"],["S001893","ClinicalTrials.gov","NCT06214741",null,"A Phase III, Randomized, Double-blind, Parallel-group, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Chinese Participants With a BMI >=28 kg/m2 or BMI >=24 kg/m2 With at Least One Weight-related Complication","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","307","Obesity; Overweight","DRUG:survodutide; DRUG:Placebo matching BI 456906","Boehringer Ingelheim","2024-02-06","FALSE","1"],["S001894","ClinicalTrials.gov","NCT07845994","SEMAFORCRANIO","SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","50","Craniopharyngioma, Child","DRUG:Semaglutide (Wegovy) weekly injection; DRUG:Placebo weekly Injection","University Hospital, Angers","2026-11","FALSE","0"],["S001895","ClinicalTrials.gov","NCT03449654","LIRAFLAME","Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes: A Randomized, Placebo-controlled, Double-blind, Parallel Clinical PET/CT Trial The Liraflame Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","102","Diabetes Mellitus, Type 2","DRUG:Liraglutide; DRUG:Placebo (for liraglutide)","Steno Diabetes Center Copenhagen","2017-10-26","FALSE","5"],["S001896","ClinicalTrials.gov","NCT07269756",null,"An Open, Fixed-sequence, Self-controlled Pharmacokinetic Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","40","Obesity; Overweight","DRUG:HRS-7535 Tablets; DRUG:Paracetamol Tablets; DRUG:Digoxin Tablets; DRUG:Rosuvastatin Calcium Tablets; DRUG:Omeprazole Enteric-coated Capsules","Shandong Suncadia Medicine Co., Ltd.","2025-12-07","FALSE","0"],["S001897","ClinicalTrials.gov","NCT07370922",null,"Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","80","Transfusion Dependent Beta Thalassemia","DRUG:Dulaglutide 0.75Mg/0.5Ml Inj Pen; DRUG:control group (insulin)","Ain Shams University","2024-11-22","FALSE","1"],["S001898","ClinicalTrials.gov","NCT06380426","ObGeSema","A Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity","OBSERVATIONAL",null,null,"RECRUITING","175","Monogenic Obesity",null,"Assistance Publique - Hôpitaux de Paris","2024-09-19","FALSE","0"],["S001899","ClinicalTrials.gov","NCT02432976","ExeQOL","Impact of Intravenous Exenatide Versus Insulin on Quality of Life in Cardiac Surgery Patients: an Ancillary Study of the ExSTRESS Phase II/III Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","64","Quality of Life","DRUG:Exenatide; DRUG:Insulin","Centre Hospitalier Universitaire de Besancon","2015-05","FALSE","0"],["S001900","ClinicalTrials.gov","NCT07511543","LEAST","A Multicentre, Prospective, Randomized, Open-label, Blinded Endpoint, Pilot Clinical Trial Evaluating Subcutaneous Semaglutide in Patients With Acute Ischaemic Stroke Due to Anterior Circulation Large Vessel Occlusion Treated With Endovascular Thrombectomy","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","100","Ischemic Stroke","DRUG:Semaglutide","Population Health Research Institute","2026-10-31","FALSE","0"],["S001901","ClinicalTrials.gov","NCT06745284",null,"An Active-comparator-controlled, Open-label, Parallel Group Study to Evaluate the Effect of Survodutide on Energy Expenditure and Fatty Acid Oxidation in Subjects With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","64","Obesity","DRUG:Survodutide; DRUG:Semaglutide","Boehringer Ingelheim","2025-03-26","FALSE","0"],["S001902","ClinicalTrials.gov","NCT04515849",null,"A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","248","Type 2 Diabetes Mellitus; Chronic Kidney Diseases","DRUG:Cotadutide 100 micrograms; DRUG:Cotadutide 300 micrograms; DRUG:Cotadutide 600 micrograms; DRUG:Semaglutide; DRUG:Placebo","AstraZeneca","2020-08-31","TRUE","3"],["S001903","ClinicalTrials.gov","NCT02621489","Rebuild","Effects on Re-endothelialisation With Bydureon Treatment Add on to Insulin Versus Insulin Alone, Both in Combination With Metformin in Type 2 Diabetic Subjects","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","38","Atherosclerosis; Diabetes; Restenosis","DRUG:Bydureon; DRUG:Humulin kwickpen; DRUG:Metformin","Karolinska Institutet","2015-12","FALSE","5"],["S001904","ClinicalTrials.gov","NCT07221214","GL1DER HIV RCT","GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV - GL1DER HIV RCT","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","200","HIV; Alcohol; Smoking Cigarette; Cardiovascular Disease Prevention","DRUG:Semaglutide (Rybelsus®); DRUG:Placebo","Vanderbilt University Medical Center","2026-04-17","FALSE","0"],["S001905","ClinicalTrials.gov","NCT07553299",null,"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Identify the Optimal Weekly Oral Dose of Ecnoglutide (VRB-101) for Maintaining Body Weight in Participants With Obesity or Overweight Who Have Weight-Related Comorbidities","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","8","Obesity; Overweight; Weight Maintenance","DRUG:VRB-101; DRUG:Placebo","Verdiva Bio Dev Limited","2026-06-12","FALSE","0"],["S001906","ClinicalTrials.gov","NCT00382239",null,"A Dose Response Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","153","Type 2 Diabetes Mellitus","DRUG:exenatide (LY2148568); DRUG:Placebo","AstraZeneca","2006-09","FALSE","2"],["S001907","ClinicalTrials.gov","NCT07424430","SEMA-CKM","Real-world Canadian Retrospective Study Evaluating Longitudinal SEMAglutide Use on Cardio-Kidney-Metabolic Outcomes","OBSERVATIONAL",null,null,"COMPLETED","3392","Diabetes (DM); Type 2 Diabetes; Obesity (Disorder)","DRUG:Semaglutide (SEMA)","LMC Diabetes & Endocrinology Ltd.","2026-02-20","FALSE","0"],["S001908","ClinicalTrials.gov","NCT07797036",null,"Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes: An Effectiveness-Implementation Hybrid Type 1 Randomized Trial","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","NOT_YET_RECRUITING","226","Gestational Diabetes Mellitus (GDM); Metabolic Syndrome","DRUG:Semaglutide (Wegovy) weekly injection","University of Massachusetts, Worcester","2027-09-01","FALSE","0"],["S001909","ClinicalTrials.gov","NCT05822544",null,"A Phase 1/1b Study of Single and Multiple Ascending Doses of TLC 6740 in Healthy Subjects, Including Evaluation of Food Effect and Potential Drug-Drug Interactions, and Preliminary Safety and Efficacy in Subjects With Obesity, With or Without Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","564","Healthy Subjects; Obesity; Type 2 Diabetes","DRUG:TLC-6740 Oral Solution; OTHER:Placebo Oral Solution; DRUG:TLC-6740 Tablet; DRUG:Drug Metabolizing Enzyme; DRUG:Tirzepatide; OTHER:Placebo Tablet","OrsoBio, Inc","2023-04-22","FALSE","1"],["S001910","ClinicalTrials.gov","NCT07029009",null,"Investigating Enteroendocrine Dysfunction, Metabolism, and Response to Liraglutide in Patients With Maturity-onset Diabetes of the Young (MODY)","INTERVENTIONAL",null,"PHASE2","RECRUITING","50","Maturity Onset Diabetes of the Young","DRUG:Liraglutide","Mansa","2025-05-08","FALSE","0"],["S001911","ClinicalTrials.gov","NCT00354536",null,"A Single-blinded Randomized, Placebo-controlled, Staggered-parallel, Escalating-dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injections of GSK 716155 in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","60","Diabetes Mellitus, Type 2","DRUG:GSK716155 subcutaneous injections; BIOLOGICAL:placebo injection","GlaxoSmithKline","2006-02","FALSE","1"],["S001912","ClinicalTrials.gov","NCT05394519","REDEFINE 2","Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1200","Overweight; Obesity; Type 2 Diabetes Mellitus","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide","Novo Nordisk A/S","2023-02-01","FALSE","1"],["S001913","ClinicalTrials.gov","NCT07613307","ACHIEVE-RAM","A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)","INTERVENTIONAL",null,"PHASE3","RECRUITING","130","Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Metabolic Diseases; Endocrine System Diseases; Feeding Behavior; Behavior; Fasting; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide Receptors; Receptors, G-Protein-Coupled; Receptors, Cell Surface; Membrane Proteins; Proteins; Receptors, Peptide","DRUG:Orforglipron","Eli Lilly and Company","2026-07-15","FALSE","0"],["S001914","ClinicalTrials.gov","NCT07621419","SEMA-REAL ARG","New Formulation of Semaglutide in the Treatment of Type 2 Diabetes in Argentina: a Prospective, Multicenter, Real-world Study","OBSERVATIONAL",null,null,"RECRUITING","145","Diabetes Mellitus","DRUG:semaglutide","Hospital Italiano de Buenos Aires","2025-08-04","FALSE","3"],["S001915","ClinicalTrials.gov","NCT06124807",null,"A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","179","Obesity; Overweight and Obesity","DRUG:Mazdutide; DRUG:Placebo","Eli Lilly and Company","2023-11-17","TRUE","3"],["S001916","ClinicalTrials.gov","NCT04892199",null,"Does the Glucagon-like Peptide-1 Receptor Agonist Semaglutide Prevent Deterioration of Metabolic State in Prediabetic or Diabetic Patients With Schizophrenia Treated With the Antipsychotic Compounds Clozapine or Olanzapine?","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","104","Metabolic Disturbance; Schizophrenia; Type 2 Diabetes; Clozapine; GLP-1; Olanzapine","DRUG:Semaglutide, 1.34 mg/mL; DRUG:Semaglutide-placebo","Anders Fink-Jensen, MD, DMSci","2021-09-01","FALSE","2"],["S001917","ClinicalTrials.gov","NCT02908087",null,"Incretin-based Therapy in Early Diagnosed Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","13","Type 1 Diabetes","DRUG:Victoza® (liraglutide); DRUG:Placebo","University of Oulu","2016-03","FALSE","1"],["S001918","ClinicalTrials.gov","NCT06309992",null,"Multicentre, Randomised, Double-blind, Placebo-controlled, 48-week, Phase III Trial to Evaluate the Efficacy and Safety of Survodutide Administered Subcutaneously in Participants With Overweight or Obesity and Presumed or Confirmed Nonalcoholic Steatohepatitis (NASH)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","218","Obesity; Non-Alcoholic SteatoHepatitis (NASH)","COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo","Boehringer Ingelheim","2024-04-02","FALSE","0"],["S001919","ClinicalTrials.gov","NCT05628311",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study (DREAMS-1) to Evaluate the Efficacy and Safety of IBI362 in Chinese Type 2 Diabetes Patients With Poor Glycemia Control Only Through Diet and Exercise","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","319","Type 2 Diabetes","OTHER:placebo; DRUG:IBI362","Innovent Biologics (Suzhou) Co. Ltd.","2023-01-06","FALSE","0"],["S001920","ClinicalTrials.gov","NCT01136798",null,"Impact of Exenatide on Sleep and Circadian Function in Type 2 Diabetes: A Pilot Study","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","18","Type 2 Diabetes; Sleep Disordered Breathing","DRUG:Exenatide; DRUG:Placebo","University of Chicago","2010-06-01","TRUE","0"],["S001921","ClinicalTrials.gov","NCT05556512","SURMOUNT-MMO","A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","15374","Obesity; Overweight","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2022-10-11","FALSE","4"],["S001922","ClinicalTrials.gov","NCT06893211","TABFAT","Effect of Tirzepatide-Induced Weight Loss on Adipose Tissue in Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","34","Obesity","DRUG:Tirzepatide; DRUG:Placebo","University Medical Centre Ljubljana","2025-03-18","FALSE","1"],["S001923","ClinicalTrials.gov","NCT06557811","SemaFatCard","Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction: a Randomized and Double-blind Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","88","Diabetic Patients; Acute Myocardial Infarction","DRUG:Semaglutide","University of Sao Paulo General Hospital","2024-09-01","FALSE","0"],["S001924","ClinicalTrials.gov","NCT07642635",null,"Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","NOT_YET_RECRUITING","30","Duchenne Muscular Dystrophy (DMD)","DRUG:Semaglutide (Rybelsus®); OTHER:Placebo","Vanderbilt University Medical Center","2026-09-01","FALSE","0"],["S001925","ClinicalTrials.gov","NCT05129891",null,"A Study Investigating Pharmacokinetic Properties When Dosing Different Formulations of Oral Peptide Therapeutics in Healthy Male Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","384","Healthy Volunteers; High Blood Cholesterol Levels; Type 2 Diabetes","DRUG:Semaglutide D; DRUG:Semaglutide G; DRUG:Semaglutide H; DRUG:Semaglutide I; DRUG:NNC0385-0434 B; DRUG:NNC0385-0434 C; DRUG:NNC0385-0434 D; DRUG:NNC0385-0434 E","Novo Nordisk A/S","2021-11-03","FALSE","0"],["S001926","ClinicalTrials.gov","NCT06581120",null,"Assessment of Gastric Contents in Patients Taking Glucagon-Like Peptide-1 Receptor Agonists: a Prospective Observational Cross-sectional Study","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","100","Glucagon Like Peptide-1 (GLP-1; Delayed Gastric Emptying; Risk of Aspiration; Diabetes; Morbid Obesity","DRUG:Glucagon-Like Peptide-1 receptor agonists; DIAGNOSTIC_TEST:Point of Care Gastric Ultrasound","Children's Hospital Medical Center, Cincinnati","2024-07-08","FALSE","0"],["S001927","ClinicalTrials.gov","NCT05916560",null,"A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Hepatic Impairment Compared With Healthy Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","43","Healthy; Hepatic Insufficiency","DRUG:LY3437943","Eli Lilly and Company","2023-07-13","FALSE","0"],["S001928","ClinicalTrials.gov","NCT01625260",null,"A Phase Ib/II Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-muscle Invasive Bladder Cancer","INTERVENTIONAL","NON_RANDOMIZED","PHASE1; PHASE2","TERMINATED","12","Non-muscle Invasive Bladder Cancer","BIOLOGICAL:ALT-801; DRUG:Gemcitabine","Altor BioScience","2012-03-30","TRUE","0"],["S001929","ClinicalTrials.gov","NCT01516476",null,"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of RO6807952 in Type 2 Diabetic Patients Inadequately Controlled With Metformin Alone","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","2","Diabetes Mellitus Type 2","DRUG:Placebo; DRUG:RO6807952; DRUG:liraglutide","Hoffmann-La Roche","2011-11","FALSE","0"],["S001930","ClinicalTrials.gov","NCT01060059",null,"EBIRIOS - Exenatide and Basal Insulins Use in the Real Setting: an Italian Observational Study in Patients With Type 2 Diabetes and Secondary Failure of Oral Antihyperglycemic Treatment","OBSERVATIONAL",null,null,"COMPLETED","888","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:basal insulin","AstraZeneca","2010-04","TRUE","0"],["S001931","ClinicalTrials.gov","NCT07599410",null,"A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Phase 2 Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus.","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","240","T2DM","DRUG:HRS9531 Tablet; DRUG:HRS9531 Tablet placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-07-14","FALSE","0"],["S001932","ClinicalTrials.gov","NCT06723691",null,"A Single Center, Open-label, Two Cohorts, Fixed Sequence Trial, Investigating the Influence of HRS9531 Injection on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","57","Type 2 Diabetes","DRUG:Acetaminophen; DRUG:Metformin; DRUG:Warfarin; DRUG:Atorvastatin; DRUG:Digoxin; DRUG:HRS9531","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-12-18","FALSE","0"],["S001933","ClinicalTrials.gov","NCT01720446","SUSTAIN™ 6","A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","3297","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2013-02-21","TRUE","40"],["S001934","ClinicalTrials.gov","NCT07083154",null,"Effects of Mazdutide on Cognitive Function in Patients With Type 2 Diabetes and Early-Stage Cognitive Impairment: A Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","420","Dementia, Mild; Mild Cognitive Impairment; Type 2 Diabetes","DRUG:Mazdutide; DRUG:Placebo","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2025-09-27","FALSE","0"],["S001935","ClinicalTrials.gov","NCT01610934",null,"Phase 2 Study: A Double-blind, Randomised, Clinical Cross-over Trial to Investigate the Treatment Potential of Liraglutide Compared to Glimepiride in MODY Patients","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","15","Maturity-onset Diabetes of the Young","DRUG:liraglutide; DRUG:Glimepiride","University Hospital, Gentofte, Copenhagen","2012-08","FALSE","1"],["S001936","ClinicalTrials.gov","NCT02654665","CGH-LiNASH","Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults","INTERVENTIONAL","NON_RANDOMIZED","PHASE3","UNKNOWN","36","Non-alcoholic Fatty Liver Disease (NAFLD); Weight Loss; Non-alcoholic Steatohepatitis (NASH)","BEHAVIORAL:Lifestyle modification; DRUG:Liraglutide","Changi General Hospital","2014-03","FALSE","1"],["S001937","ClinicalTrials.gov","NCT06234111",null,"Semaglutide and Physical Activity for Obesity and Multimorbidity: Co-designing Healthy Healthcare","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","35","Obesity Morbid; Multimorbidity; Obesity","COMBINATION_PRODUCT:Semaglutide 2.4 mg, total diet replacement, behavioural intervention","Hvidovre University Hospital","2024-02-20","FALSE","1"],["S001938","ClinicalTrials.gov","NCT05510245",null,"A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS OF PF-07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT RENAL IMPAIRMENT","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","TERMINATED","18","Type 2 Diabetes; Renal Impairment","DRUG:PF-07081532","Pfizer","2022-08-29","TRUE","0"],["S001939","ClinicalTrials.gov","NCT07104500","VANQUISH 1","A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","4500","Weight Loss","DRUG:VK2735","Viking Therapeutics, Inc.","2025-06-23","FALSE","0"],["S001940","ClinicalTrials.gov","NCT05564039","SURPASS-SWITCH","A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","282","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Dulaglutide","Eli Lilly and Company","2022-11-30","TRUE","2"],["S001941","ClinicalTrials.gov","NCT05680129",null,"A Phase 3, Multi-center, Open-label, Randomized Study to Evaluate the Efficacy and Safety of XW003 Versus Dulaglutide in Patients With T2DM Inadequately Controlled by Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","623","T2DM; Type 2 Diabetes Mellitus","DRUG:Ecnoglutide high dosage; DRUG:Ecnoglutide low dosage; DRUG:Dulaglutide; DRUG:Metformin","Hangzhou Sciwind Biosciences Co., Ltd.","2023-01-10","FALSE","1"],["S001942","ClinicalTrials.gov","NCT07323134",null,"The Effect of Semaglutide on the Intestinal Flora in Obesity","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","40","Obesity","DRUG:Semaglutide Injection","Beijing Chao Yang Hospital","2026-02-01","FALSE","0"],["S001943","ClinicalTrials.gov","NCT03018028","PIONEER 9","Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","243","Diabetes; Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo; DRUG:Liraglutide","Novo Nordisk A/S","2017-01-10","TRUE","4"],["S001944","ClinicalTrials.gov","NCT01104701",null,"A Randomized, Multi-dose, Controlled Trial Investigating the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","121","Type 2 Diabetes","DRUG:exenatide once weekly; DRUG:exenatide once monthly suspension","AstraZeneca","2010-05","TRUE","1"],["S001945","ClinicalTrials.gov","NCT07590219",null,"Efficacy, Metabolic and Cardiovascular Effects of Liraglutide in Children Aged 6-12 Years With Severe Obesity: A Randomized Controlled Trial With Advanced Echocardiographic Assessment","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","30","Severe Obesity; Cardiovascular Function; Liraglutide; Childhood Obesity; Echocardiography; Speckle Tracking","DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml","University of Sao Paulo General Hospital","2024-03-30","FALSE","4"],["S001946","ClinicalTrials.gov","NCT01051011",null,"A Multi-center, Randomized, Open-label, Active-controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin-naive Type 2 Diabetic Patients Inadequately Controlled With Metformin and Sulphonylurea Combination Therapy.","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","370","Diabetes Mellitus Type 2","DRUG:insulin glargine; DRUG:metformin; DRUG:taspoglutide","Hoffmann-La Roche","2010-01","FALSE","0"],["S001947","ClinicalTrials.gov","NCT03862716","REMITiDegLira","Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira (REMIT IDegLira): A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","159","Type 2 Diabetes Mellitus","DRUG:IDegLira; DRUG:insulin degludec; DRUG:Metformin; BEHAVIORAL:Lifestyle Therapy","Population Health Research Institute","2019-04-23","FALSE","1"],["S001948","ClinicalTrials.gov","NCT01677104",null,"The Microvascular Function of GLP-1 and Its Analogues in Humans, in Vivo: the Role of DPP-IV Inhibition","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","63","Type 2 Diabetes; Obesity","DRUG:GLP-1; DRUG:Placebo","Katarina Kos","2012-08","FALSE","1"],["S001949","ClinicalTrials.gov","NCT01473147","AGAC2","Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","51","Type 2 Diabetes Mellitus","DRUG:Exenatide; DRUG:Normal saline","Chang Gung Memorial Hospital","2011-10","FALSE","0"],["S001950","ClinicalTrials.gov","NCT05971940","ACHIEVE-1","A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","559","Type 2 Diabetes","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2023-08-09","TRUE","1"],["S001951","ClinicalTrials.gov","NCT03645421",null,"A Phase IIa, Randomised, Parallel, Double-Blind,Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","61","Type 2 Diabetes","DRUG:MEDI0382 100 μg; DRUG:MEDI0382 200 μg; DRUG:MEDI0382 300 μg; DRUG:PlaceboA; DRUG:MEDI0382 50 ug; DRUG:PlaceboB","AstraZeneca","2018-08-10","TRUE","0"],["S001952","ClinicalTrials.gov","NCT06047548",null,"A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Once Weekly 5 mg and/or Maximum Tolerated Dose Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","441","Overweight; Obesity","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2023-09-20","FALSE","2"],["S001953","ClinicalTrials.gov","NCT00799435",null,"Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","2","Diabetes Mellitus, Type 2; Heart Failure, Diastolic","DRUG:Exenatide","Baylor College of Medicine","2009-07","TRUE","0"],["S001954","ClinicalTrials.gov","NCT06671587","China Soli-CGM","A 20-week, Multicenter, Prospective, Parallel-group Treatment, Open-label, 2-Arm, Phase 4, Randomized Study to Evaluate the Efficacy of iGlarLixi Versus Gla-100 on Glycemic Time in Range (TIR) From Continuous Glucose Monitoring (CGM) in Chinese Insulin Naïve Patients With Type 2 Diabetes (T2D) Inadequately Controlled With Oral Antidiabetics","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","678","Type 2 Diabetes (T2D)","DRUG:iGlarLixi (insulin glargine/lixisenatide); DRUG:Gla-100 (insulin glargine)","Sanofi","2024-12-10","FALSE","0"],["S001955","ClinicalTrials.gov","NCT07139548",null,"A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","600","T2DM","DRUG:RAY1225; DRUG:Semaglutide","Guangdong Raynovent Biotech Co., Ltd","2025-08-31","FALSE","0"],["S001956","ClinicalTrials.gov","NCT06148649",null,"A Phase 2, Multicenter, Randomised, Paralleled, Placebo-controlled (Double-blind) and Active Drug-controlled (Open) Study to Investigate Efficacy and Safety of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","234","Type 2 Diabetes","DRUG:HEC88473, Placebo, Dulaglutide","Dongguan HEC Biopharmaceutical R&D Co., Ltd.","2023-12-10","FALSE","0"],["S001957","ClinicalTrials.gov","NCT07081178","WeGoReal","A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany Non-interventional.","OBSERVATIONAL",null,null,"TERMINATED","100","Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2025-08-08","FALSE","0"],["S001958","ClinicalTrials.gov","NCT05459285",null,"Pharmacokinetics, Safety and Immunogenicity of 14028 Injection Versus Dulaglutide Injection in Healthy Subjects: a Phase I ，Single-center, Randomized, Open-label, Single-dose, Parallel-controlled Clinical Study","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","68","Type 2 Diabetes","BIOLOGICAL:14028 injection; BIOLOGICAL:dulaglutide injection","Sunshine Lake Pharma Co., Ltd.","2022-05-31","FALSE","5"],["S001959","ClinicalTrials.gov","NCT02811484","Dexlar","Efficacy of Exenatide-LAR Alone and in Combination With Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Uncontrolled Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","WITHDRAWN","0","Diabetes Mellitus, Type 2","DRUG:Exenatide-LAR plus Dapagliflozin placebo; DRUG:Exenatide-LAR plus Dapagliflozin; DRUG:Insulin Titration; BEHAVIORAL:Behavioral Therapy","Weill Medical College of Cornell University","2016-06","FALSE","0"],["S001960","ClinicalTrials.gov","NCT03439943","LixiPark","Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","156","Parkinson Disease","DRUG:Lixisenatide; DRUG:placebo","University Hospital, Toulouse","2018-06-13","FALSE","1"],["S001961","ClinicalTrials.gov","NCT06482411","WRRFA","Exploration of Effect Weight Loss Outcome Related to Factors After Treatment of Weight Loss (WRRFA).","OBSERVATIONAL",null,null,"COMPLETED","3602","Weight Regain",null,"E-DA Hospital","2024-06-27","FALSE","0"],["S001962","ClinicalTrials.gov","NCT07850063",null,"A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase IIIb Trial to Evaluate the Effect of Survodutide on Cardiac Structure and Function of Participants With Overweight or Obesity and Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); (ELEVATE-LIVER)","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","600","Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease","COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo matching survodutide","Boehringer Ingelheim","2026-10-23","FALSE","0"],["S001963","ClinicalTrials.gov","NCT01632163",null,"A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","447","Type 2 Diabetes Mellitus","DRUG:Lixisenatide (AVE0010); DRUG:Placebo","Sanofi","2012-10","FALSE","2"],["S001964","ClinicalTrials.gov","NCT07280221",null,"WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","500","Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2025-11-10","FALSE","0"],["S001965","ClinicalTrials.gov","NCT02607306","DUAL™ I Japan","A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","819","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin degludec; DRUG:liraglutide","Novo Nordisk A/S","2015-11-18","TRUE","2"],["S001966","ClinicalTrials.gov","NCT00676338",null,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","820","Type 2 Diabetes Mellitus","DRUG:exenatide once weekly; DRUG:metformin; DRUG:sitagliptin; DRUG:pioglitazone","AstraZeneca","2008-11","TRUE","5"],["S001967","ClinicalTrials.gov","NCT05680155",null,"A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","211","T2DM; Type 2 Diabetes Mellitus","DRUG:Ecnoglutide; DRUG:Placebo","Hangzhou Sciwind Biosciences Co., Ltd.","2022-12-29","FALSE","2"],["S001968","ClinicalTrials.gov","NCT07400107","AMAZE 8","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 8)","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","1000","Obesity; Overweight; Diabetes Mellitus, Type 2","DRUG:NNC0487-0111; DRUG:Semaglutide; DRUG:Placebo (matched to NNC0487-0111); DRUG:Placebo (matched to semaglutide)","Novo Nordisk A/S","2026-05-20","FALSE","0"],["S001969","ClinicalTrials.gov","NCT06487832",null,"Impact of the Incretin System on Brain Insulin Sensitivity in Humans with Normal Weight, Overweight and Obesity","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","60","Normal Weight; Overweight and Obesity; Insulin Sensitivity; Insulin Resistance","OTHER:Subcutaneous GLP1-RA; OTHER:Subcutaneous placebo","University Hospital Tuebingen","2024-07-01","FALSE","0"],["S001970","ClinicalTrials.gov","NCT05347147","IIH EVOLVE","A Phase III Randomised, Placebo-controlled, Double-blind, Multi-centre, Clinical Trial to Determine the Efficacy and Safety of Presendin in Idiopathic Intracranial Hypertension","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","14","Idiopathic Intracranial Hypertension","DRUG:Presendin; DRUG:Placebo","Invex Therapeutics Ltd.","2022-11-18","TRUE","1"],["S001971","ClinicalTrials.gov","NCT05768945",null,"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors","OBSERVATIONAL",null,null,"COMPLETED","742670","Diabetes","DRUG:Semaglutide; DRUG:DPP-4 inhibitor","Brigham and Women's Hospital","2022-11-30","TRUE","0"],["S001972","ClinicalTrials.gov","NCT06354101",null,"The VITALITY Registry","OBSERVATIONAL",null,null,"WITHDRAWN","0","Metabolic Health","DRUG:Tirzepatide; DRUG:Semaglutide","CorEvitas","2023-07-01","FALSE","0"],["S001973","ClinicalTrials.gov","NCT04154072",null,"Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","255","Parkinson Disease","DRUG:NLY01; DRUG:Vehicle","Neuraly, Inc.","2020-02-27","FALSE","1"],["S001974","ClinicalTrials.gov","NCT05677867",null,"A PHASE 1, OPEN-LABEL, 2-PERIOD, 2-SEQUENCE, CROSSOVER STUDY TO COMPARE THE SINGLE-DOSE PHARMACOKINETICS OF 2 DIFFERENT FORMULATIONS OF PF-07081532 ADMINISTERED ORALLY TO ADULT PARTICIPANTS WHO ARE OVERWEIGHT OR OBESE","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","20","Overweight; Obesity","DRUG:Formulation A (PF-07081532 20 mg plus 60 mg); DRUG:Formulation B (PF-07081532 80 mg)","Pfizer","2023-01-18","TRUE","0"],["S001975","ClinicalTrials.gov","NCT02843399",null,"Clinical and Economic Outcomes of Patients With Type 2 Diabetes Mellitus Initiating Bydureon and Glargine","OBSERVATIONAL",null,null,"COMPLETED","15498","Diabetes Mellitus Type 2",null,"AstraZeneca","2016-08-15","FALSE","0"],["S001976","ClinicalTrials.gov","NCT06423599","FIT-HF","Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","RECRUITING","100","Heart Failure With Reduced Ejection Fraction; Obesity; Weight Loss; Chronic Heart Failure","DRUG:Semaglutide Injectable Product; DIETARY_SUPPLEMENT:Calorie-restricted diet","Jens D Hove, MD,PHD","2024-04-30","FALSE","0"],["S001977","ClinicalTrials.gov","NCT05762471",null,"A Phase 1b/2a, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus on Metformin","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","142","Overweight or Obesity; Type2 Diabetes Mellitus","DRUG:GSBR-1290; DRUG:Placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2023-01-09","FALSE","0"],["S001978","ClinicalTrials.gov","NCT07504172","TIRZ-DOSE-NL","Real-world Effectiveness and Dosing Patterns of Tirzepatide: A Multicentre Retrospective Observational Study in the Netherlands","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","1700","Overweight , Obesity; Obesity (Disorder)","DRUG:Tirzepatide","Radboud University Medical Center","2026-04-01","FALSE","3"],["S001979","ClinicalTrials.gov","NCT07557953",null,"A Study Investigating the Effect of Cagrilintide on Energy Intake and Appetite in People With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","120","Overweight; Obesity","DRUG:Cagrilintide; DRUG:Placebo Cagrilintide","Novo Nordisk A/S","2026-04-30","FALSE","0"],["S001980","ClinicalTrials.gov","NCT06500130",null,"Effects of Liraglutide on Body Surface Gastric Mapping","INTERVENTIONAL",null,null,"COMPLETED","22","Gastroparesis; Functional Dyspepsia; Chronic Nausea and Vomiting Syndrome; Healthy","DEVICE:Body Surface Gastric Mapping","Alimetry","2024-05-30","FALSE","0"],["S001981","ClinicalTrials.gov","NCT07673900",null,"A Randomized, Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Epi/Intra-dermally Administered Semaglutide (VX-201) Compared to Subcutaneous Administration in Healthy Overweight and Obese Participants: Single and Multiple Dose Assessment","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","62","Overweight and/or Obesity","COMBINATION_PRODUCT:VX-201; DRUG:semaglutide SC","Terrestrial Bio, Inc.","2026-06-15","FALSE","0"],["S001982","ClinicalTrials.gov","NCT01652716","DURATION-NEO-1","A Randomized, Open-Label, Long-Term, Parallel-Group, Comparator-Controlled, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Exenatide Twice Daily in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","377","Diabetes Mellitus, Type 2","DRUG:Exenatide once weekly suspension; DRUG:Exenatide twice daily","AstraZeneca","2013-01","TRUE","2"],["S001983","ClinicalTrials.gov","NCT07257484",null,"Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors","INTERVENTIONAL",null,"PHASE4","RECRUITING","30","Obesity (Disorder); Breast Cancer","DRUG:Tirzepatide","Weill Medical College of Cornell University","2026-06-08","FALSE","0"],["S001984","ClinicalTrials.gov","NCT06301191",null,"The Effect of Semaglutide on Endothelial Function, Arterial Stiffness and Liver Indices in Patients Witn Type 2 Diabetes Mellitus and NAFLD","OBSERVATIONAL",null,null,"UNKNOWN","50","Diabetes Type 2","DRUG:Semaglutide, 1.0 mg/mL; DRUG:Dipeptidyl Peptidase 4 inhibitor","Attikon Hospital","2022-03-01","FALSE","0"],["S001985","ClinicalTrials.gov","NCT07247084",null,"A Phase 4 Multicenter, Randomized, Open-Label, Interventional Study With Pragmatic Elements Investigating the Effectiveness of Tirzepatide Once Weekly Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes in a Real-World Setting","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","3000","Obesity","DRUG:Tirzepatide; OTHER:Standard of Care","Eli Lilly and Company","2025-11-24","FALSE","1"],["S001986","ClinicalTrials.gov","NCT06073184","WE-FiERCE","Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium (WE-FiERCE)","INTERVENTIONAL",null,"PHASE2","RECRUITING","71","Endometrial Cancer; Atypical Hyperplasia; Fertility Perservation","DRUG:Wegovy; DRUG:Mirena","GynOncTrials","2026-09-17","FALSE","0"],["S001987","ClinicalTrials.gov","NCT07809568","TRIBUTE-PK","Real-World Effectiveness, Safety, and Patient-Reported Outcomes of Tirzepatide in Adults With Type 2 Diabetes Mellitus, Obesity, or Prediabetes in Pakistan: A Multicentre, Prospective, Observational Cohort Study","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","330","Prediabetes or Overweight; Obesity Type 2 Diabetes Mellitus; Obesity & Overweight",null,"Universiti Sains Malaysia","2026-10-01","FALSE","0"],["S001988","ClinicalTrials.gov","NCT07657676",null,"Effect of Mazdutide on Coronary Plaque Progression in Patients With Coronary Atherosclerosis and Overweight or Obesity: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","116","Obesity & Overweight; Coronary Heart Disease","DRUG:Mazdutide; DRUG:Placebo","China National Center for Cardiovascular Diseases","2026-09-14","FALSE","0"],["S001989","ClinicalTrials.gov","NCT07567378","CARTIZ","Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts (CARTIZ): A Prospective Observational Multi-Institutional Registry of the VAT-Articular-Cardiac-Aging Axis in Adults Exposed to Tirzepatide in Mexico, With Quantitative Knee Cartilage T2 Mapping, Cardiac CT Epicardial Adipose Tissue Radiomic Phenotyping, HLA Stratification, Longitudinal Multi-Frequency Bioimpedance Body Composition, and a Prespecified Surgical Tissue Acquisition Subcohort","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","30","Psoriatic Arthritis; Osteoarthitis; Knee; Diabetes (DM); Type 2 Diabetes Mellitus (T2DM); Obesity (Disorder); Insulin Resistance Syndrome; Metabolic Syndrome; Heart Failure; Preserved Ejection Fraction; Coronary Artery Disease; Atrial Fibrillation (AF); Non Alcholic Fatty Liver Disease; Sarcopenia; Pericardium","DRUG:Tirzepatide","JULIO GRANADOS MONTIEL","2026-05","FALSE","7"],["S001990","ClinicalTrials.gov","NCT04531176","EMPOWER-T2D","An ObEsity-centric Approach With and Without Anti-obesity Medications ComPared to the Usual-care ApprOach to Management of Patients With Obesity and Type 2 Diabetes in an Employer Setting: A Pragmatic Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","74","Type 2 Diabetes; Obesity","OTHER:Weight Management Program (WMP); OTHER:Traditional care; DRUG:Phentermine / Topiramate Extended Release Oral Capsule; DRUG:naltrexone/bupropion extended-release; DRUG:liraglutide 3.0 mg; DRUG:Orlistat","The Cleveland Clinic","2020-09-01","TRUE","0"],["S001991","ClinicalTrials.gov","NCT01147250","ELIXA","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","6068","Acute Coronary Syndrome","DRUG:Lixisenatide (AVE0010); DRUG:Placebo","Sanofi","2010-06","TRUE","15"],["S001992","ClinicalTrials.gov","NCT05813249",null,"Therapeutic Effect of Semaglutide on Nonalcoholic Fatty Liver Disease in Obesity and/or Type 2 Diabetes Mellitus","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","COMPLETED","180","Non-alcoholic Fatty Liver Disease","DRUG:Rybelsus Oral Product; DRUG:Ozempic Injectable Product; DRUG:Tocopherol and/or Actos","Zagazig University","2023-02-15","FALSE","0"],["S001993","ClinicalTrials.gov","NCT06431308",null,"Adjuvant Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events During the Up-titration Phase","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","120","Obesity; Drug","BEHAVIORAL:nutritional intervention","Ariel University","2025-01-30","FALSE","0"],["S001994","ClinicalTrials.gov","NCT07586150","LIFETRAIN","Personalised Pharmaco-Lifestyle Interventions for Severe Mental Illnesses Enhanced by Digital Health and Immersive Technologies","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","140","Severe Mental Illness; Depression / Major Depressive Disorder; Bipolar Disorder (BD); Schizophrenia","DRUG:Semaglutide (SEMA); BEHAVIORAL:Exercise module; BEHAVIORAL:Anti-inflammatory diet module; BEHAVIORAL:Sleep intervention module; BEHAVIORAL:Social prescribing module; DEVICE:Closed-loop transcranial alternating current stimulation (CL-tACS); BEHAVIORAL:Structured lifestyle psychoeducation; DEVICE:Sham CL-tACS","Ludwig-Maximilians - University of Munich","2028-10","FALSE","0"],["S001995","ClinicalTrials.gov","NCT02829502","EGRABIS1","The Effect of Glucagon-like Peptide 1 (GLP-1) Receptor Agonist on Cerebral Blood Flow Velocity in Stroke Patients","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","30","Ischemic Stroke","DRUG:Byetta; DRUG:Normosaline","Christina Kruuse","2016-08","FALSE","0"],["S001996","ClinicalTrials.gov","NCT07859137",null,"Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher: a Randomized, Double-blind, Placebo-controlled Trial of Surgical Feasibility and Safety","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","100","Morbid Obesity","DRUG:Semaglutide weekly injection; DRUG:Placebo","General Committee of Teaching Hospitals and Institutes, Egypt","2026-10","FALSE","0"],["S001997","ClinicalTrials.gov","NCT04561245",null,"A Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of ALT-801 in Healthy Overweight and Obese Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","100","Obesity; Nonalcoholic Steatohepatitis","DRUG:ALT-801; OTHER:Placebo","Altimmune, Inc.","2020-11-10","FALSE","0"],["S001998","ClinicalTrials.gov","NCT07811895",null,"Dual Glucose-dependent Insulinotropic Peptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonist in Women With Obesity for Frozen Embryo Transfer (FET): Pragmatic, Multicenter, Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","1510","Tirzepatide; Frozen Embryo Transfer; Obesity","DRUG:Dual GIP/GLP-1 receptor agonist","RenJi Hospital","2026-09","FALSE","0"],["S001999","ClinicalTrials.gov","NCT05086445",null,"A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","62","Diabetes Mellitus, Type 2","DRUG:LY3502970; DRUG:Placebo","Eli Lilly and Company","2021-11-12","TRUE","0"],["S002000","ClinicalTrials.gov","NCT03888157","VIEW-Iran","A Multi-centre, Prospective, Non-interventional Study Investigating the Effect of Victoza® in Patients With Type 2 Diabetes in Iran Followed in a Real World Setting","OBSERVATIONAL",null,null,"COMPLETED","839","Diabetes Mellitus, Type 2","DRUG:Liraglutide","Novo Nordisk A/S","2019-03-10","FALSE","0"],["S002001","ClinicalTrials.gov","NCT07614412","SHIELD-T1D","Recombinant Zoster Vaccine (Shingrix) and GLP-1 Receptor Agonist for the Preservation of Beta-Cell Function in Adults With Recent-Onset Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial.","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","240","Type 1 Diabetes Mellitus","DRUG:Recombinant Zoster Vaccine (Shingrix; RZV); DRUG:Semaglutide (Ozempic®); DRUG:Placebo (saline injection)","Ministry of Health, Saudi Arabia","2027-01-01","FALSE","0"],["S002002","ClinicalTrials.gov","NCT06445075","EMBRAZE","A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apitegromab in Overweight and Obese Adult Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","102","Overweight and Obesity","DRUG:Apitegromab; DRUG:Placebo; DRUG:Tirzepatide","Scholar Rock, Inc.","2024-05-21","FALSE","1"],["S002003","ClinicalTrials.gov","NCT00423501",null,"A Double Blind, Placebo-controlled, Dose-ranging Study to Investigate the Effect on Glycemic Control, Safety, Pharmacokinetics and Pharmacodynamics of GLP-1 in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","306","Diabetes Mellitus Type 2","DRUG:Placebo; DRUG:taspoglutide","Hoffmann-La Roche","2007-02","FALSE","1"],["S002004","ClinicalTrials.gov","NCT05659537",null,"A 24-week Multicenter, Open-label, Single-arm Study to Evaluate Safety in Patients With Type 2 Diabetes Mellitus in India Treated With Dulaglutide","INTERVENTIONAL",null,"PHASE4","COMPLETED","212","Diabetes Mellitus, Type 2","DRUG:Dulaglutide","Eli Lilly and Company","2022-12-29","TRUE","0"],["S002005","ClinicalTrials.gov","NCT07653477","UNIGUIDE-2","A Multicenter, Randomized, Open-Label, Semaglutide Injection-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Treatment With Metformin Alone or in Combination With Sulfonylurea/Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Therapy (UNIGUIDE-2)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","956","Type 2 Diabetes","DRUG:UBT251 Injection 2.0 mg group; DRUG:UBT251 Injection 4.0 mg group; DRUG:UBT251 Injection 6.0 mg group; DRUG:Semaglutide Injection","The United Bio-Technology (Hengqin) Co., Ltd.","2026-09-07","FALSE","0"],["S002006","ClinicalTrials.gov","NCT05788601","DREAM","Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","54","Obesity; Inflammation","DRUG:Dapiglutide; DRUG:Placebo","University Hospital, Gentofte, Copenhagen","2023-04-27","FALSE","1"],["S002007","ClinicalTrials.gov","NCT06246175",null,"A Multi-center, Single-dose, Open-label, Parallel Design, Pharmacokinetics Study of HRS9531injection in Healthy Subjects and Subjects With Impaired Renal Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","32","Type 2 Diabetes","DRUG:HRS9531","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-02-28","FALSE","0"],["S002008","ClinicalTrials.gov","NCT06672939",null,"Efficacy, Safety, and Pharmacokinetics of Orforglipron Once Daily Oral Versus Placebo in Adolescent Participants Who Have Obesity, or Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (ADVANCE-ATTAIN-ADOLESCENTS)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","150","Obesity; Overweight","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2024-11-18","FALSE","0"],["S002009","ClinicalTrials.gov","NCT01593137","ADELANTE","A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","WITHDRAWN","0","Type 2 Diabetes","DRUG:Liraglutide + metformin; DRUG:Glimepiride + metformin","Fundación Fernández-Cruz","2012-05","FALSE","0"],["S002010","ClinicalTrials.gov","NCT05694221",null,"A Single-centre, Open Labeled, Fixed-sequence Study to Evaluate the Effect of Supaglutide on Digoxin or Metformin Pharmacokinetics","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","34","Healthy Volunteers","DRUG:Supaglutide injection; DRUG:Digoxin; DRUG:Metformin","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2023-03-20","FALSE","1"],["S002011","ClinicalTrials.gov","NCT05390892","PRECIDENTD","PRECIDENTD: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","6000","Type2Diabetes; ASCVD","DRUG:SGLT2 inhibitor; DRUG:GLP-1 receptor agonist","Brigham and Women's Hospital","2022-09-26","FALSE","1"],["S002012","ClinicalTrials.gov","NCT04788511","STEP-HFpEF","Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","529","Obesity","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2021-03-16","TRUE","16"],["S002013","ClinicalTrials.gov","NCT01455857",null,"Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","460","Type 2 Diabetes","DRUG:ITCA 650; OTHER:ITCA placebo","Intarcia Therapeutics","2013-03","FALSE","1"],["S002014","ClinicalTrials.gov","NCT02041234",null,"Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes vs Best Medical Treatment","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","40","Type II Diabetes in Subjects BMI 27 to 32","PROCEDURE:Roux-en-Y Gastric Bypass (RYGB); DRUG:Incretin analogues; DRUG:Xenical; DRUG:SGLT2 inhibitors; DRUG:DPP-4 Inhibitors","Khoo Teck Puat Hospital","2014-02","FALSE","1"],["S002015","ClinicalTrials.gov","NCT01237119","LEAN","48-week Phase II, Randomised, Double Blinded Placebo Controlled Multicentre Trial on Liraglutide's Safety, Efficacy and Action on Liver Histology and Metabolism in Overweight Patients With NASH +/- Type II Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","52","Nonalcoholic Steatohepatitis","DRUG:Liraglutide; OTHER:Liraglutide-placebo","University of Birmingham","2010-08","FALSE","8"],["S002016","ClinicalTrials.gov","NCT01363609","LIBRA","Central Effects of Endogenous Glucagon Like Peptide-1 (GLP-1) and the GLP-1 Analog Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","50","Obesity; Type 2 Diabetes","DRUG:Liraglutide treatment 12 weeks; DRUG:insulin glargine treatment; DRUG:GLP-1 receptor antagonist","Amsterdam UMC, location VUmc","2011-10","FALSE","1"],["S002017","ClinicalTrials.gov","NCT07518121","BRIDGE-BR","A Randomized, Double-Blind, Placebo-Controlled Bridging Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Efsubaglutide Alfa in Healthy Adult Participants in Brazil","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","48","Diabete Type 2","DRUG:Efsubaglutide Alfa Injection; DRUG:Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2026-06-01","FALSE","0"],["S002018","ClinicalTrials.gov","NCT02749890","LIXILAN JP-O1","A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Combination to Lixisenatide on Top of OADs in Japanese Patients With Type 2 DM With an Extension Period","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","321","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide (HOE901/AVE0010); DRUG:Lixisenatide (AVE0010); DRUG:Oral anti-diabetic drugs","Sanofi","2016-05-09","FALSE","2"],["S002019","ClinicalTrials.gov","NCT04032197",null,"A Trial Investigating the Effect of Semaglutide on Atherosclerosis in Patients With Cardiovascular Disease and Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","101","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-08-12","FALSE","1"],["S002020","ClinicalTrials.gov","NCT07163650",null,"A Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of Efsubaglutide Alfa in Patients Remaining Obese 6 Months After Metabolic Surgery","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","60","Obesity; Weight Loss; Metabolic Surgery","DRUG:Efsubaglutide Alfa Injection; BEHAVIORAL:Diet and exercise guidelines","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2025-09-16","FALSE","0"],["S002021","ClinicalTrials.gov","NCT06478550",null,"A Pilot Study Investigating the Effect of Patient Support Solution App With Connectivity on Once-weekly Semaglutide s.c. Treatment Persistence in Patients With Type 2 Diabetes in a Clinical Practice Setting","OBSERVATIONAL",null,null,"COMPLETED","304","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2024-06-26","FALSE","0"],["S002022","ClinicalTrials.gov","NCT01916174",null,"A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","50","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:insulin degludec/liraglutide","Novo Nordisk A/S","2013-08","FALSE","0"],["S002023","ClinicalTrials.gov","NCT00715624","GETGOAL-L","A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","496","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DRUG:Basal Insulin; DRUG:Metformin; DEVICE:Pen auto-injector","Sanofi","2008-07","TRUE","4"],["S002024","ClinicalTrials.gov","NCT06247748",null,"Evaluation of the Effects of Exendin-4 Fc Fusion Protein (JY09) Injection on the Pharmacokinetic Profiles of Metformin Hydrochloride Tablets, Rosuvastatin Calcium Tablets, and Digoxin Tablets and on the QT Interval in Overweight Chinese Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","28","Diabetes Mellitus, Type 2; Overweight","DRUG:Exendin-4 Fc fusion protein (JY09) injection; DRUG:Metformin Hydrochloride tablet; DRUG:Rosuvastatin calcium tablets; DRUG:Digoxin tablet","Beijing Dongfang Biotech Co., Ltd.","2023-10-19","FALSE","0"],["S002025","ClinicalTrials.gov","NCT02827708","PIONEER 5","Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","324","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2016-09-20","TRUE","9"],["S002026","ClinicalTrials.gov","NCT06485089",null,"Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers in Women With Obesity and Other Risk Factors for Breast Cancer","OBSERVATIONAL",null,null,"COMPLETED","25","Obesity; Breast Cancer Risk","DRUG:tirzepatide","University of Kansas Medical Center","2024-09-14","FALSE","0"],["S002027","ClinicalTrials.gov","NCT02092597","SAFEGUARD","Safety Evaluation of Adverse Reactions in Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","42","Type 2 Diabetes Mellitus","DRUG:Exenatide; DRUG:Linagliptin; DRUG:Gliclazide","Charles University, Czech Republic","2013-10","FALSE","0"],["S002028","ClinicalTrials.gov","NCT06252623",null,"A Human Laboratory Study of Exenatide for Reducing the Reinforcing Effects of Cocaine","INTERVENTIONAL","RANDOMIZED","PHASE1","WITHDRAWN","0","Cocaine Use Disorder","DRUG:Exenatide; DRUG:Placebo","Christopher D. Verrico","2024-08-01","FALSE","0"],["S002029","ClinicalTrials.gov","NCT00782418",null,"A Randomized Clinical Trial to Study Glucose Dependent Insulin Secretion Methodologies in Healthy Lean Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","27","The Methodology Assessment of Glucose Dependent Insulin Secretion","DRUG:Comparator: exenatide; DRUG:Comparator: Placebo","Merck Sharp & Dohme LLC","2008-09","TRUE","1"],["S002030","ClinicalTrials.gov","NCT05114590","Soli-CGM","A 16-week, Multicenter, Prospective, Open-label, Single-arm, Phase 4 Study to Evaluate the Effect of Soliqua™ 100/33 on the Percentage of Time in Range (TIR) From Continuous Glucose Monitoring (CGM) in Insulin-naïve Patients With Very Uncontrolled Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE4","COMPLETED","124","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide","Sanofi","2022-01-27","TRUE","4"],["S002031","ClinicalTrials.gov","NCT07314684","STABLE-GLP1","Impact of GLP1-RAs on Inflammation and Endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","80","T2DM (Type 2 Diabetes Mellitus)","DRUG:semaglutide; DRUG:Standard Treatment (Guideline-Based)","Federico II University","2025-09-08","FALSE","0"],["S002032","ClinicalTrials.gov","NCT05328843",null,"An Open-label Phase I Clinical Study to Evaluate the Pharmacokinetic Characteristics of Single-dose of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","UNKNOWN","24","Type2Diabetes","DRUG:PB119","PegBio Co., Ltd.","2022-05-01","FALSE","0"],["S002033","ClinicalTrials.gov","NCT01969149","ExSTRESS","Intravenous Exenatide (Byetta®) Versus Insulin for Perioperative Glycemic Control in Cardiac Surgery: the Open-labeled Randomized Phase II/III ExStress Study","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","110","Stress Hyperglycemia","DRUG:Exenatide; DRUG:Insulin","Centre Hospitalier Universitaire de Besancon","2015-01","FALSE","1"],["S002034","ClinicalTrials.gov","NCT07265752",null,"Tirzepatide for the Treatment of Cannabis Use Disorder: A Pilot Double-blind, Placebo-controlled, Crossover Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","6","Cannabis Use Disorder","DRUG:Tirzepatide; DRUG:Placebo","Brigham and Women's Hospital","2027-03-01","FALSE","0"],["S002035","ClinicalTrials.gov","NCT02887625",null,"Efficacy and Durability of Glucagon Like Peptide 1 Receptor Agonists (GLP-1 RA)/Thiazolidinedione Versus Basal Bolus Insulin Therapy in Poorly Controlled Type 2 Diabetic Patients (T2DM) Patients on Sulfonylurea Plus Metformin","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","410","Type 2 Diabetes","DRUG:Pioglitazone plus exenatide; DRUG:insulin glargine and insulin aspart","Dr. Muhammad Abdulghani","2015-02","FALSE","2"],["S002036","ClinicalTrials.gov","NCT04529278","LIRADIAL","Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients","INTERVENTIONAL",null,"PHASE2","UNKNOWN","18","Diabetes Mellitus, Type 2; Hemodialysis; Obese","DRUG:Liraglutide","Fondation Hôpital Saint-Joseph","2021-01-18","FALSE","7"],["S002037","ClinicalTrials.gov","NCT07684235",null,"A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","3200","Obesity; Overweight","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2026-07-23","FALSE","0"],["S002038","ClinicalTrials.gov","NCT02911948","DUAL™ II Japan","A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","210","Diabetes; Diabetes Mellitus, Type 2","DRUG:Insulin degludec/liraglutide; DRUG:Insulin degludec","Novo Nordisk A/S","2016-09-21","TRUE","4"],["S002039","ClinicalTrials.gov","NCT03550378",null,"A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects With Type 2 Diabetes Mellitus and Renal Impairment","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","41","Type II Diabetes Mellitus; Renal Insufficiency","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2018-06-29","TRUE","4"],["S002040","ClinicalTrials.gov","NCT02503943",null,"What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone（BLOOD STUDY）","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","90","Type 2 Diabetes; Overweight; Obesity; Masked Hypertension","DRUG:\"Liraglutide\" and \"Mitiglinide\"; DRUG:\"Metformin\" and \"Mitiglinide\"; DRUG:\"Mitiglinide\"","Third Affiliated Hospital of Third Military Medical University","2015-05","FALSE","0"],["S002041","ClinicalTrials.gov","NCT01794429","TAO","Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","45","Obesity; Metabolic Syndrome X; Drug-induced Obesity; Schizophrenia","DRUG:Exenatide; DRUG:Placebo","Bjorn H. Ebdrup","2013-02","FALSE","4"],["S002042","ClinicalTrials.gov","NCT07457437","FLEX","Effect of a Progressive Resistance Exercise Program on Muscle Mass and Physical Function During a Tirzepatide Induced Weight Loss in Overweight and Obese Females: a Randomised Parallel Group Study","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","60","Muscle Mass and Strength; Obesity & Overweight; Physical Function","OTHER:Progressive Resistance Exercise Training Program; OTHER:Habitual physical activity guidelines","University of Exeter","2026-04-01","FALSE","3"],["S002043","ClinicalTrials.gov","NCT05184322",null,"A Phase 1, Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ecnoglutide Tablet in Healthy Adult Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","87","Obesity; Type 2 Diabetes Mellitus","DRUG:T2026; DRUG:Placebo; DRUG:Oral ecnoglutide tablet","Sciwind Biosciences APAC CO Pty. Ltd.","2022-04-12","FALSE","0"],["S002044","ClinicalTrials.gov","NCT07824895",null,"A Single-Arm, Open-Label, Pre-Post Controlled Clinical Study to Evaluate the Effect of Mazdutide on Annualized Flare Rate in Adults With Obesity and Gout","INTERVENTIONAL",null,"PHASE4","NOT_YET_RECRUITING","30","Gout; Obesity (BMI>30); Hyperuricemia; Metabolic Syndrome","DRUG:Mazdutide","Hongwei Jiang","2026-09-15","FALSE","0"],["S002045","ClinicalTrials.gov","NCT01507337",null,"An Open Label, Single Dose Trial With Two Groups Comparing the Pharmacokinetics of Liraglutide in Young Versus Elderly Healthy Subjects of Both Sexes","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","32","Diabetes; Healthy","DRUG:liraglutide","Novo Nordisk A/S","2004-04","FALSE","1"],["S002046","ClinicalTrials.gov","NCT03374956",null,"Individualized Pharmacological Approach to Obesity Management: A Randomized Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","193","Obesity","DRUG:Phentermine-Topiramate; DRUG:Liraglutide; DRUG:Naltrexone/bupropion; DRUG:Phentermine","Mayo Clinic","2017-12-11","TRUE","1"],["S002047","ClinicalTrials.gov","NCT00623545",null,"Bioenergetic Alterations After Exenatide Administration","INTERVENTIONAL",null,"PHASE4","COMPLETED","28","Healthy","DRUG:Exenatide","University of Wisconsin, Madison","2008-01","TRUE","2"],["S002048","ClinicalTrials.gov","NCT05897372","WP3","Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","1","Diabetic Kidney Disease","DRUG:ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib","Iain Bressendorff","2023-08-01","FALSE","0"],["S002049","ClinicalTrials.gov","NCT05110794",null,"A Phase 1 Multiple Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of LY3502970 in Fed and Fasted Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","34","Healthy","DRUG:LY3502970","Eli Lilly and Company","2021-11-05","TRUE","1"],["S002050","ClinicalTrials.gov","NCT07304141",null,"Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity","OBSERVATIONAL",null,null,"COMPLETED","128","Obesity (Disorder); Child Obesity","OTHER:Liraglutide 3 mg (Saxenda)","Göteborg University","2023-12-20","FALSE","0"],["S002051","ClinicalTrials.gov","NCT04159766",null,"A Phase 2a Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NLY01, a PEGylated Exenatide, When Administered as a Single Dose in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","20","Type2 Diabetes; Diabetes Mellitus, Type 2","DRUG:NLY01; DRUG:Placebo","Neuraly, Inc.","2019-10-16","FALSE","0"],["S002052","ClinicalTrials.gov","NCT07251556",null,"Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Subclinical Atherosclerosis in Non-diabetic Patients With Psoriatic Arthritis - a Proof-of-concept Randomized Study","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","40","Psoriasis Arthritis","DRUG:Semaglutide 0.5 mg; DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 0.25 mg; OTHER:No intervention","Chinese University of Hong Kong","2025-12-01","FALSE","0"],["S002053","ClinicalTrials.gov","NCT05548231",null,"A Multiple Dose Escalation Study in Chinese Participants With Overweight BMI or Obesity to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Overweight; Obesity","DRUG:LY3437943; DRUG:Placebo","Eli Lilly and Company","2022-10-24","FALSE","0"],["S002054","ClinicalTrials.gov","NCT04889183","SMART","SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","125","Obesity; Albuminuria","DRUG:Semaglutide; DRUG:Placebo","University Medical Center Groningen","2022-03-14","FALSE","2"],["S002055","ClinicalTrials.gov","NCT07417631",null,"Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.","OBSERVATIONAL",null,null,"COMPLETED","300000","Type 2 Diabetes","DRUG:Dulaglutide; DRUG:Sitagliptin","Brigham and Women's Hospital","2026-02-03","FALSE","0"],["S002056","ClinicalTrials.gov","NCT07285902",null,"A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of HRS9531 Injection Versus Semaglutide Injection in Subjects With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","572","Obesity","DRUG:HRS9531 injection; DRUG:Semaglutide Injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2025-12-25","FALSE","0"],["S002057","ClinicalTrials.gov","NCT01511172",null,"Effect on Glycemic Control of Individual Maximum Effective Dose of NNC 90-1170 as Add on Therapy to Metformin Compared to Monotherapy of NNC 90-1170 or Metformin or a Metformin-SU Combination Therapy in Patients With Type 2 Diabetes. A Double-blind, Double-dummy, Randomised, Parallel-group, Dose Titration Study With an Open Labelled OHA Arm","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","145","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:metformin; DRUG:placebo; DRUG:glimepiride","Novo Nordisk A/S","2002-08","FALSE","2"],["S002058","ClinicalTrials.gov","NCT07640139",null,"Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","125000","Obesity","DRUG:Incretin-based therapies (GLP-1 and GLP-1/GIP)","Indiana University","2026-01-01","FALSE","0"],["S002059","ClinicalTrials.gov","NCT06005012","SAMARA","Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","120","Fibrosis, Liver; Type 2 Diabetes Mellitus in Obese; Non-Alcoholic Fatty Liver Disease","DRUG:Semaglutide; DRUG:Placebo","University of California, San Diego","2023-07-25","FALSE","0"],["S002060","ClinicalTrials.gov","NCT07613437","GLICH","GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","200","Intracerebral Hemorrhage","DRUG:Semaglutide, 0.5 mg/mL","Chinese University of Hong Kong","2026-06-15","FALSE","0"],["S002061","ClinicalTrials.gov","NCT06271200",null,"Effects of Intensive Lifestyle Interventions (ILI) on Weight Loss and Cardiometabolic Risks in Obese Adults With Metabolic Syndrome: A Randomized Clinical Trial","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","200","Metabolic Syndrome","OTHER:Strategic lifestyle and drug interventions; OTHER:Control","National Health Research Institutes, Taiwan","2024-03-14","FALSE","0"],["S002062","ClinicalTrials.gov","NCT03596177",null,"An Exploratory Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","28","Diabetes Mellitus, Type II; Obesity","DRUG:MEDI0382; DRUG:Placebo","MedImmune LLC","2018-09-26","TRUE","1"],["S002063","ClinicalTrials.gov","NCT07793019",null,"A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of Single-Dose IBI3042 in Healthy Participants and Multiple-Dose IBI3042 in Overweight or Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","104","Overweight; Healthy Participants; Obesity","DRUG:Orforglipron; DRUG:Matching Placebo; DRUG:IBI3042","Innovent Biologics (Suzhou) Co. Ltd.","2026-09-07","FALSE","0"],["S002064","ClinicalTrials.gov","NCT04982575",null,"Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","92","Diabetes Mellitus, Type 2","DRUG:Semaglutide 2.4 mg; DRUG:Cagrilintide 2.4 mg; DRUG:Placebo (semaglutide); DRUG:Placebo (cagrilintide)","Novo Nordisk A/S","2021-08-02","TRUE","3"],["S002065","ClinicalTrials.gov","NCT02447601",null,"An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","16","Type 2 Diabetes Mellitus","DRUG:PEX168; DRUG:Simvastatin","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2015-03-30","FALSE","0"],["S002066","ClinicalTrials.gov","NCT01982630",null,"A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","87","Diabetes Mellitus","DRUG:MK-8521; DRUG:Liraglutide; DRUG:Placebo","Merck Sharp & Dohme LLC","2013-11-07","TRUE","0"],["S002067","ClinicalTrials.gov","NCT06635057","T-RAM","A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants With Type 2 Diabetes During Ramadan","INTERVENTIONAL",null,"PHASE4","COMPLETED","166","Type 2 Diabetes","DRUG:Tirzepatide","Eli Lilly and Company","2024-10-11","FALSE","0"],["S002068","ClinicalTrials.gov","NCT01700075","PCSAM","Comparative Physical and Chemical Study of the Mechanisms of Atherosclerosis With Development of Concept of Treatment and Prevention","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","97","Myocardial Infarction; Coronary Artery Diseases; Diabetes Mellitus, Type 2; Atherosclerosis of Femoral Artery","DRUG:Conventional treatment; DIETARY_SUPPLEMENT:Weight loss treatment","Nazarbayev University","2009-01","FALSE","0"],["S002069","ClinicalTrials.gov","NCT03002675","exe01","The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men","INTERVENTIONAL",null,"PHASE4","UNKNOWN","24","Obesity","DRUG:Bydureon","Ingrid Jazet","2016-08","FALSE","1"],["S002070","ClinicalTrials.gov","NCT07036172",null,"A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection and WEGOVY® in Chinese Obese Patients","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","460","Obesity Control","DRUG:HDM1702; DRUG:Wegovy ®","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-01-03","FALSE","0"],["S002071","ClinicalTrials.gov","NCT03881995","Lixibrain01","Effect of Insulin Glargine and Lixisenatide Versus Insulin Glargine on Brain Insulin Sensitivity in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","1","Diabetes Mellitus, Type 2","DRUG:IGlarLixi; DRUG:Insulin Glargine 100 UNT/ML","University Hospital Tuebingen","2019-03-18","FALSE","0"],["S002072","ClinicalTrials.gov","NCT06559722",null,"A 26-Week,Randomised,Open-Label,Multicenter,Active-Controlled,Parallel-Design,Phase III Clinical Trial to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide Injection With XULTOPHY® Once Daily Via Subcutaneous Injection in Chinese Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","510","Type 2 Diabetes","DRUG:Insulin Degludec/liraglutide Injection; DRUG:XULTOPHY®","Tonghua Dongbao Pharmaceutical Co.,Ltd","2024-08","FALSE","0"],["S002073","ClinicalTrials.gov","NCT00566813",null,"Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression","INTERVENTIONAL","NON_RANDOMIZED","PHASE1; PHASE2","COMPLETED","10","Diabetes Mellitus, Type 1","DRUG:Islet Cell Transplant; DRUG:Islet Cell Transplant plus","University of Illinois at Chicago","2004-11","TRUE","1"],["S002074","ClinicalTrials.gov","NCT00845559",null,"The Effects of Exenatide on Post-Prandial Glucose Excursions and Vascular Health in Obese/Pre-Diabetic Young Adults","INTERVENTIONAL","RANDOMIZED","PHASE4","WITHDRAWN","0","Obesity; Insulin Resistance; Impaired Glucose Tolerance; Cardiovascular Disease","DRUG:Exenatide","Yale University","2008-08","FALSE","0"],["S002075","ClinicalTrials.gov","NCT04269642",null,"Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","99","Early Parkinson's Disease","DRUG:PT320 2.0mg Placebo; DRUG:PT320 2.0 mg; DRUG:PT320 2.5 mg","Peptron, Inc.","2020-03-19","FALSE","0"],["S002076","ClinicalTrials.gov","NCT04447859",null,"A Randomized Controlled Open Label Pilot Study Examining the Safety of a 16 Week Flexible Titration Regimen vs. Label-recommended 8-week Semaglutide Titration Regimen","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","100","Diabetes type2","DRUG:Semaglutide; OTHER:label recommended titration","Tel-Aviv Sourasky Medical Center","2020-02-23","FALSE","0"],["S002077","ClinicalTrials.gov","NCT06449703",null,"A Randomized, Open-label, Two-period, Cross-over Trial to Evaluate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Injection Compared With Xultophy® in Healthy Chinese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","UNKNOWN","44","Healthy","DRUG:insulin degludec/liraglutide; DRUG:Xultophy®","Tonghua Dongbao Pharmaceutical Co.,Ltd","2024-05-06","FALSE","0"],["S002078","ClinicalTrials.gov","NCT05920889","GALLOP","Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies - a Pilot Study","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","140","Stroke; Stroke, Acute; Stroke, Ischemic; Brain Diseases","DRUG:Semaglutide","Chinese University of Hong Kong","2023-08-01","FALSE","1"],["S002079","ClinicalTrials.gov","NCT06790160",null,"Observational Study of Patients Being Treated With Anti-obesity Medication","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","100","Obesity and Overweight",null,"Texas Tech University","2025-01-31","FALSE","0"],["S002080","ClinicalTrials.gov","NCT05952882",null,"Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","188","Polycystic Ovary Syndrome; Obesity; Infertility, Female","DRUG:Liraglutide + Metformin; DRUG:Metformin","Mỹ Đức Hospital","2023-11-01","FALSE","8"],["S002081","ClinicalTrials.gov","NCT03353350","AMPLITUDE-M","A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","406","Type 2 Diabetes Mellitus","DRUG:efpeglenatide (SAR439977); DRUG:placebo","Hanmi Pharmaceutical Company Limited","2017-12-05","TRUE","1"],["S002082","ClinicalTrials.gov","NCT02254291","SUSTAIN™","Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily, Both as Monotherapy in Japanese Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","308","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:sitagliptin","Novo Nordisk A/S","2014-10-02","TRUE","3"],["S002083","ClinicalTrials.gov","NCT05227196",null,"A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","546","Healthy Volunteers; Type 2 Diabetes","DRUG:Semaglutide D Dose 1; DRUG:Semaglutide D Dose 2; DRUG:Semaglutide D Dose 3; DRUG:Semaglutide Dose 4; DRUG:Semaglutide Dose 5; DRUG:Semaglutide Dose 6","Novo Nordisk A/S","2022-02-04","FALSE","1"],["S002084","ClinicalTrials.gov","NCT06616961",null,"Efficacy and Safety of Semaglutide in Weight Reduction in Overweight or Obese Bangladeshi Adults With or Without Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE3","NOT_YET_RECRUITING","480","Obesity; Type 2 Diabetes Mellitus (T2DM)","DRUG:Semaglutide Pen","Popular Medical College Hospital","2024-11-01","FALSE","0"],["S002085","ClinicalTrials.gov","NCT06605703",null,"The Comparative Effectiveness of Step-down Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide: A Randomized Controlled Trial (GLP1 Transition Trial)","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","226","Obesity; Overweight","BEHAVIORAL:WW Clinic; DRUG:Bupropion-Naltrexone; DRUG:Bupropion-Naltrexone-Metformin","WW International Inc","2024-09-18","FALSE","0"],["S002086","ClinicalTrials.gov","NCT01779362","RISE Adult","Restoring Insulin Secretion Adult Medication Study","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","267","Prediabetes; Type 2 Diabetes","DRUG:Metformin; DRUG:Liraglutide; DRUG:Glargine; DRUG:Placebo","RISE Study Group","2013-04","TRUE","6"],["S002087","ClinicalTrials.gov","NCT02288273",null,"A Randomized Double-blind, Parallel-group Study to Evaluate the Effect of BYDUREON Compared With Placebo on 24-hour Glucose Control in Metformin-treated Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","239","Type 2 Diabetes","DRUG:Bydureon; DRUG:Placebo","AstraZeneca","2014-12","TRUE","0"],["S002088","ClinicalTrials.gov","NCT02690883",null,"Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","92","Diabetic Nephropathies","DRUG:Exenatide; DRUG:Lispro","Nanfang Hospital, Southern Medical University","2016-04-08","FALSE","8"],["S002089","ClinicalTrials.gov","NCT06345066",null,"A Multiple Dose Combination Study to Evaluate the Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","96","Obesity; Overweight","DRUG:Tirzepatide; DRUG:LY3841136; DRUG:Placebo","Eli Lilly and Company","2024-04-03","FALSE","0"],["S002090","ClinicalTrials.gov","NCT05516966",null,"A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","64","Diabetes Mellitus, Type 2","DRUG:HRS9531; DRUG:Placebo; DRUG:Dulaglutide Injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2022-10-12","FALSE","0"],["S002091","ClinicalTrials.gov","NCT07820722",null,"Assessing Heart and Brain Metabolism in Type II Diabetes Mellitus Patients Using Carbon-13 MRI","INTERVENTIONAL","NON_RANDOMIZED","EARLY_PHASE1","NOT_YET_RECRUITING","32","Diabete Type 2","DRUG:C13 Hyperpolarized pyruvate injection","Sunnybrook Health Sciences Centre","2026-10-01","FALSE","0"],["S002092","ClinicalTrials.gov","NCT07513168",null,"Efficacy and Safety of Low-Dose Semaglutide for Weight Loss and Cardiometabolic Improvement in Obese Pakistani Adults Without Type 2 Diabetes: A Single-Arm Open-Label Single-Center Trial","INTERVENTIONAL",null,"PHASE4","RECRUITING","60","Obesity; Weight Reduction; Cardiometabolic Risk Factors","DRUG:Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)","Asian Institute Of Medical Sciences","2025-08-01","FALSE","20"],["S002093","ClinicalTrials.gov","NCT04515576",null,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of LY3493269 in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","56","Diabetes Mellitus, Type 2","DRUG:LY3493269; DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2020-08-25","TRUE","0"],["S002094","ClinicalTrials.gov","NCT03659682","GIPD","Effect of GLPIR Stimulation on Neuroprotection and Inflammation in Parkinson's Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","120","Parkinson Disease","DRUG:Semaglutide","Oslo University Hospital","2019-01-02","FALSE","0"],["S002095","ClinicalTrials.gov","NCT07835360",null,"Cambios en la composición Corporal Tras el Inicio de Agonistas Del Receptor de GLP-1 (GLP-1RA) en Adultos Con Obesidad o Diabetes Tipo 2: Cohorte Prospectiva multicéntrica en Vida Real","OBSERVATIONAL",null,null,"RECRUITING","200","Obesity (Disorder); Type 2 Diabetes Mellitus",null,"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","2026-07-10","FALSE","11"],["S002096","ClinicalTrials.gov","NCT06742710","LITOP","Liraglutide Treatment in Obese Infertile PCOS Women","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","890","PCOS; Obesity; Infertility","DRUG:Liraglutide and metformin; DRUG:Metformin","Peking University Third Hospital","2025-05-22","FALSE","0"],["S002097","ClinicalTrials.gov","NCT02147431",null,"A Randomised, Single-centre, Double-blind, Cross-over Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counter-regulation Compared to Placebo in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","38","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-05-21","FALSE","1"],["S002098","ClinicalTrials.gov","NCT00331851","LEAD-5","Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine Added to Glimepiride and Metformin Combination Therapy in Subjects With Type 2 Diabetes.A Six-month Randomised, Double-blind, Parallel-group, Multi-centre, Multi-national Trial With an Open-label Treat-to-target Insulin Glargine Control Arm.","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","584","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:insulin glargine; DRUG:metformin; DRUG:glimepiride","Novo Nordisk A/S","2006-05","FALSE","14"],["S002099","ClinicalTrials.gov","NCT05872022",null,"Wegovy® (Semaglutide 2.4 mg) Pregnancy Registry Study: A Prospective Cohort Study to Investigate Safety Outcomes of Exposure to Wegovy During Pregnancy","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","728","Pregnancy; Obesity; Overweight","OTHER:No Intervention","Novo Nordisk A/S","2023-07-05","FALSE","0"],["S002100","ClinicalTrials.gov","NCT01406262",null,"A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","94","Diabetes Mellitus, Type 2","BIOLOGICAL:Albiglutide; DRUG:Moxifloxacin","GlaxoSmithKline","2011-07-06","FALSE","1"],["S002101","ClinicalTrials.gov","NCT01478074",null,"A Single-center Open-label Phase I Study of ALT-801 for ex Vivo Maturation and in Vivo Retargeting of Haploidentical Natural Killer Cells Delivered Following Fludarabine, Cytarabine, and G-CSF in Patients With Relapsed/Refractory Acute Myeloid Leukemia","INTERVENTIONAL",null,"PHASE1","WITHDRAWN","0","Acute Myeloid Leukemia","DRUG:G-CSF; DRUG:Cytarabine; DRUG:Fludarabine; BIOLOGICAL:Donor Natural Killer (NK) cells; BIOLOGICAL:ALT-801","Altor BioScience","2011-11","FALSE","0"],["S002102","ClinicalTrials.gov","NCT03811574","STEP 6","Effect and Safety of Semaglutide Once-weekly in East Asian Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","401","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-01-21","TRUE","3"],["S002103","ClinicalTrials.gov","NCT07092618",null,"Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation: A Randomized, Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","RECRUITING","150","Longevity; GLP-1; Geroscience; Aging","DRUG:Metformin; DRUG:Rapamycin; DRUG:Naltrexone; DIETARY_SUPPLEMENT:Vitamin C","AgelessRx","2024-12-17","FALSE","0"],["S002104","ClinicalTrials.gov","NCT05316662",null,"A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Mexico","OBSERVATIONAL",null,null,"COMPLETED","187","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2022-04-06","FALSE","0"],["S002105","ClinicalTrials.gov","NCT00013910",null,"NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","30","Diabetes Mellitus, Non-Insulin-Dependent","DRUG:NNC 90-1170","National Center for Research Resources (NCRR)",null,"FALSE","0"],["S002106","ClinicalTrials.gov","NCT07220759","RENEW 2","Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","330","Overweight; Obesity; Type 2 Diabetes","DRUG:Cagrilintide; DRUG:Placebo (matched to Cagrilintide)","Novo Nordisk A/S","2025-11-05","FALSE","0"],["S002107","ClinicalTrials.gov","NCT01931982","EGOFIP","Effect of GLP-1 on Microvascular Myocardial Function in Patients With Type 2","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","20","Type 2 Diabetes; Microvascular Dysfunction","DRUG:Victoza","Bispebjerg Hospital","2013-05","FALSE","1"],["S002108","ClinicalTrials.gov","NCT05990374",null,"Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","100","Diabetes","DRUG:Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc","Nanjing First Hospital, Nanjing Medical University","2023-08-01","FALSE","1"],["S002109","ClinicalTrials.gov","NCT06515418","STRIDES","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Proof-of-Concept Study to Investigate Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over (STRIDES)","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","204","Obesity","DRUG:Oral Azelaprag (BGE-105); DRUG:Oral Placebo for Azelaprag (BGE-105); DRUG:Tirzepatide; DRUG:Tirzepatide Placebo","BioAge Labs, Inc.","2024-06-27","FALSE","0"],["S002110","ClinicalTrials.gov","NCT03798080","Lixilan-L-CN","A Randomized, 30-week, Active-controlled, Open-label, 2 Treatment-arm, Parallel Group, Multicenter Study Comparing Efficacy and Safety of iGlarLixi to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled on Basal Insulin With or Without Oral Antidiabetic Drug(s)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","426","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/Lixisenatide (HOE901/AVE0010); DRUG:Insulin glargine (HOE901); DRUG:Metformin","Sanofi","2019-02-19","FALSE","4"],["S002111","ClinicalTrials.gov","NCT02060383",null,"A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","249","Cushing's Disease; Acromegaly","DRUG:Pasireotide s.c.; DRUG:Sitagliptin; DRUG:Liraglutide; DRUG:Insulin; DRUG:Pasireotide LAR; DRUG:Metformin","Novartis Pharmaceuticals","2014-05-23","TRUE","5"],["S002112","ClinicalTrials.gov","NCT04383197","EXISECRET","Effects of 12 Weeks of Endurance Exercise Training Alone or in Combination With Glucagon Like Peptide 1 Receptor Agonist (GLP-1 RA) Treatment on Insulin Secretory Capacity in Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","30","Type 2 Diabetes","BEHAVIORAL:Endurance exercise training; DRUG:Semaglutide","University of Copenhagen","2019-12-10","FALSE","1"],["S002113","ClinicalTrials.gov","NCT01037582",null,"Investigation on Safety, Tolerability and Bioavailability of Oral NN9924 in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","155","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:NN9924 (oral); DRUG:placebo; DRUG:NN9924 (s.c.); DRUG:NN9924 (i.v.)","Novo Nordisk A/S","2009-12-17","FALSE","1"],["S002114","ClinicalTrials.gov","NCT03479762",null,"In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database","OBSERVATIONAL",null,null,"COMPLETED","105","Obesity; Overweight","DRUG:Liraglutide","Novo Nordisk A/S","2018-04-20","FALSE","0"],["S002115","ClinicalTrials.gov","NCT00650546","NAFLD","Role of Exenatide in Treatment of NASH-a Pilot Study","INTERVENTIONAL",null,"PHASE2; PHASE3","COMPLETED","8","Nonalcoholic Fatty Liver Disease","DRUG:Exenatide","Indiana University","2006-08","TRUE","5"],["S002116","ClinicalTrials.gov","NCT02092896","T1DMLIRA","Treatment With Liraglutide as add-on to Insulin in Type 1 Diabetic Patients. Effects on Glycemic Control and Counterregulation and Cognitive Performance During Hypoglycaemia","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","40","Diabetes; Diabetes Mellitus, Type 1","DRUG:Liraglutide; DRUG:Placebo","Hvidovre University Hospital","2013-03","FALSE","1"],["S002117","ClinicalTrials.gov","NCT05767255",null,"Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","66","Diabetes Mellitus, Type 2 Treated With Insulin","DRUG:insulin degludec + liraglutide; DRUG:Insulin Glargine - Insulin Aspart","Hospital Universitario San Ignacio","2022-12-01","FALSE","1"],["S002118","ClinicalTrials.gov","NCT05078255",null,"The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","61","Type 2 Diabetes; Obesity","DRUG:Semaglutide 1.34 MG/ML [Ozempic]; DRUG:Glucose-dependent insulinotropic polypeptide (GIP); OTHER:Semaglutide 1.34 mg/ml placebo; OTHER:GIP placebo","Asger Lund, MD","2022-01-27","FALSE","2"],["S002119","ClinicalTrials.gov","NCT07411378","OBA","A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of 20-hydroxyecdysone (20E) in Reducing the Muscle Strength Loss From the GLP1 Agonist Semaglutide in Combination With Dieting in Obese and Overweight Adult Patients (OBA).","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","164","Muscle Wasting; Obesity & Overweight; Obesity","DRUG:BIO101; OTHER:Placebo; DRUG:Semaglutide","Biophytis","2026-07","FALSE","0"],["S002120","ClinicalTrials.gov","NCT04148209",null,"A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF-07081532 IN HEALTHY ADULT PARTICIPANTS","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","22","Healthy","DRUG:PF-07081532; DRUG:Placebo","Pfizer","2019-11-05","FALSE","0"],["S002121","ClinicalTrials.gov","NCT04998032",null,"Efficacy and Safety of Once-weekly Supaglutide Versus Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Metformin: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","620","Type2 Diabetes","BIOLOGICAL:supaglutide injection+metformin; OTHER:placebo+metformin","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2021-10-12","FALSE","4"],["S002122","ClinicalTrials.gov","NCT06408532",null,"The Evaluation of the Efficacy and Safety of Switching to Once-daily IDegLira in Patients With Type 2 Diabetes Receiving Premixed Insulin Therapy, a Multi-center, Randomized Control Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","256","Diabetes Mellitus, Type 2","DRUG:IDegLira; DRUG:Premixed insulin","Peking University People's Hospital","2024-04-30","FALSE","0"],["S002123","ClinicalTrials.gov","NCT07849348",null,"Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","266","Obesity; Chronic Kidney Disease; Albuminuria","DRUG:Finerenone; DRUG:Finerenone Placebo; DRUG:Semaglutide","Peking University People's Hospital","2026-09","FALSE","0"],["S002124","ClinicalTrials.gov","NCT04903509",null,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 1820237 Alone (Trial Parts 1+2) or Together With a Low Dose of Liraglutide (Trial Part 3) in Otherwise Healthy Male Subjects With Overweight/Obesity (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","95","Healthy","DRUG:BI 1820237; DRUG:Placebo; DRUG:Saxenda®; DRUG:Paracetamol-ratiopharm®","Boehringer Ingelheim","2021-06-08","FALSE","1"],["S002125","ClinicalTrials.gov","NCT05996848","REDEFINE 6","Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-Weekly in Chinese Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","300","Obesity or Overweight","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo Semaglutide; DRUG:Placebo Cagrilintide","Novo Nordisk A/S","2023-08-15","FALSE","0"],["S002126","ClinicalTrials.gov","NCT02641899",null,"A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly Studied Drug/Drug Interaction (DDI) Probe Compounds","INTERVENTIONAL",null,"PHASE1","COMPLETED","33","Healthy","DRUG:ITCA 650 20/60 mcg/day; DRUG:Acetaminophen; DRUG:Atorvastatin; DRUG:Lisinopril; DRUG:Warfarin; DRUG:Digoxin","Intarcia Therapeutics","2015-12","FALSE","0"],["S002127","ClinicalTrials.gov","NCT07035093","TRIUMPH-7","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","586","Obesity; Overweight; Chronic Low Back Pain (CLBP)","DRUG:Retatrutide; DRUG:Placebo","Eli Lilly and Company","2025-05-29","FALSE","0"],["S002128","ClinicalTrials.gov","NCT06010004","ACHIEVE-J","A Phase 3, Long-term Safety Study of LY3502970 in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone or in Combination With Oral Antihyperglycemic Medications (ACHIEVE-J)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","401","Type 2 Diabetes","DRUG:Orforglipron","Eli Lilly and Company","2023-09-28","TRUE","1"],["S002129","ClinicalTrials.gov","NCT01416649",null,"Impact of Exenatide on Sleep Duration and Quality in Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","8","Type 2 Diabetes","DRUG:Exenatide","University of Chicago","2011-02-01","FALSE","0"],["S002130","ClinicalTrials.gov","NCT02049034",null,"The Effect of Lixisenatide on Postprandial Lipid and Glucose Metabolism in Patients with Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","8","Type 2 Diabetes","OTHER:Lixisenatide; OTHER:Placebo","University of Surrey","2014-01","FALSE","1"],["S002131","ClinicalTrials.gov","NCT07685834",null,"Pilot Observational Evaluation of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiating Tirzepatide for Weight Loss","INTERVENTIONAL","RANDOMIZED",null,"ACTIVE_NOT_RECRUITING","30","Lax Skin","DEVICE:SUPERB","Sofwave Medical LTD","2026-02-27","FALSE","0"],["S002132","ClinicalTrials.gov","NCT05646199",null,"The Effect of Semaglutide Compared to Metformin in Obese Women With Polycystic Ovary Syndrome (PCOS): a Randomised Controlled Study (Semaglutide-PCOS Trial).","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","UNKNOWN","60","Polycystic Ovary Syndrome","DRUG:Metformin; DRUG:Semaglutide Injectable Product","University of Hull","2025-03-01","FALSE","0"],["S002133","ClinicalTrials.gov","NCT01934816",null,"Effects of KATP Channel Blockers on GLP-1 and Its Analogues' Mediated Microvascular Function","INTERVENTIONAL","RANDOMIZED",null,"TERMINATED","2","Healthy Subjects","OTHER:Intradermal injections of GLP-1 and its analogues","Katarina Kos","2013-06","FALSE","0"],["S002134","ClinicalTrials.gov","NCT07794579","ATTAIN-NOW","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Individuals With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","2001","Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2026-08-26","FALSE","0"],["S002135","ClinicalTrials.gov","NCT06934642",null,"Effect of Tirzepatide on Markers of MASLD in Patients With Obesity: A Pilot Study","INTERVENTIONAL",null,"EARLY_PHASE1","RECRUITING","8","MASLD; Obesity","DRUG:Tirzepatide","University of New Mexico","2025-06-30","FALSE","0"],["S002136","ClinicalTrials.gov","NCT07463846",null,"A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","RECRUITING","156","Obesity","DRUG:ALN-2232; DRUG:Placebo; DRUG:Tirzepatide","Alnylam Pharmaceuticals","2026-03-02","FALSE","0"],["S002137","ClinicalTrials.gov","NCT06761703","COSMOS-DIGITAL","Community Outreach Support and Engagement Using Online Strategies - Decentralized Insights Into Therapy Adoption and Value","OBSERVATIONAL",null,null,"COMPLETED","200","Obesity","DEVICE:TAP® Micro Select Device (Touch Activated Phlebotomy)","Amgen","2024-11-14","FALSE","0"],["S002138","ClinicalTrials.gov","NCT07225686","MARITIME-OSA-1","A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","250","Obesity; Obstructive Sleep Apnea","DRUG:Maridebart cafraglutide; DRUG:Placebo","Amgen","2025-12-19","FALSE","0"],["S002139","ClinicalTrials.gov","NCT01971242","EXENATIDE-PD","A Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of Exenatide Once Weekly for the Treatment of Moderate Severity Parkinson's Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","60","Parkinson's Disease","DRUG:Exenatide; OTHER:Placebo","University College, London","2014-06","FALSE","2"],["S002140","ClinicalTrials.gov","NCT02635386",null,"Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","119","Polycystic Ovary Syndrome; Obesity","DRUG:Exenatide once weekly (EQW ); DRUG:Dapagliflozin (DAPA); DRUG:EQW plus DAPA; DRUG:Dapagliflozin plus Glucophage (MET ER); DRUG:Phentermine /Topiramate (PHEN/ TPM) ER","Woman's","2016-03-22","TRUE","1"],["S002141","ClinicalTrials.gov","NCT07373834","TIRMO","Effects of Tirzepatide on Skeletal Muscle in Obesity","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","30","Obesity (Disorder)","DRUG:Tirzepatide; DRUG:Placebo","University Medical Centre Ljubljana","2026-01","FALSE","0"],["S002142","ClinicalTrials.gov","NCT04972721","SELECT-LIFE","SELECT-LIFE (SELECT Follow-up Study to Evaluate Long-term Impact oF Anti-obEsity Medication)","OBSERVATIONAL",null,null,"COMPLETED","3439","Overweight; Obesity","OTHER:No treatment given","Novo Nordisk A/S","2023-09-01","FALSE","0"],["S002143","ClinicalTrials.gov","NCT07729332",null,"Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1-based Therapy Discontinuation","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","60","Obesity","DRUG:Phentermine Pill; DRUG:Orforglipron","Massachusetts General Hospital","2026-11-01","FALSE","0"],["S002144","ClinicalTrials.gov","NCT01507311",null,"Effect of NNC90-1170 on Pulsatile Insulin Secretion in Type 2 Diabetic Patients. A Double-blind, Placebo-controlled, Randomised, Single-dose, Cross-over Trial","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","11","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","1999-09","FALSE","1"],["S002145","ClinicalTrials.gov","NCT07602699",null,"A Multi-Site Trial of Tirzepatide for Smoking Cessation","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","300","Smoking Cessation; Smoking Behaviors","DRUG:Tirzepatide; OTHER:Placebo","University of Southern California","2026-06-05","FALSE","0"],["S002146","ClinicalTrials.gov","NCT02962492",null,"An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","70","Evaluate Ketogenic Stress","DRUG:Exenatide/Exenatide extended release; DRUG:Dapagliflozin; DRUG:Placebo","University at Buffalo","2016-11-01","TRUE","0"],["S002147","ClinicalTrials.gov","NCT03799198",null,"Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity - a Pragmatic Randomized Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","200","Obesity","OTHER:Weight Management Program (WMP); DRUG:Medication for chronic weight management (Rx)","Novo Nordisk A/S","2019-01-07","TRUE","1"],["S002148","ClinicalTrials.gov","NCT05203237",null,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist, in Healthy Adults and Otherwise Healthy Adults Who Have an Increased Body Mass Index","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","92","Weight Loss; NASH","BIOLOGICAL:VK2735; BIOLOGICAL:Placebo; DRUG:VK2735 Placebo; DRUG:VK2735 Drug","Viking Therapeutics, Inc.","2021-12-14","FALSE","0"],["S002149","ClinicalTrials.gov","NCT07777575","RESIST","A Phase IV, Randomized Controlled Trial to Evaluate the Effects of Resistance Training Versus Usual Care on Thigh Muscle Volume During Treatment With the Dual GIP/GLP-1 Receptor Agonist Tirzepatide in Adults With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","150","Obesity (BMI>30)","DRUG:Dual GIP/GLP-1 Receptor Agonist Tirzepatide; BEHAVIORAL:Resistance Training","Technical University of Munich","2026-09-07","FALSE","0"],["S002150","ClinicalTrials.gov","NCT04998136",null,"Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Asians With Obesity Diagnosed as BMI ≥ 25 kg/m2 According to Local Guidelines","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","150","Obesity","DRUG:Semaglutide 2.4 mg; DRUG:Placebo (semaglutide 2.4 mg)","Novo Nordisk A/S","2022-08-15","TRUE","1"],["S002151","ClinicalTrials.gov","NCT05938712","HALLMARK","A Two Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of the Combined Use of Once Daily 10mg Dapagliflozin and Once Weekly 1.0mg Semaglutide in Kidney Transplant Recipients","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","20","Kidney Transplant Recipients","DRUG:Dapagliflozin 10 MG; DRUG:Semaglutide, 1.0 mg/mL","University Health Network, Toronto","2023-10-24","FALSE","0"],["S002152","ClinicalTrials.gov","NCT01791465",null,"Pilot Study of Extended-release Exenatide to Improve Glucose Control and Reduce Systemic Inflammation in Diabetic, HIV-infected Adults on Antiretroviral Therapy","INTERVENTIONAL",null,"PHASE4","TERMINATED","6","Human Immunodeficiency Virus Infection; Diabetes Mellitus","DRUG:extended-release exenatide","Vanderbilt University","2013-03","TRUE","0"],["S002153","ClinicalTrials.gov","NCT01064687","AWARD-1","A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","978","Diabetes Mellitus, Type 2","DRUG:LY2189265; DRUG:Exenatide; DRUG:Placebo; DRUG:Metformin; DRUG:Pioglitazone","Eli Lilly and Company","2010-02","TRUE","3"],["S002154","ClinicalTrials.gov","NCT02802514",null,"An Exploratory Randomized, 2-Part, Single-blind, 2-Period Crossover Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","5","Diabetes Mellitus","DRUG:Albiglutide 50mg; DRUG:Albiglutide matching placebo; DRUG:Exenatide 10microgram; DRUG:Exenatide placebo (saline)","GlaxoSmithKline","2016-09-20","TRUE","0"],["S002155","ClinicalTrials.gov","NCT06726577",null,"A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial Evaluating the Safety, Efficacy, and Pharmacokinetic Characteristics of TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","RECRUITING","60","Amyotrophic Lateral Sclerosis","DRUG:TP04HN106; DRUG:Saline","Talengen Institute of Life Sciences, Shenzhen, P.R. China.","2026-06-04","FALSE","0"],["S002156","ClinicalTrials.gov","NCT01281228","Braini-Ex","The Effect of GLP-1 Receptor Activation on Central Reward and Satiety Circuits in Response to Food Stimuli in Obesity and Diabetes","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","48","Diabetes Mellitus; Diabetes Mellitus, Type 2; Obesity","DRUG:exenatide; DRUG:exenatide + exendin (9-39); DRUG:placebo","Amsterdam UMC, location VUmc","2011-09","FALSE","1"],["S002157","ClinicalTrials.gov","NCT04657016","SURMOUNT-3","Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","579","Obesity; Overweight","DRUG:Tirzepatide; OTHER:Placebo","Eli Lilly and Company","2021-03-29","TRUE","11"],["S002158","ClinicalTrials.gov","NCT01029873",null,"Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma","INTERVENTIONAL","NON_RANDOMIZED","PHASE1; PHASE2","TERMINATED","22","Metastatic Melanoma","DRUG:Cisplatin; BIOLOGICAL:ALT-801","Altor BioScience","2010-02","TRUE","0"],["S002159","ClinicalTrials.gov","NCT02477969",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating PEGylated Loxenatide Injection（PEX168）Combined With Metformin in the Treatment of Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","587","Type 2 Diabetes Mellitus","DRUG:PEX168(100µg); DRUG:PEX168(200µg); DRUG:Placebo; DRUG:Metformin","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2014-02-27","FALSE","0"],["S002160","ClinicalTrials.gov","NCT02198209",null,"Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation","INTERVENTIONAL",null,"PHASE4","WITHDRAWN","0","Type 2 Diabetes","DRUG:Liraglutide","Cedars-Sinai Medical Center","2019-12","FALSE","0"],["S002161","ClinicalTrials.gov","NCT01269047",null,"Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-prandial Hyperglycemia","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","37","Type 1 Diabetes","DRUG:Pramlintide; DRUG:Exenatide; DRUG:Insulin","Albert Einstein College of Medicine","2009-08","TRUE","0"],["S002162","ClinicalTrials.gov","NCT03823339","INTENSIFY","A Multicenter Prospective Non-interventional Study Investigating the Treatment Effect of Xultophy® Intensification in a Real World Population With Type 2 Diabetes in United Arab Emirates","OBSERVATIONAL",null,null,"COMPLETED","300","Diabetes Mellitus, Type 2","DRUG:Insulin degludec/liraglutide","Novo Nordisk A/S","2019-01-29","FALSE","0"],["S002163","ClinicalTrials.gov","NCT00546728",null,"The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","50","Impaired Glucose Tolerance","DRUG:Exenatide; DRUG:Metformin","St. Paul Heart Clinic","2007-10","TRUE","1"],["S002164","ClinicalTrials.gov","NCT02505334",null,"A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","635","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide","Novo Nordisk A/S","2015-07-21","TRUE","1"],["S002165","ClinicalTrials.gov","NCT02351232",null,"The Lira Pump Trial. The Effects of Liraglutide in Patients With Insulin Pump Treated Type 1 Diabetes: A Randomized Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","44","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Placebo","Hvidovre University Hospital","2015-02","FALSE","1"],["S002166","ClinicalTrials.gov","NCT00324363",null,"Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","466","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:Placebo","AstraZeneca","2006-01","FALSE","2"],["S002167","ClinicalTrials.gov","NCT00572689",null,"Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","WITHDRAWN","0","Gestational Diabetes","DRUG:Exenatide; GENETIC:Buccal/blood Sample Collection","Georgetown University","2013-08","FALSE","0"],["S002168","ClinicalTrials.gov","NCT01825148","GLP-1-CPOP","Clinical Proof-of-principle of the Determination of the Beta Cell Mass in Vivo by SPECT Imaging With the 111-In-labeled GLP-1 Analogue DTPA(Diethylenetriamine Pentaacetic Acid)-[K40]-Exendin 4","OBSERVATIONAL",null,null,"COMPLETED","20","Type 1 Diabetes","OTHER:radiolabeled Exendin","Radboud University Medical Center","2012-12","FALSE","1"],["S002169","ClinicalTrials.gov","NCT00516048",null,"An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes","INTERVENTIONAL","NON_RANDOMIZED","PHASE3","COMPLETED","58","Type 2 Diabetes Mellitus","DRUG:exenatide","AstraZeneca","2007-08","TRUE","0"],["S002170","ClinicalTrials.gov","NCT06825793",null,"Clinical Assessment of Semaglutide-Induced Weight Reduction in Obese Populations","INTERVENTIONAL","NON_RANDOMIZED",null,"NOT_YET_RECRUITING","56","Obesity","DRUG:Semaglutide Subcutaneous Injection","Beijing Chao Yang Hospital","2025-02-20","FALSE","0"],["S002171","ClinicalTrials.gov","NCT05517226",null,"A Phase I, Parallel-group, Multi-center, Open-label, Investigation of the Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Injection of Cotadutide in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Participants With Normal Hepatic Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","TERMINATED","24","Hepatic Impairment","COMBINATION_PRODUCT:Cotadutide","AstraZeneca","2022-09-06","FALSE","0"],["S002172","ClinicalTrials.gov","NCT03986008",null,"Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","60","Obesity","DRUG:Benaglutide; DRUG:Liraglutide","Xiangya Hospital of Central South University","2019-12-01","FALSE","0"],["S002173","ClinicalTrials.gov","NCT06934655",null,"Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth: A Randomized Clinical Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","150","Pediatric Obesity; Metabolic and Bariatric Surgery; Semaglutide","DRUG:Semaglutide 2.4 mg","Children's Hospital Los Angeles","2026-09-01","FALSE","0"],["S002174","ClinicalTrials.gov","NCT04146155",null,"Liraglutide Efficacy and Action on Type 2 Diabetes With Peripheral Atherosclerotic intErmittent Claudication (LEADPACE STUDY): a Prospective, 24-week, Multicenter, Randomized, Controlled Clinical Study","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","200","Type 2 Diabetes; Peripheral Vascular Disorder Due to Diabetes Mellitus","DRUG:Liraglutide+standard-of-care treatment; OTHER:standard-of-care treatment","Second Affiliated Hospital, Zhejiang University, School of Medicine","2020-05-01","FALSE","3"],["S002175","ClinicalTrials.gov","NCT07767552",null,"Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","249","Diabetes Mellitus, Type 2","DRUG:Mazdutide; DRUG:Placebo","Yanbing Li","2026-09-30","FALSE","0"],["S002176","ClinicalTrials.gov","NCT04733508","GLP1R-T2D","Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes - the Role of Glucose Homeostasis on Uptake of Beta-cell Tracer Exendin-4","INTERVENTIONAL","NON_RANDOMIZED",null,"UNKNOWN","28","Diabetes Mellitus; Diabetes Mellitus, Type 2","DRUG:111In-DTPA-exendin-4; DRUG:IRDye800CW-exendin-4","Radboud University Medical Center","2019-11-01","FALSE","1"],["S002177","ClinicalTrials.gov","NCT06282458","QUALITY","A Phase 2 Dose-Finding and Proof-of-Concept Study to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight Management","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","168","Muscle Loss; Obesity","DRUG:Enobosarm; DRUG:Semaglutide","Veru Inc.","2024-04-29","FALSE","1"],["S002178","ClinicalTrials.gov","NCT05236517",null,"The Effect of Oral Semaglutide 50 mg Once-daily on Energy Intake, Gastric Emptying, Appetite, Control of Eating and Pharmacokinetics in Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","60","Obesity","DRUG:Semaglutide D Dose 1; DRUG:Semaglutide D Dose 2; DRUG:Semaglutide D Dose 3; DRUG:Semaglutide C Dose 4; DRUG:Semaglutide C Dose 5 (50 mg); DRUG:Placebo (Semaglutide C); DRUG:Placebo ( Semaglutide D)","Novo Nordisk A/S","2022-02-08","FALSE","1"],["S002179","ClinicalTrials.gov","NCT03914326","SOUL","Semaglutide Cardiovascular Outcomes Trial in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","9651","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Placebo (semaglutide)","Novo Nordisk A/S","2019-06-17","TRUE","15"],["S002180","ClinicalTrials.gov","NCT02767596",null,"A Pilot Single-Arm Open-Label Study to Evaluate the Efficacy of Treatment With Lixisenatide in Diabetes Mellitus Type 2 Patients With Failure of Other GLP-1 Analog","INTERVENTIONAL",null,"PHASE4","TERMINATED","2","Diabetes Mellitus Type 2","DRUG:Lixisenatide; DRUG:Basal insulins","Laniado Hospital","2016-07-12","FALSE","0"],["S002181","ClinicalTrials.gov","NCT07487103",null,"A Multicenter, Randomized, Open-label, Parallel-group, Active-controlled Clinical Trial to Evaluate Efficacy and Safety of QLG1091 Versus Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","478","Type 2 Diabetes","DRUG:QLG1091; DRUG:Rybelsus","Qilu Pharmaceutical Co., Ltd.","2026-05-01","FALSE","0"],["S002182","ClinicalTrials.gov","NCT05716724","O-SEMA-Fast","A Prospective, Non-interventional Study, Investigating Glycaemic Control and Treatment Patterns Associated With the Use of Once-daily Oral Semaglutide in Type 2 Diabetes Patients Who Intend to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait","OBSERVATIONAL",null,null,"COMPLETED","288","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2023-01-25","FALSE","1"],["S002183","ClinicalTrials.gov","NCT05959096",null,"Effect of Injection Site on the Relative Bioavailability of a Single Dose of LY3437943 in Healthy Participants With a High Body Mass Index","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","85","Healthy","DRUG:LY3437943","Eli Lilly and Company","2023-07-18","FALSE","0"],["S002184","ClinicalTrials.gov","NCT02161588",null,"A Multiple Dose, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","48","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2014-06","FALSE","0"],["S002185","ClinicalTrials.gov","NCT07228741",null,"Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity","INTERVENTIONAL",null,"PHASE2","RECRUITING","20","Acute Lymphoblastic Leukemia; Obesity","DRUG:Tirzepatide; BEHAVIORAL:Resistance Exercise; BEHAVIORAL:Lifestyle Counseling","St. Jude Children's Research Hospital","2026-04-23","FALSE","0"],["S002186","ClinicalTrials.gov","NCT02344641",null,"Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","234","Type 2 Diabetes Mellitus; Heart Failure","DRUG:Exenatide","Chinese Academy of Medical Sciences, Fuwai Hospital","2015-01","FALSE","0"],["S002187","ClinicalTrials.gov","NCT07478653",null,"MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease: Effects Of Semaglutide Treatment","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","50","Obesity; Dental Care for Children","PROCEDURE:Dental Cleaning and Oral Hygiene Instruction (OHI); BEHAVIORAL:Oral Hygiene Instruction (OHI)","Oelisoa Andriankaja","2026-08-31","FALSE","0"],["S002188","ClinicalTrials.gov","NCT00712673","GETGOAL-M","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","680","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector; DRUG:Metformin","Sanofi","2008-06","TRUE","4"],["S002189","ClinicalTrials.gov","NCT06579105","SOLSTICE","A Phase IIb, Randomized, Double-blind, Placebo-controlled and Open-label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults With Type 2 Diabetes Mellitus.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","406","Diabetes Mellitus, Type 2","DRUG:Placebo (placebo matching AZD5004 film-coated tablet); DRUG:AZD5004; DRUG:Semaglutide","AstraZeneca","2024-10-08","FALSE","1"],["S002190","ClinicalTrials.gov","NCT06716307",null,"Comparing the Pharmacokinetics of Cagrilintide and Semaglutide Following Single Subcutaneous Doses of Different CagriSema Presentations, in a Crossover Manner in Adult Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","18","Obesity","DRUG:CagriSema (cagrilintide B and semaglutide I); DRUG:CagriSema A","Novo Nordisk A/S","2024-12-02","FALSE","0"],["S002191","ClinicalTrials.gov","NCT07668336","ACHIEVE-PEDS","A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","170","Diabetes Mellitus, Type 2","DRUG:Orforglipron; DRUG:Dulaglutide","Eli Lilly and Company","2026-09","FALSE","0"],["S002192","ClinicalTrials.gov","NCT06497049",null,"An Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221, Solution for Subcutaneous Administration 1.34 mg/ml (GEROPHARM) and Ozempic®, Solution for Subcutaneous Administration 1.34 mg/ml in Healthy Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","120","Pharmacokinetics; Safety Issues; Bioequivalence","DRUG:GP40221; DRUG:ozempic","Geropharm","2023-06-30","FALSE","0"],["S002193","ClinicalTrials.gov","NCT07136714","SEMAMOOD","Is the GLP-1 Receptor Agonist Semaglutide Able to Alleviate Mood in Patients With Major Depressive Disorder and Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","116","Major Depressive Disorder","DRUG:Semaglutide Injectable Product; DRUG:Placebo","Nordsjaellands Hospital","2025-09-11","FALSE","0"],["S002194","ClinicalTrials.gov","NCT07065552",null,"A Pre-Operative Window Study of Tirzepatide in Obesity-Driven Endometrial Cancer","INTERVENTIONAL",null,"EARLY_PHASE1","RECRUITING","20","Endometrial Cancer; Obesity","DRUG:Tirzepatide","UNC Lineberger Comprehensive Cancer Center","2026-04-27","FALSE","0"],["S002195","ClinicalTrials.gov","NCT00835848","POSTCON II","Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI in Patients With STEMI","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","100","Myocardial Infarction","DRUG:Exenatide; DRUG:Saline","Copenhagen University Hospital, Rigshospitalet","2009-01","FALSE","3"],["S002196","ClinicalTrials.gov","NCT01740921","GLP-1ADDS","Does Glucagon-like Polypeptide 1 Improve Vascular Function and Inflammation?","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","39","Type 2 Diabetes","DRUG:Liraglutide; OTHER:diet; DRUG:Aspirin","Royal Devon and Exeter NHS Foundation Trust","2011-01","FALSE","1"],["S002197","ClinicalTrials.gov","NCT02879409",null,"Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?","INTERVENTIONAL","RANDOMIZED",null,"ACTIVE_NOT_RECRUITING","150","Diabetes Mellitus Type 2","DRUG:Metformin; DRUG:Gliclazide; DRUG:Sitagliptin; DRUG:Liraglutide; DRUG:Pioglitazone; DRUG:Dapagliflozin; DRUG:human insulin","Weill Cornell Medical College in Qatar","2016-11","FALSE","0"],["S002198","ClinicalTrials.gov","NCT02461914",null,"An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","16","Healthy","DRUG:PEX168; DRUG:Warfarin","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2015-08-01","FALSE","0"],["S002199","ClinicalTrials.gov","NCT07299084",null,"A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","40","Diabetes Mellitus, Type 2; Overweight; Obesity","DRUG:Tirzepatide","Eli Lilly and Company","2026-01-14","FALSE","0"],["S002200","ClinicalTrials.gov","NCT06184633","DUTCH-WAIST","DUTCH Weight Control in Atrial Fibrillation Study, a Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","280","Atrial Fibrillation; Obesity; Weight Loss","DRUG:Semaglutide 3.2 MG/ML; DRUG:Placebo","Rijnstate Hospital","2024-07-21","FALSE","0"],["S002201","ClinicalTrials.gov","NCT01580514","EMPIRE","Cardioprotective Effects of Exenatide in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention ; Results of Exenatide Myocardial Protection In REvascularization (EMPIRE) Study","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","127","Myocardial Infarction","DRUG:exenatide BYETTA® (Amylin-Lilly); DRUG:Saline","Kyunghee University Medical Center","2009-09","FALSE","3"],["S002202","ClinicalTrials.gov","NCT02987348",null,"Evaluation of the Clinical and Economic Outcomes Associated With Exenatide Versus Basal Insulin in People With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","18000","Type 2 Diabetes","DRUG:exenatide once weekly; DRUG:exenatide twice daily; DRUG:basal insulin","AstraZeneca","2015-06-30","FALSE","1"],["S002203","ClinicalTrials.gov","NCT06820047",null,"Impact of Sleeve Gastrectomy Versus Intensive Lifestyle Modifications With Obesity Management Medications on BMI Trajectory and Target Attainment: a Prospective Matched Cohort Study","OBSERVATIONAL",null,null,"COMPLETED","190","Obesity and Obesity-related Medical Conditions","PROCEDURE:Laparoscopic sleeve gastrectomy; OTHER:Obesity pharmacotherapy","University of Roma La Sapienza","2022-05-01","FALSE","0"],["S002204","ClinicalTrials.gov","NCT00359879",null,"Safety and Efficacy of Exenatide Taken Before Lunch and Before Dinner Compared With Before Breakfast and Before Dinner in Patients With Type 2 Diabetes Using Oral Antidiabetic Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","377","Type 2 Diabetes","DRUG:exenatide","AstraZeneca","2006-09","FALSE","1"],["S002205","ClinicalTrials.gov","NCT02299388",null,"To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","11","Diabetes Mellitus, Non-Insulin-Dependent; Hypertensive Disease","DRUG:Liraglutide or Placebo","Tulane University School of Medicine","2014-10","TRUE","0"],["S002206","ClinicalTrials.gov","NCT06819488",null,"A Clinical Study of Mass Balance of [14C]HRS-7535 in Healthy Adult Chinese Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","6","Type 2 Diabetes Mellitus; Weight Loss","DRUG:[14C]HRS-7535","Shandong Suncadia Medicine Co., Ltd.","2025-02-27","FALSE","0"],["S002207","ClinicalTrials.gov","NCT06331286",null,"The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","60","Bipolar Disorder; Obesity; Cognition","DRUG:dulaglutide injection","First Affiliated Hospital of Zhejiang University","2023-09-01","FALSE","0"],["S002208","ClinicalTrials.gov","NCT07207148",null,"People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists","OBSERVATIONAL",null,null,"RECRUITING","100","Multiple Sclerosis","DRUG:GLP-1; DRUG:Ocrelizumab (US)","Northwestern University","2025-11-15","FALSE","7"],["S002209","ClinicalTrials.gov","NCT00747968",null,"The Effect of the GLP-1 Analogue Exenatide on Glucose Metabolism in the CNS and Heart During Hyperglycemia in Type-2 Diabetic Patients Assessed by PET","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","8","Type 2 Diabetes","DRUG:Byetta, Exenatide","University of Aarhus","2010-02","FALSE","1"],["S002210","ClinicalTrials.gov","NCT05804162",null,"A Thorough QTc Study Evaluating the Effect of Cagrilintide on Cardiac Repolarisation in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","107","Obesity","DRUG:Cagrilintide; DRUG:Cagrilintide Placebo; DRUG:Moxifloxacin; DRUG:Moxifloxacin Placebo","Novo Nordisk A/S","2023-04-12","FALSE","1"],["S002211","ClinicalTrials.gov","NCT04839393",null,"A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-06882961 AND PF-06865571 IN HEALTHY ADULT PARTICIPANTS (PART A) AND OVERWEIGHT ADULTS OR ADULTS WITH OBESITY WHO ARE OTHERWISE HEALTHY (PART B)","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","27","Healthy Volunteer","DRUG:PF-06882961 followed by PF-06882961/PF-06865571; DRUG:PF-06882961/PF-06865571 followed by PF-06882961; DRUG:PF-06882961 + PF-06865571","Pfizer","2021-04-05","TRUE","0"],["S002212","ClinicalTrials.gov","NCT04255433","SURPASS-CVOT","The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","13299","Type 2 Diabetes Mellitus","DRUG:Tirzepatide; DRUG:Dulaglutide","Eli Lilly and Company","2020-05-29","TRUE","13"],["S002213","ClinicalTrials.gov","NCT07152756",null,"Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores: A Single-Center, Prospective, Observational Study","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","418","Gastric Retention","PROCEDURE:Esophagogastroduodenoscopy","Fudan University","2025-09-15","FALSE","0"],["S002214","ClinicalTrials.gov","NCT06446531","Pre-DM","Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in Hispanics","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","64","Pre-Diabetes; Weight, Body; Cardiovascular Diseases","DRUG:Placebo; DRUG:Rybelsus Tablet; DRUG:Jardiance 25Mg Tablet; DRUG:Metformin; DRUG:Actos","The University of Texas Health Science Center at San Antonio","2024-09-11","FALSE","0"],["S002215","ClinicalTrials.gov","NCT06807970","NPO-OOPS-TKR","Novel Perioperative Optimization of Obese Osteoarthritic Patients Pending Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist (NPO-OOPS-TKR)","INTERVENTIONAL","RANDOMIZED","EARLY_PHASE1","ACTIVE_NOT_RECRUITING","54","Osteoarthritis (OA) of the Knee","DRUG:Glucagon-like peptide-1 receptor agonists (GLP 1 RA); OTHER:Control (Standard treatment)","The University of Hong Kong","2025-09-01","FALSE","0"],["S002216","ClinicalTrials.gov","NCT01077505",null,"An Open-label Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK716155 in Healthy Adult Female Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","16","Diabetes Mellitus, Type 2","BIOLOGICAL:albiglutide; DRUG:Oral contraceptive (Brevicon)","GlaxoSmithKline","2010-03-15","FALSE","2"],["S002217","ClinicalTrials.gov","NCT07392151",null,"REVERsal to Normoglycemia by Treating PREDIABETES: The REVERT-PREDIABETES Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","158","Prediabetes; Chronic Coronary Syndrome","DRUG:Intensified medical follow-up and glucose-lowering drugs; OTHER:No intervention","Michael Mæng","2026-02","FALSE","0"],["S002218","ClinicalTrials.gov","NCT02745470",null,"Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain Measured by Functional MRI","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","30","Diabetes Mellitus","DRUG:Lixisenatide; OTHER:Placebo","Seoul National University Hospital","2016-02","FALSE","0"],["S002219","ClinicalTrials.gov","NCT07770841","OASIS 5","Efficacy and Safety of Once Daily Oral Semaglutide in Adults With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","450","Overweight; Obesity","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2026-08-12","FALSE","0"],["S002220","ClinicalTrials.gov","NCT00254254",null,"A Randomized, Single-Blind, Dose-Rising, Placebo-Controlled, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","13","Type 2 Diabetes Mellitus","DRUG:Exenatide - Exenatide - Placebo; DRUG:Exenatide - Placebo - Exenatide; DRUG:Placebo - Exenatide - Exenatide","AstraZeneca","2006-02","FALSE","1"],["S002221","ClinicalTrials.gov","NCT07866066","MARITIME-T2D-3","A Phase 3, Randomized, Open-Label Trial Comparing the Efficacy and Safety of Maridebart Cafraglutide Once Monthly Versus Semaglutide Once Weekly as Add-on Therapy to Metformin With or Without a Sodium-glucose Cotransporter-2 Inhibitor in Participants With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","1300","Diabetes Mellitus, Type 2","DRUG:Maridebart cafraglutide; DRUG:Semaglutide","Amgen","2026-11-02","FALSE","0"],["S002222","ClinicalTrials.gov","NCT00333151","LEAD-4","Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","576","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:rosiglitazone; DRUG:metformin","Novo Nordisk A/S","2006-05","FALSE","15"],["S002223","ClinicalTrials.gov","NCT03419624",null,"A 28-week, Multi-center Randomized, Double-blind, Placebo-controlled Study to Evaluate the Potential of Dapagliflozin Plus Exenatide in Combination With High-dose Intensive Insulin Therapy Compared to Placebo in Obese Insulin-resistant Patients With Type 2 Diabetes Mellitus (Proof-of-concept Study)","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","13","Obesity; Diabetes Mellitus, Type 2","DRUG:Dapagliflozin 10mg; DRUG:Exenatide 2 mg [Bydureon]; DRUG:Placebo Oral Tablet; DRUG:Placebo injection; DRUG:Insulin; DRUG:Metformin, if taken before","Universitätsklinikum Hamburg-Eppendorf","2018-02-19","FALSE","5"],["S002224","ClinicalTrials.gov","NCT01776788",null,"Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy on β-cell Function and Glycemic Remission Rate in Newly Diagnosed Type 2 Diabetic Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","156","Diabetes Mellitus, Type 2","DRUG:insulin lispro injection, exenatide injection; DRUG:insulin lispro injection","The First Affiliated Hospital of Xiamen University","2012-08","FALSE","0"],["S002225","ClinicalTrials.gov","NCT01455441",null,"Does the GLP-1 Receptor Agonist (Victoza®) Improve the Metabolic Response to Physical Training in Patients With Type 2 Diabetes?","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","40","Type 2 Diabetes","OTHER:Training and liraglutide; OTHER:Training and placebo","Tina Vilsboll","2011-10","FALSE","0"],["S002226","ClinicalTrials.gov","NCT07191873","TIIHT","A Phase IV Placebo-controlled Single Center Trial for Tirzepatide in Idiopathic Intracranial Hypertension Trial (TIIHT)","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","60","Idiopathic Intracranial Hypertension (IIH)","DRUG:Tirzepatide; DRUG:Tirzepatide Placebo","Duke University","2026-08-25","FALSE","0"],["S002227","ClinicalTrials.gov","NCT01394341",null,"Safety and Effect of Liraglutide in Patients With Type 2 Diabetes and Severe Renal Insufficiency","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","40","Type 2 Diabetes Mellitus; End-stage Renal Disease","DRUG:Liraglutide","Bo Feldt-Rasmussen","2011-09","FALSE","3"],["S002228","ClinicalTrials.gov","NCT03309241",null,"A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06882961 In Healthy Adult Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","25","Healthy Subjects","DRUG:PF-06882961; OTHER:Placebo","Pfizer","2017-10-17","FALSE","3"],["S002229","ClinicalTrials.gov","NCT07846956",null,"Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in Non-Diabetic Obese Patients Using Glucagon-Like Peptide-1 Receptor Agonists: A Retrospective Real-World Study","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","28","Non-arteritic Anterior Ischemic Optic Neuropathy Obesity; Obesity","DRUG:GLP-1 Receptor Agonist Therapy","Istanbul Saglik Bilimleri University","2026-09-21","FALSE","5"],["S002230","ClinicalTrials.gov","NCT00518882","LEAD-6","Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","467","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:exenatide","Novo Nordisk A/S","2007-08","TRUE","16"],["S002231","ClinicalTrials.gov","NCT01425580",null,"Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","62","Congestive Heart Failure; Type 2 Diabetes Mellitus","DRUG:liraglutide; DRUG:glimepiride; DRUG:Metformin","Thomas Nystrom","2012-01","FALSE","3"],["S002232","ClinicalTrials.gov","NCT06804603",null,"A Proof of Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight Class I or Class II Obese Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","124","Obesity","DRUG:Tradipitant; DRUG:Placebo","Vanda Pharmaceuticals","2025-02-25","FALSE","0"],["S002233","ClinicalTrials.gov","NCT07728383",null,"A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Topical-Lingual Semaglutide (T-L Semaglutide) in Adults With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","40","Obesity & Overweight","DRUG:Semaglutide 6 mg liquid emulsion formulation; DRUG:Wegovy® (semaglutide) Tablet; DRUG:Placebo liquid emulsion formulation","Gila Therapeutics, Inc.","2026-06-17","FALSE","0"],["S002234","ClinicalTrials.gov","NCT07065383","Re-CHARM","Intramyocellular Lipid Compartments After Glucagon-like Peptide 1 Receptor Agonist Therapy in Type 2 Diabetes - Rebalancing the Fat Content of the Heart and Muscles","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","60","Diabetes Mellitus Type 2","DRUG:Semaglutide administration plus dietary counselling and physical activity encouragement; DRUG:Semaglutide plus a personalised and supervised program of resistance and endurance training","University of Aberdeen","2025-08-01","FALSE","5"],["S002235","ClinicalTrials.gov","NCT06085482",null,"A Single-Group, Open-Label, Single-Period, Phase 1 Study to Determine the Absolute Bioavailability of LY3502970 in Healthy Participants","INTERVENTIONAL",null,"PHASE1","COMPLETED","10","Healthy","DRUG:LY3502970; DRUG:[14C]-LY3502970","Eli Lilly and Company","2023-10-19","TRUE","0"],["S002236","ClinicalTrials.gov","NCT07430059","SLIM-1","A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Semaglutide Implant","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","20","Obesity & Overweight","COMBINATION_PRODUCT:Semaglutide Implant (NPM-139); DRUG:Semaglutide (Wegovy) weekly injection","Vivani Medical, Inc","2026-07","FALSE","0"],["S002237","ClinicalTrials.gov","NCT03529123",null,"A Randomized, 24-week, Controlled, Open Label, Parallel Arm, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Type 2 Diabetes Patients, Inadequately Controlled on Basal Insulin With or Without Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","247","Type 2 Diabetes Mellitus","DRUG:INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010); DRUG:INSULIN GLARGINE (HOE901); DRUG:Metformin; DRUG:Insulin Glulisine (HMR1964)","Sanofi","2018-06-19","FALSE","0"],["S002238","ClinicalTrials.gov","NCT04604496",null,"A Phase 1, Non-randomized, Open-label, Single-dose, Parallel Cohort Study to Compare the Pharmacokinetics of PF-06882961 in Adult Participants With Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment.","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","24","Hepatic Impairment; Healthy Volunteers","DRUG:PF-06882961 20MG","Pfizer","2020-12-30","TRUE","0"],["S002239","ClinicalTrials.gov","NCT07528027",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS-7535 for the Treatment of Hypertension in Participants With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","648","Hypertension With Overweight or Obesity","DRUG:HRS-7535; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2026-05-29","FALSE","0"],["S002240","ClinicalTrials.gov","NCT02016846",null,"Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","36","Glucocorticoid Induced Hyperglycemia","DRUG:Liraglutide; DRUG:Placebo","Rabin Medical Center","2014-01","FALSE","0"],["S002241","ClinicalTrials.gov","NCT06737042",null,"EFFICACY AND SAFETY OF GZR18 INJECTED EVERY 2 WEEKS (Q2W) IN PARTICIPANTS WITHOUT TYPE 2 DIABETES, WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, TIRZEPATIDE- AND PLACEBO-CONTROLLED STUDY","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","326","Obesity and Overweight","DRUG:GZR18; DRUG:Tirzepatide","Gan and Lee Pharmaceuticals, USA","2025-02-24","FALSE","0"],["S002242","ClinicalTrials.gov","NCT03632759",null,"Targeting Beta Cell Dysfunction in Longstanding T1D","INTERVENTIONAL","NON_RANDOMIZED","EARLY_PHASE1","COMPLETED","16","Type 1 Diabetes Mellitus","DRUG:Liraglutide; DRUG:Golimumab","Carla Greenbaum, MD","2018-08-15","FALSE","1"],["S002243","ClinicalTrials.gov","NCT05371496",null,"Evaluation of the Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction (CAMEO-SEMA)","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","81","Cardiomyopathy; Heart Failure With Preserved Ejection Fraction (HFpEF); Obesity","DRUG:Semaglutide; DRUG:Placebo; BEHAVIORAL:Counselling on healthy lifestyle intervention","Mayo Clinic","2022-09-06","FALSE","0"],["S002244","ClinicalTrials.gov","NCT07732426",null,"A Prospective Clinical Study to Investigate Dopamine Level Changes in the Brain at Food Cognition by GLP-1 Receptor Agonists","INTERVENTIONAL","NON_RANDOMIZED",null,"RECRUITING","30","Food Addiction Tendency; Obesity; Overweight","DRUG:Semaglutide","Seoul National University Hospital","2026-07-15","FALSE","0"],["S002245","ClinicalTrials.gov","NCT02157974","APPLE","Assessment of Hepatic Glucose and Fat Regulation in Overweight Adolescent Girls","INTERVENTIONAL","NON_RANDOMIZED","PHASE2; PHASE3","COMPLETED","92","Hepatic Steatosis; Polycystic Ovarian Syndrome; Obesity","DRUG:Byetta 5Mcg Pen Injection","University of Colorado, Denver","2014-08","TRUE","0"],["S002246","ClinicalTrials.gov","NCT07154238","OUTSTEP-1","Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","2546","Obesity","OTHER:No treatment given","Novo Nordisk A/S","2025-09-26","FALSE","0"],["S002247","ClinicalTrials.gov","NCT03011008",null,"Effect of Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","20","Type 1 Diabetes Mellitus; Autoimmune Diabetes","DRUG:Liraglutide; DRUG:Insulin","Second Xiangya Hospital of Central South University","2017-01","FALSE","1"],["S002248","ClinicalTrials.gov","NCT00456885",null,"The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","41","Obesity; Impaired Glucose Tolerance","DRUG:exenatide; DRUG:Placebo","Beth Israel Deaconess Medical Center","2007-04","TRUE","1"],["S002249","ClinicalTrials.gov","NCT05965908",null,"Effect of Liraglutide on Different Parameters (Clinical , Metabolic and Hormonal) in Obese Women With Polycystic Ovary Syndrome","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","183","Polycystic Ovary","DRUG:liraglutide; DRUG:Metformin","Beni-Suef University","2024-08-01","FALSE","0"],["S002250","ClinicalTrials.gov","NCT03048578",null,"Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","132","Obesity","DRUG:Saxenda; DRUG:Placebo","NYU Langone Health","2017-05-22","TRUE","0"],["S002251","ClinicalTrials.gov","NCT00103935",null,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine Safety and Pharmacokinetics of Exenatide Long-Acting Release Administered Weekly in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","45","Type 2 Diabetes Mellitus","DRUG:placebo; DRUG:Exenatide LAR","AstraZeneca","2005-02","FALSE","1"],["S002252","ClinicalTrials.gov","NCT01966978","SIMPLE","The Effect of Simple Insulin Detemir Titration, Metformin Plus Liraglutide Compared to Simple Insulin Detemir Titration Plus Insulin Aspart and Metformin for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study: A 26 Week, Randomized, Open Label, Parallel-group, Intention to Treat Study","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","157","Diabetes Mellitus, Type 2; Diabetes","DRUG:Metformin; DRUG:Detemir; DRUG:Liraglutide; DRUG:Insulin Aspart","University of Texas Southwestern Medical Center","2014-11","TRUE","1"],["S002253","ClinicalTrials.gov","NCT07790861","ATTAIN-CN","A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbidities","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","192","Obesity; Overweight","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2026-12","FALSE","0"],["S002254","ClinicalTrials.gov","NCT05202353",null,"Open-label, Randomised, 4 Parallel-group, Phase I Clinical Trial to Investigate BI 456906 Occupancy of Glucagon Receptors in Liver and Glucagon-like Peptide 1 Receptors in Pancreas in Comparison With Semaglutide After Administration of Radiolabeled Tracer in Male and Female Subjects With Obesity Using PET and MRI","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","29","Obesity","DRUG:BI 456906; DRUG:Semaglutide","Boehringer Ingelheim","2024-11-01","FALSE","0"],["S002255","ClinicalTrials.gov","NCT01628445","SAIL","Phase 3 Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin","INTERVENTIONAL","RANDOMIZED","PHASE3","TERMINATED","52","Type 2 Diabetes","DRUG:liraglutide; DRUG:placebo injection","University of Manitoba","2012-08","FALSE","0"],["S002256","ClinicalTrials.gov","NCT03311724",null,"A Phase 2, Double-Blind, Placebo-Controlled, 3-Month Trial of LY3298176 Versus Placebo in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","111","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2017-10-19","TRUE","0"],["S002257","ClinicalTrials.gov","NCT05473286","PIONEER REAL","A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Germany","OBSERVATIONAL",null,null,"WITHDRAWN","0","Diabetes Mellitus, Type 2","DRUG:Oral Semaglutide","Novo Nordisk A/S","2022-09-30","FALSE","0"],["S002258","ClinicalTrials.gov","NCT06937086","COMMIT-UC","A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","350","Ulcerative Colitis; Obesity or Overweight","DRUG:Mirikizumab; DRUG:Tirzepatide; DRUG:Placebo","Eli Lilly and Company","2025-06-26","FALSE","0"],["S002259","ClinicalTrials.gov","NCT01940770",null,"Specific Clinical Experience Investigation for Long-term Use of Bydureon Subcutaneous Injection 2 mg and Bydureon Subcutaneous Injection 2 mg PEN","OBSERVATIONAL",null,null,"COMPLETED","1137","Type 2 Diabetes",null,"AstraZeneca","2013-10-18","FALSE","0"],["S002260","ClinicalTrials.gov","NCT02981069",null,"Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in Type 2 Diabetes Mellitus (T2DM)","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","90","Diabetes Mellitus, Type 2","DRUG:Dapagliflozin; DRUG:Exenatide; DRUG:Placebo","The University of Texas Health Science Center at San Antonio","2017-12-15","TRUE","0"],["S002261","ClinicalTrials.gov","NCT02617654",null,"A Randomized, Double-blinded Placebo-controlled, Paralleled Designed, Investigator Sponsored Study of the Effect of the GLP-1 Receptor Agonist Liraglutide on Beta-cell Function in C-peptide Positive Type 1 Diabetic Patients","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","18","Type 1 Diabetes","DRUG:Liraglutide; DRUG:Placebo for liraglutide","Per-Ola Carlsson","2015-11","FALSE","0"],["S002262","ClinicalTrials.gov","NCT03158805",null,"A Randomized, Placebo-Controlled Study of Liraglutide 3mg Daily (Saxenda®) in Obese or Overweight Patients With Stable Bipolar Disorder","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","60","Bipolar Disorder; Obesity","DRUG:LIRAGLUTIDE; OTHER:Placebo","Lindner Center of HOPE","2017-04-26","TRUE","1"],["S002263","ClinicalTrials.gov","NCT01910194",null,"A Bicentric Open-label, Randomized, Two-parallel-group Study Investigating the Impact of Combined Lantus Insulin Glargine) and Lyxumia(Lixisenatide) on Insulin Secretion and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled on Diet and Oral Antidiabetic Medication","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","39","Diabetes Mellitus","DRUG:Luyxumia versus Lantus","Profil Institut für Stoffwechselforschung GmbH","2013-12","FALSE","0"],["S002264","ClinicalTrials.gov","NCT01455870",null,"A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","535","Type 2 Diabetes","DRUG:ITCA 650 60 mcg/day; DRUG:sitagliptin","Intarcia Therapeutics","2013-05","FALSE","0"],["S002265","ClinicalTrials.gov","NCT05048719",null,"A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","383","Type 2 Diabetes","DRUG:LY3502970; DRUG:Dulaglutide; DRUG:Placebo","Eli Lilly and Company","2021-09-15","TRUE","3"],["S002266","ClinicalTrials.gov","NCT03804411",null,"Search for Highly Specific Predictors of Response to Different Hypoglycemic Therapy for Cardiovascular Prognosis","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","800","Diabetes Mellitus, Type 2","DRUG:Automatic system guided treatment; DRUG:Standard treatment","Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","2017-08-01","FALSE","0"],["S002267","ClinicalTrials.gov","NCT02607865","PIONEER 3","Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1864","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:sitagliptin; DRUG:placebo","Novo Nordisk A/S","2016-02-15","TRUE","13"],["S002268","ClinicalTrials.gov","NCT05087342","LSS","A Randomized Latino Semaglutide 2.4mg Study","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","119","Obesity; Obesity; Drug; Overweight or Obesity; Weight Loss; Weight Loss Trajectory; Weight, Body","DRUG:Semaglutide 2.4mg; DRUG:Placebo","Loma Linda University","2022-12-13","FALSE","0"],["S002269","ClinicalTrials.gov","NCT01460069",null,"The Effect of GLP-1 in Psoriasis","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","20","Psoriasis","DRUG:liraglutide; DRUG:Placebo","Annesofie Faurschou","2011-10","FALSE","0"],["S002270","ClinicalTrials.gov","NCT06023095",null,"A Multiple Dose Titration Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Chinese Participants Who Have Obesity or Are Overweight With Weight-related Comorbidities","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Overweight; Obesity","DRUG:LY3502970; DRUG:Placebo","Eli Lilly and Company","2023-09-21","TRUE","1"],["S002271","ClinicalTrials.gov","NCT06131437",null,"Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","809","Obesity","DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Tirzepatide","Novo Nordisk A/S","2023-11-27","FALSE","0"],["S002272","ClinicalTrials.gov","NCT04945070","IDEAL","INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","96","Type 2 Diabetes Treated With Insulin","DRUG:IGlarLixi; DRUG:MDI - Multiple dose insulin injection","Institute for Clinical and Experimental Medicine","2021-07","FALSE","1"],["S002273","ClinicalTrials.gov","NCT07220629","RESOLVE-2","A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide Plus a Reduced Calorie Diet and Increased Physical Activity in Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","82","Obesity","DRUG:NT-0796; DRUG:Placebo","Rezera (formerly NodThera Limited)","2025-10-02","FALSE","0"],["S002274","ClinicalTrials.gov","NCT05812183",null,"The Effect of Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Patients with Obesity: a Feasibility Study","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","WITHDRAWN","0","Dyspnea; Quality of Life","DEVICE:Bariatric surgery; DRUG:Medical weight loss","University of California, Los Angeles","2023-07-09","FALSE","0"],["S002275","ClinicalTrials.gov","NCT06250946",null,"A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","235","Overweight and Obesity","DRUG:HRS-7535;Placebo; DRUG:Placebo","Shandong Suncadia Medicine Co., Ltd.","2024-02-23","FALSE","1"],["S002276","ClinicalTrials.gov","NCT06324461","GLUMINS","Glucagon-like Peptide-1 Receptor Agonist for Reduction of Myocardial Injury After Non-Cardiac Surgery","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","372","Myocardial Injury","DRUG:Dulaglutide 0.75mg subcutaneous injection","The University of Hong Kong","2024-03-20","FALSE","0"],["S002277","ClinicalTrials.gov","NCT04196231","BEYOND","Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes: a Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","258","Type 2 Diabetes","DRUG:IDegLira; DRUG:IGlarLixi; DRUG:Insulin/Canaglifozin; DRUG:Insulin/Dapaglifozin; DRUG:Insulin/Empaglifozin; DRUG:Basal Bolus","University of Campania Luigi Vanvitelli","2019-11-27","FALSE","2"],["S002278","ClinicalTrials.gov","NCT03070704",null,"A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India","OBSERVATIONAL",null,null,"WITHDRAWN","0","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide","Novo Nordisk A/S","2017-08-16","FALSE","0"],["S002279","ClinicalTrials.gov","NCT00308139",null,"A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects With Type 2 Diabetes Mellitus Managed With Diet Modification and Exercise and/or Oral Antidiabetic Medications","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","303","Type 2 Diabetes Mellitus","DRUG:exenatide, long acting release; DRUG:exenatide","AstraZeneca","2006-04","TRUE","13"],["S002280","ClinicalTrials.gov","NCT05611957",null,"A Parallel-group, Phase 1, Open-label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Renal Impairment Compared With Healthy Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","29","Healthy; Renal Insufficiency","DRUG:LY3437943","Eli Lilly and Company","2022-11-16","FALSE","0"],["S002281","ClinicalTrials.gov","NCT01550653",null,"Liraglutide Effects on Memory in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","40","Healthy","DRUG:liraglutide; DRUG:Placebo","University of Luebeck","2012-05","FALSE","0"],["S002282","ClinicalTrials.gov","NCT01399645","LIRAINS","Randomized Trial of Liraglutide and Insulin Therapy on Hepatic Steatosis as Measured by MRI and MRS in Metformin-treated Patients With Type 2 Diabetes: an Open Pilot Study","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","35","Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Type 2 Diabetes","DRUG:Liraglutide-metformin vs insulin-metformin","Centre hospitalier de l'Université de Montréal (CHUM)","2011-05","FALSE","1"],["S002283","ClinicalTrials.gov","NCT06976619",null,"The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","60","Type 1 Diabetes; Type 2 Diabetes","DRUG:Liraglutide Pen Injector; OTHER:Saline Injections","Mayo Clinic","2025-10-03","FALSE","0"],["S002284","ClinicalTrials.gov","NCT07011667",null,"Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c. (CagriSema s.c.) Once Weekly for Weight Management and Long-term Weight Maintenance in Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","609","Obesity","DRUG:CagriSema (Cagrilintide B and Semaglutide I); DRUG:Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)","Novo Nordisk A/S","2025-06-03","FALSE","0"],["S002285","ClinicalTrials.gov","NCT01392573","DUAL™ II","A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","413","Diabetes; Diabetes Mellitus, Type 2","DRUG:insulin degludec/liraglutide; DRUG:insulin degludec","Novo Nordisk A/S","2011-11-28","TRUE","7"],["S002286","ClinicalTrials.gov","NCT05419856","LASARE","A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of 4P004 Versus Placebo Injected in the Target Knee of Patients With Grade 2 to 4 Osteoarthritis on the Kellgren and Lawrence Severity Index","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","34","Knee Osteoarthritis","DRUG:4P-004; DRUG:Placebo","4Moving Biotech","2022-08-09","TRUE","1"],["S002287","ClinicalTrials.gov","NCT02917057",null,"A Cohort Study of the Benefits of Bydureon in Customary Clinical Care in the United States - Additional Analyses","OBSERVATIONAL",null,null,"COMPLETED","6024","Type 2 Diabetes","DRUG:exenatide once weekly; DRUG:basal insulin","AstraZeneca","2015-08-01","FALSE","1"],["S002288","ClinicalTrials.gov","NCT06701305",null,"A Single and Multiple-Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Efinopegdutide (MK-6024) in Otherwise Healthy Obese Participants and the Effect of Multiple Doses of Efinopegdutide on the Pharmacokinetics of Acetaminophen","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","48","Healthy","DRUG:Efinopegdutide; DRUG:Placebo; DRUG:Acetaminophen","Merck Sharp & Dohme LLC","2024-06-13","FALSE","0"],["S002289","ClinicalTrials.gov","NCT06083675",null,"Efficacy and Safety of First Line Use of Oral Semaglutide 25 mg or 50 mg Once Daily Versus Empagliflozin 25 mg or Versus Metformin 2000 mg in Newly Diagnosed Treatment naïve Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Diabetes Mellitus, Type 2","DRUG:Semaglutide; DRUG:Empagliflozin; DRUG:Metformin","Novo Nordisk A/S","2024-01-26","FALSE","0"],["S002290","ClinicalTrials.gov","NCT01899430",null,"Short-term Liraglutide Treatment in Obese Women With Polycystic Ovary Syndrome","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","32","PCOS; Obesity","DRUG:liraglutide; DRUG:metformin","University Medical Centre Ljubljana","2011-11","FALSE","0"],["S002291","ClinicalTrials.gov","NCT07700030",null,"High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","32","Weight Loss","OTHER:High protein diet; BEHAVIORAL:Resistance Training (RT) Programs","NYU Langone Health","2026-07","FALSE","0"],["S002292","ClinicalTrials.gov","NCT02172313",null,"Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","78","Diabetes; Healthy","DRUG:semaglutide","Novo Nordisk A/S","2014-06","FALSE","2"],["S002293","ClinicalTrials.gov","NCT04019561",null,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)/ Non-Alcoholic Steatohepatitis (NASH)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","74","Non-alcoholic Fatty Liver Disease (NAFLD); Non-alcoholic Steatohepatitis (NASH)","DRUG:MEDI0382 high dose; DRUG:Placebo for MEDI0382 high dose; DRUG:MEDI0382 low dose; DRUG:Placebo for MEDI0382 low dose","MedImmune LLC","2019-09-23","TRUE","1"],["S002294","ClinicalTrials.gov","NCT02274740",null,"Effect of GLP-1 Receptors Agonist Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","2","Type II Diabetes Mellitus","DRUG:LIXISENATIDE AVE0010; DRUG:metformin","Sanofi","2015-04","FALSE","0"],["S002295","ClinicalTrials.gov","NCT06533527",null,"Randomized Trial of Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","69","Diabetes Mellitus, Type 2; Obesity; Gastroparesis","DRUG:GLP-1 medication","The Cleveland Clinic","2024-07-31","TRUE","3"],["S002296","ClinicalTrials.gov","NCT01373450",null,"Evaluation of the Glucoregulatory Effects of GLP-1 Receptor Activation in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","12","Type 2 Diabetes Mellitus","DRUG:Oxyntomodulin; DRUG:Liraglutide 0.6 mg; DRUG:Liraglutide 1.2 mg; DRUG:Placebo for Oxyntomodulin; DRUG:Placebo for Liraglutide","Merck Sharp & Dohme LLC","2011-06","TRUE","2"],["S002297","ClinicalTrials.gov","NCT01174810",null,"An Open Label, Single Site, 12 Month, Phase II, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exendin-4 (Exenatide) in the Treatment of Patients With Moderate Severity Parkinson's Disease.","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","40","Parkinson's Disease","DRUG:Exenatide","University College, London","2010-07","FALSE","1"],["S002298","ClinicalTrials.gov","NCT06564441",null,"An Open-label, Non-randomised, Fixed-sequence, Two Period, Phase I Trial to Evaluate the Effect of Different Doses of BI 456906 (Survodutide) on the Single Dose Pharmacokinetics of Bupropion, Caffeine and Midazolam on Otherwise Healthy Volunteers With Overweight or Obesity","INTERVENTIONAL",null,"PHASE1","COMPLETED","34","Overweight; Obesity","COMBINATION_PRODUCT:Survodutide; DRUG:Bupropion; DRUG:Caffeine; DRUG:Midazolam","Boehringer Ingelheim","2024-10-01","FALSE","0"],["S002299","ClinicalTrials.gov","NCT06982859",null,"A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","95","Diabetes Mellitus; Insulin Sensitivity","DRUG:Retatrutide; DRUG:Semaglutide; DRUG:Placebo","Eli Lilly and Company","2025-06-02","FALSE","0"],["S002300","ClinicalTrials.gov","NCT04838743","GOAL","A Non-interventional, Single-arm, Multicentre, Prospective Study Investigating the Glycaemic Control and Treatment Pattern Associated With the Use of Xultophy® (IDegLira) in a Real-world Adult Population With Type 2 Diabetes Mellitus in Japan. GOAL (Glycaemic Outcome Assessment IDegLira) Study","OBSERVATIONAL",null,null,"COMPLETED","244","Diabetes Mellitus, Type 2","DRUG:IDegLira","Novo Nordisk A/S","2021-04-23","FALSE","0"],["S002301","ClinicalTrials.gov","NCT00039013",null,"A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With Metformin Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","336","Diabetes Mellitus, Type 2","DRUG:AC2993; DRUG:Placebo","AstraZeneca","2002-03","FALSE","4"],["S002302","ClinicalTrials.gov","NCT02104037","LIRA-CSV","Liraglutide in Spinal Fluid","INTERVENTIONAL","NON_RANDOMIZED",null,"COMPLETED","8","Liraglutide Blood-brain Transfer","PROCEDURE:Lumbar puncture","Mikkel Christensen","2012-01","FALSE","0"],["S002303","ClinicalTrials.gov","NCT03486392",null,"A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","474","Obesity","DRUG:JNJ-64565111 Dose Level 1; DRUG:JNJ-64565111 Dose Level 2; DRUG:JNJ-64565111 Dose Level 3; DRUG:Liraglutide; DRUG:Placebo","Janssen Research & Development, LLC","2018-03-26","TRUE","0"],["S002304","ClinicalTrials.gov","NCT06066528","SYNCHRONIZE™-2","A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","755","Obesity; Diabetes Mellitus, Type 2","COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo","Boehringer Ingelheim","2023-11-27","FALSE","3"],["S002305","ClinicalTrials.gov","NCT02752828","LIXILAN JP-O2","A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine on Top of OADs in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","521","Type 2 Diabetes Mellitus","DRUG:Insulin glargine/lixisenatide (HOE901/AVE0010); DRUG:Insulin glargine (HOE901); DRUG:Oral anti-diabetic drugs","Sanofi","2016-05-23","FALSE","2"],["S002306","ClinicalTrials.gov","NCT04572165",null,"Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data","OBSERVATIONAL",null,null,"COMPLETED","194928","Diabetes Mellitus, Type 2","DRUG:Ozempic®; DRUG:Active Comparator; DRUG:Rybelsus®","Novo Nordisk A/S","2021-01-26","FALSE","0"],["S002307","ClinicalTrials.gov","NCT07187856",null,"A Phase 2 Randomised Controlled Study to Investigate the Efficacy and Safety of Subcutaneously Administered PG-102 for 24 Weeks Compared With Placebo and Open-Label Semaglutide in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","80","Type 2 Diabetes Mellitus (T2DM)","DRUG:PG-102; DRUG:Placebo; DRUG:Semaglutide","ProGen. Co., Ltd.","2026-01","FALSE","0"],["S002308","ClinicalTrials.gov","NCT05577728",null,"Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data","OBSERVATIONAL",null,null,"COMPLETED","2316","Diabetes Mellitus, Type 2","DRUG:New use of semaglutide injection; DRUG:New initiation of \"standard of care\" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)","Brigham and Women's Hospital","2021-07-01","FALSE","1"],["S002309","ClinicalTrials.gov","NCT04680767",null,"Disposition of [¹⁴C]-LY3502970 Following Oral Administration in Healthy Male Participants","INTERVENTIONAL",null,"PHASE1","COMPLETED","6","Healthy","DRUG:[¹⁴C]-LY3502970","Eli Lilly and Company","2021-03-29","TRUE","0"],["S002310","ClinicalTrials.gov","NCT07087795",null,"A Study to Investigate Efficacy and Safety of NNC0194-0499 Versus Placebo, Both Administered Alone or in Combination With Semaglutide in People With Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","96","Diabetes Mellitus, Type 1","DRUG:NNC0194-0499; DRUG:Placebo; DRUG:Semaglutide","Novo Nordisk A/S","2025-07-01","FALSE","0"],["S002311","ClinicalTrials.gov","NCT06243536",null,"The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","60","Type 2 Diabetes; Overweight; Disordered Eating Behaviors","DRUG:Semaglutide; DRUG:standard of care","University Hospital Sestre Milosrdnice","2024-02-01","FALSE","16"],["S002312","ClinicalTrials.gov","NCT01744236",null,"A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Effect of 12-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Liraglutide or Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Sitagliptin on the Cardiovascular, Renal and Gastrointestinal System in Insulin-naïve Patients With Type 2 Diabetes (T2DM).","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","70","Type 2 Diabetes","DRUG:Liraglutide; DRUG:Sitagliptin; DRUG:Exenatide; DRUG:Liraglutide placebo; DRUG:Sitagliptin placebo; DRUG:Exenatide placebo; DRUG:L-NMMA","Amsterdam UMC, location VUmc","2013-04","FALSE","6"],["S002313","ClinicalTrials.gov","NCT07796477",null,"A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of SYH2069 Injection in Participants With Type 2 Diabetes Mellitus With Inadquate Glycemic Control After Diet and Exercise Alone or Metformin Monotherapy","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","240","T2DM (Type 2 Diabetes Mellitus)","DRUG:SYH2069 Injection (group 1); DRUG:SYH2069 Injection (group 2); DRUG:SYH2069 Injection (group 3); DRUG:SYH2069 Injection (group 4); DRUG:SYH2069 Injection placebo; DRUG:Tirzepatide Injection 15mg","CSPC Ouyi Pharmaceutical Co., Ltd.","2026-11-06","FALSE","0"],["S002314","ClinicalTrials.gov","NCT02664441","ECHO","Glucagon-Like Peptide-1 Agonist Effects on Energy Balance in Hypothalamic Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","42","Hypothalamic Obesity","DRUG:Exenatide; DRUG:placebo","Seattle Children's Hospital","2016-03","TRUE","0"],["S002315","ClinicalTrials.gov","NCT01557166",null,"Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","359","Metabolism and Nutrition Disorder; Obesity; Obstructive Sleep Apnoea","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2012-06-07","TRUE","6"],["S002316","ClinicalTrials.gov","NCT05689372",null,"A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic Solution for Injection 1.34mg/ml (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","600","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2026-02-02","FALSE","0"],["S002317","ClinicalTrials.gov","NCT02453711",null,"Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","957","Metabolism and Nutrition Disorder; Obesity","DRUG:semaglutide; DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2015-10-01","TRUE","2"],["S002318","ClinicalTrials.gov","NCT01237314","REACT2","Evaluation of the Glycemic Impact of Food in Patients With Type 2 Diabetes Taking Glargine and/or Exenatide","OBSERVATIONAL",null,null,"COMPLETED","46","Type 2 Diabetes",null,"HealthPartners Institute","2010-11","FALSE","0"],["S002319","ClinicalTrials.gov","NCT06950684","PRIME","The Effect of Protein Supplementation and Resistance Training on Body Composition, Functional Parameters, Metabolic Adaptation, and Nitrogen Balance in Adults (Aged ≥45 Years) With Overweight/Obesity Receiving Incretin-Based Weight Loss Medication for 6 Months: A Multicenter RCT","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","180","Obesity; Overweight (BMI &gt; 25); Weight Loss","DIETARY_SUPPLEMENT:Whey Protein Supplement; BEHAVIORAL:Resistance Training Program","Assuta Medical Center","2025-07-01","FALSE","0"],["S002320","ClinicalTrials.gov","NCT03011021",null,"Phase 1/ Phase 2 Study of the Therapeutic Effect of Ex-vivo Expanded Umbilical Cord Blood Regulatory T Cells With Liraglutide on Autoimmune Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","UNKNOWN","40","Type1 Diabetes Mellitus; Autoimmune Diabetes","DRUG:Liraglutide; BIOLOGICAL:UCB-Treg; DRUG:Insulin","Second Xiangya Hospital of Central South University","2017-01","FALSE","2"],["S002321","ClinicalTrials.gov","NCT05537233","ADJUST-T1D","Efficacy and Safety of Once Weekly Semaglutide in Adults With Obesity and Inadequately Controlled Type 1 Diabetes Using Hybrid Closed-Loop System.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","115","Type 1 Diabetes; Obesity","DRUG:Semaglutide; DRUG:Placebo","Viral N. Shah","2023-04-11","TRUE","2"],["S002322","ClinicalTrials.gov","NCT03466021",null,"Effects of GLP-1 Receptor Agonist Treatment on Pulmonary Function and Quality of Life in Obese Patients With Chronic Obstructive Pulmonary Disease.","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","40","Pulmonary Disease, Chronic Obstructive","DRUG:Liraglutide; DRUG:Placebo","Claus Bogh Juhl","2018-01-01","FALSE","2"],["S002323","ClinicalTrials.gov","NCT07096063","TIRZSEMA-CVOT","Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk","OBSERVATIONAL",null,null,"COMPLETED","887132","Type 2 Diabetes; Overweight; Cardiovascular (CV) Risk","DRUG:Tirzepatide; DRUG:Dulaglutide; DRUG:Semaglutide; DRUG:Sitagliptin","Brigham and Women's Hospital","2024-10-01","FALSE","1"],["S002324","ClinicalTrials.gov","NCT07202884","RESTRAIN-SUI","A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","1000","Urinary Incontinence,Stress","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-09-30","FALSE","0"],["S002325","ClinicalTrials.gov","NCT00456300",null,"The Role of Exenatide in Type 1 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","11","Type 1 Diabetes","DRUG:Exenatide; DRUG:Insulin","Montefiore Medical Center","2007-03","TRUE","1"],["S002326","ClinicalTrials.gov","NCT02690987","GHADD","Do Appetitive Gut Hormones Reduce Addictive and Eating Behaviours in Obesity, and Nicotine and Alcohol Dependence?","INTERVENTIONAL","RANDOMIZED","EARLY_PHASE1","UNKNOWN","95","Obesity; Smoking Cessation; Alcoholism","DRUG:Exenatide; BIOLOGICAL:Desacyl ghrelin; BIOLOGICAL:Saline","Imperial College London","2015-08","FALSE","3"],["S002327","ClinicalTrials.gov","NCT06611904",null,"Study of Endothelial Glycocalyx and Vascular Function in Patients With Type 2 Diabetes and Albuminuria After Administration of Dulaglutide and Dapagliflozin vs DPP-4 Inhibitors","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","60","Urine Albumin (UAlb); Glycocalyx; Arterial Stiffness","DRUG:Dulaglutide; DRUG:DPP-4 Inhibitors","Attikon Hospital","2018-02-01","FALSE","2"],["S002328","ClinicalTrials.gov","NCT01429506",null,"Effect of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","30","Diabetes Mellitus; Obesity","PROCEDURE:Sleeve gastrectomy; DRUG:Intensive medical management","Post Graduate Institute of Medical Education and Research, Chandigarh","2011-01","FALSE","0"],["S002329","ClinicalTrials.gov","NCT06649344",null,"A Phase III,Multicenter,Randomized,Open-label,Parallel-controlled Study Comparing the Efficacy and Safety of HRS9531 With Semaglutide in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin Monotherapy or in Combination With SGLT2 Inhibitors","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","884","Type 2 Diabetes","DRUG:HRS9531 Injection; DRUG:Semaglutide Injection","Fujian Shengdi Pharmaceutical Co., Ltd.","2024-10-31","FALSE","0"],["S002330","ClinicalTrials.gov","NCT07276763",null,"Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention: A Retrospective Observational Study","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","16509","Gastric Retention","OTHER:No Intervention: Observational Cohort","Fudan University","2025-12-10","FALSE","0"],["S002331","ClinicalTrials.gov","NCT04466904",null,"A Multiple Dose Human Tolerability and Pharmacokinetic Study of IBI362 in Chinese Patients With Type 2 Diabetes Mellitus and Poor Glycemic Control","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","42","Type 2 Diabetes","DRUG:IBI362; DRUG:Placebo; DRUG:Dulaglutide","Innovent Biologics (Suzhou) Co. Ltd.","2020-09-12","FALSE","1"],["S002332","ClinicalTrials.gov","NCT04389775","XW003","A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XW003 Injection in Healthy Adult Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","64","Type 2 Diabetes Mellitus; Obesity; Nonalcoholic Steatohepatitis","DRUG:Cohort A; DRUG:Placebo A; DRUG:Cohort B; DRUG:Placebo B","Sciwind Biosciences APAC CO Pty. Ltd.","2020-03-29","FALSE","1"],["S002333","ClinicalTrials.gov","NCT00688701","GETGOAL-MONO","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 12-week Study Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Not Treated With Antidiabetic Agents","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","361","Diabetes Mellitus, Type 2","DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DEVICE:Pen auto-injector","Sanofi","2008-05","TRUE","2"],["S002334","ClinicalTrials.gov","NCT00508287",null,"Randomized, Placebo-Controlled, Single-Dose, Crossover Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","36","Type 2 Diabetes","DRUG:BMS-686117; DRUG:Byetta; DRUG:Placebo","Bristol-Myers Squibb","2007-08","FALSE","0"],["S002335","ClinicalTrials.gov","NCT05891496",null,"A Randomised Double-blind Placebo-controlled Clinical Study Investigating the Effects of Semaglutide s.c. Once-weekly Versus Placebo on Central and Peripheral Inflammation in Participants With Alzheimer's Disease","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","23","Alzheimers Disease","DRUG:Semaglutide; DRUG:Placebo","Novo Nordisk A/S","2023-06-20","TRUE","1"],["S002336","ClinicalTrials.gov","NCT02557620",null,"A Randomised, Double-blind, Placebo Controlled, Double Dummy, Single-centre Trial in Healthy Subjects Comparing the Steady-state Exposure of Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","113","Diabetes; Healthy","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2015-09","FALSE","0"],["S002337","ClinicalTrials.gov","NCT05051579",null,"A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","272","Obesity; Overweight and Obesity","DRUG:LY3502970; DRUG:Placebo","Eli Lilly and Company","2021-09-29","TRUE","2"],["S002338","ClinicalTrials.gov","NCT02860923","CRANIOEXE","Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","42","Craniopharyngiomas; Hypothalamic Obesity","DRUG:Exenatide; DRUG:Placebo","University Hospital, Bordeaux","2017-01-11","FALSE","1"],["S002339","ClinicalTrials.gov","NCT06954090","SIGNAL","SIGNAL - Body Fluid Proteome SIGnatures for persoNALised Intervention to Prevent Cardiovascular and Renal Complications in Diabetes","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","ENROLLING_BY_INVITATION","50","Type 2 DM; Type 2 DM /Diabetic Nephropathy; Albuminuria","DRUG:Semaglutide, 1.34 mg/mL; DRUG:Finerenone Oral Tablet; DRUG:Dapagliflozin (DAPA)","Steno Diabetes Center Copenhagen","2025-11-20","FALSE","0"],["S002340","ClinicalTrials.gov","NCT00909597",null,"A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","756","Diabetes Mellitus Type 2","DRUG:pioglitazone; DRUG:taspoglutide","Hoffmann-La Roche","2009-05","FALSE","0"],["S002341","ClinicalTrials.gov","NCT01836523","ADJUNCT ONE™","The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1398","Diabetes; Diabetes Mellitus, Type 1","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2013-11","TRUE","4"],["S002342","ClinicalTrials.gov","NCT05708859","T-PLAQUE","Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","120","Type II Diabetes; Atherosclerosis","DRUG:Tirzepatide; DRUG:Placebo","Matthew J. Budoff","2024-01-02","FALSE","0"],["S002343","ClinicalTrials.gov","NCT02770885","GOLD","Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia: \"The GOLD-Study\"","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","50","Primary Polydipsia","DRUG:Dulaglutide; DRUG:Placebo","University Hospital, Basel, Switzerland","2016-03","FALSE","2"],["S002344","ClinicalTrials.gov","NCT00579150","Exenatide","Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy","OBSERVATIONAL",null,null,"TERMINATED","7","Birth Defects; Type 2 Diabetes; Preterm Birth",null,"AstraZeneca","2009-01","FALSE","0"],["S002345","ClinicalTrials.gov","NCT02641990",null,"A Phase 1, Randomized, Double-blind, Placebo-Controlled, Crossover Study to Assess the Effect of ITCA 650 on the Pharmacokinetics and Pharmacodynamics of a Combination Oral Contraceptive in Healthy Premenopausal Female Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","28","Healthy Adult Premenopausal Female Volunteers","DRUG:ITCA 650 20/60 mcg/day, ITCA placebo; DRUG:ITCA placebo, ITCA 650 20/60 mcg/day","Intarcia Therapeutics","2015-12","FALSE","0"],["S002346","ClinicalTrials.gov","NCT05006885",null,"A Phase 1, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","95","Non-Alcoholic Fatty Liver Disease","DRUG:ALT-801; OTHER:Placebo","Altimmune, Inc.","2021-09-30","FALSE","1"],["S002347","ClinicalTrials.gov","NCT04094415","SURE ITALY","SURE ITALY: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","581","Diabetes Mellitus, Type 2","DRUG:Semaglutide","Novo Nordisk A/S","2019-10-28","FALSE","1"],["S002348","ClinicalTrials.gov","NCT06162715","GRABS-0","GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","ACTIVE_NOT_RECRUITING","30","Severe Obesity; Obesity; BMI Greater Than 30","DRUG:Tirzepatide; OTHER:Standard of Care post-gastric bypass","Vanderbilt University Medical Center","2024-10-30","FALSE","1"],["S002349","ClinicalTrials.gov","NCT06732960","LIGHT","A Randomized, Double-Blind, Placebo-controlled Study of Efsubaglutide Alfa on Weight Management in Subjects With Overweight or Obesity to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics, and Efficacy.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","50","Overweight or Obesity","BIOLOGICAL:Efsubaglutide Alfa; OTHER:Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","2024-04-21","FALSE","1"],["S002350","ClinicalTrials.gov","NCT01800968","FIGHT","Functional Impact of GLP-1 for Heart Failure Treatment","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","300","Acute Heart Failure","DRUG:Liraglutide; DRUG:Placebo","Duke University","2013-04","TRUE","5"],["S002351","ClinicalTrials.gov","NCT05153590",null,"Weight Loss and Treatment Patterns in a Real World Population of Adults Receiving Saxenda® for Weight Management in Routine Clinical Practice in Switzerland","OBSERVATIONAL",null,null,"COMPLETED","269","Obesity or Overweight","DRUG:Saxenda®","Novo Nordisk A/S","2021-12-03","FALSE","0"],["S002352","ClinicalTrials.gov","NCT05591391",null,"The Efficacy of Mallya in Type 2 Diabetes Transiting From Oral Antidiabetic Drugs to iGlarLixi: a Randomized Controlled Trial Using Real-time Continuous Glucose Monitoring","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","40","Mallya","OTHER:Mallya cap; OTHER:Standard care","Taipei Veterans General Hospital, Taiwan","2022-09-28","FALSE","0"],["S002353","ClinicalTrials.gov","NCT06139055",null,"A 2-part, Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Comparative Bioavailability of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","UNKNOWN","70","Healthy Volunteers","DRUG:GSBR-1290 (Capsule/Tablet); DRUG:GSBR-1290; DRUG:Placebo; DRUG:Placebo (Capsule/Tablet)","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2023-10-02","FALSE","0"],["S002354","ClinicalTrials.gov","NCT07018544",null,"A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea.","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","840","Obesity and Overweight","OTHER:semaglutide","Novo Nordisk A/S","2024-11-19","FALSE","0"],["S002355","ClinicalTrials.gov","NCT05681299",null,"Effects of Administration of Growth Hormone, Without and With Liraglutide, on AgRP, Energy and Glucose Metabolism in Healthy and GH Deficient Humans","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","40","Healthy; Growth Hormone Deficiency","DRUG:growth hormone and lirglutide; DRUG:growth hormone; DRUG:liraglutide; DRUG:Placebo","Columbia University","2023-05-01","FALSE","0"],["S002356","ClinicalTrials.gov","NCT06335134",null,"A Single-Center, Open-Label Study to Evaluate the Effect of XW003 Injection on the Pharmacokinetics of Metformin, Warfarin, Rosuvastatin or Digoxin in Healthy Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","57","Healthy Volunteers","DRUG:XW003 injection; DRUG:Metformin; DRUG:Warfarin; DRUG:Rosuvastatin; DRUG:Digoxin","Hangzhou Sciwind Biosciences Co., Ltd.","2023-07-14","FALSE","0"],["S002357","ClinicalTrials.gov","NCT02113332",null,"Addition of Liraglutide to Overweight Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections (MDI) With Inadequate Glycaemic Control","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","124","Type 2 Diabetes Mellitus","DRUG:Liraglutide; DRUG:Placebo","Vastra Gotaland Region","2013-01","FALSE","9"],["S002358","ClinicalTrials.gov","NCT00642538",null,"A Phase 1, Repeated Single-Dose, Double Blind, Randomized, Five Treatment Controlled Safety and Pharmacological Response Evaluation Trial of MKC253 Inhalation Powder in Adult Male and Postmenopausal Female Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","20","Diabetes Mellitus, Type 2","DRUG:MKC253 Inhalation Powder; DRUG:Technosphere Inhalation Powder; DRUG:subcutaneous injection","Mannkind Corporation","2008-02","FALSE","0"],["S002359","ClinicalTrials.gov","NCT05895643","SEMALCO","Does the Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","108","Alcohol Abuse; Alcohol Addiction; Alcohol Dependence; Alcohol Use Disorder","DRUG:Semaglutide Injectable Product; DRUG:Placebo","Psychiatric Centre Rigshospitalet","2023-06-13","FALSE","3"],["S002360","ClinicalTrials.gov","NCT07671391",null,"A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body Composition in Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","60","Obesity Adult Onset","DRUG:LAE102 +Tirzepatide; DRUG:LAE102 placebo,+Tirzepatide","Shanghai Zhongshan Hospital","2026-08","FALSE","0"],["S002361","ClinicalTrials.gov","NCT00700817",null,"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Extension","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","665","Diabetes; Diabetes Mellitus, Type 2","DRUG:liraglutide; DRUG:sitagliptin; DRUG:metformin","Novo Nordisk A/S","2008-06","TRUE","16"],["S002362","ClinicalTrials.gov","NCT07820358","SWIFT","Semaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer","INTERVENTIONAL",null,"PHASE2","NOT_YET_RECRUITING","48","Endometrial Atypical Hyperplasia; Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Cancer Stage I; Endometrial Cancer; Fertility-Sparing Treatment (FST); Obesity & Overweight","DRUG:Semaglutide (Wegovy) weekly injection; DEVICE:LNG-IUD (Progestin); BEHAVIORAL:Structured Weight Loss Program","The Methodist Hospital Research Institute","2027-01-01","FALSE","6"],["S002363","ClinicalTrials.gov","NCT06468748",null,"The Effects of a GLP-1R Agonist (the Drug Wegovy®) on Body Composition and Performance in Military Personnel","INTERVENTIONAL",null,"PHASE4","WITHDRAWN","0","Obesity","DRUG:Semaglutide","United States Army Research Institute of Environmental Medicine","2024-08-01","FALSE","0"],["S002364","ClinicalTrials.gov","NCT01432405",null,"Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","24","Type 2 Diabetes Mellitus","DRUG:Exenatide; DRUG:Pioglitazone","Baylor College of Medicine","2007-06","TRUE","1"],["S002365","ClinicalTrials.gov","NCT07635953",null,"Combination Therapy With Tirzepatide, Empagliflozin and Pioglitazone Versus Standard Therapy in Newly Diagnosed Type 2 Diabetes: a Multi-center Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","296","Diabetes Mellitus","DRUG:Group A (triple combination intensive therapy group); DRUG:Group B (standard therapy group)","Sun Yat-sen University","2026-07-01","FALSE","0"],["S002366","ClinicalTrials.gov","NCT06779929",null,"Comparative Study of Tirzepatide vs Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","70000","Type 2 Diabetes","DRUG:Tirzepatide; DRUG:Dulaglutide; DRUG:Semaglutide","Brigham and Women's Hospital","2024-11-01","FALSE","2"],["S002367","ClinicalTrials.gov","NCT05419726",null,"Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.","OBSERVATIONAL",null,null,"RECRUITING","20","Obesity","DRUG:Semaglutide Injectable Product (not provided by the study)","University of California, Los Angeles","2023-02-01","FALSE","11"],["S002368","ClinicalTrials.gov","NCT04591626","AWARD-CHN3","A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","291","Type 2 Diabetes Mellitus","DRUG:Dulaglutide; DRUG:Placebo; DRUG:Insulin Glargine","Eli Lilly and Company","2020-12-07","TRUE","1"],["S002369","ClinicalTrials.gov","NCT03021187","PIONEER 8","Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin. A 52-week, Randomised, Double-blind, Placebo-controlled Trial (PIONEER 8 - Insulin add-on)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","731","Diabetes; Diabetes Mellitus, Type 2","DRUG:semaglutide; DRUG:placebo","Novo Nordisk A/S","2017-02-02","TRUE","9"],["S002370","ClinicalTrials.gov","NCT00477581",null,"A Randomized, Double-Blind, Crossover Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","102","Type 2 Diabetes Mellitus","DRUG:exenatide; DRUG:sitagliptin","AstraZeneca","2007-05","FALSE","1"],["S002371","ClinicalTrials.gov","NCT05249881",null,"\"Efficacy of Once-weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan.\"","INTERVENTIONAL",null,"EARLY_PHASE1","UNKNOWN","300","Diabetes Mellitus, Type 2; Weight Change, Body","DRUG:Semaglutide Pen Injector","Aga Khan University","2022-03-10","FALSE","0"],["S002372","ClinicalTrials.gov","NCT02602600","GAP","Effect of Glucagon-like Peptide-1 Stimulation on Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Obstructive Stenosis of Major Coronary Vessels","INTERVENTIONAL",null,"PHASE4","COMPLETED","33","Microvascular Angina","DRUG:Liraglutide","Eva Prescott","2015-11-19","FALSE","7"],["S002373","ClinicalTrials.gov","NCT07154719","GRAMS","GLP-1R Actions on Muscle and the Skeleton","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","50","Musculoskeletal Abnormalities; Obesity; Sarcopenic Obesity; Osteoporosis; Drug Effect","DRUG:Tirzepatide; BEHAVIORAL:Lifestyle toolkit","Pennington Biomedical Research Center","2025-10-09","FALSE","3"],["S002374","ClinicalTrials.gov","NCT06993792",null,"A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","1400","Obesity; Overweight; Type 2 Diabetes","DRUG:Orforglipron; DRUG:Placebo","Eli Lilly and Company","2025-05-15","FALSE","0"],["S002375","ClinicalTrials.gov","NCT04667377",null,"A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","387","Obesity","DRUG:BI 456906; DRUG:Placebo","Boehringer Ingelheim","2021-03-08","TRUE","7"],["S002376","ClinicalTrials.gov","NCT00099619",null,"Efficacy of Exenatide Compared With Insulin Glargine in Patients With Type 2 Diabetes Using Metformin or Sulfonylurea for Whom Insulin is the Next Appropriate Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","138","Type 2 Diabetes Mellitus","DRUG:exenatide/insulin glargine; DRUG:insulin glargine/exenatide","AstraZeneca","2004-09","FALSE","1"],["S002377","ClinicalTrials.gov","NCT00744367",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","326","Diabetes Mellitus Type 2","DRUG:metformin; DRUG:pioglitazone; DRUG:placebo; DRUG:taspoglutide","Hoffmann-La Roche","2008-10","FALSE","0"],["S002378","ClinicalTrials.gov","NCT02036372","PILGRIM","PILGRIM - Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus Type II","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","150","Diabetes Mellitus Type II","DRUG:Liraglutide; DRUG:Insulin bolus; DRUG:GIK infusion","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","2014-01","FALSE","1"],["S002379","ClinicalTrials.gov","NCT07850765",null,"sEMa-LIFE: Unveiling Semaglutide's Impact on Daily Life - Patient and Physicians Experience Across Six Emerging Markets","OBSERVATIONAL",null,null,"COMPLETED","1260","Overweight; Obesity","DRUG:Semaglutide","Novo Nordisk A/S","2026-08-28","FALSE","0"],["S002380","ClinicalTrials.gov","NCT06858839","MARITIME-1","A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","3853","Obesity","DRUG:Maridebart Cafraglutide; DRUG:Placebo","Amgen","2025-03-12","FALSE","0"],["S002381","ClinicalTrials.gov","NCT01536665",null,"The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","45","Diabetes; Diabetes Mellitus, Type 1","DRUG:liraglutide; DRUG:placebo","Novo Nordisk A/S","2012-02","FALSE","3"],["S002382","ClinicalTrials.gov","NCT07711548","DIET-SLIM","DIETary Strategies to stabiLize Incretin-based Weight Loss in Obesity Management","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","292","Obesity & Overweight; Weight Loss Maintenance","BEHAVIORAL:NutriAct plus; BEHAVIORAL:Rescue VLCD","Knut Mai","2027-03","FALSE","0"],["S002383","ClinicalTrials.gov","NCT06691243","STAC","Evaluation Of Semaglutide Safety and Tolerability in Adults With Cocaine Use Disorder With and Without HIV","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","40","Cocaine Use Disorder; HIV","DRUG:Semaglutide; DRUG:Placebo","University of Maryland, Baltimore","2025-08-07","FALSE","0"],["S002384","ClinicalTrials.gov","NCT06299098","COURAGE","A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","1005","Obesity","DRUG:Trevogrumab-Part A; DRUG:Trevogrumab-Part B and Part C; DRUG:Garetosmab; DRUG:Semaglutide; DRUG:Matching Placebo-Part A; DRUG:Matching Placebo-Trevogrumab; DRUG:Matching Placebo-Garetosmab","Regeneron Pharmaceuticals","2024-03-13","FALSE","1"],["S002385","ClinicalTrials.gov","NCT04135287",null,"Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients","INTERVENTIONAL",null,"PHASE4","UNKNOWN","315","Diabetes Mellitus, Type 2","DRUG:GLP-1 receptor agonist","Dasman Diabetes Institute","2020-03-01","FALSE","0"],["S002386","ClinicalTrials.gov","NCT05890807","PARODIABNOSTIC","Evaluation of the Concordance in the Diagnosis of Periodontitis in Diabetic Patients Between an Indirect Method Based on a Photograph of the Oral Cavity and a Direct Method Based on the Clinical Examination of This Oral Cavity (Reference).","INTERVENTIONAL",null,null,"COMPLETED","145","Diabetes Complications; Periodontal Diseases","DIAGNOSTIC_TEST:Front view photography of the patient's oral cavity with the help of a smartphone in the diabetology department.","Centre Hospitalier Universitaire de Nīmes","2023-03-20","FALSE","0"],["S002387","ClinicalTrials.gov","NCT07852988",null,"The Effect of Pancreatin Added to Standard Antihyperglycemic Therapy on Metabolic Control in Patients With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","100","Type 2 Diabetes (T2DM)","DRUG:Pancreatin; DRUG:Placebo","Silesian Centre for Heart Diseases","2026-08-01","FALSE","0"],["S002388","ClinicalTrials.gov","NCT06576375",null,"Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome: A Prospective Comparative Randomized Blinded Trial.","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","70","Polycystic Ovary Syndrome","DRUG:Dapagliflozin; DRUG:Metformin","Future University in Egypt","2024-09-02","FALSE","0"],["S002389","ClinicalTrials.gov","NCT07314528",null,"A Phase II Multi-institutional Randomized Trial Evaluating the Impact of GLP-1 Receptor Agonists in Combination With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","42","Rectal Cancer Patients; Obesity &Amp; Overweight; Locally Advanced Rectal Cancer (LARC); Total Neoadjuvant Therapy; GLP-1","DRUG:GLP-1 receptor agonist; DRUG:Total neoadjuvant therapy (TNT)","St. James's Hospital, Ireland","2026-04","FALSE","6"],["S002390","ClinicalTrials.gov","NCT07770737",null,"Evaluation of Cardioprotective Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Korean Patients With Type 2 Diabetes: A Multicenter CDM-Based Retrospective Cohort Study With Prospective AI-ECG Validation","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","100","Type 2 Diabetes Mellitus (T2DM); Cardiovascular Diseases; Stage B Heart Failure",null,"Dongtan Sacred Heart Hospital","2026-09","FALSE","0"],["S002391","ClinicalTrials.gov","NCT02417012",null,"Does Intensive Life Style Intervention Reduce the Need for Glucose Lowering Medications in Patients With Type 2 Diabetes? The U-TURN Project","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","97","Diabetes Mellitus, Type 2","BEHAVIORAL:U-TURN; BEHAVIORAL:Standard care","Copenhagen University Hospital, Rigshospitalet","2015-04","FALSE","0"],["S002392","ClinicalTrials.gov","NCT07616037",null,"A Preliminary Study to Explore the Efficacy of a GLP-1/FGF21 Dual Agonist (HEC88473) in Patients With Polycystic Ovary Syndrome (PCOS)","INTERVENTIONAL",null,"PHASE2","RECRUITING","30","PCOS (Polycystic Ovary Syndrome)","DRUG:GLP-1/FGF21 dual agonist (HEC88473)","Shanghai Zhongshan Hospital","2026-06","FALSE","0"],["S002393","ClinicalTrials.gov","NCT07611552",null,"The Effect of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Medications for Weight Loss: a Randomized Double-blind Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","600","Obesity & Overweight","DIETARY_SUPPLEMENT:inulin (prebiotics); DIETARY_SUPPLEMENT:Placebo Comparator: maltodextrin","Huazhong University of Science and Technology","2026-06","FALSE","0"],["S002394","ClinicalTrials.gov","NCT07605390",null,"RAPID-CKM: RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care.","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","600","Chronic Kidney Disease; Type 2 Diabetes","OTHER:Epic-Based Clinician Notification; OTHER:Usual Care","Baylor Research Institute","2026-08","FALSE","0"],["S002395","ClinicalTrials.gov","NCT03526289","GASOLIN II","GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","22","Type 2 Diabetes Mellitus; Overweight and Obesity","BIOLOGICAL:GIP1-42 infusion; OTHER:Saline","University Hospital, Gentofte, Copenhagen","2017-11-08","FALSE","1"],["S002396","ClinicalTrials.gov","NCT06528405","ESS-AKD","The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","264","Acute Kidney Injury","DRUG:dapagliflozin; OTHER:Other anti-diabetic drug or no anti-diabetic drug; DRUG:empagliflozin; DRUG:canagliflozin","National Taiwan University Hospital","2024-11-21","FALSE","0"],["S002397","ClinicalTrials.gov","NCT05177653","GA-19","Separate and Combined Extrapancreatic Effects of Glucose-dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","13","Pancreatectomy; Hyperglycemia","OTHER:Intravenous infusion","University Hospital, Gentofte, Copenhagen","2022-04-07","FALSE","0"],["S002398","ClinicalTrials.gov","NCT06996886",null,"An Open-Label, Randomized, Four-Treatment, Four-Period, Single-Dose Crossover Study in Healthy Participants to Assess the Relative Bioavailability of AZD5004 in Three Solid Oral Formulations (F1, F3, F4)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","16","Healthy Participants","DRUG:AZD5004","AstraZeneca","2025-05-22","FALSE","0"],["S002399","ClinicalTrials.gov","NCT07775404","Elecoglipron","A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (EMBOLD-Asia)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","351","Obesity; Overweight","DRUG:Elecoglipron; DRUG:Placebo","AstraZeneca","2026-08-21","FALSE","0"],["S002400","ClinicalTrials.gov","NCT06577584",null,"The Profile of People with Diabetes Followed Up in the Context of the Care Trajectory Versus the Diabetes Convention","OBSERVATIONAL",null,null,"UNKNOWN","20000","Type 2 Diabetes","OTHER:Follow-up in the Diabetes Care Trajectory; OTHER:Follow-up in the Diabetes Convention","Universitaire Ziekenhuizen KU Leuven","2025-02-01","FALSE","0"],["S002401","ClinicalTrials.gov","NCT06915090","FIT-COACH","FIT-COACH: Fitbit Intervention With Coordinated Health Coaching and PCP Support","INTERVENTIONAL",null,null,"COMPLETED","15","GLP - 1; Diabetes; Obesity and Obesity-related Medical Conditions; Cardiovascular Diseases","BEHAVIORAL:Health Coach/Fitbit","University of Massachusetts, Worcester","2025-03-18","FALSE","0"],["S002402","ClinicalTrials.gov","NCT07202910","VALiBi-PED","Imaging-Based Biomarkers for Non-Invasive Pediatric Liver Diagnostics","OBSERVATIONAL",null,null,"RECRUITING","550","Hepatic Disorders; Intestinal Failure-associated Liver Disease; Cystic Fibrosis Liver Disease; MAFLD; Pediatric Liver Transplantation",null,"Sahlgrenska University Hospital","2019-03-28","FALSE","0"],["S002403","ClinicalTrials.gov","NCT04295005",null,"The Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists Cost of Care Study: a German Claims Data Analysis","OBSERVATIONAL",null,null,"COMPLETED","24500","Diabetes Mellitus, Type 2","DRUG:Empagliflozin; DRUG:DPP-4i; DRUG:GLP-1-RA","Boehringer Ingelheim","2020-11-16","TRUE","0"],["S002404","ClinicalTrials.gov","NCT07056595",null,"Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial","INTERVENTIONAL","NON_RANDOMIZED",null,"RECRUITING","30","IgA Nephropathy (IgAN)","DRUG:Finerenone","Botkin Hospital","2025-05-21","FALSE","0"],["S002405","ClinicalTrials.gov","NCT06913881",null,"Comparative Cardiovascular Effectiveness of GLP-1 RAs vs. Insulin in Early-Onset Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","92100","Type 2 Diabetes Mellitus (T2DM)","DRUG:GLP-1","Karolinska Institutet","2010-01-01","FALSE","0"],["S002406","ClinicalTrials.gov","NCT07614230","SCOPE","Effects of SGLT2 Inhibitors on Coronary Atherosclerosis Progression in Diabetes Mediated by Perivascular Adipose Tissue: The SCOPE Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","144","Type 2 Diabetes Mellitus (T2DM); Coronary Artery Disease; Atherosclerosis","DRUG:Dapagliflozin (DAPA); OTHER:Standard Care (Treatment as Usual)","Junjie Yang","2026-01-01","FALSE","0"],["S002407","ClinicalTrials.gov","NCT05037058","CDCV","China Diabetes Cardiovascular Initiative","OBSERVATIONAL",null,null,"UNKNOWN","9600","Acute Coronary Syndrome; Diabetes Mellitus","OTHER:Quality improvement activities","Beijing Institute of Heart, Lung and Blood Vessel Diseases","2021-09-01","FALSE","0"],["S002408","ClinicalTrials.gov","NCT05297045",null,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Oral RGT001-075 in Adult Patients With Uncontrollable Type 2 Diabetes Mellitus on Metformin Therapy","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","17","Type 2 Diabetes Mellitus","DRUG:RGT001-075; OTHER:Placebo","Regor Pharmaceuticals Inc.","2022-03-29","FALSE","0"],["S002409","ClinicalTrials.gov","NCT06236672",null,"Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Compared to Basal Insulin Start on Metabolic Targets in Patients Living With Type 2 Diabetes and Chronic Kidney Disease (Impact GLP-1 CKD)","OBSERVATIONAL",null,null,"COMPLETED","348","Type 2 Diabetes; Chronic Kidney Diseases","DRUG:GLP-1 receptor agonist; DRUG:basal insulin","LMC Diabetes & Endocrinology Ltd.","2023-02-15","FALSE","1"],["S002410","ClinicalTrials.gov","NCT06938529",null,"A Phase I Pharmacokinetic Study of VCT220 in Subjects With Varying Degrees of Hepatic Impairment and Normal Hepatic Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","24","Obesity, Overweight","DRUG:VCT220; DRUG:Placebo","Vincentage Pharma Co., Ltd","2025-04-18","FALSE","0"],["S002411","ClinicalTrials.gov","NCT02844153","CKD-Met","Metformin Use in Chronic Kidney Disease: The CKD-Met Study","OBSERVATIONAL",null,null,"UNKNOWN","1000","Type 2 Diabetes; Chronic Kidney Disease","OTHER:modalities of metformin prescription","Hospices Civils de Lyon","2014-03","FALSE","0"],["S002412","ClinicalTrials.gov","NCT05037045",null,"Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University","INTERVENTIONAL",null,null,"COMPLETED","338","Type 2 Diabetes Mellitus","DRUG:GLP-1 receptor agonist","The Affiliated Hospital of Xuzhou Medical University","2019-01-10","FALSE","0"],["S002413","ClinicalTrials.gov","NCT05694741",null,"A Phase 1 Randomized, Single-blind, Placebo-controlled, First-in-Human and Sequential Group Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186 Following Single Ascending Doses Via Oral Administration","INTERVENTIONAL","RANDOMIZED","PHASE1","TERMINATED","31","Type 2 Diabetes","DRUG:AZD0186; DRUG:Placebo","AstraZeneca","2022-12-20","FALSE","1"],["S002414","ClinicalTrials.gov","NCT06278207","FINEROD","Finerenone Research of Outcomes and Drug Utilization","OBSERVATIONAL",null,null,"RECRUITING","50000","Chronic Kidney Disease; Type 2 Diabetes Mellitus","DRUG:Finerenone (BAY 94-8862)","Bayer","2024-05-15","FALSE","1"],["S002415","ClinicalTrials.gov","NCT07550621",null,"A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of MDR-001 and the Effect of Itraconazole on the Pharmacokinetics of MDR-001 in Healthy Adult Study Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","NOT_YET_RECRUITING","28","Healthy Volunteers (HV)","DRUG:MDR-001; DRUG:Rifampin; DRUG:Itraconazole","MindRank AI Ltd","2026-05-06","FALSE","0"],["S002416","ClinicalTrials.gov","NCT07842393",null,"A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of IBI3042 in Healthy Adult Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","32","Healthy Volunteers (HV)","DRUG:Investigational Drug: IBI3042; DRUG:Matching Placebo","Fortvita Biologics (USA)Inc.","2026-09-29","FALSE","0"],["S002417","ClinicalTrials.gov","NCT07787533","PLAN-RT","Developing a Scalable Digital Resistance Training Intervention to Preserve Muscle Function in Midlife Women Receiving GLP-1 Therapy","INTERVENTIONAL",null,null,"NOT_YET_RECRUITING","15","Women's Health; Obesity & Overweight; Perimenopausal Women; Digital Intervention; Behavior Change; glp1 Agonist; Resistance Exercise","BEHAVIORAL:PLAN-RT 1.0","Louisiana State University and A&M College","2026-11-01","FALSE","0"],["S002418","ClinicalTrials.gov","NCT06877572","ECS Weight","Enacting Active Survivorship: Implementation of Weight Management Strategies in Endometrial Cancer Survivors","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","50","Endometrial Cancer Survivors; Weight Management; Early Stage Endometrial Cancer","BEHAVIORAL:Weight loss with pharmacotherapy; BEHAVIORAL:Weight loss without pharmacotherapy","University of Kansas Medical Center","2025-03-25","FALSE","4"],["S002419","ClinicalTrials.gov","NCT06895408","GA-19b","Separate and Combined Extrapancreatic Effects of Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide 1 (GLP-1)","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","12","Pancreatectomy; Hyperglycemia","OTHER:Intravenous Infusion","University Hospital, Gentofte, Copenhagen","2025-02-19","FALSE","1"],["S002420","ClinicalTrials.gov","NCT05198284",null,"A Prospective Decision Impact Clinical Utility Trial of KidneyIntelX in Patients With Type 2 Diabetes and Existing Chronic Kidney Disease","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","2000","Diabetic Kidney Disease; Chronic Kidney Diseases; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Chronic Kidney Disease Stage 3","DIAGNOSTIC_TEST:KidneyIntelX","Renalytix AI, Inc.","2021-11-01","FALSE","0"],["S002421","ClinicalTrials.gov","NCT07708610",null,"Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes: A Target Trial Emulation","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","71775","Pneumonia; Type 2 Diabetes Mellitus (T2DM)",null,"Chung Shan Medical University","2026-07-31","FALSE","2"],["S002422","ClinicalTrials.gov","NCT07280325",null,"Moxie: A Self-management Education and Support Program Using Advertising Principles to Reduce Rehospitalization for Cardiovascular-related Illnesses","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","9000","Chronic Kidney Disease; Diabetes (DM); Heart Disease; Stroke; Chronic Disease","BEHAVIORAL:Moxie SMES Letters; BEHAVIORAL:Facilitated Relay Letter","University of Calgary","2026-06-01","FALSE","0"],["S002423","ClinicalTrials.gov","NCT07810998",null,"Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","NOT_YET_RECRUITING","60","Poly Cystic Ovary Syndrome","DRUG:Metformin; DRUG:Dapagliflozin (10mg Tab)","Tanta University","2026-09-10","FALSE","0"],["S002424","ClinicalTrials.gov","NCT02157298",null,"A 16-week Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","266","Type 2 Diabetes Mellitus","DRUG:Dapagliflozin 5 mg; DRUG:Placebo tablet","AstraZeneca","2014-06","TRUE","0"],["S002425","ClinicalTrials.gov","NCT04788836","BrainFood","How Altered Gut-Brain-Axis Influences Food Choices. (BrainFood) Part 2: Digital Receipts","OBSERVATIONAL",null,null,"COMPLETED","61","Food Preferences; Obesity","OTHER:Questionnaire (Survey and Food Frequency Questionnaire (FFQ)); OTHER:Collection of digital receipts from grocery shopping","Lia Bally","2021-11-01","FALSE","0"],["S002426","ClinicalTrials.gov","NCT07776509","SELENE 3","A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus (SELENE 3)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","500","Obesity or Overweight; Weight-Related Comorbidity; With/Without Diabetes Mellitus, Type 2","DRUG:Lenbelintide; DRUG:Placebo","AstraZeneca","2026-08-24","FALSE","0"],["S002427","ClinicalTrials.gov","NCT07006272","STABILOOP","Cohort Study to Refine the Positioning of Closed-loop Therapy Versus Islet Transplantation in the Management of Patients With Unstable Type 1 Diabetes","OBSERVATIONAL",null,null,"RECRUITING","35","Type 1 Diabetes (T1D)",null,"University Hospital, Grenoble","2025-06-04","FALSE","0"],["S002428","ClinicalTrials.gov","NCT06694558",null,"Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease","OBSERVATIONAL",null,null,"RECRUITING","60","Chronic Kidney Disease(CKD); Type 1 Diabetes (T1D)",null,"The Cleveland Clinic","2025-03-01","FALSE","0"],["S002429","ClinicalTrials.gov","NCT06003985",null,"Assessment of Preoperative Gastric Content With Ultrasound in Patients Taking GLP1 Agonists","OBSERVATIONAL",null,null,"COMPLETED","354","Gastric Ultrasound; Glucagon-like Peptide 1; Point of Care Ultrasound","OTHER:Gastric Ultrasound Exam","Hospital for Special Surgery, New York","2023-08-29","FALSE","3"],["S002430","ClinicalTrials.gov","NCT06273163",null,"Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation","INTERVENTIONAL","RANDOMIZED",null,"TERMINATED","39","Obesity","OTHER:Medically tailored meals; BEHAVIORAL:Noom®; OTHER:Usual care","University of Texas Southwestern Medical Center","2024-03-05","FALSE","0"],["S002431","ClinicalTrials.gov","NCT03936660","COORDINATE","COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs (COORDINATE) - Diabetes","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","1049","Diabetes Mellitus, Type 2; Cardiovascular Diseases","OTHER:Intense Education Intervention","Duke University","2019-07-25","TRUE","5"],["S002432","ClinicalTrials.gov","NCT06939517",null,"Antiemetic Effect of Acupressure Wristbands for GLP-1RA Related Nausea","INTERVENTIONAL",null,null,"ACTIVE_NOT_RECRUITING","35","Nausea","DEVICE:SeaBand","Florencia Ziemke","2024-02-01","FALSE","0"],["S002433","ClinicalTrials.gov","NCT07585526",null,"Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease. A Randomized Control Trial.","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","160","MASLD; Chronic Kidney Diseases","DRUG:Finerenone; DRUG:Spironolactone; OTHER:Standard Medical Treatment","Institute of Liver and Biliary Sciences, India","2026-04-15","FALSE","0"],["S002434","ClinicalTrials.gov","NCT07602348","ARIADNE","Assessment of Retinal-Angio Findings in Patients With Diabetes Type II Treated With Novel Antidiabetic Therapies","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","40","Diabetic Retinopathy; GLP-1; SGLT 2 Inhibitors; Endothelial Dysfunction; Microvascular Circulation; Retinal Vascular Diseases",null,"University of Athens","2024-03-01","FALSE","0"],["S002435","ClinicalTrials.gov","NCT01967589",null,"Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","82","Diabetes; Healthy","DRUG:NNC0113-0987; DRUG:placebo","Novo Nordisk A/S","2013-10","FALSE","0"],["S002436","ClinicalTrials.gov","NCT07455825",null,"A Phase I, Randomized, Single-dose, 3-Period, Open-Label Study to Assess the Pharmacokinetic Formulation Bridging, Safety, and Food Effect of Different Oral Formulations of AZD5004 in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","65","Healthy Participants","DRUG:AZD5004","AstraZeneca","2026-03-05","FALSE","0"],["S002437","ClinicalTrials.gov","NCT07001553","GLaD","Understanding the Dietary Adjustments Following GLP-1 Agonist Treatment: The GLaD Feasibility Study","OBSERVATIONAL",null,null,"COMPLETED","37","Obesity; Type 2 Diabetes Mellitus (T2DM)",null,"Australian Catholic University","2025-05-28","FALSE","0"],["S002438","ClinicalTrials.gov","NCT07082114",null,"A Phase 3, Randomized, Double-blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of HDM1002 Tablets Compared With Dapagliflozin in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","800","Type 2 Diabetes","DRUG:HDM1002 100 mg; DRUG:HDM1002 200 mg; DRUG:HDM1002 400 mg; DRUG:Dapagliflozin (DAPA)","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-07-14","FALSE","0"],["S002439","ClinicalTrials.gov","NCT06167135","POMODORI","Polycystic Ovary Syndrome, Insulin Resistance, Infertility, Obesity, and the Associated Mitochondrial Dysfunction With These Disorders in Hungarian Patients","OBSERVATIONAL",null,null,"RECRUITING","150","Infertility, Female; Polycystic Ovary Syndrome; Insulin Resistance; Primary Ovarian Insufficiency; Mitochondrial Alteration; Obesity",null,"Semmelweis University","2021-09-10","FALSE","0"],["S002440","ClinicalTrials.gov","NCT03912623","DIABEO2THERMES","Evaluation of the Benefit at 6 Months of a 3 Weeks Spa Treatment in the Type 2 Diabetic Patient. Multicenter Randomized Therapeutic Trial","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","200","Diabetes Mellitus; Physical Activity; Dietetic Rules; Therapeutic Education","OTHER:SPA Treatment with therapeutic education and physical activity; OTHER:Week end","Association Francaise pour la Recherche Thermale","2019-09-13","FALSE","1"],["S002441","ClinicalTrials.gov","NCT07348718",null,"Rubix LS DKD Equity Registry (RUBIX-DKD): A Prospective Observational Patient Registry to Characterize Diabetic Kidney Disease Trajectories, Treatment Patterns, and Outcomes in Underserved Communities and to Enable a Future Embedded Phase IV Pragmatic Study","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","2000","Diabetic Kidney Disease (DKD)","DRUG:Kidney-Protective Therapies Used in Routine Care","Rubix LS","2025-12-15","FALSE","0"],["S002442","ClinicalTrials.gov","NCT02589626",null,"A 52-week Randomised, Double-blind, Parallel Group, Safety and Efficacy Study of Empagliflozin Once Daily as add-on Therapy to Glucagon-like Peptide-1 Receptor Agonist in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","65","Diabetes Mellitus, Type 2","DRUG:empagliflozin 10mg; DRUG:empagliflozin 25 mg; DRUG:Placebo","Boehringer Ingelheim","2015-10-29","TRUE","1"],["S002443","ClinicalTrials.gov","NCT07270172","MICRON","Multifactorial Intervention to Reduce Cardiac and Renal Oxygen Need in Type 1 Diabetes (the MICRON Study) - A Steno 1 Substudy","OBSERVATIONAL",null,null,"RECRUITING","40","Type 1 Diabetes Mellitus",null,"University of Aarhus","2025-10-27","FALSE","1"],["S002444","ClinicalTrials.gov","NCT07703683","SARC-ENDO","Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases","OBSERVATIONAL",null,null,"RECRUITING","100","Diabetes; Obesity & Overweight; Cushing Syndrome; Metabolic Diseases; Endocrine Diseases; Sarcopenia; Sarcopenic Obesity","DRUG:GLP-1 Receptor Agonists","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","2026-02-19","FALSE","0"],["S002445","ClinicalTrials.gov","NCT05196958","DiagMICI","Interest of GLP1 Analogues (aGLP1) in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease (IBD)","INTERVENTIONAL",null,null,"UNKNOWN","20","Inflammatory Bowel Diseases; Diabetes Mellitus, Type 2","OTHER:GLP1 analogues","Fondation Hôpital Saint-Joseph","2022-01-25","FALSE","3"],["S002446","ClinicalTrials.gov","NCT07806838",null,"The Effect of Daily Mixed Spice Consumption and Protein Supplementation on Muscle Mass and Function in Adults Using GLP-1 Agonists for Weight Management: A Pilot Study","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","75","Obesity & Overweight; Muscle Mass and Strength; Muscle Function","DIETARY_SUPPLEMENT:Whey Protein Supplementation; DIETARY_SUPPLEMENT:Maltodextrin Placebo Capsules; DIETARY_SUPPLEMENT:Mixed Spice Capsules","University of California, Los Angeles","2026-09-10","FALSE","0"],["S002447","ClinicalTrials.gov","NCT07431086",null,"A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, Tolerability, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity in the US","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","120","Overweight or Obesity","DRUG:Olatorepatide; DRUG:Placebo","Regeneron Pharmaceuticals","2026-03-16","FALSE","0"],["S002448","ClinicalTrials.gov","NCT07697469","ATRIO-CKM","Atrial Cardiomyopathy in Patients With Cardiovascular-Kidney-Metabolic Syndrome: Non-invasive Characterization (ATRIO-CKM)","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","200","Cardiovascular-Kidney-Metabolic Syndrome; Atrial Cardiomyopathy; Atrial Fibrillation; Chronic Kidney Disease; Metabolic Syndrome",null,"Grigore T. Popa University of Medicine and Pharmacy","2026-07-10","FALSE","0"],["S002449","ClinicalTrials.gov","NCT01503112","PRIBA","Does Urinary C-peptide Creatinine Ratio Predict Response to Incretin Based Agents in Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","957","Type2 Diabetes","OTHER:No intervention, observational study","Royal Devon and Exeter NHS Foundation Trust","2011-05","FALSE","3"],["S002450","ClinicalTrials.gov","NCT07687667",null,"Effects of GLP-1 Receptor Agonists Combined With Healthy Lifestyle Education Prior to Fertility Treatment on Reproductive Outcomes in Obese Women With Polycystic Ovary Syndrome","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","406","Polycystic Ovary Syndrome (PCOS); Obesity; Infertility, Female","DRUG:GLP-1 receptor agonist; DRUG:Metformin","Peking University Third Hospital","2026-07","FALSE","0"],["S002451","ClinicalTrials.gov","NCT06576401",null,"A Phase1 Study to Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects","INTERVENTIONAL",null,"PHASE1","UNKNOWN","10","Healthy Adult Subject","DRUG:[14C] HDM1002","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-08-27","FALSE","0"],["S002452","ClinicalTrials.gov","NCT01879228",null,"A Randomized, Double-blind, Placebo Controlled Study of the Effectiveness of Chronic Incretin-based Therapy on Insulin Secretion in Cystic Fibrosis","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","26","Cystic Fibrosis; Pancreatic Insufficiency","DRUG:Sitagliptin; DRUG:Placebo","University of Pennsylvania","2013-06","TRUE","0"],["S002453","ClinicalTrials.gov","NCT07190794",null,"Evaluation of Endoscopic Sleeve Gastroplasty (ESG) as an Alternative Weight Loss Strategy for Patients With Obesity Discontinuing GLP-1 Receptor Agonists Due to Intolerance or Ineffectiveness: A Retrospective Study","OBSERVATIONAL",null,null,"TERMINATED","18","Obesity","DEVICE:OverStitch™ or OverStitch NXT™; BEHAVIORAL:Lifestyle Modification","Boston Scientific Corporation","2025-12-17","FALSE","0"],["S002454","ClinicalTrials.gov","NCT02105324",null,"The Summer Camp Study 2: Outpatient Automated Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas in a Pediatric Population Ages 6-11 at the Clara Barton Diabetes Camps","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","19","Type 1 Diabetes","DEVICE:Bionic Pancreas; OTHER:Usual Care","Massachusetts General Hospital","2014-06","TRUE","0"],["S002455","ClinicalTrials.gov","NCT02882477",null,"Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy","INTERVENTIONAL","NON_RANDOMIZED","PHASE2; PHASE3","UNKNOWN","20","Diabetes Mellitus; Iron Metabolism Disorders; Gastroduodenal Ulcer; Optic Atrophy; Sensorineural Hearing Loss; Platelet Dysfunction","DRUG:Deferiprone; DRUG:Acetylcysteine; DRUG:Sitagliptin and Metformin","Hadassah Medical Organization","2016-12","FALSE","4"],["S002456","ClinicalTrials.gov","NCT07629544","PANDA-1","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","840","Overweight and Obesity","DRUG:DA-302168S; DRUG:Placebo","Chendu DIAO Pharmaceutical Group CO., LTD.","2026-06-19","FALSE","0"],["S002457","ClinicalTrials.gov","NCT04960514",null,"A Prospective Decision Impact Trial of KidneyIntelX in Patients With Type 2 Diabetes and Existing Chronic Kidney Disease","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","2000","Diabetic Kidney Disease; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Chronic Kidney Disease, Stage 3 (Moderate)","DIAGNOSTIC_TEST:KidneyIntelX","Renalytix AI, Inc.","2021-11-22","FALSE","0"],["S002458","ClinicalTrials.gov","NCT07854990","CKM-T2D","Clinical Predictors and Therapeutic Gaps Across Stages of Cardio-Renal-Metabolic (CKM) Syndrome Among Adults With Type 2 Diabetes: A Cross-Sectional Study","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","231","Type 2 Diabetes Mellitus; Cardiovascular-Kidney-Metabolic Syndrome; Diabetic Kidney Disease","DIAGNOSTIC_TEST:clinical and laboratory CKM staging evaluation","Assiut University","2026-10-20","FALSE","0"],["S002459","ClinicalTrials.gov","NCT07216352",null,"Open-label Study Evaluating the Safety and Efficacy of AGE Serum in Non-menopausal Patients on Glucagon-like Peptide-1 Agonists","INTERVENTIONAL",null,null,"NOT_YET_RECRUITING","25","Laxity; Skin","OTHER:AGE Serum","Goldman, Butterwick, Fitzpatrick and Groff","2025-10-25","FALSE","0"],["S002460","ClinicalTrials.gov","NCT07104539","STRONG-GLP","Strength Training Response of Muscle in GLP-1 Users","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","30","Muscle Mass","BEHAVIORAL:Strength Training; OTHER:Wait first, then strength training","Virginia Polytechnic Institute and State University","2025-10-08","FALSE","0"],["S002461","ClinicalTrials.gov","NCT01674972",null,"Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls","OBSERVATIONAL",null,null,"COMPLETED","102","Non Alcoholic Fatty Liver Disease; Non Alcoholic Steatohepatitis","OTHER:Oral glucose tolerance test","University Hospital, Basel, Switzerland","2011-01","FALSE","0"],["S002462","ClinicalTrials.gov","NCT07842757",null,"Clinical and Metabolic Determinants of High Residual Gastric Volume in Patients With Type 2 Diabetes Mellitus","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","120","Type 2 Diabetes Mellitus (DM); Gastric Ultrasound","DIAGNOSTIC_TEST:Preoperative Gastric Ultrasonography; DIAGNOSTIC_TEST:Capillary Fasting Blood Glucose Measurement","Bakirkoy Dr. Sadi Konuk Research and Training Hospital","2026-10-01","FALSE","1"],["S002463","ClinicalTrials.gov","NCT07701291",null,"Feasibility and Acceptability of a Digital Mindfulness-Based Nutrition Group Intervention During Pharmacological Treatment for Weight Reduction","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","28","Obesity & Overweight; Emotional Eating; Emotional Eating Behaviour; Online Intervention","BEHAVIORAL:Online Group Intervention on Mindful Eating","Bern University of Applied Sciences","2026-08-15","FALSE","0"],["S002464","ClinicalTrials.gov","NCT07789106","Project Zest","A Randomised, Placebo-Controlled Trial to Evaluate the Effect of Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Who Are Self-Administering GLP-1 Agonists (\"Project Zest\")","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","90","Obesity & Overweight; GLP - 1; Fatigue Severity Scale; Ubiquinol; Muscle Contraction","DIETARY_SUPPLEMENT:Ubiquinol 100 MG Oral Capsule; DIETARY_SUPPLEMENT:Placebo","StudySetGo","2026-09-01","FALSE","0"],["S002465","ClinicalTrials.gov","NCT07422987","GLOW","GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","50","Body Composition; Muscle Function; GLP-1; Estrogen Level",null,"University of Kansas Medical Center","2026-02-12","FALSE","0"],["S002466","ClinicalTrials.gov","NCT07327281",null,"A Phase Ia Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of TQF3250 Capsules in Healthy Adult Subjects After Single Administration and Escalating Doses","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","66","Hyperglycemia","DRUG:TQF3250 placebo; DRUG:TQF3250 capsule","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","2025-12-18","FALSE","0"],["S002467","ClinicalTrials.gov","NCT06865456",null,"Predictors of Survival of DKD Patients in Assiut University Hospital","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","129","Chronic Kidney Disease(CKD)",null,"Assiut University","2025-05-01","FALSE","0"],["S002468","ClinicalTrials.gov","NCT07513259",null,"Pre-Diagnosis GLP-1 Receptor Agonist Use and Post-Cancer Mortality in Adults With Obesity and Type 2 Diabetes: A Target Trial Emulation","OBSERVATIONAL",null,null,"COMPLETED","203424","Obesity & Overweight; Diabetes Mellitus Type 2; Neoplasms",null,"Chung Shan Medical University","2018-01-01","TRUE","17"],["S002469","ClinicalTrials.gov","NCT07736963",null,"Discontinuation Recommendations for GLP-1 Receptor Agonists Prior to Colonoscopy: A Randomized Controlled Trial in Taiwan.","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","240","GLP-1","BEHAVIORAL:GLP-1 not stop for 1 week; BEHAVIORAL:GLP-1 stop for 1 week","Fu Jen Catholic University Hospital","2026-06-01","FALSE","0"],["S002470","ClinicalTrials.gov","NCT06142006",null,"A Pilot Study to Test the Feasibility and Acceptability of a Novel Diabetes Staging System in Patient Aligned Care Teams in the Durham VA System","OBSERVATIONAL",null,null,"UNKNOWN","120","Diabetes Mellitus; Type 2 Diabetes","OTHER:Diabetes Staging System (DSS) use among Primary Care Teams","Durham VA Medical Center","2023-09-01","FALSE","0"],["S002471","ClinicalTrials.gov","NCT05948969","CVRiD","Transform CV Risk in Diabetes","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","750","Type 2 Diabetes","OTHER:Decision support; OTHER:Facilitated referral to a cardiometabolic team-based center","American College of Cardiology","2023-09-01","FALSE","0"],["S002472","ClinicalTrials.gov","NCT07724288","CKD Safety-Net","Designing and Implementing a Safety Net Surveillance Program for High Risk CKD (CKD Safety Net)","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","972","Chronic Kidney Diseases","OTHER:Letter to participants","University of Manitoba","2026-08","FALSE","0"],["S002473","ClinicalTrials.gov","NCT05734989",null,"Improving Screening and Therapy Provision Among Hispanics/Latinx at Risk for Chronic Kidney Disease","OBSERVATIONAL",null,null,"COMPLETED","248","Type 2 Diabetes; Chronic Kidney Diseases","DIAGNOSTIC_TEST:BP; DIAGNOSTIC_TEST:HbA1c; BEHAVIORAL:PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD","Duke University","2023-05-18","TRUE","0"],["S002474","ClinicalTrials.gov","NCT07104461","APPETITE","A Single-blind Randomised Study to Test the Effects of Protein-enriched Breakfast Meals With Varying Protein Sources Compared to a Standard Meal on the Regulation of Appetite and Satiety in Healthy Human Volunteers","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","12","Appetite and General Nutritional Disorders","OTHER:Oat porridge; DIETARY_SUPPLEMENT:Whey protein isolate; DIETARY_SUPPLEMENT:Potato protein isolate; DIETARY_SUPPLEMENT:Meal replacement shake","University of Westminster","2023-06-09","FALSE","3"],["S002475","ClinicalTrials.gov","NCT04931030",null,"Effects of Low Carbohydrate Diet (LCBD) on Weight and Renal Outcome in Patients With Diabetic Kidney Disease (DKD)- A Pilot Study","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","30","Type 2 Diabetes Mellitus; Diabetic Kidney Disease; Obesity","OTHER:Dietary advice","Universiti Teknologi Mara","2019-03-15","FALSE","0"],["S002476","ClinicalTrials.gov","NCT05569304","EGG","Endoscopic Sleeve Gastroplasty Versus GLP-1 Analogue for Class 1 and 2 Obesity Study (EGG Study)","INTERVENTIONAL","NON_RANDOMIZED",null,"UNKNOWN","66","Obesity","PROCEDURE:Endoscopic sleeve gastroplasty","Sengkang General Hospital","2022-10-07","FALSE","0"],["S002477","ClinicalTrials.gov","NCT05182359","PORTRAIT-DM","Pragmatic Impact of Proteomic Risk Stratification in Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","150","Type 2 Diabetes","OTHER:SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test","University Hospitals Cleveland Medical Center","2022-01-26","FALSE","0"],["S002478","ClinicalTrials.gov","NCT07478198","PLLA-GLP-1","Study on the Efficacy and Safety of PLLA Injections for Improving Facial Laxity Following GLP-1 Analog Therapy","INTERVENTIONAL",null,null,"ENROLLING_BY_INVITATION","22","Facial Skin Laxity","DEVICE:PLLA injection","Shanghai Punan Hospital of Pudong New District","2025-07-03","FALSE","1"],["S002479","ClinicalTrials.gov","NCT02857764",null,"SGLT2 Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States","OBSERVATIONAL",null,null,"COMPLETED","127690","Diabetes Mellitus, Type 2",null,"Janssen Research & Development, LLC","2016-02-15","FALSE","0"],["S002480","ClinicalTrials.gov","NCT06666049","POCUS","Gastric POCUS for Airway Management in Patients Using Glucagon-like Peptide-1 Receptor Agonist (Multicentric)","OBSERVATIONAL",null,null,"RECRUITING","39","Aspiration Pneumonia","DIAGNOSTIC_TEST:Gastric Ultrasound","Clinica Universidad de Navarra, Universidad de Navarra","2024-10-21","FALSE","0"],["S002481","ClinicalTrials.gov","NCT07566299",null,"Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Target Trial Emulation","OBSERVATIONAL",null,null,"COMPLETED","118805","Obesity Type 2 Diabetes Mellitus; Cardiovascular-kidney-metabolic Syndrome; Metabolic Dysfunction-Associated Steatotic Liver Disease",null,"Chung Shan Medical University","2017-01-01","TRUE","13"],["S002482","ClinicalTrials.gov","NCT07770906","GLP1-PERIO","Effect of Glucagon-Like Peptide-1 Receptor Agonist Use on Periodontal Health and Response to Non-Surgical Periodontal Therapy","INTERVENTIONAL","NON_RANDOMIZED",null,"NOT_YET_RECRUITING","40","Periodontal Disease; Obesity & Overweight","PROCEDURE:non-surgical periodontal therapy","Cukurova University","2026-09-01","FALSE","0"],["S002483","ClinicalTrials.gov","NCT06500299",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","180","Overweight and Obesity","DRUG:HDM1002 100 mg QD; DRUG:HDM1002 200 mg QD 12weeks; DRUG:HDM1002 400 mg QD 12weeks; DRUG:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-07-15","FALSE","1"],["S002484","ClinicalTrials.gov","NCT06987903","CAPS-OB","Impact of a Perioperative Physical Exercise and Respiratory Physiotherapy Program on the Patient Undergoing Bariatric Surgery","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","132","Bariatric Surgery and Physical Activity; Obesity/Therapy; Bariatric Surgery Complications; Bariatric Patients","PROCEDURE:Pre- and post-operative physical exercise programme; PROCEDURE:Pre- and post-operative respiratory physiotherapy","Fundacin Biomedica Galicia Sur","2025-05-07","FALSE","0"],["S002485","ClinicalTrials.gov","NCT04813146",null,"Role of Synchronized Lifestyle Modification Program on Diabetic Peripheral Neuropathy Patients Taking Oral Hypoglycemics and GLP-1 Analogues","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","216","Diabetic Neuropathies","OTHER:SLP; OTHER:SLP along with Physiotherapy; OTHER:Physiotherapy","Riphah International University","2021-02-05","FALSE","0"],["S002486","ClinicalTrials.gov","NCT07747857",null,"A Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profiles and Preliminary Efficacy of TQF3250 Capsules in Trial Participants With Type 2 Diabetes Mellitus Complicated With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","72","Type 2 Diabetes Mellitus Combined With Overweight or Obesity","DRUG:TQF3250 capsules; DRUG:TQF3250 placebo","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","2026-08-25","FALSE","0"],["S002487","ClinicalTrials.gov","NCT06850129","DDC","Efficacy of a Digital Educational Intervention in Patients With Type 2 Diabe-tes Mellitus. A Multicenter, Randomized and Prospective 6-month Follow-up Study","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","85","Diabetes Mellitus Type 2","BEHAVIORAL:DIGITAL INTERVENTION","HOSPITAL VITHAS SEVILLA","2020-10-26","FALSE","2"],["S002488","ClinicalTrials.gov","NCT06300086","NUDGE-CKD","Nationwide Utilization of Danish Government Electronic Letter System for Increasing Guideline-directed Medical Therapy in Chronic Kidney Disease","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","28388","Chronic Kidney Diseases; Behavior and Behavior Mechanisms","BEHAVIORAL:Electronically delivered nudging letters to patients with CKD; BEHAVIORAL:Electronically delivered nudging letter to associated GPs of patients with CKD","Tor Biering-Sørensen","2024-08-19","FALSE","0"],["S002489","ClinicalTrials.gov","NCT05831085","DEFINE-DM","A Comparison of Imaging- and Physiology-Guided State-of-the-Art Percutaneous Coronary Intervention and Coronary-Artery Bypass Grafting in Patients With Diabetes and Three-Vessel Coronary Artery Disease: DEFINE-DM Trial (Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease)","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","1500","Coronary Artery Stenosis","PROCEDURE:State-of-the-Art Percutaneous Coronary Intervention; PROCEDURE:standard CABG","Duk-Woo Park, MD","2024-06-14","FALSE","0"],["S002490","ClinicalTrials.gov","NCT06388213",null,"Investigation of Gastric Emptying in Patients Treated With GLP-1 Receptor Agonists","OBSERVATIONAL",null,null,"UNKNOWN","40","Diabetes Mellitus, Type 2; Anesthesia; Pulmonary Aspiration of Gastric Contents","DEVICE:Gastric Ultrasonography","University Hospital, Geneva","2024-06","FALSE","0"],["S002491","ClinicalTrials.gov","NCT06438874",null,"Type 2 Diabetes Post Exercise Arterial Stiffness","INTERVENTIONAL",null,null,"WITHDRAWN","0","Type 2 Diabetes","OTHER:Exercise Test","University of Illinois at Chicago","2024-07","FALSE","0"],["S002492","ClinicalTrials.gov","NCT07027995","FFWM","Food and Fitness With Medicine","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","200","Cardiovascular Kidney Metabolic Syndrome; Type 2 Diabetes","BEHAVIORAL:Exercise is Medicine (EIM); BEHAVIORAL:Culinary Education; BEHAVIORAL:Food is Medicine; BEHAVIORAL:Nutrition Counseling; BEHAVIORAL:Participant Website","Ohio State University","2026-01-14","FALSE","0"],["S002493","ClinicalTrials.gov","NCT04866667",null,"Screening and Intervention of Arteriosclerotic Cardiovascular Disease in Type 2 Diabetes in Zhejiang Province","OBSERVATIONAL",null,null,"COMPLETED","316","Type 2 Diabetes Mellitus; Arteriosclerotic Cardiovascular Disease; Liraglutide",null,"Zhejiang Provincial People's Hospital","2021-05-01","FALSE","0"],["S002494","ClinicalTrials.gov","NCT06745544","DiaACTIVE","Impact of Screening and Multicomponent Exercise on Fall Rates, Fractures, and Cardiovascular Health in Diabetes: Protocol for a Randomized Control Trial: DIACTIVE","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","490","Type 2 Diabetes; Osteoporosis; Diabetic Neuropathies; Fall Prevention; Cardiovascular Diseases","OTHER:Rhythm- and Multitask-Based Activity (RYMA) and Activities of Daily Living (ADL)","Aalborg University Hospital","2025-10-01","FALSE","0"],["S002495","ClinicalTrials.gov","NCT07032311","SIPPA-QH_HHC-2","Effect of Behavioral Intervention/Therapy to Reduce Diabetes and Liver Disease Risk Through Prescribed Digital Therapeutics Enabled by AI/ML Powered Predictive Analytics","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","180","Type 2 Diabetes; Liver Disease","DEVICE:Behavioral Treatment","SIPPA Solutions INC","2026-08-20","FALSE","0"],["S002496","ClinicalTrials.gov","NCT07736911",null,"Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy: A Randomized Controlled Trial.","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","140","GLP-1","DRUG:GLP-1 Stop for 1 week; DRUG:GLP-1 non stop","Fu Jen Catholic University Hospital","2026-06-01","FALSE","0"],["S002497","ClinicalTrials.gov","NCT06659159","GLP-1","Effects of Beginning a GLP1-Agonist Therapy on Residual Gastric Content and Gastric Emptying: a Prospective Ultrasound Approach with Focus on Perioperative Aspiration Risk.","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","50","Pulmonary Aspiration During Anaesthetic Induction","DIAGNOSTIC_TEST:Gastric ultrasound","Sascha Battig","2024-11-01","FALSE","0"],["S002498","ClinicalTrials.gov","NCT00588380",null,"A Pilot Study Examining How Common Genetic Variation in GLP1R Alters Response to GLP1 Infusion","INTERVENTIONAL",null,null,"COMPLETED","88","Diabetes","DRUG:GLP-1","Mayo Clinic","2007-11","TRUE","1"],["S002499","ClinicalTrials.gov","NCT02026024","IBCT2","Clinical and Genetic Variations Study of Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients","OBSERVATIONAL",null,null,"COMPLETED","10","Type 2 Diabetes Mellitus",null,"Chang Gung Memorial Hospital","2013-10","FALSE","0"],["S002500","ClinicalTrials.gov","NCT07437716",null,"Impact Of Laparoscopic Sleeve Gastrectomy On Obesity-Related Comorbidities In Patients Over 65 Years: A Prospective Comparative Study","INTERVENTIONAL","NON_RANDOMIZED",null,"COMPLETED","60","Laparascopic Sleeve Gastrectomy; Obesity & Overweight; Obesity Type 2 Diabetes Mellitus; Obstructive Sleep Apnea (OSA); Hypertension (HTN); Osteo Arthritis of the Knee","PROCEDURE:Laparoscopic Sleeve Gastrectomy (LSG); BEHAVIORAL:Structured Dietary Counseling","Kafrelsheikh University","2023-01-01","FALSE","0"],["S002501","ClinicalTrials.gov","NCT06593704","PROSPERA","Proactive Population Health Management of Cardiovascular Disease in Primary Care Using a Multilevel Guideline Adherence Toolkit (the PROSPERA-program).","INTERVENTIONAL","RANDOMIZED",null,"ENROLLING_BY_INVITATION","848","Cardiovascular Diseases","OTHER:PROSPERA-program","Leiden University Medical Center","2025-02-17","FALSE","0"],["S002502","ClinicalTrials.gov","NCT07642921","The EPIC-HFpEF","Phenotyping Heart Failure With Preserved Ejection Fraction (HFpEF) Using Echocardiographic, Clinical, and Biomarker Parameters","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","500","Heart Failure With Preserved Ejection Fraction (HFPEF)",null,"University Of Perugia","2026-06-02","FALSE","0"],["S002503","ClinicalTrials.gov","NCT02130778",null,"Natriuretic Effect of GLP-1 in Healthy Non Obese Subjects Followed by Oral Sodium Load: A Randomized, Placebo-controlled, Cross-over Study","INTERVENTIONAL","NON_RANDOMIZED","EARLY_PHASE1","COMPLETED","15","Sodium Excretion by Urination","DRUG:Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline; OTHER:500 ml 0.9% saline","Clinical Hospital Centre Zagreb","2014-04","FALSE","1"],["S002504","ClinicalTrials.gov","NCT03678727",null,"Effects of Exercise on VLDL-TG Metabolism in Individuals With NAFL and NASH","OBSERVATIONAL",null,null,"COMPLETED","19","NAFLD - Nonalcoholic Fatty Liver Disease; NASH - Nonalcoholic Steatohepatitis",null,"University of Aarhus","2018-12-01","FALSE","0"],["S002505","ClinicalTrials.gov","NCT06593314",null,"Identifying Undiagnosed HFpEF Among Patients With Type 2 Diabetes Using Ultromics AI HFpEF Algorithm","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","800","Heart Failure; Diabetes","BEHAVIORAL:Message with EchoGo; BEHAVIORAL:Standard Message","University of Texas Southwestern Medical Center","2025-08-06","FALSE","0"],["S002506","ClinicalTrials.gov","NCT04287387",null,"Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","180","Type2 Diabetes Mellitus","DRUG:Glucophage 500Mg Tablet; DRUG:Acarbose Tablets; DRUG:Sitagliptin tablet; DRUG:Dapagliflozin Tablet; DRUG:Pioglitazone Tablets; DRUG:Glimepiride Tablets","Peking Union Medical College Hospital","2020-03-02","FALSE","0"],["S002507","ClinicalTrials.gov","NCT07713901",null,"Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","93600000","Medullary Thyroid Carcinoma","OTHER:No treatment given","Novo Nordisk A/S","2025-12-31","FALSE","0"],["S002508","ClinicalTrials.gov","NCT06904846","DETECT","Prospective Post-market Clinical Follow-up (PMCF) Study Aimed to Evaluate the Change in Glucometric Parameters in Adult Patients With Type 1 or Type 2 DiabETes From Europe Using the iCan o3 CGM SysTem for a 60-day Period","INTERVENTIONAL",null,null,"ENROLLING_BY_INVITATION","70","Diabetes Mellitus; Continuous Glucose Monitoring System","DEVICE:iCan o3 CGM Continuous Glucose Monitoring System","Sinocare","2025-04-23","FALSE","0"],["S002509","ClinicalTrials.gov","NCT02029846",null,"Glycemia in Diabetic Elders Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","TERMINATED","2","Type 2 Diabetes Mellitus","DRUG:Standard Treatment; DRUG:Incretin-Based Treatment","Johns Hopkins University","2013-04","TRUE","0"],["S002510","ClinicalTrials.gov","NCT07670520","ACT","Acute Kidney Injury In Care Transitions (ACT): Pragmatic Clinical Trial","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","2260","Acute Kidney Injury","BEHAVIORAL:Acute Kidney Injury in Care Transitions (ACT); BEHAVIORAL:Usual Care","Mayo Clinic","2026-04-16","FALSE","0"],["S002511","ClinicalTrials.gov","NCT07100691","GEM-GLP1RA","Preoperative Metoclopramide to Enhance Gastric Emptying in Patients on Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss: A Randomised Controlled Trial With Ultrasound Assessment","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","80","Pulmonary Aspiration During Anaesthetic Induction; Gastric Emptying Time; Preoperative Risk Assessment; Obesity (Disorder)","DRUG:Metoclopramide","Mater Misericordiae University Hospital","2025-08","FALSE","6"],["S002512","ClinicalTrials.gov","NCT07182123",null,"The Influence of GLP1-RA on Periodontal Health - a Pilot Study","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","30","Periodontitis; Diabetes (DM)",null,"Medical University of Graz","2025-10-24","FALSE","0"],["S002513","ClinicalTrials.gov","NCT07217743",null,"Prospective, Single Center, Open-label Study Assessing Impact of Poly-L-lactic Acid on Adipogenesis in Patients on Glucagon-like Peptide-1 Agonists","INTERVENTIONAL","NON_RANDOMIZED","PHASE2","NOT_YET_RECRUITING","20","Laxity; Skin","DEVICE:Sculptra Aesthetic","Goldman, Butterwick, Fitzpatrick and Groff","2025-10-27","FALSE","0"],["S002514","ClinicalTrials.gov","NCT07723833",null,"A Phase I, Randomized, Single-dose, Crossover, 2-Period, Open-Label Study to Assess the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","152","Healthy Participants","DRUG:Elecoglipron Reference Formulation Dose A; DRUG:Elecoglipron Test formulation 1 Dose A; DRUG:Elecoglipron Reference Formulation Dose B; DRUG:Elecoglipron Test formulation 1 Dose B; DRUG:Elecoglipron Test formulation 2 Dose A; DRUG:Elecoglipron Test formulation 2 Dose B","AstraZeneca","2026-07-27","FALSE","0"],["S002515","ClinicalTrials.gov","NCT05578352",null,"The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","20","Type 2 Diabetes Mellitus","OTHER:Add oral hyppoglycemia drug; OTHER:Add GLP-1 receptor agonist; OTHER:Change insulin","Nanjing First Hospital, Nanjing Medical University","2022-08-05","FALSE","0"],["S002516","ClinicalTrials.gov","NCT06182852",null,"An Observational Clinical Study on the Effect of GLP-1 Receptor Agonist on Bone Metabolism in Patients With Diabetes Mellitus","OBSERVATIONAL",null,null,"UNKNOWN","330","Diabete Type 2; Bone Metabolism",null,"Nanjing First Hospital, Nanjing Medical University","2024-01-01","FALSE","0"],["S002517","ClinicalTrials.gov","NCT04813003","BrainFood","How Altered Gut-Brain-Axis Influences Food Choices. (BrainFood) Part 1: Brain Imaging and Computational Modelling","OBSERVATIONAL",null,null,"COMPLETED","50","Obesity; Food Preferences","OTHER:Functional Brain Imaging and neurobehavioural tasks","Lia Bally","2021-04-12","FALSE","0"],["S002518","ClinicalTrials.gov","NCT06953063","DA168","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study To Evaluate The Efficacy And Safety Of DA-302168S Tablets In Overweight/Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","250","Overweight and Obesity","DRUG:DA-302168S; DRUG:Placebo of DA-302168S","Chendu DIAO Pharmaceutical Group CO., LTD.","2025-05-15","FALSE","0"],["S002519","ClinicalTrials.gov","NCT04017221",null,"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes: a Multicenter Cohort Study","OBSERVATIONAL",null,null,"COMPLETED","1249636","Diabetes Mellitus, Type 2; Urosepsis; Diabetic Ketoacidosis; Lower Extremity Amputation","DRUG:Sodium-glucose cotransporter 2 (SGLT2) inhibitors; DRUG:Dipeptidyl peptidase-4 (DPP-4) inhibitors; DRUG:Other treatment combinations","Canadian Network for Observational Drug Effect Studies, CNODES","2018-10-01","FALSE","0"],["S002520","ClinicalTrials.gov","NCT03415139",null,"Islet Cell and ST2 Axis Dysregulation in Post-Transplant Diabetes Mellitus","OBSERVATIONAL",null,null,"UNKNOWN","120","Diabetes Mellitus; Cancer","DRUG:Oral Glucose Tolerance Test (OGTT); DRUG:2 OGTTs with and without GLP-1 analogue; DRUG:Hyperglycemic clamp procedure","Vanderbilt-Ingram Cancer Center","2019-03-12","FALSE","0"],["S002521","ClinicalTrials.gov","NCT07576777","HOVIGAMI-ESG","Roles of Hormonal Modulation and the Microbiota in Gastric Emptying and Metabolic Response After Endoscopic Sleeve Gastroplasty","INTERVENTIONAL","NON_RANDOMIZED",null,"NOT_YET_RECRUITING","40","Obesity (Disorder); Metabolic Disorders","PROCEDURE:Laparoscopic sleeve gastrectomy; PROCEDURE:Endoscopic sleeve gastroplasty","Assistance Publique - Hôpitaux de Paris","2026-05-04","FALSE","0"],["S002522","ClinicalTrials.gov","NCT07360262",null,"Time-dependent Recovery of Gastric Emptying After Cessation of Glucagon-like Peptide-1 Receptor Agonists: a Prospective Observational Gastric Ultrasound Study","OBSERVATIONAL",null,null,"COMPLETED","186","Gastric Emptying; Gastroparesis; Preoperative Care","OTHER:Preoperative gastric ultrasound","Wonkwang University Hospital","2025-11-20","FALSE","0"],["S002523","ClinicalTrials.gov","NCT07055386",null,"A Phase II Clinical Study to Compare the Efficacy and Safety of Once-Weekly GZR102 Injection and Bi-weekly GZR18 Injection in Type 2 Diabetes Mellitus With Inadequate Glycemic Control on GLP-1 Receptor Agonists, With or Without Oral Antidiabetic Drugs","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","90","Type 2 Diabetes Mellitus (T2DM)","DRUG:GZR102; DRUG:GZR18","Gan & Lee Pharmaceuticals.","2025-08-07","FALSE","0"],["S002524","ClinicalTrials.gov","NCT07006142",null,"Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists","INTERVENTIONAL",null,null,"RECRUITING","150","Upper Endoscopy; GLP1-R-related Disease","OTHER:Modified Fasting Guidelines","Mayo Clinic","2025-08-01","FALSE","0"],["S002525","ClinicalTrials.gov","NCT06967337",null,"Short, Animated Storytelling Video and Written Messages to Promote Adoption of Health \"Microsteps\": an Online Randomized Experiment","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","5431","Behavior, Health","BEHAVIORAL:Microsteps; BEHAVIORAL:Storytelling video; BEHAVIORAL:Instructional Video","Stanford University","2025-06-19","FALSE","1"],["S002526","ClinicalTrials.gov","NCT07400653",null,"EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","1078","Obesity; Overweight and/or Obesity; Overweight; Diabetes, Type 2; Type 2 Diabetes","DRUG:PF-08653944; OTHER:Placebo","Pfizer","2026-02-24","FALSE","0"],["S002527","ClinicalTrials.gov","NCT07639684","MEASURE","Metabolic Effects of Endoscopic Sleeve Gastroplasty in Obese Adults With Type 2 Diabetes: Evaluation of Glycemic Control, Insulin Use and Obesity Response","INTERVENTIONAL",null,null,"NOT_YET_RECRUITING","50","Type 2 Diabetes Mellitus (T2D); Obesity (BMI>30)","DEVICE:ESG with OverStitch","Boston Scientific Corporation","2027-04","FALSE","0"],["S002528","ClinicalTrials.gov","NCT07798284",null,"Phase 1b Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","80","Overweight/Obesity","DRUG:TQF3250 capsules; DRUG:TQF3250 placebo","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","2026-09","FALSE","0"],["S002529","ClinicalTrials.gov","NCT07234916","VITAGLP","The Impact of Multivitamin Supplementation on Micronutrient Levels in GLP-1 Users: A Randomized, Double-Blind, Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"ENROLLING_BY_INVITATION","246","Weight Loss; Nutritional Deficiencies; GLP - 1; Obese Patients","DIETARY_SUPPLEMENT:Multivitamin Supplementation; OTHER:Placebo","Erasmus Medical Center","2025-12-16","FALSE","9"],["S002530","ClinicalTrials.gov","NCT07837973","PRESERVE","A Double-Blind, Randomized, Multi-Center, Dose-Ranging, Phase 2 Study of the Efficacy and Safety of ALV-100 Versus Placebo for Maintenance of Weight Loss in Patients Previously Treated With Incretin-Based Therapies","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","220","Overweight , Obesity; Adults","DRUG:ALV-100; DRUG:Placebo","Alveus Therapeutics, Inc.","2026-08-10","FALSE","0"],["S002531","ClinicalTrials.gov","NCT06355219","M6","Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes and Obesity: Comparison of Metabolic Surgery Versus GLP-1 Receptor Agonists","OBSERVATIONAL",null,null,"COMPLETED","3932","Type 2 Diabetes Mellitus; Obesity; Microvascular Disease; Macrovascular Disease; Major Adverse Cardiovascular Events; Nephropathy; Retinopathy; Heart Failure; All Cause Mortality",null,"Ali Aminian","2010-01-01","FALSE","0"],["S002532","ClinicalTrials.gov","NCT07140055",null,"A Phase 1 Randomized, Double-blind, Placebo-controlled Single-ascending Dose and Multiple-ascending Dose (SAD and MAD) Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Novel Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) BLX-7006 in Healthy Adults With a Body Mass Index (BMI) of 20 - 35 kg/m2","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","76","Normal Healthy Volunteer; Safety After Oral Intake","DRUG:BLX-7006; DRUG:Placebo","Biolexis Therapeutics","2025-09","FALSE","0"],["S002533","ClinicalTrials.gov","NCT07652333","STRONG","The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication: A Pilot Study","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","40","Muscle Composition; Obesity; Quality of Life (QOL)","BEHAVIORAL:Resistance Exercise; DRUG:GLP-1 RAs","University of Pittsburgh","2026-05-25","FALSE","0"],["S002534","ClinicalTrials.gov","NCT07723820","GLIDE","Glycemic Velocity as a Modifiable Determinant of Early Retinal Microvascular and Choroidal Change During Initiation of GLP-1 Receptor Agonist Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: A Prospective Multimodal Retinal Imaging Cohort Study (the GLIDE Study)","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","126","Type 2 Diabetes Mellitus; Diabetic Retinopathy (DR)","DRUG:GLP-1 Receptor Agonists; DRUG:SGLT2 inhibitor","Thammasat University Hospital","2026-09-01","FALSE","5"],["S002535","ClinicalTrials.gov","NCT07419854",null,"Restoring Facial Volume After GLP-1 Weight Loss With Radiesse","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","48","Volume Loss (Soft Tissue Ptosis or Atrophy )","DEVICE:Hyperdiluted Calcium Hydroxylapatite; DEVICE:Calcium hydroxylapatite; DEVICE:Calcium hydroxylapatite with integral lidocaine","Kalpna Kay Durairaj, MD, FACS","2026-02-01","FALSE","0"],["S002536","ClinicalTrials.gov","NCT07506356","SAGUSE","Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors Agonists","OBSERVATIONAL",null,null,"RECRUITING","38","Diabete Type 2; Regurgitation; Pulmonary Aspiration During Anaesthetic Induction",null,"University Hospital, Geneva","2026-04-01","FALSE","0"],["S002537","ClinicalTrials.gov","NCT01033500",null,"Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients","INTERVENTIONAL","NON_RANDOMIZED",null,"WITHDRAWN","0","Islets of Langerhans Transplantation; Diabetes Mellitus, Type 1; Kidney Transplantation","DRUG:Belatacept","University of Wisconsin, Madison","2010-07","FALSE","0"],["S002538","ClinicalTrials.gov","NCT05662332","QWINT-1","A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naïve Adults With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","795","Type 2 Diabetes; T2D","DRUG:Insulin Efsitora Alfa; DRUG:Insulin Glargine","Eli Lilly and Company","2023-01-14","TRUE","0"],["S002539","ClinicalTrials.gov","NCT04128995","ST2OMP","Surgical or Medical Treatment for Pediatric Type 2 Diabetes","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","ACTIVE_NOT_RECRUITING","88","Diabetes Mellitus, Type 2; Pediatric Obesity; Bariatric Surgery Candidate","PROCEDURE:Advanced Medical Therapy and Bariatric Surgery; DRUG:Advanced Medical Therapy; PROCEDURE:Bariatric Surgery","Children's Hospital Medical Center, Cincinnati","2019-12-15","FALSE","0"],["S002540","ClinicalTrials.gov","NCT07575932","SOLIS-1","A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE-RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","940","Overweight; Obesity; Overweight and/or Obesity; Overweight or Obesity; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight","DRUG:PF-08653945; DRUG:PF-08653944; DRUG:Placebo","Pfizer","2026-05-11","FALSE","0"],["S002541","ClinicalTrials.gov","NCT07773272","SLIM-3","Cardiovascular-kidney-metabolic (CKM)-Guided Therapy for Patients After Acute Coronary Syndrome","OBSERVATIONAL",null,null,"RECRUITING","1215","Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI); Hypercholerolemia; Hypertension; Diabete Mellitus; Cardiovascular Risk Management","DRUG:Rapid ESC-guideline based secondary prevention following myocardial infaction","Zuyderland Medisch Centrum","2026-03-16","FALSE","0"],["S002542","ClinicalTrials.gov","NCT02671864","ANGIOSAFE2","Impact of Incretin-mimetic Hypoglycaemic Drugs on Diabetic Retinopathy in Type 2 Diabetic Patients and Study of Biomarkers in the Development of Severe Retinopathy: Angiosafe-T2D Study 2","INTERVENTIONAL","NON_RANDOMIZED",null,"UNKNOWN","7200","Type 2 Diabetes","OTHER:1: incretin-based therapy; OTHER:2: other antidiabetic","Assistance Publique - Hôpitaux de Paris","2016-04-11","FALSE","1"],["S002543","ClinicalTrials.gov","NCT03108521",null,"Study on Polymorphism of DPP-4 and GLP-1R Genes in Chinese Population and Its Empirical Study on Treatment of Diabetes","INTERVENTIONAL","NON_RANDOMIZED","PHASE4","COMPLETED","119","Diabetes Mellitus","DRUG:Sitagliptin","Sichuan Provincial People's Hospital","2016-04-21","TRUE","1"],["S002544","ClinicalTrials.gov","NCT02094521",null,"Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","122","Diabetes; Healthy","DRUG:NNC0113-0987","Novo Nordisk A/S","2014-03","FALSE","0"],["S002545","ClinicalTrials.gov","NCT07251803",null,"An Observational Study to Examine Non-inferiority of the Standard ASA Fasting Guidelines Versus 24-hour Clear Liquid Diet for Gastric Volume in Patients Taking GLP-1 Agonists","OBSERVATIONAL",null,null,"RECRUITING","150","Gastric Retention","DIAGNOSTIC_TEST:Gastric Ultrasound","Medical University of South Carolina","2026-02-03","FALSE","0"],["S002546","ClinicalTrials.gov","NCT06520540",null,"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Oral Administration of HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","UNKNOWN","72","Glucagon-Like Peptide-1 Receptor Agonists","DRUG:HDM1002 100 mg QD 12weeks; DRUG:HDM1002 200 mg QD 12weeks; DRUG:HDM1002 400 mg QD 12weeks，Q 2W for titration; DRUG:HDM1002 400 mg QD 12weeks，Q 3W for titration; DEVICE:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-07-28","FALSE","0"],["S002547","ClinicalTrials.gov","NCT06654219",null,"Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor Agonist Prior to Anesthesia","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","136","Pulmonary Aspiration","OTHER:GLP-1 RA users with prolonged fasting instructions; OTHER:GLP-1 RA users with standard NPO instructions","The University of Texas Health Science Center, Houston","2025-10-30","FALSE","0"],["S002548","ClinicalTrials.gov","NCT06981936",null,"Evaluation of Balance Tablets in Reducing Vitamin and Mineral Deficiencies in Patients Using GLP-1 Receptor Agonists for Weight Loss","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","150","Micronutrient Deficiencies","DRUG:Balance Tablet; DRUG:Control (placebo)","General Committee of Teaching Hospitals and Institutes, Egypt","2025-05-15","FALSE","0"],["S002549","ClinicalTrials.gov","NCT07625202",null,"A Pilot Study on Creatine Supplementation During Resistance-training for Prevention of Lean Tissue Mass Loss During GLP-1 Receptor Agonist Therapy","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","40","Sarcopenia","DIETARY_SUPPLEMENT:Dietary supplementation during a 12 week resistance-training program (creatine); DIETARY_SUPPLEMENT:Dietary supplementation during a 12 week resistance-training program (placebo)","University of Saskatchewan","2026-05-25","FALSE","0"],["S002550","ClinicalTrials.gov","NCT07550634",null,"A Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of MDR-001 Tablets in Patients With Mild and Moderate Hepatic Impairment and Matched Participants With Normal Hepatic Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","NOT_YET_RECRUITING","32","Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B); Hepatic Insufficiency (MeSH ID: D048550)","DRUG:MDR-001","MindRank AI Ltd","2026-06-01","FALSE","0"],["S002551","ClinicalTrials.gov","NCT05781334","IMPLEMENT-CRM","Identifying Barriers to and optiMizing In-hosPitaL usE of Evidenced-based Medical thErapies for patieNTs With Cardio-Renal-Metabolic Disease","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","202","Heart Failure; Type 2 Diabetes; Chronic Kidney Diseases","OTHER:Virtual Consult Intervention","Duke University","2023-06-09","FALSE","0"],["S002552","ClinicalTrials.gov","NCT00530309",null,"Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus -A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of GSK716155 in Japanese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","40","Diabetes Mellitus, Type 2","DRUG:GSK716155 for injection; DRUG:Placebo","GlaxoSmithKline","2007-08-01","FALSE","2"],["S002553","ClinicalTrials.gov","NCT06569355",null,"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VCT220 Tablets in Overweight/Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","250","Obesity; Overweight","DRUG:VCT220; DRUG:Placebo","Vincentage Pharma Co., Ltd","2023-12-27","FALSE","1"],["S002554","ClinicalTrials.gov","NCT07385547",null,"A Phase 1 Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of GL0034","INTERVENTIONAL",null,"PHASE1","RECRUITING","40","Type II Diabetes Mellitus","DRUG:GL0034","Sun Pharmaceutical Industries Limited","2026-02-25","FALSE","0"],["S002555","ClinicalTrials.gov","NCT07670416",null,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 in Adult Chinese Patients With Obesity or Overweight, With or Without Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","300","Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM)","COMBINATION_PRODUCT:Enicepatide; COMBINATION_PRODUCT:Placebo","Hoffmann-La Roche","2026-07-03","FALSE","0"],["S002556","ClinicalTrials.gov","NCT07409831","HARMONY","Holistic Approach to Cardiometabolic Health and Obesity: Incretin-based Therapies, Nutrition, and Active Lifestyle","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","120","Obesity & Overweight; Cardiometabolic Conditions","BEHAVIORAL:Intervention; DRUG:Incretin-Based Treatment","Laval University","2026-07-06","FALSE","0"],["S002557","ClinicalTrials.gov","NCT05832151",null,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Diabetic Gastroparesis","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","382","Diabetic Gastroparesis","DRUG:CIN-102 Dose 15mg or 10mg; DRUG:Placebo","CinDome Pharma, Inc.","2023-03-27","FALSE","0"],["S002558","ClinicalTrials.gov","NCT07130396",null,"A Single Arm Trial to Evaluate the Effect of PhytoMulti® Multivitamin and UltraFlora® Balance Probiotic on Bowel Symptoms in Individuals Using GLP-1 Receptor Agonists, Assessed by the IBS Symptom Severity Score (IBS-SSS)","INTERVENTIONAL",null,null,"NOT_YET_RECRUITING","100","GLP-1; Adults","DIETARY_SUPPLEMENT:Multivitamin and a Probiotic","Metagenics, Inc.","2025-11-01","FALSE","0"],["S002559","ClinicalTrials.gov","NCT06867718","COMO-1","A Phase 2 Study of Once-Daily RGT001-075 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities (COMO-1)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","267","Obesity or Overweight","DRUG:RGT001-075; DRUG:Placebo Comparator","Regor Pharmaceuticals Inc.","2025-01-24","FALSE","0"],["S002560","ClinicalTrials.gov","NCT07283978","RENEW","Real-world Exploration of Digital iNnovation in the Management of Excess Weight","INTERVENTIONAL","NON_RANDOMIZED",null,"ENROLLING_BY_INVITATION","580","Obesity; Obesity & Overweight","OTHER:Digital Weight Management Programme","Guy's and St Thomas' NHS Foundation Trust","2025-12-16","FALSE","0"],["S002561","ClinicalTrials.gov","NCT07784127",null,"Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation","INTERVENTIONAL",null,null,"NOT_YET_RECRUITING","20","Diabetes","PROCEDURE:Gut motility quantification using a capsule after initiating GLP-1RA therapy","The Cleveland Clinic","2026-12","FALSE","0"],["S002562","ClinicalTrials.gov","NCT07012317",null,"A Randomized, Double-Blind Crossover Trial to Assess Gastrointestinal Responses to Dietary Fibers in Adults Using Weight Loss Medications","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","50","Gastrointestinal Symptoms; Weight Loss; GLP-1","OTHER:High Fiber Bar with Inulin; OTHER:High Fiber bar with Fiber Blend; OTHER:High Fiber Bar with Resistant Starch type 4; OTHER:Low Fiber Bar","Midwest Center for Metabolic and Cardiovascular Research","2025-05-29","FALSE","0"],["S002563","ClinicalTrials.gov","NCT07702825","FIT-YOUNG","Impact of Weight Loss Interventions on Multiorgan Health, Detected by Quantitative MRI, in Children and Young People With Severe Obesity.","OBSERVATIONAL",null,null,"RECRUITING","30","Childhood Obesity",null,"Alder Hey Children's NHS Foundation Trust","2026-03-06","FALSE","0"],["S002564","ClinicalTrials.gov","NCT03363464",null,"EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program","OBSERVATIONAL",null,null,"COMPLETED","230000","Diabetes Mellitus, Type 2","DRUG:Empagliflozin; DRUG:DPP-4 inhibitor; DRUG:GLP-1 receptor agonist","Boehringer Ingelheim","2017-10-16","FALSE","0"],["S002565","ClinicalTrials.gov","NCT03566693","MOBILE","Continuous Glucose Monitoring (CGM) in Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","176","Diabetes Mellitus, Type 2","DEVICE:Dexcom G6 CGM System; DEVICE:Blood glucose meter","DexCom, Inc.","2018-07-30","FALSE","0"],["S002566","ClinicalTrials.gov","NCT02537834",null,"An Open-Label, Multicenter Study to Evaluate 52-Week Long-Term Safety, Tolerability and Efficacy of Tofogliflozin With Glucagon-like Peptide-1(GLP-1) Analogue Treatment In Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE4","COMPLETED","65","Type 2 Diabetes Mellitus","DRUG:Tofogliflozin; DRUG:GLP-1 analogue","Kowa Company, Ltd.","2015-08","FALSE","1"],["S002567","ClinicalTrials.gov","NCT05161793","TELEMTRRDM","Telemedicine Continuous Remote Monitoring of Adults With Uncontrolled Diabetes Mellitus","OBSERVATIONAL",null,null,"COMPLETED","200","Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2","DEVICE:Tele-Monitor DM","University of Southern California","2022-05-01","FALSE","0"],["S002568","ClinicalTrials.gov","NCT07833813","BIOM","Effects of Incretin Memetics and Exercise on Gut-brain and Metabolic Health in Persons With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","110","Type 2 Diabetes Mellitus","BEHAVIORAL:Structured Exercise Program","University of Regina","2026-09","FALSE","0"],["S002569","ClinicalTrials.gov","NCT04791358",null,"A Prospective Decision Impact Trial of KidneyIntelX in Patients With Type 2 Diabetes and Existing Chronic Kidney Disease","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","1500","Diabetic Kidney Disease","DIAGNOSTIC_TEST:KidneyIntelX","Renalytix AI, Inc.","2021-11-01","FALSE","0"],["S002570","ClinicalTrials.gov","NCT07676565","ATT1D","Safety and Efficacy of Adjunct Therapies in Adults With Type 1diabetes: Multicenter, Registry Study","OBSERVATIONAL",null,null,"RECRUITING","300","Type 1 Diabetes",null,"Indiana University","2026-03-24","FALSE","0"],["S002571","ClinicalTrials.gov","NCT05349955","GUARD","Effects and Safety of GUideline Algorithm Based Intervention on CaRdiovascular and Renal Outcomes in Elderly Diabetic Patients With High Cardiovascular Risk in the Community- A Cluster Randomized Controlled Trial (GUARD-Community Study)","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","5600","Type 2 Diabetes; Cardiovascular Complication; Diabetic Kidney Disease","OTHER:Intensive guideline algorithm implementation; OTHER:Conventional guideline algorithm implementation","Shanghai Zhongshan Hospital","2022-11-21","FALSE","3"],["S002572","ClinicalTrials.gov","NCT06278285","Maigrir_OT","Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery","INTERVENTIONAL","NON_RANDOMIZED",null,"RECRUITING","40","Obesity","OTHER:Blood GLP1; OTHER:Blood No treated GLP1","Centre Hospitalier Universitaire de Nice","2024-03-06","FALSE","0"],["S002573","ClinicalTrials.gov","NCT05299697",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study of TG103 Injection in the Management of Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","195","Overweight or Obesity","DRUG:TG103 15 mg; DRUG:TG103 22.5 mg; DRUG:Placebo","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2022-05-20","FALSE","0"],["S002574","ClinicalTrials.gov","NCT07223216",null,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-650 in Otherwise Healthy Overweight or Obese Participants.","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","80","Obesity","DRUG:BMF-650","Biomea Fusion Inc.","2025-10-23","FALSE","0"],["S002575","ClinicalTrials.gov","NCT06851858","ARAY","A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","69","Endocrinology; Diabetes, Type II; Obesity","DRUG:AZD6234; DRUG:Placebo to match","AstraZeneca","2025-03-12","FALSE","0"],["S002576","ClinicalTrials.gov","NCT06777238","Optimum 1","A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","274","Type 2 Diabetes Mellitus (T2DM)","DRUG:GZR18; DRUG:Placebo","Gan & Lee Pharmaceuticals.","2025-01-16","FALSE","0"],["S002577","ClinicalTrials.gov","NCT03430284",null,"Effects of Multifactorial Intervention on Type 2 Diabetes - A Multicenter, Open-Label, Randomized, Parallel Controlled, Community Trial.","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","6300","Diabetes Mellitus, Type 2","BEHAVIORAL:Lifestyle therapy; DRUG:Pharmacotherapy; OTHER:Monitoring and management; OTHER:General treatment","Shandong Provincial Hospital","2018-04-01","FALSE","0"],["S002578","ClinicalTrials.gov","NCT02109978","RetroMASTER","Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes:","OBSERVATIONAL",null,null,"COMPLETED","562","Diabetes",null,"Royal Devon and Exeter NHS Foundation Trust","2013-04","FALSE","0"],["S002579","ClinicalTrials.gov","NCT03549754","iCaReMe","Real-world Multinational Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases","OBSERVATIONAL",null,null,"RECRUITING","35000","Type 2 Diabetes; Hypertension; Chronic Kidney Disease; Heart Failure",null,"AstraZeneca","2018-02-17","FALSE","0"],["S002580","ClinicalTrials.gov","NCT07127354",null,"The Impact of GLP-1 Agonist and GIP Agonist on Bowel Preparation Quality: A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","132","GLP - 1; Bowel Preparation for Colonoscopy","DRUG:Continue GLP/GIP","The Cleveland Clinic","2025-08-01","FALSE","0"],["S002581","ClinicalTrials.gov","NCT07444203","TRIDENT 2","Transformative Research in Diabetic Nephropathy 2.0: A Proof of Principle Study of SGLT2 Inhibitors (TRIDENT 2.0)","OBSERVATIONAL",null,null,"RECRUITING","200","Diabetic Nephropathies; Kidney Diseases; Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2","DRUG:Sodium-glucose cotransporter 2 inhibitors (SGLT2i); DRUG:Renin-angiotensin-aldosterone system blockade; DRUG:Glucagon-like peptide-1 receptor agonists (GLP 1 RA); DRUG:Mineralocorticoid Receptor Antagonists(MRAs)","University of Pennsylvania","2025-11-12","FALSE","0"],["S002582","ClinicalTrials.gov","NCT06351358",null,"A Multi-center, Open-label Study to Evaluate the Synergistic Effects of Biostimulator and Dermal Fillers for Cheek Augmentation and Correction of Contour Deficiencies","INTERVENTIONAL",null,null,"COMPLETED","41","Photoaging; Weight Loss; Skin Laxity; Photodamaged Skin; Volume Deficiency of the Midface","DEVICE:Sculptra treatment; DEVICE:Restylane Treatment","Galderma R&D","2024-02-19","FALSE","0"],["S002583","ClinicalTrials.gov","NCT05875636",null,"GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy","OBSERVATIONAL",null,null,"COMPLETED","260","Gastric Content Aspiration","OTHER:Esophagogastroduodenoscopy","Medical University of South Carolina","2023-08-21","FALSE","0"],["S002584","ClinicalTrials.gov","NCT02941445",null,"Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","24","Polycystic Ovary Syndrome; Body Weight","DRUG:sitagliptin and metformin; DRUG:Metformin","University Medical Centre Ljubljana","2015-10","FALSE","0"],["S002585","ClinicalTrials.gov","NCT06657339",null,"National Registry of Obesity Treatment by Endosleeve","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","354","Obesity","PROCEDURE:Therapeutic endoscopy endosleeve using a gastric suturing device (OverStitch™/Endomina™)","Société Française d'Endoscopie Digestive","2024-12","FALSE","0"],["S002586","ClinicalTrials.gov","NCT07646457",null,"Comparative Effectiveness of Western Pharmacotherapy Versus Integrative Western and Traditional Chinese Medicine for Weight Management in Central Taiwan: A Real-World Cohort Study","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","296","Obesity & Overweight",null,"National Yang Ming Chiao Tung University","2026-04-01","FALSE","0"],["S002587","ClinicalTrials.gov","NCT03222245",null,"The Effect of Injectable Therapies on Health Status, Quality of Life and Treatment Satisfaction in Patients With Type 2 Diabetes: Prospective Observational Cohort Study","OBSERVATIONAL",null,null,"COMPLETED","256","Diabetes",null,"Portsmouth Hospitals NHS Trust","2017-06-30","FALSE","0"],["S002588","ClinicalTrials.gov","NCT05889637",null,"Gastric Ultrasound Assessment for Preoperative Prandial State of Patients Taking Glucagon-Like Peptide-1(GLP-1) Receptor Agonists","OBSERVATIONAL",null,null,"COMPLETED","132","Pulmonary Aspiration","DIAGNOSTIC_TEST:Gastric ultrasound","The University of Texas Health Science Center, Houston","2023-06-06","FALSE","0"],["S002589","ClinicalTrials.gov","NCT06682351",null,"Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention","INTERVENTIONAL","RANDOMIZED","PHASE4","NOT_YET_RECRUITING","200","Prediabetes / Type 2 Diabetes","DRUG:Metformin; DRUG:GLP-1A; DIETARY_SUPPLEMENT:MED","Stanford University","2024-11","FALSE","0"],["S002590","ClinicalTrials.gov","NCT06854952","FALCON","A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","167","Overweight or Obesity","DRUG:TERN-601; OTHER:Matching Placebo","Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","2025-03-07","TRUE","1"],["S002591","ClinicalTrials.gov","NCT07743567","GROW","Gestational Response, Outcomes, and Weight After GLP-1 Use","OBSERVATIONAL",null,null,"RECRUITING","400","Pregnant Individuals; Obesity & Overweight; Gestational Weight Gain",null,"University of Kansas Medical Center","2026-04-13","FALSE","2"],["S002592","ClinicalTrials.gov","NCT02954692","EASE","A National, Multicenter, Prospective, Interventional, Open-label, Single-arm, 24-Week Phase IV Study to Evaluate the Effectiveness and Safety of Initiation and Titration of Insulin Glargine U300 in Insulin-naïve Patients With T2DM Inadequately Controlled on OAD Treatment in Turkey","INTERVENTIONAL",null,"PHASE4","COMPLETED","112","Type 2 Diabetes Mellitus","DRUG:INSULIN GLARGINE (U300); DRUG:metformin; DRUG:sulfonylurea; DRUG:meglitinides; DRUG:thiazolidinediones; DRUG:alpha-glucosidase inhibitors; DRUG:GLP1 Receptor Agonist; DRUG:Dipeptidyl peptidase-IV (DPP-IV) inhibitors; DRUG:Sodium-glucose transport-2 (SGLT-2) inhibitors","Sanofi","2016-11-30","FALSE","0"],["S002593","ClinicalTrials.gov","NCT04709263","Priority-HF","Heart Failure Patients Registry A Prospective Observational Multicenter Registry of Patients With Chronic Heart Failure in the Population of the Russian Federation (PRIORITY-HF)","OBSERVATIONAL",null,null,"COMPLETED","19990","Heart Failure",null,"AstraZeneca","2020-12-21","FALSE","0"],["S002594","ClinicalTrials.gov","NCT06017544",null,"Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium-glucose Cotransporter-2 Inhibitors (SGLT2is) Combination Therapy and Major Adverse Cardiovascular Events After Acute Myocardial Infarction: an Observational Study in Patients with Type 2 Diabetes.","OBSERVATIONAL",null,null,"COMPLETED","257","Diabetes Mellitus, Type 2; Myocardial Infarction","PROCEDURE:PCI","University of Campania Luigi Vanvitelli","2017-01-01","FALSE","1"],["S002595","ClinicalTrials.gov","NCT06038734",null,"Using Point-of-Care-Ultrasound (POCUS) to Assess Gastric Contents Among Fasting Pre-operative Patients Taking GLP-1 Agonists.","OBSERVATIONAL",null,null,"COMPLETED","108","Delayed Gastric Emptying; Gastroparesis","DIAGNOSTIC_TEST:gastric ultrasound","University of North Carolina, Chapel Hill","2023-11-10","FALSE","0"],["S002596","ClinicalTrials.gov","NCT06982378","OMICS in MASLD","Effect of Glucagon-like Peptide -1 Receptor Agonist on Liver Tissue and Plasma Lipids in MASLD","OBSERVATIONAL",null,null,"WITHDRAWN","0","NAFLD; Diabetes; Obesity","DRUG:GLP-1 receptor agonist","Medical College of Wisconsin","2026-07-01","FALSE","0"],["S002597","ClinicalTrials.gov","NCT05997576",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","675","Overweight or Obesity","DRUG:TG103 22.5 mg; DRUG:Placebo","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2023-11-22","FALSE","0"],["S002598","ClinicalTrials.gov","NCT03314844",null,"Plasma Glucagon-like Peptide-1 Levels Predict In-hospital Complications in ST-segment Elevation Myocardial Infarction","OBSERVATIONAL",null,null,"COMPLETED","564","STEMI - ST Elevation Myocardial Infarction; Glucagon-like Peptide-1; Bleeding; Complications",null,"Chinese PLA General Hospital","2013-02-01","FALSE","0"],["S002599","ClinicalTrials.gov","NCT07744360",null,"An Open-label, Randomized Controlled Pilot Study Evaluating the Impact of a Prebiotic Soda on Gastrointestinal Symptoms in Users of GLP-1 Agonists","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","80","GI Symptoms","OTHER:Prebiotic Soda","Olipop, PBC","2026-02-10","FALSE","0"],["S002600","ClinicalTrials.gov","NCT07361640","DiaMester","DiaMester: E-health Lifestyle Program for Improved Self-management and Remission of Type 2 Diabetes - a Pilot RCT","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","99","Diabetes Mellitus, Type 2","BEHAVIORAL:e-health lifestyle program; BEHAVIORAL:Low calorie diet","Oslo University Hospital","2026-01-14","FALSE","0"],["S002601","ClinicalTrials.gov","NCT07140289",null,"The Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying Before Elective Surgery","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","100","Gastric Emptying; Glucagon-Like Peptide-1 Receptor Agonists; Intermittent Fasting; Intraoperative Complication Due to Anesthesia; Respiratory Aspiration of Gastric Contents","DIAGNOSTIC_TEST:Ultrasound of gastric contents","Wael Saasouh, MD","2025-09-01","FALSE","0"],["S002602","ClinicalTrials.gov","NCT07701460","AFTER-GLP","Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","200","Weight Maintenance","BEHAVIORAL:Digital Behavioral Application","Tufts University","2026-08-01","FALSE","0"],["S002603","ClinicalTrials.gov","NCT05465317",null,"Comparative Cardiovascular and Renal Effectiveness and Safety of Empagliflozin and Other SGLT2i in Patients With Type 2 Diabetes (T2D) With and Without Baseline Kidney Disease in the United States","OBSERVATIONAL",null,null,"COMPLETED","62197","Diabetes Mellitus, Type 2","DRUG:Empagliflozin; DRUG:Dipeptidyl Peptidate-4 inhibitors","Boehringer Ingelheim","2022-08-08","TRUE","1"],["S002604","ClinicalTrials.gov","NCT04272359","Sulfa-Zero","Prospective, Parallel Goups Study, Aimed to Evaluating Possible Benefits of the Treatment of New Generation Hypoglycaemic Drugs Compared to Sulphonylureas for the Tratment of Type 2 Diabetes Mellitus","OBSERVATIONAL",null,null,"UNKNOWN","138","T2DM (Type 2 Diabetes Mellitus); Diet, Healthy; Renal Function Disorder; Albuminuria","DRUG:Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas","University of Milan","2019-05-06","FALSE","3"],["S002605","ClinicalTrials.gov","NCT07021443","GLP1_NAFLD","The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting","OBSERVATIONAL",null,null,"COMPLETED","50","Non-Alcoholic Fatty Liver Disease","OTHER:non-interventional","Universitair Ziekenhuis Brussel","2023-10-09","TRUE","0"],["S002606","ClinicalTrials.gov","NCT05362058","QWINT-2","A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","928","Diabetes; Type 2 Diabetes","DRUG:Insulin Efsitora Alfa; DRUG:Insulin Degludec","Eli Lilly and Company","2022-06-03","TRUE","1"],["S002607","ClinicalTrials.gov","NCT07270497",null,"The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight","OBSERVATIONAL",null,null,"RECRUITING","100","GLP-1; Nutrition",null,"Medical University of Warsaw","2025-08-15","FALSE","0"],["S002608","ClinicalTrials.gov","NCT07602803",null,"GLP1 Agonists Once Weekly for the Treatment of Obesity in Patients With Bardet-Biedl Syndrome (BBS)","OBSERVATIONAL",null,null,"COMPLETED","300","Bardet-Biedl Syndrome",null,"The Queen Elizabeth Hospital","2023-01-01","FALSE","0"],["S002609","ClinicalTrials.gov","NCT07360457",null,"Association of GLP1 Analogues and SGLT2 Inhibitors With the Risk of Osteoarthritis in Type 2 Diabetic Patients","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","390","Osteoarthritis","DRUG:GLP-1 analog; DRUG:SGLT2 inhibitor; DRUG:Antidiabetic","Beni-Suef University","2026-02-01","FALSE","0"],["S002610","ClinicalTrials.gov","NCT04445181",null,"Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study","OBSERVATIONAL",null,null,"COMPLETED","14873","Chronic Kidney Disease in Type 2 Diabetes","DRUG:The physician's prescription in routine clinical practice","Bayer","2020-07-01","FALSE","1"],["S002611","ClinicalTrials.gov","NCT07175805",null,"Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","200","Lower Urinary Tract Symptoms; Stress Urinary Incontinence; Urge Urinary Incontinence; Overactive Bladder; Pelvic Organ Prolapse; Weight Loss; Fecal Incontinence; Bariatric Surgery; glp1 Agonist","PROCEDURE:Bariatric Surgery; DRUG:GLP1 receptor agonist","Hartford HealthCare","2025-10","FALSE","0"],["S002612","ClinicalTrials.gov","NCT06665919",null,"Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","283","Coronary Artery Disease; Clopidogrel Resistance; Coronary Thrombosis; Adverse Cardiac Events; Bleeding; Hospitalisations; Death; Death From Cardiovascular Disease","OTHER:CYP2C19 Genotype-Guided Clopidogrel Treatment; OTHER:CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel; OTHER:The Conventional Clopidogrel Treatment","Vistamedi Ltd.","2023-06-15","TRUE","0"],["S002613","ClinicalTrials.gov","NCT07455630","BEYOND","Effect of Weight Loss on Cardiac Function and Biomarkers in Patients With Cardiovascular Risk Factors, Obesity, or Overweight","OBSERVATIONAL",null,null,"COMPLETED","30","Obesity & Overweight","DRUG:Weight loss with pharmacotherapy; BEHAVIORAL:Weight loss without pharmacotherapy","TecSalud Investigación Clínica","2023-06-20","FALSE","0"],["S002614","ClinicalTrials.gov","NCT06660134",null,"Strict Weight Management and Glycemic Control Based on Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment VS. Conventional Antidiabetic Drugs for Ablation Outcomes in Overweight or Obese Patients with Type 2 Diabetes and Atrial Fibrillation","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","174","Type 2 Diabetes Mellitus (T2DM); Atrial Fibrillation (AF)","DRUG:Glucagon-like peptide-1 receptor agonists (GLP 1 RA)","Shanghai Chest Hospital","2021-08-01","FALSE","0"],["S002615","ClinicalTrials.gov","NCT07014709","IPMN-GLP1RA","Impact of GLP-1 Receptor Agonists on Patients With Intraductal Papillary Mucinous Neoplasms: A Retrospective Multicentric Cohort Study","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","30","IPMN; IPMN, Pancreatic; GLP-1; Intraductal Papillary Mucinous Neoplasm of Pancreas; Glucagon-Like Peptide-1 Receptor Agonists","DRUG:GLP1 receptor agonist","Hôpital Fribourgeois","2025-05-31","FALSE","1"],["S002616","ClinicalTrials.gov","NCT02176681",null,"A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","70","Haemodialyzed, Type 2 Diabetes","DRUG:Vildagliptin (Galvus); DRUG:Insulin","University Hospital, Strasbourg, France","2014-06","FALSE","0"],["S002617","ClinicalTrials.gov","NCT07518407","DINE-GLP1","Dietary Insights and Nutritional Education in Adults on GLP-1 Therapy","INTERVENTIONAL",null,null,"RECRUITING","50","Obesity Type 2 Diabetes Mellitus; Obesity","BEHAVIORAL:SWITCH Diets - Mobile Nutrition Behavioral Intervention","University of South Carolina","2026-04-06","FALSE","0"],["S002618","ClinicalTrials.gov","NCT02291874",null,"Postmarketing Clinical Study of Ipragliflozin - Long-term Study in Combination With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE4","COMPLETED","100","Type 2 Diabetes Mellitus","DRUG:Ipragliflozin","Astellas Pharma Inc","2014-10-08","FALSE","1"],["S002619","ClinicalTrials.gov","NCT07803185",null,"Longitudinal Evaluation of Anhedonia and Emotional Eating Behavior in Individuals Using Glucagon-Like Peptide-1 Receptor Agonists","OBSERVATIONAL",null,null,"RECRUITING","60","Obesity; Emotional Eating; Anhedonia",null,"TC Erciyes University","2026-06-01","FALSE","1"],["S002620","ClinicalTrials.gov","NCT07783113","GLP-1","Estudo da eficácia de um Suplemento Alimentar na redução da Queda Capilar em Participantes Com eflúvio telógeno Associado ao Uso de análogos de GLP-1 Por Meio de avaliação clínica, percepção Subjetiva e Tricograma","INTERVENTIONAL",null,null,"NOT_YET_RECRUITING","48","Alopecia","DIETARY_SUPPLEMENT:Dietary Supplement for Hair Loss","Farmoquimica S.A.","2026-10","FALSE","0"],["S002621","ClinicalTrials.gov","NCT07240246",null,"Effect of a Dietary Supplement (FitLine TopShape) on the Incretin Response","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","40","GLP-1; Obesity &Amp; Overweight; Dietary Supplement","DIETARY_SUPPLEMENT:Intervention: Dietary Supplement with Plant Extracts; OTHER:Placebo","FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation","2025-10-24","FALSE","6"],["S002622","ClinicalTrials.gov","NCT06151964","CONTEMPO","A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD9550 Monotherapy and Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity and Overweight With or Without Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","ACTIVE_NOT_RECRUITING","166","Overweight and Obesity","DRUG:AZD9550; DRUG:placebo; DRUG:AZD9550 and AZD6234","AstraZeneca","2023-09-29","FALSE","0"],["S002623","ClinicalTrials.gov","NCT06601517",null,"A Phase I, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Effect of Repeated Administration of HDM1002 on the Pharmacokinetics of Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy and Overweight Adult Chinese Subjects","INTERVENTIONAL",null,"PHASE1","UNKNOWN","30","Healthy Adult Subject; Overweight Subject","DRUG:Repaglinide; DRUG:Atorvastatin; DRUG:Digoxin; DRUG:Rosuvastatin; DRUG:HDM1002","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-10","FALSE","0"],["S002624","ClinicalTrials.gov","NCT07194317","FIDGET","A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment","INTERVENTIONAL",null,null,"COMPLETED","64","Obese Patients","DEVICE:Testing 3 different digital dietary assessment tools in a random order (Nutritics-Libro, MyFood24 and Intake24)","King's College London","2025-09-01","FALSE","2"],["S002625","ClinicalTrials.gov","NCT07495904","LEAN-PRO GLP-1","The Effect of GLP-1 Receptor Agonist-based Treatment on Body Composition and Muscle Mass in Adults With Obesity: The Role of Dietary Protein Consumption in Muscle Mass Maintenance","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","130","Obesity","BEHAVIORAL:High Protein Dietary Intervention; BEHAVIORAL:Control (Standard Mediterranean Diet Counseling)","Hellenic Mediterranean University","2026-03-30","FALSE","0"],["S002626","ClinicalTrials.gov","NCT05039450",null,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","213","NASH - Nonalcoholic Steatohepatitis","DRUG:EFX; DRUG:Placebo","Akero Therapeutics, Inc","2021-07-30","TRUE","2"],["S002627","ClinicalTrials.gov","NCT07271043",null,"Evaluating the Efficacy of High-Protein Diabetes Specific Formula (HP-DSF) on Body Composition in Overweight/Obese Patients With Type 2 Diabetes Treated With Incretin Mimetic Drugs","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","60","Type 2 Diabetes","DIETARY_SUPPLEMENT:protein supplement","Joslin Diabetes Center","2026-01-01","FALSE","0"],["S002628","ClinicalTrials.gov","NCT07685808",null,"A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","360","Overweight or Obesity","DRUG:Olatorepatide; DRUG:Placebo","Regeneron Pharmaceuticals","2026-07-28","FALSE","0"],["S002629","ClinicalTrials.gov","NCT06740435",null,"Pilot Study Enhancing Telemedicine Care Delivery for Adults With Complex Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"ACTIVE_NOT_RECRUITING","50","Type 2 Diabetes","OTHER:Enhanced Telemedicine for Type 2 Diabetes; OTHER:Usual Telemedicine Endocrinology Care for T2D","University of Pittsburgh","2025-02-03","FALSE","0"],["S002630","ClinicalTrials.gov","NCT01408862",null,"Effects of Incretins on Human Platelet Function","OBSERVATIONAL",null,null,"COMPLETED","20","Inhibition of Platelet Aggregation by Incretins","OTHER:venous puncture","National Council of Scientific and Technical Research, Argentina","2012-12","TRUE","0"],["S002631","ClinicalTrials.gov","NCT07558603",null,"A Prospective, Single Center, Open-label Study Evaluating the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonists","INTERVENTIONAL","NON_RANDOMIZED",null,"NOT_YET_RECRUITING","50","Laxity; Skin","DRUG:On GLP1 plus HRT; DRUG:On GLP1 Only","Goldman, Butterwick, Fitzpatrick and Groff","2026-04-20","FALSE","0"],["S002632","ClinicalTrials.gov","NCT07087431","PROACT 3","PROACT 3: Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","500","Coronary Artery Disease","BEHAVIORAL:Immediate disclosure of CAD PRS results; BEHAVIORAL:Deferred Disclosure of CAD PRS results","Massachusetts General Hospital","2025-10-15","FALSE","0"],["S002633","ClinicalTrials.gov","NCT06478173",null,"The Effect of Complex Exercise Training on General Health Status in Patients with Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","126","Type2diabetes","BEHAVIORAL:Exercise training","University of the Faroe Islands","2024-08-01","FALSE","1"],["S002634","ClinicalTrials.gov","NCT07224880",null,"Safety and Outcomes of Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A Case Series","OBSERVATIONAL",null,null,"COMPLETED","9","glp1 Agonist; Gene Expression; Skin Laxity","DEVICE:ellacor","Cytrellis Biosystems, Inc.","2025-10-14","FALSE","0"],["S002635","ClinicalTrials.gov","NCT07481305","LCIRN","Lifestyle Change Implementation Research Network at PRC at UMass Chan","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","220","GLP - 1","OTHER:Digital Lifestyle Coaching Program","University of Massachusetts, Worcester","2026-07-22","FALSE","0"],["S002636","ClinicalTrials.gov","NCT02451137",null,"A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in Insulin-naive Patients With Uncontrolled Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","3304","Diabetes Mellitus, Type 2","DRUG:Insulin glargine, 300 U/ml; DRUG:Insulin glargine, 100 U/ml; DRUG:Insulin detemir; DRUG:Background Therapy","Sanofi","2015-06-16","TRUE","1"],["S002637","ClinicalTrials.gov","NCT06661174","EBSDKD","A Cohort Study on the Efficacy of Bariatric Surgery for Rapidly Progressing Diabetic Nephropathy","OBSERVATIONAL",null,null,"RECRUITING","100","Bariatric Surgeries; Diabetic Nephropathy","PROCEDURE:Bariatric surgery; OTHER:Non-surgical therapy","China-Japan Friendship Hospital","2023-10-01","FALSE","0"],["S002638","ClinicalTrials.gov","NCT05535322",null,"Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity in the Department of Health of Valencia Clínico-Malvarrosa","OBSERVATIONAL",null,null,"COMPLETED","26944","Type 2 Diabetes; Obesity","DRUG:GLP-1RA; DRUG:SGLT2i; DRUG:Insulin; DRUG:Miscellany","Ana Palanca","2014-01-01","FALSE","15"],["S002639","ClinicalTrials.gov","NCT07789223","WMMS","A Randomised, Double-Blind, Placebo-Controlled Trial Evaluating the Effects of elénzia CONTROL® on Weight and Metabolic Health in Adults Naïve to or Who Have Recently Discontinued Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","200","Overweight; Obesity; Weight Maintenance","DIETARY_SUPPLEMENT:elénzia CONTROL®; DIETARY_SUPPLEMENT:Placebo","Elenzia","2026-09-15","FALSE","0"],["S002640","ClinicalTrials.gov","NCT06562088",null,"A Phase I, Open-Label, Parallel, Fixed-Sequence Study to Evaluate the Effect of Repeated Administration of Rifampicin or Itraconazole on the Pharmacokinetics of HDM1002 in Healthy Adult Chinese Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","UNKNOWN","40","Healthy Adult Subject","DRUG:HDM1002 and rifampicin; DRUG:HDM1002 and itraconazole","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-08-16","FALSE","0"],["S002641","ClinicalTrials.gov","NCT07623148",null,"Time-dependent Association Between Cessation of Glucagon-like Peptide-1 Receptor Agonists and Residual Gastric Contents Assessed by Point-of-care Gastric Ultrasound: a Prospective Observational Study","OBSERVATIONAL",null,null,"COMPLETED","186","Residual Gastric Contents; Delayed Gastric Emptying","OTHER:GLP-1 RA Cessation Interval","Wonkwang University Hospital","2026-07-01","FALSE","0"],["S002642","ClinicalTrials.gov","NCT05542420","CONVERGE","A Multicentre Retrospective Study of Characterization of Treatment Intensified (Add on to Metformin) Real World Adult Population With Type 2 Diabetes Mellitus in India, Pakistan, and Thailand.","OBSERVATIONAL",null,null,"COMPLETED","3000","Diabetes Mellitus, Type 2","OTHER:No treatment given","Novo Nordisk A/S","2022-10-19","FALSE","1"],["S002643","ClinicalTrials.gov","NCT07536516","DM OPF ROXY","Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients","INTERVENTIONAL",null,null,"RECRUITING","20","Diabetes Mellitus","DEVICE:• Laser Speckle Flowgraphy (LSFG); DEVICE:• Optical Coherence Tomography (OCT); DEVICE:• Optical Coherence Tomography Angiography (OCT-A)","Medical University of Vienna","2025-11-28","FALSE","0"],["S002644","ClinicalTrials.gov","NCT07830329",null,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 52-Week Trial to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","300","Hidradenitis Suppurativa","DRUG:Olatorepatide; DRUG:Placebo","Regeneron Pharmaceuticals","2026-10-30","FALSE","0"],["S002645","ClinicalTrials.gov","NCT06608329",null,"A Randomized, Open-label, Crossover Study to Evaluate Relative Bioavailability, and Food Effect of HDM1002 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","UNKNOWN","33","Healthy Adult Subject","DRUG:HDM1002","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-10","FALSE","0"],["S002646","ClinicalTrials.gov","NCT03288402","DIB-NET","Investigation of the Effects of Breakfast or Caffeine Containing Beverages on the Measurement of Plasma Chromogranin A in Patients With Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","346","Neuroendocrine Tumors","OTHER:ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast","University Hospitals Coventry and Warwickshire NHS Trust","2017-02-01","FALSE","0"],["S002647","ClinicalTrials.gov","NCT07244445",null,"Dietary Pistachio Intake and Nutrition-Related Outcomes in Individuals Using GLP-1 Receptor Agonists: A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","108","Dietary Change; Obesity & Overweight; Food Acceptance","DIETARY_SUPPLEMENT:Pistachios; PROCEDURE:Dual-energy X-ray absorptiometry (DEXA) scans","Ian J. Neeland, MD","2026-01-29","FALSE","0"],["S002648","ClinicalTrials.gov","NCT06030726","NUDGE-FLU-2","Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behavioral Nudges in Increasing InFLUenza Vaccine Uptake Among Older Adults","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","881373","Influenza; Behavior and Behavior Mechanisms","BEHAVIORAL:Behavioral Economic Principles","Tor Biering-Sørensen","2023-09-14","FALSE","0"],["S002649","ClinicalTrials.gov","NCT02446834",null,"Research of Intensive Lifestyle Intervention for Overweight PCOS Patients With Impaired Glucose Tolerance in Their Metabolic and Reproductive Abnormalities Treatment","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","40","Polycystic Ovary Syndrome","BEHAVIORAL:intensive lifestyle intervention; DRUG:GLP-1 Receptor Agonists; DRUG:Metformin; DRUG:Acarbose","RenJi Hospital","2015-04","FALSE","0"],["S002650","ClinicalTrials.gov","NCT07437911",null,"A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","120","Nutrition Intake; Nutrition Status; Gastrointestinal Microbiome; GLP-1","DIETARY_SUPPLEMENT:AG1 - Nutritional Supplement; DIETARY_SUPPLEMENT:Placebo","Athletic Greens International","2026-02","FALSE","0"],["S002651","ClinicalTrials.gov","NCT02105792","PROMASTER","PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes","OBSERVATIONAL",null,null,"COMPLETED","820","Diabetes","DRUG:second- or third-line glucose-lowering diabetes treatment","Royal Devon and Exeter NHS Foundation Trust","2013-03","FALSE","0"],["S002652","ClinicalTrials.gov","NCT06203275",null,"The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","UNKNOWN","44","Diabetes Mellitus, Type 2","DRUG:Paroxetine; DRUG:Placebo","aya ramadan ashmawy sarhan","2024-01","FALSE","0"],["S002653","ClinicalTrials.gov","NCT02694575","IGLOOS","The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","241","Diabetes Mellitus, Type 2; Cardiovascular Diseases",null,"University of Leicester","2015-03-01","FALSE","4"],["S002654","ClinicalTrials.gov","NCT01192659",null,"Identification of Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes: An Analysis of Data From the SAVOR Study","OBSERVATIONAL",null,null,"COMPLETED","16492","Diabetes Mellitus, Type 2",null,"AstraZeneca","2010-05","FALSE","0"],["S002655","ClinicalTrials.gov","NCT06944353","STIRRED","Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED (STIRRED)","INTERVENTIONAL","RANDOMIZED",null,"ENROLLING_BY_INVITATION","4704","Non-Alcoholic Fatty Liver Disease; Steatosis of Liver; Metabolic Dysfunction-Associated Steatotic Liver Disease","BEHAVIORAL:STIRRED","Northwestern University","2025-12-04","FALSE","0"],["S002656","ClinicalTrials.gov","NCT01972893","ZYD1","A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, a Selective Glucagon-like Peptide (GLP) 1 Agonist, Following Subcutaneous Administration in Healthy Volunteers.","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","56","Type 2 Diabetes Mellitus","DRUG:ZYD1; DRUG:Placebo","Zydus Lifesciences Limited","2011-02","FALSE","0"],["S002657","ClinicalTrials.gov","NCT01856907",null,"A Randomized Pilot Study Evaluating Combination Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Plus Metformin Compared to Metformin Monotherapy and Placebo on Metabolic Abnormalities in Women With a Recent History of GDM","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","36","Disorder of Glucose Regulation","DRUG:Sitagliptin-Metformin; DRUG:Metformin; DRUG:Placebo pill","Woman's","2013-09-28","TRUE","0"],["S002658","ClinicalTrials.gov","NCT01827280",null,"Acute and Short-term Chronic Effects of Galvus (Vildagliptin) on Endothelial Function and Oxidative Stress on Recently Diagnosed Type 2 Diabetic Obese Women: the Role of Intestinal Peptides During Lipid Overload","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","40","1- Microvascular Function; 2-oxidative Stress; 3-inflammation","DRUG:Vildagliptin","Rio de Janeiro State University","2013-04","FALSE","0"],["S002659","ClinicalTrials.gov","NCT05275608","KETO-MI","Effects of Very Low Calorie Ketogenic Diet on Microbiota, Adipose Tissue and Immunitary Regulation: Pilot Study on Patients With Metabolic Syndrome","INTERVENTIONAL","RANDOMIZED",null,"ACTIVE_NOT_RECRUITING","40","Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Obesity; Metabolic Syndrome","DIETARY_SUPPLEMENT:VLCKD diet with replacing meals; BEHAVIORAL:Hypocaloric mediterranean Diet","Azienda Ospedaliero Universitaria Maggiore della Carita","2022-11-07","FALSE","0"],["S002660","ClinicalTrials.gov","NCT07588750","SIBUTAMATE","Retrospective Evaluation of Sibutramine-Topiramate Therapy for Obesity in Real-World Outpatient Practice","OBSERVATIONAL",null,null,"COMPLETED","278","Obesity & Overweight","DRUG:Sibutramine + Topiramate","Falquetomed","2026-06-01","FALSE","0"],["S002661","ClinicalTrials.gov","NCT03921242",null,"Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease","OBSERVATIONAL",null,null,"COMPLETED","4888","Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic","DRUG:Metformin; DRUG:Sulfonylurea; DRUG:DPP-4 inhibitor; DRUG:SGLT2 inhibitor; DRUG:GLP1 receptor agonist","Weill Medical College of Cornell University","2019-08-01","FALSE","0"],["S002662","ClinicalTrials.gov","NCT07434791","GOLD-STANDARD","GOaL Directed-STrategic Approach With New Disease-modifying theraApies to Reduce Kidney and Cardiovascular Risk in Patients With Diabetic Kidney Disease","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","100","Diabetic Kidney Disease (DKD); Type 2 Diabetes Mellitus (T2DM); Chronic Kidney Disease","OTHER:Early goal-directed Cardio-Kidney-Metabolic (CKM) care; OTHER:Standard care (Comparison arm)","Sunnybrook Health Sciences Centre","2026-08-26","FALSE","8"],["S002663","ClinicalTrials.gov","NCT05324241",null,"A Proof of Principle Study of the Laxative Properties of Microencapsulated Lipid in Patients Experiencing Constipation Related to Intentional Weight Loss","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","31","Constipation","DIETARY_SUPPLEMENT:Fat Microcapsules","University College Dublin","2022-04-15","FALSE","0"],["S002664","ClinicalTrials.gov","NCT02738151","BRIGHT","A 24-week, Multicenter, Randomized, Open-Label, Parallel-group StudyComparing the Efficacy and Safety of Toujeo® and Tresiba® in Insulin-NaivePatients With Type 2 Diabetes Mellitus Not Adequately Controlled With OralAntihyperglycemic Drug(s) ± GLP-1 Receptor Agonist","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","929","Diabetes Mellitus, Type 2","DRUG:Insulin glargine, 300U/mL; DRUG:Insulin degludec, 100 U/mL; DRUG:Non-insulin anti-diabetic treatment","Sanofi","2016-05-19","TRUE","5"],["S002665","ClinicalTrials.gov","NCT05268081","STAR","Virtual Specialist Conferences Between General Practitioners and Endocrinologists About Type 2.Diabetes: a Pragmatic Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","25","Diabetes Mellitus, Type 2","OTHER:Virtual specialist conferences","University of Aarhus","2022-01-01","FALSE","1"],["S002666","ClinicalTrials.gov","NCT06988397","SPEED-US","Food Type and Physical Activity Influence on Gastric Emptying Time Assessed by Ultrasound in Healthy Volunteers","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","60","Gastric Emptying; Preoperative Risk Assessment; Healthy Volunteer Study","BEHAVIORAL:Physical activity after different type of meals","Medical University of Warsaw","2025-06-01","FALSE","0"],["S002667","ClinicalTrials.gov","NCT07499518","FERTIOPK","Description of Fertility and Pregnancies in Patients With Polycystic Ovary Syndrome","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","473","Polycystic Ovary Syndrome (PCOS)","OTHER:Questionnaires","Assistance Publique - Hôpitaux de Paris","2026-06-01","FALSE","0"],["S002668","ClinicalTrials.gov","NCT01000688",null,"The Effect of Vildagliptin on Endothelium-dependent Vasodilatation. A Double Blind Cross-over Study in Type 2 Diabetes Mellitus.","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","16","Type 2 Diabetes; Endothelial Dysfunction","DRUG:vildagliptin + acarbose; DRUG:acarbose + vildagliptin","Radboud University Medical Center","2010-01","FALSE","0"],["S002669","ClinicalTrials.gov","NCT07484061",null,"Evaluation of the Efficacy and Safety of a Drinkable Nutraceutical in Improving Hair Loss in Patients Treated With GLP-1/GIP Receptor Agonists: a Double-blind, 1:1 Randomized, Placebo-controlled Study.","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","40","Telogen Effluvium","DIETARY_SUPPLEMENT:Drinkable multifactorial food supplement containing vitamins, minerals, amino acids, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women +45.; OTHER:Placebo control","Olistic Research Labs S.L.","2026-03-16","FALSE","0"],["S002670","ClinicalTrials.gov","NCT03455049",null,"The Effect of Andrographis Paniculata to GLP-1, Fasting Insulin, Insulin 2-h Post OGTT, and HOMA-IR in Normal and Prediabetes Subject","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","73","Increased Insulin","OTHER:Andrographis Paniculata Ext","Universitas Indonesia","2017-10-17","FALSE","0"],["S002671","ClinicalTrials.gov","NCT07075341",null,"Healthy Living BEYOND Weight Study","OBSERVATIONAL",null,null,"RECRUITING","1000000","Overweight or Obesity","OTHER:None - Observational study","American Heart Association","2025-06-30","FALSE","0"],["S002672","ClinicalTrials.gov","NCT07031596","Probiotic","Study on the Weight Loss Effects and Mechanisms of Probiotic Preparation Intervention in Weight Cyclers: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","198","Obesity and Obesity-related Medical Conditions","DIETARY_SUPPLEMENT:WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100).; DIETARY_SUPPLEMENT:WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100) + WONDERLAB Weight Management Probiotic Food.; DIETARY_SUPPLEMENT:Placebo","Peking Union Medical College Hospital","2025-06","FALSE","0"],["S002673","ClinicalTrials.gov","NCT04856683","PROMETEO","PRecisiOn MEdicine to Target Frailty of Endocrine-metabolic Origin","OBSERVATIONAL",null,null,"UNKNOWN","1100","Frailty",null,"University of Roma La Sapienza","2020-08-10","FALSE","0"],["S002674","ClinicalTrials.gov","NCT07226947","BICEP","BIA Monitoring and Exercise for the Prevention of Muscle Loss With Incretin Therapy (BICEP Study)","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","100","Obesity; Body Composition","DEVICE:Smartwatch activity and body composition monitor; BEHAVIORAL:General guidance on recommended exercise","Massachusetts General Hospital","2025-11-24","FALSE","5"],["S002675","ClinicalTrials.gov","NCT05290506",null,"Association of Fasting GLP-1 Level With the Effect of Linagliptin After an Oral Glucose Tolerance Test in Prediabetes and Type 2 Diabetes Mellitus","INTERVENTIONAL","NON_RANDOMIZED","PHASE3","COMPLETED","50","PreDiabetes; Type 2 Diabetes","DRUG:Dipeptidyl-Peptidase IV Inhibitors","National University of Malaysia","2020-08-01","FALSE","0"],["S002676","ClinicalTrials.gov","NCT01056107",null,"Effect of ROSE-010 on Gastrointestinal Motor Functions in Female Patients With Constipation Predominant Irritable Bowel Syndrome (C-IBS)","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","52","Irritable Bowel Syndrome Constipation Predominant","DRUG:ROSE-010; DRUG:Placebo","Mayo Clinic","2010-01","TRUE","1"],["S002677","ClinicalTrials.gov","NCT01681550",null,"Effect of Incretin-based Therapy Combined With Insulin on HbA1c, Hypoglycemia and Chronic Diabetic Complications in Type 2 Diabetic Patients","INTERVENTIONAL",null,null,"UNKNOWN","500","Type 2 Diabetes Mellitus","DRUG:Incretin-based therapy","Nagaoka Red Cross Hospital","2012-10","FALSE","0"],["S002678","ClinicalTrials.gov","NCT02585674","AUTOMATIX","A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regimen Versus Routine Titration in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","151","Type 2 Diabetes Mellitus","DRUG:Insulin glargine (U300); DEVICE:MyStar DoseCoach","Sanofi","2015-12","FALSE","0"],["S002679","ClinicalTrials.gov","NCT05854979",null,"Ultrasound Assessment of Preoperative Gastric Volume in Fasted, Diabetic Surgical Patients: A Prospective Observational Cohort Study on the Effects of GLP-1 Agonists on Gastric Emptying","OBSERVATIONAL",null,null,"COMPLETED","210","Diabetes; Gastric Content Aspiration; Glucagon-like Peptide 1; GLP-1","DIAGNOSTIC_TEST:Gastric Ultrasound","Medical University of South Carolina","2023-08-09","FALSE","0"],["S002680","ClinicalTrials.gov","NCT06927401",null,"Evaluate the Detection of Retained Gastric Contents and Assess Safety Using the Flower Capsule Endoscopy in Healthy Individuals and GLP-1 Receptor Agonist Users","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","36","Endoscopy, Digestive System; GLP1-R-related Disease","DEVICE:Flower","Asian Institute of Gastroenterology, India","2025-04-08","FALSE","2"],["S002681","ClinicalTrials.gov","NCT04769765","TELXCODIA","Evaluation of the Feasability of a Care Pathway Integrating Collaborative Tele-expertise for the Prevention of Recurrent Hospitalisations for Patients With Diabetes","INTERVENTIONAL",null,null,"TERMINATED","200","Diabetes Mellitus","OTHER:Definition of the Individualized Care Pathway","Centre Hospitalier Universitaire de Nīmes","2022-05-04","FALSE","0"],["S002682","ClinicalTrials.gov","NCT06839248",null,"Effect of Fasting Recommendations on Residual Gastric Contents Among Patients Using Glucagon-like Peptide-1 Receptor Agonists: A Randomised Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","154","Residual Gastric Contents; Pulmonary Aspiration of Gastric Contents","OTHER:24-hour clear liquid diet; OTHER:Standard fasting guidelines","St Vincent's Hospital Melbourne","2025-06-20","FALSE","0"],["S002683","ClinicalTrials.gov","NCT07829016","GLOW","GLP-1 Longitudinal Outcomes in Weight Management","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","100","Weight Management; Disordered Eating Behaviors",null,"University of California, San Francisco","2026-10-20","FALSE","0"],["S002684","ClinicalTrials.gov","NCT07611201",null,"The Effects of GLP-1 Receptor Agonists on Sensory Systems and Ingestive Behavior","OBSERVATIONAL",null,null,"COMPLETED","90","Obesity; Overweight; Taste Perception; Olfaction; Eating Behavior; Appetite",null,"Purdue University","2025-02-20","FALSE","2"],["S002685","ClinicalTrials.gov","NCT07451938","ODHM","A Cohort Study on Obese Patients' Multidisciplinary Integrated Health Management","OBSERVATIONAL",null,null,"COMPLETED","1500","Obesity; Diabete Type 2; Bariatric Surgery","PROCEDURE:Bariatric surgery; OTHER:Non-surgical threapy","China-Japan Friendship Hospital","2017-07-01","FALSE","0"],["S002686","ClinicalTrials.gov","NCT01303315",null,"TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy","INTERVENTIONAL","NON_RANDOMIZED",null,"TERMINATED","20","Diabetes Mellitus, Type 2","DEVICE:TANTALUS System","MetaCure (USA), Inc.","2011-01","FALSE","0"],["S002687","ClinicalTrials.gov","NCT07340112","EXCEL-CLTI","Expression of GLP1 Receptor on Peripheral Blood Mononuclear Cells in Advanced Peripheral Artery Disease: Paving the Way for GLP1R Agonists Treatment in Chronic Limb Threatening Ischemia","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","50","Peripheral Arterial Disease (PAD); Claudication, Intermittent; Chronic Limb-Threatening Ischemia","DIAGNOSTIC_TEST:Analysis of GLP-1 receptor expression","University Hospital, Strasbourg, France","2026-06","FALSE","0"],["S002688","ClinicalTrials.gov","NCT07627048","GM","INFLUENCE OF GUT MICROBIOTA ON THE DEVELOPMENT OF TYPE 2 DIABETES MELLITUS AND PERSONALIZATION OF DIABETES-LOWING THERAPY","OBSERVATIONAL",null,null,"COMPLETED","100","Type 2 Diabetes (T2DM)",null,"Pirogov Russian National Research Medical University","2021-12-01","FALSE","0"],["S002689","ClinicalTrials.gov","NCT06481085",null,"A Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of HDM1002 Tablets in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin or Diet and Exercise","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","324","Type 2 Diabetes","DRUG:HDM1002 50 mg; DRUG:HDM1002 100 mg; DRUG:HDM1002 200 mg; DRUG:HDM1002 400 mg; DRUG:HDM1002 200 mg BID; DRUG:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-06-27","FALSE","0"],["S002690","ClinicalTrials.gov","NCT07628556",null,"Antidiabetic Medications and Risk of Cancer","OBSERVATIONAL",null,null,"COMPLETED","74799","Cancer","DRUG:Metformin; DRUG:sulphonylurea; DRUG:DPP-4 inhibitor; DRUG:GLP-1 Receptor Agonists; DRUG:SGLT-2 inhibitor; DRUG:insulin; DRUG:MET + SU; DRUG:MET + DPP-4 inhibitor; DRUG:MET + GLP-1RA; DRUG:MET + SGLT2i; DRUG:MET + INS","University of Pecs","2025-03-15","FALSE","0"],["S002691","ClinicalTrials.gov","NCT07117695","DUKE PREVENT","Efficacy of Multidisciplinary Prevention Clinic Model for Cardiovascular Risk Reduction in High Risk Patients","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","150","ASCVD; Hyperlipidemia; Hypertension","OTHER:Referral to the Duke Cardiometabolic Prevention Clinic","Duke University","2026-10-02","FALSE","0"],["S002692","ClinicalTrials.gov","NCT07833501","SIMPEC-E2","Evaluation of Serum Estradiol Levels According to Body Mass Index Categories in Premenopausal Patients With Hormone Receptor-Positive Breast Cancer Receiving Aromatase Inhibitors and Pharmacologic Ovarian Suppression","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","172","Hormone Receptor-Positive Breast Cancer",null,"D'Or Institute for Research and Education","2026-09-03","FALSE","0"],["S002693","ClinicalTrials.gov","NCT06897202","VESPER-2","A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight, and Type 2 Diabetes Mellitus (VESPER-2)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","133","Obesity in Diabetes; Type 2 Diabetes Mellitus (T2DM)","DRUG:MET097 Injection; DRUG:Placebo","Pfizer","2025-03-14","FALSE","0"],["S002694","ClinicalTrials.gov","NCT03050619",null,"Characteristics of Patients Initiating Empagliflozin or Other Non-insulin Glucose Lowering Drugs in the United Kingdom","OBSERVATIONAL",null,null,"COMPLETED","31908","Type 2 Diabetes","DRUG:Empagliflozin; DRUG:Other SGLT2 inhibitors; DRUG:Other non-insulin GLDs","Boehringer Ingelheim","2016-09-10","TRUE","0"],["S002695","ClinicalTrials.gov","NCT07595575","Leuvate001","Investigating the Effectiveness of Novel Amino Acid-enriched Supplement Beverages to Determine Post-ingestion Glycemia, Insulinemia, Aminoacidemia, and Whole-body Protein Synthesis Rates in Adults Prescribed GLP-1 RA Drugs","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","8","The Whole-body Protein Synthesis Response to Protein With Amino Acid or Amino Acids","DIETARY_SUPPLEMENT:GLP-1","Nutraceutical Innovations LLC","2026-06-01","FALSE","0"],["S002696","ClinicalTrials.gov","NCT07336329","PERIODIC-CGM","Effectiveness of Periodic Use of Continuous Glucose Monitoring After Three Months of Continuous Use in Patients With Non-Insulin-Treated Type 2 Diabetes Patients: A Multicenter, Randomized, Parallel-Group, Open-Label, Non-Inferiority, Investigator-Initiated Trial","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","150","Diabetes Mellitus, Type 2","DEVICE:FreeStyle Libre 2 Continuous Glucose Monitoring","Kangbuk Samsung Hospital","2026-01-02","FALSE","0"],["S002697","ClinicalTrials.gov","NCT07221461",null,"Prospective, Single Center, Open-label Study Assessing Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality and Biomarkers in Patients on Glucagon-like Peptide-1 Agonists","INTERVENTIONAL","NON_RANDOMIZED","PHASE2","NOT_YET_RECRUITING","24","Wrinkle","DEVICE:Skinvive","Goldman, Butterwick, Fitzpatrick and Groff","2025-11-01","FALSE","0"],["S002698","ClinicalTrials.gov","NCT07393360","MYO-PRESERVE","Evaluating the Effect of a Food for Special Medical Purposes Containing Essential Amino Acids (EAA), Carnitine, Arginine, and Sucrosomial Minerals on the Preservation of Appendicular Skeletal Muscle Mass (ASMM) During a Weight Loss Program With GLP-1 Receptor Agonists","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","144","Obesity & Overweight","DIETARY_SUPPLEMENT:Myosave®; OTHER:Placebo","Pharmanutra S.p.a.","2025-12-11","FALSE","0"],["S002699","ClinicalTrials.gov","NCT07193459",null,"A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of HDM1002 Tablets in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise Only","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","360","Type 2 Diabetes","DRUG:HDM1002 200 mg; DRUG:HDM1002 400 mg; DRUG:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-08-12","FALSE","0"],["S002700","ClinicalTrials.gov","NCT07663591",null,"Prediction of Changes in Pulmonary Function, Respiratory Muscle Performance, and Ventilatory Responses Following Incretin-Based Therapy in Individuals With Obesity Using Machine Learning","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","48","Obesity (BMI>30)","OTHER:Incretin-based therapy","Biruni University","2026-07-01","FALSE","0"],["S002701","ClinicalTrials.gov","NCT06046560","DRIVE","DRIVE Program: Diabetes Remote Intervention to improVe Use of Evidence-based Medications","INTERVENTIONAL","RANDOMIZED","PHASE4","COMPLETED","200","Cardiovascular Diseases; Diabetes","DRUG:SGLT2 inhibitor, GLP-1 RA; BEHAVIORAL:Education-First","Brigham and Women's Hospital","2021-03-22","TRUE","3"],["S002702","ClinicalTrials.gov","NCT06317051","OPTIMAR","A Phase III/IV Factorial Randomized Double-blind Trial to Compare the Addition of Dapagliflozin vs Placebo and Rosuvastatin/Ezetimibe Versus Pitavastatin in Patients With HIV on Integrase Strand Transfer Inhibitor-based Antiretrovirals With Elevated Metabolic Risk","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","300","HIV Infections; Weight Gain","DRUG:Dapagliflozin 10mg Tab; DRUG:Pitavastatin 4 Mg Oral Tablet; DRUG:Rosuvastatin and Ezetimibe; DRUG:Placebo","Kirby Institute","2024-12-16","FALSE","0"],["S002703","ClinicalTrials.gov","NCT07866846","PasiAcroKeto","'Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Eucaloric Very-low Carbohydrate Ketogenic Diet Versus Diabetes Medication: a Multicentre, Randomized, Open-label Proof-of-concept Study'","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","30","Acromegaly Due to Pituitary Adenoma; Hyperglycemia; Ketogenic Diet; Standard Care Control","DIETARY_SUPPLEMENT:Ketogenic diet; DRUG:Diabetes Medication","Leiden University Medical Center","2025-07-29","FALSE","0"],["S002704","ClinicalTrials.gov","NCT05903482",null,"Gastric Volume in Patients on GLP-1 Medications","OBSERVATIONAL",null,null,"COMPLETED","70","Diabetes","OTHER:None - observational","Children's Hospital of Philadelphia","2023-06-06","FALSE","0"],["S002705","ClinicalTrials.gov","NCT07012642",null,"Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema","INTERVENTIONAL",null,"EARLY_PHASE1","RECRUITING","110","Lymphedema","DRUG:GLP-1 Receptor Agonists","Advanced Reconstructive Surgery Alliance","2025-04-09","FALSE","0"],["S002706","ClinicalTrials.gov","NCT07760896","GLOW","The GLOW Study: GLP-1 and Lifestyle for Optimal Wellness","INTERVENTIONAL",null,null,"RECRUITING","200","Wellness","BEHAVIORAL:WILD 5 Wellness Program","Saundra Jain","2026-09-15","FALSE","0"],["S002707","ClinicalTrials.gov","NCT06600490",null,"Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behavioral Nudges in Increasing InFLUenza Vaccine Uptake Among Adults With Chronic Disease","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","308978","Influenza; Behavior and Behavior Mechanisms","BEHAVIORAL:Behavioral Economic Principles","Tor Biering-Sørensen","2024-10-01","FALSE","0"],["S002708","ClinicalTrials.gov","NCT05214573",null,"Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk","OBSERVATIONAL",null,null,"COMPLETED","386301","Type 2 Diabetes; Cardiac Disease","DRUG:Glucagon like peptide 1 receptor agonist; DRUG:Sodium-glucose cotransporter 2 inhibitor; DRUG:Dipeptidyl Peptidase 4 Inhibitor; DRUG:Sulfonylurea","Mayo Clinic","2021-12-01","TRUE","3"],["S002709","ClinicalTrials.gov","NCT02227849",null,"An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to GLP-1 Analogue in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE4","COMPLETED","71","Type 2 Diabetes Mellitus","DRUG:Canagliflozin (TA-7284); DRUG:GLP-1 analogue","Tanabe Pharma Corporation","2014-08","TRUE","1"],["S002710","ClinicalTrials.gov","NCT04151849",null,"Complementary Effects of New Diabetes Medications on Adrenal Function and Intestinal Microbiota","OBSERVATIONAL",null,null,"COMPLETED","23","Type 2 Diabetes","DRUG:GLP-1 receptor agonist; DRUG:SGLT2 inhibitor","University of Tartu","2019-11-07","FALSE","0"],["S002711","ClinicalTrials.gov","NCT07546357",null,"AIManage: Using an AI-driven CDS and Chatbot for the Management of Patients on Incretin Mimetic Medications","INTERVENTIONAL","NON_RANDOMIZED",null,"NOT_YET_RECRUITING","16","Diabetes; Obesity; Medication Side Effects","OTHER:AIManage","NYU Langone Health","2026-06-01","FALSE","0"],["S002712","ClinicalTrials.gov","NCT00432809",null,"STAMPEDE: Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","150","Diabetes Mellitus, Type 2; Obesity","PROCEDURE:Gastric bypass; PROCEDURE:Sleeve Gastrectomy","The Cleveland Clinic","2007-02","TRUE","0"],["S002713","ClinicalTrials.gov","NCT05284344",null,"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","78","Type 2 Diabetes","DRUG:Anti-Diabetics","University of Adelaide","2021-01-24","FALSE","1"],["S002714","ClinicalTrials.gov","NCT04626323","OBESE-DKD","Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","60","Diabetes Mellitus, Type 2; Kidney Disease, Chronic; Kidney Injury","PROCEDURE:Roux-en-Y gastric bypass; DRUG:Best medical treatment","Hospital Alemão Oswaldo Cruz","2021-05-25","FALSE","1"],["S002715","ClinicalTrials.gov","NCT07636395",null,"Qualitative and Quantitative Measures of Eating Behaviours in Humans Taking Obesity Medications Before, During, and After.","OBSERVATIONAL",null,null,"RECRUITING","30","Obesity Type 2 Diabetes Mellitus; Obesity & Overweight",null,"University College Dublin","2026-05-25","FALSE","0"],["S002716","ClinicalTrials.gov","NCT07316816",null,"Stanford Pediatric Healthy Weight Index","INTERVENTIONAL","NON_RANDOMIZED",null,"RECRUITING","120","Obesity & Overweight","OTHER:Remote Monitoring Program","Stanford University","2026-01-05","FALSE","0"],["S002717","ClinicalTrials.gov","NCT02015780",null,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasiglifam (TAK-875) Compared to Placebo as Add-on to Preexisting Antihyperglycemic Therapy Over 16 Weeks With 36-week Extension in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or Stage 5 on Dialysis","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Type 2 Diabetes Mellitus; Chronic Kidney Disease","DRUG:Fasiglifam; DRUG:Placebo; DRUG:Antihyperglycemic therapy","Takeda","2013-12","FALSE","0"],["S002718","ClinicalTrials.gov","NCT06927973",null,"Leveraging Exercise Stress Echocardiography for Heart Failure With Preserved Ejection Fraction","INTERVENTIONAL",null,null,"COMPLETED","30","Chest Pain; Shortness of Breath","DIAGNOSTIC_TEST:Echocardiogram","Duke University","2025-05-30","FALSE","0"],["S002719","ClinicalTrials.gov","NCT06105931",null,"Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes","INTERVENTIONAL",null,"PHASE1","ACTIVE_NOT_RECRUITING","15","type1diabetes; Obesity","BIOLOGICAL:Hyperinsulinemic-euglycemic clamp; OTHER:High Fat Mixed Meal Tolerance Test","Yale University","2023-12-13","FALSE","0"],["S002720","ClinicalTrials.gov","NCT06795360",null,"Weight Changes After Incretin-mimetics","INTERVENTIONAL",null,null,"NOT_YET_RECRUITING","52","Obesity and Obesity-related Medical Conditions","OTHER:discontinuation of weight loss medication","Medical College of Wisconsin","2026-12-01","FALSE","0"],["S002721","ClinicalTrials.gov","NCT06451458","E4DMMC","ECHO for Diabetes and Multiple Chronic Conditions Study","INTERVENTIONAL","RANDOMIZED",null,"ENROLLING_BY_INVITATION","20","Diabetes Mellitus; Chronic Disease","BEHAVIORAL:ECHO program for DMMC; BEHAVIORAL:Usual care","University of New Mexico","2024-10-16","FALSE","0"],["S002722","ClinicalTrials.gov","NCT05933174",null,"Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","220","Type2diabetes","OTHER:Prompt-sheet; OTHER:Usual education","University Hospitals Cleveland Medical Center","2023-10-01","FALSE","0"],["S002723","ClinicalTrials.gov","NCT06889454",null,"The Effect of Different Treatment Options on Markers of Vascular, Myocardial and Endothelial Function in Women With Polycystic Ovary Syndrome and the Association With Metabolic and Hormonal Abnormalities of the Syndrome","OBSERVATIONAL",null,null,"RECRUITING","120","PCOS; Hyperinsulinism; Hyperandrogenism; Metabolic Syndrome","DRUG:GLP-1 receptor agonist; DRUG:Oral contraceptive; DRUG:Metformin; OTHER:Lifestyle modification","Attikon Hospital","2024-02-01","FALSE","0"],["S002724","ClinicalTrials.gov","NCT07244458",null,"Dietary Peanut Intake and Nutrition-Related Outcomes in Individuals Using GLP-1 Receptor Agonists: A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","64","Dietary Change; Obesity & Overweight; Food Acceptance","DIETARY_SUPPLEMENT:Peanuts; PROCEDURE:Dual-energy X-ray absorptiometry (DEXA) scans","Ian J. Neeland, MD","2026-04-20","FALSE","0"],["S002725","ClinicalTrials.gov","NCT02299050",null,"Effect of Cycloset on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled on GLP-1 Analogue Therapy","INTERVENTIONAL",null,"PHASE4","COMPLETED","23","Type 2 Diabetes","DRUG:Cycloset","The University of Texas Health Science Center at San Antonio","2014-06","TRUE","0"],["S002726","ClinicalTrials.gov","NCT07465926","GLP1-SGLT2-CKM","Associations of Early Add-On GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy With Mortality and Kidney Outcomes in Adults With Obesity and Type 2 Diabetes Across Cardiovascular-Kidney-Metabolic Stages 2-3: A Target-Trial Emulation","OBSERVATIONAL",null,null,"COMPLETED","451036","Cardiovascular-kidney-metabolic Syndrome; Cardiovascular Disease Risk Factor; Kidney Disease; Type 2 Diabetes; Obesity & Overweight","DRUG:GLP-1 receptor agonist; DRUG:SGLT2 inhibitor","Chung Shan Medical University","2017-01-01","TRUE","15"],["S002727","ClinicalTrials.gov","NCT07818226",null,"Prospective Evaluation of the Effects of GLP-1 Receptor Agonists on Salivary Physicochemical Parameters, Antimicrobial Peptide Levels, and Oral Health","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","50","Type 2 Diabetes; Obesity & Overweight; Xerostomia; Dental Caries","DRUG:GLP-1 Receptor Agonists","Kırıkkale University","2026-10-16","FALSE","0"],["S002728","ClinicalTrials.gov","NCT07593105",null,"Effect of Oat Flakes β-glucan on Glycemic Variability, Pancreatic Reserve, and Dyslipidemia Among Adolescents With Type 1 Diabetes: A Randomized Crossover Study","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","60","Type 1 Diabetes; Nutrition","DIETARY_SUPPLEMENT:Oat Flour","Ain Shams University","2024-10-12","FALSE","0"],["S002729","ClinicalTrials.gov","NCT01096277",null,"Metabolism-independent Vascular Effects of the Dipetidylpeptidase-4-inhibitor Sitagliptin in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","70","Type 2 Diabetes Mellitus","DRUG:Sitagliptin; DRUG:Placebo; OTHER:Control","Hannover Medical School","2010-10","FALSE","0"],["S002730","ClinicalTrials.gov","NCT05463705",null,"Addressing Diffusion of Responsibility and Prescribing Burden to Improve Use of Diabetes Medications","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","1580","Diabetes; SGLT-2i and GLP-1RA Therapies; Diffusion of Responsibility; Prescribing Burden","BEHAVIORAL:Intervention to address diffusion of responsibility; BEHAVIORAL:Intervention to address diffusion of responsibility + simplification of prescribing","Brigham and Women's Hospital","2023-05-04","TRUE","1"],["S002731","ClinicalTrials.gov","NCT06030739",null,"Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake Among Adults With Chronic Disease","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","299881","Influenza; Behavior and Behavior Mechanisms","BEHAVIORAL:Behavioral Economic Principles","Tor Biering-Sørensen","2023-09-24","FALSE","0"],["S002732","ClinicalTrials.gov","NCT05526157","FINEGUST","FINErenone druG Utilization Study and Assessment of Temporal Changes Following Availability of Different Treatment Options in Patients With Chronic Kidney Disease and Type 2 Diabetes","OBSERVATIONAL",null,null,"COMPLETED","50000","Chronic Kidney Disease; Type 2 Diabetes Mellitus","DRUG:Finerenone (Kerendia, BAY 948862); DRUG:Sodium-glucose cotransporter 2 inhibitors (SGLT2i); DRUG:Glucagon-like peptide-1 receptor agonists (GLP 1 RA); DRUG:Steroidal mineral corticoid receptor antagonists (sMRA); DRUG:Non-steroidal mineral corticoid receptor antagonists (nsMRA)","Bayer","2022-10-01","FALSE","4"],["S002733","ClinicalTrials.gov","NCT07111494",null,"Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE4","RECRUITING","22","Psoriatic Arthritis (PsA)","DRUG:GLP-1 agonists; OTHER:Nutrition Counseling","Medical College of Wisconsin","2026-05-01","FALSE","0"],["S002734","ClinicalTrials.gov","NCT03665350","Insulin-HF","Management of the Patient With Heart Failure and Diabetes: May Insulin be a Problem? A Pilot Randomized Clinical Study (Insulin-HF)","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","10","Heart Failure; Diabetes Mellitus, Type 2","DRUG:Insulin","Mario Negri Institute for Pharmacological Research","2018-11-08","FALSE","0"],["S002735","ClinicalTrials.gov","NCT07495020","MACBIPARTFCG","The Laparoscopic Transit Bipartition Without Gastrectomy With Use of Metallic Anastomosis Clip (MAC) and Circular Fundocorporeal Gastroplication for Treating Type 2 Diabetes Mellitus and Obesity","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","90","Type 2 Diabetes Mellitus (T2DM); Obesity & Overweight; Marginal Ulcer (Peptic) or Erosion; Leakage, Anastomotic","PROCEDURE:Laparoscopic transit bipartition with Metallic Anastomotic Clip and Circular Fundocorporeal Gastroplication; PROCEDURE:Laparoscopic transit bipartition (gastroenteroanastomosis and entero-enteric anastomosis) use the Metallic Anastomotic Clip and with sleeve gastrectomy; PROCEDURE:laparoscopic duodenal transit bipartition using the Metallic Anastomotic Clip with circular fundocorporeal gastroplication without gastrectomy","The Society of Bariatric and Metabolic Surgeons of Kazakhstan","2026-04-30","FALSE","0"],["S002736","ClinicalTrials.gov","NCT01405261",null,"Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","101","Diabetes; Diabetes Mellitus, Type 2; Healthy","DRUG:oral NNC 0113-0987; DRUG:I.v. NNC 0113-0987; DRUG:oral placebo","Novo Nordisk A/S","2011-08","FALSE","0"],["S002737","ClinicalTrials.gov","NCT07311850","VESPER-4","Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","3578","Obesity and Overweight","DRUG:MET097; DRUG:Placebo","Pfizer","2025-12-19","FALSE","0"],["S002738","ClinicalTrials.gov","NCT04559191","OPTIMAL","The Efficacy of Glycemic Control With Continuous Glucose Monitoring on Atheroma Progression: Rationale and Design of the Observation of Coronary Atheroma Progression Under Continuous Glucose Monitoring Guidance in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","90","Coronary Atherosclerosis","DEVICE:continuous glucose monitoring (CGM)","National Cerebral and Cardiovascular Center, Japan","2019-03-01","FALSE","0"],["S002739","ClinicalTrials.gov","NCT05818995",null,"Therapeutic Drug Use in Patients With Chronic Kidney Disease (CKD): a Multicenter Retrospective Real-world Study","OBSERVATIONAL",null,null,"UNKNOWN","10000","Chronic Kidney Disease","DRUG:angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker","Qianfoshan Hospital","2022-07-01","FALSE","0"],["S002740","ClinicalTrials.gov","NCT05342545","CKD-DETECT","Electronic Alert-Based Computerized Decision Support to Increase Detection of Chronic Kidney Disease in Patients With Type II Diabetes Mellitus (CKD-DETECT)","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","400","Chronic Kidney Diseases; Type2Diabetes","OTHER:Alert-based computerized decision support","Brigham and Women's Hospital","2022-12-01","FALSE","0"],["S002741","ClinicalTrials.gov","NCT04802395",null,"Real World Evidence Clinical Utility Study of KidneyIntelX in Patients With Type 2 Diabetes and Chronic Kidney Disease","OBSERVATIONAL",null,null,"RECRUITING","10000","Chronic Kidney Diseases; Diabetic Kidney Disease","DIAGNOSTIC_TEST:KidneyIntelX","Renalytix AI, Inc.","2021-03-02","FALSE","2"],["S002742","ClinicalTrials.gov","NCT06101667","ANGEL-BAO","Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window -- A Multicenter, Prospective, Open-label, Blind Endpoint, Randomized Controlled Trial（ANGEL-BAO）","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","224","Acute Ischemic Stroke; Basilar Artery Occlusion","DRUG:Best medical management; PROCEDURE:Endovascular treatment","Beijing Tiantan Hospital","2023-11-16","FALSE","0"],["S002743","ClinicalTrials.gov","NCT07269821",null,"Evaluation of a Nutritional Intervention With Dietary Supplements in People Who Have Recently Lost Weight: Effects on Body Composition, Emotional Health, and Gut Microbiota","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","70","GLP-1; Weight Loss Trajectory; Emotional Disorder; Microbiota Balance","DIETARY_SUPPLEMENT:Metabolaid®-based nutraceutical formulation; DIETARY_SUPPLEMENT:Placebo capsules","University of Alicante","2025-07-01","FALSE","0"],["S002744","ClinicalTrials.gov","NCT04162067",null,"Type 1 Diabetes in Canada: The Demographic, Care Profiles and Glycemic Control of Patients Living With Type 1 Diabetes From the LMC Diabetes Patient Registry","OBSERVATIONAL",null,null,"COMPLETED","3600","Type1diabetes",null,"LMC Diabetes & Endocrinology Ltd.","2020-01-06","FALSE","0"],["S002745","ClinicalTrials.gov","NCT07551947","HOMA-PULSE","HOMA-PULSE: Assessment of Glucose Metabolism and Insulin Resistance as a Predictor of Pulsed Field Ablation Success in Atrial Fibrillation","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","120","Atrial Fibrillation; Insulin Resistance; Catheter Ablation; Artificial Intelligence",null,"Nemocnice AGEL Trinec-Podlesi a.s.","2026-04-01","FALSE","0"],["S002746","ClinicalTrials.gov","NCT04964388",null,"Effect of GLP-1 Receptor Agonists on Trabecular Bone Score and Visceral Adiposity in Postmenopausal Women With Type 2 Diabetes Mellitus.","INTERVENTIONAL","NON_RANDOMIZED","PHASE2","TERMINATED","5","Osteoporosis, Postmenopausal; Diabetes Mellitus, Type 2","DRUG:GLP-1 receptor agonist","University of Mississippi Medical Center","2021-11-09","TRUE","0"],["S002747","ClinicalTrials.gov","NCT07817823",null,"Evaluation of the Intervention Effect of Yeast Protein Supplementation on Muscle Loss in Individuals Undergoing Weight Loss With Glucagon-Like Peptide-1 Receptor Agonists","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","200","Overweight and Obesity in Adults Receiving GLP-1RA Treatment","DIETARY_SUPPLEMENT:Yeast Protein; DIETARY_SUPPLEMENT:Whey Protein; DIETARY_SUPPLEMENT:Yeast Protein/Whey Protein Blend (1:1)","Huazhong University of Science and Technology","2026-09-20","FALSE","2"],["S002748","ClinicalTrials.gov","NCT06668935",null,"Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring","OBSERVATIONAL",null,null,"RECRUITING","800","Diabetes Mellitus","DEVICE:To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists","Abbott Diabetes Care","2024-10-24","FALSE","0"],["S002749","ClinicalTrials.gov","NCT07755150",null,"A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study Assessing the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes Mellitus.","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","272","Type 2 Diabetes Mellitus","DRUG:DA-302168S; DRUG:Placebo of DA-302168S","Chendu DIAO Pharmaceutical Group CO., LTD.","2026-08-30","FALSE","0"],["S002750","ClinicalTrials.gov","NCT01568125",null,"Effect of Incretin-related Drugs on Energy and Contents of Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus","OBSERVATIONAL",null,null,"UNKNOWN","100","Type 2 Diabetes Mellitus","DRUG:Incretin-related drugs","Nagaoka Red Cross Hospital","2010-01","FALSE","0"],["S002751","ClinicalTrials.gov","NCT06621017",null,"A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Daily Administrations of the GLP-1 Analogue ROSE-010 on Appetite and Food Intake in Overweight and Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","40","Obesity; Overweight","DRUG:ROSE-010 99 mcg; DRUG:Placebo; DRUG:ROSE-010 150 mcg","Rose Pharma Inc","2024-09-26","TRUE","0"],["S002752","ClinicalTrials.gov","NCT04862858",null,"Improving Outcomes in Patients With Comorbid T2DM and ASCVD: Population Health Management Interventions Supporting Guideline-recommended SGLT2i and GLP-1 RA Medications","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","4197","Diabetes Mellitus, Type 2; Cardiovascular Diseases","OTHER:Educational Intervention","Humana Inc.","2021-08-18","FALSE","1"],["S002753","ClinicalTrials.gov","NCT02971722",null,"Randomized,Double-blind,Placebo-controlled,Dose-escalating Phase I,Healthy Subjects Study of JY09,a Recombinant GLP-1 Receptor Agonist","INTERVENTIONAL","RANDOMIZED","PHASE1","UNKNOWN","26","Healthy","DRUG:JY09; DRUG:Placebo","Beijing Dongfang Biotech Co., Ltd.","2016-12","FALSE","2"],["S002754","ClinicalTrials.gov","NCT07736729","SMART-BMI","Effect of Continuous Wearable Biometric Monitoring on Weight Loss and Metabolic Outcomes in Adults Undergoing Obesity Treatment: A Sensor-Mediated Adaptive Randomized Controlled Trial in Bariatric and Metabolic Intervention (SMART-BMI)","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","260","Obesity","BEHAVIORAL:Biometric-informed care; BEHAVIORAL:Control Arm: Standard Care","Jeff Reeves","2026-08-17","FALSE","1"],["S002755","ClinicalTrials.gov","NCT06775093",null,"Effects of GLP-1 Receptor Agonists Combined with Metformin and Healthy Lifestyle Education Prior to Fertility Treatment on Reproductive Outcomes in Women with PCOS and Obesity","INTERVENTIONAL","RANDOMIZED",null,"NOT_YET_RECRUITING","392","Polycystic Ovary Syndrome; Obesity; Infertility, Female","DRUG:GLP-1 receptor agonist; DRUG:Metformin; BEHAVIORAL:healthy lifestyle education","Peking University Third Hospital","2025-03-01","FALSE","0"],["S002756","ClinicalTrials.gov","NCT06554054",null,"A Randomized, Open Phase I Trial to Evaluate the Bioavailability, Pharmacokinetics, Pharmacodynamics, Safety and Tolerance of GZR18 Tablet and Evaluate the Effect of Meal Time on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerance of GZR18 Tablet in Chinese Healthy Adult Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","UNKNOWN","92","Diabetes Mellitus, Type 2","DRUG:GZR18","Gan and Lee Pharmaceuticals, USA","2024-04-01","FALSE","0"],["S002757","ClinicalTrials.gov","NCT03374241",null,"A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Dose of HM15211(Efocipegtrutide) in Healthy Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","41","Obesity","BIOLOGICAL:HM15211 or Placebo","Hanmi Pharmaceutical Company Limited","2018-04-04","TRUE","0"],["S002758","ClinicalTrials.gov","NCT06628362",null,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","447","Overweight or Obese; Type 2 Diabetes Mellitus (T2DM)","DRUG:Placebo; DRUG:Enicepatide","Carmot Therapeutics, Inc.","2024-11-21","FALSE","1"],["S002759","ClinicalTrials.gov","NCT07057674",null,"A Bioequivalence Study of HS-20094 Multi-dose Pre-filled Injection and HS-20094 Single-dose Pre-filled Injection in Overweight or Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","144","Overweight or Obesity","DRUG:HS-20094 AI pen;; DRUG:HS-20094 MDV pen","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2025-04-16","FALSE","0"],["S002760","ClinicalTrials.gov","NCT07141030",null,"To Assess the Pharmacokinetic (PK) Differences of GZR18 Injection Between Subjects With Renal Impairment and Those With Normal Renal Function, Providing a Basis for Establishing a Clinical Dosing Regimen for Patients With Renal Impairment","INTERVENTIONAL",null,"PHASE1","RECRUITING","32","Obesity/Overweight","DRUG:GZR18 injection","Gan & Lee Pharmaceuticals.","2025-04-11","FALSE","0"],["S002761","ClinicalTrials.gov","NCT03520972",null,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of Twelve Once-weekly Subcutaneous Doses of PB-119 in Drug-naïve Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","251","Type 2 Diabetes Mellitus","DRUG:PB-119 75ug; DRUG:PB-119 150ug; DRUG:PB-119 200ug; DRUG:placebo","PegBio Co., Ltd.","2018-06-05","FALSE","3"],["S002762","ClinicalTrials.gov","NCT07668401","AMAZE 13","Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","400","Obesity; Overweight","DRUG:Zenagamtide; DRUG:Placebo ( matched to Zenagamtide)","Novo Nordisk A/S","2027-01-07","FALSE","0"],["S002763","ClinicalTrials.gov","NCT07395687",null,"A Study Investigating Safety, Tolerability and Efficacy of UBT251 in Participants Living With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","333","Overweight; Obesity","DRUG:UBT251; DRUG:Placebo","Novo Nordisk A/S","2026-02-02","FALSE","0"],["S002764","ClinicalTrials.gov","NCT06555640",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous Injection of DR10624 in Subjects With Severe Hypertriglyceridemia","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","79","Severe Hypertriglyceridemia","DRUG:DR10624 Injection; DRUG:Placebo","Zhejiang Doer Biologics Co., Ltd.","2024-08-01","FALSE","0"],["S002765","ClinicalTrials.gov","NCT05328726",null,"A Double-blind, Randomized, Placebo-controlled, Sequential, Single, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Parameters of Subcutaneous Injections of GZR18 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Diabetes Mellitus, Type 2","DRUG:GZR-18; OTHER:Placebo","Gan and Lee Pharmaceuticals, USA","2022-03-08","FALSE","0"],["S002766","ClinicalTrials.gov","NCT07693777",null,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy and Safety of DR10624 in Subjects With Severe Hypertriglyceridemia Receiving Stable Lipid-Modifying Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","480","Severe Hypertriglyceridemia (sHTG); Hypertriglyceridemia","BIOLOGICAL:DR10624 Injection; OTHER:Matching Placebo for DR10624","Zhejiang Doer Biologics Co., Ltd.","2026-08-17","FALSE","0"],["S002767","ClinicalTrials.gov","NCT07648225",null,"A PhaseⅢ Study to Evaluate the Efficacy and Safety of UBT251 Injection in Overweight/Obese Patients","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","600","Obesity & Overweight","DRUG:UBT251 Injection 4.0 mg; DRUG:UBT251 Injection 6.0 mg; DRUG:UBT251 Injection Placebo 4.0 mg; DRUG:UBT251 Injection Placebo 6.0 mg","The United Bio-Technology (Hengqin) Co., Ltd.","2026-07-31","FALSE","0"],["S002768","ClinicalTrials.gov","NCT05254158",null,"Investigation of Pharmacokinetic Properties of Single Subcutaneous Doses of NNC0174-0833 in Chinese Male Subjects Being Normal Weight, Overweight or With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Overweight and Obesity","DRUG:NNC0174 0833","Novo Nordisk A/S","2022-03-03","FALSE","0"],["S002769","ClinicalTrials.gov","NCT02300844",null,"Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","54","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC0174-0833; DRUG:placebo","Novo Nordisk A/S","2014-12-01","FALSE","0"],["S002770","ClinicalTrials.gov","NCT04209049",null,"An Open-label Trial Investigating the Pharmacokinetics and the Tolerability of NNC0174-0833 in Subjects With Normal Renal Function and Impaired Renal Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","33","Overweight; Obesity","DRUG:NNC0174-0833","Novo Nordisk A/S","2020-01-15","FALSE","1"],["S002771","ClinicalTrials.gov","NCT03604419",null,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of Twelve Once-weekly Subcutaneous Doses of PB-119 to Patients With Type 2 Diabetes Mellitus (T2DM) Not Well-controlled by Metformin Monotherapy","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","214","Type 2 Diabetes Mellitus (T2DM)","DRUG:PB-119 100 μg+ Glucophage®; DRUG:PB-119 150 μg+ Glucophage®; DRUG:PB-119 200 μg+ Glucophage®; DRUG:PB-119 placebo + Glucophage®","PegBio Co., Ltd.","2018-06-13","FALSE","1"],["S002772","ClinicalTrials.gov","NCT07659574","UNIGUIDE-1","A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Trial to Evaluate the Efficacy and Safety of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","360","Type 2 Diabetes","DRUG:UBT251 Injection 2.0 mg; DRUG:UBT251 Injection 4.0 mg; DRUG:UBT251 Injection 6.0 mg; DRUG:UBT251 Injection Placebo 2.0 mg; DRUG:UBT251 Injection Placebo 4.0 mg; DRUG:UBT251 Injection Placebo 6.0 mg","The United Bio-Technology (Hengqin) Co., Ltd.","2026-09-07","FALSE","0"],["S002773","ClinicalTrials.gov","NCT07134335",null,"A Phase II Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese/Overweight Chronic Kidney Disease (CKD) Population","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","180","Obesity &Amp; Overweight; Chronic Kidney Disease","DRUG:UBT251","The United Bio-Technology (Hengqin) Co., Ltd.","2025-09-01","FALSE","0"],["S002774","ClinicalTrials.gov","NCT07119450",null,"A Mass Balance Study of [14C] GZR18 in Chinese Overweight or Obese Male Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","6","Overweight; Obese; Obesity","DRUG:GZR18 injection、[14C]GZR18 injection","Gan & Lee Pharmaceuticals.","2025-05-07","FALSE","0"],["S002775","ClinicalTrials.gov","NCT06118021",null,"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HS-20094 in Overweight and Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","200","Overweight and Obesity","DRUG:HS-20094; DRUG:Placebo","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2023-10-16","FALSE","0"],["S002776","ClinicalTrials.gov","NCT06256523",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","72","Type 2 Diabetes","DRUG:GZR18; OTHER:Placebo","Gan and Lee Pharmaceuticals, USA","2022-06-29","FALSE","1"],["S002777","ClinicalTrials.gov","NCT04074174",null,"Investigation of the Effect of NNC0174-0833 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) in Females of Non-childbearing Potential","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","31","Overweight; Obesity","DRUG:NNC0174-0833; DRUG:Oral contraceptive (OC) tablets; DRUG:Acetaminophen","Novo Nordisk A/S","2019-09-12","FALSE","0"],["S002778","ClinicalTrials.gov","NCT06670209",null,"A Phase I, Open-label, Fixed-sequence Study to Evaluate the Effect of Repeated Subcutaneous Injections of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese Subjects","INTERVENTIONAL",null,"PHASE1","NOT_YET_RECRUITING","32","Type 2 Diabetes","DRUG:GZR18 and metformin","Gan and Lee Pharmaceuticals, USA","2024-10-30","FALSE","0"],["S002779","ClinicalTrials.gov","NCT06649773",null,"A Study to Evaluate the Efficacy and Safety of Noiiglutide Injection in Type 2 Diabetes Patients Who Received Metformin in Combination With or Without Another Oral Hypoglycemic Drug for Poor Blood Glucose Control -- a Phase III Clinical Trial of Multicenter, Randomized, Double-blind, Placebo Parallel Control","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","137","Type 2 Diabetes","DRUG:Noiiglutide Injection; DRUG:Noiiglutide Placebo","Jiangsu HengRui Medicine Co., Ltd.","2024-11-06","FALSE","0"],["S002780","ClinicalTrials.gov","NCT05333835",null,"A 26-week, Randomized, Open-label, 3-arm Parallel, Treat-to-target Study Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin With or Without One Other Oral Anti-diabetic Drug","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","455","Type 2 Diabetes","DRUG:HR17031 injection; DRUG:INS068 injection; DRUG:SHR20004 injection","Jiangsu HengRui Medicine Co., Ltd.","2022-07-08","FALSE","0"],["S002781","ClinicalTrials.gov","NCT06548945",null,"A Randomized, Double-Blind, Placebo-Controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PK/PD) of a Single Dose of GZR18 Injection in Obese/Overweight Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","16","Overweight and Obesity","DRUG:GZR18; OTHER:Placebo","Gan and Lee Pharmaceuticals, USA","2023-04-25","FALSE","0"],["S002782","ClinicalTrials.gov","NCT06256536",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GZR18 Injection in Chinese Obese/Overweight Patients","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","60","Obesity; Overweight","DRUG:GZR18; OTHER:Placebo","Gan and Lee Pharmaceuticals, USA","2022-07-14","FALSE","1"],["S002783","ClinicalTrials.gov","NCT06350812",null,"A Single-center, Randomized, Double-blind, Placebo-controlled, Multiple Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","32","Obesity","DRUG:PB-119; DRUG:Placebo","PegBio Co., Ltd.","2024-05-27","FALSE","0"],["S002784","ClinicalTrials.gov","NCT07815067",null,"Investigating the Effect of Post-dose Meal Timings and Water Volume at Dosing on the Pharmacokinetic Properties of Oral Zenagamtide in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","320","Overweight; Obesity","DRUG:Zenagamtide injection; DRUG:Zenagamtide tablet","Novo Nordisk A/S","2026-09-07","FALSE","0"],["S002785","ClinicalTrials.gov","NCT05031871",null,"Pharmacokinetic Study of HR17031 Injection in Healthy Subjects (Single-center, Randomized, Open-label, 4 Cycles, 4 Sequences)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Type 2 Diabetes Mellitus","DRUG:HR17031 injection ；INS068 injection；SHR20004 injection","Jiangsu HengRui Medicine Co., Ltd.","2021-09-02","FALSE","0"],["S002786","ClinicalTrials.gov","NCT07351045","Enith1","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","2000","Obesity or Overweight","COMBINATION_PRODUCT:Placebo; COMBINATION_PRODUCT:Enicepatide","Hoffmann-La Roche","2026-03-16","FALSE","0"],["S002787","ClinicalTrials.gov","NCT07710768",null,"An Open-label, Single-sequence, Crossover Study Investigating the Influence of UBT251 on Pharmacokinetics of Index Substrates for Cytochrome P450 Enzymes in Participants With Overweight or Obesity","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","RECRUITING","44","Obesity; Overweight","DRUG:UBT251; DRUG:Cocktail (Warfarin/Caffeine/Midazolam)","Novo Nordisk A/S","2026-07-15","FALSE","0"],["S002788","ClinicalTrials.gov","NCT07767942","UNISHAPE-OSA-1","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese Participants With Moderate-to-severe Obstructive Sleep Apnea (OSA) Not on Positive Airway Pressure (PAP) Therapy（UNISHAPE-OSA-1）","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","150","Obstructive Sleep Apnea, Obesity","DRUG:UBT251; DRUG:Placebo","The United Bio-Technology (Hengqin) Co., Ltd.","2026-09-18","FALSE","0"],["S002789","ClinicalTrials.gov","NCT06548997",null,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GZR18 Injection in Healthy Subjects Following Single Dose and Once-weekly Dose for 2 Consecutive Weeks Until Reaching the Target Dose","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","57","Type 2 Diabetes; Overweight and Obesity","DRUG:GZR18; OTHER:Placebo","Gan and Lee Pharmaceuticals, USA","2021-12-02","FALSE","0"],["S002790","ClinicalTrials.gov","NCT06256562",null,"A Multicenter, Randomized, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Obese/Overweight Patients","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","340","Obesity; Overweight","DRUG:GZR18; OTHER:Placebo","Gan and Lee Pharmaceuticals, USA","2023-06-08","FALSE","1"],["S002791","ClinicalTrials.gov","NCT05378893",null,"A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-and-Multiple-Ascending Subcutaneous Doses of DR10624","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","153","Healthy, Obesity, Metabolically","DRUG:DR10624 for injection; DRUG:Placebo","Zhejiang Doer Biologics Co., Ltd.","2022-06-22","FALSE","0"],["S002792","ClinicalTrials.gov","NCT07145151","MASH","A Phase 2, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of UBT251 Injection in Adult Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","156","Metabolic Dysfunction-associated Steatohepatitis (MASH)","DRUG:UBT251; DRUG:Placebo","The United Bio-Technology (Hengqin) Co., Ltd.","2025-09-30","FALSE","0"],["S002793","ClinicalTrials.gov","NCT07720271","AMAZE 9","Efficacy and Safety of Once-daily Oral Zenagamtide in Participants With Obesity (AMAZE 9)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","950","Overweight; Obesity","DRUG:zenagamtide; DRUG:Placebo","Novo Nordisk A/S","2026-08-31","FALSE","0"],["S002794","ClinicalTrials.gov","NCT05116410",null,"A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-20094","INTERVENTIONAL","RANDOMIZED","PHASE1","UNKNOWN","68","Type 2 Diabetes","DRUG:HS-20094; DRUG:Placebo","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2021-11-01","FALSE","0"],["S002795","ClinicalTrials.gov","NCT07626515",null,"A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Enicepatide in Adult Chinese Participants With Body Mass Index ≥23.0 kg/m2","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","36","Healthy Participants","COMBINATION_PRODUCT:Enicepatide; COMBINATION_PRODUCT:Placebo","Hoffmann-La Roche","2026-07-02","FALSE","0"],["S002796","ClinicalTrials.gov","NCT03787225",null,"Investigation of Pharmacokinetic Properties, Safety and Tolerability of Single Subcutaneous Doses of NNC0174-0833 in Male Japanese and Caucasian Subjects Being Normal Weight, Overweight or With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","66","Obesity; Overweight","DRUG:NNC0174-0833; DRUG:Placebo (NNC0174-0833)","Novo Nordisk A/S","2019-01-07","FALSE","0"],["S002797","ClinicalTrials.gov","NCT07501832",null,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Moderate to Severe Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","140","Obstructive Sleep Apnea (OSA)","DRUG:GZR18 injection; DRUG:Placebo","Gan & Lee Pharmaceuticals.","2026-03-27","FALSE","0"],["S002798","ClinicalTrials.gov","NCT07785934",null,"A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of UBT251 on the Pharmacokinetics of Single Oral Doses of Metformin, Warfarin, Atorvastatin, and Digoxin in Overweight or Obese Participants.","INTERVENTIONAL",null,"PHASE1","RECRUITING","48","Drug Drug Interaction (DDI); Pharmacokinetics and Pharmacodynamics","DRUG:UBT251; DRUG:Metformin hydrochloride; DRUG:Warfarin Sodium; DRUG:Atorvastatin calcium; DRUG:Digoxin","The United Bio-Technology (Hengqin) Co., Ltd.","2026-05-27","FALSE","0"],["S002799","ClinicalTrials.gov","NCT03848793",null,"A Phase 2, Multiple Centers, Double-blind, Placebo-Controlled, Randomised Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","128","Diabetes Mellitus, Type 2","DRUG:HS-20004","Jiangsu HengRui Medicine Co., Ltd.","2019-03-06","FALSE","0"],["S002800","ClinicalTrials.gov","NCT07680829",null,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of DR10624 Added to Standard Icosapent Ethyl Therapy in Adults With Severe Hypertriglyceridemia","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","378","Severe Hypertriglyceridemia","DRUG:DR10624 Subcutaneous Injection; DRUG:Icosapent Ethyl Oral Capsule; DRUG:Matching Placebo Subcutaneous Injection","Zhejiang Doer Biologics Co., Ltd.","2026-08","FALSE","0"],["S002801","ClinicalTrials.gov","NCT07710729",null,"A Single-Centre, Open-Label Study of the Effect of UBT251 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) and Gastric Emptying in Women of Non-Childbearing Potential With Overweight or Obesity","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","RECRUITING","40","Overweight; Obesity","DRUG:UBT251; DRUG:Oral contraceptive; DRUG:Acetaminophen","Novo Nordisk A/S","2026-07-17","FALSE","0"],["S002802","ClinicalTrials.gov","NCT07128888",null,"A Study to Evaluate the Effect of GZR18 Injection on Gastric Emptying and Its Drug-Drug Interactions With Digoxin, Rosuvastatin Calcium and Warfarin Sodium in Obese or Overweight Subjects","INTERVENTIONAL",null,"PHASE1","RECRUITING","60","Obesity or Overweight","DRUG:GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets","Gan & Lee Pharmaceuticals.","2025-11-17","FALSE","0"],["S002803","ClinicalTrials.gov","NCT07351058","Enith2","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","1600","Obesity or Overweight; Type 2 Diabetes Mellitus","COMBINATION_PRODUCT:Placebo; COMBINATION_PRODUCT:Enicepatide","Hoffmann-La Roche","2026-03-23","FALSE","0"],["S002804","ClinicalTrials.gov","NCT04505436","HM-TRIA-201","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","215","NASH - Nonalcoholic Steatohepatitis","DRUG:HM15211; DRUG:Placebo of HM15211","Hanmi Pharmaceutical Company Limited","2020-07-31","FALSE","1"],["S002805","ClinicalTrials.gov","NCT06839664",null,"A Randomized, Double-blind, Placebo-controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of HS-20094 in Overweight and Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","604","Overweight; Obesity","DRUG:HS-20094 injection; DRUG:Placebo injection","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2024-11-16","FALSE","0"],["S002806","ClinicalTrials.gov","NCT03062774",null,"The Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Continuous Multiple Dose PB-119 Injection in Health Volunteers","INTERVENTIONAL",null,"PHASE1","COMPLETED","36","Type2 Diabetes Mellitus","BIOLOGICAL:PB-119 injection","PegBio Co., Ltd.","2014-11-15","FALSE","1"],["S002807","ClinicalTrials.gov","NCT06525935",null,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered for 48 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","469","Obesity; Overweight","DRUG:Placebo; DRUG:Enicepatide","Carmot Therapeutics, Inc.","2024-08-16","FALSE","1"],["S002808","ClinicalTrials.gov","NCT07050134",null,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque","INTERVENTIONAL","RANDOMIZED",null,"ENROLLING_BY_INVITATION","40","Hypertriglyceridemia; Carotid Atherosclerotic Plaques","DRUG:DR10624 Injection；; DRUG:DR10624 Injection Placebo (referred to as placebo)","Junbo Ge","2025-07-01","FALSE","1"],["S002809","ClinicalTrials.gov","NCT06728124",null,"A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","630","Obesity/Overweight","DRUG:GZR18; OTHER:Placebo","Gan & Lee Pharmaceuticals.","2024-12-30","FALSE","0"],["S002810","ClinicalTrials.gov","NCT07806851","UNISHAPE-OSA-2","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese Participants With Moderate-to-Severe Obstructive Sleep Apnea (OSA) on Positive Airway Pressure (PAP) Therapy（UNISHAPE-OSA-2）","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","150","Obstructive Sleep Apnea; Obesity","DRUG:UBT251; DRUG:Placebo","The United Bio-Technology (Hengqin) Co., Ltd.","2026-10-10","FALSE","0"],["S002811","ClinicalTrials.gov","NCT06137469",null,"A Single-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Multiple Subcutaneous Injections of SHR20004 in Healthy Subjects on Gastric Emptying","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","28","Type 2 Diabetes Mellitus","DRUG:Acetaminophen/SHR20004; DRUG:Acetaminophen/Placebo","Jiangsu HengRui Medicine Co., Ltd.","2023-12-26","FALSE","0"],["S002812","ClinicalTrials.gov","NCT07024212",null,"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of DR10624 Injection in Subjects at High Risk of Liver Fibrosis With Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction and Alcohol Associated Steatotic Liver Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","110","MASLD","DRUG:DR10624 Injection; DRUG:Placebo","Zhejiang Doer Biologics Co., Ltd.","2025-04-22","FALSE","0"],["S002813","ClinicalTrials.gov","NCT07177469",null,"A Phase II Study to Evaluate the Efficacy and Safety of UBT251 Injection in Overweight/Obese Patients","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","205","Obesity &Amp; Overweight","DRUG:UBT251 Injection 2.0 mg and UBT251 Injection Placebo; DRUG:UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo; DRUG:UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo; DRUG:UBT251 Injection 6.0 mg and UBT251 Injection Placebo","The United Bio-Technology (Hengqin) Co., Ltd.","2025-03-14","FALSE","2"],["S002814","ClinicalTrials.gov","NCT07355738",null,"A Randomized, Open-label, Single-dose, Parallel Comparison Study to Evaluate the Bioequivalence of GZR18 Injection Before and After CMC Change in Healthy Adult Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","138","Obesity&T2D","DRUG:GZR18 injection A; DRUG:GZR18 injection B","Gan & Lee Pharmaceuticals.","2026-01-09","FALSE","0"],["S002815","ClinicalTrials.gov","NCT07848880",null,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate the Efficacy and Safety of Multiple Doses of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","315","Hypertriglyceridemia","DRUG:DR10624 Injection; DRUG:Placebo","Zhejiang Doer Biologics Co., Ltd.","2026-10","FALSE","0"],["S002816","ClinicalTrials.gov","NCT04799327",null,"A Multi-center, Randomized, Double-blind, Placebo-controlled，Parallel-group Clinical Trial to Assess the Efficacy and Safety of Noiiglutide Injection in Obese Subjects Without Diabetes.","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","254","Obesity","DRUG:SHR20004; DRUG:placebo","Jiangsu HengRui Medicine Co., Ltd.","2021-03-29","FALSE","0"],["S002817","ClinicalTrials.gov","NCT07589686","ZYNERGY","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Petrelintide Co-Administered With RO7795068 in Adults With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","486","Obesity or Overweight","DRUG:Petrelintide; COMBINATION_PRODUCT:Enicepatide; DRUG:Petrelintide-matching Placebo; COMBINATION_PRODUCT:Enicepatide-matching Placebo","Hoffmann-La Roche","2026-09-30","FALSE","0"],["S002818","ClinicalTrials.gov","NCT07292441","GZR18-BWM-303","A Multicenter Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","500","Overweight or Obesity","DRUG:GZR18 injection; OTHER:Placebo","Gan & Lee Pharmaceuticals.","2026-01-22","FALSE","0"],["S002819","ClinicalTrials.gov","NCT07493057",null,"A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Moderate to Severe Obstructive Sleep Apnea（OSA） Not Treated With Positive Airway Pressure（PAP）","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","140","Obstructive Sleep Apnea (OSA)","DRUG:Placebo; DRUG:GZR18 injection","Gan & Lee Pharmaceuticals.","2026-04-27","FALSE","0"],["S002820","ClinicalTrials.gov","NCT07144098",null,"Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","RECRUITING","24","Obesity/Overweight","DRUG:GZR18 injection","Gan & Lee Pharmaceuticals.","2025-08-12","FALSE","0"],["S002821","ClinicalTrials.gov","NCT03072407",null,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Group, MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","40","Type2 Diabetes Mellitus","BIOLOGICAL:PB-119 injection; BIOLOGICAL:PB-119 injection placebo","PegBio Co., Ltd.","2015-11-24","FALSE","0"],["S002822","ClinicalTrials.gov","NCT07156500",null,"A Multicenter, Randomized, Double-Blind, Placebo- Parallel Controlled, Phase III Study to Evaluate the Efficacy and Safety of HS-20094 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","204","Type 2 Diabetes","DRUG:HS-20094 Injection; DRUG:HS-20094 Placebo Injection","Jiangsu Hansoh Pharmaceutical Co., Ltd.","2025-09-30","FALSE","0"],["S002823","ClinicalTrials.gov","NCT03744182",null,"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","66","NAFLD","DRUG:HM15211; DRUG:Placebo of HM15211","Hanmi Pharmaceutical Company Limited","2018-11-01","TRUE","0"],["S002824","ClinicalTrials.gov","NCT04838405",null,"A Phase 1 Randomized, Double Blind, Placebo Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-388 in Otherwise Healthy Overweight and Obese Adult Participants and in Obese Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","129","Diabetes","DRUG:CT-388; DRUG:Placebo","Carmot Therapeutics, Inc.","2021-04-29","FALSE","3"],["S002825","ClinicalTrials.gov","NCT07861100","AMBIENCE","Zenagamtide Use for the Reduction of Risk of Major Adverse Cardiovascular Events in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","8500","Cardiovascular Risk; Obesity","DRUG:Zenagamtide; DRUG:Placebo","Novo Nordisk A/S","2026-10-26","FALSE","0"],["S002826","ClinicalTrials.gov","NCT02958085",null,"Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","96","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC0174-0833; DRUG:Placebo","Novo Nordisk A/S","2016-11-04","FALSE","0"],["S002827","ClinicalTrials.gov","NCT07797335","AMBITION 7","Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Insulin Glargine s.c. Once Daily in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Inadequately Controlled on 1-3 Oral Glucose-lowering Medications (AMBITION 7)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","1778","Type 2 Diabetes; Cardiovascular Risk","DRUG:Zenagamtide; DRUG:Insulin glargine U-100","Novo Nordisk A/S","2026-08-24","FALSE","0"],["S002828","ClinicalTrials.gov","NCT06974487",null,"A Randomized, Double-Blind, Crossover Phase I Clinical Study to Evaluate the Safety, Tolerability, PK and PD Profiles of a Single Dose of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","30","Type 2 Diabetes","DRUG:GZR102 injection; DRUG:GZR4 injection; DRUG:GZR18 injection","Gan & Lee Pharmaceuticals.","2025-05-08","FALSE","0"],["S002829","ClinicalTrials.gov","NCT03617081",null,"A First Human Dose Trial Investigating the Safety, Tolerability and Pharmacokinetics of Single Doses of Oral NNC0113-2023 in Healthy Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","40","Diabetes Mellitus, Type 2","DRUG:NNC0113-2023; DRUG:Placebo (NNC0113-2023)","Novo Nordisk A/S","2018-08-09","FALSE","0"],["S002830","ClinicalTrials.gov","NCT03965130",null,"The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation and Pyruvate Carboxylase Flux in Man Assessed by Positional Isotopomer NMR Tracer Analysis (PINTA)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","10","Healthy Participants","BIOLOGICAL:Glucagon; OTHER:Control Study","Yale University","2019-06-05","TRUE","0"],["S002831","ClinicalTrials.gov","NCT06891287",null,"A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RT-114 in Healthy Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","60","Obesity","COMBINATION_PRODUCT:RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity; DRUG:PG-102; OTHER:Placebo","RANI Therapeutics","2025-12-30","FALSE","0"],["S002832","ClinicalTrials.gov","NCT03774095",null,"Effects of Pine Nut and Olive Oil as FFA1/FFA4 and GPR119 Agonists on Glucose Tolerance in Healthy Overweight or Obese Subjects","INTERVENTIONAL","RANDOMIZED",null,"UNKNOWN","10","Type 2 Diabetes Mellitus; Obesity","DIETARY_SUPPLEMENT:Hydrolyzed pine nut oil; DIETARY_SUPPLEMENT:Hydrolyzed pine nut oil and olive oil","Karina Vejrum Sørensen","2018-06-11","FALSE","0"],["S002988","ClinicalTrials.gov","NCT05654831",null,"A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, First-Time-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ECC5004 in Healthy Participants and in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","69","Type 2 Diabetes Mellitus","DRUG:Placebo; DRUG:ECC5004","Eccogene","2022-12-01","FALSE","1"],["S003063","ClinicalTrials.gov","NCT04855292",null,"A Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase Ib Study in Overweight/Obese Subjects Without Diabetes to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of TG103 Injection","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","48","Diabetes","DRUG:TG103 injection; DRUG:Placebo","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2021-07-01","FALSE","1"],["S003095","ClinicalTrials.gov","NCT02941042",null,"This Trial is Conducted in the United State of America. The Aim of This Trial is to Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","49","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC9204-1177; DRUG:Placebo","Novo Nordisk A/S","2016-10-10","FALSE","0"],["S003096","ClinicalTrials.gov","NCT03308721",null,"A Multiple Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Multiple Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","99","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC9204-1177 A 1.0 mg/mL; DRUG:PLACEBO","Novo Nordisk A/S","2017-10-16","FALSE","0"],["S003097","ClinicalTrials.gov","NCT04059367",null,"An Open-label, Single-sequence, Crossover Trial Investigating the Influence of NNC9204-1177 on Pharmacokinetics of Index Substrates for Cytochrome P450 Enzymes","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","45","Healthy Volunteers; Overweight; Obesity","DRUG:NNC9204-1177; DRUG:Cocktail of 5 already approved drugs","Novo Nordisk A/S","2019-08-15","FALSE","0"],["S003192","ClinicalTrials.gov","NCT06478563",null,"Investigating the Exposure of NNC0487-0111 in Different Oral Formulations and the Effect of Food Intake on Pharmacokinetics of NNC0487-0111 in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","133","Obesity; Overweight","DRUG:NNC0487-0111 (formulation D); DRUG:NNC0487-0111 (formulation C)","Novo Nordisk A/S","2024-06-27","FALSE","0"],["S003193","ClinicalTrials.gov","NCT07481630","AMAZE 5","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 5)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","400","Obesity; Knee Osteoarthritis (OA)","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111 )","Novo Nordisk A/S","2026-04-13","FALSE","0"],["S003194","ClinicalTrials.gov","NCT07567001","HF-POLARIS","Efficacy and Safety of NNC0487-0111 Compared to Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","5610","Obesity; Heart Failure","DRUG:NNC0487-0111; DRUG:Placebo","Novo Nordisk A/S","2026-05-11","FALSE","0"],["S003195","ClinicalTrials.gov","NCT07571005","AMAZE 3","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure (AMAZE 3)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","300","Obesity; Overweight; Obstructive Sleep Apnoea","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-05-05","FALSE","0"],["S003196","ClinicalTrials.gov","NCT07871799","ELITE","Evidence-Based Longevity Interventions and Targeted Engagement (E.L.I.T.E.)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","31","Healthy Aging","DIETARY_SUPPLEMENT:AgeBiotics AB-01; DIETARY_SUPPLEMENT:AgeBiotics AB-02; DRUG:Metformin; DRUG:semaglutide; DRUG:empagliflozin","Sheba Medical Center","2025-11-17","FALSE","0"],["S003197","ClinicalTrials.gov","NCT07503210","AMAZE 12","Efficacy and Safety of NNC0487-0111 s.c. Once Weekly in Participants With Obesity Who Have Reached Target Dose During run-in Period (AMAZE 12)","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","606","Obesity","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-04-21","FALSE","0"],["S003198","ClinicalTrials.gov","NCT06461039",null,"Investigation of the Effect of NNC0487-0111 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) and Gastric Emptying in Females of Non-childbearing Potential","INTERVENTIONAL",null,"PHASE1","COMPLETED","43","Obesity","DRUG:NNC0487-0111 A; DRUG:NNC0487-0111 C; DRUG:Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC); DRUG:Acetaminophen - 500 mg/15 ml","Novo Nordisk A/S","2024-06-14","FALSE","0"],["S003199","ClinicalTrials.gov","NCT07535307",null,"Effect of NNC0487-0111 on Insulin Sensitivity and Pancreatic Endocrine Function in Adults With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","80","Diabetes Mellitus","DRUG:NNC0487-0111; DRUG:Placebo","Novo Nordisk A/S","2026-04-10","FALSE","0"],["S003200","ClinicalTrials.gov","NCT07458269",null,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","264","Obesity","DRUG:Ribupatide; DRUG:Placebo","Kailera","2026-03-04","FALSE","0"],["S003201","ClinicalTrials.gov","NCT07508020",null,"Effect of Once-weekly Subcutaneous Administration of NNC0487-0111 on Energy Intake, Appetite and Postprandial Metabolism in Participants With Obesity - a Randomised, Placebo-controlled, Double Blinded Study","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","120","Obesity","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-03-30","FALSE","0"],["S003202","ClinicalTrials.gov","NCT07709910",null,"A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","382","Participants With Obesity and Knee Osteoarthritis","DRUG:Ribupatide Injection; DRUG:Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-07","FALSE","0"],["S003203","ClinicalTrials.gov","NCT07757087",null,"The Effect of Once-weekly Subcutaneous NNC0487-0111 Compared to an Energy-restricted Diet or Placebo on Energy Metabolism in Adults Living With Overweight or Obesity: a Randomised, Placebo-controlled Study","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","120","Overweight; Obesity","DRUG:NNC0487-0111; DRUG:Placebo; BEHAVIORAL:LED","Novo Nordisk A/S","2026-08-03","FALSE","0"],["S003204","ClinicalTrials.gov","NCT07822061","AMAZE 10","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Japanese Participants With Overweight or Obesity (AMAZE 10)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","400","Overweight; Obesity","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-09-07","FALSE","0"],["S003205","ClinicalTrials.gov","NCT03586830",null,"A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","196","Obesity and Diabetes Mellitus, Type 2","DRUG:JNJ-64565111 Dose Level 1; DRUG:JNJ-64565111 Dose Level 2; DRUG:JNJ-64565111 Dose Level 3; DRUG:Placebo","Janssen Research & Development, LLC","2018-06-26","TRUE","0"],["S003206","ClinicalTrials.gov","NCT00394030",null,"An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different Injection Sites in Adult Male and Female Subjects With Type 2 Diabetes and of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy, Normal Volunteers","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","63","Diabetes Mellitus, Type 2","DRUG:GSK716155 subcutaneous injections","GlaxoSmithKline","2006-10-16","FALSE","1"],["S003207","ClinicalTrials.gov","NCT06559527",null,"Investigation of Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Dose of NNC0487-0111 in Participants With Various Degrees of Renal Impairment and Normal Renal Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","42","Diabetes Mellitus, Type 2; Obesity; Overweight","DRUG:NNC0487-0111","Novo Nordisk A/S","2024-08-20","FALSE","1"],["S003208","ClinicalTrials.gov","NCT01357850",null,"A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","82","Heart Failure, Congestive","DRUG:GSK716155; DRUG:Placebo","GlaxoSmithKline","2010-09-15","TRUE","1"],["S003209","ClinicalTrials.gov","NCT06000891",null,"A Randomised, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 Administered in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","TERMINATED","84","Safety and Tolerability","DRUG:ZP7570; DRUG:Placebo","Zealand Pharma","2023-09-15","FALSE","0"],["S003210","ClinicalTrials.gov","NCT07509307","AMAZE 6","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 6)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","400","Obesity; Overweight; Osteoarthritis, Knee","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-04-20","FALSE","0"],["S003211","ClinicalTrials.gov","NCT07284875","KaiNETIC-1","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","2530","Obesity; Overweight","DRUG:Ribupatide; DRUG:Placebo","Kailera","2025-12-18","FALSE","1"],["S003212","ClinicalTrials.gov","NCT07121153",null,"Investigation of Safety, Tolerability and Pharmacokinetic Properties of Single Doses of Subcutaneous NNC0487-0111 in Chinese Participants With Overweight or Obesity.","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","36","Overweight; Obesity","DRUG:NNC0487-0111 A; DRUG:Placebo A","Novo Nordisk A/S","2025-08-11","FALSE","0"],["S003213","ClinicalTrials.gov","NCT07284901","KaiNETIC-2","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","1270","Obesity With Diabetes; Overweight With Diabetes","DRUG:Ribupatide; DRUG:Placebo","Kailera","2026-01-12","FALSE","1"],["S003214","ClinicalTrials.gov","NCT06820476",null,"Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Oral Doses of NNC0487-0111 in Chinese Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","29","Overweight; Obesity","DRUG:NNC0487-0111; DRUG:Placebo (NNC0487-0111)","Novo Nordisk A/S","2025-02-09","FALSE","0"],["S003215","ClinicalTrials.gov","NCT07793929",null,"A Phase 1, Open Label, Parallel Group Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics of Ribupatide in Healthy Participants and in Participants Living With Severe Renal Impairment or End Stage Kidney Disease","INTERVENTIONAL",null,"PHASE1","RECRUITING","32","End Stage Renal Disease; Renal Impairment; Obesity; Overweight","DRUG:Ribupatide","Kailera","2026-09-08","FALSE","0"],["S003216","ClinicalTrials.gov","NCT03593668",null,"Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control :A Randomized, Open, Controlled and Single-site Clinical Trail","INTERVENTIONAL","RANDOMIZED","PHASE4","UNKNOWN","60","Obesity; Drug","DRUG:Metformin; DRUG:Benaglutide","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","2017-12-30","FALSE","0"],["S003217","ClinicalTrials.gov","NCT07533175","AMAZE 2","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","630","Diabetes Mellitus; Overweight; Obesity","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-04-13","FALSE","0"],["S003218","ClinicalTrials.gov","NCT07870538","SEM-BEAT","A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum","INTERVENTIONAL",null,"PHASE4","RECRUITING","96","Obesity & Overweight","DRUG:Semaglutide 3,2 mg/ml","Universitaire Ziekenhuizen KU Leuven","2026-08-26","FALSE","0"],["S003219","ClinicalTrials.gov","NCT07497880",null,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","306","Obesity; Overweight","DRUG:KAI-7535; DRUG:Placebo","Kailera","2026-04-06","FALSE","0"],["S003220","ClinicalTrials.gov","NCT07872033",null,"A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Aleniglipron Pharmacokinetics","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","NOT_YET_RECRUITING","36","Hepatic Impairment","DRUG:Aleniglipron","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","2026-10","FALSE","0"],["S003221","ClinicalTrials.gov","NCT03994549",null,"A First in Human, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of ZP7570 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","EARLY_PHASE1","COMPLETED","64","Healthy","DRUG:Dual GLP-1/GLP-2 Receptor agonists","Zealand Pharma","2019-06-14","FALSE","0"],["S003222","ClinicalTrials.gov","NCT07587710",null,"A Study Investigating the Pharmacokinetic Properties, Safety and Tolerability of NNC0487-0111 in Participants With Various Degrees of Hepatic Impairment and Participants With Normal Hepatic Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","NOT_YET_RECRUITING","35","Overweight; Obesity","DRUG:NNC0487-0111","Novo Nordisk A/S","2026-05-13","FALSE","0"],["S003223","ClinicalTrials.gov","NCT06064006",null,"A Randomised, Placebo-controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0487-0111 in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","125","Obesity; Overweight","DRUG:NNC0487-0111; DRUG:Placebo (NNC0487-0111)","Novo Nordisk A/S","2023-09-15","FALSE","2"],["S003224","ClinicalTrials.gov","NCT06542874",null,"Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding Study","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","448","Type 2 Diabetes (T2D)","DRUG:NNC0487-0111 subcutanous; DRUG:Placebo (NNC0487-0111 subcutanous); DRUG:NNC0487-0111 oral; DRUG:Placebo (NNC0487-0111 oral)","Novo Nordisk A/S","2024-08-07","FALSE","2"],["S003225","ClinicalTrials.gov","NCT07339423","AMAZE 1","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","1150","Obesity","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-02-24","FALSE","0"],["S003226","ClinicalTrials.gov","NCT03586843",null,"A Single-dose, Open-label, Randomized, 3-period, 6-sequence, Crossover Study to Evaluate the Relative Bioavailability of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Subjects and A Multiple Dose, Open-label, Titration Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ 64565111 in Otherwise Healthy Obese Adult Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","52","Obesity","DRUG:JNJ-64565111","Janssen Research & Development, LLC","2018-06-29","FALSE","0"],["S003227","ClinicalTrials.gov","NCT05226000",null,"Pharmacokinetics of Benaglutide Injection in Overweight/Obese Adults","INTERVENTIONAL",null,"PHASE1","COMPLETED","16","Overweight/Obese Adults","DRUG:Benaglutide Injection","The Affiliated Hospital of Qingdao University","2020-07-07","FALSE","0"],["S003228","ClinicalTrials.gov","NCT03546205",null,"A Single-dose, Open-label, Parallel-group Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Subjects With Varying Degrees of Renal Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","40","Kidney Failure, Chronic","DRUG:JNJ-64565111","Janssen Research & Development, LLC","2018-06-06","FALSE","0"],["S003229","ClinicalTrials.gov","NCT04612517",null,"A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Doses of ZP7570 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","EARLY_PHASE1","COMPLETED","40","Healthy","DRUG:ZP7570; DRUG:Placebo","Zealand Pharma","2020-10-26","FALSE","0"],["S003230","ClinicalTrials.gov","NCT05369390",null,"Safety, Tolerability and Pharmacokinetics of NNC0487-0111 in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","144","Obesity","DRUG:NNC0487-0111 A; DRUG:NNC0487-0111 B; OTHER:Placebo B (NNC0487-0111 B); OTHER:Placebo A (NNC0487-0111 A)","Novo Nordisk A/S","2022-05-11","FALSE","1"],["S003231","ClinicalTrials.gov","NCT03235219",null,"A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Men and Women With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","39","Diabetes Mellitus, Type 2","DRUG:JNJ-64565111; DRUG:Placebo","Janssen Research & Development, LLC","2017-08-01","FALSE","0"],["S003232","ClinicalTrials.gov","NCT07044401",null,"A Phase 1, Randomized, Open-label, Single-Dose, Crossover Study to Investigate the Effect of Injection Site on Relative Bioavailability of KAI-9531 Subcutaneous Injection in Participants With a Range of Body Mass Indices","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","51","Healthy Volunteers","DRUG:KAI-9531","Kailera","2025-07-14","FALSE","0"],["S003233","ClinicalTrials.gov","NCT03606057",null,"A Randomized, Double-Blind, Parallel, Nested Crossover Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","188","Healthy","DRUG:JNJ-64565111; DRUG:Moxifloxacin; DRUG:JNJ-64565111-matching Placebo; DRUG:Moxifloxacin-matching Placebo","Janssen Research & Development, LLC","2018-07-13","FALSE","0"],["S003234","ClinicalTrials.gov","NCT03618160",null,"A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Japanese Subjects and An Open-label, Single Dose Study to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","TERMINATED","42","Healthy","DRUG:JNJ-64565111; DRUG:Placebo","Janssen Pharmaceutical K.K.","2018-08-06","FALSE","0"],["S003235","ClinicalTrials.gov","NCT07294898",null,"A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Effect of a Low-Fat Meal and Evening Dosing on the Pharmacokinetics of KAI-7535 in Healthy Participants Living With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","18","Obesity; Overweight","DRUG:KAI-7535","Kailera","2025-12-15","FALSE","0"],["S003236","ClinicalTrials.gov","NCT07571109","AMAZE 4","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Treated With Positive Airway Pressure (AMAZE 4)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","300","Obesity; Overweight; Obstructive Sleep Apnoea","DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)","Novo Nordisk A/S","2026-05-05","FALSE","0"],["S003237","ClinicalTrials.gov","NCT02862431",null,"A Double-Blind, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Men and Women With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","TERMINATED","24","Diabetes Mellitus, Type 2","DRUG:JNJ-64565111; DRUG:Placebo","Janssen Research & Development, LLC","2016-07-12","FALSE","0"],["S003238","ClinicalTrials.gov","NCT07871409","MARITIME-PEN","A Phase 3 Multicenter, Open-label, Single-arm Trial Evaluating Home Self-Administration of Subcutaneous Maridebart Cafraglutide Via Autoinjector in Adult Participants Living With Obesity or Overweight Without Type 2 Diabetes Mellitus","INTERVENTIONAL",null,"PHASE3","NOT_YET_RECRUITING","230","Obesity; Overweight","DRUG:Maridebart cafraglutide; DEVICE:Autoinjector","Amgen","2026-10-28","FALSE","0"],["S003239","ClinicalTrials.gov","NCT07550816",null,"A Drug-drug Interaction Study to Evaluate the Impact of Multiple Subcutaneous Injections of ZT002 on the Pharmacokinetics of Metformin, Warfarin, Rosuvastatin and Digoxin in Overweight and Obese Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","RECRUITING","60","Overweight,Obesity","DRUG:ZT002 injection, metformin, warfarin; DRUG:ZT002 injection, rosuvastatin, digoxin","Beijing QL Biopharmaceutical Co.,Ltd","2026-05-27","FALSE","0"],["S003240","ClinicalTrials.gov","NCT07166081",null,"A Phase 1, Double-Blind, Randomized, Ascending-Dose, Placebo-Controlled, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets Orally Administered in Non-diabetic Overweight or Obese Adult Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","80","Non-diabetic Overweight or Obese","DRUG:BGM0504; DRUG:Placebo","BrightGene Bio-Medical Technology Co., Ltd.","2025-08-11","FALSE","0"],["S003241","ClinicalTrials.gov","NCT07394114",null,"A Multicenter, Randomized, Double-blind, Placebo-Controlled , Phase 3 Study Comparing the Efficacy and Safety of HDM1005 Versus Placebo in Subjects With T2DM Inadequate Glycemic Control With Diet and Exercise Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","240","Type 2 Diabetes","DRUG:HDM1005 1; DRUG:HDM1005 2; DRUG:HDM1005 injection or placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-02-24","FALSE","0"],["S003242","ClinicalTrials.gov","NCT04521738",null,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of SAR441255 in Lean to Overweight Adult Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","48","Overweight; Healthy Subjects","DRUG:SAR441255; DRUG:placebo","Sanofi","2019-04-25","FALSE","1"],["S003243","ClinicalTrials.gov","NCT04790006",null,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Multiple Ascending Dose Phase Ib Study in Subjects With Type 2 Diabetes to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TG103 Injection","INTERVENTIONAL","RANDOMIZED","PHASE1","UNKNOWN","54","Type 2 Diabetes","DRUG:TG103; DRUG:Placebo","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","2021-04","FALSE","0"],["S003244","ClinicalTrials.gov","NCT07073170",null,"A Phase 1, Participant- and Investigator-Blind, Placebo-Controlled, Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Daily Doses of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","36","Type 2 Diabetes","DRUG:LY3549492; DRUG:Placebo","Eli Lilly and Company","2025-07-25","FALSE","0"],["S003245","ClinicalTrials.gov","NCT06062069",null,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants With Type 1 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","111","Overweight; Obese; Type 1 Diabetes Mellitus","DRUG:CT-868; DEVICE:CT-868 Pen Injector; DRUG:CT-868 Pen Injector, Placebo","Carmot Therapeutics, Inc.","2023-10-19","FALSE","0"],["S003246","ClinicalTrials.gov","NCT07857265",null,"A Clinical Study on the Mass Balance of [14C]DA-302168S in Healthy Adult Male Trial Participants in China","INTERVENTIONAL",null,"PHASE1","NOT_YET_RECRUITING","10","Healthy Adult Subjects","DRUG:[14C] DA-302168S","Chendu DIAO Pharmaceutical Group CO., LTD.","2026-11-20","FALSE","0"],["S003247","ClinicalTrials.gov","NCT06548932",null,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerance, PK and PD Parameters of Single Dose Escalation of GZR33 and Single Administration of GZR101 in Healthy Male Adult Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","52","Healthy Subjects","DRUG:GZR33 Injection; DRUG:GZR101 Injection; DRUG:Placebo","Gan and Lee Pharmaceuticals, USA","2022-06-30","FALSE","0"],["S003248","ClinicalTrials.gov","NCT05063253",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","208","Type 2 Diabetes Mellitus","DRUG:TG103; DRUG:Placebo","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2021-10","FALSE","0"],["S003249","ClinicalTrials.gov","NCT07741604",null,"A Two-part, Non-randomized, Open-label, Parallel-group Study to Assess the Effect of Renal Impairment on the Pharmacokinetics and Safety of RO7795081 Following a Single Oral Dose of RO7795081","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","RECRUITING","60","Renal Impairment","DRUG:RO7795081","Hoffmann-La Roche","2026-09-09","FALSE","0"],["S003250","ClinicalTrials.gov","NCT06948747",null,"An Open-label, Fixed-sequence, Three-part Study to Assess the Effect of AZD5004 on the Pharmacokinetics of Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and to Assess the Effect of Erythromycin on AZD5004 in Healthy Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","49","Healthy Participants","DRUG:AZD5004; DRUG:Rosuvastatin; DRUG:Erythromycin; DRUG:Atorvastatin; DRUG:Simvastatin; DRUG:Repaglinide","AstraZeneca","2025-05-06","FALSE","0"],["S003251","ClinicalTrials.gov","NCT06147544",null,"A Single Center, Randomized, Double Blind, Placebo Controlled, Multiple Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","36","Obesity","DRUG:PB-718; DRUG:Placebo","PegBio Co., Ltd.","2023-07-06","FALSE","1"],["S003252","ClinicalTrials.gov","NCT06712836","VESPER-1","A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of 28 Weeks to Investigate the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight Followed by a 32-Week Extension (VESPER-1)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","239","Obesity; Overweight or Obesity","DRUG:MET097; DRUG:Placebo","Pfizer","2024-10-09","TRUE","0"],["S003253","ClinicalTrials.gov","NCT02188303",null,"A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of the Oxyntomodulin Analog, LY2944876, in Healthy Japanese Subjects and Healthy Non-Japanese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","TERMINATED","48","Healthy Volunteers","DRUG:LY2944876; DRUG:Placebo","OPKO Health, Inc.","2014-07","TRUE","0"],["S003254","ClinicalTrials.gov","NCT00674466",null,"A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Twice-a-week Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","90","Type 2 Diabetes Mellitus","DRUG:1.5 mg or 2.0 mg CJC-1134-PC; DRUG:Placebo","ConjuChem","2008-03","TRUE","0"],["S003255","ClinicalTrials.gov","NCT06988553",null,"A Phase Ib, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","45","Obesity or Overweight; Type 2 Diabetes","DRUG:AZD5004; DRUG:Placebo","Eccogene","2025-06-17","FALSE","0"],["S003256","ClinicalTrials.gov","NCT06577428",null,"Effect of Injection Site on the Relative Bioavailability of a Single Dose of RAY1225 in Subjects With Low and High Body Mass Index","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","48","Healthy","DRUG:RAY1225","Guangdong Raynovent Biotech Co., Ltd","2024-07-30","FALSE","0"],["S003257","ClinicalTrials.gov","NCT05943886",null,"A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","164","Healthy Subjects; Obesity; T2DM (Type 2 Diabetes Mellitus)","DRUG:HEC88473 injection; DRUG:Placebo","Dongguan HEC Biopharmaceutical R&D Co., Ltd.","2021-08-11","FALSE","2"],["S003258","ClinicalTrials.gov","NCT07056842",null,"A Single-Center, Open-Label, Single-Arm, Fixed-Sequence Phase I Clinical Study to Evaluate the Effect of Multiple Doses of Rifampin or Itraconazole on the Pharmacokinetics of VCT220 in Healthy Subjects","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","32","Obesity &Amp; Overweight","DRUG:Rifampin + VCT220; DRUG:Itraconazole + VCT220","Vincentage Pharma Co., Ltd","2025-07-20","FALSE","0"],["S003259","ClinicalTrials.gov","NCT06199505",null,"A Phase II Trial Comparing Efficacy and Safety of GZR101 and Insulin Degludec/Insulin Aspart in Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drug (OAD) Therapy or OAD Therapy in Combination with Insulin","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","153","Type 2 Diabetes","DRUG:GZR101; DRUG:insulin degledec/insulin aspart","Gan and Lee Pharmaceuticals, USA","2023-11-21","FALSE","0"],["S003260","ClinicalTrials.gov","NCT02653599",null,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Multi-Center Study to Evaluate the Efficacy and Safety of TTP273 Following 12 Weeks Administration in Subjects With Type 2 Diabetes Mellitus on a Stable Dose of Metformin","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","174","Type 2 Diabetes Mellitus","DRUG:TTP273; DRUG:Placebo","vTv Therapeutics","2015-12","FALSE","0"],["S003261","ClinicalTrials.gov","NCT06613763",null,"Pharmacokinetics of RAY1225 Following Administration to Subjects With Impaired Renal Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","32","Kidney Impairment","DRUG:RAY1225","Guangdong Raynovent Biotech Co., Ltd","2024-09-11","FALSE","0"],["S003262","ClinicalTrials.gov","NCT07872436","VICTOR-DM","A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VCT220 Tablets in Adults With Type 2 Diabetes Mellitus Inadequately Controlled With Lifestyle Intervention, Metformin Monotherapy, or Metformin in Combination With an SGLT2 Inhibitor","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","120","Type 2 Diabetes Mellitus (DM)","DRUG:VCT220 tablets; DRUG:Placebo","Vincentage Pharma Co., Ltd","2026-11-01","FALSE","0"],["S003263","ClinicalTrials.gov","NCT06886126",null,"Phase II Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Obese Nondiabetic Adult Subjects","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","240","Obesity","DRUG:HDM1005 injection or placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-02-07","FALSE","1"],["S003264","ClinicalTrials.gov","NCT06857695",null,"An Open-Label Study to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5004 and Absolute Bioavailability of AZD5004 in Healthy Male Participants","INTERVENTIONAL",null,"PHASE1","COMPLETED","8","Healthy Participants","DRUG:AZD5004 film-coated tablet; DRUG:[14C]AZD5004 Solution for Infusion; DRUG:[14C]AZD5004 Oral Solution","AstraZeneca","2025-03-06","FALSE","0"],["S003265","ClinicalTrials.gov","NCT07340320",null,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","240","Type II Diabetes Mellitus","DRUG:CX11; OTHER:Placebo","Corxel Pharmaceuticals","2026-02-06","FALSE","0"],["S003266","ClinicalTrials.gov","NCT07360275","VICTOR-HTN","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of VCT220 in Participants With Hypertension and Obesity or Overweight.","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","160","Hypertension","DRUG:VCT220 Tablet; DRUG:VCT220 Placebo Tablet","Vincentage Pharma Co., Ltd","2026-03-01","FALSE","0"],["S003267","ClinicalTrials.gov","NCT07807059",null,"An Open-Label, Parallel-Group, Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","RECRUITING","32","Overweight/Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH); Type 2 Diabetes Mellitus","DRUG:HRS-4729","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-09-09","FALSE","0"],["S003268","ClinicalTrials.gov","NCT07827027",null,"Evaluation of the Bioequivalence of RAY1225 Injection in Healthy Participants in a Single-center, Randomized, Open-label, Parallel Study","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","68","Basic Science","DRUG:RAY1225","Guangdong Raynovent Biotech Co., Ltd","2026-09-21","FALSE","0"],["S003269","ClinicalTrials.gov","NCT04973111",null,"A Randomized, Double-Blind, Placebo and Comparator-Controlled Crossover Study to Assess Pharmacokinetic and Pharmacodynamic Effects of CT-868 on the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Diabetes","DRUG:CT-868 as SC Injection; DRUG:Placebo as SC Injection; DRUG:Active Comparator as SC Injection","Carmot Therapeutics, Inc.","2021-07-16","FALSE","0"],["S003270","ClinicalTrials.gov","NCT06893016",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants Who Have Obesity or Are Overweight","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","640","Obesity","DRUG:RAY1225; DRUG:Placebo","Guangdong Raynovent Biotech Co., Ltd","2025-06-15","FALSE","0"],["S003271","ClinicalTrials.gov","NCT03406377",null,"A Phase 2, Double-blind Dose Escalation Regimen of Once-Weekly OPK-88003 in Subjects With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","113","Type 2 Diabetes Mellitus","DRUG:OPK-88003; DRUG:Placebo","OPKO Health, Inc.","2018-04-02","TRUE","0"],["S003272","ClinicalTrials.gov","NCT07652047",null,"A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","90","Obesity & Overweight","DRUG:CX11; OTHER:Placebo","Corxel Pharmaceuticals","2026-05-11","FALSE","0"],["S003273","ClinicalTrials.gov","NCT01665352",null,"Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","186","Type 2 Diabetes Mellitus","DRUG:TTP054; DRUG:Placebo","vTv Therapeutics","2012-08","FALSE","0"],["S003274","ClinicalTrials.gov","NCT06481098",null,"A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","74","Obesity","DRUG:HM15275; DRUG:Placebo of HM15275","Hanmi Pharmaceutical Company Limited","2024-05-28","FALSE","0"],["S003275","ClinicalTrials.gov","NCT03095807",null,"Investigation on Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","34","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC9204-1706 A; DRUG:Placebo","Novo Nordisk A/S","2017-03-20","FALSE","1"],["S003276","ClinicalTrials.gov","NCT05110846",null,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Center Study to Evaluate the Efficacy, Safety, and Tolerability of CT-868 Administered for 26 Weeks to Overweight and Obese Participants With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","103","Obesity; Overweight; Type 2 Diabetes Mellitus","DRUG:Placebo; DRUG:CT-868","Carmot Therapeutics, Inc.","2022-02-22","FALSE","0"],["S003277","ClinicalTrials.gov","NCT07030868",null,"A Phase 2, Parallel-Group, Double-Blind 4-arm Study to Investigate the Effects of Treatment With LY3549492 Tablets Compared With Placebo in an Obese or Overweight Population With Type-2 Diabetes (T2D)","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","1","Obesity; Overweight; Type 2 Diabetes","DRUG:LY3549492; DRUG:Placebo","Eli Lilly and Company","2025-06-19","TRUE","0"],["S003278","ClinicalTrials.gov","NCT06194500",null,"An Open-label, Two-part Study of the Disposition and Absolute Bioavailability of [14C]-LY3549492 in Healthy Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","18","Healthy Male","DRUG:[14C]-LY3549492; DRUG:LY3549492","Eli Lilly and Company","2024-01-03","FALSE","0"],["S003279","ClinicalTrials.gov","NCT05491421",null,"A Phase 1, Randomized, Parallel Assignment, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of ZT002 in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Type 2 Diabetes Mellitus","DRUG:ZT002; OTHER:Placebo","QL Biopharmaceutical Australia Pty Ltd","2022-09-02","FALSE","0"],["S003280","ClinicalTrials.gov","NCT07349381",null,"An Open-label, Randomized, Multiple-dose, Two-cycle, Two-way Crossover Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of CX11 Tablets in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Obesity & Overweight; Type 2 Diabetes","DRUG:CX11 (VCT220)","Vincentage Pharma Co., Ltd","2026-03-04","FALSE","0"],["S003281","ClinicalTrials.gov","NCT03376802",null,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Repeated Subcutaneous Doses of SAR425899 on Energy Expenditure and Safety in Overweight to Obese Male and Female Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Type 2 Diabetes Mellitus","DRUG:SAR425899; DRUG:Placebo","Sanofi","2018-04-18","FALSE","0"],["S003282","ClinicalTrials.gov","NCT07444424",null,"An Open-label, Fixed-sequence, Two-part Study to Assess the Effect of AZD5004 on the Pharmacokinetics of Mitiglinide and Pioglitazone in Healthy Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","32","Healthy Participants","DRUG:AZD5004; DRUG:Mitiglinide; DRUG:Pioglitazone","AstraZeneca","2026-03-13","FALSE","0"],["S003283","ClinicalTrials.gov","NCT05151705",null,"Pharmacokinetics and Safety of HR17031 Injection in Subjects With Mild and Moderate Liver Impairment and Normal Liver Function.","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","UNKNOWN","24","Improved Glycemic Control in Patients With Type 2 Diabetes","DRUG:HR17031 injection","Jiangsu HengRui Medicine Co., Ltd.","2021-12-20","FALSE","0"],["S003284","ClinicalTrials.gov","NCT07658560",null,"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","200","Overweight or Obese Participants Without Diabetes","DRUG:BGM0504 tablets; DRUG:BGM0504 placebo","BrightGene Bio-Medical Technology Co., Ltd.","2026-06-30","FALSE","0"],["S003285","ClinicalTrials.gov","NCT06258148",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial of TG103 Injection Monotherapy Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","465","Type 2 Diabetes Mellitus","DRUG:TG103; DRUG:Placebo","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2024-04-15","FALSE","0"],["S003286","ClinicalTrials.gov","NCT07347808",null,"A Phase 1, Single-Dose, Open-Label, Parallel-Group Pharmacokinetic Study of VCT220 in Subjects With Moderate Renal Impairment and Matched Subjects With Normal Renal Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","16","Obesity & Overweight","DRUG:VCT220","Vincentage Pharma Co., Ltd","2025-12-25","FALSE","0"],["S003287","ClinicalTrials.gov","NCT07828197",null,"A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","135","Overweight and/or Obesity; Healthy Participants","DRUG:HDM1005","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-09-03","FALSE","0"],["S003288","ClinicalTrials.gov","NCT07527650",null,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","180","Type 2 Diabetes Mellitus; T2DM","DRUG:HM15275; DRUG:Placebo of HM15275","Hanmi Pharmaceutical Company Limited","2026-05-18","FALSE","0"],["S003289","ClinicalTrials.gov","NCT06929156",null,"A Multi-center, Single-dose, Open-label, Parallel Design, Pharmacokinetics Study of BGM0504 Injection in Healthy Participants and Participants With Impaired Renal Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","34","Type 2 Diabetes Mellitus (T2DM); Overweight or Obese","DRUG:BGM0504","BrightGene Bio-Medical Technology Co., Ltd.","2025-05-06","FALSE","0"],["S003290","ClinicalTrials.gov","NCT07794761",null,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-WEEKLY BEROBENATIDE IN ADULTS WITH OBESITY DISEASE IN JAPAN (VESPER-JW)","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","180","Obesity","DRUG:Berobenatide; OTHER:Placebo","Pfizer","2026-09-28","FALSE","0"],["S003291","ClinicalTrials.gov","NCT07058545",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once Weekly in Antidiabetic Treatment-naive Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","474","Type 2 Diabetes Mellitus - Poor Control","DRUG:CJC-1134-PC Injection; DRUG:Placebo","Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.","2021-04-16","FALSE","0"],["S003292","ClinicalTrials.gov","NCT04839744",null,"A Randomized, Open-label, Parallel-Group, Comparative Study in Chinese Healthy Male Subjects to Evaluate the Safety and Pharmacokinetic Profile of TG103 Injection Produced by Two Different Manufacturing Processes","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Healthy Male Subjects","DRUG:TG103 produced by the modified manufacturing process; DRUG:TG103 produced by the original manufacturing process","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2021-05-18","FALSE","0"],["S003293","ClinicalTrials.gov","NCT05021666",null,"A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PB-718 Following Subcutaneous Administration in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","82","Healthy Subjects","DRUG:Placebo; DRUG:PB 718","PegBio Co., Ltd.","2020-07-29","FALSE","0"],["S003294","ClinicalTrials.gov","NCT07400679",null,"A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, PARALLEL GROUP STUDY TO ASSESS RELATIVE BIOAVAILABILITY OF PF-08653944 WHEN ADMINISTERED ACROSS DIFFERENT INJECTION SITES IN ADULTS WITH OVERWEIGHT OR OBESITY","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","48","Overweight; Obesity; Healthy","DRUG:PF-08653944","Pfizer","2026-02-04","FALSE","0"],["S003295","ClinicalTrials.gov","NCT06742762",null,"A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","16","Renal Impairment","DRUG:AZD5004","AstraZeneca","2024-12-17","FALSE","0"],["S003296","ClinicalTrials.gov","NCT00638716","DM200-101","A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","122","Type 2 Diabetes Mellitus","DRUG:CJC-1134-PC; DRUG:Placebo","ConjuChem","2008-02","TRUE","0"],["S003297","ClinicalTrials.gov","NCT06226090",null,"A Randomized, Double-blind, Placebo-controlled Phase 2 Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","314","Obesity; Overweight","DRUG:TG103 7.5 mg; DRUG:Placebo 7.5 mg; DRUG:TG103 15 mg; DRUG:Placebo 15 mg; DRUG:TG103 22.5 mg; DRUG:Placebo 22.5 mg","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","2024-02-21","FALSE","0"],["S003298","ClinicalTrials.gov","NCT04812262",null,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DD01 in Overweight/Obese Subjects With T2DM and NAFLD","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","255","Overweight and Obesity; Type2 Diabetes; NAFLD","DRUG:DD01; DRUG:Placebo","Neuraly, Inc.","2021-02-24","FALSE","0"],["S003299","ClinicalTrials.gov","NCT06423872",null,"A Phase 1, Randomized, Parallel Assignment, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of ZT002 in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","28","Type 2 Diabetes Mellitus","DRUG:ZT002; OTHER:Placebo","Beijing QL Biopharmaceutical Co.,Ltd","2023-06-19","FALSE","0"],["S003300","ClinicalTrials.gov","NCT06637020",null,"A Randomized, Double-blind, Placebo-controlled, Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous (SC) Doses of HDM1005 Injection in Overweight or Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","80","Overweight and Obesity","DRUG:HDM1005 injection or placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-06-21","FALSE","1"],["S003301","ClinicalTrials.gov","NCT03661879",null,"A Randomised, Double-blinded, Multiple-dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC9204-1706 in Subjects Being Overweight or With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","60","Metabolism and Nutrition Disorder; Obesity","DRUG:NNC9204-1706; DRUG:Placebo (NNC9204-1706)","Novo Nordisk A/S","2018-09-12","FALSE","1"],["S003302","ClinicalTrials.gov","NCT06268145",null,"An Open-Label, Randomized, Single Dose, Crossover Clinical Study to Assess the Relative Bioavailability of Current Tablet Formulation (F1) Compared to New Tablet Formulation (F2) of ECC5004 and Food Effects on F1 and F2 of ECC5004 in Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","14","Type 2 Diabetes Mellitus","DRUG:ECC5004","Eccogene","2024-02-06","FALSE","0"],["S003303","ClinicalTrials.gov","NCT02411825",null,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Repeated Subcutaneous Doses of SAR425899 in Healthy Male Subjects and Overweight to Obese Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","76","Type 2 Diabetes Mellitus","DRUG:SAR425899; DRUG:placebo; DRUG:metformin","Sanofi","2015-03","FALSE","3"],["S003304","ClinicalTrials.gov","NCT07499050",null,"An Investigator- and Participant-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","30","Healthy Volunteers; Overweight or Obesity","DRUG:RO7795081; DRUG:Placebo","Hoffmann-La Roche","2026-03-30","FALSE","0"],["S003305","ClinicalTrials.gov","NCT07690826",null,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","252","Overweight or Obesity","DRUG:HRS-4729 Injection; DRUG:HRS-4729 Injection;; DRUG:HRS-4729 Injection Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.","2026-07","FALSE","0"],["S003306","ClinicalTrials.gov","NCT07232732",null,"A Phase-1, Parallel-Design, Open-Label, Randomized, Multiple-Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3549492 in Healthy Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","120","Healthy; Obesity; Overweight","DRUG:LY3549492","Eli Lilly and Company","2025-10-27","FALSE","0"],["S003307","ClinicalTrials.gov","NCT07085468",null,"A Parallel-Group, Double-Blind Study to Investigate the Safety and Tolerability of LY3549492 Compared With Placebo in Adult Participants Aged 55 to 80 Years With a BMI of 22 to 25 kg/m2","INTERVENTIONAL","RANDOMIZED","PHASE2","TERMINATED","1","Healthy","DRUG:LY3549492; DRUG:Placebo","Eli Lilly and Company","2025-07-21","TRUE","0"],["S003308","ClinicalTrials.gov","NCT07787260",null,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","200","Obstructive Sleep Apnea (OSA) and Obesity","DRUG:HDM1005; DRUG:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-08","FALSE","0"],["S003309","ClinicalTrials.gov","NCT03437720","Restore","A 52-week Double-blind, Randomized, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of SAR425899 for the Treatment of Non-alcoholic Steatohepatitis (NASH)","INTERVENTIONAL","RANDOMIZED","PHASE2","WITHDRAWN","0","Non-alcoholic Steatohepatitis; Type 2 Diabetes Mellitus","DRUG:SAR425899; DRUG:Placebo","Sanofi","2019-05-23","FALSE","0"],["S003310","ClinicalTrials.gov","NCT06577415",null,"A Single Dose Pharmacokinetic Study of ray1225 in Subjects With Varying Degrees of Hepatic Impairment","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","UNKNOWN","24","Hepatic Impairment","DRUG:RAY1225","Guangdong Raynovent Biotech Co., Ltd","2024-08-26","FALSE","0"],["S003311","ClinicalTrials.gov","NCT06857617",null,"A Phase 1/2 Randomized Placebo-Controlled Double-Blind Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Doses of MET097 in Adult Participants With Obesity and Overweight But Otherwise Healthy","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","120","Obesity and Overweight","BIOLOGICAL:(Part C) MET097; BIOLOGICAL:(Part C) Placebo","Metsera, a wholly owned subsidiary of Pfizer","2024-04-01","FALSE","0"],["S003312","ClinicalTrials.gov","NCT06716203",null,"A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of BGM0504 Versus Placebo in Patients with Type 2 Diabetes, Inadequately Controlled with Diet and Exercise Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","207","Type 2 Diabetes Mellitus (T2DM)","DRUG:Drug: 5 mg BGM0504 Administered SC; DRUG:Drug: : 10 mg BGM0504 Administered SC; DRUG:Drug: Placebo Administered SC","BrightGene Bio-Medical Technology Co., Ltd.","2024-12-02","FALSE","0"],["S003313","ClinicalTrials.gov","NCT07460284",null,"A Mass Balance Study of 14C-RAY1225 Injection in Healthy Chinese Participants","INTERVENTIONAL",null,"PHASE1","NOT_YET_RECRUITING","8","Basic Science","DRUG:14C-RAY1225","Guangdong Raynovent Biotech Co., Ltd","2026-03-15","FALSE","0"],["S003314","ClinicalTrials.gov","NCT06640647",null,"A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HDM1005 After a Single Subcutaneous Dose in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","65","Obesity and Overweight","DRUG:HDM1005 injection or placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2024-03-19","FALSE","1"],["S003315","ClinicalTrials.gov","NCT05848440",null,"A Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","48","Non-alcoholic Steatohepatitis","DRUG:AZD9550; DRUG:Placebo","AstraZeneca","2023-05-02","FALSE","0"],["S003316","ClinicalTrials.gov","NCT05292495",null,"A Single-dose, Open Design Study to Evaluate The Pharmacokinetics of HR17031 Injection With Renal Insufficiency","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","24","Improved Glycemic Control in Patients With Type 2 Diabetes","DRUG:HR17031 injection","Jiangsu HengRui Medicine Co., Ltd.","2022-10-12","FALSE","0"],["S003317","ClinicalTrials.gov","NCT07594847",null,"A Phase I, Single-center, Randomized, Double-blind, Placebo- and Positive-controlled, Four-period, Crossover Clinical Study to Evaluate the Effect of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","72","Healthy Adult Subject","DRUG:HDM1002 200 mg; DRUG:HDM1002 400 mg; DRUG:Placebo; DRUG:Moxifloxacin 400 mg","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-03-07","FALSE","0"],["S003318","ClinicalTrials.gov","NCT07081958",null,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 38 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","352","Obesity or Overweight","DRUG:RO7795081; DRUG:Placebo","Hoffmann-La Roche","2025-07-29","FALSE","0"],["S003319","ClinicalTrials.gov","NCT06703658",null,"A Phase I, Randomised, Single-blind, Placebo-controlled, Single and Repeated Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5004 in Healthy Japanese Participants and With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","35","Healthy Participants; Type 2 Diabetes","DRUG:AZD5004(Part A); DRUG:Placebo(Part A); DRUG:AZD5004(Part B); DRUG:Placebo(Part B)","AstraZeneca","2024-11-02","FALSE","0"],["S003320","ClinicalTrials.gov","NCT06410924",null,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Treatment With DD01 for 48 Weeks in Overweight/Obese Subjects With MASLD/MASH","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","67","NAFLD; NASH","DRUG:DD01; DRUG:Placebo","Neuraly, Inc.","2024-06-13","FALSE","1"],["S003321","ClinicalTrials.gov","NCT07508241",null,"A PHASE 1, OPEN-LABEL, MULTIPLE DOSE STUDY TO INVESTIGATE THE IMPACT OF PF 08653944 ON GASTRIC EMPTYING IN ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY","INTERVENTIONAL",null,"PHASE1","ACTIVE_NOT_RECRUITING","22","Obesity; Overweight and/or Obesity; Overweight; Drug Interaction","DRUG:PF-08653944; DRUG:Acetaminophen","Pfizer","2026-03-31","FALSE","0"],["S003322","ClinicalTrials.gov","NCT07205900",null,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","267","Obese; Obesity","DRUG:HM15275; DRUG:Placebo of HM15275","Hanmi Pharmaceutical Company Limited","2025-12-02","FALSE","0"],["S003323","ClinicalTrials.gov","NCT02055547",null,"A Single and Multiple-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8521 in Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","61","Type 2 Diabetes Mellitus","DRUG:MK-8521 35μg; DRUG:MK-8521 100μg; DRUG:MK-8521 125μg; DRUG:MK-8521 150μg; DRUG:MK-8521 175μg; DRUG:MK-8521 200μg; DRUG:MK-8521 300μg; DRUG:MK-8521 50/72μg; DRUG:MK-8521 72/125μg; DRUG:MK-8521 100/150μg; DRUG:MK-8521 125/150μg; DRUG:Placebo","Merck Sharp & Dohme LLC","2013-05-10","TRUE","0"],["S003324","ClinicalTrials.gov","NCT06371326",null,"A Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Phase Ic Study Evaluating the Safety, Tolerability, and Pharmacokinetics of ZT002 Injection in Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","28","Overweight or Obesity","DRUG:ZT002 Injection; DRUG:Placebo","Beijing QL Biopharmaceutical Co.,Ltd","2023-11-21","FALSE","0"],["S003325","ClinicalTrials.gov","NCT07139535",null,"A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of RAY1225 Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","350","T2DM","DRUG:RAY1225; DRUG:placebo","Guangdong Raynovent Biotech Co., Ltd","2025-08-31","FALSE","0"],["S003326","ClinicalTrials.gov","NCT06683508",null,"A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3549492 Once Daily Compared With Placebo in Adult Participants With Obesity or Overweight","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","288","Obesity; Overweight","DRUG:LY3549492; DRUG:Placebo","Eli Lilly and Company","2024-11-13","FALSE","0"],["S003327","ClinicalTrials.gov","NCT07546760",null,"A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD9550 and AZD6234","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","RECRUITING","28","Hepatic Impairment","DRUG:AZD6234; DRUG:AZD9550","AstraZeneca","2026-03-20","FALSE","0"],["S003328","ClinicalTrials.gov","NCT07065058",null,"A Phase I, Single-Center, Open-Label, Single-Arm, Fixed-Sequence Clinical Study to Evaluate the Pharmacokinetic Interactions of VCT220 With Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects","INTERVENTIONAL",null,"PHASE1","COMPLETED","24","Obesity &Amp; Overweight","DRUG:Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin","Vincentage Pharma Co., Ltd","2025-07-01","FALSE","0"],["S003329","ClinicalTrials.gov","NCT06254274",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants With Type 2 Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","210","T2DM (Type 2 Diabetes Mellitus)","DRUG:RAY1225; DRUG:Placebo","Guangdong Raynovent Biotech Co., Ltd","2024-02-26","FALSE","0"],["S003330","ClinicalTrials.gov","NCT06973681",null,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Study to Evaluate the Safety, Tolerability, PK/PD Profile, and Efficacy of Multiple Doses of BGM0504 Injection in Overweight or Obese Subjects Without Diabetes","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","120","Overweight or Obesity","DRUG:BGM0504; DRUG:Placebo","BrightGene Bio-Medical Technology Co., Ltd.","2023-10-13","FALSE","1"],["S003331","ClinicalTrials.gov","NCT06558708",null,"A Phase II Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection and GZR33-70 Injection in Type 2 Diabetes Inadequately Controlled on Basal Insulin or Premixed Insulin Once Daily at Least With or Without Pre-dinner Meal-time Insulin","INTERVENTIONAL","RANDOMIZED","PHASE2","UNKNOWN","60","Type 2 Diabetes","DRUG:GZR101 Injection; DRUG:GZR33 Injection; DRUG:Insulin aspart","Gan and Lee Pharmaceuticals, USA","2024-06-28","FALSE","0"],["S003332","ClinicalTrials.gov","NCT06973720","VESPER-3","A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Multiple Dose Regimens of Once-Weekly Switching to Once-Monthly MET097 in Participants With Obesity or Overweight (VESPER-3)","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","268","Obesity; Overweight or Obesity","DRUG:MET097; DRUG:Placebo","Pfizer","2025-04-07","FALSE","0"],["S003333","ClinicalTrials.gov","NCT06871761",null,"A Randomized, Open-label, Parallel, Treat to Target Study Comparing the Efficacy and Safety of HR17031 Injection With Insulin Glargine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin, Metformin in Combination With or Without One Other Oral Antidiabetic Drug (OAD)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","393","Adult Patients With Type 2 Diabetes","DRUG:HR17031 injection; DRUG:insulin glargine","Jiangsu HengRui Medicine Co., Ltd.","2024-05-08","FALSE","0"],["S003334","ClinicalTrials.gov","NCT06293742",null,"A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of ECC5004 on the Single Dose Pharmacokinetics of Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","48","Type 2 Diabetes Mellitus","DRUG:ECC5004; DRUG:Midazolam; DRUG:Rosuvastatin; DRUG:Digoxin; DRUG:Atorvastatin","Eccogene","2024-02-08","FALSE","0"],["S003335","ClinicalTrials.gov","NCT05814107",null,"A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CT-996 in Overweight/Obese Participants and in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","94","Type 2 Diabetes; Overweight or Obesity","DRUG:CT-996; DRUG:Placebo","Carmot Australia First Pty Ltd","2023-05-09","FALSE","0"],["S003336","ClinicalTrials.gov","NCT06881264",null,"A Randomized, Open-label, Parallel, Treat to Target Study Comparing the Efficacy and Safety of HR17031 With Insulin Glargine in Chines Subjects With Type 2 Diabetes Inadequately Controlled With Metformin in Combination With or Without Another Oral Antidiabetic Drug (OAD)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","401","Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs","DRUG:HR17031 injection; DRUG:insulin glargine","Jiangsu HengRui Medicine Co., Ltd.","2024-04-30","FALSE","0"],["S003337","ClinicalTrials.gov","NCT05327595",null,"A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","80","Diabetes Mellitus, Type 2","DRUG:LY3549492; DRUG:Placebo; DRUG:Atorvastatin; DRUG:Midazolam","Eli Lilly and Company","2022-05-09","FALSE","0"],["S003338","ClinicalTrials.gov","NCT06939296",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VCT220 Tablets in Overweight or Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","840","Obesity; Overweight","DRUG:VCT220; DRUG:Placebo","Vincentage Pharma Co., Ltd","2024-12-24","FALSE","0"],["S003339","ClinicalTrials.gov","NCT06579092","VISTA","A Phase IIb Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD5004 in Participants Living With Obesity or Overweight With Comorbidity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","310","Obesity or Overweight","DRUG:AZD5004; DRUG:Placebo","AstraZeneca","2024-10-08","FALSE","1"],["S003340","ClinicalTrials.gov","NCT04829123",null,"A Phase 1, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","64","Non-alcoholic Steatohepatitis","DRUG:HEC88473 injection; DRUG:Placebo","Dongguan HEC Biopharmaceutical R&D Co., Ltd.","2021-05-14","FALSE","0"],["S003341","ClinicalTrials.gov","NCT07011797",null,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","250","Obesity","DRUG:CX11; OTHER:Placebo","Corxel Pharmaceuticals","2025-06-17","FALSE","0"],["S003342","ClinicalTrials.gov","NCT06704581",null,"A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of BGM0504 Injection in Chinese Non-diabetes Participants with Overweight or Obese","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","620","Overweight or Obesity","DRUG:5 mg BGM0504 injection; DRUG:10 mg BGM0504 injection administered subcutaneously (SC) once a week; DRUG:15 mg BGM0504 injection; DRUG:BGM0504 placebo","BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.","2024-10-28","FALSE","0"],["S003343","ClinicalTrials.gov","NCT07519135",null,"A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-08653944 IN ADULTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIRMENT","INTERVENTIONAL",null,"PHASE1","RECRUITING","26","Healthy","DRUG:PF-08653944","Pfizer","2026-04-15","FALSE","0"],["S003344","ClinicalTrials.gov","NCT07331389",null,"A Phase I, Single-center, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Drug-Drug Interaction of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin in Overweight/Obese Adult Chinese Subjects","INTERVENTIONAL",null,"PHASE1","RECRUITING","111","Overweight Subject; Healthy Subjects","DRUG:Metformin; DRUG:Empagliflozin; DRUG:Midazolam; DRUG:Valsartan; DRUG:Warfarin; DRUG:HDM1002","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-09-24","FALSE","0"],["S003345","ClinicalTrials.gov","NCT06924320",null,"A PHASE 1/2A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MET233 CO-ADMINISTERED WITH MET097 IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT INCLUDING PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","RECRUITING","381","Obesity and Obesity-related Medical Conditions","DRUG:MET233 and MET097; OTHER:Placebo; DRUG:MET097","Pfizer","2025-03-06","FALSE","1"],["S003346","ClinicalTrials.gov","NCT07794397",null,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","200","Obstructive Sleep Apnea (OSA) and Obesity","DRUG:HDM1005; DRUG:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-09","FALSE","0"],["S003347","ClinicalTrials.gov","NCT07566572",null,"A Randomized, Open-label, Multiple-dose Phase I Clinical Study to Evaluate the Effect of a High-fat Meal and Different Dosing Conditions on the Pharmacokinetics of BGM0504 Tablets in Healthy Chinese Participants.","INTERVENTIONAL",null,"PHASE1","COMPLETED","144","Chinese Healthy Volunteers","DRUG:BGM0504 tablets","BrightGene Bio-Medical Technology Co., Ltd.","2026-03-26","FALSE","0"],["S003348","ClinicalTrials.gov","NCT06813781",null,"A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","33","Hepatic Impairment","DRUG:AZD5004","AstraZeneca","2024-12-19","FALSE","0"],["S003349","ClinicalTrials.gov","NCT06556641",null,"Phase Ib Clinical Study on the Safety, Tolerance, Pharmacokinetics, and Pharmacodynamics of GZR33 and GZR101 in Healthy Adult Male Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","28","Healthy Subjects","DRUG:GZR33 Injection; DRUG:GZR101 Injection; DRUG:Placebo; DRUG:Insulin Degludec","Gan and Lee Pharmaceuticals, USA","2022-12-17","FALSE","0"],["S003350","ClinicalTrials.gov","NCT07502001",null,"A Phase I, Single-center, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Influence of HDM1005 on Gastric Emptying and Drug-Drug Interaction of HDM1005 and Metformin, Atorvastatin, Warfarin, and Digoxin in Overweight/Obese Adult Chinese Subjects","INTERVENTIONAL",null,"PHASE1","NOT_YET_RECRUITING","42","Overweight; Obesity","DRUG:Acetaminophen; DRUG:Metformin; DRUG:Warfarin; DRUG:Atorvastatin; DRUG:Digoxin; DRUG:HDM1005 injection","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-04-08","FALSE","0"],["S003351","ClinicalTrials.gov","NCT07057271",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Designed to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once A Week in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","464","Type 2 Diabetes Mellitus - Poor Control","DRUG:CJC-1134-PC Injection; DRUG:Placebo","Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.","2021-05-27","FALSE","0"],["S003352","ClinicalTrials.gov","NCT04758234",null,"A Randomized, Double-Blind, Single-Ascending Dose and Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","54","Healthy","DRUG:LY3549492; DRUG:Placebo","Eli Lilly and Company","2021-02-22","FALSE","0"],["S003353","ClinicalTrials.gov","NCT03414736",null,"A Randomized, Comparative, Open Label Study to Assess the Safety and Tolerability of 3-arm, Parallel, Repeated Subcutaneous Dose Regimens of SAR425899 in Overweight to Obese Subjects and T2DM Patients Not Requiring Anti-diabetic Pharmacotherapy, With an Optional 6-month Safety Extension Period","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","60","Type 2 Diabetes Mellitus","DRUG:SAR425899","Sanofi","2018-01-19","FALSE","0"],["S003354","ClinicalTrials.gov","NCT06714955",null,"A Phase 1, Double-Blind, Parallel-arm, Placebo-Controlled, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection Administered Subcutaneously in Non-diabetic Overweight or Obese Adult Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","30","Non-diabetic Overweight or Obese","DRUG:Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.; DRUG:Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.; DRUG:Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.","BrightGene Bio-Medical Technology Co., Ltd.","2024-10-21","FALSE","0"],["S003355","ClinicalTrials.gov","NCT04221945",null,"A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047)","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","1060","Uterine Cervical Neoplasms","BIOLOGICAL:Pembrolizumab; DRUG:Placebo for pembrolizumab; DRUG:Cisplatin; RADIATION:External Beam Radiotherapy (EBRT); RADIATION:Brachytherapy","Merck Sharp & Dohme LLC","2020-05-12","TRUE","0"],["S003356","ClinicalTrials.gov","NCT05579314",null,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose Study to Assess Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","127","Type 2 Diabetes Mellitus","DRUG:XW014; DRUG:Placebo","Sciwind Biosciences USA Co., Ltd.","2022-09-26","FALSE","0"],["S003357","ClinicalTrials.gov","NCT07020884",null,"A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of ZT002 Injection in Subjects With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","303","Overweight or Obesity","DRUG:ZT002 Injection; DRUG:ZT002 Placebo","Beijing QL Biopharmaceutical Co.,Ltd","2024-08-14","FALSE","0"],["S003358","ClinicalTrials.gov","NCT07017179",null,"A Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD6234, AZD9550, and AZD6234 in Combination With AZD9550 in Chinese Participants Living With Obesity/Overweight","INTERVENTIONAL","RANDOMIZED","PHASE2","ACTIVE_NOT_RECRUITING","16","Obesity/Overweight","DRUG:AZD6234; DRUG:Placebo; DRUG:AZD9550; DRUG:Plocebo; DRUG:AZD6234 in combination with AZD9550","AstraZeneca","2025-05-20","FALSE","0"],["S003359","ClinicalTrials.gov","NCT07362030",null,"A Open-Label, Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin in Healthy Participants","INTERVENTIONAL",null,"PHASE1","ACTIVE_NOT_RECRUITING","32","Obesity","DRUG:RAY1225; DRUG:atorvastatin calcium tablet; DRUG:Metformin Tablets; DRUG:Warfarin Sodium Tablets; DRUG:Digoxin Tablets","Guangdong Raynovent Biotech Co., Ltd","2025-04-14","FALSE","0"],["S003360","ClinicalTrials.gov","NCT06942936",null,"An Open-label, Fixed-sequence and Two-part Study to Assess the Impact of Multiple Doses of Itraconazole on the Pharmacokinetics of AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on the Pharmacokinetics of Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","51","Healthy Participants","DRUG:AZD5004; DRUG:Itraconazole; DRUG:EE/LNG","AstraZeneca","2025-05-28","FALSE","0"],["S003361","ClinicalTrials.gov","NCT07794774",null,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBESITY DISEASE IN JAPAN (VESPER-JM)","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","197","Obesity","DRUG:Berobenatide; OTHER:Placebo","Pfizer","2026-09-28","FALSE","0"],["S003362","ClinicalTrials.gov","NCT06985615",null,"A Multi-center, Parallel Cohort, Open Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of HDM1002 in Subjects With Normal Hepatic Function and Hepatic Impairment.","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","40","Hepatic Impairment; Healthy Volunteers","DRUG:Single dose of HDM1002 on Day 1","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-03-18","FALSE","0"],["S003363","ClinicalTrials.gov","NCT06809608",null,"An Open-Label, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Itraconazole, Multiple Oral Doses of Gemfibrozil, and Single Oral Dose of Cyclosporine, on the Pharmacokinetics of a Single Oral Dose of RO7795081 in Healthy Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","36","Healthy Participants","DRUG:RO7795081; DRUG:Itraconazole; DRUG:Gemfibrozil; DRUG:Cyclosporine","Hoffmann-La Roche","2025-02-13","FALSE","0"],["S003364","ClinicalTrials.gov","NCT07013643",null,"An Open-label, Single-sequence Multiple Cohort Study to Assess the Effect of Multiple Doses of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on the Pharmacokinetics of Single Doses of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","100","Healthy Participants","DRUG:AZD6234; DRUG:Ethinyl estradiol/Levonorgestrel (EE/LEVO); DRUG:Acetaminophen (APAP); DRUG:AZD9550","AstraZeneca","2025-06-04","FALSE","0"],["S003365","ClinicalTrials.gov","NCT05835752",null,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RAY1225","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","68","Obese; Healthy","DRUG:RAY1225; DRUG:Placebo","Guangdong Raynovent Biotech Co., Ltd","2023-05-18","FALSE","0"],["S003366","ClinicalTrials.gov","NCT07559240",null,"A Multicenter, Single-Dose, Parallel-Group, Open-Label Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","NOT_YET_RECRUITING","30","Overweight; Obese","DRUG:HDM1005","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2026-05-15","FALSE","0"],["S003367","ClinicalTrials.gov","NCT06982131",null,"A Phase I, Randomized, Investigator/Participant-Blind, Placebo-Controlled, Fixed-Sequence Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Orally Administered RO7795081 and the Effect of Steady-State Dose of Orally Administered RO7795081 on the Pharmacokinetics of Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","ACTIVE_NOT_RECRUITING","40","Overweight; Obesity","DRUG:RO7795081; DRUG:Placebo; DRUG:Rosuvastatin; DRUG:Pitavastatin","Hoffmann-La Roche","2025-06-04","FALSE","0"],["S003368","ClinicalTrials.gov","NCT06555822",null,"A Phase I, Two-Part Study in Healthy Volunteers Consisting of a Randomized, Single-blind, Placebo-controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5004 and a Randomized, Open-Label, Two-way Cross-over Study to Compare the Relative Bioavailability of Two Oral Tablet Strengths of AZD5004","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","31","Healthy Participants","DRUG:AZD5004; DRUG:Placebo","AstraZeneca","2024-08-15","FALSE","0"],["S003369","ClinicalTrials.gov","NCT06869018",null,"A Randomized, Investigator- and Participant-blinded, Multiple-ascending Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus and Healthy Japanese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","92","Healthy; Type 2 Diabetes Mellitus (T2D)","DRUG:LY3549492; DRUG:Placebo","Eli Lilly and Company","2025-05-07","FALSE","0"],["S003370","ClinicalTrials.gov","NCT06086912",null,"A Single-center, Randomized, Open, Three-period, Three-sequence Crossover Clinical Study to Compare the Bioavailability and Safety of a Single Subcutaneous Injection of HR17031 in Healthy Subjects at Different Sites","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","24","Type 2 Diabetes","DRUG:HR17031","Jiangsu HengRui Medicine Co., Ltd.","2023-11-07","FALSE","0"],["S003371","ClinicalTrials.gov","NCT07382908",null,"A Single-Center, Single-Dose, Randomized, Open-Label, Single-Period, Parallel Bioequivalence Study of BGM0504 Injection in Overweight/Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","RECRUITING","144","Overweight/Obesity","DRUG:BGM0504 Injection multi-dose pen; DRUG:BGM0504 Injection single-dose pen","BrightGene Bio-Medical Technology Co., Ltd.","2025-12-23","FALSE","0"],["S003372","ClinicalTrials.gov","NCT07697846",null,"Phase 1, Single-Center, Randomized, Double-Blind, Parallel-Group Placebo-Controlled（Concentration）-QTc（C-QTc）Study to Evaluate the Impact of ZT002 Injection on QTc Interval in Chinese Overweight and Obese Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","40","Overweight, Obesity","DRUG:ZT002 injection; DRUG:ZT002 injection matching placebo","Beijing QL Biopharmaceutical Co.,Ltd","2026-07-18","FALSE","0"],["S003373","ClinicalTrials.gov","NCT07279194",null,"Efficacy and Safety of HDM1005 Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","825","Obesity & Overweight","DRUG:HDM1005 1; DRUG:HDM1005 2; DRUG:Placebo","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-10-14","FALSE","0"],["S003374","ClinicalTrials.gov","NCT07230119",null,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Zovaglutide in Adults With Overweight or Obesity.","INTERVENTIONAL","RANDOMIZED","PHASE3","ACTIVE_NOT_RECRUITING","755","Overweight , Obesity","DRUG:Zovaglutide dose 1; DRUG:Zovaglutide dose 2; DRUG:Placebo","Beijing QL Biopharmaceutical Co.,Ltd","2026-01-16","FALSE","0"],["S003375","ClinicalTrials.gov","NCT07823608",null,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBSTRUCTIVE SLEEP APNEA AND OVERWEIGHT OR OBESITY RECEIVING POSITIVE AIRWAY PRESSURE THERAPY (VESPER-OSA 1)","INTERVENTIONAL","RANDOMIZED","PHASE3","RECRUITING","258","Apnea; Sleep Disorders; Overweight and/or Obesity","DRUG:Berobenatide; OTHER:Placebo","Pfizer","2026-09-17","FALSE","0"],["S003376","ClinicalTrials.gov","NCT03990090",null,"A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase Ia Study in Chinese Healthy Adult Subjects to Investigate the Safety, Tolerability and Pharmacokinetic of TG103","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Healthy","DRUG:TG103; DRUG:Placebo","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","2019-07-29","FALSE","1"],["S003377","ClinicalTrials.gov","NCT07065032",null,"A Single-center, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Phase Id/IIa Study Evaluating the Safety, Tolerability, and Pharmacokinetics of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","COMPLETED","27","Type 2 Diabetes","DRUG:ZT002 Injection; DRUG:ZT002 Placebo","Beijing QL Biopharmaceutical Co.,Ltd","2024-02-19","FALSE","0"],["S003378","ClinicalTrials.gov","NCT06254261",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants With Obesity","INTERVENTIONAL","RANDOMIZED","PHASE2","RECRUITING","270","Obesity","DRUG:RAY1225; DRUG:Placebo","Guangdong Raynovent Biotech Co., Ltd","2024-02-21","FALSE","0"],["S003379","ClinicalTrials.gov","NCT07443059",null,"A Phase I Clinical Study to Evaluate the Pharmacokinetic Characteristics and Safety of Single-dose of Zovaglutide (ZT002 Injection) in Participants With Different Degrees of Renal Insufficiency and Matched Participants With Normal Renal Function","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","RECRUITING","40","Overweight , Obesity","DRUG:Zovaglutide","Beijing QL Biopharmaceutical Co.,Ltd","2026-04-13","FALSE","0"],["S003380","ClinicalTrials.gov","NCT06862791","ASCEND","A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight With Co-morbidity (ASCEND)","INTERVENTIONAL","RANDOMIZED","PHASE2","COMPLETED","377","Obesity or Overweight","DRUG:AZD9550; DRUG:AZD6234; DRUG:Placebo comparator","AstraZeneca","2025-02-18","FALSE","0"],["S003381","ClinicalTrials.gov","NCT06920056",null,"A Single Center, Open-label, Fixed Sequence Trial, Investigating the Influence of BGM0504 Injection on Gastric Emptying and Pharmacokinetics of Metformin and Warfarin in Overweight or Obese Participants","INTERVENTIONAL",null,"PHASE1","COMPLETED","28","Overweight or Obese","DRUG:Paracetamol; DRUG:Metformin Hydrochloride; DRUG:Warfarin; DRUG:BGM0504","BrightGene Bio-Medical Technology Co., Ltd.","2025-03-25","FALSE","0"],["S003382","ClinicalTrials.gov","NCT07239973",null,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","75","Healthy; Non-diabetic Overweight or Obese","DRUG:BGM0504 tablets; DRUG:Placebo tablets","BrightGene Bio-Medical Technology Co., Ltd.","2025-10-24","FALSE","0"],["S003383","ClinicalTrials.gov","NCT05054530",null,"A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF GMA106 IN HEALTHY, OVERWEIGHT AND OBESE ADULTS","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","73","Overweight and Obesity","DRUG:GMA106 Injection; DRUG:GMA106 Matching Placebo","Gmax Biopharm Australia Pty Ltd.","2021-11-11","FALSE","0"],["S003384","ClinicalTrials.gov","NCT02731664","GLPMOT","GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans: Native GLP-1 Compared With Analogue ROSE-010 in Vitro","INTERVENTIONAL","NON_RANDOMIZED","PHASE1","COMPLETED","12","Functional Gastrointestinal Disorders","BIOLOGICAL:GLP-1; BIOLOGICAL:Intravenous saline","Uppsala University","2012-09","FALSE","3"],["S003385","ClinicalTrials.gov","NCT06885021",null,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults","INTERVENTIONAL","RANDOMIZED","PHASE3","NOT_YET_RECRUITING","780","Overweight and Obesity","DRUG:HDM1002 200mg, oral, once daily, 52 weeks; DRUG:HDM1002 400mg, oral, once daily, 52 weeks; DRUG:HDM1002 placebo, oral, once daily, 52 weeks","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","2025-03-28","FALSE","0"],["S003386","ClinicalTrials.gov","NCT06655740","STEAM-IE","A Pilot Human Study of the Safety, Tolerability and Effectiveness of the Aqua Medical Circumferential RF Vapor (RFV) Ablation System for Duodenal Mucosal Ablation for the Management of Insulin Requiring Type-2 Diabetes Mellitus","INTERVENTIONAL",null,null,"ACTIVE_NOT_RECRUITING","16","Diabetes Mellitus, Type 2","DEVICE:RF Vapor Ablation","Aqua Medical, Inc.","2024-10-01","FALSE","3"],["S003387","ClinicalTrials.gov","NCT00306098",null,"Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression","INTERVENTIONAL",null,"PHASE2","COMPLETED","26","Diabetes Mellitus, Type I","DRUG:islets","Rodolfo Alejandro","2000-12","FALSE","2"],["S003388","ClinicalTrials.gov","NCT05015894",null,"Investigation of the Pharmacokinetics of Subcutaneously Administered NNC0480-0389 in Participants With Various Degrees of Impaired Renal Function Compared to Participants With Normal Renal Function","INTERVENTIONAL",null,"PHASE1","COMPLETED","42","Diabetes Mellitus, Type 2","DRUG:NNC0480-0389","Novo Nordisk A/S","2021-08-30","FALSE","0"],["S003389","ClinicalTrials.gov","NCT02910544",null,"The Association Between Weight Loss and Changes in Physical Activity in Overweight/Obese Individuals With Knee Osteoarthritis: An Observational Cohort Study","OBSERVATIONAL",null,null,"COMPLETED","150","Osteoarthritis, Knee","DIETARY_SUPPLEMENT:Intensive dietary intervention","Parker Research Institute","2016-11","FALSE","0"],["S003390","ClinicalTrials.gov","NCT06883019",null,"A Real World Study of Lecanemab Treatment in Participants with Early Onset Familial Alzheimer's Disease","OBSERVATIONAL",null,null,"RECRUITING","114","Alzheimer Disease",null,"RenJi Hospital","2025-03-13","FALSE","0"],["S003391","ClinicalTrials.gov","NCT05597475",null,"Visualizing Beta Cells in Patients With Hyperinsulinemic Hypoglycemia After Bariatric Surgery","INTERVENTIONAL",null,null,"UNKNOWN","24","Obesity; Hypoglycemia Post Gastric Bypass Surgery; Hyperinsulinemic Hypoglycemia","DIAGNOSTIC_TEST:GLP-1R PET","Rijnstate Hospital","2016-11-01","FALSE","0"],["S003392","ClinicalTrials.gov","NCT03785236","GLP1-transpl","Visualizing Beta Cells After Intrahepatic Islet of Langerhans Transplantation","OBSERVATIONAL",null,null,"TERMINATED","13","Type 1 Diabetes Mellitus","RADIATION:68Ga-NODAGA-exendin PET/CT","Radboud University Medical Center","2016-06-06","FALSE","1"],["S003393","ClinicalTrials.gov","NCT04354090",null,"Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09, a Long-acting Glucagon-like Peptide-1 Mimetic, in Healthy Subjects","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","41","Diabetes Mellitus, Type 2","DRUG:JY09","Beijing Dongfang Biotech Co., Ltd.","2018-04-26","FALSE","0"],["S003394","ClinicalTrials.gov","NCT01017302",null,"A Randomized, Double-blind, Placebo-controlled, Titration Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose and Escalating Doses of RO5095932 in Patients With Type 2 Diabetes Mellitus on Stable Background Therapy","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","32","Diabetes Mellitus Type 2","DRUG:Placebo; DRUG:RO5095932","Hoffmann-La Roche","2009-12","FALSE","0"],["S003395","ClinicalTrials.gov","NCT04268862",null,"Ethnic Dependence of the Metabolic Defects in Prediabetic Individuals: Kuwaiti Arabs Versus Indians","OBSERVATIONAL",null,null,"UNKNOWN","120","Pathophysiology; Metabolic Glucose Disorders",null,"Dasman Diabetes Institute","2020-03-01","FALSE","1"],["S003396","ClinicalTrials.gov","NCT04815278","NCW4H","NC Works4Health: Reducing Chronic Disease Risks in Socioeconomically Disadvantaged, Unemployed Populations","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","455","Diabetes; Chronic Disease; Psychological Distress","BEHAVIORAL:Immediate Chronic Disease Prevention Program (CDPP); BEHAVIORAL:Workplace Equity, Job and Health Supports Employer Intervention; BEHAVIORAL:Delayed, attenuated Chronic Disease Prevention Program (CDPP)","University of North Carolina, Chapel Hill","2021-09-17","FALSE","0"],["S003397","ClinicalTrials.gov","NCT00353587",null,"Phase 2/3, Randomized, Double-blind, Placebo- and Active Comparator-controlled, Parallel, Multicenter Study to Determine Safety and Efficacy of Metaglidasen in Treatment of Type 2 Diabetes Suboptimally Controlled on Insulin","INTERVENTIONAL","RANDOMIZED","PHASE2; PHASE3","COMPLETED","396","Type 2 Diabetes","DRUG:MBX-102; DRUG:Placebo; DRUG:Actos","Gilead Sciences","2006-05","FALSE","0"],["S003398","ClinicalTrials.gov","NCT05521256",null,"A First Human Dose Study Investigating Safety, Tolerability, and Pharmacokinetics of Oral Single Doses of NNC0113-6856 in Healthy Male Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","70","Healthy Volunteers; Type 2 Diabetes","DRUG:NNC0113-6856; DRUG:Placebo","Novo Nordisk A/S","2022-08-26","FALSE","0"],["S003399","ClinicalTrials.gov","NCT07525037",null,"Chinese Registry of Overweight or Obesity, a Multicenter Real-World Registry Study on Clinical Management - CROWN Study","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","10000","Obesity Type 2 Diabetes Mellitus",null,"Chinese PLA General Hospital","2026-05-30","FALSE","0"],["S003400","ClinicalTrials.gov","NCT06790225","GINEBRA","Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)","INTERVENTIONAL","RANDOMIZED",null,"COMPLETED","13","Bone Disease, Metabolic; Diabetes Mellitus, Type 2; Obesity and Obesity-related Medical Conditions","OTHER:Glucose-dependent Insulinotropic Polypeptide (GIP)","Esbjerg Hospital - University Hospital of Southern Denmark","2025-11-10","FALSE","0"],["S003401","ClinicalTrials.gov","NCT06069895",null,"Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","170","Healthy Participants","DRUG:NNC0113-6856; DRUG:Placebo","Novo Nordisk A/S","2023-10-04","FALSE","0"],["S003402","ClinicalTrials.gov","NCT03917238","Honeymoon","Comparison of the Beta Cell Mass During and Shortly After the Honeymoon Phase of Type 1 Diabetes Using Gallium-68-exendin PET","INTERVENTIONAL",null,null,"ACTIVE_NOT_RECRUITING","14","Type 1 Diabetes Mellitus","RADIATION:gallium-68-exendin injection followed by PET/CT scan","Radboud University Medical Center","2019-10-11","FALSE","0"],["S003403","ClinicalTrials.gov","NCT07179796",null,"Digital Physical Activity Programs: a Large Scale Prospective, Observational Study","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","300000","Overall Health; Wellbeing; Quality of Life; Mental Health","BEHAVIORAL:Observation","Sword Health, SA","2025-09-09","FALSE","0"],["S003404","ClinicalTrials.gov","NCT00637338",null,"A Phase 1, Randomized, Placebo-Controlled, Sequential Parallel Group, Multiple Dose Escalation Trial To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of 4, Once-Weekly Subcutaneous Doses Of PF-04603629 To Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE1","TERMINATED","42","Diabetes Mellitus, Type 2","BIOLOGICAL:PF-04603629; BIOLOGICAL:Placebo","Pfizer","2008-04","FALSE","0"],["S003405","ClinicalTrials.gov","NCT07809945",null,"A Randomized, Double Blind, Placebo Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of IBI3046 in Chinese Participants With Overweight or Obesity","INTERVENTIONAL","RANDOMIZED","PHASE1","NOT_YET_RECRUITING","128","Obesity and Overweight","DRUG:IBI3046; DRUG:placebo","Innovent Biologics (Suzhou) Co. Ltd.","2026-09-15","FALSE","0"],["S003406","ClinicalTrials.gov","NCT07557355",null,"A Phase 1/2a, Randomized, Double Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD384 in Overweight or Obese Participants","INTERVENTIONAL","RANDOMIZED","PHASE1; PHASE2","NOT_YET_RECRUITING","78","Overweight , Obesity","DRUG:SRSD384 injection; DRUG:Placebo","Sirius Therapeutics Co., Ltd.","2026-06","FALSE","0"],["S003407","ClinicalTrials.gov","NCT07503028",null,"An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events","INTERVENTIONAL",null,"EARLY_PHASE1","ENROLLING_BY_INVITATION","10","T1DM - Type 1 Diabetes Mellitus; Pancreatogenic Diabetes Mellitus","DRUG:CRG002","Celregen Therapeutics","2025-10-17","FALSE","0"],["S003408","ClinicalTrials.gov","NCT01406717",null,"Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus","INTERVENTIONAL","RANDOMIZED","PHASE3","COMPLETED","360","Type 2 Diabetes Mellitus","DRUG:SPIL1033; DRUG:Placebo","Sun Pharmaceutical Industries Limited","2013-03-01","TRUE","0"],["S003409","ClinicalTrials.gov","NCT04880005","DICTA","Protocol for the Digital, Individualized, and Collaborative Treatment of Type 2 Diabetes in General Practice Based on Decision Aid (DICTA) - A Randomized Controlled Trial","INTERVENTIONAL","RANDOMIZED",null,"RECRUITING","400","Diabetes type2","BEHAVIORAL:Clinical decision support; BEHAVIORAL:Digital Lifestyle Coaching; BEHAVIORAL:Integration to Standard Electronic Health Record","University of Southern Denmark","2021-06-01","FALSE","0"],["S003410","ClinicalTrials.gov","NCT01446003",null,"A Multiple-Dose Clinical Trial to Study the Effect of MK-8457 on Ambulatory Blood Pressure in Hypertensive Patients","INTERVENTIONAL","RANDOMIZED","PHASE1","COMPLETED","31","Hypertension","DRUG:MK-8457; DRUG:Placebo for MK-8457","Merck Sharp & Dohme LLC","2011-10-25","TRUE","0"],["S003411","ClinicalTrials.gov","NCT00843479",null,"The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly.","OBSERVATIONAL",null,null,"COMPLETED","24","Diabetes Mellitus, Type 2; Insulin Resistance",null,"University of Campinas, Brazil","2009-06","TRUE","0"],["S003412","ClinicalTrials.gov","NCT07387003",null,"A Multicenter Phase 2 Clinical Study to Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs or Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin","INTERVENTIONAL","RANDOMIZED","PHASE2","NOT_YET_RECRUITING","345","Type 2 Diabetes (T2DM)","DRUG:GZR101-80; DRUG:GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)","Gan & Lee Pharmaceuticals.","2026-04-10","FALSE","0"],["S003413","ClinicalTrials.gov","NCT04621656",null,"Sugar Challenge Study","OBSERVATIONAL",null,null,"UNKNOWN","1022","Type 2 Diabetes; Pre-Diabetes; Healthy","COMBINATION_PRODUCT:January Mobile Application (Sugar AI)","January, Inc.","2017-11-01","FALSE","0"],["S003414","ClinicalTrials.gov","NCT03635671","DIRECTION","Diabetic Retinopathy and Subclinical Signs of Disease Transition","OBSERVATIONAL",null,null,"TERMINATED","5","Diabetic Retinopathy","DIAGNOSTIC_TEST:Optical Coherence Tomography Angiography","University of British Columbia","2018-09-01","FALSE","0"],["S003415","ClinicalTrials.gov","NCT07404150",null,"Women, Weight, and Well-Being: An Observational Study of an Interdisciplinary Lifestyle Program With or Without GLP-1 Therapy to Support Intentional Weight Loss, Reduce Internalized Weight Bias, and Improve Positive Health Behaviors in Women With Obesity.","OBSERVATIONAL",null,null,"ENROLLING_BY_INVITATION","60","Obesity and Cardiovascular Risk","OTHER:lifestyle change program","Heather Conradson","2026-01-12","FALSE","0"],["S003416","ClinicalTrials.gov","NCT07860814",null,"Accuracy of Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy Using MRI as the Reference Standard","OBSERVATIONAL",null,null,"NOT_YET_RECRUITING","524","Metabolic Dysfunction-steatohepatitis (MASH)",null,"Radnet Management, Inc.","2026-10","FALSE","0"],["S003417","ClinicalTrials.gov","NCT01972542",null,"The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk in Healthy People, Impaired Glucose Tolerance and Type 2 Diabetes","INTERVENTIONAL","NON_RANDOMIZED",null,"COMPLETED","80","Diabetes; Prediabetes","DIETARY_SUPPLEMENT:Oral fat tolerance test","Seoul National University Bundang Hospital","2013-06","FALSE","0"],["S003418","ClinicalTrials.gov","NCT07313384","DINE-GLP1","Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy","OBSERVATIONAL",null,null,"ACTIVE_NOT_RECRUITING","50","Obesity Type 2 Diabetes Mellitus; Obesity (Disorder)","DRUG:GLP-1 Therapy","University of South Carolina","2026-02-11","FALSE","0"],["S003419","ClinicalTrials.gov","NCT03249506",null,"Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus","OBSERVATIONAL",null,null,"COMPLETED","25358","Diabetes Mellitus, Type 2","DRUG:Canagliflozin; DRUG:Empagliflozin; DRUG:Dapagliflozin; DRUG:Dipeptidyl Peptidase-4 Inhibitor (DPP-4); DRUG:Glucagon-Like Peptide-1 Agonist (GLP-1); DRUG:Thiazolidinedione (TZD); DRUG:Sulfonylureas; DRUG:Insulin","Janssen Research & Development, LLC","2016-05-12","FALSE","0"],["S003420","ClinicalTrials.gov","NCT01762644","IIT","A Phase IIB/III Multicenter Randomized Trial to Evaluate the Combination of Low-Dose Cyclosporine and Omeprazole Versus Omeprazole Alone in Participants With New Onset Type 1 Diabetes.","INTERVENTIONAL","RANDOMIZED","PHASE3","WITHDRAWN","0","Type 1 Diabetes","DRUG:Oral Cyclosporine and Oral Omeprazole; DRUG:Oral Omeprazole","Perle Bioscience, Inc.","2015-08","FALSE","0"]]}